



# ISTH 2011



KYOTO JAPAN

## XXIII Congress of the International Society on Thrombosis and Haemostasis

57th Annual SSC Meeting

Venue : ICC Kyoto (Kyoto International Conference Center)

Dates : **July 23-28, 2011**



[www.isth2011.com](http://www.isth2011.com)



**FACTOR FORWARD**

## We are Biogen Idec Hemophilia, and we're exploring ways to make clotting factors last longer.

Together with our development partner, Swedish Orphan Biovitrum, we welcome you to ISTH 2011. Start your experience with our **special symposium**, "Clinical Evaluation of Coagulation Factors With Prolonged Pharmacokinetic Activity," on **Sunday, July 24**, from **12:30-14:30**.

### Visit us at booth #42 to:

- **Discover** our unique core technology, Fc fusion, which is being studied to determine its potential to prolong half-life.
- **Learn** about our hemophilia research.
- **Test** your knowledge with the Factor Forward Challenge and receive your booth giveaway.

### Can't wait to learn more about Fc fusion technology?

Fast forward to our ad on the inside back cover.

➤ Sign up for updates on our research at [www.BiogenIdecHemophilia.com](http://www.BiogenIdecHemophilia.com).



© 2011 Biogen Idec Inc and Swedish Orphan Biovitrum. All rights reserved. BIH 60-8010-01

No2

Table of Contents



# Venue & Contacts

## Venue

### Kyoto International Conference Center ( ICC Kyoto )

Takaragaike, Sakyo-ku, Kyoto 606-0001 Japan

Tel : +81-75-705-1234 Fax : +81-75-705-1100

The Kyoto International Conference Center is a compact and user-friendly facility which meets the global standard and can be easily accessed from the main Kyoto Station.

For the 2011 Exhibition two additional halls will be constructed temporarily next to the existing Event Hall. Meeting rooms for oral presentations and symposia are located in the Main Building and Annex Hall.

For further information on the ICC Kyoto, please visit

[http : //www.icckyoto.or.jp/en/index.html](http://www.icckyoto.or.jp/en/index.html)



## Contacts

For further information contact :

### ISTH Headquarters

610 Jones Ferry road, Suite 205

Carrboro, NC 27510 USA

Tel : +1-919-929-3807

Fax : +1-919-929-3935

E-mail : [headquarters@isth.org](mailto:headquarters@isth.org)

Website : <http://www.isth.org/>

### General Society Information

Requests for information about ISTH and its mission may be directed to :

### Cathy Cole, ISTH Executive Secretary

E-mail : [ccole@med.unc.edu](mailto:ccole@med.unc.edu)



### Thomas Reiser, ISTH Executive Director

E-mail : [tom\\_reiser@isth.org](mailto:tom_reiser@isth.org)

### Scientific and Standardization Committee

#### Robert Cary Clark, SSC Coordinator

E-mail : [headquarters@isth.org](mailto:headquarters@isth.org)

#### Sharon Overcash, ISTH Membership Secretary

E-mail : [membership@isth.org](mailto:membership@isth.org)

### Sponsorship & Exhibit Sales, Industry Relations

Requests about sales opportunities should be directed to :

#### Margo Price, ISTH Director of Corporate Relations

Direct Line : +1-919-929-2381

E-mail : [margo\\_price@isth.org](mailto:margo_price@isth.org)



## Venue & Contacts

The Japan Convention Services, the official 2011 Congress Organizer, will process registrations and abstracts. Information about the commercial exhibition as well as the organization and sponsorship of special events may also be obtained from the Organizing Secretariat.

### ISTH2011 Congress Secretariat

**Keiko Nishimoto**



**Kei Kunimoto**

**Emi Nishimura**

**Mayumi Inaba**



#### c/o Japan Convention Services, Inc

Daido Seimei Kasumigaseki Bldg.  
1-4-2 Kasumigaseki, Chiyoda-ku, Tokyo  
100-0013, Japan

Tel : +81-3-3508-1202

Fax : +81-3-3508-0820

E-mail : [isth2011@convention.jp](mailto:isth2011@convention.jp)

Website : <http://www.isth2011.com/>

### ISTH2011 Registration Desk

**Ryoko Sanada**

**Meiko Matsuura**

#### c/o Japan Convention Services, Inc

2-2 Kanda Nishiki-cho, Chiyoda-ku, Tokyo  
101-0054, JAPAN

Tel : +81-3-3508-1250

Fax : +81-3-5283-5952

E-mail : [isth2011reg@convention.co.jp](mailto:isth2011reg@convention.co.jp)

### ISTH2011 Abstract Desk

**Kaoru Fujimoto**

**Yuko Ninagawa**

Tel : +81-3-3500-5935

Fax : +81-3-5283-5952

E-mail : [isth2011ab@convention.co.jp](mailto:isth2011ab@convention.co.jp)

### Sponsorship & Exhibit Management

**Aya Okamoto**

#### c/o Japan Convention Services, Inc

Daido Seimei Kasumigaseki Bldg. 1-4-2  
Kasumigaseki, Chiyoda-ku, Tokyo  
100-0013, Japan

Tel : +81-3-3508-1202

Fax : +81-3-3508-0820

E-mail : [isth2011sponsor@convention.co.jp](mailto:isth2011sponsor@convention.co.jp)

### Exhibition Planning & Logistics

**Takeshi Fukui / Keizo Yamamoto /**

**Aya Fukumoto**

#### Accost Corporation Kyoto Office

KRP4-111, 93 Chudojiawatacho,  
Shimogyo-ku, Kyoto 600-8815, Japan

Tel : +81-75-323-5856

Fax : +81-75-322-8025

E-mail : [isth2011@accost.co.jp](mailto:isth2011@accost.co.jp)

### Hotel Accommodations

#### JTB Global Marketing & Travel Inc.

JTB Bldg. 14F, 2-3-11, Higashishinagawa,  
Shinagawa-ku, Tokyo 140-8604, Japan

Tel : +81-3-5796-5445

Fax : +81-3-5495-0685

E-mail : [isth2011@gmt.jtb.jp](mailto:isth2011@gmt.jtb.jp)



# Message from the Congress Presidents

Dear Colleagues and Friends,

On behalf of the Local Organizing Committee, it is our great pleasure to welcome you to Kyoto and the XXIII Congress of ISTH and 57th SSC Meeting.

Since Japan encountered the unprecedented earthquake and tsunami on March 11, followed by the nuclear power plant accident, we have conducted extensive surveys and discussions on every aspects which may affect the health and transportation safety of the Congress participants. After our council decided to hold the Congress in Kyoto as planned, Dr. Henri Bounameaux personally sent messages to not only ISTH members, but also registered non-member participants, sponsors and exhibitors, indicating that Kyoto and its vicinity were unaffected by the natural disasters and radioactivity, and people in Kyoto had been having their life as normally. As Congress President, I would like to thank you all who have supported us and come here to participate in the Congress; you not only contribute to the success of ISTH2011 but also encourage Japanese people to move forward recovery and reconstruction.

We have worked hard to organize the congress during the past two years. We are proud of attractive scientific programs including Presidential Symposium, Plenary Lectures, SOA and Symposia, where you could find the most recent progress in basic and clinical research in the field of thrombosis and haemostasis. At the same time, we are very much honored to offer you exciting chances to hear 3,000 oral and poster presentations from 75 countries.

I am sure you could enjoy the highest quality of science but also taste different flavors of culture and atmosphere in Kyoto. Kyoto, the old capital of Japan, combines long-established tradition and modern convenience, bejeweled with over 2,000 temples and shrines. The Social programs include "World Cultural Heritage" tours, which take you to such popular places as the Golden Pavilion, *Kiyomizu Temple*, *Nijo Castle*, *Heian Shrine*, and etc. These architectures are not only splendid and gorgeous, but also have the souls of nobles and samurais in them. I also recommend that you try a ceremony, flower arrangement, kimono experience and *zazen* (zen meditation) during your stay in Kyoto. I'm confident that these experiences make your stay in Kyoto unforgettable.

Welcome to Kyoto!



Yasuo Ikeda, MD  
President,  
XXIII Congress of ISTH and 57th SSC Meeting



# Message from the Secretary General of ISTH

Dear Colleagues and Friends,

For the first time since the Tokyo Congress in 1989, the ISTH returns to Japan - to Kyoto for our XXIII Congress and for the 57th SSC meeting. Congress President Yasuo Ikeda and his organizing committee have worked hard and have developed an outstanding program, including an educational component aimed at clinicians and basic scientists interested in our field. As always, the scientific program features invited speakers and the latest in our science and medicine. The convention center in Kyoto provides a beautiful site for the meeting. The social program showcases the remarkable history and culture of this very special city. Given the tragedy of March 2011 in northern Japan, with the earthquake, tsunami and nuclear accident, we are especially pleased that Kyoto was unaffected and that we are able to support the Japanese during this recovery phase.

Kyoto, the former capital of Japan, is a magnificent city. A little over two hours from Tokyo on the Shinkansen (high speed train), Kyoto is home to seventeen World Heritage Sites, including Nijo Castle, Kinkaku-ji (the Golden Pavilion) and Ginkaku-ji (the Silver Pavilion). Barbara and I have traveled extensively in Japan, and it is a truly remarkable country. People are extremely friendly and Westerners should have no difficulty exploring Japan now that most signage is in transliterated Japanese-English. Some of our most memorable activities outside of Kyoto include a visit to Mount Fuji, the castles in Kumamoto, Tokyo and Osaka, a couple of days at the Benesse House in Naoshima on the Inland Sea, and the Tokyo fish market-early in the morning. The Peace Parks in Hiroshima and Nagasaki are moving experiences. However, Kyoto itself has plenty to offer, from historic temples to gardens to the famous Philosopher's Walk. The convention center, surrounded by gardens and ponds, is sited on the subway line in a lovely part of the city.

Welcome to Kyoto!



Bruce Furie, MD  
Secretary General of ISTH

A handwritten signature in black ink that reads "Bruce Furie". The signature is written in a cursive, flowing style.



# Message from the Council Chairman

Dear Colleagues and Friends,

It is my distinct privilege to extend to you a warm welcome to Kyoto. For the second time in its history, our Society will be convening in Japan—twenty-two years after the Tokyo Congress.

After the earthquake and the tsunami that devastated the region of Fukushima in North-Eastern Japan in early March, our overriding consideration was the safety of all congress participants, and based on all available objective evidence ISTH Council has firmly concluded that holding the congress in Kyoto does not present a health or transportation safety hazard. Indeed, given the reassurances that the situation is safe, this would have been the worst moment to abandon our Japanese colleagues.

Dr. Yasuo Ikeda and his colleagues on the Local Organizing Committee have set up a stellar program designed to attract and engage both basic and clinical scientists. Indeed, you will find a program tailored to reflect our biennial congresses' goal to create educational experiences where *bench meets bed for the best of our patients*.

Certainly, the other characteristic of our meetings is their international flavor. Not only do participants come from all over the world, but we meet in such different places. In the past ten years, we visited Europe (Paris, Birmingham and Geneva), Australia (Sydney), and North America (Boston). Now we come to the revered old capital of Japan.

This extraordinary diversity blended with exemplary science is part of our wealth.


So at Kyoto, we invite you not only to attend the scientific sessions but also encourage you to explore the millenary Japanese culture. The “Historic Monuments of Ancient Kyoto” are listed by the UNESCO as a World Heritage Site. Visit the shrines scattered about Kyoto along with the Nijō Castle built by the Tokugawa shoguns a few centuries ago.

And by the way, do not miss out on the cuisine. Kyoto is renowned for its abundance of delicious Japanese foods.

In summary, I would simply like to welcome you to Kyoto and encourage you to benefit from the science and enjoy and experience the culture, and the friendship!



Henri Bounameaux, MD  
ISTH, Chairman of Council





# Message from the Scientific Program Committee Chairperson and Co-chairpersons

Dear Colleagues and Friends,

We are very pleased to show you the ISTH 2011 Scientific Program - an exciting roster of lectures and programmatic elements that address a wide variety of **the articles** thrombosis and haemostasis from basic and clinical scientists.

In the invited lectures, we have 6 excellent Plenary Lectures, a memorial Presidential Symposium, 32 interesting State of the Art Lectures and 30 exciting Symposia including the Late Breaking Clinical Research.

We have kindly received presentation abstracts over 3,000 from 75 countries, nevertheless the unprecedented earthquake and tsunami followed by the nuclear plant accident in the east-north area of Japan in March. The abstracts were all reviewed and acceptance/rejection notifications have been decided by experts from Local and International Scientific Advisory Board members of the ISTH. Finally, for oral presentations, we have 8 Platelet (Basic) sessions, 6 Platelet (Clinical) sessions, 18 Coagulation Factors and Inhibitors sessions, 3 Fibrinolysis and Proteolysis sessions, 23 Thrombotic Disorders sessions, 5 VWF/VWD and ADAMTS13 sessions, 10 Hemorrhagic Disorders sessions, 5 Vascular Biology sessions, an Innovation and Technology session, and a session for Late Breaking Clinical Trials, which provides up-to-date findings. In addition, there are almost 2,500 poster presentations in total.

We are sincerely grateful to our Local Scientific Program Committee, International Scientific Advisory Board, Abstract Reviewers, and Congress Organizers, JCS, for all the hard work that went into making this excellent program.

We are truly pleased to welcome you to Kyoto to an interesting and stimulating Congress presenting the best work from across our field.



*Koji Suzuki*

Koji Suzuki PhD  
Congress Vice President  
and Chairperson, Scientific  
Program Committee



*Toshiyuki Miyata*

Toshiyuki Miyata PhD  
Co-Chairperson,  
Scientific Program Committee  
(Basic Sciences)



*Yoshiaki Tomiyama*

Yoshiaki Tomiyama MD  
Co-Chairperson,  
Scientific Program  
Committee  
(Clinical Sciences)



# Committees



## Congress Committees *Local Organizing Committee*

### **Fumimaro Takaku**

Special Adviser

### **Hidehiko Saito**

Honorary President

### **Yasuo Ikeda**

President

### **Akira Yoshioka**

Vice President, SSC Chair

### **Koji Suzuki**

Vice President,  
Scientific Program Committee Chair

### **Yukio Ozaki**

Editor, "State of the Art Book"

### **Tetsuhito Kojima**

Co-Editor, "State of the Art Book"

### **Mitsuru Murata**

Secretary General

### **Nobuhiro Yamada**

Supervisor

### **Kazuyuki Shimada**

Supervisor

### **Osamu Matsuo**

Chairman, Financial Committee

### **Hajime Tsuji**

Co-Chairman, Financial Committee

### **Yoichi Sakata**

Chairman, Registration Committee

### **Katsuyuki Fukutake**

Co-Chairman, Registration Committee

### **Akitada Ichinose**

Chairman, Promotion Committee

### **Morio Arai**

Co-Chairman, Promotion Committee

### **Katsuo Sueishi**

Chairman, Liaison Committee

### **Shinichiro Uchiyama**

Co-Chairman, Liaison Committee

### **Hiroshi Shigematsu**

Chairman, Commemoration Committee

### **Yutaka Yatomi**

Co-Chairman, Commemoration  
Committee

### **Masao Nakagawa**

Chairman, Social Program Committee

### **Junki Takamatsu**

Co-Chairman, Social Program Committee


### **Masao Nakabayashi**

Chairman, Award Committee



# Committees

## International Members

Henri Bounameaux   
Colin Chesterman  
Anna Falanga  
Barbara Furie  
Bruce Furie  
Ian Peake  
Frits R. Rosendaal  
Gilbert C. White II

## Advisers

Nobuo Aoki  
Kingo Fujimura  
Saichi Hosoda  
Sadaaki Iwanaga  
Eizo Kakishita  
Hisao Kato  
Mutsuyoshi Kazama  
Shoji Kume  
Takefumi Matsuo  
Yuji Matsuzawa  
Hisashi Mihara  
Masao Nakabayashi  
Minoru Okuma  
Nobuo Sakuragawa  
Kenzo Tanaka  
Toshihiko Terao  
Kiyooki Watanabe  
Junichiro Yamamoto  
Manabu Yamanaka  
Hiroh Yamazaki

## Scientific Program Committee



### Koji Suzuki

Chairman,  
Local Scientific Program Committee

### Toshiyuki Miyata

Co-Chairman(Basic Medicine),  
Local Scientific Program Committee

### Yoshiaki Tomiyama

Co-Chairman(Clinical Medicine),  
Local Scientific Program Committee

### *Platelets Basic*

Atsushi Oda, Chair (JP)

Lawrence Brass (US)

Johannes L. Bos (NL)

Mark H. Ginsburg (US)

Christian Gachet (FR)

Joseph E. Italiano, Jr (US)

Shaun P. Jackson (AU)

Sanford J. Shattil (US)

Yumiko Matsubara (JP)

Peter J. Newman (US)

Mortimer Poncz (US)

Steve P. Watson (UK)

Yutaka Yatomi (JP)



### *Platelets Clinical*

Makoto Handa, Chair (JP)



# Committees

Charles S. Abrams (US)  
Barry S. Coller (US)  
Marco Cattaneo (IT)  
Andreas Greinacher (DE)  
Ming Hou (CN)  
Alan D. Michelson (US)  
Alan T. Nurden (FR)  
Yukio Ozaki (JP)

## *Coagulation Factors and Inhibitors*

Takashi Morita, Chair (JP)  
Charles T. Esmon (US)  
James A. Huntington (UK)  
Takehiko Koide (JP)  
R. Manjunatha Kini (SG)  
Egon Persson (DK)  
Wolfram Ruf (US)  
Pieter H. Reitsma (NL)

## *Fibrinolysis and Proteolysis*

Tetsumei Urano, Chair (JP)  
Nuala Ann Booth (UK)  
Egbert K. O. Kruithof (CH)  
Susan T. Lord (US)  
Osamu Matsuo (JP)  
Robert L. Medcalf (AU)  
D. C. Rijken (NL)  
Yoichi Sakata (JP)  
Hua-Lin Wu (TW)  
Johann Wojta (AT)

## *Thrombotic Disorders*

Shinya Goto, Chair (JP)  
Deepak L. Bhatt (US)  
Francis K. L. Chan (HK)  
James Douketis (CA)  
Ajay Kakkar (UK)  
Takao Kobayashi (JP)  
Laiheng Lee (SG)  
Gregory Y. H. Lip (UK)  
Doyeum Oh (KR)  
Ph. Gabriel Steg (FR)  
Hideo Wada (JP)

## *VWF/VWD and ADAMTS13*

Yoshihiro Fujimura, Chair (JP)  
David Ginsburg (US)  
Koichi Kokame (JP)  
Bernhard Laemmle (CH)  
Zaverio M. Ruggeri (US)  
Changgeng Ruan (CN)  
J. Evan Sadler (US)  
Jan J. Voorberg (NL)

## *Haemorrhagic Disorders*

Midori Shima, Chair (JP)  
Kagehiro Amano (JP)  
H. Marijke van den Berg (NL)  
Donna M. DiMichele (US)  
Philip J. Fay (US)  
Nigel S. Key (US)



# Committees

David Lillicrap (CA)  
Jun Mimuro (JP)  
Claude Negrier (FR)  
Steven W. Pipe (US)  
Alok Srivastava (IN)

## *Vascular Biology*

Yujiro Asada, Chair (JP)  
Masanori Aikawa (US)  
Peter Carmeliet (BE)  
Francoise Dignat-George (FR)  
Satoshi Fujii (JP)  
Goran K. Hansson (SE)  
Nigel Mackman (US)  
Shahin Rafii (US)  
Roy L. Silverstein (US)  
Denisa D. Wagner (US)  
Yutaka Yatomi (JP)

## *Innovation and Technology*

Koji Eto, Chair (JP)  
Wolfgang Bergmeier (US)  
Rodney M. Camire (US)  
Tatsuhiko Kodama (JP)  
Thierry VandenDriessche (BE)

## Council of ISTH Officers

**Chairman of Council** (2010-2012)  
Henri Bounameaux (Switzerland)

**Secretary/Chairman-Elect**  
(2010-2012/2012-2014)  
Michael Berndt (Ireland)

**Class of 2012**  
M. Berndt (Ireland)  
H. Bounameaux (Switzerland)  
A. Nurden (France)  
B. Østerud (Norway)  
P. Reitsma (The Netherlands)

**Class of 2014**  
N.A. Booth (UK)  
F. Dignat-George (France)  
N. Key (USA)  
R. Montgomery (USA)  
H. ten Cate (The Netherlands)

**Class of 2016**  
M. Cattaneo (Italy)  
B. Dahlbäck (Sweden)  
A. Greinacher (Germany)  
P. Tracy (USA)  
Y. Ozaki (Japan)

**Secretary General**  
Bruce Furie (USA)

**President of XXIII Congress**  
Yasuo Ikeda (Japan)

**Vice President of XXIII Congress**  
Akira Yoshioka (Japan)

**Editors-in-Chief, Journal of Thrombosis and Haemostasis**

Mike Greaves and David Lane (UK)



**Chairman, Scientific and Standardization Committee**



# Committees

Anna Falanga (Italy)

## Special Assistant to the Chairman

Frits R. Rosendaal (The Netherlands)

## Past Congress Presidents

Bruce and Barbara Furie (USA)

## Secretary/Chairman-Elect, Scientific and Standardization Committee

David Lillicrap (Canada)




## ISTH Officers of the Scientific and Standardization Committee

### Chairman (2010-2012)

Anna Falanga (Italy)

### Secretary/Chairman-Elect

 2010-2012/2012-2014)

David Lillicrap (Canada)

### Special Assistant to the Chairman

(2010-2012)

Gerhard J. Johnson (USA)

### Secretary General

Bruce Furie (USA)

### Subcommittee Chairmen

 Trevor Patrick Baglin (UK)

Marco Cattaneo (Italy)

Francoise Dignat-George (France)

James Douketis (Canada)

Sabine Eichinger (Austria)

Jeroen C. J. Eikenboom (The Netherlands)

Andreas Greinacher (Germany)

~~Johan W. M. Heemskerk (The Netherlands)~~

Anthony R. Hubbard (UK)

Hans P. Kohler (Switzerland)

Agnes Y. Y. Lee (Canada)

~~Colin Longstaff (UK)~~

Mary Ann McLane (USA)

Paul Monagle (Australia)

Timothy Charles Nichols (USA)

Thomas L. Ortel (USA)

Thomas Renne (Sweden)

~~Alok Srivastava (India)~~

Hideo Wada (Japan)

~~Herbert C. Whinna (USA)~~



# Committees

## Congress International Advisory Board

Walter Ageno (IT)  
Giancarlo Agnelli (IT)  
Masanori Aikawa (US)  
Marie-Christine Alessi (FR)  
Kagehiro Amano (JP)  
Joji Ando (JP)  
Pantep Angchaisuksiri (TH)  
Anne Angelillo-Scherrer (CH)  
Jack Ansell (US)  
Morio Arai (JP)  
Valder Arruda (US)  
Yujiro Asada (JP)  
Jan Astermark (SE)  
Tatsuya Atsumi (JP)  
Gunter Karl-Heinz Auerswald (DE)  
Hellmut G. Augustin (DE)  
Lina Badimon (ES)  
Wadie Bahou (US)  
Shannon Marie Bates (CA)  
Angelika Batorova (SK)  
Kenneth Alan Bauer (US)  
Joel S. Bennett (US)  
Wolfgang Bergmeier (US)  
David Bergqvist (SE)  
Michael C. Berndt (IE)  
Erik Berntorp (SE)  
Rogier Bertina (NL)  
Paul E. Bock (US)  
Nuala A. Booth (UK)  
Lawrence Brass (US)  
Benjamin Brenner (IL)  
George Broze (US)  
Francis J. Castellino (US)  
Marco Cattaneo (IT)  
Jean-Pierre Cazenave (FR)  
Beng Chong (AU)  
Douglas Cines (US)



Sergio Coccheri (IT)  
Peter Collins (UK)  
Ramon Corbalan (CL)  
Benilde Cosmi (IT)  
Mary Cushman (US)  
Bjorn Dahlback (SE)  
Alan Daugherty (US)  
Raimondo De Cristofaro (IT)  
Philippe de Moerloose (CH)  
Valerio De Stefano (IT)  
Najet Debili (FR)  
Paul Declerck (BE)  
Jay Degen (US)  
Fransesco Dentali (IT)  
Francoise Dignat-George (FR)  
Jing-Fei Dong (US)  
Jonas Emsley (UK)  
Miguel Escobar (US)  
Naomi L. Esmon (US)  
Philip J. Fay (US)  
Augusto B. Federici (IT)  
Garrett A. Fitzgerald (US)  
Jonathan H. Foley (US)  
Kathleen Freson (BE)



## Committees

Satoshi Fujii (JP)  
Barbara C. Furie (US)  
Bruce Furie (US)  
Christian Gachet (FR)  
David Gailani (US)  
Monica Galli (IT)  
Alexander S. Gallus (AU)  
Satoshi Gando (JP)  
Sophie Gandrille (FR)  
Jonathan Gibbins (UK)  
David Ginsburg (US)  
Samuel Z. Goldhaber (US)  
Mike Greaves (UK)  
John Griffin (US)  
Alessandro Gringeri (IT)  
Yves Gruel (FR)  
John Hartwig (US)  
Tatsuya Hayashi (JP)  
John A. Heit (US)  
Coen H. Hemker (NL)  
Satoshi Higasa (JP)  
Philip Hogg (AU)  
Hisanori Horiuchi (JP)  
Tom Eugene Howard (US)  
Menno Huisman (NL)  
Beverley J. Hunt (UK)  
James A. Huntington (UK)  
Akitada Ichinose (JP)  
Masahiro Ieko (JP)  
Aida Inbal (IL)  
Toshiyuku Ishibashi (JP)  
Masaru Ishii (JP)  
Shaun P. Jackson (AU)  
Gerhard Johnson (US)  
Cecile Kaplan (FR)  
Hirokazu Kashiwagi (JP)  
Clive Kearon (CA)  
Gili Kenet (IL)  
Craig M. Kessler (US)  
Alok Anand Khorana (US)



R. Manjunatha Kini (SG)  
Cornelis Klufft (NL)  
Takao Kobayashi (JP)  
Gou Young Koh (KR)  
Takehiko Koide (JP)  
Jun Koizumi (JP)  
Hiroshi Kojima (JP)  
Tetsuhito Kojima (JP)  
Koichi Kokame (JP)  
Kimihiro Komori (JP)  
Barbara Konkle (US)  
Yukihiro Koretsune (JP)  
Steve Krilis (AU)  
Sriram Krishnaswamy (US)  
Thomas Kuehne (CH)  
Masataka Kuwana (JP)  
Bernhard Laemmle (CH)  
David A. Lane (UK)  
Dan Lawrence (US)  
Bernard Le Bonniec (FR)  
Gregoire Le Gal (FR)  
Agnes Lee (CA)  
Marcel Levi (NL)  
Howard Liebman (US)  
H. Roger Lijnen (BE)  
David Lillicrap (CA)  
Shu-Wha Lin (TW)  
Gregory Y. H. Lip (UK)  
Colin Longstaff (UK)





## Committees

Susan Lord (US)  
Gordon Lowe (UK)  
Nigel Mackman (US)  
Asrar B. Malik (US)  
Naveen Manchanda (US)  
Marilyn Jean Manco-Johnson (US)  
Ida Martinelli (IT)  
Steffen Massberg (DE)  
Yumiko Matsubara (JP)  
Osamu Matsuo (JP)  
Tadashi Matsushita (JP)  
Robert Lindsay Medcalf (AU)  
Leonid Medved (US)  
Joost Meijers (NL)  
Alan D. Michelson (US)  
Saskia Middeldorp (NL)  
Jonathan Miller (US)  
Jun Mimuro (JP)  
Tetsuro Miyata (JP)  
Kohei Miyazono (JP)  
Jun Mizuguchi (JP)  
Stephan Moll (US)  
Paul Monagle (AU)  
Paul Edward Monahan (US)  
Robert R. Montgomery (US)  
Massimo Morfini (IT)  
Eriko Morishita (JP)  
Takashi Morita (JP)  
Jim Morrissey (US)  
Michael Mosesson (US)  
Iris Felicitas Mueller (UK)  
Laszlo Muszbek (HU)  
Mashio Nakamura (JP)  
Claude Negrier (FR)  
Heyu Ni (CA)  
Bernhard Nieswandt (DE)  
Alan Nurden (FR)  
Paquita Nurden (FR)  
Tsukasa Ohmori (JP)  
Johannes Oldenburg (DE)



Susanne Osanto (NL)  
Bjarne Osterud (NO)  
Paola Patrignani (IT)  
Kathelijne Peerlinck (BE)  
Vittorio Pengo (IT)  
Egon Persson (DK)  
Flora Peyvandi (IT)  
Steven Pipe (US)  
Mortimer Poncz (US)  
Alastair William Poole (UK)  
Paolo Prandoni (IT)  
Kathleen Pratt (US)  
Klaus T. Preissner (DE)  
Martin H. Prins (NL)  
A. Koneti Rao (US)  
Peter Reitsma (NL)  
Georges E. Rivard (CA)  
Ljung Rolf (SE)  
Frits R. Rosendaal (NL)  
Jan Rosing (NL)  
Changgeng Ruan (CN)  
Wolfram Ruf (US)  
Morten Sadset (NO)  
Jean-Marie Robert Saint-Remy (BE)  
Yoichi Sakata (JP)  
Charles-Marc Samama (FR)  
Elena Santagostino (IT)  
Sentot Santoso (DE)  
Alvin Schmaier (US)



# Committees

Reinhard Schneppenheim (DE)  
Sam Schulman (CA)  
Uri Seligsohn (IL)  
Amy Shapiro (US)  
Midori Shima (JP)  
Kazuyuki Shimada (JP)  
Keiko Shinozawa (JP)  
Roy L. Silverstein (US)  
Radek C. Skoda (CH)  
Nicholas Smith (US)  
Kenji Soejima (JP)  
Henrik Sorensen (DK)  
Benny Sorensen (UK)  
Alok Srivastava (IN)  
Katsuo Sueishi (JP)  
Junichi Takagi (JP)  
Nobuyuki Takakura (JP)  
Hiroyuki Takeya (JP)  
Jerome Teitel (CA)  
Douglas Tollefsen (US)  
Mauro Torti (IT)  
Hiroko Tsuda (JP)  
Alexander G. G. Turpie (CA)  
Yoshio Uetsuka (JP)  
Tetsumei Urano (JP)  
Elizabeth Van Cott (US)  
Marijke van den Berg (NL)  
Karen Vanhoorelbeke (BE)  
David Varon (IL)  
Agnes Veyradier (FR)  
Vicente Vicente (ES)  
Jan Voorberg (NL)  
Hideo Wada (JP)  
Denisa D. Wagner (US)  
Hironao Wakabayashi (US)  
Theodore Warkentin (CA)  
Henry Watson (UK)  
Stephen Watson (UK)  
Phil Stephen Wells (CA)  
Andy Weyrich (US)

Richard H. White (US)  
David Allen Wilcox (US)  
Takeshi Yamashita (JP)  
Renchi Yang (CN)  
Masahiro Yasaka (JP)  
Yutaka Yatomi (JP)  
Neil A. Zakai (US)  
Yongqiang Zhao (CN)  
Ariella Zivelin (IL)  
Jeffrey Zwicker (US)

## Society Partner

**Japanese Society on Thrombosis and Hemostasis**

## Congress Supporters

**Japan Tourism Agency - Ministry of Land, Infrastructure, Transport and Tourism**

**City of Kyoto**

**Kyoto Prefecture**

**Ministry of Education, Culture, Sports, Science and Technology**

**Ministry of Foreign Affairs**

**Ministry of Health, Labour and Welfare**

**Japan Atherosclerosis Society**

**Japan Medical Association**

**Japan Society of Transfusion Medicine and Cell Therapy**

**Japan Stroke Society**

**Japanese Association of Medical Sciences**

**Japanese Circulation Society**

**Japanese College of Angiology**

**Japanese Society of Hematology**

**Japanese Society of Internal Medicine**

**Japanese Vascular and Medicine Organization**



# Committees

## Presidents of Past Congresses

I	1970	Fritz Koller	Montreux, Switzerland
II	1971	Paul A. Owren	Oslo, Norway
III	1972	Kenneth M. Brinkhous	Washington, DC, USA
IV	1973	Erwin Deutsch	Vienna, Austria
V	1975	Jean-Pierre Soulier	Paris, France
VI	1977	Sol Sherry	Philadelphia, PA, USA
VII	1979	Gustav V. R. Born	London, UK
VIII	1981	J. Fraser Mustard	Toronto, Canada
IX	1983	Birger Blomback	Stockholm, Sweden
X	1985	Russell F. Doolittle	San Diego, CA, USA
XI	1987	Marc Verstraete	Brussels, Belgium
XII	1989	Takeshi Abe	Tokyo, Japan
XIII	1991	Jan Sixma	Amsterdam, The Netherlands
XIV	1993	Yale Nemerson	New York, NY, USA
XV	1995	Uri Seligsohn	Jerusalem, Israel
XVI	1997	Pier M. Mannucci	Florence, Italy
XVII	1999	Victor J. Marder	Washington, DC, USA
XVIII	2001	Dominique Meyer	Paris, France
XIX	2003	Ian R. Peake	Birmingham, England
XX	2005	Colin N. Chesterman	Sydney, Australia
XXI	2007	Henri M. Bounameaux	Geneva, Switzerland
XXII	2009	Bruce and Barbara Furie	Boston, MA, USA

## Presidents of Future Congresses

XXIV	2013	Frits R. Rosendaal	Amsterdam, The Netherlands
XXV	2015	Sam Schulman	Toronto, Canada
XXVI	2017	Johannes Oldenburg	Berlin, Germany



# Congress Awards and Lectureships

## ISTH AWARDS 2011

### Robert P. Grant Medal

The Robert P. Grant Medal is the highest award of the ISTH. Presented at each biennial Congress of the Society, it recognizes outstanding service or accomplishments which have promoted the goals of the Society: research achievement, organizational activities, important public recognition and support of research activities, facilitation of institutional cooperation and communications, unusual teaching or educational initiatives, or the development of concepts which result in a clearer understanding of the meaning of research data.

*The ISTH Grant Medal will be presented at the XXIII Congress Opening Ceremony on Sunday, July 24 at 17:30*

### Harold R. Roberts Award

The ISTH Harold R. Roberts Award recognizes honors meritorious service to the Scientific and Standardization Committee of the ISTH, beyond expectations and over a significant period of time.

*This award will be presented at the Presidential Symposium on Wednesday, July 27 at 11:15*

### Biennial Awards for Contributions to Hemostasis: Investigator Recognition

Initiated in 1982, the Biennial Awards for Contributions to Hemostasis (BACH) recognize individuals who have made significant contributions to research and education in blood coagulation. The awards are presented in two categories:

The Investigator Recognition Awards recognize ISTH members whose accomplishments are internationally regarded as exemplary models of excellence in research and teaching.

The Distinguished Career Awards recognize ISTH members whose career contributions have significantly advanced

the scientific community's understanding of the diseases and disorders affecting hemostasis.

*The ISTH BACH Awards will be presented during the Presidential Dinner (invitation only) on Monday, July 25 at 19:00*

### 2010 Pier M. Mannucci Young Investigator Awards, Journal of Thrombosis and Haemostasis

The Pier M. Mannucci Young Investigator Awards recognize the best articles by investigators younger than 35 years of age published in ISTH's *Journal of Thrombosis and Haemostasis*. The prizes are made possible by a generous contribution from Bayer HealthCare, and recipients are selected by a jury of editors.


Megumi Takiguchi  
Kim Marieke Baeten  
Judith M.E.M. Cossemans, PhD  
Dr. Stuart Michael Ellison  
Hendrik B. Feys  
Matteo Bonzini  
Sofia Barbar



# Congress Awards and Lectureships

## XXIII ISTH CONGRESS SPECIAL LECTURESHIP 2011

### **Takeshi Abe Memorial Lecture**

Katherine A. High   
Monday, July 25 at 09:45

## ISTH LECTURESHIPS 2011

### **ISTH Congress Plenary Lecture**

*Made possible by a grant from the Life  
Sciences Research Partners (formerly  
Désiré Collen Research Foundation)*

Kari Alitalo  
Monday, July 25 at 17:15

### **The Oscar Ratnoff Memorial Lecture**

Kenji Kangawa  
Tuesday, July 26 at 09:45

### **The Sol Sherry Memorial Lecture**

Kenneth A. Bauer  
Tuesday, July 26 at 17:15

### **Kenneth M. Brinkhous Memorial Lecture**

Mark H. Ginsberg  
Thursday, July 28 at 9:45

### **Wright-Schulte Memorial Lecture**

James A. Huntington  
Thursday, July 28 at 13:30



# Congress Awards and Grants

## Awards

These awards are part of the ISTH's Reach the World initiative and have been made possible thanks to ISTH, the XXIII Congress of the ISTH, the Japanese Society on Thrombosis and Haemostasis and corporate sponsors.



## Young Investigator Awards (YIA)

ISTH 2011 will provide travel grants (500USD) to medical trainees and young scientists (under 35 years of age as of July 23, 2011) who submitted highly rated abstracts. The award helps subsidize travel to the Congress. The Young Investigator must be the presenter and first author of an abstract submitted to the Congress. To receive the award, a recipient must be present at the Congress, and a current passport showing date of birth is required to collect the award on site at ISTH 2011.

## Developing World Scientists Awards (DWSA)

ISTH 2011 and the International Society on Thrombosis and Haemostasis award travel grants (1,500 – 3,500USD) to scientists from developing countries to help to subsidize travel to the Congress. To be considered for a grant the scientist must be the presenter and first author of an abstract submitted to the Congress.

A current passport showing country of residence is required to collect the grant exclusively available on site at ISTH 2011.

## JSTH Asian-Pacific Scholarship (JSTH/APS)

This Scholarship is made possible by a generous contribution of the Japanese Society on Thrombosis and Haemostasis (JSTH) and is exclusive to the ISTH 2011 in Kyoto. JSTH will award scholarship (500 USD) to scientists who submitted highly rated abstracts. Scientists who are under 40 years of age and live in Asian countries, Australia, or New Zealand as of July 23, 2011 apply. The scholarship helps to subsidize travel to the Congress.

The applicant must be the presenter and first author of an abstract submitted to the Congress. To receive the award, a recipient must be present at the Congress, and a current passport showing date of birth and country of residence is required to collect the scholarship on site at ISTH 2011.



# Congress Awards and Grants

The Award Winners 

Last Name	First Name	Awards	Last Name	First Name	Awards
Agar	Cetin	YIA	Chan	Mark	JSTH/APS
Ahlbrecht	Jonas	YIA	Chanrathammachart	Pichika	YIA
Ahmadinejad	Minoo	DWSA	Chen	Younan	DWSA
Ahnstrom	Josefin	YIA	Chen	Qiong	DWSA
Aisina	Roza	DWSA	Chen	Hai	JSTH/APS
Aladahalli Mallappa	Shanthala	JSTH/APS	Chimgeen	Punsaldulam	DWSA
Albers	Cornelis	YIA	Chudzinski-Tavassi	Ana Marisa	DWSA
Alexandru	Nicoleta	DWSA	Cleuren	Audrey	YIA
Ali	Majid	YIA	Cook	P. Michael	YIA
Allan	Peter	YIA	Corrigan	Claire	YIA
Attard	Chantal	JSTH/APS	Cosemans	Judith	YIA
Ay	Cihan	YIA	Dai	Jihong	DWSA
Bagoly	Zsuzsa	DWSA	Dai	Jing	DWSA
Bai	Xia	DWSA	Dashkevich	Natalia	DWSA
Bakchoul	Tamam	YIA	Davenport	Ross	YIA
Balandina	Anna	DWSA	De Boer	Johannes	YIA
Banno	Fumiaki	JSTH/APS	De Ceunynck	Karen	YIA
Benslimane-Ahmim	Zahia	YIA	de Groot	Rens	YIA
Bermejo	Emilse	DWSA	de Jong	Paulien	YIA
Bertrand	Gerald	YIA	de Laat	Bas	YIA
Bichan	Volha	DWSA	de Paula	Erich	DWSA
Bjorkqvist	Jenny	YIA	De Wee	Eva	YIA
Blix	Kristine	YIA	Debeij	Jan	YIA
Bloem	Esther	YIA	Dickmann	Boris	YIA
Boncela	Joanna	DWSA	Dimitrov	Jordan	YIA
Borgognone	Alessandra	YIA	Ding	Qiulan	DWSA
Borhany	Munira	JSTH/APS	Djordjevic	Valentina	DWSA
Borissoff	Julian	YIA	Djunic	Irena	DWSA
Boveda Ruiz	Daniel	JSTH/APS	Dong	Jing-fei	YIA
Branchford	Brian	YIA	Dong	Xiaoyuan	JSTH/APS
Branchini	Alessio	YIA	Douma	Renee	YIA
Broos	Katleen	YIA	Dovlatova	Natalia	YIA
Brophy	Teresa	YIA	Dropinski	Jerzy	DWSA
Brzoska	Tomasz	YIA	Drozd	Lizaveta	DWSA
Buitrago	Claudia	YIA	Eckhardt	Corien	YIA
Burnier	Laurent	YIA	Erkens	Petra	YIA
Calderazzo Pereyra	Julio	DWSA	Fang	Yi	JSTH/APS
Canault	Matthias	YIA	Faxalv	Lars	YIA
Caraballo	Deborah	YIA	Feys	Hendrik	YIA
Celinska-Lowenhoff	Magdalena	DWSA	Finn	Jonathan	YIA
Chakarova	Lidija	YIA	Fiore	Mathieu	YIA



## Congress Awards and Grants

Last Name	First Name	Awards	Last Name	First Name	Awards
Fujieda	Yuichiro	YIA	Kager	Liesbeth	YIA
Fujii	Noriko	JSTH/APS	Kamada	Haruhiko	JSTH/APS
Fujita	Junko	JSTH/APS	Kameda	Sachika	JSTH/APS
Furukawa	Shoko	JSTH/APS	Kaplan	Zane	YIA
Gamzatov	Temirlan	DWSA	Kashiwakura	Yuji	JSTH/APS
Gansler	Julia	YIA	Kawao	Naoyuki	YIA
Gebuis	Edward	YIA	Khan	Gausal	DWSA
Geersing	Geert-Jan	YIA	Khawaji	Mohammed	YIA
Gharini	Putrika	DWSA	Kim	Haerin	YIA
Gil Bernabe	Paloma	YIA	Kim	Paul	YIA
Gleeson	Eimear	YIA	Kim	Ji-Yoon	JSTH/APS
Gorbacheva	Lyubov	DWSA	Kita	Toshiyuki	JSTH/APS
Goubau	Christophe	YIA	Kiyomizu	Kazunobu	JSTH/APS
Gouw	Samantha	YIA	Kleinjan	Ankie	YIA
Gribkova	Irina	DWSA	Klok	Frederikus	YIA
Guerrero	Jose	YIA	Kokabee	Leila	DWSA
gupta	shuchi	YIA	Kolyadko	Vladimir	DWSA
Hagedorn	Ina	YIA	Konings	Joke	YIA
Hampshire	Daniel	YIA	Korzsh	Oleksii	DWSA
Han	Yue	DWSA	Kozuma	Yukinori	YIA
Hansen-Krone	Ida	YIA	Laurance	Sandrine	YIA
Hanslik	Andreas	YIA	Lecut	Christelle	YIA
Hayakawa	Masaki	JSTH/APS	Li	Huiyuan	DWSA
HE	YANG	DWSA	Liao	Chien-Chang	JSTH/APS
Hendrickx	Maarten	YIA	Lin	Jiangguo	YIA
Herczenik	Eszter	YIA	Lin	Zhonghui	DWSA
Hess	Katharina	YIA	Liu	Xinguang	YIA
Hofbauer	Christoph	YIA	Lotta	Luca	YIA
Hu	Liang	YIA	Lowenberg	Ester	YIA
Hu	Yu	JSTH/APS	Lu	Bernadine	YIA
Huang	Chien-Ling	YIA	Lu	Yeling	DWSA
Huang	Jiansong	DWSA	Ma	Daoxin	DWSA
Huynh	Khon	JSTH/APS	Maas	Coen	YIA
Hwang	Sung ho	JSTH/APS	Maas	Coen	YIA
Iamsirirak	Pornchanok	JSTH/APS	Malato	Alessandra	YIA
Jadaon	Mehrez	DWSA	Manukyan	Davit	YIA
Ji	Shundong	DWSA	Martinez-Martinez	Irene	YIA
Jiang	Miao	DWSA	Matsuda	Yasuyuki	JSTH/APS
jiang	lin	JSTH/APS	Matsumoto	Tomoko	JSTH/APS
Jin	Joseph	YIA	May	Frauke	YIA
Jones	Sophie	JSTH/APS			





## Congress Awards and Grants

Last Name	First Name	Awards	Last Name	First Name	Awards
McGrath	Rachel	YIA	Pierangeli	Silvia	YIA
Meiring	Muriel	DWSA	Pinto	Patricia	DWSA
Mitsuguro	Mana	JSTH/APS	Pleines	Irina	YIA
Miyake	Yasushi	JSTH/APS	Popov	Viola Maria	DWSA
Mizurini	Daniella	DWSA	Qin	Huanhuan	DWSA
Mo	Xi	DWSA	Queiroz	Karla	YIA
Moheimani	Fatemeh	JSTH/APS	Rattanawan	Chutima	JSTH/APS
Mos	Inge	YIA	Ravanbod	Shirin	DWSA
Mueller	Felicitas	YIA	Reinhardt	Christoph	YIA
Nagasawa	Ayumi	JSTH/APS	Ren	Honggang	DWSA
Nakayama	Daisuke	JSTH/APS	Repesse	Yohann	YIA
Nakazawa	Tsuyoshi	JSTH/APS	Reshetnyak	Tatiana	DWSA
Nantakomol	Duangdao	DWSA	Rezende	Suely	DWSA
Natesirinilkul	Rungrote	JSTH/APS	Ribeiro	Daniel	DWSA
Navarro-Fernandez	Jose	YIA	Riches	Jonathan	YIA
Navin	Pai	JSTH/APS	Romeo	Giuliana	YIA
Nazir	Mohamed	JSTH/APS	Rossetto	Valeria	YIA
Nergiz-Unal	Reyhan	JSTH/APS	Rourke	Claire	YIA
Ni	Ran	YIA	Ruchutrakool	Theera	DWSA
Ni Ainle	Fionnuala	YIA	Rydz	Natalia	YIA
Niewiarowska	Jolanta	DWSA	Sanchez-Luceros	Analia	DWSA
Ninivaggi	Marisa	YIA	Savage	Joshua	YIA
Nishimoto	Tetsuya	YIA	Schattner	Mirta	DWSA
Nowak	Agata	YIA	Schiviz	Alexandra	YIA
Nuchnoi	Pornlada	JSTH/APS	Segbefia	Catherine	DWSA
Ocak	Gurbey	YIA	Seifert	Stefanie	YIA
Ogiwara	Kenichi	JSTH/APS	Sharma	Anup	YIA
Olga	Panes	DWSA	Shi	Wei	DWSA
Oliveira	Andrea	YIA	shi	yan	JSTH/APS
Osborne	Simone	JSTH/APS	Shiltagh	Nuha	YIA
Oschatz	Chris	YIA	Shmeleva	Veronika	DWSA
Otgontaj	Sumiya	DWSA	Siigur	Ene	DWSA
OuYang	Qi	DWSA	Sinauridze	Elena	DWSA
Ovanesov	Mikhail	YIA	Sirotkina	Olga	DWSA
Oymak	Yesim	DWSA	Sluka	Susanna	YIA
Ozelo	Margareth	DWSA	Snoep	Jaapjan	YIA
P	Shenbagapriya	DWSA	Sorvillo	Nicoletta	YIA
Parunov	Leonid	DWSA	Stavik	Benedicte	YIA
Pasha	Sharif	YIA	Stegeman	Bernardine	YIA
Peng	Jun	DWSA	Steinitz	Katharina	YIA
Perez-Andreu	Virginia	YIA	Stevic	Ivan	YIA



## Congress Awards and Grants

Last Name	First Name	Awards	Last Name	First Name	Awards
<i>Strukova</i>	<i>Svetlana</i>	<i>DWSA</i>	<i>Wang</i>	<i>Ying-Jie</i>	<i>YIA</i>
<i>Suzuki</i>	<i>Atsuo</i>	<i>YIA</i>	<i>Wang</i>	<i>Jiong-Wei</i>	<i>YIA</i>
<i>Suzuki</i>	<i>Eriko</i>	<i>YIA</i>	<i>Wang</i>	<i>Xiaowei</i>	<i>YIA</i>
<i>Swieringa</i>	<i>Frauke</i>	<i>YIA</i>	<i>Wang</i>	<i>Yiming</i>	<i>YIA</i>
<i>Swystun</i>	<i>Laura</i>	<i>YIA</i>	<i>Wang</i>	<i>Zhaoyue</i>	<i>DWSA</i>
<i>Takayama</i>	<i>Naoya</i>	<i>YIA</i>	<i>Wang</i>	<i>Hong-mei</i>	<i>JSTH/APS</i>
<i>Talens</i>	<i>Simone</i>	<i>YIA</i>	<i>Winckers</i>	<i>Kristien</i>	<i>YIA</i>
<i>Tamura</i>	<i>Shogo</i>	<i>JSTH/APS</i>	<i>Wohner</i>	<i>Nikolett</i>	<i>DWSA</i>
<i>Tang</i>	<i>Mariann</i>	<i>YIA</i>	<i>Wroblewska</i>	<i>Aleksandra</i>	<i>YIA</i>
<i>Tarandovskiy</i>	<i>Ivan</i>	<i>DWSA</i>	<i>Wu</i>	<i>Chengliang</i>	<i>YIA</i>
<i>Tatsumi</i>	<i>Kohei</i>	<i>YIA</i>	<i>Wu</i>	<i>Jianbo</i>	<i>DWSA</i>
<i>Techavichit</i>	<i>Piti</i>	<i>JSTH/APS</i>	<i>Xia</i>	<i>Yan</i>	<i>JSTH/APS</i>
<i>Teruel</i>	<i>Raul</i>	<i>YIA</i>	<i>Xiang</i>	<i>Yaozu</i>	<i>YIA</i>
<i>Thaler</i>	<i>Johannes</i>	<i>YIA</i>	<i>Xing</i>	<i>Zhifang</i>	<i>DWSA</i>
<i>Thomas</i>	<i>Mark</i>	<i>YIA</i>	<i>Xiong</i>	<i>Shilong</i>	<i>DWSA</i>
<i>Tichelaar</i>	<i>Vladimir</i>	<i>YIA</i>	<i>Yada</i>	<i>Koji</i>	<i>JSTH/APS</i>
<i>Timp</i>	<i>Jasmijn</i>	<i>YIA</i>	<i>Yamaguchi</i>	<i>Yusuke</i>	<i>JSTH/APS</i>
<i>Topalov</i>	<i>Nikolay</i>	<i>DWSA</i>	<i>Yamamoto</i>	<i>Hitomi</i>	<i>JSTH/APS</i>
<i>Traby</i>	<i>Ludwig</i>	<i>YIA</i>	<i>Yang</i>	<i>Aizhen</i>	<i>YIA</i>
<i>Tseng</i>	<i>Wei-Lien</i>	<i>JSTH/APS</i>	<i>Yang</i>	<i>Lei</i>	<i>DWSA</i>
<i>Tucker</i>	<i>Erik</i>	<i>YIA</i>	<i>Yanrong</i>	<i>Lu</i>	<i>DWSA</i>
<i>Tuinenburg</i>	<i>Attie</i>	<i>YIA</i>	<i>Yeh</i>	<i>Calvin</i>	<i>YIA</i>
<i>Uaprasert</i>	<i>Noppacharn</i>	<i>JSTH/APS</i>	<i>Yoshida</i>	<i>Hideo</i>	<i>YIA</i>
<i>Valizadeh</i>	<i>Nasim</i>	<i>JSTH/APS</i>	<i>Yu</i>	<i>Tingting</i>	<i>DWSA</i>
<i>Vallerinteavide Mavelli</i>	<i>Girish</i>	<i>JSTH/APS</i>	<i>Yu</i>	<i>Ziqiang</i>	<i>DWSA</i>
<i>Valls-Seron</i>	<i>Mercedes</i>	<i>YIA</i>	<i>Yu</i>	<i>Yuan-Bin</i>	<i>JSTH/APS</i>
<i>van Bladel</i>	<i>Esther</i>	<i>YIA</i>	<i>Yuki</i>	<i>Matsushima</i>	<i>JSTH/APS</i>
<i>van den Boogaard</i>	<i>Floor</i>	<i>YIA</i>	<i>Zhang</i>	<i>Yan</i>	<i>YIA</i>
<i>van den Hengel</i>	<i>Lisa</i>	<i>YIA</i>	<i>Zhou</i>	<i>Hu</i>	<i>DWSA</i>
<i>van der Pol</i>	<i>Edwin</i>	<i>YIA</i>	<i>Zhou</i>	<i>Jiawei</i>	<i>DWSA</i>
<i>van Geffen</i>	<i>Mark</i>	<i>YIA</i>	<i>Zhou</i>	<i>Junsong</i>	<i>JSTH/APS</i>
<i>van Kruchten</i>	<i>Roger</i>	<i>YIA</i>	<i>Zhu</i>	<i>Mingqing</i>	<i>DWSA</i>
<i>van Loon</i>	<i>Janine</i>	<i>YIA</i>			
<i>van Os</i>	<i>Gwendolyn</i>	<i>YIA</i>			
<i>van Schouwenburg</i>	<i>Inge</i>	<i>YIA</i>			
<i>Vanassche</i>	<i>Thomas</i>	<i>YIA</i>			
<i>Vorobyeva</i>	<i>Natalya</i>	<i>DWSA</i>			
<i>Vu</i>	<i>Trang</i>	<i>YIA</i>			
<i>Wahlmueller</i>	<i>Felix</i>	<i>YIA</i>			
<i>Wajima</i>	<i>Daisuke</i>	<i>JSTH/APS</i>			



# Other Meetings



## Friday, July 22, 2011

<del>Public Relations and Communications Room 160</del>	<del>08:00 – 09:00</del>
<del>ISTH Membership Taskforce Room 160</del>	<del>09:00 – 10:00</del>
<del>ISTH Congress Presidents Committee Room K</del>	<del>10:00 – 11:00</del>
<del>SSC Executive/Nominating Committee Room J</del>	<del>11:00 – 12:00</del>
<del>ISTH Executive Committee Room K</del>	<del>12:00 – 14:00</del>
<del>Ethics Committee Room 159</del>	<del>13:00 – 14:00</del>
<del>ISTH Finance Committee Room J</del>	<del>14:00 – 15:00</del>
<del>ISTH Awards Committee Room 159</del>	<del>14:00 – 15:00</del>
<del>ISTH Education Committee Room K</del>	<del>15:00 – 16:00</del>
<del>ISTH Publications Committee Room J</del>	<del>16:00 – 17:00</del>
<del>JTH Editor Search Committee Room 158</del>	<del>17:00 – 20:00</del>

## Saturday, July 23, 2011

<del>JTH Editor Search Committee – Debriefing Room 158</del>	<del>07:00 – 08:00</del>
<del>Nominating Committee Room 158</del>	<del>08:00 – 09:00</del>
<del>EQATH Room K</del>	<del>08:00 – 09:30</del>
<del>Predictive Variables Special Meeting Room K</del>	<del>14:00 – 17:00</del>
<del>Outreach Forum Dinner Grand Prince Hotel Kyoto, Rose Room</del>	<del>18:00 – 21:00</del>
<del>SSC Members Meeting Grand Prince Hotel Kyoto, Kisen Room</del>	<del>18:30 – 21:30</del>



# Other Meetings



## Sunday, July 24, 2011

<del>EU VWD Meeting</del>	<del>12:00 – 14:00</del>
<del>Room I</del>	
<del>WG on Coagulation Standards</del>	<del>12:30 – 14:30</del>
<del>Room C-2</del>	
RESIST-ITI and SIPPET Investigator Meeting	12:30 – 16:30
Room C-1	
JTH Editorial Board Luncheon	13:00 – 14:00
Room K	
<del>Bleeding Score SSC Standing Committee</del>	<del>15:00 – 16:00</del>
<del>Room K</del>	
ISFP 	15:00 – 17:30
Room J	
WHO-ISTH Joint Standards Liaison Group	15:30 – 17:00
Room 160	

## Monday, July 25, 2011

APSTH Council Board Meeting	12:00 – 13:00
Room I	
Seminars in Thrombosis and Hemostasis	17:15 – 19:15
Room I	


## Tuesday, July 26, 2011

multicenter hemophilia study 	<del>7:30 – 09:00</del>
<del>Room I</del>	
EUHASS meeting	11:45 – 13:15
Room C-2	
<del>GTC Bio Investigator Meeting</del>	<del>12:00 – 13:30</del>
<del>Room K</del>	
Schattauer Editorial Board Meeting	16:30 – 19:00
Room I	
ISTH Council 	18:30 – 23:00
Grand Prince Hotel Kyoto,	
Room Kurama (council reception/dinner)	
Room Hiei (council meeting)	



# Other Meetings

## Wednesday, July 27

 Industry Liaison Meeting Rose Room	7:30 – 9:30
ISTH General Membership Assembly Main Hall	11:00 – 11:15
Haemophilia Board Meeting Room I	12:00 – 14:00
ISFP-General Meeting Room C-1	13:15 – 14:00
SSC Annual Business Meeting Room E	14:30 – 17:00
<del>Individual Subcommittee Chairman Meetings</del> <del>TBA</del>	<del>TBA</del>
<del>Clinical Guidelines Committee</del> <del>TBA</del>	<del>TBA</del>



# ISTH Information

The International Society on Thrombosis & Haemostasis (ISTH) is the leading worldwide organization dedicated to the advancement of the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders.

ISTH is an international professional individual membership organization with over 3,000 members in more than 80 countries around the world. Among its highly regarded activities and initiatives are education and standardization programs, research activities, meetings and conferences, peer-reviewed publications and expert committees.

## **Membership benefits include:**

- A network of over 3,000 members in more than 80 countries
- Priority registration and discounted fees for ISTH meetings and congresses
- Complimentary print (for regular members only) and online subscription to ISTH's *Journal of Thrombosis and Haemostasis*
- Access to the ISTH members-only online resources, including educational materials, e-learning and membership directory
- Exclusive access and/or reduced fees for other educational activities, programs and publications
- The quarterly ISTH Newsletter and regular e-updates
- The right to nominate, elect and serve on ISTH committees

## **ISTH Membership Categories are:**

**Regular:** for active researchers, educators and clinicians in the field

**Associate:** for students, trainees, research staff, post-doctoral fellows as well as allied health professionals

**Reach-the-World:** for researchers, educators and clinicians in non-industrialized countries

For more information or to join the ety, please contact:

**International Society on Thrombosis & Haemostasis (ISTH)**

**Headquarters Office**

610 Jones Ferry Road, Suite 205

Carrboro, NC 27510, USA

Tel: +1 919 929-3807

Fax: +1 919 929-3935

General Inquiries: [headquarters@isth.org](mailto:headquarters@isth.org)

Membership: [membership@isth.org](mailto:membership@isth.org)

Industry opportunities: [margo\\_price@isth.org](mailto:margo_price@isth.org)



or visit us  Booth # 5 in the Exhibition Area  
[www.isth.org](http://www.isth.org)





Visit us! Booth #5,  
Exhibition Area



# join ISTH!

### Benefits of membership in ISTH include:

- An international network of over 3,000 members in more than 80 countries
- Priority registration and discounted fees for ISTH meetings and congresses
- Complimentary print subscription for regular members and online subscription for all membership categories to ISTH's *Journal of Thrombosis and Haemostasis*
- Access to the ISTH members-only online resources, including educational materials, e-learning and membership directory
- Exclusive access and/or reduced fees for other educational activities, programs and publications
- The quarterly ISTH Newsletter and regular e-updates
- The right to nominate, elect and serve on ISTH committees

[www.isth.org](http://www.isth.org)

The International Society on Thrombosis and Haemostasis is the leading worldwide organization dedicated to the advancement of the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders.

ISTH provides a forum for discussion, encourages research and fosters the dissemination and exchange of ideas through scientific meetings and publications, education initiatives, research activities, expert committees and standardization of nomenclature and methods.

No21  Information の直後

58<sup>th</sup>



# Annual Meeting of the Scientific and Standardization Committee of the ISTH



**NEW ENHANCED PROGRAMME**

[www.ssc2012.org](http://www.ssc2012.org)

No22  前



Program Overview 扉

# Program at a Glance (Saturday, July

## Saturday July 23, 2011

9:00 - 13:00

SSC Sessions  
Educational Sessions  
Nursing Forum

14:00 - 18:00

SSC Sessions  
Educational Sessions  
Nursing Forum

## Sunday July 24, 2011

8:00 - 12:00

SSC Sessions  
Educational Sessions  
Nursing Forum

12:30 - 14:30

Special Symposia

15:00 - 17:00

Special Symposia

17:30 - 21:00

Opening Ceremony  
Welcome Reception

## Monday July 25, 2011

8:00 - 9:30

Symposia

8:00 - 9:30

Oral Communications

9:45 - 10:30

Plenary Lecture

10:30 - 11:00 Coffee Break / Booth Visit

11:00 - 12:00

State-of-the-Art

12:15 - 13:15

Lunch / Poster Discussion

13:30 - 15:00

Symposia

13:30 - 15:00

Oral Communications

15:00 - 15:30 Coffee Break / Booth Visit

15:30 - 17:00

Symposia

15:30 - 17:00

Oral Communications

17:15 - 18:00

Plenary Lecture

18:15 - 20:15

Special Symposia



# ly 23, 2011 ~ Thursday, July 28, 2011)

## Tuesday July 26, 2011

8:00 - 9:30  
Symposia

8:00 - 9:30  
Oral  
Communi-  
cations

9:45 - 10:30  
Plenary Lecture

10:30 - 11:00 Coffee Break / Booth Visit

11:00 - 12:00  
State-of-the-Art

12:15 - 13:15  
Lunch / Poster Discussion

13:30 - 15:00  
Symposia

13:30 - 15:00  
Oral  
Communi-  
cations

15:00 - 15:30 Coffee Break / Booth Visit

15:30 - 17:00  
Symposia

15:30 - 17:00  
Oral  
Communi-  
cations

17:15 - 18:00  
Plenary Lecture

18:15 - 19:45  
Satellite  
Symposia

## Wednesday July 27, 2011

8:00 - 9:30  
Symposia

8:00 - 9:30  
Oral  
Communi-  
cations

9:45 - 10:45  
State-of-the-Art

10:45 - 11:15 Coffee Break / Booth Visit

11:15 - 12:45  
Presidential  
Symposium

13:00 - 14:00  
Lunch / Poster Discussion

14:15 - 15:45  
Satellite  
Symposia

16:00 - 17:00  
Technical  
Sessions

18:00 - 20:30  
All Congress  
Party

## Thursday July 28, 2011

8:00 - 9:30  
Symposia

8:00 - 9:30  
Oral  
Communi-  
cations

9:45 - 10:30  
Plenary Lecture

10:30 - 11:00 Coffee Break / Booth Visit

11:00 - 12:00  
State-of-the-Art

12:15 - 13:15  
Lunch / Poster Discussion


13:30 - 14:15  
Plenary Lecture

14:30 - 16:00  
Symposia

14:30 - 16:00  
Oral  
Communi-  
cations

16:15 - 17:45  
Symposia

16:15 - 17:45  
Oral  
Communi-  
cations

Meeting Adjourn 



# Saturday, July 23, 2011

## Room C-2

9:00 - 13:00

Nursing Forum

14:00 - 18:00

Nursing Forum

## Room D

9:00 - 10:00

Predictive Variables  
in Cardiovascular  
Disease

10:00 - 13:00

Predictive  
Variables in  
Cardiovascular  
Disease

14:00 - 15:05

Factor XIII and  
Fibrinogen

15:05 - 18:00

Factor XIII and  
Fibrinogen

## Room E

9:00 - 10:30

Vascular Biology

10:30 - 13:00

Vascular Biology

14:00 - 18:00

Biorheology

## Annex Hall 2

9:00 - 10:05

Platelet  
Immunology

10:05 - 13:00

Platelet  
Immunology

14:05 - 15:45

Animal, Cellular,  
and Molecular  
Models of  
Thrombosis

15:45 - 18:00

Animal, Cellular,  
and Molecular  
Models of  
Thrombosis

\* Coffee will be available from 10:30 to 11:00 and from 15:30 to 16:00, but coffee breaks will not be set.



# Saturday, July 23, 2011

SSC & Educational 

**Sakura**

**Room A**

**Room B-1**

**Room B-2**


9:00 - 10:15

Lupus Anticoagulant/  
Phospholipid-  
Dependent  
Antibodies

9:00 - 10:50

Factor VIII and  
Factor IX

9:00 - 11:15

Women's  
Health Issue in  
Thrombosis and  
Hemostasis 


10:15 - 13:00

Lupus Anticoagulant/  
Phospholipid-  
Dependent  
Antibodies

10:50 - 13:00

Factor VIII and  
Factor IX

11:15 - 13:00

Women's  
Health Issue  
Thrombosis and  
Hemostasis 

14:00 - 16:00

Hemostasis and  
Malignancy

14:00 - 18:00

Factor VIII and  
Factor IX

14:00 - 15:30

Perinatal /  
Pediatric  
Hemostasis

14:00 - 16:00

Plasma  
Coagulation  
Inhibitors

16:00 - 18:00

Hemostasis and  
Malignancy

15:30 - 18:00

Perinatal /  
Pediatric  
Hemostasis

16:00 - 18:00

Plasma  
Coagulation  
Inhibitors

Nursing  
Forum

Educational  
Sessions

SSC  
Sessions



5

# Sunday, July 24, 2011

**Main Hall      Room C-2      Room D      Room E      Annex Hall 1**

8:00 - 12:00  
**Nursing Forum**

8:00 - 9:00  
Fibrinolysis

9:00 - 12:00  
Fibrinolysis

8:00 - 9:30  
FactorXI and the Contact System


9:30 - 12:00  
FactorXI and the Contact System

12:30 - 14:30  
**\*\* Antiplatelet Therapy: Improving the Care of Patients with Acute Coronary Syndromes through Evidence-based Approaches**

15:00 - 17:00  
**\*\* Prophylaxis: Current and Future Trends, Insights and Controversies**

17:30 - 20:30  
**Opening Ceremony  
Welcome  
Reception**

17:30 - 18:30  
**Opening Ceremony Live**




\*\* Made possible by generous support from cooperate partners.  
\* Coffee will be available from 10:30 to 11:00, but coffee breaks will not be set.



# Sunday, July 24, 2011

SSC & Educational

**Annex Hall 2      Sakura      Room A      Room B-1      Room B-2**

8:00 - 9:30 Platelet Physiology	8:00 - 9:10 Disseminated Intravascular Coagulation	8:00 - 9:20 von Willebrand Factor	8:00 - 12:00 Control of Anticoagulation	8:00 - 9:45 Registry of Exogenous Hemostatic Factors
9:30 - 12:00 Platelet Physiology	9:10 - 12:00 Disseminated Intravascular Coagulation	9:20 - 12:00 von Willebrand Factor		9:45 - 12:00 Registry of Exogenous Hemostatic Factors
12:30 - 14:30 **Clinical Evaluation of Coagulation Factors with Prolonged Pharmacokinetic Activity		12:30 - 14:30 ** Future Directions in the Prediction and Prevention of FVIII Inhibitors		
15:00 - 17:00 ** Toward Better Anticoagulation Management: Experience and Evidence with Enoxaparin		15:00 - 17:00 ** Bypass Therapy Prophylaxis for Inhibitor Management in Hemophilia A		
17:30 - 18:30 Opening Ceremony Live 				

**Social Event      Nursing Forum      Educational Sessions      SSC Sessions      Special Symposia**



# Monday, July 25, 2011

## Main Hall

## Annex Hall 1

8:00 - 9:30

Hemorrhagic Disorders:  
Prediction of Inhibitor Development  
in Hemophilia

8:00 - 9:30

Platelet (Basic & Clinical):  
Megakaryocytes and Thrombopoiesis

9:45 - 10:30

Gene therapy for hemophilia: A long and winding road K. A. 

9:45 - 10:30

Plenary Lecture Live 

10:30 - 11:00

COFFEE BREAK at Event Hall 

11:00 - 12:00

Thrombotic Disorders: Epidemiology

11:00 - 12:00

Platelet Biology

12:15 - 13:15

LUNCH / POSTER DISCUSSION at Exhibition Hall

13:30 - 15:00

Platelet (Basic & Clinical):  
Emerging Antiplatelet Drugs

13:30 - 15:00

Innovation & Technology:  
Innovative Imaging

15:00 - 15:30

COFFEE BREAK at Event Hall

15:30 - 17:00

Thrombotic Disorders:  
Pharmacotherapy Update for  
Peripheral Arterial Disease : From  
TASC II to TASC III

15:30 - 17:00

Platelet (Basic & Clinical):  
Congenital Thrombocytopenia

17:15 - 18:00

Biological functions and therapeutic potential of  
vascular endothelial growth factors R. Alitalo 

17:15 - 18:00

Plenary Lecture Live

\*\* Made possible by generous support from cooperate partners.





# Monday, July 25, 2011

## Annex Hall 2

## Room A

Program Overview

8:00 - 9:30

Coagulation Factors and Inhibitors:  
Contact Phase Activation

8:00 - 9:45

Late Breaking Clinical Trials

9:45 - 10:30

Plenary Lecture Live

10:30 - 11:00

COFFEE BREAK at Event Hall

11:00 - 12:00

Plasminogen Activation System

11:00 - 12:00

Coagulation and Inflammation

12:15 - 13:15

LUNCH / POSTER DISCUSSION at Exhibition Hall

Oral Poster  
Exhibition

13:30 - 15:00

VWF/VWD and ADAMTS13: Structure  
and Function of ADAMTS13 and  
von Willebrand Factor

13:30 - 15:00

Malignancy and Thrombosis I

15:00 - 15:30

COFFEE BREAK at Event Hall

15:30 - 17:00

Hemorrhagic Disorders:  
FV/FVIII Synthesis and Regulation

15:30 - 17:00

Malignancy and Thrombosis II

17:15 - 18:00

Plenary Lecture Live

18:15 - 20:15

\*\* Factors for Life –  
Advances in Treatment of Congenital  
and Coagulopathic Bleeding  
Disorders

18:15 - 20:15

\*\* Challenges and Progress in the  
Management of Joint Health in  
Haemophilia Patients

Symposia

Plenary  
Lecture

SOA

Special  
Symposia

Oral  
Communication



9

# Monday, July 25, 2011

## Room B-1

8:00 - 9:30

VTE: Risk Factors I

## Room B-2

8:00 - 9:30

Thrombotic Thrombocytopenic Purpura

## Room C-1

8:00 - 9:30

Platelet Signaling

## Room C-2

8:00 - 9:30

Fibrinolysis

10:30 - 11:00

COFFEE BREAK at Event Hall

12:15 - 13:15

LUNCH / POSTER DISCUSSION at Exhibition Hall

13:30 - 15:00

Thrombotic Disorders: Clinical I

13:30 - 15:00

VTE: Epidemiology

13:30 - 15:00

Inflammatory Cells and Cytokines

13:30 - 15:00

Structures of Coagulation Factors

15:00 - 15:30

COFFEE BREAK at Event Hall

15:30 - 17:00

von Willebrand Disease

15:30 - 17:00

Thrombotic Disorders: Experimental Models

15:30 - 17:00

Platelet Receptors

15:30 - 17:00

Laboratory Tests for Coagulopathy

18:15 - 20:15

\*\* Burdens on Anti-thrombotic Therapy  
~ How Do You Select Anti-platelet Agents? ~



# Monday, July 25, 2011

Program Overview

Room D

Room E

Sakura

Exhibition Hall

Event Hall

8:00 - 9:30

Protein S and GAS6

8:00 - 9:30

Antiplatelet Therapy

8:00 - 9:30

Inherited Coagulation Disorders

9:00 - 10:30

Poster Set-up

10:30 - 11:00

COFFEE BREAK at Event Hall

11:00 - 15:00



12:15 - 13:15

LUNCH / POSTER DISCUSSION at Exhibition Hall

Exhibition

13:30 - 15:00

Pathway of Coagulation Factor VIII

13:30 - 15:00

Megakaryopoiesis and Platelet Production

13:30 - 15:00

Hemophilia: Clinical Aspects

15:00 - 15:30

COFFEE BREAK at Event Hall

15:30 - 17:00

Tissue Factor and Tissue Factor Pathway Inhibitor

15:30 - 17:00

P2Y<sub>12</sub> Antagonists



15:30 - 17:00

Acquired Coagulation Disorders

15:30 - 18:00



Exhibition

17:00 - 18:30

Poster Dismissal



18:15 - 20:15

**\*\*Chronic Anticoagulation in AF: Optimization of Treatment**

18:15 - 20:15

**\*\* Long-term Oral Anticoagulation: Debating the Future**

Oral Communication

Special Symposia



11

# Tuesday, July 26, 2011

## Main Hall

## Annex Hall 1

8:00 - 9:30

Platelet (Basic & Clinical):  
Immune Thrombocytopenia

8:00 - 9:30

VWF/VWD and ADAMTS13:  
Pathogenesis of Thrombotic  
Microangiopathy

9:45 - 10:30

Challenge to novel bioactive peptide  Kangawa


9:45 - 10:30

Plenary Lecture Live

10:30 - 11:00

COFFEE BREAK at Event Hall

11:00 - 12:00

Platelet clinical 

11:00 - 12:00

von Willebrand Factor and  
von Willebrand Disease

12:15 - 13:15

LUNCH / POSTER DISCUSSION at Exhibition Hall

13:30 - 15:00

Thrombotic Disorders:  
Acute Cerebrovascular Syndrome

13:30 - 15:00

APSTH-Genome:  
Genomes in Asian and Caucasian

15:00 - 15:30

COFFEE BREAK at Event Hall


15:30 - 17:00

Thrombotic Disorders:  
Atherothrombosis and  
Antithrombotic Therapy

15:30 - 17:00

Platelet (Basic & Clinical): Platelet  
Proteomics and Gene Expression

17:15 - 18:00

Recent progress in anticoagulant therapy  Oral direct  
inhibitors of thrombin and factor X and A. Bauer

17:15 - 18:00

Plenary Lecture Live

18:15 - 19:45

Join the Revolution:  
Advances in Oral Anticoagulation  
(Boehringer Ingelheim)



# Tuesday, July 26, 2011

## Annex Hall 2

## Room A


Program Overview


8:00 - 9:30  
Vascular Biology: Inflammation and Atherothrombosis

8:00 - 9:30  
Pregnancy and Thrombosis I

9:45 - 10:30  
Plenary Lecture Live

10:30 - 11:00 COFFEE BREAK at Event Hall

11:00 - 12:00  
Vascular biology 

11:00 - 12:00  
Cancer thrombosis 

12:15 - 13:15 LUNCH / POSTER DISCUSSION at Exhibition Hall

Oral Poster Exhibition

13:30 - 15:00  
Platelet (Basic & Clinical): Lysophospholipids in Platelets and Vasculature

13:30 - 15:00  
Anticoagulation Therapy

15:00 - 15:30 COFFEE BREAK at Event Hall

15:30 - 17:00  
Fibrinolysis and Proteolysis: t-PA Mediated Brain Injury

15:30 - 17:00  
Thrombotic Disorders: Clinical Trials I

17:15 - 18:00  
Plenary Lecture Live

18:15 - 19:45  
Progress in Haemophilia Care: New Molecules on the Horizon (Novo Nordisk)

Symposia

Plenary Lecture

SOA

Technical Sessions  
Satellite Symposia

Oral Communication



## Tuesday, July 26, 2011

### Room B-1

8:00 - 9:30

VTE: Basic

### Room B-2

8:00 - 9:30

Hemostatic  
Abnormalities in  
Thrombosis

### Room C-1

8:00 - 9:30

Integrin  $\alpha$ IIb $\beta$ 3

### Room C-2

8:00 - 9:30

Fibrinogen and  
Other Factors I

10:30 - 11:00

COFFEE BREAK at Event Hall

12:15 - 13:15

LUNCH / POSTER DISCUSSION at Exhibition Hall

13:30 - 15:00

Diagnosis and  
Treatment for  
VWD and TTP

13:30 - 15:00

Antiphospholipid  
Syndrome:  
Basic

13:30 - 15:00

Progenitor Cells  
and Stem Cells

13:30 - 15:00

Serine Protease  
Inhibitors I

15:00 - 15:30

COFFEE BREAK at Event Hall

15:30 - 17:00

VTE: Laboratory  
Tests I

15:30 - 17:00

ADAMTS13

15:30 - 17:00

Platelets:  
Experimental  
Models

15:30 - 17:00

Plasminogen  
Activation  
System: Basic

18:15 - 19:45

Atypical Hemolytic Uremic  
Syndrome (aHUS): New Insights  
and Emerging Treatment Options  
(Alexion Pharmaceuticals)

SOA Plenary  
Symposium



# Tuesday, July 26, 2011

Program Overview

Room D

Room E

Sakura

Exhibition Hall

Event Hall

8:00 - 9:30

Regulators of Coagulation

8:00 - 9:30

Heparin-induced Thrombocytopenia

8:00 - 9:30

Hemophilia: Treatment

9:00 - 10:30

Poster Set-up

10:30 - 11:00

COFFEE BREAK at Event Hall

11:00 - 15:00



12:15 - 13:15

LUNCH / POSTER DISCUSSION at Exhibition Hall

Exhibition

13:30 - 15:00

Coagulation Factors: Experimental Models I

13:30 - 15:00

Immune Thrombocytopenia

13:30 - 15:00

Hemophilia: Innovative Therapy I

15:00 - 15:30

COFFEE BREAK at Event Hall

15:30 - 17:00

Tissue Factor and Factor VII

15:30 - 17:00

Endothelial Cells

15:30 - 17:00

Hemophilia: Inhibitor Development

15:30 - 18:00

Exhibition

17:00 - 18:30

Poster Dismantle

18:15 - 19:45

Chronic Anticoagulation in Prevention and Treatment of VTE (Daiichi Sankyo)

18:15 - 19:45

Can We Predict Interventions in Haemostasis and Thrombosis? (Stago)

Oral Communication

Technical Sessions  
Satellite Symposia



15

# Wednesday, July 27, 2011

## Main Hall

## Annex Hall 1

8:00 - 9:30

Thrombotic Disorders:  
Venous Thromboembolism  
Prophylaxis


8:00 - 9:30

Platelet (Basic & Clinical):  
Platelets beyond Hemostasis

9:45 - 10:45

Atherothrombosis

9:45 - 10:45

Platelet activation 

11:00 - 11:15 Isth General Membership Assembly

COFFEE BREAK at Event Hall 10:45 - 11:15

11:15 - 12:45

Historical Perspective and Future  
Direction in Platelet, Coagulation,  
and Fibrinolysis Research

11:15 - 12:45

Presidential Symposium  
Live

13:00 - 14:00

LUNCH / POSTER DISCUSSION at Exhibition Hall

18:00 - 20:30

All Congress Party at the Grand Prince Hotel





# Wednesday, July 27, 2011

## Annex Hall 2

## Room A

Program Overview

8:00 - 9:30

Coagulation Factors and Inhibitors:  
Coagulation Initiation and  
Amplification

8:00 - 9:30

Antiphospholipid Syndrome: Clinical

9:45 - 10:45

Genetics in Thrombosis

9:45 - 10:45

Hemorrhagic and  
Thrombotic Disorders in Women

10:45 - 11:15

COFFEE BREAK at Event Hall

11:15 - 12:45

Presidential Symposium  
Live

Oral Poster  
Exhibition

13:00 - 14:00

LUNCH / POSTER DISCUSSION at Exhibition Hall

18:00 - 20:30

All Congress Party at the Grand Prince Hotel

Symposia

SOA

Presidential  
Symposium

Oral  
Communication



17

# Wednesday, July 27, 2011

## Room B-1

8:00 - 9:30

Microparticles

## Room B-2

8:00 - 9:30

Plasminogen  
Activation  
System: Tissue  
Remodeling

## Room C-1

8:00 - 9:30

Innovation and  
Technology

## Room C-2

8:00 - 9:30

Fibrinogen and  
Other Factors II

10:45 - 11:15

COFFEE BREAK at Event Hall

Presidential  
Symposium

13:00 - 14:00

LUNCH / POSTER DISCUSSION at Exhibition Hall

14:15 - 15:45

Development of New  
Anticoagulant Drugs!  
Are Unmet Needs Met?  
(Loyola University)



16:00 - 17:00

Prevention of Stroke - What Can We  
Learn from the Recent Clinical Trials?  
(Pfizer Japan)

18:00 - 20:30

All Congress Party at the Grand Prince Hotel



# Wednesday, July 27, 2011

Program Overview

Room D

Room E

Sakura

Exhibition Hall

Event Hall

8:00 - 9:30

Coagulation Factors: Experimental Models II

8:00 - 9:30

Atherosclerosis and Atherothrombosis

8:00 - 9:30

Hemophilia: Inhibitor Treatment

9:00 - 10:00

Poster Set-up

9:25 - 14:00

10:45 - 11:15

COFFEE BREAK at Event Hall

Exhibition

13:00 - 14:00

LUNCH / POSTER DISCUSSION at Exhibition Hall

14:15 - 15:45

Challenges in VTE Management in East and West (GlaxoSmithKline)

14:30 - 17:00

SSC Annual Business Meeting

14:15 - 15:45

Managing Haemophilia for Life: Treatment Trends in Haemophilia B (Pfizer)

14:00 - 15:00

Poster Dismantle

16:00 - 17:00

Inhibitors to Factor VIII: Use of a Recombinant Porcine FVIII as a Future Treatment Option (Inspiration Biopharmaceuticals)

18:00 - 20:30

All Congress Party at the Grand Prince Hotel

Oral Communication

Technical Sessions  
Satellite Symposia



# Thursday, July 28, 2011

## Main Hall

## Annex Hall 1

8:00 - 9:30

Thrombotic Disorders: Pathogenesis,  
Diagnosis and Treatment of Septic  
DIC

8:00 - 9:30

Platelet (Basic & Clinical):  
Mechanisms of Platelet Adhesive  
Function

9:45 - 10:30

Molecular Mechanism of Inside - out Integrin Regulation M. H. Ginsberg



9:45 - 10:30

Plenary Lecture Live

10:30 - 11:00

COFFEE BREAK at Event Hall

11:00 - 12:00

Hemophilia

11:00 - 12:00

Platelet and Vascular Wall

12:15 - 13:15

LUNCH / POSTER DISCUSSION at Exhibition Hall

13:30 - 14:15

Serpin structure, function and dysfunction J. A. S. Dington



13:30 - 14:15

Plenary Lecture Live

14:30 - 16:00

VWF/VWD and ADAMTS13: Function  
and Dysfunction of von Willebrand  
Factor

14:30 - 16:00

Hemorrhagic Disorders: Molecular  
Mechanisms of Coagulation  
Disorders

16:15 - 17:45

Coagulation Factors and Inhibitors:  
Protein C System

16:15 - 17:45

Fibrinolysis and Proteolysis:  
Plasminogen Activation and Its  
Modulation



# Thursday, July 28, 2011

## Annex Hall 2

## Room A

Program Overview

8:00 - 9:30  
Coagulation Factors and Inhibitors:  
Structural Biology in Thrombosis

8:00 - 9:30  
Thrombotic Disorders: Clinical Trials II

9:45 - 10:30  
Plenary Lecture Live

10:30 - 11:00 COFFEE BREAK at Event Hall

11:00 - 12:00  
Coagulation Activation

11:00 - 12:00  
Congenital and  
Acquired Thrombotic Disorders

12:15 - 13:15 LUNCH / POSTER DISCUSSION at Exhibition Hall

Oral Poster  
Exhibition

13:30 - 14:15  
Plenary Lecture Live

14:30 - 16:00  
Vascular Biology:  
Angiogenesis and Vasculogenesis

14:30 - 16:00  
Thrombotic Disorders: Clinical II

16:15 - 17:45  
Late Breaking Clinical Research

16:15 - 17:45  
VTE: Risk Factors III

Symposia

Plenary  
Lecture

SOA

Oral  
Communication



# Thursday, July 28, 2011

## Room B-1

8:00 - 9:30

VTE: Laboratory Tests II

## Room B-2

8:00 - 9:30

von Willebrand Factor

## Room C-1

8:00 - 9:30

Inherited Platelet Disorders

## Room C-2

8:00 - 9:30

Serine Protease Inhibitors II

10:30 - 11:00

COFFEE BREAK at Event Hall

12:15 - 13:15

LUNCH / POSTER DISCUSSION at Exhibition Hall

SOA Plenary Symposium

14:30 - 16:00

VTE: Risk Factors II

14:30 - 16:00

Pregnancy and Thrombosis II

14:30 - 16:00

Platelet  aling

14:30 - 16:00

Contact Phase Activation

16:15 - 17:45

Thromboprophylaxis in Children

16:15 - 17:45

Thrombotic Disorders: Genetic Determinations and Epidemiology

16:15 - 17:45

Platelet Granules

16:15 - 17:45

Thrombin Generation Test



# Thursday, July 28, 2011

Program Overview

Room D

Room E

Sakura

Exhibition Hall

Event Hall

8:00 - 9:30

Coagulation Factors I

8:00 - 9:30

Platelets as Drug Targets

8:00 - 9:30

Hemophilia: Pathophysiology

9:00 - 10:30

Poster Set-up

9:30 - 16:00

10:30 - 11:00

COFFEE BREAK at Event Hall

12:15 - 13:15

LUNCH / POSTER DISCUSSION at Exhibition Hall

Exhibition

14:30 - 16:00

Protein C

14:30 - 16:00

Laboratory Tests in Platelet Function

14:30 - 16:00

Hemophilia: Clinical Study

16:15 - 17:45

Coagulation Factors II

16:15 - 17:45

Angiogenesis and Lymphangiogenesis

16:15 - 17:45

Hemophilia: Innovative Therapy II

17:00 - 18:00  
Poster Dismantle

Oral Communication



23

SSC 扉



## 57<sup>th</sup> Annual Meeting of the Scientific and Standardization Committee and Educational Program

The SSC Annual Meeting will be held on Saturday July 23 from 9:00 - 18:00 and on Sunday July 24 from 8:00 - 12:00.

Education Sessions, sponsored jointly by the Congress and the SSC, will be a part of individual SSC scientific subcommittee sessions, and will supplement topics not addressed in the main ISTH program. Speakers will provide attendees with an introduction to, and fundamentals of, a given subject.

### Coffee Breaks

Coffee will be served near the SSC Meeting Rooms. It will be possible to purchase coffee at the main lounge of the ICC Kyoto..

### Name Badges

Name Badges are not required at SSC and Educational Session.

### SSC Speakers Preview Room

SSC and Education Session Speakers are asked to bring their formatted PowerPoint presentations to the Speaker's Preview Room (Room 104) at least two hours before their session. Files from key drives or CD-ROMs can be transferred to the Congress servers at that time. All conference rooms contain state-of-the-art technical equipment.

### Speaker Preview Room Hours:

Friday,	July 22, 2011	15:00 - 18:00
Saturday,	July 23, 2011	07:30 - 19:00
Sunday,	July 24, 2011	07:30 - 19:00

### Scientific and Standardization Committee

See page **XXX** for committee list. ( **No.12-page** )



## Message from the SSC Chairman

Dear Colleagues and Friends,

Welcome to Kyoto to the 57<sup>th</sup> Annual SSC meeting!

As the Chairman of the SSC, it is my honor to invite you to participate in the SSC Subcommittee meetings on Saturday July 23rd and Sunday July 24th. This is important because, although our understanding of the mechanisms of hemostasis and its disorders has reached significant levels, however, new challenges are constantly emerging and new tools and standards are necessary for measuring and calibrate the hemostatic process. The continuous commitment of the SSC and its components is to respond quickly to these challenges, and to render a useful service to the entire scientific community. The main goals of SSC, among the broad spectrum of activities, are to constantly improve our ability to diagnose more precociously and treat more accurately the various disorders of hemostasis, and to this purpose, to prepare simple risk models, to evaluate the reliability and relevance of new laboratory tests, to improve the quality of reagents, to carefully evaluate the new anti-thrombotic and anti-hemorrhagic strategies, to understand the real impact of some rare clinical conditions, to go deeper into pathogenetic mechanisms up to the level of individual genetic mutations.

As started in 2009 in Boston, the scientific programs of the SSC subcommittees will begin with an Educational Session, followed by the update of the ongoing scientific activities and the proposal of new ones. The Educational sessions will give an overview and information on the recent advances in each specific field, and also will better frame the work of the subcommittees. This is of particular value to the younger colleagues that face these topics for the first time.

This year program looks very exciting, and indeed all chairs and co-chairs of SSC made a great work in assembling their part of the program. Therefore, I'm confident that all of you will enjoy the SSC meetings, and that all this will be the perfect introduction to a great XXIII ISTH congress!

With all my best wishes for a successful meeting,



Anna Falanga, M.D.  
Chairman  
Scientific and Standardization Committees of the ISTH

A handwritten signature in black ink that reads "Anna Falanga". The signature is written in a cursive, flowing style.



Saturday, 23 July, 2011

## Factor VIII and IX

Chairperson: *Flora Peyvandi (IT)*

Co-Chairpersons: *C. Alok Srivastava (IN); Jan Astermark (SE); Kathelijn Fischer (NL); Charles Hay (UK); Claude Negrier (FR); Johannes Oldenburg (DE); Midori Shima (JP); Edward Tuddenham (UK); Leonard Valentino (US)*

**Educational Session** 9:00 – 10:50 **Room A**

### Welcome and introduction to the program

*Flora Peyvandi (IT) and Alok Srivastava (IN)* 9:00 – 9:20

### New Era of Treatment in Hemophilia

Chairpersons: *Claude Negrier (FR) and Kathelijn Fischer (NL)*

### New products for treatment of haemophilia- changing options

*Jerry Powell (US)* 9:20 – 9:40

### Evaluation of safety and efficacy of new products (clinical and laboratory problems)

*Elena Santagostino (IT)* 9:40 – 10:00

### FDA and EMEA regulatories: Clinical trials requirements

- **FDA** – *Nisha Jain (US)*
- **EMEA** – *Anneliese Hilger (DE)* 10:00 – 10:30

**General discussion** 10:30 – 10:40

**Break** 10:40 – 10:50

**SSC Session** 10:50 – 13:00 **Room A**

### Rare Bleeding Disorders (RBDs)

Chairpersons: *Flora Peyvandi (IT) and Alok Srivastava (IN)*

### European network on RBDs (EN-RBD): What has been obtained and next steps

*Flora Peyvandi (IT)* 10:50 – 11:05

### Nijmegen thrombin and plasmin generation assay in RBDs

*Mark van Geffen (NL)* 11:05 – 11:15



Saturday, 23 July, 2011

SSC Subcommittee Meeting

**Clinical trials in RBDs:** 11:15 – 11:55

- **Clinical development plan of a double-virus inactivated fibrinogen concentrate in patients with hereditary fibrinogen deficiency – EU and US requirements**  
*Sigurd Knaub, Octapharma (CH)*
- **Congenital FXIII deficiency, clinical and regulatory challenges**  
*Ramin Tehrani, Novonordisk (SE)*
- **Challenges in clinical development of novel coagulation factors**  
*Charmaine Gittleson, CSL Behring (AU)*
- **Ligneous conjunctivitis and plasminogen deficiency: An experience of an orphan drug development for an extremely rare disease**  
*Bruno Fiorentino, Kedrion (IT)*

**General discussion** 11:55 – 12:05

**Project Reports - 1**

*Chairpersons: Edward Tuddenham (UK) and Midori Shima (JP)*

**Report of project on thrombin generation – standardization of the method**

*Claude Negrier (FR)* 12:05 – 12:20

**Report of TEG/ROTEM project – future strategies**

*Meera Chitlur (US)* 12:20 – 12:35

**Report of project on clot wave form analysis: Application to currently available clot detection instruments**

*Midori Shima (JP)* 12:35 – 12:50

**General discussion** 12:50 – 13:00



Saturday, 23 July, 2011

## Lupus Anticoagulant / Phospholipid-Dependent Antibodies

Chairperson: *Thomas L. Ortel (US)*

Co-Chairpersons: *Tatsuya Atsumi (JP); Ph de Groot (NL); Bas de Laat (NL); Vittorio Pengo (IT); Jacob Rand (US); Guido Reber (CH); Armando Tripodi (IT)*

**Educational Session** 9:00 – 10:15 Room Sakura

### Antiphospholipid antibody testing in the real world of the diagnostic pathology laboratory

*Emmanuel Favaloro (AU)* 9:00 – 9:25

### How should we diagnose/classify APS?

*Tatsuya Atsumi (JP)* 9:25 – 9:50

### Catastrophic APS

*Thomas L. Ortel (US)* 9:50 – 10:15

**SSC Session** 10:15 – 13:00 Room Sakura

### Lupus Anticoagulant Testing

#### Compliance with the lupus anticoagulant SSC guidelines.

*Ian Jennings (UK)* 10:15 – 10:35

#### ECAT Data: Compliance with the lupus anticoagulant SSC guidelines.

*Piet Meijer (NL)* 10:35 – 10:55

#### Integrated test systems and the role of mixing studies.

*Katrien Devreese (BE)* 10:55 – 11:15

#### CLSI report on lupus anticoagulant testing.

*Thomas L. Ortel (US)* 11:15 – 11:30

### Anticardiolipin and Anti- $\beta_2$ -glycoprotein I Antibody Standards

#### Anticardiolipin antibody standards.

*Silvia Pierangeli (US)* 11:30 – 11:55

#### Anti- $\beta_2$ -glycoprotein I antibody standards.

*Bas de Laat (NL)* 11:55 – 12:20



Saturday, 23 July, 2011

**Diagnostic Strategies for APS**

**Antiphospholipid score**

*Kotaro Otomo (JP)*

12:20 – 12:45

**Updates**

**Antibodies to domain I of  $\beta_2$ -glycoprotein I**

*Bas de Laat (NL)*

12:45 – 13:00

SSC Subcommittee Meeting



Saturday, 23 July, 2011

## Platelet Immunology

Chairperson: *Andreas Greinacher (DE)*

Co-Chairpersons: *Beng Chong (AU); Yves Gruel (FR); Donald Arnold (CA); Hartmut Kroll (DE); Yoshiaki Tomiyama (JP)*

**Educational Session** 9:00 – 10:05 Annex Hall 2

### Welcome

*A. Greinacher (DE)* 9:00 – 9:05

Chairpersons: *Yoshiaki Tomiyama (JP) and Andreas Greinacher (DE)*

### Animal models for immune thrombocytopenia

*John Semple (CA)* 9:05 – 9:35

### Mechanisms of IVIgG in immune thrombocytopenia lessons learned from in-vitro studies and animal studies

*Alan Lazarus (CA)* 9:35 – 10:05

**SSC Session** 10:05 – 13:00 Annex Hall 2

### Autoimmune and Alloimmune Thrombocytopenia

Chairperson: *Beng Chong (AU)*

### Role of complement in the pathomechanism of ITP

*Ulrich Sachs (DE)* 10:05 – 10:20

### Platelet immunology SSC statement on the antibody testing in trials on immune thrombocytopenia (ITP)

*Andreas Greinacher (DE)* 10:20 – 10:35

### Predictive parameters for the fetal status in anti-HPA-1a managed pregnancies

*Gerard Bertrand, Cecile Kaplan (FR)* 10:35 – 10:50

**Break** 10:50 – 11:00

### Heparin-induced Thrombocytopenia

Chairpersons: *Yves Gruel (FR) and Theodore Warkentin (CA)*

### IL10 gene polymorphisms and the risk of HIT

*Yves Gruel (FR)* 11:00 – 11:15

### Evaluation of the platelet microparticle assay for the diagnosis of HIT

*Francois Mullier (BE)* 11:15 – 11:30



**Saturday, 23 July, 2011**

**SSC Subcommittee Meeting**

**Which "gold standard" for the diagnosis of HIT: A clinical score, an expert opinion or SRA?**

*Brigitte Tardy (FR)*

11:30 – 11:45

**Heterogeneity of the heparin dependent antigen in some atypical patients with clinically characterized HIT, and incidence in immunoassay reactivity**

*Jean Amiral (FR)*

11:40 – 12:00

**Whole blood aggregometry using the Multiplate analyzer for the diagnosis of HIT**

*Marie-Christine Morel-Kopp (AU)*

12:00 – 12:15

**Multiplate and HIT: Opportunities and limits**

*Ismail Elalamy (FR)*

12:15 – 12:30

**Interassay variability of the high heparin step**

*Andreas Greinacher (DE)*

12:30 – 12:40

**Standardization of quality control of functional HIT assays**

*Theodore Warkentin, Jane C. Moore (CA)*

12:40 – 12:55

**Concluding remarks**

*Andreas Greinacher (DE)*

12:55 – 13:00





Saturday, 23 July, 2011

## Predictive Variables in Cardiovascular Disease

Chairperson: James Douketis (CA)

Co-Chairpersons: Gordon Lowe (UK); Karel Moons (NL); Frederick Spencer (CA); Alberto Tosetto (IT); Richard White (US)

**Educational Session** 9:00 – 10:00 Room D

### CV and Thrombotic Disease Around the World

Co-Chairpersons: James Douketis (CA) and Richard White (US)

#### VTE and race/ethnicity: Linked database studies

Richard White (US) 9:00 – 9:15

#### VTE and race/ethnicity: Observational cohort studies

Neil Zakai (US) 9:15 – 9:30

#### CVD in Asians

Shinya Goto (JP) 9:30 – 9:45

#### Panel discussion

9:45 – 10:00

**SSC Session** 10:00 – 13:00 Room D

### Update of SSC-related Activities

#### Predictors of arterial disease

Olivia Wu (UK) 10:00 – 10:15

#### Epidemiology of D-dimer in venous/arterial disease

Mary Cushman (US) 10:15 – 10:30

#### D-dimer to predict stroke risk in atrial fibrillation

John Eikelboom (CA) 10:30 – 10:45

#### Panel discussion

10:45 – 11:00

#### Break

11:00 – 11:20

#### New studies (predicting recurrent VTE) – VISTA

Geert-Jan Geersing (NL) 11:20 – 11:32

#### New studies (predicting recurrent VTE) – REVERSE-2

Marc Rodger (CA) 11:32 – 11:44

#### New studies (predicting recurrent VTE) – MORGAGNI

James Douketis (CA) 11:44 – 11:56



**Saturday, 23 July, 2011**

<b>Panel discussion</b>	11:56 – 12:10
<b>Debate: Thrombophilia testing should be done routinely in patients with idiopathic first VTE: Yes</b> <i>Mary Cushman (US)</i>	12:10 – 12:30
<b>Debate: Thrombophilia testing should be done routinely in patients with idiopathic first VTE: No</b> <i>Richard White (US)</i>	12:30 – 12:50
<b>Rebuttals and adjournment</b>	12:50 – 13:00

SSC Subcommittee Meeting



11

Saturday, 23 July, 2011

## Vascular Biology

Chairperson: *Françoise Dignat George (FR)*

Co-Chairpersons: *Michael Berndt (IE); John Griffin (US); Nigel Key (US); Peter Newman (US); Florence Toti (FR)*

**Educational Session** 9:00 – 10:30 **Room E**

### Microparticles: Generation and Function

#### Cellular mechanisms underlying the formation of circulating microparticles.

*Florence Toti (FR)* 9:00 – 9:25

#### Multifaceted endothelial derived microparticles.

*Françoise Dignat-George (FR)* 9:25 – 9:50

#### Microvesicles in cancer

*Janus Rak (CA)* 9:50 – 10:15

#### Break

10:15 – 10:30

**SSC Session** 10:30 – 13:00 **Room E**

### Determination and Characterization of (Circulating) Microparticles

#### Part A : Standardized Strategies 10:30 – 11:00

- **Results from the multicentric study on standardization of preanalytical variables**  
*Nigel Key (US); On behalf of the ISTH SSC Workshop participating groups*
- **Standardized microparticle enumeration using latest generation of flow cytometers.**  
*R Lacroix (FR)*

#### Part B : Functional Assays 11:00 – 11:30

- **Differential contributions of monocyte- and platelet-derived microparticles towards thrombin generation and fibrin formation and stability**  
*Alisa Wolberg (US)*
- **A novel assay for measuring plasmin generation capacity of microparticles.**  
*Philippe Poncelet (FR)*



Saturday, 23 July, 2011

**Break**

11:30 – 11:45

**Part C : Novel Methodologies**

11:45 – 13:00

- **An update on the ISADE technique**  
*Don Gabriel (US)*
- **Novel methods to detect microparticles**  
*Edwin van der Pol (NL)*
- **Update on nanoparticle tracking analysis.**  
*Chris Gardiner (UK)*
- **Towards the use of microfluidics in combination with atomic force microscopy for the direct detection and quantification of microparticles from blood plasma.**  
*Yuana Yuana (NL)*
- **Detection of platelet- derived microparticles: An alternative strategy for the diagnosis of heparin-induced thrombocytopenia.**  
*François Mullier (BE)*

SSC Subcommittee Meeting



13

Saturday, 23 July, 2011

## Women's Health Issues in Thrombosis and Haemostasis

*Chairperson: Sabine Eichinger (AT)*

*Co-Chairpersons: Benjamin Brenner (IL); Jacqueline Conard (FR); Andra James (US); Takao Kobayashi (JP); Barbara Konkle (US); Peter Kouides (US); Claire McLintock (NZ); Claire Philipp (US)*

Educational Session

9:00 – 11:15

Room B-1

### Welcome and Introduction of Co-Chairpersons

*Sabine Eichinger (AT)*

9:00 – 9:05

*Chairperson: Sabine Eichinger (AT)*

#### **Management of thrombocytopenia during pregnancy**

*Andra James (US)*

#### **Diagnosis of VTE during pregnancy**

*Menno V. Huisman (NL)*

#### **Management of obstetric haemorrhage**

*Claire McLintock (NZ)*

### Educational Activities

10:20 – 10:30

*Chairperson: Sabine Eichinger (AT)*

### Menorrhagia Working Group

10:30 – 11:00

*Chairperson: Claire Philipp (US)*

#### **Standardized bleeding scores**

*Claire Philipp (US)*

#### **US prospective data collection of women with bleeding disorders...prospects for harmonizing data worldwide"**

*Roshni Kulkarni (US)*

#### **Menorrhagia management from the Canadian perspective**

*Rochelle Winikoff (CA)*

#### **Update on prenatal diagnosis of haemophilia**

*Rezan Kadir (UK)*

**Break**

11:00 – 11:15



Saturday, 23 July, 2011

SSC Session

11:15 – 13:00

Room B-1

SSC Subcommittee Meeting

**Symposium in Honour of Margareta Blombäck**

11:15 – 12:15

*Chairperson: Jacqueline Conard (FR)*

**“Something should be done”: A SSC working group on women’s health.**

**Hormonal influences on the coagulation system**

*Jacqueline Conard (FR)*

**An attenuated fibrinolytic profile measured with a global assay haemostasis assay is associated with risk of a first myocardial infarction in the different gender populations**

*Margareta Blombäck (SE)*

**Fibrinogen deficiency in pregnancy**

*Takao Kobayashi (JP)*

**SSC Projects**

12:15 – 12:55

*Chairperson: Sabine Eichinger (AT)*

**Prospective study using VQ scan in pregnant women with a suspected acute pulmonary embolism**

*Menno V. Huisman (NL)*

**CT scan for suspected PE in pregnancy – the PEP study –**

*Menno V. Huisman (NL)*

**Development of a clinical decision rule for suspected PE in pregnant patients**

*Menno V. Huisman (NL)*

**Heparanase procoagulant activity in oral contraceptives users and pregnancy**

*Yona Nadir (IL)*

**Highlow study - optimal dose of LMWH prophylaxis in pregnancy and postpartum period**

*Saskia Middeldorp (NL)*

**Update on Registries**

*Andra James (US)*

**Closing Remarks**

12:55 – 13:00

*Chairperson and Co-Chairpersons*



15

Saturday, 23 July, 2011

## Animal, Cellular, and Molecular Models of Thrombosis

*Chairperson: Timothy Charles Nichols (US)*

*Co-Chairpersons: Edward M. Conway (CA); Shaun R. Coughlin (US); Jay L. Degen (US); Cecile Denis (FR); Nigel Mackman (US); Toshiyuki Miyata (JP); Eva-Maria Muchitsch (AT); Susan S. Smyth (US); Hugo ten Cate (NL); Hartmut Weiler (US)*

*Participants: Tom Knudsen, Fumiaki Banno, Jianglin Fan, David Motto*

**Educational Session**

**14:05 – 15:45**

**Annex Hall 2**

*Chairpersons: Cecile Denis (FR) and Timothy C. Nichols (US)*

### **Rapid in vivo evaluation of haemostatic agents using hydrodynamic injection**

*Cecil Denis (FR)*

14:05 – 14:30

### **Models of vascular inflammation**

*Susan Smyth (US)*

14:30 – 14:55

### **Scanning electron microscopy studies of endothelial injury and thrombus formation in mouse models of thrombosis**

*David Motto (US)*

14:55 – 15:15

### **Break**

15:15 – 15:45

**SSC Session**

**15:45 – 18:00**

**Annex Hall 2**

### **Focused Talks**

*Chairpersons: Hartmut Weiler and Timothy C. Nichols (US)*

### **Characterization of canine coagulation factor VII and its complex formation with tissue factor: Canine–human cross-species compatibility**

*Tom Knudsen (DK)*

15:45 – 16:00

### **Mouse models of FVIII immunogenicity**

*David Lillicrap (CA)*

16:00 – 16:15

### **Measurement of a procoagulant state in mice**

*Nigel Mackman (US)*

16:15 – 16:30

### **Thrombin and atherosclerosis: Effects on plaque morphology**

*Hugo ten Cate (NL)*

16:30 – 16:45



Saturday, 23 July, 2011

**Genetic mouse models for evaluating pathophysiological roles of ADAMTS13**

*Fumiaki Banno (JP)*

16:45 – 17:00

**Development of a mouse model of TTP for preclinical efficacy testing of rADAMT S13**

*Eva-Maria Muchitsch (AT)*

17:00 – 17:15

**Transgenic rabbit models for the study of atherosclerosis**

*Jianglin Fang (JP)*

17:15 – 17:30

**In vivo function of human aPC in mouse models of thrombosis and inflammation**

*Hartmut Weiler (US)*

17:30 – 17:45

**Animal models committee business meeting**

*Timothy C. Nichols (US)*

17:45 – 18:00

SSC Subcommittee Meeting



17



Saturday, 23 July, 2011

## Biorheology

Chairperson: *Michael R. King (US)*

Co-Chairpersons: *Lawrence Brass (US); Thomas Diacovo (US); Johan Heemskerk (NL); Shaun Jackson (AU); Armin Reininger (DE); J. Zwaginga (NL)*

SSC Session

14:00 – 18:00

Room E

### Welcome and Opening Comments

*Michael King (US)*

14:00 – 14:10

### In Vitro Thrombosis Assays and Standardization

Chairpersons: *T. Diacovo and M. King (US)*

#### Standardization of the use of flow devices to measure thrombus formation

*Judith Cosemans (NL)*

14:10 – 14:30

#### Clinical evaluation of microfluidic flow assays

*Keith Neeves (US)*

14:30 – 14:50

#### Development of an in vitro model of occlusive thrombus formation

*Owen McCarty (US)*

14:50 – 15:10

#### Perfusion chamber with static mixer: New possibilities to study the interplay between platelets and coagulation under conditions of flow

*Attie Tuinenburg (NL)*

15:10 – 15:30

#### Questionnaires and literature review on mouse models and genes in arterial thrombus formation in vivo and in vitro

*Johan Heemskerk (NL) and Peter Lenting (FR)*

15:30 – 15:50

#### Break

15:50 – 16:00

### In Vivo Thrombosis Models

Chairpersons: *K. Neeves (US) and J. Heemskerk (NL)*

#### New approaches to investigate biomechanical platelet activation

*Shaun Jackson (AU)*

16:00 – 16:20

#### Using intravital confocal fluorescence microscopy to probe the microheterogeneity and permeability of the platelet response to laser and mechanical injury

*Lawrence Brass (US)*

16:20 – 16:40



**Saturday, 23 July, 2011**

**The utility of a humanized mouse system for multiscale analysis of thrombus growth, platelet convection, and drug efficacy**

*Tom Diacovo (US) and Michael King (US)*

16:40 – 17:00

**Disturbed blood flow induces plaque erosion and thrombus formation**

*Atsushi Yamashita (JP)*

17:00 – 17:20

**In vivo imaging of cerebral circulation in mouse models of polycythemia vera and essential thrombocythemia**

*William Olbricht (US)*

17:20 – 18:00

SSC Subcommittee Meeting



19

Saturday, 23 July, 2011

## Factor VIII and IX

Chairperson: *Flora Peyvandi (IT)*

Co-Chairpersons: *C. Alok Srivastava (IN); Jan Astermark (SE); Kathelijn Fischer (NL); Charles Hay (UK); Claude Negrier (FR); Johannes Oldenburg (DE); Midori Shima (JP); Edward Tuddenham (UK); Leonard Valentino (US)*

**SSC Session**

**14:00 – 18:00**

**Room A**

### Clinical Issues (Inhibitors, Prophylaxis, Novel Therapies)

Chairpersons: *Kathelijn Fischer (NL) and Charles Hay (UK)*

#### Considerations for optimal clinical trial design for new clotting factor concentrates

*Donna DiMichele (US)* 14:00 – 14:15

#### ITI study: Results

*Donna DiMichele (US) or Charles Hay (UK)* 14:15 – 14:30

#### Prophylaxis in patients with inhibitor

*Manuel Carcao (CA) or Claude Negrier (FR)* 14:30 – 14:45

#### On going clinical studies on inhibitor development:

– **SIPPET**

*Pier Mannuccio Mannucci (IT)*

– **RODIN (intensity of treatment and prophylaxis)**

*Marijke van den Berg (NL)*

14:45 – 15:05

#### European haemophilia safety surveillance system (EUHASS): Update

*Mike Makris (UK)* 15:05 – 15:20

#### General discussion

15:20 – 15:30

#### Break

15:30 – 15:40

### Project Reports - 2

Chairpersons: *Flora Peyvandi (IT) and Alok Srivastava (IN)*

#### Report of project on RBDs – Update

*Paula Bolton-Maggs (UK)* 15:40 – 15:55

#### Report of project on definitions in hemophilia

*Victor Blanchette (CA) and Alok Srivastava (IN)* 15:55 – 16:10

#### Report of project on potency labelling of clotting factor concentrates

*Anthony Hubbard (UK)* 16:10 – 16:25



**Saturday, 23 July, 2011**

**Report of project on PK of FVIII/FIX**

*Sven Bjorkman (SE)*

16:25 – 16:40

**General discussion**

16:40 – 16:50

**Standardization Issues**

*Chairpersons: Leonard Valentino (US) and Johannes Oldenburg (DE)*

**Monitoring recombinant FVIII concentrates and role of ReFacto AF laboratory standard**

*Steven Kitchen (UK)*

16:50 – 17:05

**Standardization of low TF and TF+tPA assays for TEG/ROTEM**

*Benny Sorensen (UK)*

17:05 – 17:20

**New approaches in FVIII inhibitor measurement and standardization**

*Sanj Raut (UK)*

17:20 – 17:35

**Standardisation of assays for rare bleeding disorders: Data from UK NEQAS**

*Steven Kitchen (UK)*

17:35 – 17:50

**General discussion**

17:50 – 18:00

SSC Subcommittee Meeting



21

Saturday, 23 July, 2011

## Factor XIII and Fibrinogen

Chairperson: Hans P. Kohler (CH)

Co-Chairpersons: Moniek P. M. de Maat (NL); Aida Inbal (IL); Muriel Maurer (US); Leonid Medved (US); Marguerite Neerman-Arbez (CH); John W Weisel (US); Sanj Raut (UK)

**Educational Session** **14:00 – 15:05** **Room D**

### Welcome and introduction to the program

Hans P. Kohler (CH) 14:00 – 14:05

Chairperson: Hans P. Kohler (CH)

### Effects of common genetic variation in fibrinogen genes

Moniek P.M. de Maat (NL) 14:05 – 14:35

### Congenital and acquired FXIII deficiency

Hans P. Kohler (CH) 14:35 – 15:05

**SSC Session** **15:05 – 18:00** **Room D**

### International collaborative study for the value assignment of the 3rd International Standard for fibrinogen, plasma

Sanj Raut (UK) 15:05 – 15:15

### International collaborative study for the value assignment of the 2nd International Standard for fibrinogen, concentrate

Sanj Raut (UK) 15:15 – 15:25

### Novel aspects of fibrinogen gamma prime

Shirley Uitte de Willige (NL) 15:25 – 15:40

### Origin of the nonadhesive properties of fibrinogen matrices: Implications for hemostasis and biomaterial science

Tatiana Ugarova (US) 15:40 – 16:00

### Characterizing the kinetics of activation of zymogen FXIII: The role of fibrinogen and thrombin exosite I

Barbara Cardinali, Brian A. Holliday, Susan T. Lord (US) 16:00 – 16:15

### Break

16:15 – 16:30

### Recombinant factor XIII. Safe and novel treatment for congenital factor XIII deficiency

Aida Inbal (IL) 16:30 – 16:45



**Saturday, 23 July, 2011**

**Characterization and quantitation of rFXIII (N13)**

*Lene Hørlyck (DK)*

16:45 – 17:00

**Proposal for measurement of FXIII B-subunit (free and total) in the WHO 1st International Standard (02/206)**

*Hans P. Kohler (CH) & Sanj Raut (UK)*

17:00 – 17:20

**International collaborative study to calibrate the ISTD/SSC secondary coagulation plasma standard lot 4: Value assignment for analyte FXIII**

*Sanj Raut (UK)*

17:20 – 17:30

**Interaction of factor XIII subunits in plasma and other body fluids**

*Muszbek L., Katona É., Bagoly Z., Péntzes K., Orosz Z.Z., Csapó A. (HU)*

17:30 – 17:45

**Update of the nation-wide campaign/study on acquired hemophilia XIII (13) and proposal for international collaboration**

*Akitada Ichinose (JP)*

17:45 – 18:00

SSC Subcommittee Meeting



23

Saturday, 23 July, 2011

## Haemostasis and Malignancy

Chairperson: Agnes Y. Y. Lee (CA)

Co-Chairpersons: Giancarlo Agnelli (IT); Marc Carrier (CA); Dominique Farge (FR); Alok Khorana (US); Marina Marchetti (IT); Wolfram Ruf (US); Jeffrey Zwicker (US)

**Educational Session** 14:00 – 16:00 Room Sakura

Chairpersons: Wolfram Ruf (US) and Agnes Lee (CA)

### Mechanism of coagulation in tumour progression and metastasis

Janus Rak (CA) 14:00 – 14:30

### Role of tissue factor and biomarkers: is it ready for prime time?

Jeff Zwicker (US) 14:30 – 15:00

### Targeted thromboprophylaxis using clinical prediction models

Alok Khorana (US) 15:00 – 15:30

### Break

15:30 – 16:00

**SSC Session** 16:00 – 18:00 Room Sakura

### Subcommittee Activity Updates

Chairpersons: Wolfram Ruf and Alok Khorana (US)

### Tissue factor assay standardization

Marina Marchetti (IT) 16:00 – 16:15

### Incidental VTE: Definition, prognosis, treatment

Casey O'Connell (US) 16:15 – 16:30

### Role of D-dimer in prognosis and diagnosis

Cihan Ay (AT) 16:30 – 16:45

### Standardizing VTE outcomes in oncology trials

Marc Carrier (CA) 16:45 – 17:00

### Ongoing Studies and New Proposals

Chairpersons: Giancarlo Agnelli and Dominique Farge

### Tissue factor as a therapeutic target for cancer

Alok Khorana (US) 17:00 – 17:15

### International working group on guidelines for VTE management in cancer: Progress report

Dominique Farge (FR) 17:15 – 17:30



**Saturday, 23 July, 2011**

**New oral anticoagulants: Celebration and cautions**

*Giancarlo Agnelli (IT)*

17:30 – 17:45

**Updates on CATCH, TILT, SAVEONC, SOME, and others**

*Agnes Lee (CA)*

17:45 – 18:00

**SSC Subcommittee Meeting**





Saturday, 23 July, 2011

## Perinatal / Paediatric Haemostasis

Chairperson: Paul Monagle (AU)

Co-Chairpersons: Anthony Chan (CA); Janna Journeycake (US); Christoph Male (AT); Ulrike Nowak Gottl (DE); Paolo Simioni (IT); Guy Young (US)

**Educational Session 14:00 – 15:30 Room B-1**

### Welcome and Introduction

Paul Monagle 14:00 – 14:05

Chairperson: Guy Young (US)

### Intracerebral bleeding in neonates, current concepts of causes, management and prognosis

Elizabeth Chalmers (UK) 14:05 – 14:30

### Haemostatic replacement therapy in non haemophiliac children

Tom Abshire (US) 14:30 – 14:55

### DIC in children. Common precipitants, presentations, management and outcome

Christoph Male (AT) 14:55 – 15:20

### Break

15:20 – 15:30

**SSC Session 15:30 – 18:00 Room B-1**

Chairpersons: Anthony Chan (CA) and Christoph Male (AT)

### PTS as an outcome measure of paediatric thrombosis therapy: Can we develop standardised criteria

Neil Goldenberg (US) 15:30 – 15:55

### Quality of life as outcome measure for anticoagulant trials in children: Developing a standardised tool

Aisha Bruce (CA) 15:55 – 16:20

### Laboratory monitoring of anticoagulants in children: Developing a uniform approach

16:20 – 16:45

#### a) Heparin monitoring

Fiona Newall (AU)

#### b) Cardiac surgery and heparin monitoring in neonates

Simon Davidson (UK)



**Saturday, 23 July, 2011**

**Diagnostic criteria for thrombosis in children: Which Radiological techniques are validated?** 16:45 – 17:10

**a) diagnosis of venous thrombosis**

*Leo Brandau (CA)*

**b) diagnosis of intracardiac thrombosis and pulmonary embolism**

*Leo Brandau (CA)*

**Developmental haemostasis: Recommendations for laboratories reporting paediatric samples**

*Paul Monagle (CA)* 17:10 – 17:30

**Role of thrombophilia testing in children: Development of standard indications for testing, and assay methodologies**

*Ulrike Nowak Gottl (DE)* 17:30 – 17:50

**Conclusion and planning for next years work**

*Paul Monagle (CA)* 17:50 – 18:00

SSC Subcommittee Meeting



27

Saturday, 23 July, 2011

## Plasma Coagulation Inhibitors

*Chairperson: Steve Kitchen (UK)*

*Co-Chairpersons: Elisabetta Castoldi (NL); Elaine Gray (UK); Tilman Hackeng (NL); Richard Marlar (US); Piet Meijer (NL); Laurent Mosnier (US)*

**Educational Session** 14:00 – 16:00 Room B-2

*Chairpersons: Steve Kitchen and Elaine Gray (UK)*

**Welcome and introduction** 14:00 – 14:05

**Thrombophilia: Who should be tested?**  
*Trevor Baglin (UK)* 14:05 – 14:35

**APC resistance : Biological basis and acquired influences**  
*Elisabetta Castoldi (NL)* 14:35 – 15:05

**Problems with laboratory assays for PC, PS and AT**  
*Richard Marlar (US)* 15:05 – 15:35

**Break** 15:35 – 16:00

**SSC Session** 16:00 – 18:00 Room B-2

**Standardisation of Protein S Assays**  
*Chairpersons: Richard Marlar (US) and Piet Meijer (NL)*

**Instability of protein S in blood samples**  
*Kieron Hickey (UK)* 16:00 – 16:25

**Calibration of SSC plasma standard lot 4 for PC, PS and AT**  
*Elaine Gray (UK)* 16:25 – 16:45

**Protein S assays: Need for standardisation**  
*Ian Jennings (UK)* 16:45 – 17:05

**Biological variation for antithrombin, protein C and protein S: Their relation to analytical quality**  
*Piet Meijer (NL)* 17:05 – 17:25

**Mutation Databases**  
*Chairpersons: Tilman Hackeng and Elisabetta Castoldi (NL)*

**Mutation databases for PC, PS and AT**  
*Carolina Pintao (NL)* 17:25 – 18:00



Sunday, 24 July 2011

## Control of Anticoagulation

Chairperson: Trevor Patrick Baglin (UK)

Co-Chairpersons: Walter Ageno (IT); Job Harenberg (DE); Clive Kearon (CA);  
John Olson (US); Gualtiero Palareti (IT); Sam Schulman (CA)

SSC Session

8:00 – 12:00

Room B-1

SSC Subcommittee Meeting

### Update of SSC activities

*Trevor Baglin (UK)* 08:00 – 08:05

### SSC registry report: Splanchnic vein thrombosis

*Walter Ageno (IT)* 08:05 – 08:15

### Quality of anticoagulation control during VKA therapy: Effects on risk of bleeding and treatment failure

*Gualtiero Palareti (IT)* 08:15 – 08:35

### Interpretation and management of INR results from patients taking VKA antagonists, a study among clinicians from 14 countries

*Ann-Helen Kristoffersen (NO)* 08:35 – 08:55

### How should INR calibrants be used?

*John Olson (US); Steve Kitchen (UK); Armando Tripodi (IT)* 08:55 – 09:35

### Update on novel non-oral anticoagulants - Including idraparinux, idrabiotoparin

*Harry Buller (NL)* 09:35 – 10:00

### SSC project report: Determination of anticoagulant effects of rivaroxaban: Towards a recommendation for assays

*Job Harenberg (DE)* 10:00 – 10:15

### SSC project report: Determination of anticoagulant effects of dabigatran: Towards a recommendation for assays

*Elaine Gray (UK)* 10:15 – 10:30

### Effects of the oral, direct thrombin inhibitor dabigatran on commonly used coagulation assays

*Tomas Lindahl (SE)* 10:30 – 10:45

### Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays

*Andreas Hillarp (SE)* 10:45 – 11:00



29

Sunday, 24 July 2011

**Systematic review of perioperative heparin bridging therapy:  
Implications of harmonization of outcome definitions and bivariate  
endpoints**

*Alex Spyropoulos (CA)*

11:00 – 11:15

**An outline for an SSC recommendation on new oral anticoagulants**

**Open discussion**

11:15 – 12:00

**Issues for Inclusion:**

- **Which patients should be treated with the new anticoagulants first?**
- **What to do in case of bleeding?**
- **How to try to assess/improve compliance.**
- **Follow up during treatment - when and by whom?**
- **Instructions and documents to be given to patients.**
- **Pharmacokinetics/dynamics / implications for bridging**
- **Influence of renal function and practical considerations**
- **Information (efficacy/safety) to be collected during treatment (for phase IV studies)**
- **Recommendations for the national regulatory agencies regarding the introduction of the NOAC in clinical practice and observational phase IV studies -**
- **Interactions with drugs/diet**
- **Different doses for different patients**
- **Side-effects**



Sunday, 24 July 2011

## Disseminated Intravascular Coagulation

Chairperson: Hideo Wada (JP)

Co-Chairpersons: Satoshi Gando (JP); Hyun Kyung Kim (KR); Jorn Nielsen (DK); Jecko Thachil (UK); Cheng-Hock Toh (UK)

Educational Session

8:00 – 9:10

Room Sakura

### Disseminated intravascular coagulation due to anthrax : A pre-clinical in vivo study

Shinichiro Kurosawa (JP)

### Pathogenesis of septic DIC

Marcel Levi (NL)

8:00 – 9:10

SSC Session

9:10 – 12:00

Room Sakura

### DIC due to Sepsis or Trauma Part I

Chairperson's report

Hideo Wada (JP)

### Mimics of DIC in the intensive care unit

Jecko Thachil (UK)

### DIC due to trauma

Satoshi Gando (JP)

9:10 – 9:55

### Break

9:55 – 10:20

### DIC due to Sepsis or Trauma Part II

#### AT

Toshiaki Iba (JP)

### Therapeutic effects of recombinant thrombomodulin in DIC patient with hematologic malignancy

Shousaku Nomura (JP)

10:20 – 11:00

### Diagnosis of DIC, TF

#### Microparticle assays in human endotoxemia

Nigel Key (US)

#### Controversies in DIC scoring

Jorn Nielsen (DK)



Sunday, 24 July 2011

**Involvement of tissue factor and annexin II in pathoclinical profiles of acute promyelocytic leukemia**

*Zhaoyue Wang (CN)*

11:00 – 12:00



Sunday, 24 July 2011

## Factor XI and the Contact System

Chairperson: Thomas Renne (SE)

Co-Chairpersons: David Gailani (US); Keith McCrae (US)

Educational Session 8:00 – 9:30 Room E

### Putting the Contact into Contact Activation

#### Historical overview

Hidehiko Saito (JP) 8:00 – 8:25

#### Roles and functions of polyphosphates

James H. Morrissey (US) 8:25 – 8:50

#### Roles of polysaccharides as contact activators

Thomas Renné (SE) 8:50 – 9:15

#### Break

9:15 – 9:30

SSC Session 9:30 – 12:00 Room E

#### Targeting factor XI

Joost Meijers (NL) 9:30 – 9:50

#### Role of factor XI in septic disease

Erik Tucker (US) 9:50 – 10:10

#### Factor XII in angiogenesis and inflammation

Alvin Schmaier (US) 10:10 – 10:30

#### Effect of factor XII on fibrin structure

José Govers (NL) 10:30 – 10:50

#### Break

10:50 – 11:15

#### Characterization of factor XI-blood cell interactions

Owen McCarty (US) 11:15 – 11:20

#### The role of factor XI in bleeding and thrombotic disorders in humans

Uri Seligsohn (IL) 11:20 – 11:40

#### Factor XII in angiogenesis and inflammation

Alvin Schmaier (US) 11:40 – 12:00

SSC Subcommittee Meeting



33



Sunday, 24 July 2011

## Fibrinolysis

Chairperson: *Ann Gils (BE)*

Co-Chairpersons: *Jonathan Foley (US); Dirk Hendriks (BE); Colin Longstaff (UK); Osamu Matsuo (JP); Nicola Mutch (UK); Michael Nesheim (CA); Craig Thelwell (UK); Tetsumei Urano (JP)*

**Educational Session** 8:00 – 9:00 **Room D**

### **PAI-1: Clinical significance and therapeutic opportunities**

*Ann Gils (BE)* 8:00 – 8:20

### **Is TAFI a target?**

*John Morser (US)* 8:20 – 8:40

### **$\alpha$ 2-antiplasmin: Clinical significance and therapeutic opportunities**

*Yosuke Kanno (JP)* 8:40 – 9:00

**SSC Session** 9:00 – 12:00 **Room D**

### **EQA for point of care D-Dimer measurement**

*Ian Jennings (UK)* 9:00 – 9:15

### **Update on WHO Internationals Standards: Urokinase, PAI-1 and D-dimer**

*Colin Longstaff (UK)* 9:15 – 9:30

### **PAI-1 deficiency-Euglobin clot lysis assay**

*Tetsu Urano (JP)* 9:30 – 9:45

### **Break**

9:45 – 10:00

### **Microplasmin degrades fibrinogen like plasmin but fibrin degradation is impaired**

*Paul Kim (CA)* 10:00 – 10:15

### **The kinetics of TAFIa-catalyzed cleavage of C-terminal lysine residues from fibrin degradation products and removal of plasminogen binding sites**

*Jonathan Foley (CA)* 10:15 – 10:30

### **In vitro evaluation of profibrinolytic properties of TAFI and PAI-1 inhibitors**

*Tine Wyseure, Ann Gils, Paul Declerck (BE)* 10:30 – 10:45



Sunday, 24 July 2011

**The role of TAFI in the regulation of growth and apoptosis in the hepatocyte**

*Taiichiro Seki (JP)*

10:54 – 11:00

**Fibrinolysis in whole blood model thrombi formed under flow**

*Nuala Booth (UK)*

11:00 – 11:15

**In vivo evaluation of TAFI inhibitors**

*Ellen Vercauteren, Paul Declerck, Ann Gils (BE)*

11:15 – 11:30

**Alternative pathway for fibrinolysis: Clinical significance and therapeutic opportunities, leukocyte elastase**

*Seiji Madoiwa (JP)*

11:30 – 11:45

**Proteolytic and genetic variation of the alpha-2-antiplasmin C-terminus in myocardial infarction**

*Shirley Uitte de Willige (NL), Megan Miedzak, Angela M. Carter (UK), Ton Lisman (NL), Frits R. Rosendaal (NL), Peter J. Grant (UK), Helen Philippou, Robert A.S. Ariëns (UK)*

11:45 – 12:00

SSC Subcommittee Meeting



35

Sunday, 24 July 2011

## Platelet Physiology

Chairperson: Marco Cattaneo (IT)

Co-Chairpersons: Christian Gachet (FR); Paolo Gresele (IT); Paul Harrison (UK); Catherine Hayward (CA); Dermot Kenny (IE); Diego Mezzano (CL); Andrew David Mumford (UK); Diane Nugent (US); Alan T. Nurden (FR)

**Educational Session** 8:00 – 9:30 Annex Hall 2

### Physiology and pharmacology of platelet activation by ADP

*Christian Gachet (FR)* 8:00 – 8:30

### Platelets, von Willebrand factor and deep vein thrombosis

*Denisa Wagner (US)* 8:30 – 9:00

### Genetic determinants of platelet function

*Paul Bray (US)* 9:00 – 9:30

**SSC Session** 9:30 – 12:00 Annex Hall 2

### Update on the project: Guidelines for the diagnosis of platelet function disorders

*Paolo Gresele (IT)* 9:30 – 10:00

### Break

10:00 – 10:30

### Could platelet function testing be of use to the internist?

*Dermot Kenny (IE)* 10:30 – 10:55

### How to measure platelet secretion in patients with platelet function disorders

*Diego Mezzano (CL) and Cathy Hayward (CA)* 10:55 – 11:35

### 96 well plate LTA assay

*Tim Warner (UK)* 11:35 – 12:00



Sunday, 24 July 2011

## Registry of Exogenous Hemostatic Factors

Chairperson: Mary Ann McLane (US)

Co-Chairperson: Kenneth Clemetson (CH); Manjunatha Kini (SG); Francis Markland Jr (US); Takashi Morita (JP); Jan Rosing (NL)

**Educational Session** 8:00 – 9:45 Room B-2

### Sialomics and functional characterization of novel proteins

Ivo Francischetti (US) 8:00 – 8:25

### Snaclecs and platelet receptor signaling

Kenneth J. Clemetson (CH) 8:25 – 8:50

### Design of potent, tunable thrombin inhibitors

R. Manjunatha Kini (SG) 8:50 – 9:15

### Break

9:15 – 9:45

**SSC Session** 9:45 – 12:00 Room B-2

**Welcome** 9:45 – 9:50

**Introduction of new members** 9:50 – 9:55

**Minutes of the last meeting** 9:55 – 10:05

**Publications of subcommittee** 10:05 – 10:20

**Annual report** 10:20 – 10:30

**New inventories/activities** 10:30 – 10:40

**Any other business (Review on exogenous factors)** 10:40 – 11:10

**A. Novel exogenous factors**

**B. Next international meeting on exogenous factors to be held in Amsterdam 2013**

**Next meeting** 11:10 – 12:00

SSC Subcommittee Meeting



37

Sunday, 24 July 2011

## von Willebrand Factor

Chairperson: Jeroen Eikenboom (NL)

Co-Chairpersons: Thomas Abshire (US); Imre Bodo (HU); Jorge DiPaola (US); Emmanuel J. Favaloro (AU); Yoshihiro Fujimura (JP); Paula D. James (CA); Bernhard Lämmle (CH); Reinhard Schneppenheim (DE)

**Educational Session** 8:00 – 9:20 Room A

Chairperson: Jeroen Eikenboom (NL)

### The clinical and laboratory diagnosis of VWD

Tom Abshire (US) 8:00 – 8:25

### Replacement therapy in von Willebrand disease: What is the choice?

Jenny Goudemand (FR) 8:25 – 8:50

### VWF: Glycosylation and function

Mike Laffan (UK) 8:50 – 9:20

**SSC Session** 9:20 – 12:00 Room A

### Bleeding Scores and Bleeding Assessment Tool

Chairperson: Paula James (CA)

### Update on activities of bleeding score working group

TBA 9:20 – 9:35

### Online bleeding assessment tool

Barry Coller (US) 9:35 – 9:50

### Standardization of Assays

Chairperson: Bernhard Lämmle (CH)

### Working party on standardization of VWFpp assays

Tony Hubbard (UK) 9:50 – 9:57

### Variation in ADAMTS13 activity assays and the need for standardization

Ian Mackie (UK) 9:57 – 10:04

### A 10 min-assay for ADAMTS13 activity with an automated biochemistry analyzer

S. Kato (JP)/M. Matsumoto (JP) 10:04 – 10:11

### ADAMTS13 activity assays: Comparison of different methods

Johanna Kremer Hovinga (CH) 10:11 – 10:18



Sunday, 24 July 2011

SSC Subcommittee Meeting

**Collagen binding assay, current status**

*Emmanuel Favaloro (AU)*

10:18 – 10:25

**Performance data of a particle enhanced VWF activity assay with no need of ristocetin**

*Jürgen Patzke (DE)*

10:25 – 10:30

**VWF and VWD Registries**

*Chairperson: Imre Bodo (HU)*

**Platelet Type–VWD registry/database ([www.pt-vwd.org/](http://www.pt-vwd.org/))**

*Maha Othman (CA)*

10:30 – 10:40

**VWF database ([www.vwf.group.shef.ac.uk/](http://www.vwf.group.shef.ac.uk/)), activities of steering committee, publication/report on database**

*Dan Hampshire (UK)*

10:40 – 10:50

**International registry on acquired von Willebrand syndrome ([www.intreavws.com](http://www.intreavws.com))**

*Augusto Federici (IT)*

10:50 – 11:00

**Multicenter Studies on VWD**

*Chairpersons: Reinhard Schneppenheim (DE) and Jorge DiPaola (US)*

**European Project on type 3 VWD**

*Augusto Federici (IT)*

11:00 – 11:10

**EUVWD Cooperative Group**

*Ian Peake (UK)*

11:10 – 11:20

**Zimmerman Project (ZPMCB-VWD)**

*Bob Montgomery (US)*

11:20 – 11:30

**Potential importance of the CHARGE loci in VWD patients**

*David Lillicrap (CA)*

11:30 – 11:40

**VWD International Prophylaxis (VIP) Study**

*Tom Abshire (US)*

11:40 – 11:50

**WIN (Willebrand in Netherlands)**

*Frank Leebeek (NL)*

11:50 – 12:00



39

## Opening Ceremony

You are cordially invited to attend the XXIII Congress' Opening Ceremony on **Sunday, July 24, 2011 at 17:30** at the Main Hall in ICC Kyoto, followed by the Welcome Reception, which will take place at the beautiful Japanese-style garden.

- **Welcome by Yasuo Ikeda**  
President of the XXIII Congress of the ISTH
- **Remarks by Hiroshi Mizohata**  
Commissioner, Japan Tourism Agency
- **Remarks and Presentation of the Grant Medal by Henri Bounameaux**  
Chairman of the ISTH Council
- **Closing Remarks by Yasuo Ikeda**  
President of the XXIII Congress of the ISTH



Nursing Forum 扉



## ISTH Nursing Forum

The ISTH mission statement is clear in its broad intent and implies that a mechanism exists for extraction of patient-related and laboratory data, and for dissemination and implementation of scientific advances. Nurses play a primary role in this mechanism because of their direct involvement in information flow, and by virtue of their direct contact with patients and the source documents that are the raw materials of scientific progress. Nursing involvement ranges from protocol design and implementation to extraction and transmission of basic quantitative data.

The purpose of the Nursing Program is to provide a forum for nurses worldwide to identify issues that directly impact their role in advancing the objectives of the organization pertaining to disorders of hemostasis and thrombosis in both pediatric and adult populations. The goal is to provide free exchange of knowledge, experience, and practice patterns to standardize and improve the quality of hands-on participation in the art and science of medicine focused on disorders of hemostasis and thrombosis. Models of care exist for patients with hemophilia (treatment protocols, practice guidelines, educational materials, etc), but do not exist for many other coagulation disorders.

The forum provides an opportunity for nurses to communicate and share protocols, strategies, and knowledge. Nurses identify similar clinical challenges and develop interventions and strategies to address the challenge, yet nurses are often isolated within their institutions making duplication of strategy development widespread. The ISTH nursing forum facilitates knowledge transfer within the profession of nursing and both reduces duplication of strategy development, and facilitates knowledge based sharing of information and strategies resulting in improved efficacy.



Saturday, July 23, 2011

9:00 – 13:00

Session 1

Room C-2

Nursing Forum

**Welcome and Introductions**

9:00 – 9:15

**A model of nursing practice in Japan**

*Orie Ono (JP)*

9:15 – 9:30

**Nursing Research Session**

*Moderators: Fiona Newall (AU), Mary Bauman (CA)*

**Nurse led research: “Raising the ‘voice’ of nursing”.**

*Fiona Newall (AU)*

9:30 – 10:00

**Selected oral communications**

**Examining the education needs of parents learning to use an infusaport in their child with hemophilia**

*Janine Furmedge (AU), Paul Monagle (AU), Chris Barnes (AU), Fiona Newall (AU)*

10:00 – 10:20

**The learning process of self infusion in haemophilia: Finally some numbers we could give to our patients**

*Liesbeth Helene Schrijvers (NL), Marlene Beijleveld-Van der Zande (NL), Marjolein Peters (NL), Kathelijn Fischer (NL)*

10:20 – 10:40

**An innovative clinic approach to increase patient participation in their health care**

*Mary Elisabeth Bauman (CA), M. Patricia Massicotte (CA), Aisha Bruce (CA)*

10:40 – 11:00

**Break**

11:00 – 11:15

**Invited research papers**

11:15 – 12:20

- **Survey on the role and challenges of nurses in education of home infusion for hemophilia patients and family**  
*Orie Ono (JP)*
- **Lower than expected clot rates in the absence of effective thromboprophylaxis**  
*Debi Smith (NZ)*
- **Initiation of warfarin therapy for patients with atrial fibrillation comparison 5mg vs. 3mg**  
*Bunis Packham (UK)*



3

Saturday, July 23, 2011

14:00 – 18:00

**Concept paper:**

12:20 – 13:00

- **Do we need a nursing scientific subcommittee-style approach to advancing nursing practice in the area of thrombosis and haemostasis?**

*Fiona Newall (AU), Mary Bauman (CA)*

**Session 2**

**Room C-2**

**Women's Health Issues in Hemostasis and Thrombosis**

*Moderators: Maura Dumas (US), Caroline Baglin (UK)*

- **Treatment options for managing menorrhagia for woman with bleeding and clotting disorders** 14:00 – 14:40  
*Andi James (US)*
- **Question and answer discussion period** 14:40 – 15:00

**Obstetrical issues**

- **The management of pregnancy, labour and delivery in severe haemophilia** 15:00 – 15:20  
*Ann O'Sullivan (IE)*
- **Guidelines for labor and delivery for carrier of neonate with hemophilia** 15:20 – 15:40  
*Regina Butler (US)*

**Pearls on the new anticoagulants**

*Karen Baker (US)* 15:40 – 16:00

**Abstract poster presentation set up in reception room.** 16:00 – 16:30

**Discrepant one-stage versus chromogenic FVIII:C assays in the management of haemophilia a carriers**

*Claire Bell (AU), Ross I. Baker (AU), Jim Thom (AU)*

**The ongoing impact of 25 years of hepatitis C (HCV) infection in people with inherited bleeding disorders (IBD)**

*Allison L. Greig (UK), Steve Austin (UK)*

**CVADs in children with haemophilia, a multi centre study**

*Karin Lindvall (SE), Kate Khair (UK), James Porter*

**Social networking in haemophilia: Adolescents' views**

*Kate Khair (UK), Mike Holland (UK), Shawn Carrington (UK)*



Saturday, July 23, 2011

14:00 – 18:00

Nursing Forum

**Functional health status assessment in haemophilia patients with the International classification of functioning, disability and health (ICF, ICF-CY)**

*Silvia Riva (IT), Gringeri Alessandro (IT), Monika Bullinger (DE),  
Sylvia von Mackensen (DE)*

**The nurse and thrombosis center in a developing country**

*Eliane Partite Nobre Sandoval (BR), Paula Ribeiro Villaca (BR), Erica Okazaki (BR),  
Audrey Kruse Zeinad Valim (BR), Dalton de Alencar Fischer Chamone (BR),  
Elbio Antonio DAmico (BR)*

**Development of a pediatric thrombosis educational tool (flash cards) for children receiving oral anticoagulation**

*Leonardo Rodrigues Brandao (CA), Elbio D'Amico (BR), Jorge D.A. Carneiro (BR),  
Frederica Cassis (BR)*

**Nurses' network meeting/ catered reception with concomitant abstract poster presentations**

16:30 – 18:00



5

Sunday, July 24, 2011

8:00 – 10:30

Session 3

Room C-2

### Optimizing Health

Moderators: Maura Dumas (US), Debi Smith (NZ)

#### Health issues

8:00 – 9:00

– **Obesity and thrombosis risk**

*Caroline Baglin (UK)*

– **General aging health issues: The impact on hemophilia population**

*Jennifer Maahs (US)*

#### Sports: What's your game plan: Risk vs. benefit?

9:00 – 9:30

– **In the pediatric bleeding population**

*James Munn (US)*

– **Applying this model to a pediatric thrombosis population**

*Mary Bauman (CA)*

#### Education, adherence, and quality of life

9:30 – 10:30

– **Developing university accredited degree module in anticoagulation and VTE prevention**

*Bunis Packham (UK)*

– **Review of adherence in health care: Is patient education always enough?**

*Regina Butler (US)*

– **Outcomes of clinical practice: The role of quality of life assessments in pediatric anticoagulation management**

*Sophie Jones (AU)*



Sunday, July 24, 2011

10:30 – 12:00

Session 4

Room C-2

Nursing Forum

### Case Studies/Discussions

Moderators: Jen Maahs (US), Fiona Newall (AU)

**Invited case studies, projects, protocols selected from nursing community.**

10:30 – 12:00

- **Teaching aids through images: A comparison between hemoaction and P-TET educational tools**  
*Frederica Cassis (BR)*
- **Identical twins with severe vWD: Medical and psychosocial challenges**  
*Ann O'Sullivan (IE)*
- **Coping with a new diagnosis - striking a healthy balance: Case study**  
*Maura Dumas (US)*



**Scientific Program**  
**Monday, July 25, 2011**

Monday, July 25, 2011

Plenary Lecture

9:45-10:30

**Takeshi Abe Memorial Lecture**

Main Hall

*Chairpersons: Gilbert White (US) and Akira Yoshioka (JP)*

**Gene therapy for hemophilia: A long and winding road**

PL-MO-001

*Katherine A. High (US)*

09:45 – 10:30

Plenary Lecture

17:15-18:00

**Life Sciences Research Partners Lecture**

Main Hall

*Chairpersons: J. Evan Sadler (US) and Katsuo Sueishi (JP)*

**Biological functions and therapeutic potential of vascular endothelial growth factors**

PL-MO-002

*Kari Kustaa Alitalo (FI), Collaborators*

17:15 – 18:00

State-of-the-Art Lecture

11:00-12:00

**Thrombotic Disorders: Epidemiology**

Main Hall

*Chairpersons: Daniel Myers Jr. (US) and Kazuyuki Shimada (JP)*

**Stroke in atrial fibrillation: Epidemiology and thromboprophylaxis**

SA-MO-001

*Gregory Y.H. Lip (UK)*

11:00 – 11:30

**Anticoagulant therapy in venous thromboembolism**

SA-MO-002

*Harry R. Büller (NL)*

11:30 – 12:00

**Platelet Biology**

Annex Hall 1

*Chairpersons: Zaverio M. Ruggeri (US) and Yukio Ozaki (JP)*

**The role of lectins and glycans in platelet clearance**

SA-MO-003

*Karin Hoffmeister (US)*

11:00 – 11:30

**Regulating thrombus growth and stability to achieve an optimal response to injury**

SA-MO-004

*Lawrence Fisher Brass (US), Kenneth M. Wannemacher, Peisong Ma,  
Timothy J. Stalker*

11:30 – 12:00





Monday, July 25, 2011

**Plasminogen Activation System**

**Annex Hall 2**

*Chairpersons: Robert Medcalf (AU) and Junichiro Yamamoto (JP)*

**Exploration of the host hemostatic system by group a streptococcus: Implications in searching for novel antimicrobial therapies** SA-MO-005  
*Hongmin Sun (US)* 11:00 – 11:30

**tPA-mediated plasminogen activation and contact activation, implications in and beyond haemostasis** SA-MO-006  
*Martijn F.B.G. Gebbink (NL)* 11:30 – 12:00

**Coagulation and Inflammation**

**Room A**

*Chairpersons: John Griffin (US) and Paula Tracy (US)*

**Crosstalk between hemostasis and inflammation** SA-MO-007  
*Charles T. Esmon (US)* 11:00 – 11:30

**Recombinant thrombomodulin: As a therapeutic regulator in coagulation and inflammation** SA-MO-008  
*Ikuro Maruyama (JP), Takashi Ito* 11:30 – 12:00

**Symposia**

**8:00-9:30**

**Hemorrhagic Disorders**

**Main Hall**

**Prediction of Inhibitor Development in Hemophilia**

*Chairpersons: H. Marijke van den Berg (NL) and Midori Shima (JP)*

**Factor VIII gene haplotype and inhibitor development** SY-MO-001  
*Tom E. Howard (US)* 08:00 – 08:30

**Genotype and inhibitor development** SY-MO-002  
*Johannes Oldenburg (DE)* 08:30 – 09:00

**Immunological aspects of inhibitor development** SY-MO-003  
*Jan Astermark (SE)* 09:00 – 09:30

Monday Science



Monday, July 25, 2011

**Platelet (Basic and Clinical)**

**Annex Hall 1**

**Megakaryocytes and Thrombopoiesis**

*Chairpersons: David J. Kuter (US) and Takashi Kato (JP)*

**Apoptotic processes in megakaryocytes and platelets**

*Benjamin Thomas Kile (AU)*

**SY-MO-004**

08:00 – 08:30

**Mechanistic insights into how platelets are produced and how they regulate angiogenesis**

*Joseph E Italiano Jr (US)*

**SY-MO-005**

08:30 – 09:00

**Towards making platelets from ex vivo grown cells**

*Mortimer Poncz (US), Yuhuan Wang, Rudy Fuentes, Michele Puzkarczuk Lambert*

**SY-MO-006**

09:00 – 09:30

**Coagulation Factors and Inhibitors**

**Annex Hall 2**

**Contact Phase Activation**

*Chairpersons: Klaus T. Preissner (DE) and Hiroko Tsuda (JP)*

**Thrombosis risk of protein deficiencies of the plasma kallikrein/kinin system**

*Alvin Harold Schmaier (US), Gregory N. Adams*

**SY-MO-007**

08:00 – 08:30

**Factor XI: Structure, activation and target for therapy**

*Joost C. M. Meijers (NL)*

**SY-MO-008**

08:30 – 09:00

**Initiation of coagulation by polyphosphates in vivo**

*Thomas Renne (SE)*

**SY-MO-009**

09:00 – 09:30

**Symposia**

**13:30-15:00**

**Platelet (Basic and Clinical)**

**Main Hall**

**Emerging Antiplatelet Drugs**

*Chairpersons: Alan D. Michelson (US) and Hisanori Horiuchi (JP)*

**New P2Y12 inhibitors for the treatment of coronary artery disease**

*Paul Alfred Gurbel (US)*

**SY-MO-010**

13:30 – 14:00

**PAR - 1 antagonists in cardiovascular disease**

*David A. Morrow (US)*

**SY-MO-011**

14:00 – 14:30



Monday, July 25, 2011

**Perspective of new PDE-3 inhibitor as anti-thrombotic drug SY-MO-012**

*Masakatsu Nishikawa (JP), Hiroyoshi Hidaka*

14:30 – 15:00

**Innovation and Technology**

**Annex Hall 1**

**Innovative Imaging**

*Chairpersons: Owen McCarty (US) and Junichi Takagi (JP)*

**In vivo molecular imaging reveals multi-cellular kinetics and pro-inflammatory cytokine involvement in developing thrombus SY-MO-013**

*Satoshi Nishimura (JP), Mika Nagasaki, Ichiro Manabe, Koji Eto, Ryoza Nagai*

13:30 – 14:00

**Dynamics of adhesion molecules studied using single-molecule mechanical experiments and molecular dynamics simulations**

**SY-MO-014**

*Cheng Zhu (US), Wei Jack Chen, Fang Kong, Wei Chen*

14:00 – 14:30

**Imaging leukocyte-thrombus interactions in vivo**

**SY-MO-015**

*Shaun Jackson (AU)*

14:30 – 15:00

**VWF/VWD and ADAMTS13**

**Annex Hall 2**

**Structure and Function of ADAMTS13 and von Willebrand Factor**

*Chairpersons: Jose Lopez (US) and X. Long Zheng (US)*

**Findings from ADAMTS13 activity assay**

**SY-MO-016**

*Koichi Kokame (JP)*

13:30 – 14:00

**How ADAMTS13 recognises and cleaves the VWF scissile bond**

**SY-MO-017**

*David A. Lane (UK)*

14:00 – 14:30

**Characterization of anti-ADAMTS13 antibodies that develop in patients with acquired thrombotic thrombocytopenic purpura**

**SY-MO-018**

*Jan Voorberg (NL), Wouter Pos, Nicoletta Sorvillo*

14:30 – 15:00

Monday Science



5

Monday, July 25, 2011

**Symposia**

**15:30-17:00**

**Thrombotic Disorders**

**Main Hall**

**Pharmacotherapy Update for Peripheral Arterial Disease: From Tasc II to Tasc III**

*Chairpersons: Lars Norgren (SE) and Hiroshi Shigematsu (JP)*

**Management of peripheral artery disease and claudication** **SY-MO-019**

*William R. Hiatt (US)* 15:30 – 16:00

**Stem cell therapy for peripheral arterial occlusive disease** **SY-MO-020**

*Dong-Ik Kim (KR)* 16:00 – 16:30

**Role of pharmacotherapy in peripheral intervention** **SY-MO-021**

*Hiroyoshi Yokoi (JP)* 16:30 – 17:00

**Platelet (Basic and Clinical)**

**Annex Hall 1**

**Congenital Thrombocytopenia**

*Chairpersons: Paquita Nurden (FR) and Taisuke Kanaji (US)*

**Diagnosis of congenital macrothrombocytopenia** **SY-MO-022**

*Shinji Kunishima (JP)* 15:30 – 16:00

**Mouse models of macrothrombocytopenia** **SY-MO-023**

*Christian Gachet (FR), Catherine Leon, Catherine Strassel, Francois Lanza*  
16:00 – 16:30

**Gray platelet syndrome: Clinical features and genetic analysis (TBD)** **SY-MO-024**

*Tzipora C. Falik-Zaccai (IL)* 16:30 – 17:00

**Hemorrhagic Disorders**

**Annex Hall 2**

**FV/FVIII Synthesis and Regulation**

*Chairpersons: Rodney Camire (US) and Tadashi Matsushita (JP)*

**Endothelial synthesis of factor VIII** **SY-MO-025**

*Claire L. Shovlin (UK)* 15:30 – 16:00

**Combined deficiency of FV and FVIII** **SY-MO-026**

*Bin Zhang (US)* 16:00 – 16:30



Monday, July 25, 2011

**A role and mechanism of plasmin-catalyzed FVIII activation in blood  
coagulation and fibrinolysis**

*Keiji Nogami (JP)*

**SY-MO-027**

16:30 – 17:00

Monday Science



## ORAL COMMUNICATIONS

Monday, July 25, 2011

8:00 - 9:30

### Platelet Signaling I

Room C-1

*Chairpersons: Bernhard Nieswandt (DE) and Mauro Torti (IT)*

- O-MO-001** **DISCOVERY OF A NEW SIGNALING COMPLEX BASED ON SPINOPHILIN THAT REGULATES PLATELET ACTIVATION IN VITRO AND IN VIVO** 08:00 - 08:15  
Peisong Ma\* (US), Aleksandra Cierniewska, Rachel Signarvic, Andrew Sinnamon, Marcin Cieslak, Timothy Stalker, Richard Neubig, Lawrence Brass
- O-MO-002** **CLP36 IS A NEGATIVE REGULATOR OF GPVI SIGNALING IN PLATELETS** 08:15 - 08:30  
shuchi gupta\* (DE), Attila Braun, Martina Morowski, Zoltan Nagy, Bernhard Nieswandt
- O-MO-003** **SEVERE GPVI DEFICIENCY AND MACROTHROMBOCYTOPENIA IN MICE LACKING G6B-B** 08:30 - 08:45  
Ying-Jie Wang\* (UK), Alexandra Mazharian, Jun Mori, Danai Bem, Brenda Finney, Silke Heising, Paul Gissen, Michael Douglas, James G White, Neel G Benjamin, R Duncan Campbell, Steve P Watson, Yotis A Senis
- O-MO-004** **THE PLATELET SURFACE THIOL ISOMERASE ERP57 IS REQUIRED FOR PLATELET FUNCTION** 08:45 - 09:00  
Ronald Geoffrey Stanley\* (UK), Lisa-Marie Holbrook, Parvathy Sasikumar, Jonathan Gibbins
- O-MO-005** **ELUCIDATING THE ROLE OF THE INTRINSIC APOPTOSIS PATHWAY IN PLATELET FUNCTION** 09:00 - 09:15  
Emma Charlotte Josefsson\* (AU), Michael J White, Simone M Schoenwaelder, Kate Jarman, Katya J Henley, Rachael M Lane, Shaun P Jackson, Benjamin T Kile
- O-MO-006** **PAR1, PAR4 AND GPIB FORM FUNCTIONAL INTERDEPENDENT UNITS IN A RECEPTOR COMPLEX MEDIATING PLATELET ACTIVATION BY THROMBIN** 09:15 - 09:30  
Lars Faxalv\* (SE), Niklas Boknas, Tomas L Lindahl

### Fibrinolysis

Room C-2

*Chairpersons: Paul Declerck (BE) and Koji Yamamoto (JP)*

- O-MO-007** **RED BLOOD CELLS CONFER LYTIC RESISTANCE TO FIBRIN** 08:00 - 08:15  
Nikolett Wohner\* (HU), Laszlo Szabo, Raymund Machovich, Marta Silva, Colin Longstaff, Krasimir Kolev
- O-MO-008** **THE INVOLVEMENT OF FACTOR XIII IN THE IMPAIRED FIBRINOLYSIS OF PATIENTS WITH FACTOR V LEIDEN MUTATION** 08:15 - 08:30  
Zsuzsa Bagoly\* (HU), Zsuzsa Koncz, Zoltan Andras Mezei, Zsolt Olah, Robert A. S. Ariens, Laszlo Muszbek



## ORAL COMMUNICATIONS

Monday, July 25, 2011

8:00 - 9:30

Monday Oral

- O-MO-009** **FIBRIN CLOTS CONTAIN FUNCTIONALLY ACTIVE ALPHA-1-ANTITRYPSIN** **08:30 - 08:45**  
Dick C Rijken\* (NL), Simone Talens, Joyce J.M.C. Malfliet, Frank W.G. Leebeek
- O-MO-010** **DNA STABILISES FIBRIN CLOTS AND MODULATES THE ACTIVITY OF STREPTOKINASE** **08:45 - 09:00**  
Colin Longstaff\* (UK), Craig Thelwell
- O-MO-011** **ALTERATIONS OF COAGULATION AND FIBRINOLYSIS IN PATIENTS WITH ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY: THE INVOLVEMENT OF THROMBOMODULIN** **09:00 - 09:15**  
Mark van Geffen\* (NL), Massimo Cugno, Paul Lap, Arnoud Loof, Marco Cicardi, Waander van Heerde
- O-MO-012** **A NEW APPROACH FOR MEASUREMENT OF MP-ASSOCIATED PLASMIN GENERATION.** **09:15 - 09:30**  
Romaric Lacroix\* (FR), Philippe Poncelet, Tarik Bouriche, Coralie Judicone, Karim Harti Souab, Sebastien Bordon, Genevieve Contant, Florence Sabatier, Jose Sampol, Eduardo Angles-Cano, Francoise Dignat-George

### Protein S and GAS6

Room D

Chairpersons: [REDACTED] and Tatsuya Hayashi (JP)

- O-MO-013** **HDL FRESHLY ISOLATED BY ULTRACENTRIFUGATION FROM PLASMA IS A COFACTOR FOR ACTIVATED PROTEIN C(APC)/PROTEIN S ANTICOAGULANT ACTIVITY: CONTROVERSY AND REEVALUATION** **08:00 - 08:15**  
John H Griffin\* (US), Jose A Fernandez, Natalie Pecheniuk, Subramanian Yegneswaran, Carole L Banka, Hiroshi Deguchi
- O-MO-014** **ACTIVATED PROTEIN S COFACTOR FUNCTION OF PROTEIN S: A NOVEL FUNCTION FOR A  $\gamma$ -CARBOXYGLUTAMIC ACID RESIDUE** **08:15 - 08:30**  
Josefin Ahnstrom\* (UK), Helena M Andersson, Kevin Canis, Eva Norstrom, Yao Yu, Bjorn Dahlback, Maria Panico, Howard R Morris, James TB Crawley, David A Lane
- O-MO-015** **GROWTH ARREST-SPECIFIC GENE 6 (GAS6) AS AN INTRA-HOSPITAL MORTALITY PREDICTOR FOR PATIENTS IN SEPTIC SHOCK** **08:30 - 08:45**  
Anne Angelillo-Scherrer (CH), Gregoire Stalder\*, Christophe Kosinski, Frederik Delodder, Beatrice Ternon, Thierry Roger, Thierry Calandra, Michel A. Duchosal, Philippe Eggimann, Anne Angelillo-Scherrer, Lausanne The Lausanne Sepsis Study Group
- O-MO-016** **COMPOUND HETEROZYGOUS PROTEIN S DEFICIENCY IN A HEALTHY WOMAN** **08:45 - 09:00**  
Carolina Pintao\* (NL), Kristien Winckers, Herm-Jan M Brinkman, Elisabetta Castoldi, Tilman M Hackeng, Pieter H Reitsma



## ORAL COMMUNICATIONS

Monday, July 25, 2011

8:00 - 9:30

**O-MO-017** **09:00 - 09:15**

**DOWNREGULATION OF PROTEIN S BY MICRO-RIBONUCLEIC ACID 494 (MIR-494)**

Giuliana Romeo (AU), Quintin Hughes, Ross Baker\*

**O-MO-018** **09:15 - 09:30**

**PHOSPHORYLATION OF PROTEIN S (PS) BY PLATELET KINASES ENHANCES ITS DIRECT ANTICOAGULANT ACTIVITY**

Fabian Stavenuiter\* (US), Mary-Jo Heeb

### Antiplatelet Therapy

Room E

*Chairpersons: Christopher Ward (AU) and Tsukasa Ohmori (JP)*

**O-MO-019** **08:00 - 08:15**

**DEVELOPMENT OF REFERENCE METHODS FOR EVALUATING THE EFFECT OF ASPIRIN AND FOR COMPARISON WITH ROUTINELY USED METHODS; THE LACK OF ASPIRIN RESISTANCE IN HEALTHY VOLUNTEERS**

Eva Katona\* (HU), Emese Gyongyver Kovacs, Zsuzsanna Bereczky, Laszlo Balogh, Nora Homorodi, Gizella Haramura, Eszter Toth, Judit Csapo, Istvan Edes, Laszlo Muszbek

**O-MO-020** **08:15 - 08:30**

**PLATELET REACTIVITY AND RECURRENT CARDIOVASCULAR EVENTS IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE USING ASPIRIN: A HEAD-TO-HEAD COMPARISON OF DIFFERENT TESTS**

Jaapjan D. Snoep\* (NL), Jeroen CJ Eikenboom, Jaap Jan Zwaginga, Mark Roest, Carlo Patrono, Bianca Rocca, Giovanna Petrucci, Frits R Rosendaal, Johanna G van der Bom

**O-MO-021** **08:30 - 08:45**

**ACETYLSALICYLIC ACID INHIBITS THROMBOXANE A<sub>2</sub> PRODUCTION AND THROMBOXANE A<sub>2</sub>-DEPENDENT PLATELET FUNCTION EQUALLY WELL IN DIABETIC AND NON-DIABETIC SUBJECTS**

Marco Cattaneo\* (IT), Eti Alessandra Femia, Mariateresa Pugliano, Gian Marco Podda, Klodiana Dosti, Cristina Razzari

**O-MO-022** **08:45 - 09:00**

**HIGH ON-TREATMENT PLATELET REACTIVITY BY VARIOUS PLATELET FUNCTION TESTS: IS THE CURRENTLY REPORTED VASP PRI CUTOFF TOO LOW?**

Paul Alfred Gurbel\* (US), Jeong Young-Hoon, Kevin P Bliden, Mark J Antonino, Udaya S Tantry, Udaya S Tantry

**O-MO-023** **09:00 - 09:15**

**EV-077-3201-2TBS, A TP ANTAGONIST AND TS INHIBITOR, REDUCES PLATELET AGGREGATION IN WHOLE BLOOD OF TYPE 2 DIABETICS WITH CORONARY ARTERY DISEASE ON CHRONIC ASPIRIN THERAPY**

Kjell S. Sakariassen\* (IT), E. Femia, R.P. Rothlin, G.-M. Podda, C. Razzari, M.-T. Pugliano, F.M. Daray, A.E. Errasti, A.R. Armesto, W. Novak, P. Alberts, R. Hermosilla, J.-P. Meyer, M. Cattaneo, A. Santana Sorensen

**O-MO-024** **09:15 - 09:30**

**ARC15105 A POTENT ANTAGONIST OF VON WILLEBRAND FACTOR (VWF) PLATELET ACTIVATION AND ADHESION**

Bernd Jilma\* (AT), Jolanta M Siller-Matula, Yahye Merhi, Jean-Francois Tanguay, Daniel Duerschmied, Kathleen E. McGinness,





## ORAL COMMUNICATIONS

Monday, July 25, 2011

8:00 - 9:30

Monday Oral

Shannon P. Pendergrast, Denisa D. Wagner, Robert G. Schaub,  
Bernd Jilma

### Inherited Coagulation Disorders

Sakura

*Chairpersons: Eriko Morishita (JP) and Kathelijn Fischer (NL)*

O-MO-025

08:00 - 08:15

#### A ZEBRAFISH MODEL FOR HUMAN FIBRINOGEN DISORDERS

Richard J Fish\* (CH), Silja Vorjohann, Alexandre Fort, Corinne DiSanza,  
Franck Bontems, Frederique Bena, Roland Dosch,  
Marguerite Neerman-Arbez

O-MO-026

08:15 - 08:30

#### THE FVII R402X NONSENSE MUTATION, ASSOCIATED WITH AN ASYMPTOMATIC PHENOTYPE, IS RESPONSIBLE FOR SMALL AMOUNTS OF CIRCULATING PROTEIN WITH IMPROVED COAGULANT ACTIVITY

Alessio Branchini\* (IT), Lara Rizzotto, Alessandro Canella, Rosella Mari,  
Mario Lapecorella, Marisanta Napolitano, Guglielmo Mariani,  
Mirko Pinotti, Francesco Bernardi

O-MO-027

08:30 - 08:45

#### "COMPENSATORY" ABERRANT SPLICING SUPPORTS RESIDUAL EXPRESSION LEVELS IN SEVERE COAGULATION FACTOR VII DEFICIENCY

Nicola Cavallari (IT), Dario Balestra, Lara Rizzotto, Alessio Branchini,  
Iva Maestri, Ampaiwan Chuansumrit, Weresak Sasanakul,  
Guglielmo Mariani, Franco Pagani, Francesco Bernardi, Mirko Pinotti\*

O-MO-028

08:45 - 09:00

#### EFFICACY OF PROPHYLAXIS AND GENOTYPE-PHENOTYPE CORRELATION IN PATIENTS WITH SEVERE FACTOR X DEFICIENCY IN IRAN

Mehran Karimi\* (IR), Armaghan Vafafar, Sezaneh Haghpanah,  
Mehrdad Payandeh, Peyman Eshghi, Hamid Hoofar, Abdolreza Afrasiabi,  
Javad Gerdabi, Rezvan Ardeshiri, Marzia Menegatti, Flora Peyvandi

O-MO-029

09:00 - 09:15

#### A RECURRENT P.GLY43ASP SUBSTITUTION OF COAGULATION FACTOR X (FX) IMPAIRS INTRACELLULAR TRAFFICKING AND FUNCTIONAL ACTIVITY CAUSING A SEVERE FX DEFICIENCY IN FOUR PATIENTS

Marzia Menegatti\* (IT), Roberta Palla, Mehran Karimi, Rossella Bader,  
Raimondo De Cristofaro, Flora Peyvandi

O-MO-030

09:15 - 09:30

#### PHENOTYPE-GENOTYPE CORRELATION OF 181 PATIENTS WITH HEREDITARY COAGULATION FACTOR XIII DEFICIENCY

Vytautas Ivaskevicius\* (DE), Arijit Biswas, Anne Thomas, Rainer Seitz,  
Seifried Erhard, Johannes Oldenburg



## ORAL COMMUNICATIONS

Monday, July 25, 2011

8:00 - 9:45

### Late Breaking Clinical Trials

Room A

*Chairpersons: Takenori Yamaguchi (JP) and Kenneth Bauer (US)*

- |                 |  |                      |
|-----------------|--|----------------------|
| <b>O-MO-031</b> | <b>APIXABAN FOR PREVENTION OF ACUTE ISCHEMIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROMES</b><br>Stefan Karl James* (SE), John H Alexander, Puneet Mohan, Lars Wallentin, Robert A Harrington  | <b>08:00 - 08:15</b> |
| <b>O-MO-032</b> | <b>J-ROCKET AF: THE SAFETY AND EFFICACY OF RIVAROXABAN FOR PREVENTION OF STROKE IN JAPANESE PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION</b><br>Masatsugu Hori* (JP), Masayasu Matsumoto, Norio Tanahashi, Shin-ichi Momomura, Shinichiro Uchiyama, Shinya Goto, Tohru Izumi, Yukihiro Koretsune, the J-ROCKET AF Study Investigators on behalf of | <b>08:15 - 08:30</b> |
| <b>O-MO-033</b> | <b>IDRABIOTAPARINUX FOR ACUTE SYMPTOMATIC PULMONARY EMBOLISM</b><br>Harry R Buller* (NL), Alex S Gallus, Gerard Pillion, Martin H Prins, Gary E Raskob   | <b>08:30 - 08:45</b> |
| <b>O-MO-034</b> | <b>RIVAROXABAN VERSUS ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS: MAGELLAN SUBGROUP ANALYSES</b><br>Alexander T Cohen* (UK), Theodore E. Spiro, Harry R. Buller, Lloyd Haskell, Dayi Hu, Russell Hull, Alexandre Mebazaa, Geno Merli, Sebastian Schellong, Alex Spyropoulos, Victor Tapson              | <b>08:45 - 09:00</b> |
| <b>O-MO-035</b> | <b>TREATMENT-RELATED RISK FACTORS OF INHIBITOR DEVELOPMENT IN PATIENTS WITH SEVERE HEMOPHILIA A: THE RODIN STUDY</b><br>Samantha C Gouw* (NL), H Marijke van den Berg, Johanna G van der Bom, On behalf of the PedNet Study group, and the RODIN Study group   | <b>09:00 - 09:15</b> |
| <b>O-MO-036</b> | <b>THE IMPACT OF LOW-MOLECULAR-WEIGHT HEPARIN (LMWH) PROPHYLAXIS ON MORTALITY IN ACUTELY ILL MEDICAL PATIENTS: THE LIFENOX STUDY</b><br>Ajay Kakkar* (UK), Claudio Cimminiello, Samuel Z Goldhaber, Rajiv Parakh, Chen Wang, Jean-Francois Bergmann  | <b>09:15 - 09:30</b> |
| <b>O-MO-037</b> | <b>DABIGATRAN VERSUS PLACEBO FOR EXTENDED MAINTENANCE THERAPY OF VENOUS THROMBOEMBOLISM</b><br>Sam Schulman* (CA), D Baanstra, H Eriksson, S Goldhaber, A Kakkar, C Kearon, P Mismetti, S Schellong, J Schnee, the RE-SONATE Study Group   | <b>09:30 - 09:45</b> |



## ORAL COMMUNICATIONS

Monday, July 25, 2011

8:00 - 9:30

Monday Oral

### VTE: Risk Factors I

Room B-1

*Chairpersons: Masataka Ikeda (JP) and Richard White (US)*

- O-MO-038** **08:00 - 08:15**  
**THE OPTIMAL DURATION OF ANTICOAGULANT THERAPY IN PATIENTS WITH CANCER-RELATED DEEP VEIN THROMBOSIS: THE ADVANTAGE OF USING RESIDUAL VEIN THROMBOSIS (THE CANCER-DACUS STUDY)**  
ALESSANDRA MALATO\* (IT), Sergio Siragusa
- O-MO-039** **08:15 - 08:30**  
**MELISSE, A LARGE MULTICENTRIC OBSERVATIONAL STUDY TO DETERMINE RISK FACTORS OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IMMUNOMODULATOR DRUGS**  
Xavier Leleu\* (FR), L Daley, P Rodon, C Hulin, C Dauriac, M Hacini, O Decaux, JC Eisemann, O Fitoussi, B Lioure, L Voillat, B Slama, A Al Jijakli, C Chaletteix, R Costello, A Lamblin, P Natta, JP Fermand, P Moreau
- O-MO-040** **08:30 - 08:45**  
**A SIMPLE NON-INVASIVE DIAGNOSTIC ALGORITHM FOR RULING OUT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION IN PATIENTS AFTER ACUTE PULMONARY EMBOLISM**  
Frederikus A Klok\* (NL), Sulaiman Surie, Tibor Kempf, Jeroen Eikenboom, Jan van Stralen, Klaas van Kralingen, Arie van Dijk, Hubert Vliegen, Paul Bresser, Kai Wollert, Menno Huisman
- O-MO-041** **08:45 - 09:00**  
**INSULIN RESISTANCE AND RISK OF VENOUS THROMBOEMBOLISM**  
Inge M van Schouwenburg\* (NL), Bakhtawar K Mahmoodi, Nic JGM Veeger, Karina Meijer, Stephan JL Bakker, Hanneke C Kluin-Nelemans, Ron T Gansevoort
- O-MO-042** **09:00 - 09:15**  
**IMPACT OF DIETARY PATTERNS ON THE RISK OF MYOCARDIAL INFARCTION AND VENOUS THROMBOEMBOLISM. THE TROMSO STUDY 1994-2005.**  
Ida Johanne Hansen-Krone\* (NO), Ida Johanne Hansen-Krone, John-Bjarne Hansen, Kristin Enga, Sigrid Braekkan
- O-MO-043** **09:15 - 09:30**  
**INCIDENCE AND RISK FACTORS FOR POST-DISCHARGE VTE AMONG MEDICALLY ILL PATIENTS HOSPITALIZED IN THE UNITED STATES: 2005-2009**  
Alex C Spyropoulos\* (CA), Maxine Fisher, Charles Mahan, Larry E Fields, Roger Mills, Judith J Stephenson, Tom Wasser, An-Chen Fu, Winslow Klaskala

### Thrombotic Thrombocytopenic Purpura

Room B-2

*Chairpersons: Paul COPPO (FR) and Masanori Matsumoto (JP)*

- O-MO-044** **08:00 - 08:15**  
**STRAIN-SPECIFIC MODIFIER GENE(S) FOR THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) SUSCEPTIBILITY IN THE MOUSE**  
Yosef Y Kalish\* (US), David Siemieniak, Karl Desch, David Ginsburg



13

## ORAL COMMUNICATIONS

Monday, July 25, 2011

8:00 - 9:30

O-MO-045

**SPLEEN-DERIVED ANTI-ADAMTS13 B-CELLS IN RELAPSING TTP PATIENTS USE THE SAME RESTRICTED GENES BUT DIFFERENT IGG SUBCLASS DISTRIBUTION WHEN TREATED WITH OR WITHOUT RITUXIMAB**

Monica Maria Schaller\* (CH), Karin Sprecher, Irmela Sulzer, Monique Vogel, Beda Stadler, Kent Kentouche, Bernhard Laemmle, Johanna Anna Kremer Hovinga

08:15 - 08:30

O-MO-046

**PRECLINICAL EFFICACY TESTING OF BAXTER'S RECOMBINANT ADAMTS13 IN A MOUSE MODEL OF TTP**

Alexandra Schiviz\* (AT), John Philip Lawo, Kuno Wuersch, Hartmut Ehrlich, Friedrich Scheiflinger, Hans-Peter Schwarz, Werner Hoellriegl, Eva-Maria Muchitsch

08:30 - 08:45

O-MO-047

**AAV LIVER-SPECIFIC EXPRESSION OF A C-TERMINAL TRUNCATED ADAMTS13 VARIANT CORRECTS THROMBOTIC THROMBOCYTOPENIC PURPURA IN A MURINE MODEL**

Sheng-Yu Jin\* (US), Juan (Jenny) Xiao, Fraser J Wright, X. Long Zheng

08:45 - 09:00

O-MO-048

**RESIDUAL PLASMATIC ACTIVITY OF ADAMTS13 IN CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA AND ITS CORRELATION WITH DISEASE PHENOTYPE**

Luca A Lotta\* (IT), Haifeng M Wu, Ian J Mackie, Marina Noris, Agnes Veyradier, Samuel J Machin, Giuseppe Remuzzi, Paul Coppo, Marie A Scully, Roberta Donadelli, Chantal Loirat, Richard A Gibbs, April Horne, Shangbin Yang, Roberta Palla, Flora Peyvandi

09:00 - 09:15

O-MO-049

**PLASMA MODIFIERS OF VWF CLEAVAGE BY ADAMTS13**

Han-Mou Tsai\* (US), Wenhua Zhou

09:15 - 09:30

### Inflammatory Cells and Cytokines

Room C-1

Chairpersons:  and Satoshi Fujii (JP)

O-MO-050

**SURFACE PROTEIN DISULFIDE ISOMERASE PLAYS AN IMPORTANT ROLE IN BETA2 INTEGRIN-MEDIATED NEUTROPHIL ADHESION TO THE ACTIVATED ENDOTHELIUM UNDER VASCULAR INFLAMMATION.**

Jaehyung Cho\* (US), Eunsil Hahm, Stella Huh, Melissa Geyer, Snezna Rogelj

13:30 - 13:45

O-MO-051

**COMPLEMENT MBL-ASSOCIATED SERINE PROTEASE-1 (MASP-1) INTERACTS WITH PLASMA CLOT FORMATION - A NOVEL LINK BETWEEN INFLAMMATION AND THROMBOSIS?**

Verena Schroeder\* (CH), Katharina Hess, Jozsef Dobo, Peter Gal, Ramzi Ajjan

13:45 - 14:00

O-MO-052

**PLATELETS REGULATE CD4+ T CELL DIFFERENTIATION VIA MULTIPLE CHEMOKINES**

Linjing Zhu\* (SE), Zhu Linjing, Norbert Gerdes, Maria Ersoy, Andreas Hermansson, Maud Daleskog, Ragnhild Stalesen, Paul Hjerdahl, Hu Hu, Goran Hansson, Nailin Li

14:00 - 14:15



## ORAL COMMUNICATIONS

Monday, July 25, 2011

13:30 - 15:00

Monday Oral

- O-MO-053** **PLASMIN AND CPB CLEAVAGE OF CHEMERIN IS NECESSARY FOR ACTIVATION TO THE ACTIVE FORM, CHEM157S, THAT FUNCTIONS AS A SIGNALING MOLECULE IN GLIOBLASTOMA.** 14:15 - 14:30  
Yasuto Yamaguchi\* (US), Xiao-yan Du, Zhao Lei, John Morser, Lawrence L. K. Leung
- O-MO-054** **LACK OF P2X<sub>1</sub> ION CHANNELS INCREASES ENDOTOXEMIA-ASSOCIATED COAGULATION AND ORGAN DAMAGE THROUGH NEUTROPHIL HYPERRESPONSIVENESS** 14:30 - 14:45  
Christelle Lecut\* (BE), Celine Faccinnetto, Richard J Evans, Vincent Bours, Cecile Oury
- O-MO-055** **MICROPARTICLES' APOPTOSIS, ANGIOGENESIS AND MIGRATION EFFECTS IN HEALTHY AND PATHOLOGICAL PREGNANCIES** 14:45 - 15:00  
Anat Aharon\* (IL), Einat Shomer, Sarah Katzenell, Yaniv Zipori, Rami Sammour, Benjamin Brenner

### Structures of Coagulation Factors

Room C-2

*Chairpersons: Weikai Li and James Huntington (UK)*

- O-MO-056** **STRUCTURAL CHARACTERIZATION OF THE THROMBIN ACTIVATION OF COAGULATION FACTOR VIII STUDIED BY HYDROGEN-DEUTERIUM EXCHANGE MASS SPECTROMETRY** 13:30 - 13:45  
Johan Henrik Faber\* (DK), Anders Svensson, Mette Dahl Andersen, Ole Hvilsted Olsen, Henning Stennicke
- O-MO-057** **PEPTIDES BINDING TO KUNITZ DOMAIN 1 OF TISSUE FACTOR PATHWAY INHIBITOR INHIBIT THE INTERACTION WITH FACTOR XA** 13:45 - 14:00  
Michael Dockal\* (AT), M. Fries, J. Brandstetter, M. Ludwiczek, G. Kontaxis, K. Prohaska, A. Hofbauer, W. Kammlander, R. Hartmann, H. Ehrlich, Fritz Scheiflinger
- O-MO-058** **THROMBIN ALLOSTERY: EFFECT OF EXOSITE-1 AND EXOSITE-2 BINDERS ON THE ENZYME MOLECULAR RECOGNITION AND CATALYSIS** 14:00 - 14:15  
Vincenzo De Filippis\* (IT), Nicola Pozzi, Roberta Frasson, Laura Acquasaliente, Davide Zaramella
- O-MO-059** **A DYNAMICAL, ATOMIC-DETAILED VIEW OF COMPLEX FORMATION BETWEEN FACTOR VIIA, TISSUE FACTOR, AND FACTOR X ON THE SURFACE OF THE MEMBRANE** 14:15 - 14:30  
Y Zenmei Ohkubo\* (US), Emad Tajkhorshid
- O-MO-060** **RESIDUES 1967-1968 AT THE A1-A2-A3 DOMAIN INTERFACE ARE PART OF A FUNCTIONAL REGION THAT EXPOSES UPON ACTIVATION OF FACTOR VIII** 14:30 - 14:45  
Esther Bloem\* (NL), Henriët Meems, Maartje van den Biggelaar, Carmen van der Zwaan, Koen Mertens, Alexander B Meijer



## ORAL COMMUNICATIONS

Monday, July 25, 2011

13:30 - 15:00

- O-MO-061** **IDENTIFICATION OF THE FACTOR XII SEQUENCE THAT MEDIATES CONTACT ACTIVATION *IN VITRO* AND *IN VIVO*** **14:45 - 15:00**  
Felicitas E Mueller\* (SE), Daniela Urlaub, Christoph Kleinschnitz, Thomas Renne

### Pathway of Coagulation Factor VIII

Room D

*Chairpersons: KAGEHIRO AMANO (JP) and Peter Collins*

- O-MO-062** **PROLONGED OSCILLATORY SHEAR STRESS INDUCES FVIII EXPRESSION IN ENDOTHELIAL PROGENITOR CELLS** **13:30 - 13:45**  
Jonathan Jacob Riches\* (CA), Barbara Vidal, Christine Brown, Colleen Notley, Christine Hough, David Lillicrap

- O-MO-063** **INCREASED FACTOR VIII LEVELS IN PATIENTS TREATED FOR VENOUS THROMBOSIS** **13:45 - 14:00**  
Vladimir Tichelaar\* (NL), Andre B. Mulder, Hanneke C. Kluin-Nelemans, Karina Meijer

- O-MO-064** **C1 DOMAIN RESIDUES LYS 2092 AND PHE 2093 ARE OF MAJOR IMPORTANCE FOR THE ENDOCYTIC UPTAKE OF COAGULATION FACTOR VIII** **14:00 - 14:15**  
Alexander B Meijer\* (NL), Henriët Meems, Maartje van den Biggelaar, Mariska Rondaij, Carmen van der Zwaan, Koen Mertens

- O-MO-065** **THE ROLE OF PROTEOLYSIS AT INDIVIDUAL CLEAVAGE SITES IN THE EXPRESSION OF FVIII COFACTOR ACTIVITY** **14:15 - 14:30**  
Mettine H.A. Bos\* (US), Lacramioara Ivanciu, Raffaella Toso, Hua Zhu, Rodney M. Camire

- O-MO-066** **MUTATION OF ALA108ILE IN THE FACTOR VIII A1 DOMAIN ENHANCES AFFINITY FOR LIGHT CHAIN VIA INTERACTION WITH THE C2 DOMAIN AND CONTRIBUTES TO INCREASED FACTOR VIII STABILITY** **14:30 - 14:45**  
Hironao Wakabayashi\* (US), Amy E Griffiths, Masahiro Takeyama, Philip J Fay

- O-MO-067** **THE GAP JUNCTION PROTEIN CONNEXIN37 REGULATES FVIII PLASMATIC ACTIVITY** **14:45 - 15:00**  
Laurent Burnier\* (CH), Pierre Fontana, Brenda R. Kwak, Anne Angelillo-Scherrer

### Megakaryopoiesis and Platelet Production

Room E

*Chairpersons: Benjamin Kile (AU) and Mortimer Poncz (US)*

- O-MO-068** **REGULATOR OF G PROTEIN SIGNALING 18 REGULATES MEGAKARYOPOIESIS AND THE CILIA-MEDIATED VERTEBRATE MECHANOSENSORY SYSTEM** **13:30 - 13:45**  
Kathleen - Freson\* (BE), Sophie Louwette, Chantal Thys, Chantal Wittevrongel, Veerle Labarque, Rik Gijsbers, Zeger Debyser, Jef Arnout, Chris Van Geet, Kathleen Freson



## ORAL COMMUNICATIONS

Monday, July 25, 2011

13:30 - 15:00

Monday Oral

- O-MO-069** **EXPRESSION AND FUNCTION OF LINE-1 DURING MEGAKARYOPOIESIS AND ITS ROLE IN HUMAN PLATELET PROGENY FORMATION** 13:45 - 14:00  
Hansjorg Schwertz\* (US), Larry W Kraiss, Andrew S Weyrich
- O-MO-070** **SEVERE MACROTHROMBOCYTOPENIA AND ABNORMAL MEGAKARYOCYTE DEVELOPMENT IN MICE LACKING SHP1 AND SHP2** 14:00 - 14:15  
Yotis A Senis\* (UK), Alexandra Mazharian, Ying-Jie Wang, Jun Mori, Silke Heising, Benjamin G. Neel, Steve P. Watson, Yotis A. Senis
- O-MO-071** **SILENCING OF RHOA NUCLEOTIDE EXCHANGE FACTOR, ARHGEF3, REVEALS ITS ROLE IN THROMBOPOIESIS AND IRON UPTAKE** 14:15 - 14:30  
Kathleen - Freson\* (BE), Jovana Serbanovic-Canic, Ana Cvejic, Nicole Soranzo, Derek Stemple, Kathleen Freson, Willem Ouwehand
- O-MO-072** **GENETIC TARGETING IN MICE REVEALS THE IMPORTANCE OF RHOA FOR PLATELET FUNCTION IN VITRO AND IN VIVO** 14:30 - 14:45  
Irina Pleines\* (DE), Ina Hagedorn, Shuchi Gupta, Frauke May, Lidija Chakarova, Jolanda van Hengel, Georg Krohne, Cord Brakebusch, Bernhard Nieswandt
- O-MO-073** **REDUNDANT FUNCTIONS OF RHOA AND CDC42 IN PLATELET BIOGENESIS AND ACTIVATION** 14:45 - 15:00  
Lidija Chakarova\* (DE), Irina Pleines, Johanna Andersson, Xunwei Wu, Jolanda van Hengel, Georg Krohne, Cord Brakebusch, Bernhard Nieswandt

### Hemophilia: Clinical Aspects

Sakura

*Chairpersons: Renchi Yang (CN) and Amy Shapiro (US)*

- O-MO-074** **IS THERE A NEED FOR A NEW STRATEGY IN GENOTYPING HAEMOPHILIA A FAMILIES?** 13:30 - 13:45  
Shirin Ravanbod\* (IR), Maryam Rassoulzadegan, Farzaneh Nassirinejad, Ghasem Rastegar Lari, Said Enayat, Fereydoun Ala
- O-MO-075** **XQ28 LARGE DELETIONS DETECTED BY OLIGONUCLEOTIDE ARRAY CGH IN PATIENTS WITH HAEMOPHILIA B AND MENTAL RETARDATION** 13:45 - 14:00  
Christine Vinciguerra\* (FR), Marie-Laure Carage, Audrey Labalme, Dorothee Pellecchia, Mathilde Fretigny, Christophe Zawadzki, Claude Negrier, Damien Sanlaville
- O-MO-076** **OUTCOME IN MODERATE HAEMOPHILIA** 14:00 - 14:15  
Ingrid den Uijl\* (NL), Douwe Biesma, Diederick Grobbee, Kathelijin Fischer



## ORAL COMMUNICATIONS

Monday, July 25, 2011

13:30 - 15:00

O-MO-077

14:15 - 14:30

**NOT MILD AT ALL: VIRAL INFECTIONS (HIV, HBV, HCV) ARE PRESENT IN OVER ONE THIRD OF 2600 MILD AND MODERATE HEMOPHILIA A PATIENTS AND CAUSE 24% OF THE OBSERVED 30-YEAR MORTALITY**

Corien Eckhardt\* (NL), Alice S. van Velzen, Marjolein Peters, Kathelijne Peerlinck, Jan Astermark, Rainer Schwaab, Charles R.M. Hay, Pieter-Willem Kamphuisen, Maria Elisa Mancuso, Johanna G. van der Borm, Karin Fijnvandraat

O-MO-078

14:30 - 14:45

**HEALTH-RELATED QUALITY OF LIFE IN RELATION TO BONE MINERAL DENSITY IN ADULT PATIENTS WITH SEVERE HAEMOPHILIA**

Sylvia von Mackensen\* (DE), Mohammed Khawaji, Jan Astermark, Kristina Akesson, Erik Berntorp

O-MO-079

14:45 - 15:00

**OBESITY-RELATED HEMOSTATIC CHANGES IN HEMOPHILIA PATIENTS**

Attie Tuinenburg\* (NL), Sara Biere-Rafi, Marjolein Peters, Peter Verhamme, Kathelijne Peerlinck, Marieke J.H.A. Kruip, Britta A.P. Laros-van Gorkom, Joost C.M. Meijers, Pieter W. Kamphuisen, Roger E.G. Schutgens

### Malignancy and Thrombosis I

Room A

*Chairpersons: Beverley Hunt (UK) and [REDACTED]*

O-MO-080

13:30 - 13:45

**SURVIVAL IN CANCER PATIENTS WITH AND WITHOUT VTE IN A PROSPECTIVE CASE-CONTROL STUDY: THE MASTER-ONCOLOGY PROJECT**

Giancarlo Agnelli\* (IT), Roberto LaBianca, Claudio Cimminiello, Giovanni Di Minno, Paolo Prandoni, Melina Verso

O-MO-081

13:45 - 14:00

**YOUNG SUBJECTS WITH OVERT CANCER HAVE SIGNIFICANTLY HIGHER RISK OF VENOUS THROMBOEMBOLISM. THE TROMSO STUDY 1994-2007.**

Kristine Blix\* (NO), Sigrid K. Braekkan, Finn E. Skjeldestad, John-Bjarne Hansen

O-MO-082

14:00 - 14:15

**OCCURRENCE OF MYOCARDIAL INFARCTION, ISCHEMIC STROKE AND PULMONARY EMBOLISM IN LUNG CANCER PATIENTS**

PW Kamphuisen\* (NL), Myrthe Van Herk-Sukel, Sumitra Shantakumar, Christof Majoor, Lucy Overbeek, Fennie Penning-van Beest, Ron Herings

O-MO-083

14:15 - 14:30

**INCIDENCE AND RISK FACTORS FOR DEVELOPING VENOUS THROMBOEMBOLISM (VTE) IN JAPANESE PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)**

Kenji Yokoyama\* (JP), Mitsuru Murata, Yasuo Ikeda, Shinichiro Okamoto

O-MO-084

14:30 - 14:45

**A WORLDWIDE SURVEY TO ASSESS THE CURRENT APPROACH TO THE TREATMENT OF PATIENTS WITH CANCER AND VENOUS THROMBOEMBOLISM**

Ankie Kleinjan\* (NL), Pieter W. Kamphuisen, Frederick R. Rickles, Charles Faselis, Dalia Mobarek, Harry R. Buller





## ORAL COMMUNICATIONS

Monday, July 25, 2011

13:30 - 15:00

Monday Oral

O-MO-085

14:45 - 15:00

**TUMOR GRADE IS ASSOCIATED WITH VENOUS THROMBOEMBOLISM IN CANCER PATIENTS: RESULTS FROM THE VIENNA CANCER AND THROMBOSIS STUDY (CATS)**

Jonas Ahlbrecht\* (AT), Boris Dickmann, Cihan Ay, Daniela Dunkler, Johannes Thaler, Manuela Schmidinger, Peter Quehenberger, Andrea Haitel, Christoph Zielinski, Ingrid Pabinger

**Thrombotic Disorders: Clinical I**

Room B-1

*Chairpersons: Valder Arruda (US) and Mashio Nakamura (JP)*

O-MO-086

13:30 - 13:45

**DABIGATRAN DOES NOT INTERACT WITH PF4 OR PF4 BINDING TO PLATELETS AND MIGHT BE USED AS AN ALTERNATIVE ANTICOAGULANT IN HEPARIN-INDUCED THROMBOCYTOPENIA**

Krystin Krauel\* (DE), Christine Hackbarth, Birgitt Fuerll, Andreas Greinacher

O-MO-087

13:45 - 14:00

**COMPLEMENT INHIBITION ATTENUATES COAGULATION, INFLAMMATION AND FIBROSIS IN THE LUNG OF SEPTIC BABOONS**

Florea Lupu\* (US), Hua Zhu, Robert Silasi-Mansat, Narcis Popescu, Glenn Peer, Cristina Lupu, Fetcher B. Taylor, Gary T. Kinasewitz, John D. Lambris

O-MO-088

14:00 - 14:15

**RIVAROXABAN AS A POTENTIAL ALTERNATIVE ANTICOAGULANT IN PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA**

Krystin Krauel\* (DE), Christine Hackbarth, Birgitt Fuerll, Andreas Greinacher

O-MO-089

14:15 - 14:30

**VISUALIZING THE ENDOTHELIAL INVOLVEMENT IN THE PATHOGENESIS OF HEPARIN INDUCED THROMBOCYTOPENIA**

Lubica Rauova\* (US), Vincent M. Hayes, Douglas B. Cines, Mortimer Poncz

O-MO-090

14:30 - 14:45

**EXTENDED FOLLOW-UP OF THE MULTI-CENTER PROSPECTIVE COHORT THAT DERIVED THE "MEN CONTINUE AND HERDOO2" CLINICAL DECISION RULE IDENTIFYING LOW RISK UNPROVOKED PATIENTS**

Marc Alan Rodger\* (CA), Marc Rodger, Mike Kovacs, Gregoire Le Gal, Susan Kahn, David Anderson, Isabelle Chagnon, Philip Wells, Marc Carrier, Mark Crowther, Richard White, Susan Solymoss, Arnaud Perrier

O-MO-091

14:45 - 15:00

**EXTRACELLULAR CHROMATIN IS AN IMPORTANT MEDIATOR OF ISCHEMIC STROKE**

Simon F De Meyer\* (US), Tobias A Fuchs, Georgette L Suidan, Alex Brill, Daphne Schatzberg, Marc Monestier, Markus Napirei, Hans G Mannherz, Denisa D Wagner



## ORAL COMMUNICATIONS

Monday, July 25, 2011

13:30 - 15:00

### VTE: Epidemiology

Room B-2

*Chairpersons: Saskia Middeldorp (NL) and Samuel Goldhaber (US)*

- O-MO-092** **PREVALENCE OF CHRONIC THROMBO-EMBOLIC PULMONARY HYPERTENSION AFTER ACUTE PULMONARY EMBOLISM : A PROSPECTIVE MULTICENTER STUDY** **13:30 - 13:45**  
Olivier Sanchez\* (FR), Laurent Guerin, Francis Couturaud, Florence Parent, Florence Gillaizeau, Gerald Simonneau, Guy Meyer
- O-MO-093** **SEASONAL VARIATION IN THE OCCURRENCE OF VENOUS THROMBOEMBOLISM IN CANADA** **13:45 - 14:00**  
Vicky Tagalakis\* (CA), Dimple Kondal, Antonio Ciampi, Susan Rebecca Kahn
- O-MO-094** **YEAR-LONG, REAL-TIME AUDIT OF HOSPITAL ACQUIRED (HAT) VENOUS THROMBOEMBOLIC EVENTS (VTE), FROM RADIOLOGICAL INVESTIGATIONS IN AN EXEMPLAR CENTRE** **14:00 - 14:15**  
Huw Raymond Rowswell\* (UK), Timothy Nokes, Kathy Clarke
- O-MO-095** **INCIDENCE OF VENOUS THROMBOEMBOLISM (VTE) IN THE GENERAL POPULATION - VTE EPIDEMIOLOGY GROUP (VEG) STUDY** **14:15 - 14:30**  
Carlos Martinez\* (DE), Stephen Rietbrock, Luke Bamber, Alexander T Cohen
- O-MO-096** **INCIDENCE OF VENOUS THROMBOEMBOLISM (VTE) IN THE MEDICALLY-ILL POPULATION - VTE EPIDEMIOLOGY GROUP (VEG) STUDY** **14:30 - 14:45**  
Alexander T Cohen\* (UK), Stephen Rietbrock, Carlos Martinez
- O-MO-097** **RECURRENT VENOUS THROMBOSIS: INCIDENCE AND CHARACTERISTICS IN A LARGE COHORT OF VT PATIENTS (MEGA)** **14:45 - 15:00**  
Linda E Flinterman\* (NL), Astrid Hylckama Vlieg, Suzanne C Cannegieter, Frits R Rosendaal

### Platelet Receptors

Room C-1

*Chairpersons: Stephanie Jung (UK) and Steve Watson (UK)*

- O-MO-098** **COMPARISON OF GENETIC AND ANTIBODY-INDUCED GPVI DEFICIENCY IN DIFFERENT MURINE ARTERIAL THROMBOSIS MODELS** **15:30 - 15:45**  
Ina Hagedorn (DE), Markus Bender\*, Bernhard Nieswandt
- O-MO-099** **SEVERELY DEFECTIVE HEMOSTASIS AND ARTERIAL THROMBUS FORMATION IN GPVI/CLEC-2 DOUBLE-DEPLETED MICE** **15:45 - 16:00**  
Frauke May\* (DE), Markus Bender, Ina Hagedorn, Attila Braun, Bernhard Nieswandt



## ORAL COMMUNICATIONS

Monday, July 25, 2011

15:30 - 17:00

Monday Oral

- O-MO-100** **16:00 - 16:15**  
**A ROLE OF PLATELET C-TYPE LECTIN LIKE RECEPTOR-2 (CLEC-2) IN THROMBUS FORMATION IN VIVO.**  
Osamu Inoue\* (JP), Hokamura Kazuo, Umemura Kazuo, Hatakeyama Kinta, Asada Yujiro, Ozaki Yukio, Suzuki-Inoue Katsue
- O-MO-101** **16:15 - 16:30**  
**CLEC-2 REGULATES LYMPHANGIOGENESIS BY INHIBITING PROLIFERATION, MIGRATION, AND TUBE FORMATION OF LYMPHATIC ENDOTHELIAL CELLS.**  
Makoto Osada\* (JP), Osamu Inoue, Guo Ding, Masanori Hirashima, Yukio Ozaki, Katsue Suzuki-Inoue
- O-MO-102** **16:30 - 16:45**  
**A NOVEL SPLICE VARIANT OF THE MER RECEPTOR TYROSINE KINASE FUNCTIONS AS AN INHIBITOR OF THE GAS6/TAM SIGNALING PATHWAY AND DECREASES PLATELET ACTIVATION RESPONSES**  
Brian R Branchford\* (US), Susan Sather, Gary Brodsky, Tara White-Adams, Deborah DeRyckere, Keith Neeves, Douglas Graham, Jorge Di Paola
- O-MO-103** **16:45 - 17:00**  
**PLATELET NMDA RECEPTORS AS MEDIATORS OF GLUTAMATE EFFECTS ON PLATELET FUNCTION**  
Maggie L Kalev-Zylinska\* (NZ), Marie-Christine Morel-Kopp, Paul Sun, Deborah Young, Matthew J During, Christopher M Ward

### Laboratory Tests for Coagulopathy

Room C-2

*Chairpersons: Masashi Taki (JP) and Anne Angelillo-Scherrer (CH)*

- O-MO-104** **15:30 - 15:45**  
**SEVERITY OF CLINICAL PHENOTYPE IN PEDIATRIC HEMOPHILIA A SUBJECTS IS INVERSELY CORRELATED WITH TISSUE FACTOR-BEARING MICROPARTICLE LEVELS AND ACTIVITY**  
Mona D Shah\* (US), Angela L Bergeron, Molly Behymer, Noha Eyada, Swapan K Dasgupta, Perumal Thiagarajan, Jing-fei Dong
- O-MO-105** **15:45 - 16:00**  
**FVIII-SPECIFIC CD4+ T CELLS ARE IMPORTANT REGULATORS OF FVIII INHIBITOR DEVELOPMENT IN PATIENTS WITH SEVERE HEMOPHILIA A**  
Christoph Hofbauer\* (AT), Eva Altinger, Peter Allacher, Johannes Oldenburg, Jerzy Windyga, Hans Peter Schwarz, Birgit Maria Reipert
- O-MO-106** **16:00 - 16:15**  
**ENOXAPARIN DOWN REGULATES INFLAMMATORY AND THROMBOTIC MEDIATORS IN CANCER PATIENTS AS STUDIED USING PROTEIN AND BIOCHIP ARRAY APPROACHES**  
Debra A Hoppensteadt\* (US), Evangelos Litinas, Hussein Khan, Josephine Cunanan, Indermohan Thethi, Jawed Fareed
- O-MO-107** **16:15 - 16:30**  
**PROCOAGULANT AND INFLAMMATORY MEDIATORS IN SMALL CELL LUNG CARCINOMA: POTENTIAL ROLE IN THROMBOEMBOLIC COMPLICATIONS**  
Indermohan Thethi\* (US), Debra Hoppensteadt, Hussein Kahn, Muzzafer Demir, Cafer Adiguzel, Evangelos Litinas, Jawed Fareed



21

## ORAL COMMUNICATIONS

Monday, July 25, 2011

15:30 - 17:00

**O-MO-108** **16:30 - 16:45**

**ADAPTATION OF THE CALIBRATED AUTOMATED THROMBOGRAPHY ASSAY FOR ACCURATE PK/PD MEASUREMENT OF BAY 86-6150 FVIII THERAPY IN CLINICAL TESTING FOR HEMOPHILIA A**  
Timothy Myles\* (US), Ji-Yun Kim, Claus Bornaes, Juliang Pan, John E. Murphy, Jesper Haaning

**O-MO-109** **16:45 - 17:00**

**SIGNIFICANT IMPROVEMENT OF THE BETWEEN-LABORATORY VARIATION OF FVIII INHIBITOR TESTING: RESULTS OF A WORKSHOP**  
H W Verbruggen\* (NL), Bert Verbruggen, Myriam Dardikh, Clint van Duren, Robert Polenewen, Piet Meijer

### Tissue Factor and Tissue Factor Pathway Inhibitor

Room D

*Chairpersons: ESTEBAN GABAZZA (JP) and*

**O-MO-110** **15:30 - 15:45**

**TISSUE FACTOR-DEPENDENT CHEMOKINE PRODUCTION AGGRAVATES EXPERIMENTAL COLITIS**  
Karla CS Queiroz\* (NL), Cornelis van t Veer, Yascha van den Berg, Jan Willem Duitman, Henri H Versteeg, Hella L Aberson, Angelique P Groot, Marlen I Verstege, Joris J.T.H. Roelofs, Anje A te Velde, C Arnold Spek

**O-MO-111** **15:45 - 16:00**

**TISSUE FACTOR DEENCRYPTION IS REQUIRED FOR NORMAL DEVELOPMENT AND HEMOSTASIS**  
Susanna HM Sluka\* (CH), Alexander Akhmedov, Giovanni G Camici, Thomas F Luscher, Felix C Tanner

**O-MO-112** **16:00 - 16:15**

**INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR (TFPI) BY SMALL PEPTIDES PROTECTS FXA AND ENHANCES FXA AND THROMBIN FORMATION IN MODEL SYSTEMS AND IN PLASMA**  
Michael Dockal\* (AT), M. C.L.G.D. Thomassen, A. C.A. Heinzmann, C. Duckers, R. Hartmann, F. Scheiflinger, J. Rosing

**O-MO-113** **16:15 - 16:30**

**INHIBITION OF TISSUE FACTOR ATTENUATES COAGULATION AND INFLAMMATION IN A MOUSE MODEL OF SICKLE CELL DISEASE**  
Pichika Chanrathammachart\* (US), Nigel S. Key, Daniel Kirchhofer, Nigel Mackman, Rafal Pawlinski

**O-MO-114** **16:30 - 16:45**

**TISSUE FACTOR PATHWAY INHIBITOR APTAMER AS A POTENTIAL DRUG FOR HEMOPHILIA TREATMENT**  
Saulius Butenas\* (US), Matthew Gissel, Thomas Orfeo, Kenneth G. Mann

**O-MO-115** **16:45 - 17:00**

**TISSUE FACTOR PATHWAY INHIBITOR (TFPI) AND TISSUE FACTOR (TF) CO-LOCALIZE IN LIPID RAFTS OF PLATELET MEMBRANES: MECHANISM TO INHIBIT PLATELET PROCOAGULANT (PCA) ACTIVITY?**  
Panos Olga\* (CL), Cesar Gonzalez, Valeria Matus, Jaime Pereira, Diego Mezzano



## ORAL COMMUNICATIONS

Monday, July 25, 2011

15:30 - 17:00

Monday Oral

### P2Y<sub>12</sub> Antagonists

Room E

Chairpersons: Christian Gachet (FR) and Stan Heptinstall (UK)

- O-MO-116** 15:30 - 15:45  
**DETECTION OF CLOPIDOGREL RESISTANCE: COMPARISON OF A NEW, P2Y<sub>12</sub> RECEPTOR SPECIFIC PLATELET AGGREGATION TEST AND OTHER LABORATORY METHODS IN PATIENTS ON CLOPIDOGREL MONOTHERAPY**  
Zsuzsa Bagoly\* (HU), Ferenc Sarkady, Tunde Magyar, Endre Pongracz, Janos Kappelmayer, Laszlo Csiba, Laszlo Muszbek
- O-MO-117** 15:45 - 16:00  
**BENEFIT OF TAILORED THERAPY WITH HIGH CLOPIDOGREL MAINTENANCE DOSE ACCORDING TO CYP2C19 GENOTYPES IN CLOPIDOGREL NON RESPONDERS UNDERGOING CORONARY STENTING FOR ACS**  
Marie-Christine Alessi\* (FR), Thomas Cuisset, Jacques Quilici, William Cohen, Laurent Fourcade, Charlotte Grosdidier, Noemie Saut, Benedicte Gaborit, Mathieu Pankert, Laurent Molines, Pierre-Emmanuel Morange, Jean Louis Bonnet
- O-MO-118** 16:00 - 16:15  
**PLATELET INHIBITION BY ADJUNCTIVE CILOSTAZOL VERSUS HIGH MAINTENANCE-DOSE CLOPIDOGREL IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION ACCORDING TO CYTOCHROME P450 2C19 GENOTYPE**  
Young-Hoon Jeong\* (US), In-Suk Kim, Yongwhi Park, Seong-Eun Yun
- O-MO-119** 16:15 - 16:30  
**IS THERE A "REBOUND" AFTER CESSATION OF ANTIPLATELET THERAPY? FIRST COMPARISON OF IRREVERSIBLE VERSUS REVERSIBLE P2Y<sub>12</sub> RECEPTOR BLOCKER**  
Paul Alfred Gurbel\* (US), Kevin P Bliden, MArk J Antonino, Martin Gesheff, Young-Hoon Jeong, Udaya S Tantry
- O-MO-120** 16:30 - 16:45  
**ROLE OF NEWLY FORMED PLATELETS IN THROMBUS FORMATION AFTER CLOPIDOGREL TREATMENT: COMPARISON TO THE REVERSIBLY BINDING P2Y<sub>12</sub> ANTAGONIST TICAGRELOR**  
Marijke J.E. Kuijpers (NL), Remco T.A. Megens, Elham Nikookhesal, Marion A.H. Feijge, Mirjam G.A. oude Egbrink, Jo G.R. De Mey, J. J.J. van Giezen, Johan W.M. Heemskerck\*
- O-MO-121** 16:45 - 17:00  
**BF061, A NOVEL ANTIPLATELET AND ANTITHROMBOTIC AGENT TARGETING P2Y<sub>12</sub> AND PDE**  
Liang Hu\* (CN), Zhichao Fan, Hongguang Du, Ran Ni, Si Zhang, Kanhua Yin, Jianqin Ye, Yan Zhang, Xunbing Wei, Xiaohui Zhang, Peter Gross, Satya P. Kunapul, Zhongren Ding

### Acquired Coagulation Disorders

Sakura

Chairpersons: Paul Edward Monahan and [REDACTED]

- O-MO-122** 15:30 - 15:45  
**BIOCHEMICAL CHARACTERIZATION OF ANTI-FACTOR XIII AUTOANTIBODIES IN PATIENTS WITH HEMORRHAGIC ACQUIRED FACTOR XIII DEFICIENCY**  
Masayoshi Soury\* (JP), Hiroki Iwata, Wei Guang Zhang, Akitada Ichinose



23

## ORAL COMMUNICATIONS

Monday, July 25, 2011

15:30 - 17:00

- O-MO-123** **ROTATIONAL THROMBOELASTOMETRY IN CIRRHOSIS: HYPERCOAGULABLE AND HYPERFIBRINOLYTIC** 15:45 - 16:00  
Paul Harrison\* (UK), Vipil Jairath, Simon Stanworth, Amber Raja, Jane Collier, Mike Murphy, Ellie Barnes
- O-MO-124** **LEFT VENTRICULAR ASSIST DEVICES CAUSE LOSS OF VON WILLEBRAND FACTOR ACTIVITY BY PROMOTING ITS PROTEOLYTIC CLEAVAGE** 16:45 - 17:00  
Han-Mou Tsai\* (US), William J Weiss, Evan Leibner, Branka Lukic, Wenhua Zhou, Gerson Rosenberg
- O-MO-125** **FACTOR SEVEN ACTIVATING PROTEASE (FSAP) IS ACTIVATED MASSIVELY IN MULTIPLE TRAUMA PATIENTS AND IN TURN ACTIVATES COMPLEMENT FACTORS.** 16:15 - 16:30  
Sandip M Kanse\* (DE), Andrea Gallenmueller, Marcus Krueger, Markus Huber-Lang
- O-MO-126** **POST CARDIAC COAGULOPATHY; A 48 HOURS LONGITUDINAL DESCRIPTIVE STUDY BASED ON WHOLE BLOOD CLOT FORMATION AND THROMBIN GENERATION** 16:30 - 16:45  
Mariann Tang\* (UK), Per Wierup, Kirsten Christiansen, Jacob Greisen, Benny Soerensen
- O-MO-127** **ACTIVATED PROTEIN C IS A PRINCIPLE MEDIATOR OF ACUTE TRAUMATIC COAGULOPATHY** 16:00 - 16:15  
Ross Davenport\* (UK), Claire Rourke, Joanna Manson, Henry De'Ath, Sean Platten, Amy Coates, Daniel Hart, Pasi Pearse, John Pasi, Simon Stanworth, Karim Brohi

### Malignancy and Thrombosis II

Room A

Chairpersons: Sigrid Braekkan (NO) and Roberto Labianca

- O-MO-128** **VENOUS THROMBOEMBOLISM IN CANCER PATIENTS: REGIONAL LYMPH NODE METASTASIS AS A RISK FACTOR** 15:30 - 15:45  
Boris Dickmann\* (AT), Jonas Ahlbrecht, Cihan Ay, Daniela Dunkler, Johannes Thaler, Roman Kanz, Werner Scheithauer, Peter Quehenberger, Christoph Zielinski, Ingrid Pabinger
- O-MO-129** **INCIDENTAL AND SYMPTOMATIC VENOUS THROMBOEMBOLIC EVENTS ARE ASSOCIATED WITH INCREASED MORTALITY IN LUNG CANCER PATIENTS.** 15:45 - 16:00  
Gregory Clayton Connolly\* (US), Laurel Menapace, Tarek Sousou, Saman Safadjou, Khorana Alok
- O-MO-130** **MALIGNANCIES AND RISK OF RECURRENT VENOUS THROMBOSIS** 16:00 - 16:15  
Jasmijn F Timp\* (NL), Linda E Flinterman, Astrid van Hylckama Vlieg, Frits R Rosendaal, Suzanne C Cannegieter



## ORAL COMMUNICATIONS

Monday, July 25, 2011

15:30 - 17:00

Monday Oral

- O-MO-131** **VENOUS THROMBOEMBOLISM (VTE) IN THE CANCER OUTPATIENT SETTING: CONTEMPORARY RATES AND PREDICTORS IN THE U.S.** 16:15 - 16:30  
Alok A Khorana\* (US), Mehul Dalal, Jay Lin, Gregory Connolly
- O-MO-132** **CELL FREE DNA AS A NOVEL PROCOAGULANT STIMULUS IN BREAST CANCER CHEMOTHERAPY** 16:30 - 16:45  
Laura Swystun\* (CA), Patricia C Liaw
- O-MO-133** **MICROPARTICLE-ASSOCIATED TISSUE FACTOR ACTIVITY AND OCCURRENCE OF VENOUS THROMBOEMBOLISM IN BRAIN, GASTROINTESTINAL AND PANCREATIC CANCER** 16:45 - 17:00  
Cihan Ay\* (AT), Nigel Mackman, Nigel S Key, Alexandra Kaider, Johannes Thaler, Christine Marosi, Christoph Zielinski, Ingrid Pabinger

### Von Willebrand Disease

Room B-1

Chairpersons: Ulrich Budde (DE) and 

- O-MO-134** **CHARACTERIZATION OF BLOOD OUTGROWTH ENDOTHELIAL CELLS DERIVED FROM VON WILLEBRAND DISEASE PATIENTS** 15:30 - 15:45  
Jiong-Wei Wang\* (NL), Eveline Bouwens, Carolina Pintao, Jan Voorberg, Karine M Valentijn, Hetty C de Boer, Pieter H Reitsma, Jeroen Eikenboom
- O-MO-135** **GENETIC VARIATIONS IN SNARE PROTEIN GENES DETERMINE VON WILLEBRAND FACTOR PLASMA LEVELS IN PATIENTS WITH TYPE I VON WILLEBRAND DISEASE** 15:45 - 16:00  
Janine E. van Loon\* (NL), Eva M. de Wee, Yvonne V. Sanders, Moniek P.M. de Maat, Frank W.G. Leebeek
- O-MO-136** **AN L1278P VON WILLEBRAND FACTOR (VWF) MUTATION IDENTIFIED IN A TYPE 1 VWD PATIENT CAUSES REDUCED VWF SECRETION AND INCREASED VWF CLEARANCE** 16:00 - 16:15  
Sandra Haberichter\* (US), Jocelyn A. Schroeder, Paula M. Jacobi, Ashley L. Gehrand, Kenneth D. Friedman, Donna DiMichele, Robert R Montgomery
- O-MO-137** **GENETIC VARIABILITY OF THE CLEC4M ENDOTHELIAL LECTIN RECEPTOR IN TYPE 1 VON WILLEBRAND DISEASE** 16:15 - 16:30  
Natalia Rydz\* (CA), B. Boonyawat, J. J. Riches, W. Hopman, A. Paterson, R. Montgomery, D. Lillicrap, P. D. James, For the ZPMCB-VWD Study Group
- O-MO-138** **COPY NUMBER VARIATION IS A SIGNIFICANT CONTRIBUTOR TO TYPE 1 VWD PATHOGENESIS IN THE EU MCMDM-1VWD COHORT** 16:30 - 16:45  
Daniel J Hampshire\* (UK), Ashley Cartwright, Lisa D Bloomer, Ahlam M Al-Buhairan, Raymon N C P Vijzelaar, David Habart, Frank G H Hill, Francesco Rodeghiero, Ulrich Budde, Jeroen C J Eikenboom, Ian R Peake, Anne C Goodeve, on behalf of the EU-VWD and ZPMCB-VWD study groups



25

## ORAL COMMUNICATIONS

Monday, July 25, 2011

15:30 - 17:00

O-MO-139

**CLASSIFICATION OF A LARGE COHORT OF PATIENTS WITH VON WILLEBRAND DISEASE BETWEEN 2004 AND 2010**

Ulrich Budde\* (DE), Sonja Schneppenheim, Rita Dittmer, Reinhard Schneppenheim

16:45 - 17:00

**Thrombotic Disorders: Experimental Models**

Room B-2

*Chairpersons: Nobuo Nagai (JP) and Alvin Schmaier (US)*

O-MO-140

**NON-HUMAN PRIMATE MODEL OF HEMOLYTIC UREMIC SYNDROME AND THERAPEUTIC TESTING**

Shinichiro Kurosawa\* (US), Deborah J. Stearns-Kurosawa

15:30 - 15:45

O-MO-141

**CD36 PARTICIPATES IN A SIGNALING PATHWAY THAT REGULATES ROS FORMATION AND CONTRIBUTES TO THROMBOSIS AND NEOINTIMAL HYPERPLASIA**

Wei Li\* (US), Roy L Silverstein

15:45 - 16:00

O-MO-142

**IDENTIFICATION OF ENU-INDUCED AND STRAIN MODIFIER GENES FOR FACTOR V LEIDEN DEPENDENT THROMBOSIS IN THE MOUSE**

Randal J Westrick\* (US), Guojing Zhu, Sara L Manning, Angela Y Yang, Audrey C.A. Cleuren, David R Siemieniak, David Ginsburg

16:00 - 16:15

O-MO-143

**EARLY DEATH OF FACTOR V LEIDEN HEMIZYGOUS MICE: A FATAL ABSENCE OF WILD TYPE FV ANTICOAGULANT FUNCTION**

Audrey CA Cleuren\* (NL), Hongmin Sun, Guojing Zhu, Bart JM van Vlijmen, Pieter H Reitsma, David Ginsburg, Randal J Westrick

16:15 - 16:30

O-MO-144

**REGULATION OF VKORC1 EXPRESSION BY MICRORNAS AND ITS POTENTIAL EFFECT ON ACENOCOUMAROL REQUIREMENTS.**

Virginia Perez-Andreu\* (ES), Raul Teruel, Rocio Gonzalez-Conejero, Javier Corral, Vanessa Roldan, Nuria Garcia-Barbera, Maria Jose Gomez-Lechon, Vicente Vicente-Garcia, Constantino Martinez

16:30 - 16:45

O-MO-145

**ADMINISTRATION OF THE ANTI-FXI ANTIBODY, 14E11, IMPROVES NEUROLOGICAL FUNCTION IN A MOUSE MODEL OF STROKE**

Owen J McCarty\* (US), Sawan Hurst, Norah Verbout, Erik I Tucker, David Gailani, Michelle A. Berny-Lang, Andras Gruber

16:45 - 17:00





## POSTER PRESENTATIONS

Monday, July 25, 2011

Monday Posters

- P-LB-001 HEPARIN-INDUCED THROMBOCYTOPENIA (HIT); RETROSPECTIVE ANALYSIS OF DATA ON INCIDENCE AND OUTCOMES (HIT-RADIO STUDY)**  
David J Kuter\* (US), E Gerstenberger, Barbara A Konkle, L Uhl, S F Assmann, T L Ortel
- P-LB-002 EFFECTS OF TANSHINONEIIA ON INFLAMMATORY CYTOKINES AND GMP-140 IN THE PATIENT WITH KAWASAKI DISEASES**  
Qing Zhang\* (CN)
- P-LB-003 PREVENTION OF VENOUS THROMBOEMBOLISM (VTE) WITH THE ULTRA-LOW-MOLECULAR-WEIGHT HEPARIN (ULMWH) SEMULOPARIN IN CANCER PATIENTS INITIATING CHEMOTHERAPY: THE SAVE ONCO STUDY**  
Giancarlo Agnelli\* (IT), Daniel George, William Fisher, Ajay Kakkar, Michael R. Lassen, Patrick Mismetti, Patrick Mouret, Umesh Chaudhari, Alexander G.G. Turpie
- P-LB-004 MULTI-CENTER TRIAL OF DESIRUDIN FOR THE PROPHYLAXIS OF THROMBOSIS: AN ALTERNATIVE TO HEPARIN-BASED ANTICOAGULATION: RESULTS FROM THE DESIRABLE TRIAL**  
Jerrod H Levy\* (US), Sergio D Bergese, Amir Jaffer, Harold S Minkowitz, Michael A Kurz, David C Sane
- P-LB-006 RIVAROXABAN VERSUS ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS: ANALYSIS OF FACTORS CONTRIBUTING TO BENEFIT AND RISK IN MAGELLAN**  
Alexander T Cohen\* (UK), Theodore E. Spiro, Harry R. Buller, Lloyd Haskell, Dayi Hu, Russell Hull, Alexandre Mebazaa, Geno Merli, Sebastian Schellong, Alex Spyropoulos, Victor Tapson
- P-LB-007 XAMOS: A NON-INTERVENTIONAL STUDY OF RIVAROXABAN IN THE PROPHYLAXIS OF VENOUS THROMBOEMBOLISM AFTER HIP OR KNEE SURGERY**  
Sylvia Haas\* (DE), Alexander G.G. Turpie, Michael Lassen, Lorenzo Mantovani, Reinhold Kreutz, Waheed Jamal, Andre Schmidt
- P-LB-008 THE ROLE OF HLA-ANTIGENS AS PREDISPOSING AND/OR PROTECTIVE FACTORS IN PATIENTS WITH IDIOPATHIC THROMBOTIC THROMBOCYTOPENIC PURPURA**  
Marie-Luise John\* (DE), Inge Scharrer
- P-LB-009 METHOD COMPARISON BETWEEN RISTOCETIN-INDEPENDENT AND RISTOCETIN-DEPENDENT VWF ACTIVITY ASSAYS**  
Michelle Ann Stapleton\* (US), Marcy Lloyd, Allison Kremers
- P-LB-011 PROTEIN S ALTERS DIFFERENTIATION, MATURATION AND ANTIGEN PRESENTATION OF MURINE DENDRITIC CELLS IN VITRO**  
Yuki Matsushima\* (JP), Masaaki Toda, Yasushi Miyake, Atsushi Yasukawa, Corina N Gabazza, Takehiro Takagi, Masahiro Naito, Daniel Boveda Ruiz, Paloma Gil Bernabe, Osamu Taguchi, John Morser, Esteban C Gabazza
- P-LB-012 MOLECULAR BASIS OF HEREDITARY FACTOR VII DEFICIENCY IN SEVEN UNRELATED TUNISIAN PATIENTS**  
Hejer Elmahmoudi\* (TN), Rim Sassi, Asma Jilizi, Kaouther Zahra, Belkis Meddeb, Amel Elgaaied Ben Ammar, Emna Gouider
- P-LB-013 RE-CANALIZATION OF CHRONIC DEEP VEIN THROMBOSIS WITH COMBINATION OF HERBAL MEDICINES DESCRIBED IN AYURVEDA**  
Abhay Narayan Kulkarni\* (IN)



27

## POSTER PRESENTATIONS

Monday, July 25, 2011

### Signal transduction of platelet activation

- P-MO-001 REGULATION OF RAP1B LOCALIZATION AND FUNCTION BY PROSTAGLANDIN E<sub>1</sub> (PGE<sub>1</sub>)**  
Jaclyn A Porath\* (US), Jenny H Petkova, Gilbert C White, II
- P-MO-002 PLATELET REACTIVITY INCREASED BY ADVANCE GLYCATED HEMOGLOBIN**  
Bahram Alamdary Badlou\* (IR), M. Bakhti, M. Habibi-Rezaei, A.A. Moosavi-Movahedi, SMR. Tabatabai, M. Asadifar, M. Ahmadinejad
- P-MO-003 PLATELET ACTIVATORS (VWF, THROMBIN, COLLAGEN) INITIATE NOVEL INHIBITORY PATHWAYS INVOLVING NO-INDEPENDENT ACTIVATION OF PKG AND CAMP-INDEPENDENT ACTIVATION OF PKA**  
Stepan Gambaryan\* (DE), Anna Kobsar, Sabine Herterich, Suzanne M Lohmann, Ulrich Walter
- P-MO-004 PEAR1 PROMOTES STABILIZATION OF PLATELET AGGREGATES VIA A PI3K PATHWAY**  
Alexandre Kauskot\* (BE), Serena Loyen, Chantal Thys, Peter Verhamme, Marc Florimond Hoylaerts
- P-MO-005 THE ALZHEIMER'S DISEASE ASSOCIATED AMYLOID  $\beta$ -PEPTIDE SUPPORTS PLATELET ADHESION AND ACTIVATION.**  
Ilaria Canobbio\* (IT), Silvia Catricala, Gianni Guidetti, Lina Cipolla, Alessandra Consonni, Cesare Balduini, Mauro Torti
- P-MO-006 SYNAPTOTAGMIN-LIKE PROTEIN 4 REGULATES PLATELET GRANULE SECRETION**  
Ashling Hampson\* (IE), Olga Neumuller, Kristina Gegenbauer, Albert Smolenski
- P-MO-007 12-LIPOXYGENASE MEDIATES PRO- AND ANTI-THROMBOTIC EFFECTS IN HUMAN PLATELETS VIA METABOLISM OF ARACHIDONIC ACID AND DGLA TO 12(S)-HETE AND 12(S)-HETRE, RESPECTIVELY**  
Michael Holinostat\* (US), Jennifer Yeung, Patrick L. Apopa, Joanne Vescei, Theodore R. Holman
- P-MO-008 REGULATOR OF G-PROTEIN SIGNALLING PROTEIN 18 (RGS18) IS A TARGET OF CYCLIC NUCLEOTIDE MEDIATED PLATELET INHIBITION**  
Kristina Gegenbauer\* (IE), Giuliano Elia, Alfonso Blanco, Albert Smolenski
- P-MO-009 PHOSPHOLIPASE D1, BUT NOT PLD2, IS ESSENTIAL FOR EFFICIENT GPIIb-DEPENDENT  $\alpha$ IIB $\beta$ 3 ACTIVATION**  
David Stegner\* (DE), Ina Thielmann, Ina Hagedorn, Christoph Kleinschnitz, Attila Braun, Johan W.M. Heemskerck, Guido Stoll, Bernhard Nieswandt
- P-MO-010 AGONIST INDUCED  $\alpha$ IIB $\beta$ 3 ACTIVATION IN GENETICALLY ENGINEERED HUMAN MEGAKARYOBLASTIC CELL LINE, CMK.**  
Tsuyoshi Nakazawa\* (JP), Tsuyoshi Kamae, Kazunobu Kiyomizu, Seiji Tadokoro, Shigenori Honda, Hirokazu Kashiwagi, Yuzuru Kanakura, Yoshiaki Tomiyama

### Biology of platelets

- P-MO-011 VWF MORPHOLOGY ON FIBRILLAR AND NON-FIBRILLAR COLLAGEN CONTROLS PLATELET DEPOSITION AT ARTERIAL AND PATHOLOGICAL SHEAR: SIPA IN MICROFLUIDIC CHAMBERS IS SENSITIVE TO AIIBB3.**  
Thomas Colace\* (US), Scott L Diamond
- P-MO-012 DIFFERENTIAL REGULATION OF PLATELET CONTACT AND SPREADING MONITORED BY REFLECTION INTERFERENCE CONTRAST MICROSCOPY**  
Dooyoung Lee\* (US), Karen P. Fong, Lawrence F. Brass, Daniel A. Hammer



## POSTER PRESENTATIONS

Monday, July 25, 2011

Monday Posters

- P-MO-013 PLATELET REACTIVITY IS A STABLE AND GLOBAL PHENOMENON IN ASPIRIN-TREATED CARDIOVASCULAR PATIENTS**  
Anne Zufferey\* (CH), Jean-Luc Reny, Christophe Combescure, Philippe de Moerloose, Jean-Charles Sanchez, Pierre Fontana
- P-MO-014 THE RESTRICTED DELETION OF THE PODOCALYXIN GENE IN MEGAKARYOCYTES PERTURBS THE CONTROL OF HEMOSTASIA**  
Matilde S. Ayuso\* (ES), Miguel Pericacho, Sonia Alonso-Martin, Susana Larrucea, Consuelo Gonzalez-Manchon, Dario Fernandez, Roberto Parrilla
- P-MO-015 MEASUREMENT OF PROCOAGULANT MICROVESICLES GENERATED WITHIN AGEING PLATELET CONCENTRATES**  
Abdulmajeed Abdullah Albanyan\* (SA), Abdulmajeed Albanyan, B Curry, R Dragovic, C Gardiner, J Biggerstaff, M Murphy, P Harrison
- P-MO-016 BCL-X<sub>L</sub> INHIBITORY BH3 MIMETICS CAN INDUCE A TRANSIENT THROMBOCYTOPATHY THAT UNDERMINES THE HEMOSTATIC FUNCTION OF PLATELETS**  
Simone Marianne Schoenwaelder\* (AU), Kate Jarman, Elizabeth Gardiner, JianLin Qiao, Michael J White, Emma C Josefsson, Imala Alwis, Robert K Andrews, Kylie D Mason, Hatem H Salem, David C.S. Huang, Benjamin T Kile, Andrew W Roberts, Shaun P Jackson
- P-MO-017 DETECTION OF THE AMINOPHOSPHOLIPID TRANSLOCASE ATP8A1 IN HUMAN PLATELETS AND ITS CLEAVAGE WHEN CALPAIN IS ACTIVATED**  
Hong Wang (CA), Adam M Gwozdz, KW Annie Bang, Marian A Packham, Margaret L Rand\*
- P-MO-018 POTENTIALITY TO NEGATIVE-REGULATE BDNF EXPRESSION VIA FORMING SENSE/ ANTISENSE DOUBLE STRAND RNA IN MEGAKARYOCYTIC CELL LINE, MEG-01**  
Shogo Tamura\* (JP), Tetsuya Tsunematsu, Masanao Hatase, Kazuhiko Matsuno, Seiichi Kobayashi, Takanori Moriyama
- P-MO-019 HYPERTHERMIA INHIBITS PLATELET HAEMOSTATIC FUNCTIONS AND SELECTIVELY REGULATES THE RELEASE OF  $\alpha$ -GRANULE PROTEINS.**  
Soledad Negrotto\* (AR), Julia Etulain, Maria J Lapponi, Santiago J Patrucchi, Maria A Romaniuk, Agustina Carestia, Giannoula L Klement, Mirta Schattner

### Integrins and other glycoproteins

- P-MO-020 MOLECULAR BASIS FOR FIBRIN BINDING BY PLATELET INTEGRIN  $\alpha_{IIb}\beta_3$**   
Nataly Podolnikova\* (US), Valentin P. Yakubenko, Tatiana P. Ugarova
- P-MO-021 THE PDZ PROTEIN SYNTENIN-1 ASSOCIATES WITH TETRASPANINS CD63 AND CD9 IN ACTIVATED PLATELETS**  
Sara J Israels\* (CA), Eileen M. McMillan-Ward
- P-MO-022 STAPHYLOCOCCUS AUREUS IRON REGULATED SURFACE PROTEIN (ISDB) DIRECTLY BINDS TO PLATELET INTEGRIN GPIIb/IIIa**  
Marta Anna Zapotoczna\* (IE), Timothy J. Foster
- P-MO-023 COATED PLATELETS FORM AGGREGATES WITH NON-COATED ONES, BUT DO NOT AGGREGATE WITH EACH OTHER**  
Alena O Yakimenko (RU), Yana N Kotova, Fazoil I Ataulakhanov, Mikhail A Panteleev\*
- P-MO-024 GLANZMANN'S THROMBASTHENIA: IDENTIFICATION OF 25 NEW MUTATIONS IN 25 PATIENTS**  
qingya cui\* (CN), qingya cui, ziqiang yu, jian su, xia bai, wei zhang, mingqing zhu, wenhong shen, li chen, changgeng ruan



29

## POSTER PRESENTATIONS

Monday, July 25, 2011

- P-MO-025 APPLICATION OF  $\alpha$ IIb $\beta$ 3 NANODISCS TO DIRECTLY ASSESS EXTENSION OF  $\alpha$ IIb $\beta$ 3 INDUCED BY  $\alpha$ IIb $\beta$ 3 ANTAGONISTS BY ELECTRON MICROSCOPY.**  
Won-Seok Choi\* (US), Barry S. Coller
- P-MO-026 GPIIb/IIIa-MEDIATED PLATELET APOPTOSIS**  
Asuman Mutlu (CA), Armen V Gyulkhandanyan, Sergiy Mykhaylov, David J Allen, Elena Lyubimov, Anna Chavlovski, Alan Lazarus, John Freedman, Valery Leytin\*
- P-MO-027 THROMBIN-INDUCED INTERACTION BETWEEN HUMAN PLATELETS AND FIBRINOGEN  $\gamma$ -CHAIN DODECAPEPTIDE-MODIFIED LIPOSOMES AS A SYNTHETIC PLATELET SUBSTITUTE.**  
Hidenori Suzuki\* (JP), Yosuke Okamura, Yasuo Ikeda, Shinji Takeoka, Makoto Handa
- P-MO-028 A MUTATION IN THE  $\beta$ 3 CYTOPLASMIC TAIL WHICH CAUSES VARIANT GLANZMANN THROMBASTENIA ABROGATES THE TRANSITION OF  $\alpha$ IIb $\beta$ 3 TO THE ACTIVE STATE**  
Hagit Hauschner\* (IL), Ronit Mor-Cohen, Uri Seligsohn, Nurit Rosenberg
- P-MO-029 DIFFERENT STRUCTURAL AND FUNCTIONAL ROLES FOR INTEGRIN UNIQUE DISULFIDE BONDS IN THE  $\beta$ 3 SUBUNIT OF  $\alpha$ IIb $\beta$ 3 AND  $\alpha$ v $\beta$ 3**  
Ronit Mor-Cohen\* (IL), Nurit Rosenberg, Yulia Einav, Ehud Zelzion, Wissam Mansour, Yulia Averbukh, Uri Seligsohn
- P-MO-030 GPVI, WHICH RECOGNIZES A HIGHER ORDER STRUCTURE IN COLLAGEN, IS MARKEDLY INCREASED UPON PLATELET ACTIVATION**  
Stephanie May Jung\* (UK), Masaaki Moroi, Kenji Soejima, Tomohiro Nakagaki, Michael Berndt, Elizabeth Gardiner, Steve P Watson, Richard W Farndale

### Platelet receptors

- P-MO-031 LXR AS AN ANTI-THROMBOTIC TARGET**  
Michael Spyridon\* (UK), Leonardo A Moraes, Chris I Jones, Tanya Sage, Parvathy Sasikumar, Jonathan M Gibbins
- P-MO-032 THE INTRACELLULAR COLLAGEN CHAPERONE HSP47 IS A COLLAGEN ADHESION PROTEIN ON THE SURFACE OF PLATELETS REQUIRED FOR NORMAL THROMBOSIS AND HAEMOSTASIS**  
Jonathan Gibbins\* (UK), William J Kaiser, Parvathy Sasikumar, Tanya Sage, Laura Dobson, Nicholas Pugh, Lisa Holbrook
- P-MO-033 RECIPROCAL REGULATION OF PLATELET FUNCTION BY ENDOGENOUS PROSTAGLANDINS - EXPERIMENTAL DATA AND MATHEMATICAL MODELING**  
Jorg Geiger\* (DE), Katharina Hubertus, Maxime Moulard, Marcel Mischnik, Jens Timmer, Ulrich Walter
- P-MO-034 PECAM-1 CLUSTERING REDUCES SURFACE EXPRESSION OF GPIB ON PLATELETS WHICH IMPAIRS THE BINDING OF THROMBIN AND DIMINISHES PLATELET ACTIVATION**  
Chris Ian Jones\* (UK), Leonardo A Moraes, Kirk Taylor, Emily Knight, Jonathan M Gibbins
- P-MO-035 SIGNALING ROLE OF CD36 IN PLATELET ADHESION AND SPREADING**  
Reyhaneh Nergiz-Unal\* (NL), Moniek M.E. Lamers, Roger van Kruchten, Judith M.E.M. Cosemans, Joost Luiken, Jan F.C. Glatz, Marijke J.E. Kuijpers, Johan W.M. Heemskerk
- P-MO-036 TRANSMEMBRANE DOMAINS ARE CRITICAL TO THE INTERACTION BETWEEN PLATELET GLYCOPROTEIN V AND GLYCOPROTEIN IB-IX COMPLEX**  
Xi Mo\* (CN), Jose A Lopez, Renhao Li



## POSTER PRESENTATIONS

Monday, July 25, 2011

Monday Posters

- P-MO-037 KAINATE RECEPTOR INHIBITOR UBP-302 REDUCES HOMOCYSTEINE- ENHANCED PLATELET AGGREGATION**  
Cezary W Watala\* (PL), Kamil Karolczak
- P-MO-038 PAR4 MEDIATES THROMBIN-INDUCED PRO-COAGULANT ACTIVITY IN HUMAN PLATELETS**  
Hannah Lee\* (AU), Cheryl Berndt, Elizabeth E Gardiner, Robert K Andrews, Shaun P Jackson, Justin R Hamilton
- P-MO-039 PAI-1 SECRETION, RE-SYNTHESIZING & THE ROLE OF THROMBIN RECEPTORS IN PLATELETS**  
Martina Nylander\* (SE), Emma Lofgren, Anders Larsson, Tomas L Lindahl

### Megakaryocytes and thrombopoiesis

- P-MO-040 PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) IMPAIRS APOPTOSIS DURING MEGAKARYOPOIESIS BY ACTIVATING NF- $\kappa$ B: A PROTEOMIC STUDY**  
Michela Di Michele\* (BE), Karen Peeters, Serena Loyen, Etienne Waelkens, Lutgart Overbergh, Marc Hoylaerts, Chris Van Geet, Kathleen Freson
- P-MO-041 DIFFERENTIATION OF OP9 BONE MARROW STROMA CELLS INTO MEGAKARYOCYTES AND PLATELETS VIA A P45NF-E2-MEDIATED MECHANISM**  
Yumiko Matsubara\* (JP), Yukako Ono, Hidenori Suzuki, Fumio Arai, Toshio Suda, Mitsuru Murata, Yasuo Ikeda
- P-MO-042 SILK FIBROIN ENGINEERED 3D SYSTEM FOR THE STUDY OF MEGAKARYOCYTES AND FUNCTIONAL PLATELET PRODUCTION**  
Isabella Pallotta (IT), Alessandra Balduini, Michael Lovett, David L. Kaplan, Alessandra Balduini\*
- P-MO-043 STUDY OF MEGAKARYOPOIESIS AND PROPLATELET FORMATION IN MYELOPROLIFERATIVE DISORDERS**  
Stefania Badalucco\* (IT), Mariateresa Pugliano, Vittorio Rosti, Marco Cattaneo, Giovanni Barosi, Alessandra Balduini
- P-MO-044 EXPRESSION OF TYPE I INTERFERON RECEPTOR IN MEGAKARYOPOIESIS**  
Soledad Negrotto\* (AR), Carolina Jaquenod de Giusti, Maria J Lapponi, Julia Etulain, Agustina Carestia, Ricardo M Gomez, Mirta Schattner
- P-MO-045 ULTRASTRUCTURAL INDICATIONS FOR AN ENDOGENOUS ORIGIN OF THE DEMARCATION MEMBRANE SYSTEM IN MURINE MEGAKARYOCYTES**  
Anita Eckly\* (FR), Fabienne Proamer, Jean-Yves Rinckel, Francois Lanza, Christian Gachet
- P-MO-046 FACTOR V SUGAR MOIETIES ARE ESSENTIAL FOR BINDING TO THE SURFACE OF MEGAKARYOCYTES**  
Claudia Zappelli\* (NL), Carmen van der Zwaan, Koen Mertens, Alexander B. Meijer
- P-MO-047 THE ABNORMAL PROPLATELET FORMATION OBSERVED IN PATIENTS WITH MYH9-RELATED SYNDROME RESULTS FROM AN INCREASE OF PMLC2**  
Yolande Chen (FR), Siham Boukour, Paquita Nurden, Ababakar Seye, Olivier Bluteau, Yunhua Chang, Larissa Lordier, Remi Favier, Beatrice Saposnik, Nicole Schlegel, Anne Galy, Alan Nurden, Hana Raslova, William Vainchenker, Najet Debili\*
- P-MO-048 CRUCIAL ROLE FOR ENDOPLASMIC RETICULUM STRESS DURING THROMBOPOIESIS**  
Jose Javier Lopez (FR), Najet Debili, Chiraz Chaabane, Evelyne Polidano, Saoussen Dally, Elisabeth Corvazier, Paquita Nurden, Jocelyne Enouf, Regis Bobe\*



## POSTER PRESENTATIONS

Monday, July 25, 2011

- P-MO-049 THE INTERACTION OF ADENOSINE DIPHOSPHATE WITH P2Y13 REGULATES IN VITRO PROPLATELET FORMATION FROM HUMAN MEGAKARYOCYTES**  
Christian Di Buduo\* (IT), Alessandro Malara, Isabella Pallotta, Anna Lecchi, Alessandra Balduini, Marco Cattaneo

### Platelets as drug targets

- P-MO-050 EVALUATION OF PLATELET AGONISTS AND ANTAGONISTS BY A NOVEL ELISA-BASED VASP ASSAY AND COMPATIBILITY WITH WHOLE BLOOD SAMPLES FROM SEVERAL ANIMAL SPECIES**  
Daniele Boulay-Moine (FR), Nicolas Bourguet, Sylvie Miet, Maxime Moulard\*
- P-MO-051 THE EFFECT OF THE ORAL DIRECT FACTOR XA INHIBITOR RIVAROXABAN ON TISSUE FACTOR MEDIATED IN VITRO PLATELET AGGREGATION IS ENHANCED BY A P2Y12 RECEPTOR BLOCKER**  
Elisabeth Perzborn\* (DE), M Harwardt, S Heitmeier, V Laux
- P-MO-052 PROTEIN KINASE C REGULATES AGONIST-MEDIATED PLATELET ACTIVATION DOWNSTREAM OF 12-LIPOXYGENASE IN HUMAN PLATELETS**  
Patrick L Apopa\* (US), Joanne Vesce, Jennifer Yeung, Michael Holinstat
- P-MO-053 ASPIRIN IS LESS EFFICIENT FOR THROMBOXANE A2 INHIBITION IN ACTIVATED PLATELETS.**  
Juana Valles (ES), Antonio Moscardo, Isabel Madrid, Maria Angeles Dasi, Belen Cortina, Ana Maria LaTorre, Maria Teresa Santos\*
- P-MO-054 ASPIRIN TREATMENT IS RESPONSIBLE FOR AN MRP4 OVER-EXPRESSION IN HUMAN PLATELETS**  
Fabio M Pulcinelli\* (IT), Isabella Massimi, Elisabetta Trifiro', Lavinia Vittoria Lotti
- P-MO-055 INCREASED VASCULAR NO & PROSTACYCLIN PROTECTS B2R KO MICE FROM THROMBOSIS BY AN ACQUIRED PLATELET GLYCOPROTEIN VI ACTIVATION AND SPREADING DEFECT**  
Chao Fang\* (US), Evi Stavrou, Alec Schmaier, Andrew Chen, Marvin Nieman, Gregory Adams, Gretchen LaRusch, Yihua Zhou, Matthew Bilodeau, Fakhri Mahdi, Mark Warnock, Douglas Tollefsen, Alvin Schmaier
- P-MO-056 THE INFLUENCE OF GENETIC POLYMORPHISM AND DRUG-DRUG INTERACTION ON ANTIPLATELET EFFECT IN PATIENTS TREATED WITH LONG-TERM DUAL ANTIPLATELET THERAPY**  
Young-Hoon Jeong\* (US), Park Yongwhi, Kim In-Suk, Jung Kwon Tae, Hwang Jin-Yong
- P-MO-057 FIRST VALIDATION OF ADJUNCTIVE CILOSTAZOL LOADING EFFECT AND DOSAGE ON PLATELET INHIBITION: RESULTS OF THE ACCEL-LOADING STUDY**  
Young-Hoon Jeong\* (US), Kim In-Suk, Yun Seong-Eun, Park Yongwhi, Jung Kwon Tae
- P-MO-058 FIRST COMPARISON OF PLATELET INHIBITION BY CILOSTAZOL VERSUS CLOPIDOGREL IN PATIENTS WITH CYTOCHROME 2C19 LOSS-OF-FUNCTION ALLELE: RESULTS OF THE ACCEL-SWITCH STUDY**  
Young-Hoon Jeong\* (US), Yongwhi Park, In-Suk Kim, Seong-Eun Yun, Kwon Tae Jung
- P-MO-059 CONSENSUS DEFINITION-BASED CUTOFFS OF HIGH ON-TREATMENT PLATELET REACTIVITY: VALIDATION BETWEEN LIGHT TRANSMITTANCE AND MULTIPLE ELECTRODE AGGREGOMETRIES**  
Young-Hoon Jeong\* (US), Yongwhi Park, In-Suk Kim, Seong-Eun Yun



## POSTER PRESENTATIONS

Monday, July 25, 2011

Monday Posters

### Molecular basis of inherited or acquired platelet disorders

- P-MO-060 MUTATION SCREENING IN GLANZMANN THROMBASTHENIA: IDENTIFICATION OF FOUR NOVEL MUTATIONS IN THE ITGA2B AND ITGB3 GENES**  
Bimal D M Theophilus\* (UK), Andrea M Guilliat, Lesley M Baugh, Jayashree Motwani, Michael D Williams
- P-MO-061 IDENTIFICATION OF TWO NOVEL *TMEM16F* MUTATIONS IN A PATIENT WITH SCOTT SYNDROME**  
Elisabetta Castoldi\* (NL), Peter W. Collins, Patrick L. Williamson, Edouard M. Bevers
- P-MO-062 PLATELET FUNCTION ABNORMALITIES IN GAUCHER DISEASE: ETIOLOGY AND EFFECT OF ENZYME REPLACEMENT THERAPY**  
Mirjana Miroslav Mitrovic\* (RS), Darko A Antic, Ivo I Elezovic, Dragana D Janic, Predrag P Miljic, Sumarac Z Zorica, Tanja T Nikolic, Nada N Suvajdzic
- P-MO-063 BLEEDING PHENOTYPE IN A PATIENT WITH MDS IN THE ABSENCE OF THROMBOCYTOPENIA IS CAUSED BY A PROFOUND DYSREGULATION OF THE SIGNALING PROTEIN, SYK**  
Elizabeth E Gardiner\* (AU), Jian L Qiao, Jane F Arthur, Amanda K Davis, Margaret Collecutt, Yang Shen, Fi-Tjen Mu, Robert K Andrews
- P-MO-064 THROMBOCYTOPENIA IN MICE LACKING SPHINGOMYELIN SYNTHASE 1**  
Takahiro Fujii\* (JP), Akira Hayashi, Yuwna Yakura, Makoto Taniguchi, Ken Watanabe, Kazuyuki Kitatani, Toshiro Okazaki, Hiroyuki Takeya
- P-MO-065 PLATELET MITOCHONDRIAL DYSFUNCTION IN PATIENTS WITH SEPTIC SHOCK**  
Andrea Artoni\* (IT), Anna Lecchi, Alessandro Protti, Giovanna Motta, Giovanni Mistraretti, Francesca Pagan, Sergio De Chiara, Luciano Gattinoni

### HIT

- P-MO-066 EVALUATION OF A FAST ELISA ASSAY FOR MEASURING HIT IGG ANTIBODIES**  
Lieselotte Wagner\* (AT), Sabine Geiter, Markus Graf, Helga Vetr, Annelie Siegemund
- P-MO-067 USEFULNESS OF 4TS SCORING SYSTEM FOR HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) IN THE FIELD OF HEMODIALYSIS**  
Keiko Wanaka\* (JP), Miyashita Kumiko, Kaneko Chieko, Walenga M Jeanine, Prechel Margaret, Escalante Vicki, Matsuo Miyako, Asada Reiko
- P-MO-068 GERMAN REGISTRY FOR THE USE OF FONDAPARINUX IN HIT OR SUSPECTED HIT**  
Marc Schindewolf\* (DE), Julia Scheuermann, Jan Beyer-Westendorf, Sebastian Schellong, Pascal Dohmen, Johannes Brachmann, Katharina Madlener, Bernd Poetzsch, Robert Klamroth, Johannes Hankowitz, Stefan Kropff, Norbert Banik, Sabine Eberle, Markus Michael Mueller, Edelgard Lindhoff-Last
- P-MO-069 DEVELOPMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) IN SIX PATIENTS WITH HEPARIN LOCK (OR FLUSH) IN THE EARLY PHASE OF HEMODIALYSIS**  
Kumiko Miyashita\* (JP), Keiko Wanaka, Chieko Kaneko, Yoshihiko Nakajima, Jeanine M Walenga, Vicki Escalante, Miyako Matsuo
- P-MO-070 HEPARIN-INDUCED THROMBOCYTOPENIA DIAGNOSIS WITH MULTIPLE ELECTRODE AGGREGOMETRY**  
Ludek Slavik\* (CZ), Jana Ulehlova, Vera Krcova, Antonin Hlusi, Jana Prochazkova



33

## POSTER PRESENTATIONS

Monday, July 25, 2011

- P-MO-071 COMPARISON OF DIAGNOSTIC PERFORMANCE OF HEPARIN EXPERT PROBABILITY (HEP) AND 4T'S SCORES IN SCREENING FOR HEPARIN-INDUCED THROMBOCYTOPENIA (HIT)**  
Noppacharn Uaprasert\* (TH), Ponlapat Rojnuckarin, Benjaporn Akkawat
- P-MO-072 COMPARISON OF CLINICAL PERFORMANCES OF TWO ELISA ASSAYS: ASSERACHROM HPIA-IGG AND PF4 IGG FOR HEPARIN INDUCED THROMBOCYTOPENIA DIAGNOSIS**  
SYLVIE LANGLET\* (FR), CHRISTINE BAHUON, CLAIRE MAUREL, STEPHANE LE FLOCH, ISMAEL ELALAMY, PIERRE EMMANUEL MORANGE, WILLIAM COHEN
- P-MO-073 SIMPLE SCORING SYSTEM FOR EARLY MANAGEMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA**  
Harry Messmore\* (US), Nanacy Fabbrini, Mary Bird, Abdul Choudhury, Miguel Cerejo, Margaret Prechel, Walter Jeske, Arshea Siddiqui, Thethi Indermohan, William Wehrmacher, Jeanine Walenga
- P-MO-074 IMMUNOLOGIC DIFFERENTIATION OF GENERIC LOW MOLECULAR WEIGHT HEPARINS**  
Jeanine Walenga\* (US), Margaret Prechel, Vicki Escalante, Walter Jeske, Mamdouh Bakhos
- P-MO-075 NON-PATHOGENIC ANTI-HEPARIN/PF4 ANTIBODIES GENERATED BY LOW MOLECULAR WEIGHT HEPARINS MEDIATE PROCOAGULANT EFFECTS**  
Jeanine Walenga\* (US), Debra Hoppensteadt, Evangelos Litinas, Harry Messmore, Bruce Lewis, Gundu Rao, Russell Hull, Jawed Fareed, Mamdouh Bakhos
- P-MO-076 RAPID DIAGNOSIS OF HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) BY WHOLE BLOOD IMPEDANCE AGGREGOMETRY: RESULTS OF THE AUSTRALIAN MULTI CENTRE STUDY**  
Marie-Christine Morel-Kopp\* (AU), Chee Wee Tan, Tim Brighton, Simon McRae, Huyen Tran, Peter Mollee, Geoff Kershaw, Joanne Joseph, Luke Coyle, Chris Ward

### Antiplatelet therapy

- P-MO-077 ANTIPLATELET THERAPY EFFECTIVELY REDUCES PLASMA PLASMINOGEN ACTIVATOR INHIBITOR-1 LEVELS**  
Toshiyuki Sakata\* (JP), Kazuomi Kario
- P-MO-078 VASODILATOR-STIMULATED PHOSPHOPROTEIN (VASP) PHOSPHORYLATION ASSAY FOR PLATELET RESPONSE TO CILOSTAZOL**  
Jun Yamanouchi\* (JP), Takaaki Hato, Toshiyuki Niiya, Masaki Yasukawa
- P-MO-079 GLYCOPROTEIN IIB-IIIa CONTENT, MEAN PLATELET VOLUME AND PLATELET AGGREGATION IN PATIENTS WITH ACUTE CORONARY SYNDROME.**  
Alexey V Mazurov\* (RU), Ilia T Zyuryaev, Vladimir V Yakushkin, Svetlana G Khaspekova, Mikhail Ya Ruda
- P-MO-080 IMPAIRED CLOPIDOGREL RESPONSIVENESS IN STEMI PATIENTS PREDISPOSES FOR CARDIOVASCULAR EVENTS**  
Andreas Schaefer\* (DE), Ulrike Flierl, Nora Seydelmann, Johann Bauersachs
- P-MO-081 PLATELET HYPERCOAGULANT ACTIVITY DUE TO REDUCED AMINOPHOSPHOLIPID TRANSLOCASE ACTIVITY IN T2DM IS AMELIORATED BY GPIIB/IIIa BLOCKADE**  
Wei Zhang\* (SE), Zhangsen Huang, Paul Hjemdahl, Nailin Li
- P-MO-082 ESSENTIAL THROMBOCYTHAEMIA TREATMENT OF A PATIENT UNDER 12 MONTHS- A CASE REPORT**  
Pawel Laguna\* (PL), Michal Romiszewski, Anna Klukowska, Michal Matysiak





## POSTER PRESENTATIONS

Monday, July 25, 2011

Monday Posters

- P-MO-083 CLINICAL OUTCOME AND PLATELET FUNCTION OF ACUTE STROKE BY GLOBAL THROMBOSIS TEST (GTT) AFTER T-PA THERAPY**  
Katsushi Taomoto\* (JP), Hideyuki Ohnishi, Yoshihiro Kuga, Kazuya Nakashima, Yuji Kodama, Hisashi Kubota, Takashi Tominaga, Makoto Hayashi, Shiro Miyata, Junichiro Yamamoto
- P-MO-084 CILOSTAZOL, A PLATELET INHIBITOR, IN TREATING INTERMITTENT CLAUDICATION. A SYSTEMATIC REVIEW.**  
David Bergqvist\* (SE), Olov Rolandsson, Juliette Sawe
- P-MO-085 FEATURES OF TREATMENT AND PROGNOSIS OF NON-ST ELEVATION ACUTE CORONARY SYNDROME IN PATIENTS WITH IRON DEFICIENCY ANEMIA**  
Anton Skotnikov\* (RU), Arcady Vertkin, Fedor Vilkoviskii
- P-MO-086 CHARACTERIZATION OF THE ANTIPLATELET EFFECT OF ASPIRIN AT ENROLLMENT AND AFTER A 2-YEAR FOLLOW-UP IN THE REAL CLINICAL SETTING IN JAPAN**  
Keiichiro Yamane\* (JP), Tomoyuki Ikeda, Ryoji Taniguchi, Toru Kita, Takeshi Kimura, Hisanori Horiuchi
- P-MO-087 100 MG OF ASPIRIN IS SUFFICIENT TO SUPPRESS PLATELET ACTIVITY IN TYPE 2 DIABETES, IRRESPECTIVE OF GLYCEMIC CONTROL**  
Bregtje Annelieke Lemkes\* (NL), Pieter W. Kamphuisen, Lonneke Bahler, An K. Stroobants, Erik J. Van den Dool, Joost B.L. Hoekstra, Rienk Nieuwland, Victor E.A. Gerdes, Frits Holleman
- P-MO-088 CLOPIDOGREL AND ASPIRIN PHARMACODYNAMIC RESPONSE IN ELDERLY INPATIENTS: A PILOT STUDY**  
Tiphaine Belleville\* (FR), Pascale Gaussem, Eric Pautas, Christilla Bachelot-Loza, Jean-Louis Golmard, Laure Raymond, Jean Szymezak, Emilie Gaillaud, Marie-Antoinette Catrux, Virginie Siguret, Isabelle Gouin-Thibault
- P-MO-089 EFFECTS OF TANSHINONEIIA ON INFLAMMATORY CYTOKINES AND GMP-140 IN THE PATIENT WITH KAWASAKI DISEASES.**  
Xiaojing Li\* (CN), Qing Zhang, Ming Zhou
- P-MO-090 MORE RAPID AND GREATER PHARMACODYNAMIC EFFECTS OF PRASUGREL IN JAPANESE PATIENTS WITH STABLE CORONARY ARTERY DISEASE (CAD) UNDERGOING ELECTIVE PCI**  
Hisanori Horiuchi\* (JP), Hiroyoshi Yokoi, Takeshi Kimura, Takaaki Isshiki, Hisao Ogawa, Yasuo Ikeda

### Inherited and acquired platelet disorders

- P-MO-091 FEATURES OF PLATELET FUNCTION IN PATIENTS WITH PORTAL HYPERTENSION SECONDARY CHRONIC MYELOPROLIFERATIVE NEOPLASMS**  
Viola Maria I Popov\* (RO), Ana Maria Vladareanu, Horia Bumbea, Eugenia Kovacs, Tudor Savopol, Adrian Tase, Minodora Onisai, Marilena Miulescu, Anca Maria Ilea, Camelia Dobrea
- P-MO-092 PLATELET DYSFUNCTION IN PATIENTS WITH PULMONARY HYPERTENSION ON SILDENAFIL**  
Edmond S K Ma\* (HK), Elaine M C Chau, Katherine Fan
- P-MO-093 CAUSES OF PLATELETS DISFUNCION IN MULTIPLE MYELOMA**  
Irena Djunic\* (RS), Ivo Elezovic, Vesna Ilic, Dragica Tomin, Nada Suvajdzic-Vukovic, Jelena Bila, Darko Antic, Ana Vidovic, Nadezda Milosevic-Jovcic



## POSTER PRESENTATIONS

Monday, July 25, 2011

- P-MO-094 FOUNDER EFFECT AND PHENOTYPIC SEVERITY OF THE FRENCH GYPSY MUTATION IN GLANZMANN THROMBASTHENIA**  
Mathieu Fiore\* (FR), Frederic Austerlitz, Xavier Pillois, Nadia Firah, Paquita Nurden, Alan T Nurden
- P-MO-095 A CASE OF ESSENTIAL THROMBOCYTHEMIA AND VERSION OF HEREDITARY THROMBOPHILIA - MTHFR MUTATION**  
Sandra Lejniece\* (LV), Viktorija Dunska-Petersone, Anna Toma, Aivars Lejnicks
- P-MO-096 MACROTHROMBOCYTOPENIA AND HEMOLYSIS ASSOCIATED WITH PHYTOSTEROLEMIA: A POTENTIAL NEW PLATELET DISORDER**  
Zhaoyue Wang\* (CN), Gaifeng Wang, Lijuan Cao, Minghua Jiang, Xia Bai, Changgeng Ruan
- P-MO-097 THROMBOTIC THROMBOCYTOPENIC PURPURA CONCOMITANT WITH AUTOIMMUNE THYROIDITIS**  
Ali Bay\* (TR), ali seckin yalcin, Goksel Leblebisatan, Enes Coskun, hatice uygun, Mehmet Yilmaz
- P-MO-098 PLATELET TRANSFUSION REQUIREMENTS INVERSELY CORRELATE WITH ENDOGENOUS PF4 LEVELS IN PATIENTS WITH STANDARD RISK ACUTE LYMPHOBLASTIC LEUKEMIA.**  
Michele Puzkarczuk Lambert\* (US), Alisa Reznikov, Liqing Xiao, Yvonne Nguyen, Lubica Rauova, Mortimer Poncz
- P-MO-099 ADOLESCENTS WITH DIABETES MELLITUS HAVE EVIDENCE OF *IN VIVO* PLATELET ACTIVATION**  
Sara J Israels\* (CA), Heather J. Dean, Elizabeth A.C. Sellers, Fabrice Cognasse, Archie McNicol
- P-MO-100 RFVIIA IS AS EFFECTIVE AS PLATELETS IN GLANZMANN THROMBASTHENIA (GT) WITH OR WITHOUT PLATELET ANTIBODIES AND/OR REFRACTORINESS (PA/PR): DATA FROM GT REGISTRY (GTR)**  
Man-Chiu Poon\* (CA), Giovanni di Minno, Rainer Zotz, Roseline dOiron

### Laboratory tests

- P-MO-101 INCREASED PLATELET AND LEUKOCYTE ACTIVATION AS CONTRIBUTING MECHANISMS FOR THROMBOSIS IN ESSENTIAL THROMBOCYTHEMIA AND CORRELATION WITH THE JAK2 MUTATION STATUS**  
Elena - Tothova\* (SK), Adriana Kafkova, Marek Sarisky, Beata Benova, Natalia Stecova, Monika Hlebaskova
- P-MO-102 DETECTION OF AUTOANTIBODIES AGAINST PLATELET GLYCOPROTEINS IN PATIENTS WITH ITP BY FLOW CYTOMETRY**  
YANG HE\* (CN), Ming Qing Zhu, Yi Ming Zhao, Chang Geng Ruan
- P-MO-103 ASSOCIATION OF PLATELET REACTIVITY WITH LIPID AND PAI-1 LEVELS IN A JAPANESE GENERAL POPULATION, THE SUITA STUDY**  
Sachika Kameda\* (JP), Toshiyuki Sakata, Yoshihiro Kokubo, Mana Mitsuguro, Akira Okamoto, Michitaka Sano, Toshiyuki Miyata
- P-MO-104 WIDE TEMPERATURE RANGE TESTING WITH SONOCLOT PLATELET FUNCTION AND ROTEM EXTEM/FIBTEM/APTEM TESTS**  
Ulf Stellan Schott\* (SE), Jens Brokopp, Attila Frigyesi, Jon Martinsson, Hans Friberg
- P-MO-105 COMPARISON STUDY BETWEEN TWO BLOOD COUNTER INSTRUMENTS: ADVIA 2120 AND LH 780**  
Selime Ayaz\* (TR), Gulsah Kacur Fidan



## POSTER PRESENTATIONS

Monday, July 25, 2011

Monday Posters

- P-MO-106 ASPIRIN RESISTANCE IN PATIENTS WITH SAPHENOUS VEIN CORONARY BYPASS GRAFT OCCLUSION**  
Selime Ayaz\* (TR), Goksel Cagirci, Yilmaz Sevinc, Ozcan Ozdemir, Dursun Aras
- P-MO-107 TRANSPLACENTAL TRANSMISSION OF EDTA DEPENDENT PSEUDOTHROMBOCYTOPENIA IN A NEONATE**  
Ali Bay\* (TR), Safak Tavil, Goksel Leblebisatan, Ercan Sivasli, Enes Coskun
- P-MO-108 A SIMPLE PORTABLE MICROSYSTEM TO MONITOR PLATELET AGGREGATION**  
Francine Rendu\* (FR), Thibault Donnet, Daniel Fruman
- P-MO-109 DIFFERENTIAL PREVALENCE OF ANTI-HEPARIN PLATELET FACTOR 4 ANTIBODIES IN ELDERLY PATIENTS UNDERGOING ORTHOPAEDIC SURGERY AND ANTICOAGULATED WITH HEPARIN.**  
Christopher Song\* (US), Josephine Cunanan, Debra Hoppensteadt, Hussein Kahn, Indermohan Thethi, Jawed Fareed
- P-MO-110 NEW MULTIPLATE AGGREGATION TEST TO SCREEN FOR GS $\alpha$  DYSFUNCTION: SCREENING OF PATIENTS WITH UNEXPLAINED MENTAL RETARDATION FOR GS $\alpha$  DYSFUNCTION.**  
Irene MLW Korver-Keularts\* (NL), Estela M Rubio-Gozalbo, Connie TRM Schrandt-Stumpel, Paul WM Verhezen, Dionne Maessen, Monique GM Willems, Paola EJ Meijden, van der, Johan WM Heemskerck, Yvonne MC Henskens, Karly Hamulyak

### Extrinsic pathway of coagulation

- P-MO-111 THE EXTENSIVE EPITOPE OVERLAP OF THE HUMANIZED MONOCLONAL ANTIBODY MAB 2021 WITH THE FXA BINDING SITE ON K2 EXPLAINS ITS NEUTRALIZING EFFECT ON TFPI**  
Jens Breinholt\* (DK), Lennart Anders Svensson, Ida Hilden, Berit Olsen Krogh, Ole Hvilsted Olsen, Jesper Pass, Jes Thorn Clausen, Helle Heibroch Petersen, Albrecht Gruhler
- P-MO-112 EFFICIENT PROCEDURE FOR PURIFICATION OF HUMAN TISSUE FACTOR PATHWAY INHIBITOR (TFPI) EXPRESSED FROM A BABY HAMSTER KIDNEY (BHK) CELL LINE**  
Christina Jespersgaard\* (DK), Jorn Meidahl Petersen, Ida Hilden
- P-MO-113 PROTEOMIC ANALYSIS OF ANGIOTENSIN II- INDUCED PROTEIN EXPRESSIONS IN U937 CELLS**  
Shilin He\* (CN), Li Bangtao, Wen ZHlbin, He Xiaofan
- P-MO-114 AN INFANT WITH PROLONGED CIRCUMCISION BLEEDING AND UNEXPLAINED COAGULOPATHY**  
Ali Bay\* (TR), Ozlem Karaoglu, Goksel Leblebisatan, Enes Coskun, Ali Seckin Yalcin, Mehmet Keskin
- P-MO-115 EXPRESSION OF TF IN MONOCYTES AND PLASMA TF DURING ACUTE PHASE AND RECOVERY STAGE IN PATIENTS WITH MYOCARDIAL INFARCTION**  
Rui WANG\* (CN), Shufu ZHANG, Yitong MA, De CHEN, Jing MA, Yimeng ZHOU, Bingzhao WEN
- P-MO-116 ACUTE HAEMOSTATIC EFFECT OF A POLYCLONAL RABBIT ANTI-MOUSE TFPI ANTIBODY IN A MURINE JOINT BLEEDING MODEL**  
Kirstine Ovlisen\* (DK), Mette Brunsgaard Hermit, Jes Thorn Clausen, Lars Christian Petersen, Mikael Tranholm, Brit Binow Sorensen, Ida Hilden
- P-MO-117 A POLYCLONAL ANTI-MOUSE TFPI ANTIBODY DOSE-DEPENDENTLY REDUCES BLOOD LOSS IN HAEMOPHILIA A MICE**  
Peter B Johansen\* (DK), Mette B Hermit, Jes T Clausen, Ida Hilden



37

## POSTER PRESENTATIONS

Monday, July 25, 2011

- P-MO-118 SELECTION AND CHARACTERISATION OF A MONOCLONAL ANTIBODY AGAINST TISSUE FACTOR PATHWAY INHIBITOR (TFPI) BLOCKING THE INTERACTION BETWEEN TFPI KUNITZ 2 DOMAIN AND FACTOR XA**  
Jes Thorn Clausen\* (DK), Berit Olsen Krogh, Andrew Neil Bowler, Christina Jespersgaard, Thomas Egebjerg, Birgitte Friedrichsen, Ida Hilden
- P-MO-119 THROMBINURIA AS A USEFUL MARKER FOR SCREENING AND MONITERING OF CRESENTIC GLOMERULONEPHRITIS**  
Yasunori Kitamoto\* (JP), Kenji Arizono, Yoshio Taguma, Takahisa Imamura
- P-MO-120 A MONOCLONAL ANTI-TFPI-ANTIBODY, MAB 2021, REDUCES BLEEDING IN HAEMOPHILIC RABBITS AFTER INTRAVENOUS AND SUBCUTANEOUS ADMINISTRATION**  
Brian Lauritzen\* (DK), Mette Brunsgaard Hermit, Kristoffer W Balling, Henrik Agersoe, Brit Binow Sorensen, Ida Hilden
- P-MO-121 A MONOCLONAL ANTI-TFPI-ANTIBODY, MAB 2021, IS EFFICACIOUS AGAINST BLEEDING IN HAEMOPHILIC RABBITS FOR AT LEAST 7 DAYS**  
Brian Lauritzen\* (DK), Lene Hansen, Henrik Agersoe, Kristoffer W Balling, Mette Brunsgaard Hermit, Jes Thorn Clausen, Ida Hilden, Brit Binow Sorensen
- P-MO-122 PLATELET UPTAKE OF RECOMBINANT FACTOR VIIA**  
Agon Hyseni\* (NL), Philip G. de Groot, Ton Lisman, Mark Roest
- P-MO-123 A MONOCLONAL ANTIBODY MAB 2021 BLOCKING TISSUE FACTOR PATHWAY INHIBITOR (TFPI) ENHANCES HAEMOSTASIS UNDER HAEMOPHILIA A LIKE CONDITIONS**  
Brit Binow Sorensen\* (DK), Ida Hilden, Lars Chr. Petersen, Mette Brunsgaard Hermit, Helle Heibroch Petersen, Kristoffer W. Balling
- P-MO-124 PHARMACOLOGICAL EVALUATION OF FVIIA/FX MIXTURE (MC710) IN ANIMAL MODELS OF HEMOPHILIA**  
Yasushi Nakatomi\* (JP), Teruhisa Nakashima, Manami Tsuji, Eisuke Takami, Hiroki Miyazaki, Emiko Kusumoto, Ai Takaki-Kakisaka, Asami Shindome, Kazuhiko Tomokiyo, Takayoshi Hamamoto, Tomohiro Nakagaki
- P-MO-125 DISCORDANT CLEARANCE PATHWAYS FOR FACTOR X AND ITS N-DEGLYCOSYLATED DERIVATIVE**  
Mohamad KURDI\* (FR), Ghislaine CHEREL, Peter J. LENTING, Cecile V. DENIS, Olivier D. CHRISTOPHE
- P-MO-126 TISSUE FACTOR PROCOAGULANT ACTIVITY IN SICKLE CELL DISEASE: NOVEL FINDINGS**  
B.N.Yamaja Setty\* (US), Nigel S Key, A. Koneti Rao, Suba Krishnan, Suhita Gayen-Betal, Marie J Stuart
- P-MO-127 STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF NON-ANTICOAGULANT SULFATED POLYSACCHARIDES FOR THE TREATMENT OF HEMOPHILIA**  
Michael Dockal\* (AT), Sabine Knappe, Susanne Till, Michael Palige, Christina Miki Szabo, Zhenqing Zhang, Klara Michalkova, Hartmut Ehrlich, Friedrich Schefflinger
- P-MO-128 ENDOGENOUS BLOOD BORNE TISSUE FACTOR CONTRIBUTES TO CLOT FORMATION IN HAEMOPHILIA-LIKE WHOLE BLOOD ASSESSED BY KAOLIN-INITIATED THROMBOELASTOGRAPHY (TEG) ANALYSIS**  
Brit Binow Sorensen\* (DK), Marie Louise Schougaard Christiansen, Mirella Ezban, Soeren Bjoern, Stefan Lethagen



## POSTER PRESENTATIONS

Monday, July 25, 2011

Monday Posters

### Intrinsic pathway of coagulation

- P-MO-129 SIMULATION AND MESUREMENT OF THROMBIN PRODUCTION IN RESTING AND CONVULXIN-TREATED WHOLE BLOOD IN VITRO: XIIA BYPASS OF CORN TRYPSIN INHIBITOR**  
Scott L Diamond\* (US), Manash Chatterjee
- P-MO-130 MILD HEMOPHILIA B IN A CASE OF SHEEHAN SYNDROME**  
Valizadeh Nasim\* (IR), Neda Valizadeh
- P-MO-131 FUNCTIONAL CHARACTERIZATION OF IMMOBILIZED FACTOR VIII IN INTRA-THROMBUS FIBRIN NETWORK FORMATION UNDER WHOLE BLOOD FLOW CONDITIONS WITH HIGH SHEAR RATES**  
Masaaki Doi\* (JP), Mitsuhiko Sugimoto, Hideto Matsui, Tomoko Matsumoto, Midori Shima
- P-MO-132 MOLECULAR PATHOLOGY OF HAEMOPHILIA B IN CHINA PATIENTS: IDENTIFICATION OF 20 NOVEL MUTATIONS.**  
Jing Dai\* (CN), Qiong Chen, Ting Ying Wu, Ling Ye Lu, Lan Qiu Ding, Li Hong Wang, Feng Xue Wang
- P-MO-133 METABOLIC REGULATION OF MOUSE LIVER *F11* GENE TRANSCRIPTION AND ITS RELATION TO *KLKB1* AND *CYP4V3* CONTROL**  
Huma Safdar\* (NL), Audery C.A. Cleuren, Ka Lei Cheung, Pieter H. Reitsma, Bart J.M. van Vlijmen
- P-MO-134 FACTOR IX ARG327ILE MUTATION RESULTING IMPAIRED AFFINITY TO FVIII AS WELL AS CATALYTIC EFFICIENCY LEADS TO SEVERE HAEMOPHILIA B**  
Jiawei Zhou\* (CN), Jing Dai, Xuefeng Wang, Tingting Yu, yeling Lu, Qiulan Ding, Hongli Wang
- P-MO-135 AN EPIDEMIOLOGIC CLINICAL STUDY ON HEMOPHILIA IN THE PATIENTS FROM THE REGION OF OLTENIA, ROMANIA**  
Polixenia Stancu\* (RO), Cristina Singer, Alina Botu, Simona Cosoveanu, Diana-Maria Trasca, Emil Tiberius Trasca
- P-MO-136 FACTOR VIII INHIBITORS IN HEMOPHILIA A PATIENTS WITH DIFFERENT TREATMENT MODALITIES**  
Ola Abdel-Halim Afifi\* (EG), Salah Abdul-Azeem Argoon, Yousreyia Abdel-Rahman Ahmad, Nabila Mohamed Thabet, Reffat Fathi Abdul-All, Gamal Ghanem Mohamed, Ahmad Farrag Thabet
- P-MO-137 AVAILABILITY OF CYCLOSPORINE A IN COMBINATION WITH CORTICOSTEROIDS FOR ACQUIRED HAEMOPHILIA A - A REVIEW OF CLINICAL COURSE IN 13 PATIENTS**  
Seiji Saito\* (JP), Teruhisa Fujii, Noboru Takata
- P-MO-138 POLYMORPHISM 4G/5G IN PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1 AS A FACTOR FOR EARLY RECURRENT PREGNANCY LOSS DEVELOPMENT**  
Petar D Ivanov\* (BG), Regina Komsa-Penkova, Emiliana Konova, Tsvetomira Tsvyatkovska, Ivan Ivanov, Katya Kovacheva, Maria Simeonova, Stoyan Tanchev
- P-MO-139 EXPRESSION OF RECOMBINANT HUMAN FACTOR IX PROTEIN IN MOUSE ERYTHROCYTES BY USING A TRANSGENIC RODENT MALARIA PARASITE, *PLASMODIUM BEGHEI* AS AN EXPRESSION VECTOR.**  
Teruko Sugo\* (JP), Hiroyuki Matsuoka, Makoto Hirai, Darrel Stafford, Paul Monahan
- P-MO-140 FACTOR VIII LIGHT CHAIN CONTAINS A BINDING SITE FOR FACTOR X**  
Masahiro Takeyama\* (US), Hironao Wakabayashi, Philip J Fay



## POSTER PRESENTATIONS

Monday, July 25, 2011

- P-MO-141 SUITABILITY OF INSECT CELLS FOR THE EXPRESSION OF HUMAN COAGULATION FACTOR VIII**  
Svetlana A Shestopal (US), Daniel J Makover, Timothy K Lee, Andrey G Sarafanov\*
- P-MO-142 INHIBITION OF FACTOR XI IMPROVES SEPSIS SURVIVAL IN MICE**  
Erik Ian Tucker\* (US), Melani Helm, Norah Verbout, Owen JT McCarty, Sawan Hurst, David Gailani, Andras Gruber
- P-MO-143 THE USE OF A VWF-CONTAINING PLASMA-DERIVED FVIII PRODUCT IN INHIBITOR PATIENTS LIKELY TO FAIL IMMUNE TOLERANCE INDUCTION**  
Margaret Heisel Kurth\* (US), J Puetz, P Kouides, J Sanders, C Sexauer, J Berstein, R Gruppo, M Manco-Johnson, E Neufeld, D Quon, N Rodriguez, B Wicklund, L Aledort
- P-MO-144 ANTI-FACTOR VIII INHIBITOR IN SEVERE HAEMOPHILIA A CAUSED BY SER470ASN BINDS TO A2 AND C2 DOMAINS**  
Qiong Chen\* (CN), Jiawei Zhou, Xuefeng Wang, Qiulan Ding, Jing Dai, Yeling Lu, Hongli Wang
- P-MO-145 GENETIC DIAGNOSIS OF TWO PEDIGREES WITH INHERITED COAGULATION FACTOR XII DEFICIENCY**  
Zhou Rong-Fu\* (CN), Jian Ouyang, Lu Chen, Xiao-yan Shao, Jing-Yan Xu

### Anticoagulant pathway

- P-MO-146 GENERIC VERSIONS OF LOW MOLECULAR WEIGHT HEPARIN MAY NOT HAVE THE SAME SAFETY-EFFICACY PROFILE AS THE BRANDED LOW MOLECULAR WEIGHT HEPARINS IN ACUTE CORONARY SYNDROME**  
Debra A Hoppensteadt\* (US), Walter Jeske, Evangelos Litinas, Omer Iqbal, Jeanine Walenga, Bruce Lewis, Hussein Kahn, Fareed Jawed
- P-MO-147 TESTSTRIP-BASED GENOTYPING TO ASSIST IN THE PREDICTION OF ANTICOAGULANT DOSE REQUIREMENT**  
Christian Oberkanins\* (AT), Helene Puehringer, Gudrun Klose, Brigitte Schreyer, Walter Krugluger, Ralph M. Loreth
- P-MO-148 INTER-INDIVIDUAL DIFFERENCES IN BASELINE COAGULATION ACTIVITIES AND THEIR CLINICAL IMPLICATIONS FOR WARFARIN THERAPY**  
Harumi Takahashi\* (JP), Yosuke Ichimura, Michael MT Lee, Mari Shiomi, Kiyoshi Mihara, Takashi Morita, Yuan-Tsong Chen, Hirotochi Echizen
- P-MO-149 DEVELOPMENTAL EFFECTS ON THE GLYCOSYLATION OF ANTICOAGULANT PROTEIN C**  
Maria C Van Walderveen\* (CA), Leslie R Berry, Anthony K C Chan
- P-MO-150 PHENOTYPIC AND GENOTYPIC CHARACTERIZATION OF PROTEIN C DEFICIENCY CASES FROM INDIA**  
PAI P NAVIN\* (IN), RONIT MOR-COHEN, SHRIMATI S SHETTY, BIPIN P KULKARNI, KANJAKSHA GHOSH
- P-MO-151 CIRCULATING NUCLEOSOMES AS PROGNOSTIC MARKER AND TARGET OF PROTEIN C IN CHILDREN WITH MENINGOCOCCAL SEPSIS**  
Sacha Zeerleder\* (NL), Femke Stephan, Marijke Emonts, Ester de Kleijn, Charles Esmon, Katalin Varadi, Erik Hack, Jan Hazelzet
- P-MO-153 PROTEIN Z LEVELS IN PREGNANT OMANI WOMEN: CORRELATION WITH PREGNANCY OUTCOMES**  
Anil Pathare\* (OM), Vaidyanathan Gowri, Mariam Mathew, Karima AlFalahi, David Gravell, Ibrahim Zakwani



## POSTER PRESENTATIONS

Monday, July 25, 2011

Monday Posters

- P-MO-154 CHANGE OF BEHAVIOR IN C4B BINDING PROTEIN AND PROTEIN S IN THE PATIENT WITH INFLAMMATORY DISEASE.**  
Makoto Ikejiri\* (JP), Junji Nishioka, Yuko Sakamoto, Yuji Shimokariya, Katsura Noma, Yasunori Abe, Kaname Nakatani, Hideo Wada, Tatsuya Hayashi, Koji Suzuki, Tsutomu Nobori
- P-MO-155 WHAT IS THE ORIGIN OF FACTOR V LEIDEN MUTATION IN ARABS? THE FIRST MOLECULAR PROOF**  
Mehrez M Jadaon\* (KW), Ali A Dashti, Hend L Lewis
- P-MO-156 NEUTRALIZABLE PARENTERAL ANTICOAGULATION: EP217609 AND ITS SPECIFIC ANTIDOTE, AVIDIN, IN HEALTHY SUBJECTS. A NEW PARADIGM?**  
ERIC NEUHART\* (FR), Pierre Gueret, Chantal Krezel, Eliane Fuseau, Maurice Petitou
- P-MO-157 REVERSION OF VITAMIN K ANTAGONISTS (VKA) EFFECT IN PATIENTS WITH BLEEDING COMPLICATIONS: AN OBSERVATIONAL STUDY FOR MONITORING PCC USE.**  
Marc C Samama\* (FR), Claudine Hecquard, Roland Jaussaud, Christian Guillaudin, Thibaut Desmettre, Flavie Lefebvre, Jean-Charles Crave, Pierre Clerson
- P-MO-158 COMPARISON OF THE PHARMACOKINETICS AND PHARMACODYNAMICS OF TAK-442, A NOVEL FACTOR XA INHIBITOR, BETWEEN JAPANESE ACUTE CORONARY SYNDROME PATIENTS AND HEALTHY JAPANESE MALES**  
Koki Nakamura\* (JP), Hiroyuki Okamoto, Fran Stringer, Masashi Hirayama, Emi Nakata, Yuki Minamide, Masaki Kawamura, Hisao Ogawa
- P-MO-159 EVALUATION OF INTERETHNIC DIFFERENCES IN THE PHARMACOKINETICS AND PHARMACODYNAMICS OF TAK-442, A NOVEL FACTOR XA INHIBITOR, IN HEALTHY MALE JAPANESE AND EUROPEAN SUBJECTS**  
Hiroyuki Okamoto\* (JP), Fran Stringer, Masashi Hirayama, Koki Nakamura, Emi Nakata, Yuki Minamide, Masaki Kawamura

### Serine protease inhibitors

- P-MO-160 DEVELOPMENT OF A NEW IMMUNO-ACTIVITY ASSAY FOR QUANTIFICATION OF ALPHA-2-MACROGLOBULIN COMPLEXES**  
Helen M. Atkinson\* (CA), Nagina Parmar, Leslie R. Berry, Anthony K. C. Chan
- P-MO-161 INCREASED MARGIN OF PATHOGEN SAFETY OF A HIGHLY-PURIFIED, PLASMA-DERIVED C1 ESTERASE INHIBITOR FOR THE TREATMENT OF HEREDITARY ANGIOEDEMA**  
Albrecht Groener\* (DE), Thomas Nowak, Birgit Popp, Wolfram Schaefer
- P-MO-162 NOVEL THROMBIN BINDING DNA APTAMER EXHIBITS HIGH INHIBITORY POTENTIAL FOR BLOOD COAGULATION**  
Elena Zavyalova\* (RU), Roman Reshetnikov, Andrey Golovin, Nikolay Mudrik, Dmitriy Panteleev, Galina Pavlova, Alexey Kopylov
- P-MO-163 EFFICACY AND SAFETY OF EDOXABAN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE OR HIP ARTHROPLASTY: A POOLED ANALYSIS OF TWO PIVOTAL STUDIES VERSUS ENOXAPARIN**  
Takeshi Fuji\* (JP), Ching-Jen Wang, Satoru Fujita, Shintaro Tachibana, Yohko Kawai, Yukihiro Koretsune, Takeshi Yamashita, Mashio Nakamura
- P-MO-164 CALCULATION OF A SENSITIVITY INDEX USING THE WHO RBT/90 THROMBOPLASTIN ELIMINATES THE VARIABILITY OF THROMBOPLASTIN REAGENTS FOR PLASMA SAMPLES SPIKED WITH RIVAROXABAN**  
Job Harenberg\* (DE), Christina Giese, Christel Weiss, Svetlana Marx, Roland Kraemer



## POSTER PRESENTATIONS

Monday, July 25, 2011

- P-MO-165 WHICH PATIENTS WOULD BE WILLING TO CHANGE ANTICOAGULATION WITH VITAMIN-K ANTAGONISTS TO A NEW ORAL ANTICOAGULANT**  
Job Harenberg\* (DE), Nadja Abou-Ayash, Svetlana Marx, Vera Hoeing, Kathrin Schirk, Christel Weiss, Lutz Froelich
- P-MO-166 AN ANTIBODY SELECTIVE TO DABIGATRAN SAFELY NEUTRALIZES BOTH DABIGATRAN-INDUCED ANTICOAGULANT AND BLEEDING ACTIVITY IN IN VITRO AND IN VIVO MODELS**  
Joanne Van Ryn\* (US), Tobias Litzenburger, Alisa Waterman, Keith Canada, Norbert Hael, Chris Sarko, Rachel Kroe-Barrett, Sanjaya Singh, John Park
- P-MO-167 COMPARISON OF DIRECT FACTOR XA INHIBITOR YM150 WITH OTHER ORAL FXA INHIBITORS ON PROTHROMBIN TIME CLOTTING TESTS USING COMMERCIALY AVAILABLE THROMBOPLASTIN REAGENTS**  
Toshiyuki Funatsu\* (JP), Yoshiyuki Iwatsuki, Seiji Kaku
- P-MO-168 EFFECTS OF YM150 AND ENOXAPARIN IN RABBIT MODELS OF VENOUS THROMBOSIS AND SURGICAL BLEEDING**  
Toshio Uemura\* (JP), Seiji Kaku
- P-MO-169 THE ANTICOAGULANT EFFECT OF YM150 CAN BE REVERSED BY ADMINISTERING COAGULATION FACTORS *IN VITRO* AND *IN VIVO***  
Seiji Kaku\* (JP), Toshio Uemura, Ken-ichi Suzuki
- P-MO-170 COMPARISON OF YM150 WITH WARFARIN IN A MOUSE MODEL OF PULMONARY EMBOLISM**  
Yoshiyuki Iwatsuki\* (JP), Mami Suzuki, Tomihisa Kawasaki

### Structural biology and drug design

- P-MO-171 DISSOCIATION OF THE HOMODIMER RFXIII MOLECULE UPON CALCIUM INDUCED ACTIVATION AND REASSOCIATION DUE TO ELIMINATION OF CALCIUM**  
Lene Hoerlyck\* (DK), Gunhild Klarskov Kristiansen, Mette Dahl Andersen
- P-MO-172 CHARACTERIZATION OF TYROSINE SULFATION IN RFVIII (N8) EXPRESSED IN CHO AND HEK-293 CELLS**  
Per Franklin Nielsen\* (DK), Brian Vandahl, Steffen Bak
- P-MO-173 ANALYSIS AND CHARACTERIZATION OF A GLYCOPEGYLATED RECOMBINANT HUMAN FACTOR VIII**  
Henrik Rahbek-Nielsen\* (DK), Jytte Pedersen, Helle Hassan, Jensen Skyt Peter, Anne Kroll Kristensen, Niels Kristian Klausen
- P-MO-174 METHYL CHLORIDE AS AN IMPURITY IN GENERIC CLOPIDOGREL PREPARATIONS**  
Indermohan Thethi\* (US), Alain Duguet, Helene Belva-Besnet, Christine Conocar, Marc Daumas, Rakesh Wahli, Gundu Rao, Lekha Pathak, Jawed Fareed
- P-MO-175 DISTINCT STRUCTURE FOR MG(II)-PROTHROMBIN FRAGMENT 1**  
Whyte G Owen\* (US), Franklyn G Prendergast, Joel Schrock, Jack Hedstrom
- P-MO-176 RESULTS OF A PATIENT SURVEY OF HEMOPHILIA PATIENTS WITH INHIBITORS IN THE US AND EU**  
Sangeeta Krishnan\* (US), Yan Xiong, Diane Ito





## POSTER PRESENTATIONS

Monday, July 25, 2011

Monday Posters

- P-MO-177 A DISCRETE CHOICE EXPERIMENT TO ELICIT PHYSICIAN PREFERENCES FOR MEDICATION ATTRIBUTES IN THE TREATMENT OF PATIENTS WITH SEVERE HEMOPHILIA A AND INHIBITORS TO FACTOR VIII**  
Sangeeta Krishnan\* (US), Heather Gelhorn, Elizabeth Merikle, Josephine Li-McLeod, Leonard A. Valentino
- P-MO-178 CAPTURING MEMBRANE BINDING OF COAGULATION FACTORS AT ATOMIC RESOLUTION USING A NOVEL MEMBRANE MIMETIC MODEL**  
Emad Tajkhorshid\* (US), Y. Zenmei Ohkubo
- P-MO-179 HEREDITARY THROMBOFILIA IN VENEZUELAN WOMEN WITH RECURRENT FETAL LOSS**  
Aixa J Muller Soyano\* (VE), Aixa Elena Soyano, Juan Aller, Anibal Pulido, Andres L Soyano, Ana Ferreira, Gustavo Salazar, Gisela Mendez, Rafael Cortes

### Exogenous hemostatic factors

- P-MO-180 USE OF RECOMBINANT FACTOR IX (BENEFIX) IN HIP REPLACEMENT IN A PATIENT WITH SEVERE HAEMOPHILIA B**  
Kai Severin\* (DE), Michael Heyl, Markus Compes, H. Tilman Steinmetz, Stephan Schmitz
- P-MO-181 PROLONGED EFFECT OF N8-GP IN HAEMOPHILIA A DOGS SUPPORTS LESS FREQUENT DOSING**  
Henrik Agersoe\* (DK), Henning Stennicke, Hermann Pelzer, Eva Norling Olsen, Tim Nichols, Mirella Ezban
- P-MO-182 THE USE OF RFVIIA AND APCC IN THERAPY OF BLEEDINGS OF DIFFERENT ORIGIN - THREE YEARS EXPERIENCE OF LODZ HEMOPHILIA TREATMENT CENTER.**  
Jacek Trelinski\* (PL), Michal Zamolski, Krzysztof Chojnowski
- P-MO-183 CONTINUOUS INFUSION FOR THE MANAGEMENT OF MAJOR POST-TRAUMATIC, LONG-LASTING MUSCULOSKELETAL BLEEDINGS IN HAEMOPHILIA A CHILDREN AND ADOLESCENTS**  
Brigitte A Pautard Muchemle\* (FR), Valerie Li Thiao Te, Christine Vinciguerra, Julie Notheaux-Micheli, Anne Lutun, Marie Anne Guersing, Bertrand Roussel, Claude Negrier
- P-MO-184 ADDITIONAL IMPACT OF MORNING HEMOSTATIC RISK FACTORS AND MORNING BLOOD PRESSURE SURGE ON STROKE RISK IN OLDER JAPANESE HYPERTENSIVE PATIENTS**  
Yuichiro Yano\* (JP), Takefumi Matsuo, Satoshi Hoshide, Kazuo Eguchi, Kazuyuki Shimada, Kazuomi Kario
- P-MO-185 GLYCOPEGYLATED RFVIII (N8-GP) HAS PROLONGED HAEMOSTATIC EFFECT IN HAEMOPHILIA A MICE.**  
Torben Elm\* (DK), Mirella Ezban, Mikael Tranholm, Henning Stennicke, Heidi Holmberg
- P-MO-186 ADVATE HAEMOPHILIA A OUTCOME DATABASE (AHEAD): A LONG-TERM REGISTRY FOCUSING ON JOINT HEALTH OUTCOMES AND QUALITY OF LIFE**  
Clara K Song\* (US), Johannes Oldenburg, Gerald D Spotts, Ingo Abraham, Manfred Pirck, Werner Engl, Armin J Reininger
- P-MO-187 APCC (FEIBA) PROPHYLAXIS: LONG TERM EXPERIENCE (1998-2011) IN A SEVERE HAEMOPHILIA A PATIENT WITH FVIII INHIBITOR**  
michele schino\* (IT), pierosandro sbrighi, Massimo Morfini



## POSTER PRESENTATIONS

Monday, July 25, 2011

- P-MO-188 PLASMA DERIVED FACTOR VIII IN THE TREATMENT OF PATIENTS WITH HEMOPHILIA A: UPDATE OF A LONG-TERM PHARMACOVIGILANCE**  
Robert Klamroth (DE), Rainer Zimmermann, Susanne Holzhauer, Mathias Juers\*,  
Claudia Zacharias, Karin Kurnik
- P-MO-189 IMPACT OF THE 2500 U VIAL SIZE FOR APCC ON DOSE AND VIAL BURDEN IN A US SPECIALTY PHARMACY DATABASE**  
Sangeeta Krishnan\* (US), Yan Xiong
- P-MO-190 P.I.S.A. POST-MARKETING ITALIAN SURVEILLANCE STUDY ON ADVATE TREATMENT OF HAEMOPHILIA A PATIENTS IN ORDER TO EVALUATE ITS EFFICACY, SAFETY AND IMMUNOGENICITY.**  
michele schino\* (IT), angiola rocino, Elena Santagostino, MariaGabriella Mazzuconi
- P-MO-191 PRECLINICAL SAFETY PHARMACOLOGY OF BAXTER'S RECOMBINANT FACTOR IX**  
Barbara Dietrich\* (AT), Susan Kubik, Hartmut Ehrlich, Friedrich Scheiflinger, Hans Peter Schwarz,  
Eva Maria Muchitsch
- P-MO-192 REPEATED APPLICATION OF BAXTER'S RECOMBINANT FACTOR IX IN RATS AND CYNOMOLGUS MONKEYS**  
Barbara Dietrich\* (AT), Wilfried Auer, Kuno Wuersch, Martin Wolfsegger, Hartmut Ehrlich,  
Friedrich Scheiflinger, Hans Peter Schwarz, Eva Maria Muchitsch
- P-MO-193 IMMUNE TOLERANCE INDUCTION IN HEMOPHILIA A PATIENTS WITH INHIBITORS BY TREATMENT WITH RECOMBINANT FACTOR VIII (IN FACT): A RETROSPECTIVE NON-INTERVENTIONAL STUDY**  
Georges E. Rivard\* (CA), Chantal Rothschild, Teresa Toll
- P-MO-194 A COMPARISON OF HEALTH-RELATED QUALITY OF LIFE AND JOINT HEALTH OUTCOMES BETWEEN HEMOPHILIA A PATIENTS WITH INHIBITORS AND NON-INHIBITOR PATIENTS**  
Diane Ito\* (US), Yan Xiong, Sangeeta Krishnan

### Fibrinogen and other factors

- P-MO-195 COMPARISON OF BRANDED ENOXAPARIN (LOVENOX) AND A BIOSIMILAR VERSION OF ENOXAPARIN (FIBRINOX)**  
Walter Jeske\* (US), Elizabeth McGeehan, Omer Iqbal, Debra Hoppensteadt, Jeanine Walenga,  
Jawed Fareed
- P-MO-196 MOLECULAR MECHANISMS THAT CONTROL CLOT STRUCTURE: EXPLORING THE  $\alpha$ C REGION WITH A HUMAN/CHICKEN HYBRID FIBRINOGEN**  
Susan T Lord\* (US), Lifang Ping, Nathan E Hudson, Michael R. Falvo
- P-MO-197 FACTOR X DEFICIENCY CAUSED BY DOUBLE NOVEL HETEROZYGOUS MUTATIONS ((IVS5+1G>A AND ASP368DEL)**  
Jiawei Zhou\* (CN), Qiong Chen, Xuefeng Wang, Qiulan Ding, Hongli Wang
- P-MO-198 ABDOMINAL AORTIC CALCIFICATION IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE: PREVALENCE AND COAGULATION ABNORMALITY.**  
Vladimir A Zelinskiy\* (RU), Vladimir V Andreev
- P-MO-200 "SNAPSHOTS" OF FIBRIN POLYMERIZATION: ANALYSIS OF FORMALDEHYDE-FIXED PRODUCTS**  
Susan T Lord\* (US), Lihong Huang



## POSTER PRESENTATIONS

Monday, July 25, 2011

Monday Posters

- P-MO-201 THE INTERIORS OF THE FIBERS IN A FIBRIN CLOT ARE ACCESSIBLE TO LARGE PROTEINS LIKE ACTIVATED FACTOR XIII.**  
Susan T Lord\* (US), Shelby L Allen, Oleg V Gorkun
- P-MO-202 RESTORATION OF IMPAIRED HEMOSTASIS BY PLATELETS AND COAGULATION FACTORS IN PATIENTS UNDERGOING CARDIOTHORACIC SURGERY**  
Marisa Ninivaggi\* (NL), Marcus D. Lance, Gerhardus J. Kuiper, Saskia E. Schols, Marion A. Feijge, Marco Marcus, Hugo ten Cate, Johan W. Heemskerk
- P-MO-203 CHARACTERIZATION OF FIBRINOGEN DEPLETION AND RESPONSE TO REPLACEMENT THERAPY IN BLEEDING TRAUMA PATIENTS**  
Claire Rourke\* (UK), Nicola S Curry, Sirat Khan, Simon Stanworth, Karim Brohi
- P-MO-204 DISCREPANCY BETWEEN ACTIVITY AND ANTIGEN LEVELS OF FACTOR(F) XIII AFTER ADMINISTRATION OF FXIII CONCENTRATES IN HEMORRHAGIC ACQUIRED FXIII DEFICIENCY DUE TO ITS AUTOANTIBODY**  
Fumihiko Ishida\* (JP), Kentaro Okubo, Toshiro Ito, Nobuo Okumura, Masayoshi Souri, Akitada Ichinose
- P-MO-205 IDENTIFICATION OF FIBRIN CLOT-BOUND PLASMA PROTEINS**  
Simone Talens\* (NL), Frank W.G. Leebeek, Jeroen A.A. Demmers, Dick C. Rijken
- P-MO-206 ANALYSIS AND CHARACTERIZATION OF GLYCOPEGYLATED RECOMBINANT HUMAN FIX**  
Lisbeth C Palm\* (DK), Karen Hansen, Anders Dybdal Nielsen, Finn Stausholm Nielsen, Anette Skammelsen Schmidt

### Laboratory tests

- P-MO-207 ABSENCE OF LOW-DOSE TISSUE FACTOR INDUCED-THROMBIN GENERATION IN SOME SEPTIC SHOCK PATIENTS.**  
Jean-Christophe Raymond Gris\* (FR), Eva Cochery-Nouvellon, Erik Mercier, Marie Bozon, Geraldine Lissalde-Lavigne, Christian Bengler, Guillaume Louart, Jean-Yves Lefrant
- P-MO-208 DETERMINING THE ACTIVITY OF RIVAROXABAN TREATMENT: THE NEW PROTHROMBIN TIME REAGENT TECHNOCLOT PT PLUS**  
Lieselotte Wagner\* (AT), Jutta Mager, Viktoria Kaufmann, Nikolaus Binder
- P-MO-209 THE EVALUATION OF THE ISI AND MNPT USING FRESH PATIENT SAMPLES AND AK-CALIBRANT: A COMPARISON.**  
Lieselotte Wagner\* (AT), Viktoria Kaufmann, Jutta Mager, Nikolaus Binder
- P-MO-210 EVALUATION OF ASSAY PERFORMANCE MONITORING XA INHIBITORS WITH TECHNOCHROM ANTI-XA (AT+) AND TECHNOCHROM ANTI-XA**  
Lieselotte Wagner\* (AT), Sabine Geiter, Stephan Stranz, Viktoria Kaufmann, Jutta Mager, Markus Graf
- P-MO-211 ABNORMAL APTT SECOND DERIVATIVE CLOT CURVES ON THE ACL TOP ANALYSER AND THEIR DIAGNOSTIC UTILITY.**  
Simon J Davidson\* (UK), Cristina Valenciano, Stephen Fox, Farah Kamani, Louise Tillyer
- P-MO-212 FACTOR XIII LEVELS IN CHILDREN WITH CYANOTIC AND ACYANOTIC CONGENITAL HEART DEFECTS: THE IMPACT OF CARDIOPULMONARY BYPASS**  
Leo A. Bockeria (RU), Natalia N. Samsonova, Ivan A. Yurlov, Ludmila G. Klimovitch, Elena F. Kozar, Iya Tsagareli, Nikolay N. Eliseev, Eva HN. Olsen, Sergey B. Zaets\*
- P-MO-213 THE STATUS OF CARRIER AND PRENATAL DIAGNOSIS OF HAEMOPHILIA IN CHINA**  
Jing Dai\* (CN), Ling Ye Lu, Lan Qiu Ding, Li Hong Wang, Feng Xue Wang



45

## POSTER PRESENTATIONS

Monday, July 25, 2011

- P-MO-214 HAEMOLYSIS DURING SAMPLE COLLECTION CAUSES VARIABLE BUT SOMETIMES CLINICALLY IMPORTANT ERRORS**  
Anita Woolley\* (UK), Kevin Horner, Steve Kitchen
- P-MO-215 EFFECT OF MATRINE ON THE EXPRESSION OF TISSUE FACTOR INDUCED BY LIPOPOLYSACCHARIDE IN MONOCYTES**  
Zhibin Wen\* (CN), Xudong Tang, Xiaofan He, Shinlin He
- P-MO-216 A NEW APTT REAGENT WITH SYNTHETIC PHOSPHOLIPIDS**  
Virginia Montanini\* (ES), Maite Munoz, Albert Huisman, Ana Chiva
- P-MO-217 HIGH ANTI-FACTOR V (AFV) ACTIVITY AND NO-SPONTANEOUS BLEEDING: A CASE REPORT**  
Silvia Grosso\* (AR), Marcelo Ingratti, Graciela Alfonso, Analia Sanchez Luceros, Susana Meschengieser, Alicia Blanco, Maria Lazzari
- P-MO-218 UPREGULATION OF INFLAMMATORY MEDIATORS IN END STAGE RENAL DISEASE AS MEASURED VIA BIOCHIP ARRAY TECHNOLOGY**  
Vinod Bansal\* (US), Rachel Davis, Evangelos Litinas, Debra Hoppensteadt, Jawed Fareed
- P-MO-219 THE INHIBITORY EFFECT OF SERUM ALBUMINS ON THE HYDROLYSIS OF ZGGR-AMC BY THROMBIN AND  $\alpha$ 2M-THROMBIN AND ITS CONSEQUENCES FOR FLUOROGENIC THROMBIN GENERATION METHODS.**  
Erik De Smedt\* (NL), Rob Wagenvoord, C. H. Hemker
- P-MO-220 EVALUATION OF THE Q HEMOSTASIS ANALYSER (GRIFOLS) FOR ROUTINE TESTS OF HAEMOSTASIS**  
Anita Woolley\* (UK), Steve Kitchen
- P-MO-221 COAGULATION TESTING: INFLUENCE OF BLOOD COLLECTION TUBE AND PRE-ANALYTICAL STORAGE TEMPERATURE**  
Marie-Claire F Kleinegriss\* (NL), M.C.F. Kleinegriss, R. Loeffen, F.J.M. van der Meer, P.H. Reitsma, S.T.B.G. Loubele, H.M.H. Spronk, H. ten Cate
- P-MO-222 COMPARISON OF SYSMEX CS AND CA SERIES ANALYSERS FOR ROUTINE TESTS OF HAEMOSTASIS**  
Julie M Smith\* (UK), Jackie Deeming, Kevin Horner, Anne Sermon, Jackie Storr, Anita Woolley, Steve Kitchen
- P-MO-223 SCALING UP Q HEMOSTASIS ANALYZER TO HIGH THROUGHPUT LABORATORIES**  
Josep Pages\* (ES), Ramon Cases, Susanna Torres
- P-MO-224 IMPORTANCE OF THROMBIN GENERATION ASSAY IN MONITORING OF HEMOSTASIS IN PATIENTS WITH HEMOPHILIA**  
Kaan Kavakli\* (TR), Yilmaz Ay, Can Balkan, Deniz Yilmaz, Basri Bilenoglu, Kaan Kavakli
- P-MO-225 DECREASED PROCOAGULANT PHOSPHOLIPIDS IN PATIENTS WITH VITAMIN K ANTAGONISTS**  
Barry J Woodhams\* (FR), Aurelie Rousseau, Barry Woodhams, Bernard Lenormand, Marc Vasse
- P-MO-226 ATYPICAL VARIANTS OF THE F8 INTRON 22 INVERSION IDENTIFIED USING INVERSE SHIFTING-PCR**  
Felicity Catherine Edwards\* (UK), Jacky Cutler, Steve Austin, Savita Rangarajan, Mike Mitchell
- P-MO-227 COMPARISON OF INHIBITION OF THROMBIN GENERATION BY DIFFERENT CLASSES OF ANTICOAGULANTS**  
Yiming Xu\* (US), KehDih Lai, Barry Antonacci, Madhu Chintala



## POSTER PRESENTATIONS

Monday, July 25, 2011

Monday Posters

- P-MO-228 POLYBRENE CAN NEUTRALISE ENOXAPARIN IN PLASMA BEING TESTED FOR THROMBIN GENERATION, HOWEVER THIS EFFECT IS CONCENTRATION DEPENDENT**  
Jignesh P Patel\* (UK), Lara N Roberts, Raj K Patel, Michael S Marsh, Bruce Green, John G Davies, Roopen Arya
- P-MO-229 ACCURACY AND RELIABILITY OF INTERNATIONAL NORMALIZED RATIO (INR) IN MONITORING OF WARFARIN ON QUICK-PT (INR) AND OWREN-TT (INR) REAGENTS**  
Masahiro Okuda\* (JP), Tasuku Sakayori, Sumiyoshi Naito, Mika Yoshida, Noriyoshi Kato, Nobuhiko Takahashi, Masahiro Ieko
- P-MO-230 PASTEURIZATION EFFECTIVELY INACTIVATES CLOTTING ACTIVITIES DURING MANUFACTURING OF TWO LIQUID READY TO USE DIFFERENT INTRAVENOUS IMMUNOGLOBULIN (IVIG) PRODUCTS**  
Marta Jose\* (ES), Marzo Nuria, Lopez Laura, Lopez Maite, Ristol Pere, Jorquera I. Juan
- P-MO-231 THROMBIN GENERATION (TG) ASSAYS IN HAEMOPHILIACS WITH INHIBITORS TREATED WITH BY-PASSING AGENTS: THE UTILITY OF ADDING CORN TRYPSIN INHIBITOR (CTI).**  
Veena Chantarangkul\* (IT), Maria Elisa Mancuso, Laura Lemma, Marigrazia Clerici, Elena Santagostino, Armando Tripodi
- P-MO-232 COMPARISON BETWEEN ACT+ AND ACT-LR RESULTS USING THE HEMOCHRON SIGNATURE ELITE**  
Tarek Owaidah\* (SA), Merlito De Torres
- P-MO-233 COAGULATION TESTING BEFORE EPIDURAL ANALGESIA AT DELIVERY: COST-ANALYSIS**  
Eugenia Biguzzi\* (IT), Franca Franchi, Buthaina Ibrahim, Federica Rossi, Maria Luisa Maspero, Oronzo Morabito, Daniela Asti, Paolo Bucciarelli
- P-MO-234 CORRECTION OF INR DISCREPANCY BETWEEN LABORATORIES USING VARIOUS PT SYSTEMS**  
Felix JM Van Der Meer\* (NL), Anton M. Van den Besselaar, Anton P. Van Zanten, Helen M. Brandjes, Mark G. Elisen, Dennis C. Poland, August Sturk, Anja Leyte, Ad Castel
- P-MO-235 EVALUATION AND PERFORMANCE CHARACTERISTICS OF THE Q HEMOSTASIS ANALYZER.**  
Pierre A Toulon\* (FR), Florence Fischer, Anny Appert-Flory, Didier Jambou
- P-MO-236 A LOW MAGNESIUM EVACUATED BLOOD COLLECTION TUBE MINIMIZES INR DISCREPANCIES AMONGST DISPARATE PROTHROMBIN TIME SYSTEMS**  
Keith Moskowitz\* (US), Evelina Witteveen, Karen Byron, Amy Mouser, David Warunek, A.M.H.P. van den Besselaar
- P-MO-237 ANTITHROMBIN-INDEPENDENT IMPAIRED THROMBIN INACTIVATION IS NOT A FREQUENT FINDING AMONG THROMBOPHILIC PATIENTS**  
Heiko Ruehl\* (DE), Jens Mueller, Ursula Harbrecht, Johannes Oldenburg, Bernd Poetzsch

### Experimental models

- P-MO-238 PROLONGED HAEMOSTATIC EFFECT OF N8-GP ON JOINT BLEEDS IN HAEMOPHILIA A MICE**  
Kirstine Ovlisen\* (DK), Mirella Ezban, Mikael Tranholm



47

## POSTER PRESENTATIONS

Monday, July 25, 2011

- P-MO-239 EXPERIMENTAL USE OF RECOMBINANT FACTOR XIII (RF XIII) IN CRITICAL CONDITIONS: COMPARISON OF EFFECTIVENESS IN DIFFERENT ANIMAL MODELS**  
Sergey B. Zaets\* (US), Da-Zhong Xu, Qi Lu, Eleonora Feketova, Tamara Berezina, Inga Malinina, Edwin Deitch, Eva Olsen
- P-MO-240 THE EFFECT OF COMMON BETA2-RECEPTOR HAPLOTYPES ON CATECHOLAMINE LEVELS AND HEMOSTASIS AFTER STANDING UP**  
Olav R De Peuter\* (NL), Joost C Meijers, Bas Van den Bogaard, Yu-Sok Kim, Marianna C Schaap, Rienk Nieuwland, Wouter E Kok, Harry R Buller, Pieter W Kamphuisen
- P-MO-241 DEVELOPMENT OF AN EX VIVO MODEL OF OCCLUSIVE THROMBUS FORMATION**  
Ishan A Patel\* (US), Garth Tormoen, Hrebesh Subhash, Erik I Tucker, Andras Gruber, Owen JT McCarty
- P-MO-242 EFFICACY OF BAXTER'S RECOMBINANT FACTOR VIIA IN ANIMAL MODELS OF HEMOPHILIA**  
Alexandra Schiviz\* (AT), John Philip Lawo, Marlene Resch, Peter Leidenmuehler, Bettina Bischetsrieder, Hartmut Ehrlich, Friedrich Scheifflinger, Hans-Peter Schwarz, Werner Hoellriegl, Eva-Maria Muchitsch
- P-MO-243 EFFICACY OF BAXTER'S RECOMBINANT FACTOR IX IN MOUSE MODELS OF HEMOPHILIA B**  
Werner Hoellriegl\* (AT), Alexandra Schiviz, Barbara Eder, John Philip Lawo, Martin Wolfsegger, Hartmut Ehrlich, Friedrich Scheifflinger, Hans-Peter Schwarz, Eva-Maria Muchitsch
- P-MO-244 PHARMACOKINETICS OF BAXTER'S RECOMBINANT FIX IN FACTOR IX KO MICE, RATS AND CYNOMOLGUS MONKEYS**  
Gerald Hoebarth\* (AT), Susan Kubik, John Philip Lawo, Alfred Weber, Herbert Gritsch, Alexandra Schiviz, Hartmut Ehrlich, Friedrich Scheifflinger, Hans-Peter Schwarz, Eva-Maria Muchitsch
- P-MO-245 PHARMACOKINETICS OF BAXTER'S RECOMBINANT FVIIA IN FACTOR VIII KO MICE, RATS AND CYNOMOLGUS MONKEYS**  
Gerald Hoebarth\* (AT), Susan Kubik, Martin Wolfsegger, John Philip Lawo, Alfred Weber, Herbert Gritsch, Alexandra Schiviz, Hartmut Ehrlich, Friedrich Scheifflinger, Hans-Peter Schwarz, Eva-Maria Muchitsch
- P-MO-246 REVERSAL AGENTS FOR EDOXABAN, A FACTOR XA INHIBITOR: EFFECTS OF FACTOR VIIA, ANTI-INHIBITOR COAGULANT COMPLEX, PROTHROMBIN COMPLEX CONCENTRATE, FRESH PLASMA, AND VITAMIN K**  
Yoshiyuki Morishima\* (JP), Yuko Honda, Chikako Kamisato, Taketoshi Furugohri, Toshiro Shibano
- P-MO-247 IMPAIRED CARBOXYLATION OF OSTEOCALCIN BY WARFARIN, BUT NOT BY EDOXABAN, AN ORAL DIRECT FACTOR XA INHIBITOR, IN RATS**  
Yoshiyuki Morishima\* (JP), Chikako Kamisato, Yuko Honda, Taketoshi Furugohri, Toshiro Shibano
- P-MO-248 CHARACTERIZATION OF A NOVEL VITAMIN K EPOXIDE REDUCTASE INHIBITOR**  
Yoshiyuki Morishima\* (JP), Toshiyuki Sato, Naoki Tsuji, Mina Delawary, Yuko Honda, Chikako Kamisato, Toshiro Shibano
- P-MO-249 PROGRESSION OF THE HYPERCOAGULABLE STATE IN AGEING BMAL1 DEFICIENT MICE**  
Bianca Hemmerlyckx\* (BE), Cor E Van Hove, Paul Fransen, Jan Emmerechts, Alexandre Kauskot, Hidde Bult, Henri Roger Lijnen, Marc Hoylaerts



## POSTER PRESENTATIONS

Monday, July 25, 2011

Monday Posters

### Plasminogen activator inhibitors

- P-MO-250 EFFECT OF INSULIN ON THE PRODUCTION OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 IN HEPG2 CELLS: INDUCTION THROUGH 3'-UNTRANSLATED REGION**  
Satoshi Fujii\* (JP), Ryu Miyagawa, Takefumi Asakura, Tomomi Nakamura, Hiromi Okada, Soichiro Iwaki, Burton E Sobel
- P-MO-251 EFFECT OF FIBRINOGEN AND FACTOR XIII ON CLOT FORMATION AND THROMBIN GENERATION IN GLANZMANN THROMBASTHENIA BLOOD**  
Boris Shenkman\* (IL), Tami Livnat, Mudi Misgav, Ivan Budnik, Uri Martinowitz
- P-MO-252 PLASMINOGEN ACTIVATOR INHIBITOR -1 4G/5G POLYMORPHISM AND RISK OF ACUTE ONSET ISCHEMIC STROKE IN YOUNG ASIAN INDIANS**  
Mohd S Akhter\* (IN), Arijit Biswas, Ravi Ranjan, Amit Sharma, Sunil Kumar, Madhuri Behari, Renu Saxena
- P-MO-253 AGE- AND GENDER-RELATED DIFFERENCES IN PAI-1 ANTIGEN LEVELS IN A JAPANESE GENERAL POPULATION, THE SUITA STUDY**  
Okamoto Akira\* (JP), Toshiyuki Sakata, Yoshihiro Kokubo, Michitaka Sano, Toshiyuki Miyata
- P-MO-254 PAI-1 DEFICIENCY IN HUMANS AND MICE**  
Takayuki Iwaki\* (JP), Takao Kobayashi, Kazuo Umemura, Tetsumei Urano, Tetsuhito Kojima, Naohiro Kanayama
- P-MO-255 XANTHOANGELOLS ISOLATED FROM *ANGELICA KEISKEI* INHIBIT INFLAMMATORY-INDUCED PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI-1) PRODUCTION**  
Naoki Ohkura\* (JP), Yoshitaka Nakakuki, Masahiko Taniguchi, Shiho Kanai, Katsunori Ohnishi, Toshiyuki Sakata, Tomoyoshi Nohira, Juzo Matsuda, Kimiye Baba, Gen-ichi Atsumi
- P-MO-256 INCREASED FIBRINOLYTIC POTENTIAL IN PATIENTS WITH TYPE 1 DIABETES**  
Anna Agren\* (SE), Gun Jorneskog, Per-Eric Lins, Graciela Elgue, Hakan Wallen, Bjorn Wiman
- P-MO-257 AUGMENTATION OF CIRCADIAN PAI-1 EXPRESSION IN A KETOGENIC DIET-FED PPAR $\alpha$ -NULL MICE : THE POSSIBLE INVOLVEMENT OF PPAR $\gamma$  ACTIVATION IN THE INDUCTION**  
Shuichi Horie\* (JP), Daisuke Uchida, Naoki Ohkura, Katsutaka Oishi

### Fibrinogen and fibrin

- P-MO-258 EFFECTS OF MONOMERIC C-REACTIVE PROTEIN ON CLOT DYNAMICS AND FIBRIN STRUCTURE FROM ENDOTHELIAL CELLS: A POSSIBLE MECHANISM OF THE INCREASED THROMBOTIC RISK**  
Jianbo Wu\* (CN), Tammy L Strawn, William P Fay
- P-MO-259 FIBRINOGEN MINTO: CONGENITAL HYPOFIBRINOGENAEMIA DUE TO HETEROZYGOSITY FOR A NOVEL MUTATION IN THE FIBRINOGEN GAMMA CHAIN CORRESPONDING TO A  $\gamma$ 346GLY TO VAL SUBSTITUTION**  
Diane Zebeljan\* (AU), Lye Lin HO, Penelope MOTUM, Stephen LANG, Stephen BRENNAN, Sarah JUST
- P-MO-260 A NOVEL MECHANISM FOR HYPOFIBRINOLYSIS IN DIABETES: THE ROLE OF COMPLEMENT C3**  
Katharina Hess\* (DE), Verena Schroeder, Saad Alzahrani, Mathew Mathai, Gareth Howell, Kerrie Smith, Angela M Carter, Nikolaus Marx, Peter J Grant, Ramzi Ajjan



## POSTER PRESENTATIONS

Monday, July 25, 2011

- P-MO-261 MATURITY ONSET DIABETES OF THE YOUNG IS CHARACTERISED BY LESS THROMBOTIC FIBRIN NETWORK STRUCTURE COMPARED WITH PHENOTYPICALLY SIMILAR TYPE 2 DIABETES SUBJECTS**  
Ramzi A Ajjan\* (UK), Matthew J Bottomley, Gaya Thanabalasingham, Saad H Alzahrani, Katharina Hess, Katharine R Owen
- P-MO-262 THE PREDICTIVE ABILITY OF D-DIMER FOR THE EFFECT OF THROMBOLYTIC THERAPY AT DEEP VEIN THROMBOSIS**  
SATOSHI OTA\* (JP), NORIKAZU YAMADA, YOSHITO OGIHARA, AKIHIRO TSUJI, KEN ISHIKURA, MASHIO NAKAMURA, MASAACKI ITO
- P-MO-263 EFFECTS OF B $\beta$ ARG448LYS POLYMORPHISM ON FIBRIN CLOT STRUCTURE/ FIBRINOLYSIS AND CARDIOVASCULAR COMPLICATIONS IN SUBJECTS WITH TYPE 2 DIABETES.**  
Katie Amy Greenhalgh\* (UK), Saad Alzahrani, J Price, M Strachan, P Baxter, Kristina Standeven, Z Kurdee, Peter Grant, Ramzi Ajjan, Robert SA Ariens
- P-MO-264 A HIGH DOSE OF ASPIRIN IS REQUIRED FOR POSITIVE INFLUENCE ON PLASMA FIBRIN NETWORK IN PATIENTS WITH TYPE 1 DIABETES.**  
Sara Tehrani\* (SE), Aleksandra Antovic, Fariborz Mobarrez, Koteiba Mageed, Per-Eric Lins, Ulf Adamson, Hakan Wallen, Gun Jorneskog
- P-MO-265 PULMONARY COAGULATION IS INCREASED DEPENDENT ON MAST CELLS IN A MURINE ASTHMA MODEL USING INTRANASAL INOCULATION OF HOUSE DUST MITE EXTRACT.**  
Johannes Daan De Boer\* (NL), C Van t Veer, TJ Hommes, AF De Vos, JJTH Roelofs, JS Van der Zee, T Van der Poll
- P-MO-266 COMPLEMENT C3 IS SUBSTRATE FOR PLASMIN AND IMPAIRS TPA-MEDIATED PLASMIN GENERATION RESULTING IN IMPAIRED FIBRINOLYSIS**  
Victoria R Richardson\* (UK), Kristina F Standeven, Peter J Grant, Angela M Carter
- P-MO-267 IN VIVO N-HOMOCYSTEINYLACTION OF FIBRINOGEN AND ITS ROLE IN THROMBOSIS**  
Amy L Cilia La Corte\* (UK), Majid Ali, Rafal Glowacki, Hieronim Jakubowski, Victoria Ridger, Richard Pease, Julian Scott, Robert A Ariens, Helen Philippou
- P-MO-268 THE ANTIFIBRINOLYTIC FUNCTION OF FACTOR XIII IS EXCLUSIVELY EXPRESSED THROUGH  $\alpha_2$ ANTIPLASMIN CROSS-LINKING**  
Nicola J Mutch\* (UK), Steven R Fraser, Nuala A Booth
- P-MO-269 FIBRIN CLOT FORMATION IS A REVERSIBLE PROCESS**  
Irina N Chernysh\* (US), John W Weisel, Chandrasekaran Nagaswami, Prashant K Purohit
- P-MO-270 POSSIBILITY OF FIBRIN MONOMER AS A EARLY MARKER FOR DISSEMINATED INTRAVASCULAR COAGULATION**  
Hyeun Shim\* (KR), Seongsoo Jang, Borae G. Park, Chan-Jeoung Park, Hyun-Sook Chi, Sang-Bum Hong

### Laboratory tests

- P-MO-271 MEASUREMENT OF IMPAIRMENT OF SPONTANEOUS THROMBOLYTIC ACTIVITY IN HABITUAL SMOKERS BY THE GLOBAL THROMBOSIS TEST**  
Akira Suehiro\* (JP), Ichiro Wakabayashi, Tsutomu Yamashita, Junichiro Yamamoto





## POSTER PRESENTATIONS

Monday, July 25, 2011

Monday Posters

- P-MO-272 ACETYSALICYLIC ACID THERAPY IN TYPE 2 DIABETIC PATIENTS AND ASSOCIATION WITH URINARY 11-DEHYDRO THROMBOXANE B2 LEVELS**  
Marinez Oliveira Sousa\* (BR), Lillian Harboe Goncalves, Karina Braga Gomes, Ana Paula Fernandes, Luci Maria Sant'Ana Dusse, Adriana Aparecida Bosco, Fernanda Rocha Freitas, Gerson Antonio Pianetti, Maria das Gracas Carvalho
- P-MO-273 FISH INGREDIENT TAURINE MIGHT RAISE ENDOGENOUS THROMBOLYTIC ACTIVITY IN HEALTHY MIDDLE-AGED JAPANESE, ASSESSED BY A GLOBAL THROMBOSIS TEST (GTT)**  
Yoshinobu Ijiri\* (JP), Hideo Ikarugi, Yukinori Tamura, Mayumi Ura, Mai Morishita, Mari Mori, Hiromitsu Ishii, Yukio Yamori, Junichiro Yamamoto
- P-MO-274 IS THERE AN ASSOCIATION BETWEEN APOLIPOPROTEIN A5 -1131T>C POLYMORPHISM AND HEMOSTATIC VARIABLES?**  
Marinez Oliveira Sousa\* (BR), Claudia Natalia Ferreira, Ana Paula Fernandes, Karina Braga Gomes, Isabela Ribeiro Santos, Fernanda Fonseca Coelho, Poliana Silva Pinheiro, Kathryn Fontana Rodrigues, Nathalia Gomide Cruz, Maria das gracas Carvalho
- P-MO-275 HEMOSTATIC AND LIPIDIC VARIABLES IN NORMOLIPIDEMIC AND DYSLIPIDEMIC SUBJECTS**  
Marinez Oliveira Sousa\* (BR), Claudia Natalia Ferreira, Luciana Moreira Lima, Karina braga Gomes, Poliana Silva Pinheiro, Geralda Fatima Guerra Lages, Maria das Gracas Carvalho
- P-MO-276 HYPERFIBRINOLYSIS - TIME REQUIRED TO REACH THE DIAGNOSIS USING STANDARD THROMBOELASTOMETRY ASSAYS**  
Ole Halfdan Larsen\* (DK), Christian Fenger-Eriksen, Kirsten Christiansen, Jorgen Ingerslev, Benny Sorensen
- P-MO-277 HIGHLY SENSITIVE ELISA METHOD FOR THE DETERMINATION OF  $\alpha$ 2-PLASMIN INHIBITOR ANTIGEN LEVEL IN PLASMA AND OTHER BODY FLUIDS**  
Eva Katona\* (HU), Adrienn Orosz, Andrea Csapo, Laszlo Muszbek
- P-MO-278 DEVELOPMENT OF AN IMMUNOASSAY FOR THROMBOMODULIN ON STACIA SYSTEM**  
Shuhei Matsushita\* (JP), Tomoko Ono

### Deep vein thrombosis and pulmonary embolism

- P-MO-279 TWO TEST-SYSTEMS FOR QUANTIFICATION OF SOLUBLE FIBRIN AND D-DIMER. APPROBATION IN CLINICS.**  
Eduard Vitalievich Lugovskoy\* (UA), Serhiy Vasilievich Komisarenko, Irina Nikolaevna Kolesnikova, Tetyana Anatoliivna Koshel, Ievgen Oleksandrovich Koliesnik, Nataliya Eduardovna Lugovskaya, Lesya Petrivna Urvant, Olena Petrivna Kostyuchenko
- P-MO-280 CAUSAL RELATIONSHIP BETWEEN HYPERFIBRINOGENEMIA, THROMBOSIS, AND RESISTANCE TO THROMBOLYSIS**  
Kellie Rae Machlus (US), Jessica Cardenas, Frank Church, Alisa S Wolberg\*
- P-MO-281 STRESS-INDUCED HYPERGLYCEMIA AND VENOUS THROMBOEMBOLISM FOLLOWING TOTAL HIP OR TOTAL KNEE ARTHROPLASTY: ANALYSIS FROM THE RECORD TRIALS**  
Danny Michael Cohn\* (NL), Jeroen Hermanides, J. Hans DeVries, Pieter-Willem Kamphuisen, Sylvia Kuhls, Martin Homering, Joost B.L. Hoekstra, Anthonie W.A. Lensing, Harry R. Buller
- P-MO-282 'RISING LEUKOCYTE COUNT ' COULD MAKE A GOOD MARKER FOR VENOUS THROMBOEMBOLISM!**  
Raghavendra R Allareddy\* (US)



51

## POSTER PRESENTATIONS

Monday, July 25, 2011

- P-MO-283 RESIDUAL VEIN OBSTRUCTION TO PREDICT THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN PATIENTS WITH DEEP VEIN THROMBOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS.**  
Marc Carrier\* (CA), Marc A Rodger, Phil S Wells, M Righini, Gregoire Le Gal
- P-MO-284 ENDOVENOUS HEAT INDUCED THROMBOSIS: A NEW CLINICAL ENTITY.**  
Markiyana Soloviy\* (UA)
- P-MO-285 VENOUS THROMBOEMBOLIC EVENTS AT A SPECIALIST HEART AND LUNG CENTRE**  
M Louise Tillyer\* (UK)
- P-MO-286 HIGH LEVELS OF GLUCOSE AT TIME OF DIAGNOSING VENOUS THROMBOSIS: A CASE-CONTROL STUDY**  
Vladimir Tichelaar\* (NL), Willem M. Lijfering, Jan C. ter Maaten, Hanneke C. Kluin-Nelemans, Karina Meijer
- P-MO-287 EVALUATION OF DIAGNOSTIC PROCEDURES FOR DIAGNOSIS OF HEPARIN-INDUCED DELAYED-TYPE HYPERSENSITIVITY REACTIONS (DTH)**  
Marc Schindewolf\* (DE), Katja Hardt, Manfred Wolter, Roland Kaufmann, Birgit Kahle, Wolf-Henning Boehncke, Edelgard Lindhoff-Last, Ralf J. Ludwig
- P-MO-288 DEEP VEIN THROMBOSIS AFTER TOTAL KNEE OR HIP ARTHROPLASTY IS ASSOCIATED WITH INCREASED CALF MUSCLE DEOXYGENATION BEFORE SURGERY**  
Takashi Yamaki\* (JP), Atsumori Hamahata, Daisuke Fujisawa, Hisato Konoeda, Kazuyuki Kubo, Taro Kono, Mitohiro Nozaki, Hiroyuki Sakurai
- P-MO-289 INCREASING OF ISCHEMIC STROKE IN RESIDENTS WITH DVT AFTER MID NIIGATA PREFECTURE EARTHQUAKE**  
Kazuhiko Hanzawa\* (JP), Maiko Ikura, Takeshi Okamoto, Kohichi Sato, Kyoko Shinada, Takashi Nakajima
- P-MO-290 HYPERTENSION IS A RISK FACTOR FOR DVT IN JAPANESE QUAKE RESIDENTS.**  
Kazuhiko Hanzawa\* (JP), Maiko Ikura, Takeshi Okamoto, Kohichi Sato, Kyoko Shinada, Takashi Nakajima
- P-MO-291 RELEVANCE OF THROMBOPHILIA IN DEEP VEIN THROMBOSIS FOLLOWING A MAJOR EARTHQUAKE**  
Mana Mitsuguro\* (JP), Toshiyuki Sakata, Akira Okamoto, Kazuhiko Hanzawa, Kyoko Shinada, Takashi Nakajima, Sachika Kameda, Michitaka Sano, Toshiyuki Miyata
- P-MO-292 QUALITY AND SAFETY LABORATORY MONITORING OF INDIRECT ANTICOAGULANTS THERAPY**  
Alyona I. Vorobyeva (RU), Ludmila A. Isaeva, Aleksandra S. Rogozina, Petr A. Lavrinov, Nadezda A. Vorobyeva\*
- P-MO-293 HEREDITARY PROTEIN C DEFICIENCY CAUSED BY COMPOUND HETEROZYGOUS MUTANTS IN TWO UNRELATED CHINESE FAMILIES**  
Yingting Wu\* (CN), Xuefeng Wang, Hongli Wang, Qiulan Ding, Jing Dai, Yeling Lu
- P-MO-294 LOW INCIDENCE OF POSTOPERATIVE DEEP VEIN THROMBOSIS IN PATIENTS UNDERGOING COLORECTAL CANCER SURGERY SEEN IN TAIWAN**  
Ching-Yeh Lin\* (TW), Ming Ching Shen, Hung Chang Chen, Ting Ming Huang, Tsang Chi Lin, Jau Jie You, Shyuann Yuh Lin, Han Ni Hsieh
- P-MO-295 THROMBIN GENERATION IS INCREASED IN AFRICAN-CARIBBEANS COMPARED TO CAUCASIANS WITH DEEP VEIN THROMBOSIS.**  
Lara N Roberts\* (UK), Raj K Patel, Roopen Arya



## POSTER PRESENTATIONS

Monday, July 25, 2011

Monday Posters

- P-MO-296 PROGNOSTIC VALUE OF THE GENEVA PREDICTION RULE IN PATIENTS WITH PULMONARY EMBOLISM.**  
Laurent Bertoletti\* (FR), Gregoire Le Gal, Drahomir Aujesky, Olivier Sanchez, Pierre-Marie Roy, Franck Verschuren, Henri Bounameaux, Arnaud Perrier, Marc Righini
- P-MO-297 PROGNOSTIC VALUE OF THE GENEVA PREDICTION RULE IN PATIENTS IN WHOM PULMONARY EMBOLISM IS RULED OUT.**  
Laurent Bertoletti\* (FR), Gregoire Le Gal, Drahomir Aujesky, Olivier Sanchez, Pierre-Marie Roy, Franck Verschuren, Henri Bounameaux, Arnaud Perrier, Marc Righini
- P-MO-298 HEMATOCRIT AND THE RISK OF RECURRENT VENOUS THROMBOSIS: A PROSPECTIVE COHORT STUDY**  
Lisbeth Eischer\* (AT), Verena Tscholl, Georg Heinze, Ludwig Traby, Paul Alexander Kyrle, Sabine Eichinger
- P-MO-299 PAST PROVOKING VENOUS THROMBOSIS RISK SITUATIONS ON THE RISK OF A RECURRENT THROMBOTIC EVENT: A COHORT STUDY**  
Daniel Dias Ribeiro\* (BR), Willem Lijfering, Sandhi Barreto, Izabella Silva, Mariana Chalup, Frits Rosendaal, Suely Rezende
- P-MO-300 IS DEEP-VEIN THROMBOSIS ALWAYS THE ORIGIN OF PULMONARY EMBOLISM? IMAGING OF VEINS WITH A TOTAL-BODY DIRECT THROMBUS MRI TECHNIQUE.**  
Kirsten van Langevelde\* (NL), A. Sramek, P. W.J. Vincken, C.J. van Rooden, F. R. Rosendaal, S. C. Cannegieter
- P-MO-301 HOMOZYGOUS FACTOR V LEIDEN AND COMPOUND HETEROZYGOSITY FOR FACTOR V LEIDEN AND PROTHROMBIN MUTATION**  
Ymir Saemundsson\* (SE), Signy Vala Sveinsdottir, Henrik Svantesson, Peter J. Svensson
- P-MO-302 SOCIOECONOMIC FACTORS AND CONCOMITANT DISEASES ARE RELATED TO THE RISK FOR VENOUS THROMBOEMBOLISM DURING 13 YEARS OF PROSPECTIVE FOLLOW-UP.**  
Nazim Isma\* (SE), Peter J Svensson, Bengt Lindblad, Juan Merlo, Henrik Ohlsson, Anders Gottsater
- P-MO-303 SAFETY AND EFFICACY OF FONDAPARINUX FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM (VTE) IN JAPANESE PATIENTS UNDERGOING COLORECTAL CANCER SURGERY.**  
Taishi Hata\* (JP), Masayoshi Yasui, Kohei Murata, Masaki Okuyama, Masayuki Ohue, Masataka Ikeda, Shigeyuki Ueshima, Kotaro Kitani, Junichi Hasegawa, Hiroshi Tamagawa, Makoto Fujii, Atsushi Ohkawa, Takeshi Kato, Shunji Morita, Takayuki Fukuzaki, Tsunekazu Mizushima, Mitsugu Sekimoto, Riichiro Nezu, Yuichiro Doki, Masaki Mori
- P-MO-304 DOES RESIDUAL VEIN OBSTRUCTION PREDICT RECURRENT THROMBOEMBOLISM AFTER DEEP VEIN THROMBOSIS? A PATIENT-LEVEL META-ANALYSIS**  
MARCO P DONADINI\* (IT), WALTER AGENO, BENILDE COSMI, DANIELA POLI, PAOLO PRANDONI, SERGIO SIRAGUSA, LAURA YOUNG, FRANCESCO DENTALI, MONICA CAPRIOLI, JAMES DOUKETIS
- P-MO-305 ACTIVATION OF COAGULATION BY A THALIDOMIDE-BASED REGIMEN**  
Yu Isozumi\* (JP), Aya Matsumoto, Asuka Hoshi, Jihwa Chung, Takatoshi Koyama
- P-MO-306 BENCHMARK OF THE INTERNATIONAL NORMALIZED RATIO DURING VITAMIN K TREATMENT IN VENOUS THROMBOEMBOLISM: A SYSTEMATIC REVIEW**  
Petra MG Erkens\* (NL), Hugo ten Cate, Martin H Prins
- P-MO-307 THROMBOSIS RISK IN MEDICAL INPATIENTS: ASSESSMENT OF TWO THROMBOSIS RISK SCORES**  
Neil Adrian Zakai\* (US), Peter W Callas, Allen B Repp, Mary Cushman



## POSTER PRESENTATIONS

Monday, July 25, 2011

- P-MO-308 THE MANAGEMENT OF SUB-SEGMENTAL PULMONARY EMBOLISM: A CROSS-SECTIONAL SURVEY OF CANADIAN THROMBOSIS PHYSICIANS**  
Marc Carrier\* (CA), Gregoire Le Gal, Susan Kahn, Michael Kovacs, Philip Wells, David Anderson, Marc Rodger
- P-MO-309 DEVELOPMENT AND APPLICATION OF AN AUTOMATED THROMBIN GENERATION ASSAY WHICH IS SENSITIVE TO DEFECTS OF PROTEIN C PATHWAY**  
Laura Green\* (UK), Andrew S Lawrie, Ian J Mackie, Kim Ryland, Hannah Cohen, Ri Liesner, Samuel J Machin
- P-MO-310 EVALUATION OF A NEW D-DIMER TEST IN COMBINATION WITH PRETEST CLINICAL PROBABILITY SCORE FOR DIAGNOSIS OF PULMONARY EMBOLISM AND DEEP VENOUS THROMBOSIS**  
Tarek M Owaidah (SA), Nahla Al.Ghasham, Khalid Magrabi
- P-MO-311 BLEEDING-THE MOST FREQUENT UNEXPECTED EFFECT OF THE THERAPY WITH ORAL ANTICOAGULANT DRUGS**  
Deniza Donco Stambolieva\* (MK), Tanja Timova, Jani Angelovski, Meri Sorova, Laura Gorcaj, Lence Maseva, Mirjana Trencveva, Ivanka Nikoloska
- P-MO-312 ANTICOAGULANT PROTOCOL FOR TREATING CEREBRAL VEIN THROMBOSIS: A PROSPECTIVE SINGLE-CENTER STUDY**  
Maria Teresa Sartori\* (IT), Sofia Barbar, Paolo Zampieri, Marina Munari, Carla Carollo, Chiara Briani, Gianluigi Ricchieri, Laura Pasetto, Graziella Saggiorato, Paolo Prandoni
- P-MO-313 INCREASED INCIDENCE OF PULMONARY EMBOLISM IN PATIENTS WITH SEVERE ASTHMA.**  
Christof J Majoor\* (NL), Aelko H Zwinderman, Harry B Buller, Pieter W Kamphuisen
- P-MO-314 PROGNOSTIC MARKERS FOR RESIDUAL PERFUSION DEFECTS IN PATIENTS WITH ACUTE PULMONARY EMBOLISM**  
Roger EG Schutgens\* (NL), Mariette Agterof, Roger Schutgens, Fred Verzijlbergen, Monique van Buul, Repke Snijder, Rene Eijkemans, Douwe Biesma
- P-MO-316 ASSESSMENT OF THROMBIN GENERATION IN PRIMARY THROMBOPHILIA AND ACQUIRED RISK FACTORS FOR VENOUS THROMBOEMBOLISM**  
Antonin Hlusi\* (CZ), Ludek Slavik, Jana Ulehlova, Jana Prochazkova, Vera Krcova
- P-MO-317 PROC GLOBAL ASSAY IN PATIENTS WITH VENOUS THROMBOEMBOLISM AND PREGNANCY COMPLICATIONS**  
Pablo Alberto Martinez\* (AR), Maria Luciana Roumeque, Romina Valeria Suarez, Solange Alejandra Rodriguez
- P-MO-318 EFFICACY OF RIVAROXABAN FOR PREVENTION OF VENOUS THROMBOEMBOLISM AFTER KNEE ARTHROSCOPY: A RANDOMIZED DOUBLE-BLIND TRIAL (ERIKA STUDY)**  
Giuseppe Camporese\* (IT), Enrico Bernardi, Franco Noventa
- P-MO-319 EMERGENCY DEPARTMENT ACCESS RATE FOR VENOUS THROMBOEMBOLISM, CARDIOVASCULAR AND PULMONARY DISEASES IN RELATIONSHIP WITH THE COARSE AND FINE PARTICULATE MATTER AIR POLLUTION.**  
Nicola Martinelli\* (IT), Davide Cigolini, Marco Sandri, Domenico Girelli, Giorgio Ricci, Giampaolo Rocca, Oliviero Olivieri
- P-MO-320 ANTICOAGULANT UTILIZATION IN CANCER ASSOCIATED THROMBOSIS (CAT) PATIENTS**  
Elham Rahme\* (CA), Guillaume Feugere, Elodie Ramos, Myriam Antoun



## POSTER PRESENTATIONS

Monday, July 25, 2011

Monday Posters

- P-MO-321 AIR POLLUTION-INDUCED PROCOAGULANT CHANGES ARE TRIGGERED BY CIRCULATING MICROVESICLES**  
Jan Emmerechts\* (BE), Lotte Jacobs, Soetkin Van kerckhoven, Serena Loyen, Chantal Mathieu, Frans Fierens, Ben Nemery, Tim Nawrot, Marc Hoylaerts
- P-MO-322 A COMMON STANDARD IS INAPPROPRIATE FOR DETERMINING THE POTENCY OF SEMULOPARIN AND BEMIPARIN**  
Walter Jeske\* (US), Debra Hoppensteadt, Angel Gray, Jeanine Walenga, Josephine Cunanan, Lauren Meyer, Jawed Fareed, Alain Bayol, Helene Rigal, Christian Viskov
- P-MO-323 CYSTATIN C IS ASSOCIATED WITH RISK OF VENOUS THROMBOEMBOLISM IN SUBJECTS WITH NORMAL KIDNEY FUNCTION - THE TROMSO STUDY**  
Ellen E Brodin\* (NO), Sigrid Braekkan, Anders Vik, Jan Brox, John-Bjarne Hansen
- P-MO-324 EMOTIONAL STATES AND FUTURE RISK OF VENOUS THROMBOEMBOLISM: THE TROMSO STUDY**  
Kristin F Enga\* (NO), Sigrid K Braekkan, Ida J Hansen-Krone, John-Bjarne Hansen
- P-MO-325 INPATIENT RISKS OF VENOUS THROMBOEMBOLISM AND BLEEDING FOLLOWING HIP AND KNEE REPLACEMENT SURGERY**  
Elham Rahme\* (CA), Kaberi Dasgupta, Susan R Kahn, Sasha Bernatsky, Greg K Berry, Alain Cirkovic, Yves Laflamme, Ronald A Dimentberg, Mark Burman, Youssef Habel, Celine Khodr
- P-MO-326 OUTPATIENT RISKS OF VENOUS THROMBOEMBOLISM AND BLEEDING FOLLOWING HIP AND KNEE REPLACEMENT SURGERY**  
Elham Rahme\* (CA), Kaberi Dasgupta, Susan R Kahn, Sasha Bernatsky, Greg K Berry, Mark Burman, Alain Cirkovic, Yves Laflamme, Ronald A Dimentberg, Youssef Habel, Celine Khodr
- P-MO-327 EPIDEMIOLOGY OF VENOUS THROMBOEMBOLISM IN TRAUMA PATIENTS WITH LOWER EXTREMITY INJURIES**  
Kerry Hitos\* (AU), Patrick Chu, John P Fletcher
- P-MO-328 CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND THE RISK OF PE AND DVT**  
Linda E Flinterman\* (NL), Astrid Hylckama Vlieg, Suzanne C Cannegieter, Frits R Rosendaal
- P-MO-329 INFLUENCE OF PUBLIC AWARENESS OF SYMPTOMS OF DEEP VEIN THROMBOSIS AND BURDEN OF THE DISEASE ON THE RATE OF CONFIRMED THROMBOTIC EVENTS**  
Malgorzata Dybowska (PL), Witold Z Tomkowski\*, Renata Galec, Janusz Burakowski, Adam Jozwik, Pawel Kuca
- P-MO-330 SEASONAL RATE OF DEEP VENOUS THROMBOSIS**  
Pawel Kuca (PL), Malgorzata Dybowska, Renata Galec, Janusz Burakowski, Adam Jozwik, Witold Z Tomkowski\*

### Genetic determinants and epidemiology

- P-MO-331 INTERACTION BETWEEN HYPERHOMOCYSTEINEMIA AND SEVERAL DNA POLYMORPHISMS INVOLVED IN ENDOTHELIAL DYSFUNCTION IN VENOUS THROMBOEMBOLISM**  
Veronika Shmeleva\* (RU), Sergei Kapustin, Anastasia Polyakova, Mikhail Blinov
- P-MO-332 PROTHROMBIN G20210A MUTATION IS ASSOCIATED WITH HIGHER DILUTE RUSSELL VIPER VENOM TIME, WHICH HAS MODERATE POWER TO PREDICT CARRIER STATUS**  
Kristi Johnson Smock\* (US), George M Rodgers, Brian H Shirts



55

## POSTER PRESENTATIONS

Monday, July 25, 2011

- P-MO-333 PREVALENCE OF GENETIC RISK FACTORS FOR CARDIOVASCULAR DISEASE IN THE IRANIAN POPULATION**  
Christian Oberkanins\* (AT), Helene Puehringer, Valeh Hadavi, Kimia Kahrizi, Hossein Najmabadi
- P-MO-334 ROLE OF GENE ENVIRONMENTAL INTERACTIONS IN DEVELOPMENT OF PERIPHERAL ARTERIAL OCCLUSIVE DISEASE IN NORTH WEST RUSSIA.**  
Veronika Shmeleva\* (RU), Sergei Kapustin, Mikhail Blinov, Ludmila Papayan
- P-MO-335 SUPERFICIAL VEIN THROMBOSIS AS A PRECURSOR FOR VENOUS THROMBOSIS IN THE MEGA STUDY.**  
Kirsten van Langevelde\* (NL), Willem M. Lijfering, Frits R. Rosendaal
- P-MO-336 R147W MUTATION OF PROTEIN C GENE IS COMMON IN THAI POPULATION**  
Ampaiwan Chuansumrit\* (TH), Werasak Sasanakul, Duangrurdee Wattanasirichaigoon, Nongnuch Sirachainan, Natjava Yudhasompop, Arijit Tiraganjana, Praguaywan Kadegasem
- P-MO-337 A NOVEL PROTHROMBIN GENE MUTATION LEADS TO AN AT-RESISTANT THROMBIN IN A FAMILY WITH INHERITED THROMBOPHILIA.**  
Yuhri Miyawaki\* (JP), Atsuo Suzuki, Yuhta Fujimori, Junko Fujita, Asuka Maki, Akira Takagi, Takashi Murate, Michio Sakai, Kohji Okamoto, Tadashi Matsushita, Tetsuhito Kojima
- P-MO-338 STUDY ON THE DEFICIENCY OF ANTICOAGULANT PROTEINS IN PATIENTS OF THROMBOTIC EVENTS WITH NO EVIDENT ACQUIRED FACTORS: CLINICAL PREVALENCE, RISKS, AND GENETIC ANALYSIS**  
Changcheng Zheng\* (CN), Jingsheng Wu, Kaiyang Ding, Jie Li, Xin Liu, Xiaoyan Cai, Weibo Zhu
- P-MO-339 PON2 SER<sub>311</sub> CYS POLYMORPHISM IS A PREDICTOR OF TOTAL AND CARDIOVASCULAR MORTALITY IN PATIENTS WITH ANGIOGRAPHICALLY CONFIRMED CORONARY ARTERY DISEASE.**  
Nicola Martinelli\* (IT), Domenico Girelli, Elisa Grison, Letizia Consoli, Roberta Micaglio, Elisabetta Trabetti, Giovanni Malerba, Simonetta Friso, Francesca Pizzolo, Pier Franco Pignatti, Roberto Corrocher, Olivieri Oliviero
- P-MO-340 RISK OF VENOUS THROMBOEMBOLISM ASSOCIATED WITH DIFFERENT PLASMA LEVELS OF ANTITHROMBIN, PROTEIN C AND PROTEIN S**  
Ida Martinelli\* (IT), Paolo Bucciarelli, Francesca Gianniello, Serena M Passamonti, Franca Franchi, Eugenia Biguzzi, Pier Mannuccio Mannucci
- P-MO-341 STUDY ON THE PATHOGENESIS OF PROC P275S MUTATION IN PROTEIN C DEFICIENCY AND THE ROLE OF ITS CORRESPONDING LOOP**  
Tingting Yu (CN), Jing Dai\*, Jian Wang, Xuefeng Wang, Qihua Fu
- P-MO-342 PHYSICAL ACTIVITY AND RISK OF FIRST VENOUS THROMBOSIS: A SUBGROUP ANALYSIS WITHIN THE MEGA CASE-CONTROL STUDY**  
Willem M Lijfering\* (NL), Frits Rosendaal, Suzanne Cannegieter
- P-MO-343 OVER FIFTY PERCENT OF DUTCH VTE FAMILIES WITH PROTEIN C DEFICIENCY SHARE A FOUNDER R272C MUTATION.**  
Jorine S Koenderman\* (NL), Rogier M Bertina, Pieter H Reitsma, Marieke CH de Visser
- P-MO-344 MULTIVARIATE ANALYSIS OF GENETIC, BEHAVIOURAL AND SOCIO-PSYCHOLOGICAL DETERMINANTS OF VITAMIN K-ANTAGONIST DOSE**  
Jane Skov\* (DK), Else-Marie Bladbjerg, Morten Arendt Rasmussen, Johannes Sidelmann, Anja Leppin, Joergen Jespersen



## POSTER PRESENTATIONS

Monday, July 25, 2011

Monday Posters

### Antiphospholipid syndrome

- P-MO-345 LATE ONSET WARFARIN INDUCED SKIN NECROSIS IN A YOUNG FEMALE WITH ANTIPHOSPHOLIPID ANTIBODY SYNDROME**  
Valizadeh Nasim\* (IR), Mir Amir Aghdashi, Sona Nori Vahed, Kamran Keyvan Pazhuh, Fathollah Moradi
- P-MO-346 PLATELET ACTIVATION AND PARADOXICAL INHIBITION OF ADP INDUCED AGGREGATION BY ANTIPHOSPHOLIPID ANTIBODIES *IN VITRO***  
Kenji Oku\* (JP), Tatsuya Atsumi, Olga Amengual, Yuuichirou Fujieda, Kotaro Otomo, Masaru Kato, Shin Furukawa, Hirohiko Kitakawa, Shinsuke Yasuda, Tetsuya Horita, Yuuji Hori, Tetsuhiro Nishikawa, Kazuyoshi Nihei, Masahiro Ieko, Takao Koike
- P-MO-347 ARTERIAL THROMBOSIS IN ANTIPHOSPHOLIPID SYNDROME**  
Nuria Bermejo\* (ES), M.J. Garcia Blanco, C. Martin Aguilera, M.L. Bengochea, F. Carnicero, J. Bergua
- P-MO-348 HAEMOSTATIC CHANGES IN CORONARY ARTERY DISEASE PATIENTS WITH HYPERHOMOCYSTEINEMIA AND ANTI-BETA2 GLYCOPROTEIN-I AND/OR ANTI-PROTHROMBIN ANTIBODIES**  
Veronika Shmeleva\* (RU), Olga Smirnova, Vera Kobilyanskaya, Ludmila Papayan
- P-MO-349 FIBRINOLYSIS IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES**  
Karen A Breen\* (UK), Kiran Parmar, Beverley J Hunt
- P-MO-350 COMPLEMENT ACTIVATION IN PATIENTS WITH ISOLATED ANTIPHOSPHOLIPID ANTIBODIES (APL) AND PRIMARY ANTIPHOSPHOLIPID SYNDROME (PAPS)**  
Karen A Breen\* (UK), Paul Seed, Kiran Parmar, Beverley J Hunt
- P-MO-351 USEFULNESS OF THROMBOELASTOGRAPHY IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES OR PRIMARY ANTIPHOSPHOLIPID SYNDROME**  
Karen A Breen\* (UK), Beverley J Hunt
- P-MO-352 MESENTERIC VASCULAR THROMBOEMBOLISM IN ASSOCIATION WITH ANTIPHOSPHOLIPID ANTIBODIES: A CASE SERIES**  
Karen A Breen\* (UK), Beverley J Hunt
- P-MO-353 THE PROBLEM OF INTER-ASSAY VARIABILITY IN ANTIPHOSPHOLIPID ANTIBODY ASSAYS PERSISTS**  
Katrien M.J. Devreese\* (BE)
- P-MO-354 AUTOANTIBODIES AGAINST PROTHROMBIN AND PROTHROMBIN-PHOSPHATIDYLSERIN COMPLEX: A DIAGNOSTIC TOOL FOR THE ANTIPHOSPHOLIPID SYNDROME?**  
Katrien M.J. Devreese\* (BE), Marc F Hoylaerts
- P-MO-355 THE RISK OF MISSING LUPUS ANTICOAGULANT: VALIDATION OF ISTH GUIDELINES 2009**  
Jun Teruya\* (US), Ozlem Bilen, Barry Myones
- P-MO-356 FOLLOW-UP OF 148 PATIENT WITH ANTIPHOSPHOLIPID SYNDROME (APS) DURING A 18-YEAR PERIOD.**  
Tatiana M Reshetnyak\* (RU), Tatiana M Reshetnyak, Inna B Shtivelband, Natatia V Seredavkina, Elena N Aleksandrova, Lubov V Kondratyeva, Evgenii L Nassonov
- P-MO-357 RENAL TRANSPLANTATION IN A PATIENT WITH CATASTROPHIC APLS AND HIT AND DOUBLE TRANSPLANTATION (LIVER AND RENAL) IN A PATIENT WITH TTP.**  
Dorit Blickstein\* (IL), Eytan Mor, Ruth Rahamimov, Aida Inbal



## POSTER PRESENTATIONS

Monday, July 25, 2011

### Pregnancy, hormones, women's issues

- P-MO-358 MONITORING ANTI-XA ACTIVITY OF TINZAPARIN AND BEMIPARIN [LOW MOLECULAR WEIGHT HEPARINS(LMWHS)]AT THERAPEUTIC DOSAGES DURING PREGNANCY.**  
Amparo Santamaria\* (ES), Adriana Sierra, Laura Hernandez, Marina Carrasco, Montse Borrell, Dolores Llobet, Jordi Fontcuberta
- P-MO-359 INCREASED LEVELS OF TISSUE FACTOR ACTIVITY ON SYNCYTIOTROPHOBLAST MICROVESICLES RELEASED INTO THE MATERNAL CIRCULATION DURING PRE-ECLAMPSIA.**  
Chris Gardiner\* (UK), Dionne S Tannetta, Paul Harrison, Christopher WG Redman, Ian L Sargent
- P-MO-360 A "NEW" THROMBOPHILIA MARKER IN THE PROTEIN C PATHWAY - A LIKELY CAUSE FOR UNEXPLAINED RECURRENT PREGNANCY LOSS IN YOUNG MALAYSIAN WOMEN!**  
Thiruchelvam Ayadurai\* (BN), Faraizah Abdul Karim, Sekaran Muniandy
- P-MO-361 PREGNANCY IS A HIGH RISK FACTOR FOR HEPARIN-INDUCED ALLERGIC SKIN REACTIONS - RESULTS OF A PROSPECTIVE STUDY**  
Marc Schindewolf\* (DE), Corinna Gobst, Hartmut Kroll, Andreas Recke, Frank Louwen, Manfred Wolter, Roland Kaufmann, Wolf-Henning Boehncke, Edelgard Lindhoff-Last, Ralf J. Ludwig
- P-MO-362 STUDY OF VARIABILITY IN THE MANAGEMENT OF THROMBOEMBOLIC DISEASE (TD) IN WOMEN IN SPAIN: NATIONAL MULTICENTER STUDY.**  
Amparo Santamaria\* (ES), Dolores Tassies, Oscar Martinez, F.Javier Rodriguez-Martorell, R. Lecumberri, M. Casellas, M.Jose Gutierrez-Pimentel, IM Ramirez
- P-MO-363 INCIDENCE OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH CUSHING'S SYNDROME: A MULTICENTER COHORT STUDY**  
Danka J Stuijver\* (NL), Bregje van Zaane, Richard A Feelders, Jan Debeij, Suzanne C Cannegieter, Ad R Hermus, Gerrit van den Berg, Alberto M Pereira, Wouter W de Herder, Margreet A Wagenmakers, Michiel N Kerstens, Pierre M Zelissen, Eric Fliers, Nicolaas Schaper, Madeleine L Drent, Olaf M Dekkers, Victor E Gerdes
- P-MO-364 THROMBOPHILIC STATUS OF WOMEN WITH COMPLICATED OBSTETRIC HISTORY**  
Nadezda A. Vorobyeva\* (RU), Nadezda A. Vorobyeva, Diana R. Gamyrkina, Yana A. Dremova Ya
- P-MO-365 POSTPARTUM LIFE-THREATENING THROMBOEMBOLIC COMPLICATIONS IN A PATIENT WITH PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA: A 'RESCUER' ROLE FOR ECULIZUMAB?**  
Kristin Jochmans\* (BE), Frederik Vandenbroucke, Marc De Waele, Fabienne Trullemans
- P-MO-366 OCCURRENCE OF OBSTETRIC AND THROMBOEMBOLIC COMPLICATIONS IN FAMILY MEMBERS OF WOMEN WITH COMMON INHERITED THROMBOPHILIAS AND PREVIOUS OBSTETRIC COMPLICATIONS.**  
Elvira Grandone\* (IT), Michela Villani, Donatella Colaizzo, Giovanni Tiscia, Elena Chinni, Filomena Cappucci, Patrizia Vergura, Gennaro Vecchione, Lucia Fischetti, Maurizio Margaglione
- P-MO-367 THE THROMBIN GENERATION PROFILES OF WOMEN ON PROPHYLACTIC ENOXAPARIN DURING PREGNANCY AND THE PUERPERIUM**  
Jignesh P Patel\* (UK), Raj K Patel, Michael S Marsh, Bruce Green, John Graham Davies, Roopen Arya
- P-MO-368 WOMEN'S VIEWS AND ADHERENCE TO ENOXAPARIN THERAPY DURING PREGNANCY AND THE PUERPERIUM**  
Jignesh P Patel\* (UK), Vivian Auyeung, Raj K Patel, Michael S Marsh, Bruce Green, Roopen Arya, John Graham Davies





## POSTER PRESENTATIONS

Monday, July 25, 2011

Monday Posters

- P-MO-369 PREGNANCY COMPLICATIONS AND ANTIPHOSPHOLIPID ANTIBODIES**  
Katia M Taouli\* (DZ), Riad Benhabib, Nabila Baba Ahmed, Sara Ayad
- P-MO-370 THE RISK OF RECURRENT VENOUS THROMBOSIS ASSOCIATED WITH ORAL CONTRACEPTIVE USE**  
Astrid van Hylckama Vlieg\* (NL), Linda E. Flinterman, Suzanna C. Cannegieter, Frits R. Rosendaal
- P-MO-371 CAN ANTICOAGULANT THERAPY IMPROVE THE OUTCOME OF PREGNANCY IN THROMBOPHILIC WOMEN?**  
Mirjana K Kovac\* (RS), Zeljko Mikovic, Gorana Mitic, Valentina Djordjevic, Ivana Jaglicic, Vesna Mandic, Dragica Radojkovic
- P-MO-372 RESULTS OF THROMBOPHILIA SCREENING IN ORAL CONTRACEPTIVE USERS WITH VENOUS THROMBOTIC COMPLICATIONS IN NORTH WEST RUSSIA.**  
Veronika Shmeleva\* (RU), Natalia Saltikova, Ludmila Papayan, Natalia Aganezova
- P-MO-373 RISK OF PPH IN WOMEN USING THERAPEUTIC DOSAGE OF LMWH DURING PREGNANCY AND PUERPERIUM**  
H. Marieke Knol\* (NL), Lejan Schultinge, Jan Jaap H.M. Erwich, Nic J.G.M. Veeger, Hanneke C. Kluin-Nelemans, Karina Meijer
- P-MO-374 RISK OF RECURRENCE AFTER CONTRACEPTION-RELATED VENOUS THROMBOSIS: COHORT STUDY**  
Emmanuelle Le Moigne\* (FR), Aurelien Delluc, Emmanuel Novak, Dominique Mottier, Gregoire Le Gal

### Cancer and thrombosis

- P-MO-375 CIRCULATING BLASTS, PLATELET COUNT AND D-DIMER IN ACUTE LEKEMIA : IS THERE ANY CORRELATION?**  
Amaylia Oehadian\* (ID), Anggun Mekar, Rachmat Sumantri, Nadjwa Zamalek
- P-MO-376 SPLANCHNIC VENOUS THROMBOEMBOLISM IN AMBULATORY CANCER PATIENTS RECEIVING CHEMOTHERAPY.**  
Rita Carlotta Santoro\* (IT), Simona Prejano', Piergiorgio Iannaccaro
- P-MO-377 CLINICHAEMATOLOGICAL RESPONSE AND RESISTANCE/INTOLERANCE TO HYDROXYCARBAMIDE IN ESSENTIAL THROMBOCYTHAEMIA.**  
Rita Carlotta Santoro\* (IT), Simona Prejano', Piergiorgio Iannaccaro
- P-MO-378 PROTEIN C PATHWAY AND ANTITHROMBIN IN THROMBOSIS-RELATED GASTROINTESTINAL DISORDERS**  
Selime Ayaz\* (TR), Huseyin Alkim, Canan Alkim, Nurgul Sasmaz
- P-MO-379 HYPERHOMOCYSTEINEMIA AS PREDICTOR OF THROMBOTIC COMPLICATIONS IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE DISEASES AND MULTIPLE MYELOMA**  
Veronika Shmeleva\* (RU), Ludmila Papayan, Kudrat Abdulkadyrov, Stanislav Bessmeltsev, Ekaterina Chait, Tatyana Zamotina
- P-MO-380 INCIDENTAL PULMONARY EMBOLISM IN CANCER PATIENTS IS ASSOCIATED WITH SIGNIFICANT MORBIDITY AND MORTALITY. A COMPREHENSIVE CANCER CENTER EXPERIENCE**  
Hikmat N. Abdel-Razeq\* (JO), Asem H Mansour, Yousef M Ismael



## POSTER PRESENTATIONS

Monday, July 25, 2011

- P-MO-381 THE RISK OF STROKE AND MYOCARDIAL INFARCTION IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS. A STUDY OF THE IMPORTANCE OF PLATELET AGGREGATION.**  
Viola Maria I Popov\* (RO), Ana Maria Vladareanu, Horia Bumbea, Eugenia Kovacs, Tudor Savopol, Adrian Tase, Minodora Onisai, Mihaela Camelia Stancu, Anca Maria Ilea, Camelia Marioara Dobrea, Stanciu Marian
- P-MO-382 RECOMBINANT THROMBOMODULIN MAY PLAY A PREVENTIVE ROLE FOR VENOCCLUSIVE DISEASE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION**  
Shosaku Nomura\* (JP), Shinya Fujita, Ryotaro Ozasa, Takahisa Nakanishi, Michihiko Miyaji, Shinichiro Mori, Tomoki Ito, Kazuyoshi Ishii
- P-MO-383 CURRENT USE OF PROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) IN COLORECTAL CANCER SURGERY PATIENTS: THE SCALA STUDY**  
Walter Ageno\* (IT), Charles M Samama, Fred A Anderson
- P-MO-384 LONG-TERM USE OF CURATIVE DOSES OF TINZAPARIN VERSUS VITAMIN K ANTAGONISTS IN THE TREATMENT OF VENOUS THROMBOEMBOLISM (VTE): META-ANALYSIS OF 5 RANDOMIZED TRIALS**  
Silyv Laporte\* (FR), Laurent Bertoletti, Patrick Mismetti
- P-MO-385 IDENTIFICATION OF GLYCOPROTEIN IB (GPIB), LRP1 AND ANNEXIN II MRNA IN DIFFERENT HUMAN AND MOUSE TUMOR CELL LINES**  
Yanina P Powazniak\* (AR), Ana C Kempfer, Julio C Calderazzo Pereyra, Daniel F Alonso, Maria A Lazzari, Analia Sanchez-Luceros
- P-MO-386 CANCER-CELL EPCR CONTRIBUTES TO CELL-SURVIVAL, TUMOR-PROGRESSION AND PROMOTES HYPERCOAGULABILITY.**  
Elodie Ducros (FR), Shahsoltan Mirshahi, Pezhman Mirshahi, Anne Marie Faussat, Francoise Dagonnet, Dalel Azzazene, Sophie Camilleri-Brouet, Eliane Mery, Amu Therwath, Eric Pujade-Lauraine, Jeannette Soria, Massoud Mirshahi\*
- P-MO-387 EXPRESSION OF ENDOTHELIAL PROTEIN C RECEPTOR BY HUMAN HEMATOLOGIC MALIGNANCIES: IMPLICATION IN CANCER-ASSOCIATED HYPERCOAGULABILITY.**  
Elodie Ducros (FR), Shahsoltan Mirshahi, Anne Marie Faussat, Pezhman Mirshahi, Sophie Dimicoli, Ruoping Tang, Nadia Benabbou, Julia Pardo, Fanny Fava, Amu Therwath, Jean Pierre Marie, Jeannette Soria, Massoud Mirshahi\*
- P-MO-388 LONG-TERM THERAPY WITH LOW-MOLECULAR-WEIGHT HEPARIN IN CANCER PATIENTS WITH VENOUS THROMBOEMBOLISM. FINDINGS FROM THE RIETE REGISTRY.**  
Pablo Javier Marchena Yglesias\* (ES), Jose Antonio Nieto Rodriguez, Maria Guil, Ferran Garcia-Bragado, Ramon Rabunal, Henri Bocalon, Manel Monreal

### Pediatric thrombosis

- P-MO-389 BILATERAL CAROTID ARTERY THROMBOSIS IN A NEWBORN**  
Monika Hannelore Girsch\* (DE), Michael Alber, Gesa Wiegand, Michael Hofbeck
- P-MO-390 TESTING FOR HERITABLE THROMBOPHILIA IN CHILDREN AT STARSHIP CHILDREN'S HOSPITAL: AN AUDIT OF REQUESTS BETWEEN 2004 AND 2009.**  
Peter Bradbeer\* (NZ), Nyree Cole, Lochie Teague
- P-MO-391 INFLUENCE OF GENETIC THROMBOPHILIC DISORDERS IN EXTRAHEPATIC PORTAL VEIN THROMBOSIS IN CHILDREN AND ADOLESCENTS**  
Matteo Luciani\* (IT), Andrea Pietrobattista, Juan G Abraldes, Manila Candusso, Simona Pancotti, Massimo Soldati, Lidia Monti, Giuliano Torre, Valerio Nobili



## POSTER PRESENTATIONS

Monday, July 25, 2011

Monday Posters

- P-MO-392 NORMALIZED COAGULATION MARKERS AND ANTICOAGULATION PROTEINS IN CHILDREN WITH SEVERE  $\beta$ -THALASSEMIA DISEASE AFTER STEM CELL TRANSPLANTATION**  
Nongnuch Sirachainan\* (TH), Jaruwat Thongsad, Samart Pakakasama, Suradej Hongeng, Ampaiwan Chaunsamrit, Praguynwan Kadegasem, Arijit Tirakanjana, Napaporn Archararit, Somtawin Sirireung
- P-MO-393 THROMBIN AND PLASMIN GENERATION IN CHILDREN FOLLOWING PERINATAL ARTERIAL ISCHEMIC STROKE**  
Jennifer Armstrong-Wells\* (US), Mindy Simpson, Elizabeth Villalobos-Menuet, Timothy Bernard, Neil Goldenberg, Marilyn Manco-Johnson
- P-MO-394 ATYPIC HEPARIN THROMBOCYTOPENIA: ABOUT A PAEDIATRIC CASE**  
Dominique Desprez\* (FR), Julien Exinger, Annie Heidt, Monique Gladin, Pauline Vernay, Francois Depasse\*, Laurent Mauvieux, Lelia Grunebaum, Harry Magnani
- P-MO-395 A COMPARISON OF CAT AND A MANUAL SUB-SAMPLING THROMBIN GENERATION ASSAYS IN HEALTHY CHILDREN.**  
Robyn G Summerhayes\* (AU), Paul Monagle, Vera Ignjatovic
- P-MO-396 THE INFLUENCE OF PLASMA ALPHA 2-MACROGLOBULIN LEVELS AND COMPLEXION TO THROMBIN DURING THROMBIN GENERATION IN HEALTHY CHILDREN.**  
Robyn G Summerhayes\* (AU), Paul Monagle, Vera Ignjatovic
- P-MO-397 AGE-RELATED DIFFERENCES IN HEPARIN COFACTOR ANTIGEN AND ACTIVITY IN HEALTHY CHILDREN: EVIDENCE FOR STRUCTURAL DIFFERENCES IN HEPARIN COFACTOR II IN NEONATES.**  
Robyn G Summerhayes\* (AU), Paul Monagle, Vera Ignjatovic
- P-MO-398 PROGNOSTIC FACTORS FOR PERSISTENT VENOUS OCCLUSION IN CHILDREN WITH VENOUS THROMBOEMBOLISM**  
Courtney A Lyle\* (US), Amy E Lovejoy, Neil A Goldenberg
- P-MO-399 RISK FACTORS FOR ELEVATED INR VALUES DURING WARFARIN THERAPY AT A PEDIATRIC HOSPITAL**  
Lisa Bomgaars\* (US), Meng Ung, Brady Moffett
- P-MO-400 A THAI BOY WITH SEVERE PROTEIN C DEFICIENCY; CLINICAL PRESENTATIONS, GENETIC MUTATION ANALYSIS AND TREATMENT OUTCOMES**  
Bunchoo Pongtanakul\* (TH), Kleebsabai Sanpakit, Jassada Buaboonnam, Nongnuch Sirachainan
- P-MO-401 TRENDS OF THE COAGULATION INHIBITOR PROTEINS: PROTEIN C, PROTEIN S AND ANTITHROMBIN (AT) IN CHILDREN FOLLOWING LIVER TRANSPLANT**  
Patricia Massicotte\* (CA), Mary Bauman, Aisha Bruce, Jessica Tan, Ketan Kulkarni, Jason Yap, Norm Kneteman
- P-MO-402 EVALUATION OF UPPER VENOUS THROMBOSIS AND ITS ASSOCIATION WITH CHYLOTHORAX IN POST SURGICAL CHILDREN WITH CONGENITAL HEART DISEASE**  
Patricia Massicotte\* (CA), Satvinder Kaur, Mary Bauman, Luis Quinonez, Aisha Bruce

### Microparticles

- P-MO-403 NOVEL METHODOLOGY IN THE CHARACTERIZATION OF PLATELET-DERIVED MICROVESICLES**  
Pia R-M Siljander\* (FI), Maria T. Aatonen, Mikaela Gronholm



61

## POSTER PRESENTATIONS

Monday, July 25, 2011

- P-MO-404 DETECTION OF 100 NM BEADS WITH OPTICAL PROPERTIES CLOSE TO MICROPARTICLES AND EXOSOMES USING A REGULAR FLOW CYTOMETER**  
Edwin van der Pol\* (NL), A Sturk, T G van Leeuwen, R Nieuwland
- P-MO-405 SIZE DISTRIBUTION AND CONCENTRATION OF MICROPARTICLES AND EXOSOMES DETERMINED BY ADVANCED OPTICAL AND NON-OPTICAL DETECTION METHODS**  
Edwin van der Pol\* (NL), C Gardiner, P Harrison, A E Grootemaat, A Sturk, T G van Leeuwen, R Nieuwland
- P-MO-406 PLATELET-DERIVED MICROPARTICLES AND TISSUE FACTOR ACTIVITY ARE ENHANCED IN BEHCET'S DISEASE**  
Elena G Arias-Salgado\* (ES), I. Fernandez-Bello, M. Martin-Salces, M.T. Alvarez-Roman, A. Moreno-Rubio, A. Chicon-Arias, V. Jimenez-Yuste, A. R.de la Rua, J. Lopez-Longo, I. Rivas-Pollmar, N. Butta-Coll
- P-MO-407 INCREASED NUMBERS OF MICROPARTICLES AND INCREASED MICROPARTICLE SPECIFIC THROMBIN GENERATION IN PATIENTS WITH MYELOPROLIFERATIVE DISEASE**  
Muriel van Schilfgaarde\* (NL), Muriel van Schilfgaarde, Marijke C. Trappenburg, Michiel C. van Aalderen, Pascal J. Molenaar, Hugo ten Cate, Anja Leyte, Wim E. Terpstra
- P-MO-408 PLACENTA-SPECIFIC RNA IS PRESENT IN VESICLES ISOLATED FROM MATERNAL BLOOD**  
Guus Sturk\* (NL), Anita Boing, Elke de Grouw, Chi Hau, Wessel Ganzevoort, Carrie Ris-Stalpers, Rienk Nieuwland
- P-MO-409 PLATELET MICROPARTICLES PARTICIPATE TO IMMUNE COMPLEXE FORMATION IN RHEUMATOID ARTHRITIS.**  
Nathalie Cloutier\* (CA), Ruslan Shnayder, William Robinson, Richard Farndale, David M Lee, Eric Boilard
- P-MO-410 TISSUE-FACTOR BEARING MICROPARTICLES ARE INCREASED IN NON-HODGKIN'S LYMPHOMA, AND MAINLY DERIVED FROM B-LYMPHOCYTES**  
Brandon James McMahon\* (US), Hau C. Kwaan, Ivy Weiss, James Marvin
- P-MO-411 ACTIVATED FACTOR X-BASED ASSAY FOR THE DETECTION OF PROCOAGULANT PHOSPHOLIPID ACTIVITY IN PATIENTS WITH CANCER AND/OR VENOUS THROMBOEMBOLISM**  
Claudia Maria Radu (IT), Luca Spiezia, Elena Campello, Sabrina Gavasso, Sara Carraro, Valeria Ferri, Barry Woodhams\*, Paolo Simioni
- P-MO-412 MICROPARTICLE ANALYSIS BY FLOWCYTOMETRY DEPENDS ON WELL DEFINED PRE-ANALYTICAL CONDITIONS.**  
Muriel van Schilfgaarde\* (NL), Saskia V Oussoren, Anja Leyte
- P-MO-413 ELEVATION OF TOTAL CELL-DERIVED MICROPARTICLE IN THE PATEINT WITH ESSENTIAL HYPERTENSION**  
Pornlada Nuchnoi\* (TH), Duangdao Nantakomol, Chartchalerm Isarankura-Na-Ayudhya, Virapong Prachayasittikul

### Clinical trials and registries

- P-MO-414 LOW ALLERGENICITY OF FONDAPARINUX - RESULTS OF A PROSPECTIVE INVESTIGATION**  
Marc Schindewolf\* (DE), Julia Scheuermann, Hartmut Kroll, Jurate Garbaraviciene, Carola Hecking, Ingo Marzi, Manfred Wolter, Roland Kaufmann, Wolf-Henning Boehncke, Edelgard Lindhoff-Last, Ralf J. Ludwig



## POSTER PRESENTATIONS

Monday, July 25, 2011

Monday Posters

- P-MO-415 INCIDENCE AND CAUSES OF HEPARIN-INDUCED SKIN LESIONS - RESULTS OF A PROSPECTIVE INVESTIGATION**  
Marc Schindewolf\* (DE), Svantje Schwaner, Manfred Wolter, Hartmut Kroll, Andreas Recke, Roland Kaufmann, Wolf-Henning Boehncke, Edelgard Lindhoff-Last, Ralf J. Ludwig
- P-MO-416 THE EFFECT OF POLYMORPHISMS OF CYP2C9 AND VKORC1 ON STABILITY OF THE INR WHEN SUPPLEMENTED WITH VITAMIN K1**  
Edward P.A. Gebuis\* (NL), Frits R Rosendaal, Erik van Meegen, Felix J.M. van der Meer
- P-MO-417 VENOUS THROMBOEMBOLISM (VTE) AFTER SURGERY FOR BENIGN PROSTATIC HYPERPLASIA (BHP). A SYSTEMATIC REVIEW ON THROMBOPROPHYLAXIS.**  
David Bergqvist\* (SE)
- P-MO-418 SAFETY OF LOW MOLECULAR WEIGHT HEPARINS IN SWEDEN AS REFLECTED BY ADVERSE EVENTS REPORTED TO NATIONAL AUTHORITIES.**  
David Bergqvist\* (SE), Nils Feltelius
- P-MO-419 ORAL FACTOR XA INHIBITORS VERSUS ENOXAPARIN FOR THROMBOPROPHYLAXIS AFTER JOINT REPLACEMENT SURGERY: A META-ANALYSIS**  
Simon Mantha\* (US)
- P-MO-420 HEMOSTASIS IN THE PRIMARY MULTIPLE MYELOMA PATIENTS**  
Evdokiya S Urnova\* (RU), Larissa P Mendeleeva, Olga S Pokrovskaya, Elena I Sinauridze, Anna N Balandina, Elena N Lipets, Irina V Gribkova, Sergey A Vasiliev, Valery G Savchenko
- P-MO-421 CLINICAL OUTCOME IN PATIENTS WITH PULMONARY EMBOLISM SELECTED FOR OUTPATIENT OR HOSPITAL TREATMENT WITH THE HESTIA CRITERIA**  
Wendy Zondag\* (NL), Inge Mos, Dina Creemers-Schild, Lidia Hoogerbrugge, Olaf Dekkers, Anneke Dolsma, Michiel Eijsvogel, Laura Faber, Herman Hofstee, Marcel Hovens, Ge Jonkers, Klaas van Kralingen, Marieke Kruip, Tom Vlasveld, Marielle de Vreede, Menno Huisman
- P-MO-422 NATURAL HISTORY OF PATIENTS DEVELOPING THROMBOCYTOPENIA WHILE RECEIVING ANTICOAGULANT THERAPY FOR VENOUS THROMBOEMBOLISM.**  
Adriana Visona\* (IT), Pierpaolo Di Micco, Nicolas Falvo, Justo Ruiz, Jose M. Pedrajas, Mariano Valdes, Manuel Monreal, and the RIETE INVESTIGATORS
- P-MO-423 DESIRUDIN-REACTIVE IGG ANTIBODIES IN THE DESIR-ABLE THROMBOSIS PREVENTION CLINICAL TRIAL: LOW PREVALENCE OF ANTIGENICITY IN DESIRUDIN-TREATED SUBJECTS**  
Robert G Hamilton\* (US), Jerrold H. Levy

### Intravascular devices and thrombosis

- P-MO-424 VENOUS THROMBOSIS AS A COMPLICATION OF PACEMAKER IMPLANTATION - IN OWN OBSERVATIONS**  
Teresa Barbara Domagala\* (PL), Jacek Lelakowski, Anna Rydlewska, Justyna Piekarz, Rafal Januszek, Grzegorz Karkowski, Katarzyna Kotula-Horowitz, Jacek Musial
- P-MO-425 DESIGN OF THE CATHETER DIRECTED THROMBOLYSIS AND ANTICOAGULATION THERAPY VS ANTICOAGULATION ALONE; THE DUTCH CAVA-STUDY; MULTICENTER RANDOMIZED CONTROLLED TRIAL.**  
Rob H.W. Strijkers\* (NL), Arina J. ten Cate - Hoek, Martin H Prins, Hugo ten Cate, Cees H.A. Wittens
- P-MO-426 POLYURETHANE IMMOBILIZED WITH A COVALENT ANTITHROMBIN-HEPARIN COMPLEX FOR REDUCING THROMBOSIS ON BLOOD CONTACTING DEVICES**  
Kyla N Sask\* (CA), Leslie R Berry, Anthony KC Chan, John L Brash



## POSTER PRESENTATIONS

Monday, July 25, 2011

- P-MO-427** **ROLE OF LOW MOLECULAR WEIGHT HEPARINS IN PROPHYLAXIS OF THROMBOEMBOLIC EVENTS IN ONCOLOGICAL PATIENTS RECEIVING ANTITUMOR THERAPIES**  
Oksana Vasilievna Somonova\* (RU), Albina Vasilievna Madzhuga, Anna Lyvovna Elizarova
- P-MO-428** **REASONS FOR FAILURE TO REMOVE INFERIOR VENA CAVA FILTERS (IVCF): 2 YEAR RETROSPECTIVE STUDY IN A TERTIARY CARE AND TRAUMA CENTRE**  
Erica Ann Peterson\* (CA), Paul Richard Yenson, Dave Liu, Andy Lee, Agnes Yuet Ying Lee
- P-MO-429** **IN VITRO AND IN VIVO COMPARISON OF VKORC1 MUTATIONS**  
Katrin Jeannette Czogalla\* (DE), Matthias Watzka, Philipp Westhofen, Ann-Christin Wendeln, Johannes Oldenburg
- P-MO-430** **LOW SULFATED HEPARIN (ODSH) INTERFERES WITH ANTI-PF4/HEPARIN ANTIBODY INDUCED PLATELET ACTIVATION BY DISRUPTING PF4/HEPARIN COMPLEXES**  
Krystin Krauel\* (DE), Christine Hackbarth, Birgitt Fuerll, Andreas Greinacher
- P-MO-431** **THE EVALUATION OF BLOOD COAGULATION AND FIBRINOLYTIC FACTORS IN HEMODIALYSIS**  
Elizaveta Alexandrovna Vlasova\* (RU), Irina Anatol'evna Vasilenko, Maria Sergeevna Surovikina, Vera Vladimirovna Samoylenko, Vladimir Procop'evich Suslov
- P-MO-432** **DISORDERS OF MORPHOLOGY AND FUNCTION OF LIVING PLATELETS IN PATIENTS TREATED WITH HEMODIALYSIS**  
Elizaveta Vlasova\* (RU), Irina Vasilenko, Vladimir Suslov
- P-MO-433** **TWO CASES OF THROMBOTIC COMPLICATIONS IN INFANTS ON ECMO: HETEROZYGOUS FACTOR V LEIDEN AND COCCIDIODOMYCOSIS**  
Fong W Lam\* (US), Ozlem Bilen, Trung C Nguyen, Jun Teruya

### Health service and outcomes

- P-MO-434** **THE IMPACT OF ANTICOAGULANT MONITORING AND CONTROL ON RECURRENT VENOUS THROMBOEMBOLISM AND BLEEDING IN ROUTINE CLINICAL PRACTICE**  
Neil S Roskell (UK), Sorrel E Wolowacz, Ryan Ziemiecki, Arlene M Gallagher, Martin Feuring, Mandy Fraessdorf, Bastian Hass\*
- P-MO-435** **INTERPLAY BETWEEN DIET AND VITAMIN K-ANTAGONISTS: DISCLOSED BY VISUALIZATION OF A MULTIVARIATE MODEL**  
Jane Skov\* (DK), Else-Marie Bladbjerg, Morten Arendt Rasmussen, Johannes Sidelmann, Marianne Vamosi, Joergen Jespersen
- P-MO-436** **A COLLABORATIVE STUDY OF OUTCOMES FROM ROOT CAUSE ANALYSIS OF HOSPITAL-ASSOCIATED THROMBOSIS**  
Lara N Roberts\* (UK), Kim Carter, Huw Rowswell, Christopher James, Lorraine Albon, Tim Nokes, Raj K Patel, Roopen Arya
- P-MO-437** **ANTICOAGULATED PATIENTS: HOW THE POPULATION IS CHANGING**  
Sophie Testa\* (IT), Oriana Paoletti, Laura Bassi, Emilia Cancellieri, Silvia Zambelli, Anke Zimmermann
- P-MO-438** **COST-EFFECTIVENESS OF APIXABAN PROPHYLAXIS FOR VENOUS THROMBOEMBOLISM (VTE) IN TOTAL KNEE AND HIP REPLACEMENT (TKR/THR)**  
Dale Rublee\* (US), Teresa Simon, Kristen Migliaccio-Walle, Elizabeth Merikle, Jamie Caro, Nick Marchant, Pieter Drost



## POSTER PRESENTATIONS

Monday, July 25, 2011

Monday Posters

- P-MO-439 PROTAMINE DRUG UTILIZATION EVALUATION TO DETERMINE POSSIBLE FUTURE ROLES FOR THE HEPATONIST REVERSAL AGENT PMX-60056**  
Charles Mahan\* (US)
- P-MO-440 REDUCTION IN HOSPITAL ACQUIRED VTE BY IMPROVED COMPLIANCE WITH VTE RISK ASSESSMENT**  
Jamie M Maddox\* (UK), Anthony P Roberts
- P-MO-441 USE OF NATIONAL PATIENT SAFETY AGENCY / BRITISH SOCIETY OF HAEMATOLOGY SAFETY INDICATORS FOR ORAL ANTICOAGULANTS IN HOSPITALISED PATIENTS**  
Jamie M Maddox\* (UK)
- P-MO-442 REDUCTION OF EMERGENCY DEPARTMENT (ED) UTILIZATION FOR COMPLICATIONS OF WARFARIN THERAPY USING ORGANIZED ANTICOAGULATION CLINICS IN AN ACADEMIC MEDICAL INSTITUTION**  
Patrick Michael Klem\* (US), Tiffany Brown, William Pace, Gina Woodhouse, Kathryn Hassell, Christiana Thienelt, Shardul Poydal, Julie Cantlon, Gregory Misky, William LeBlanc, Kristen Nordenholz, Carolee Whitehill

### von Willebrand factor

- P-MO-443 INTERACTION BETWEEN A1, A2 AND A3 DOMAINS REGULATES THE BINDING OF VWF TO PLATELET GPIIb/IIIa IN SOLUTION.**  
Miguel A. Cruz\* (US), Matthew Auton, Katie E. Sowa
- P-MO-444 INCREASED VON WILLEBRAND FACTOR LEVELS IN LATER LIFE ARE ASSOCIATED WITH EVIDENCE OF BOTH ENHANCED BIOSYNTHESIS AND REDUCED CLEARANCE**  
Silvia Albanez\* (CA), Julie Grabell, Erin Burnett, Kate Sponagle, Paula D James, David Lillcrap
- P-MO-445 STABILIZATION OF FVIII BY VWF FRAGMENTS**  
Andrew Yee\* (US), Beth M McGee, David Ginsburg
- P-MO-446 EPI TOPE MAPPING OF HUMAN VWF A3 RECOGNIZED BY MONOCLONAL ANTIBODY SZ-123 USING MALDI MASS SPECTROMETRY**  
Miao Jiang\* (CN), Yiming Zhao, Yang He, Fei Shen, Changgeng Ruan
- P-MO-447 VON WILLEBRAND FACTOR PLASMA LEVELS IN PATIENTS WITH ESSENTIAL THROMBOCYTHAEMIA**  
Jerzy Windyga\* (PL), Ksenia Bykowska, Ewa Czajkowska, Bozena Sokolowska, Krzysztof Warzocha, Edyta Odnoczko, Jerzy Windyga
- P-MO-448 PHARMACOKINETIC (PK) EVALUATION OF A NEWLY INTRODUCED VON WILLEBRAND FACTOR (VWF) CONCENTRATE AT TWO LONDON HAEMOPHILIA CENTRES.**  
Natasha M Wiles\* (UK), Anne Wareing, Bella Madan, Steven K Austin
- P-MO-449 AFFINITY AND KINETICS OF VWF PROPEPTIDE BINDING TO MATURE VWF**  
Sriram Neelamegham\* (US), Sri R. Madabhushi, Chengwei Shang, Kannayakanahalli M. Dayananda, Thomas E. Ryan
- P-MO-450 THE INTERACTION OF VON WILLEBRAND FACTOR WITH ANGIOPOIETINS-1 & 2**  
Thomas McKinnon\* (UK), Agata Nowak, Kushani Ediriwickrema, Mike Laffan
- P-MO-451 THE DISCOVERY AND CHARACTERIZATION OF A SECOND GENERATION VON WILLEBRAND FACTOR (VWF) A-1 DOMAIN INHIBITORY APTAMER**  
Robert G Schaub\* (US), P Shannon Pendergrast, Kathleen E McGinness, Xianbin Tian



## POSTER PRESENTATIONS

Monday, July 25, 2011

**P-MO-452 IN VITRO AND IN VIVO CHARACTERIZATION OF VON WILLEBRAND FACTOR COLLAGEN BINDING VARIANTS USING A MOUSE MODEL SYSTEM**

Yasuaki Shida\* (CA), Christine Ann Brown, Jeff Mewburn, Kate Sponagle, Carol Anne Hegadorn, David Lillcrap

### von Willebrand disease

**P-MO-453 ESTABLISHMENT OF A VON WILLEBRAND FACTOR RISTOCETIN CO-FACTOR ACTIVITY ELISA AND ITS APPLICATION IN THE DIAGNOSIS AND CLASSIFICATION OF VWD**

Yiming Zhao\* (CN), Ying Gu, Jianfeng Yang, Changgeng Ruan

**P-MO-454 MUTATION SPECTRUM AND CHARACTERIZATION OF TWO NOVEL LARGE DELETIONS CAUSING SEVERE TYPE 3 VON WILLEBRAND DISEASE**

Firdos Ahmad\* (US), Reinhard Schneppenheim, Florian Oyen, Tobias Obser, Meganathan Kannan, Renu Saxena

**P-MO-455 -1 TO +4 VS. 0 TO +3?: COMPARING SCORING SYSTEMS FOR BLEEDING SYMPTOMS IN THE CONDENSED MCMDM-1 VWD AND THE PEDIATRIC BLEEDING QUESTIONNAIRES**

Paula D James\* (CA), Tina T Biss, Dewi S Clark, Julie Grabell, Jim Riddel, Mariana Silva, Dilys Rapson, Margaret L Rand

**P-MO-456 EFFECT OF FIBRINOLYSIS ON BLEEDING PHENOTYPE IN MODERATE AND SEVERE**

Eva M De Wee (NL), Kevin Klaij, Jeroen Eikenboom, Johanna van der Bom, Manon Degenaar-Dujardin, Karin Fijnvandraat, Arja Goede-Bolder, Britta Laros-van Gorkom, Eveline Mauser-Bunschoten, Karina Meijer, Gerard Goverde, Peter-Willem van der Linden, Dingeman Rijken, Frank Leebeek\*

**P-MO-457 WILATE® 500 AND WILATE® 1000 - ADVANCED CONTENT OF VWF AND FVIII: A COMPARISON OF ACTIVE INGREDIENTS AND EXCIPIENTS DRUG RATIOS**

Gerhard Gruber\* (AT), Monika Stadler, Manfred Karlovits, Josef Weinberger, Juergen Roland Roemisch

**P-MO-458 DETERMINANTS OF BLEEDING PHENOTYPE IN PATIENTS WITH MODERATE OR SEVERE VON WILLEBRAND DISEASE**

Eva M De Wee (NL), Eveline Mauser-Bunschoten, Anske van der Bom, Manon Degenaar-Dujardin, Jeroen Eikenboom, Arja de Goede-Bolder, Britta Laros-van Gorkom, Karina Meijer, Karly Hamulyak, Marten Nijziel, Karin Fijnvandraat, Frank Leebeek\*

**P-MO-459 UNUSUAL FINDING IN LABORATORY TESTS IN A PREGNANT PATIENT WITH VON WILLEBRAND DISEASE TYPE 2B**

Adriana I Woods\* (AR), Analia Sanchez-Luceros, Maria Fabiana Alberto, Ana Catalina Kempfer, Alicia Noemi Blanco, Maria Angela Lazzari

**P-MO-460 THE P.CYS1060TYR MUTATION IS RESPONSIBLE FOR VON WILLEBRAND DISEASE TYPE 2N**

Bas J.T. van Haren\* (NL), Selene C.M. Schoormans, Tom G.J. Hofste, Britta A.P. Laros-van Gorkom, Paul P.T. Brons, Lies H. Hoefsloot, Waander L. van Heerde

**P-MO-461 COLLAGEN BINDING ASSAY AND GENOTYPIC ANALYSIS HAVE AN ADDITIONAL VALUE IN THE SUBCLASSIFICATION OF VON WILLEBRAND DISEASE TYPE 2M**

Bas J.T. van Haren\* (NL), Selene C.M. Schoormans, Tom G.J. Hofste, Britta A.P. Laros-van Gorkom, Paul P.T. Brons, Lies H. Hoefsloot, Waander L. van Heerde

**P-MO-462 ASSESSMENT OF THE BURDEN OF VON WILLEBRAND DISEASE IN A US COMMERCIAL POPULATION**

Diane Ito\* (US), Yan Xiong, Josephine Li-McLeod





## POSTER PRESENTATIONS

Monday, July 25, 2011

Monday Posters

- P-MO-463 DEVELOPMENT OF A HEALTH-RELATED QUALITY OF LIFE INSTRUMENT FOR VON WILLEBRAND DISEASE**  
Diane Ito\* (US), Kathy Lasch, Kristina Fitzgerald, Andrea Zeytoonjian, Steve Hwang, Josephine Li-McLeod
- P-MO-464 DIAGNOSIS OF TYPE 2N VON WILLEBRAND DISEASE IN A JAPANESE PATIENT BY PHARMACOKINETICS, FACTOR VIII BINDING ASSAY AND GENE ANALYSIS**  
Yushi Chikasawa\* (JP), Kagehiro Amano, Keiko Shinozawa, Tomoko Matsumoto, Hiroshi Inaba, Midori Shima, Katsuyuki Fukutake
- P-MO-465 A GLY1609ARG MISSENSE MUTATION IN THE VWF GENE IN A KOREAN PATIENT WITH VON WILLEBRAND DISEASE TYPE 2A**  
Duck Jin Hong (KR), Seung Jun Choi\*, Jonghyeon Choi, Sue Jung Kim, Hee-Jin Kim, Kyung-A Lee, Jaewoo Song, Jong-Rak Choi, Jong-Ha Yoo
- P-MO-466 A FAMILY WITH TYPE 2M VWD WITH NORMAL VWF:RCO BUT REDUCED VWF:CB DUE TO A M1761K MUTATION IN THE A3 DOMAIN**  
David M Keeling\* (UK), James Beavis, Rhiannon Marr, Kampta Sukhu, Patricia Bignell

### Acquired von Willebrand syndrome

- P-MO-467 TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) AND THE EFFECTS ON VON WILLEBRAND FACTOR (VWF) AND ADAMTS-13 CONCENTRATIONS**  
Simon J Davidson\* (UK), Jayenthan Karunanantham, Kaltun Farah, Sarah Barker, Simon W Davies, Moat Neil
- P-MO-468 MITRAL VALVE PROSTHESIS LEAK AND ACQUIRED VON WILLEBRAND SYNDROME (AVWS)**  
Javier Batlle\* (ES), Almudena Perez-Rodriguez, Joana Costa Pinto, Esther Loures, Angela Rodriguez-Trillo, Jose Joaquin Cuenca, Javier Batlle, Maria Fernanda Lopez-Fernandez
- P-MO-469 VWF & PROPEPTIDE ASSAY (GTI DIAGNOSTICS) EVALUATION IN ACQUIRED VON WILLEBRAND SYNDROME**  
Claudine Caron\* (FR), Jacqueline Tapon-Bretoniere, Sylvia Bellucci, Philippe Cauchie, Isabelle Martin Toutain, Brigitte Pan Petesch, Catherine Ternisien, Jenny Goudemand
- P-MO-470 A RARE CASE OF ACQUIRED VON WILLEBRAND SYNDROME IN THE SETTING OF NEW DIAGNOSIS POLYMYOSITIS**  
Adrienne Lee\* (CA), Gary D Sinclair, Karen Valentine, Man-Chiu Poon
- P-MO-471 EXCESS PROTEOLYSIS OF VON WILLEBRAND FACTOR IN AORTIC STENOSIS DOES NOT ENHANCE THE RISK OF BLEEDING AFTER AORTIC VALVE REPLACEMENT**  
Sophie Susen\* (FR), Andre Vincentelli, Thierry Le Tourneau, Claudine Caron, Annie Borel-Derlon, Massimo Massetti, Jeanne-Yvonne Borg, Helene Eltchaninoff, Fabrice Bauer, Eric Van Belle, Jenny Goudemand, Brigitte Jude
- P-MO-472 THERAPEUTIC ALGORITHM FOR PATIENTS WITH ACQUIRED VON WILLEBRAND SYNDROME AND MONOCLONAL GAMMOPATHY**  
Peter Staritz\* (DE), Peter Lages, Manuela Krause, Rainer Zimmermann, Angela Huth-Kuehne
- P-MO-473 ACQUIRED LOSS OF THE LARGEST VON WILLEBRAND FACTOR MULTIMERS IN SEVERE TETRALOGY OF FALLOT: A CASE REPORT**  
Sofia Barbar\* (IT), Alessandra Casonato, Emiliano De Bon, Elena Pontara, Antonella Bertomoro



67

## POSTER PRESENTATIONS

Monday, July 25, 2011

- P-MO-474 A NEGATIVE FEEDBACK MECHANISM OF REGULATING VWF PROTEOLYSIS BY ADAMTS-13**  
Trung Chanh Nguyen\* (US), Chalmette Ball, Miguel A Cruz, Xiaowen Liang, Zhou Zhou, Jing-fei Dong
- P-MO-475 ACQUIRED VON WILLEBRAND DISEASE (AVWD) SECONDARY TO ACUTE MYELOPATHY**  
Erica Okazaki\* (BR), Audrey Kruse Zeinad Valim, Paula Ribeiro Villaca, Patricia Lima Junqueira, Dalton de Alencar Fischer Chamone, Elbio Antonio DAmico

### ADAMTS13

- P-MO-476 UPREGULATION OF VON WILLEBRAND FACTOR, VON WILLEBRAND FACTOR PROPEPTIDE AND ADAMTS-13 IN END STAGE RENAL DISEASE**  
Vinod Bansal\* (US), Rachel Davis, Evangelos Litinas, Debra Hoppensteadt, Indermohan Thethi, Jawed Fareed
- P-MO-477 DETERMINATION OF ADAMTS13 AND ITS CLINICAL SIGNIFICANCE RELATED TO ENDOTOXEMIA IN PATIENTS WITH HEPATIC FAILURE**  
Hiroaki Takaya\* (JP), Masahito Uemura, Masao Fujimoto, Tomomi Matsuyama, Chie Morioka, Masatoshi Ishikawa, Tatsuhiro Tsujimoto, Hideto Kawaratani, Shinya Takeyama, Masanori Matsumoto, Yoshihiro Fujimura, Hiroshi Fukui
- P-MO-478 CILOSTAZOL DOWN-REGULATES THE HEIGHT OF MURAL PLATELET THROMBI FORMED UNDER A HIGH SHEAR RATE FLOW IN THE ABSENCE OF ADAMTS13 ACTIVITY**  
Hideo Yagi\* (JP), Naoko Yamaguchi, Yasuaki Shida, Masanori Matsumoto, Mitsuhiro Sugimoto, Kazuo Tsubaki, Yoshihiro Fujimura
- P-MO-479 ISOELECTRIC FOCUSING ANALYSIS WITH A LARGE-PORE AGAROSE-ACRYLAMIDE COMPOSITE GEL IDENTIFIED TWO FORMS OF ADAMTS13, UNBOUND AND BOUND TO VON WILLEBRAND FACTOR, IN PLASMA MILIEU**  
Yuji Hori\* (JP), Ayami Isonishi, Kenji Soejima, Masanori Matsumoto, Midori Shima, Yoshihiro Fujimura
- P-MO-480 ESTIMATION OF THE NUMBER OF INDIVIDUALS WITH A CONGENITAL ADAMTS13 DEFICIENCY IN JAPAN**  
Koichi Kokame\* (JP), Yoshihiro Kokubo, Toshiyuki Miyata
- P-MO-481 POTENTIAL ROLE OF ADAMTS13 ASSOCIATED WITH POST ERCP PANCREATITIS**  
Chie Morioka\* (JP), Masahito Uemura, Hiroaki Takaya, Masayoshi Sawai, Motoyuki Yoshida, Akira Mitoro, Jyunichi Yamao, Masanori Matsumoto, Yoshihiro Fujimura, Hiroshi Fukui
- P-MO-482 THE ADAMTS13 ACTIVITY REFLECTS THE CUMULATIVE SURVIVAL OF PATIENTS WITH LIVER CIRRHOSIS**  
Masahito Uemura\* (JP), Yoshihiro Fujimura, Masanori Matsumoto, Hiromichi Ishizashi, Tomomi Matsuyama, Seiji Kato, Yuji Hori, Chie Morioka, Hiroaki Takaya, Masao Fujimoto, Tatsuhiro Tsujimoto, Hideto Kawaratani, Hiroshi Fukui
- P-MO-483 VWF AND ADAMTS13 LEVELS AND THE RISK OF MYOCARDIAL INFARCTION AND ISCHAEMIC STROKE IN YOUNG WOMEN: RESULTS FROM THE RATIO CASE-CONTROL STUDY**  
Bob Siegerink\* (NL), Helena M Andersson, Brenda M Luken, James TB Crawley, Ale Algra, David A Lane, Frits R Rosendaal
- P-MO-484 EVALUATION OF A NEW ADAMTS13 ELISA BASED ACTIVITY ASSAY AND COMPARISON TO AN IN-HOUSE COLLAGEN BINDING ASSAY**  
Wahbi Hammouda\* (CA), Jacqueline Ongteco, Nellie Ku



## POSTER PRESENTATIONS

Monday, July 25, 2011

Monday Posters

- P-MO-485 CHARACTERIZATION OF TWO CASES OF CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA ASSOCIATED WITH PREGNANCY**  
Xia Bai\* (CN), Jian Su, Minghua Jiang, Changgeng Ruan
- P-MO-486 DISCREPANCIES BETWEEN DIFFERENT TYPES OF ADAMTS13 ASSAYS IN PATIENTS WITH THROMBOTIC MICROANGIOPATHIES**  
Ian J Mackie\* (UK), Katy Langley, Andrew Chitolie, Ri Leisner, Marie Scully, Sam Machin, Flora Peyvandi
- P-MO-487 NOVEL ADAMTS13 MUTATIONS IN CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA**  
Ziqiang Yu\* (CN), Yunwen Bu, Jian Su, Qingya Cui, Xia Bai, Changgeng Ruan

### Hemophilia

- P-MO-488 PROFILING OF F8 GENE MUTATIONS IN 262 CHINESE HAEMOPHILIA A PATIENTS**  
Yeling Lu\* (CN), Xuefeng Wang, Qiulan Ding, Jing Dai, Hongli Wang, Xiaodong Xi
- P-MO-489 SPORADIC HAEMOPHILIA A PEDIGREE WITH MOSAICISM OF THE F8 GENE MUTATION IN THE INDEX'S MATERNAL GRANDMOTHER**  
Yeling Lu\* (CN), Xuefeng Wang, Qiulan Ding, Jing Dai, Hongli Wang, Xiaodong Xi
- P-MO-490 IMPROVEMENTS OF HEMOPHILIA CARES IN 30 YEARS SEEN IN TAIWAN**  
Ming Ching Shen\* (TW), Wei Tsay, Young Li Yang, Shyuann Yuh Lin, Ching Yeh Lin, Po Kuang Chen, In Ling Chang, Ta Sen Wei, Chin Ming Jeng, Chao Yu Hsu, Rwei Pung Lin, Cheng Hsiung Chang
- P-MO-491 CHARACTERIZATION AND VALIDATION OF A NOVEL PANEL OF 6 SHORT TANDEM REPEATS FOR CARRIER AND PRENATAL DIAGNOSIS OF HAEMOPHILIA A**  
Qiulan Ding\* (CN), Yeling Lu, Jing Dai, Xiaodong Xi, Xuefeng Wang, Hongli Wang
- P-MO-492 F8 LOCUS ITSELF SEEMS TO EXPLAIN ALL CASES OF HEMOPHILIA A PATIENTS WITHOUT MUTATIONS IN THE F8 CDNA**  
Osman El-Maarri\* (DE), Behnaz Pezeshkpoor, Natascha Vidocich, Nicole Nuesgen, Indrajit Nanda, Thomas Haaf, Ulrich Budde, Johannes Oldenburg, Osman El-Maarri
- P-MO-493 CARRIER AND PRENATAL DIAGNOSIS IN A HAEMOPHILIA A FAMILY WITH LARGE F8 GENE DELETION BY FLUORESCENT QUANTITATION PCR METHOD**  
Yeling Lu\* (CN), Xuefeng Wang, Qiulan Ding, Jing Dai, Xiaodong Xi, Hongli Wang
- P-MO-494 INCREASED PREVALENCE OF HYPERTENSION IN HAEMOPHILIA PATIENTS**  
Roger EG Schutgens\* (NL), Dietje Fransen van de Putte, Kathelijn Fischer, Mike Makris, Campbell Tait, Pratima Chowdary, Peter Collins, Karina Meijer, Goris Roosendaal, Eveline Mauser-Bunschoten
- P-MO-495 INCREASED QRISK2 CARDIOVASCULAR DISEASE RISK SCORE IN HAEMOPHILIA PATIENTS**  
Roger EG Schutgens\* (NL), Dietje Fransen van de Putte, Kathelijn Fischer, Mike Makris, Campbell Tait, Pratima Chowdary, Peter Collins, Karina Meijer, Goris Roosendaal, Eveline Mauser-Bunschoten
- P-MO-496 DECREASED OCCURRENCE OF CARDIOVASCULAR DISEASE IN HAEMOPHILIA PATIENTS**  
Roger EG Schutgens\* (NL), Dietje Fransen van de Putte, Kathelijn Fischer, Astrid Pulles, Goris Roosendaal, Eveline Mauser-Bunschoten



## POSTER PRESENTATIONS

Monday, July 25, 2011

- P-MO-497 MALIGNANCIES IN HAEMOPHILIA PATIENTS**  
Roger EG Schutgens\* (NL), Dietje Fransen van de Putte, Kathelijin Fischer, Astrid Pulles, Goris Roosendaal, Eveline Mauser-Bunschoten
- P-MO-498 THE PROVISION OF GENETIC TESTING FOR BLEEDING DISORDERS IN THE UK - AN OVERVIEW AND AUDIT OF UKHCDO GENETIC NETWORK LABORATORIES**  
Marian Hill\* (UK), Jacky Cutler, Mike Mitchell
- P-MO-499 A COST-EFFECTIVE PROVINCIAL REDISTRIBUTION SYSTEM TO PREVENT WASTAGE OF CLOTTING FACTOR CONCENTRATES**  
Jerome Teitel\* (CA), Sarah Crymble, Monique Anderson, Antonette Travas, Georgina Floros
- P-MO-500 DISTINCT X-CHROMOSOMAL REARRANGEMENTS WITH *F8*-INTRON22 INVERSION IN THREE UNRELATED JAPANESE SEVERE HEMOPHILIA A PATIENTS WITH HIGH TITER INHIBITOR**  
Junko Fujita\* (JP), Atsuo Suzuki, Yuhri Miyawaki, Asuka Maki, Yuhta Fujimori, Akira Takagi, Takashi Murate, Tadashi Matsushita, Nobuaki Suzuki, Hidehiko Saito, Tetsuhito Kojima
- P-MO-501 HELICOBACTER PYLORI INFECTION IN PATIENTS WITH HEREDITARY HEMORRHAGIC DISORDERS: A COMPARISON OF STOOL ANTIGEN TEST AND SEROLOGY TESTS**  
Dolatkhah Roya\* (IR), Khoshbaten Manouchehr, Asvadi Kermani Iraj, Bonyadi Mohammad Reza, Ghojzadeh Morteza, Sanaat Zohreh
- P-MO-502 SAFETY AND EFFICACY OF RALTEGRAVIR IN PATIENTS WITH HAEMOPHILIA AND ANTI-HIV MULTIDRUG RESISTANCE**  
Alessandro Gringeri\* (IT), Lucia Mangiafico, Myrvete Muca-Perja, Silvia Riva, Francesco Fusco, Debora Mago
- P-MO-503 MUTATION ANALYSIS OF HEMOPHILIA A IN THE JAPANESE POPULATION: INCREASED PREVALENCE OF TYR473CYS CAUSED BY FOUNDER EFFECT**  
Hiroshi Inaba\* (JP), Keiko Shinozawa, Takashi Suzuki, Manabu Otaki, Ikuo Seita, Kyoichi Ogata, Mihoko Yotsumoto, Takashi Muramatsu, Yushi Chikasawa, Takeshi Hagiwara, Yasuyuki Yamamoto, Kagehiro Amano, Katsuyuki Fukutake
- P-MO-504 PSEUDOTUMOR SURGERY IN HAEMOPHILIA A PATIENTS: COMPARATIVE RESULTS BETWEEN INHIBITOR AND NON-INHIBITOR PATIENTS**  
Caviglia Horacio\* (AR), Alejandra Baques, Ana Laura Douglas Price, Daniela Neme, Guillermo Arbesu, Raul Perez Bianco
- P-MO-505 IMAGING EVALUATION OF ARTHROPATHY AT THE BEGINNING OF PROPHYLAXIC THERAPY FOR SEVERE HEMOPHILIA CHILDREN**  
Kaoru Kitsukawa\* (JP), Hideyuki Takedani, Midori Shima, Masashi Taki
- P-MO-506 IDENTIFICATION AND CHARACTERIZATION OF AN ANCIENT HAEMOPHILIA A FOUNDER MUTATION**  
Sylvia Elisabeth Reitter\* (AT), Arndt von Haeseler, Birgit Horvath, Raute Sunder-Plassmann, Vera Tiedje, Ingrid Pabinger-Fasching, Christine Mannhalter
- P-MO-507 THE EFFECT OF CRYOPRECIPITATE ON THE SEROPREVALENCE OF VARICELLA ZOSTER VIRUS IN PATIENTS WITH SEVERE HEMOPHILIA**  
Thomas W van der Vaart\* (NL), Marc van der Valk, Jan TM van der Meer, Caroline Valk, Hans L Zaaijer, Pieter Willem Kamphuisen
- P-MO-508 WIDE VARIATION IN FACTOR VIII PLASMA LEVELS IN MILD AND MODERATE HEMOPHILIA A PATIENTS WITH THE SAME MISSENSE MUTATION IS PRESENTLY UNEXPLAINED**  
Corien Eckhardt\* (NL), Alice S. van Velzen, Marjolein Peters, Elena Santagostino, Kathelijne Peerlinck, Jan Astermark, Johannes Oldenburg, Charles R.M. Hay, Pieter-Willem Kamphuisen, Johanna G. van der Bom, Karin Fijnvandraat



## POSTER PRESENTATIONS

Monday, July 25, 2011

Monday Posters

### Hemophilia therapy

- P-MO-509 EFFECTIVE PATHOGEN REDUCTION OF A PLASMA-DERIVED FACTOR VIII CONCENTRATE THROUGH MULTIPLE DEDICATED MEASURES**  
Albrecht Groener\* (DE), Thomas Nowak, Birgit Popp, Wolfram Schaefer
- P-MO-510 POST MARKETING SURVEILLANCE OF BLOOD PRODUCTS IN JAPAN**  
Teruyo Arato\* (JP), Kaori Nomura, Madoka Hiraki, Jun Matsumoto, Atsushi Yoshimura, Toyotaka Iguchi, Masanari Takayama
- P-MO-511 CURRENT SITUATION OF CLINICAL TRIALS OF BLOOD COAGULATION FACTORS FOR HAEMOPHILIA PATIENTS IN JAPAN**  
Atsushi Yoshimura\* (JP), Masayuki Nagasaki, Jun Matsumoto, Madoka Hiraki, Yasuhiro Kishioka, Masanari Takayama, Teruyo Arato
- P-MO-512 THE COMBINED TREATMENT OF APCC AND TRANEXAMIC ACID IN PATIENTS WITH HAEMOPHILIA A WITH INHIBITORS AND IN PATIENTS WITH ACQUIRED HAEMOPHILIA A - A TWO-CENTRE EXPERIENCE**  
Hoa Thi Tuyet Tran\* (NO), Margareta Holmstrom, Paal Andre Holme
- P-MO-513 SUCCESSFUL TREATMENT OF PROSTATE CANCER IN A CASE OF SEVERE HAEMOPHILIA A PATIENT**  
Sandra Lejniece\* (LV), Gunta Kluce, Armands Balins, Peteris Tomins, Aivars Lejnicks
- P-MO-514 IMPROVED KINETICS OF RIX-FP, A RECOMBINANT FUSION PROTEIN LINKING COAGULATION FACTOR IX WITH ALBUMIN, IN CYNOMOLGUS MONKEYS AND HEMOPHILIA B DOGS**  
Marc W Nolte (DE), Timothy Nichols, Sabine Zollner, Jochen Mueller-Cohrs, Ingo Pragst, Gerhard Dickneite\*
- P-MO-515 FINE (FEIBA INHIBITOR ENTRY) POST-AUTHORIZATION SAFETY SURVEILLANCE (PASS) : CAPTURING LONG-TERM EXPERIENCE IN JAPANESE INHIBITOR SUBJECTS UNDER ROUTINE CLINICAL MANAGEMENT**  
Satoshi Higasa\* (JP), Kagehiro Amano, Hideji Hanabusa, Shinji Muto, Tadashi Matsushita, Midori Shima, Teruhisa Fujii, Michio Sakai, Study Group FINE
- P-MO-516 CLINICAL AND LABORATORY DATA OF SAFETY, EFFICACY OF A RECOMBINANT FACTOR VIII CONCENTRATE IN PATIENTS WITH SEVERE HAEMOPHILIA A IN A PRIVATE PRACTICE CCC**  
Katalin KoehlerVajta\* (DE), Gerhard Froesner, Reinhard Zachoval
- P-MO-517 GASTROINTESTINAL BLEEDING FROM UPPER GASTROINTESTINAL TRACT IN PATIENTS WITH HEMOPHILIA**  
Sergey Shutov\* (RU), S R Karagyulyan, V Y Zorenko, A V Grzhimolovsky, K I Danishyan, E E Karpov, T Y Polyanskay, G M Galstyan
- P-MO-518 FINAL PHARMACOKINETIC, EFFICACY AND SAFETY DATA OF THE FIRST STUDY WITH A RECOMBINANT FACTOR VIII FROM A HUMAN CELL LINE**  
Sigurd Knaub\* (CH), Nadezhda Zozulya, Olga Plyushch, Martina Jansen
- P-MO-519 ANTI-FIBRINOLYTIC EFFECTS OF RECOMBINANT FACTOR VIIA IN PLASMA FROM PATIENTS WITH HEMOPHILIA A WITH INHIBITORS**  
Kamran Bakhtiari\* (NL), Maria Elisa Mancuso, Karly Hamulyak, Elena Santagostino, Roger E.G. Schutgens, Pieter W. Kamphuisen, Joost C.M. Meijers



## POSTER PRESENTATIONS

Monday, July 25, 2011

### Inherited coagulation disorders (except for von Willebrand disease)

- P-MO-520** **ATHEROSCLEROSIS IN PATIENTS WITH CONGENITAL BLEEDING DISORDERS**  
Marjan Zwiers\* (NL), Joop D. Lefrandt, Andries J. Smit, Rijk O.B. Gans, Rozemarijn Vliegenthart, Angélique V.M. Brands-Nijenhuis, Hanneke (J) C. Kluin-Nelemans, Karina Meijer
- P-MO-521** **SURVIVAL AMONG 5118 PATIENTS WITH BLEEDING DISORDERS COMPARED TO MATCHED CONTROLS IN SWEDEN: RESULTS FROM A COHORT REGISTER STUDY**  
Karin M Henriksson\* (SE), Jan Astermark, Jan-Ake Nilsson, Fariba Baghaei, Margareta Holmstrom, Erik Berntorp
- P-MO-522** **A PLASMA-DERIVED FXIII CONCENTRATE WITH A VERY HIGH MARGIN OF VIRUS SAFETY FOR THE TREATMENT OF CONGENITAL FXIII DEFICIENCY**  
Albrecht Groener\* (DE), Thomas Nowak, Birgit Popp, Wolfram Schaefer
- P-MO-523** **A FIRST TAIWANESE PATIENT OF SEVERE PREKALLIKREIN DEFICIENCY WITH NOVEL MUTATIONS SEEN IN TAIWAN**  
Jiaan-Der Wang\* (TW), Ming Ching Shen, Kuo Shu Hua, Chuan Cheng Wang, Ching Ye Lin, Bo Do Lin, Su Feng Kuo, Jen Shiou Lin, Shyuann Yuh Lin, Kuan Ju Lai, Cheng Shyong Chang, Chih-Yuan Chong
- P-MO-524** **POINT MUTATIONS REGARDED AS MISSENSE MUTATIONS CAUSE SPLICING DEFECTS IN THE FACTOR XI GENE**  
Michal Zucker\* (IL), Nurit Rosenberg, Hava Peretz, David Green, Frederic Bauduer, Ariella Zivelin, Uri Seligsohn
- P-MO-525** **PREVENTION OF BLEEDING AND HAEMORRHAGIC COMPLICATIONS IN PERIOPERATIVE PERIOD IN PATIENTS WITH INHERITED FACTOR VII DEFICIENCY**  
Adam Wiszniewski\* (PL), Ksenia Bykowska, Piotr Szopinski, Alfred Jerzy Meissner
- P-MO-526** **NOVEL L13Q MUTATION OF ENDOGLIN GENE IN HEREDITARY HEMORRHAGIC TELANGIECTASIA CAUSED IMPAIRED COTRANSLATIONAL PROCESSING AND CELL-SURFACE EXPRESSION**  
Atsuo Suzuki\* (JP), Yuhri Miyawaki, Junko Fujita, Asuka Maki, Yuta Fujimori, Akira Takagi, Takashi Murate, Masaaki Teranishi, Tadashi Matsushita, Hidehiko Saito, Tetsuhito Kojima
- P-MO-527** **A NOVEL HEREDITARY BLEEDING DISORDER CHARACTERIZED BY LOW THROMBIN GENERATION CAUSED BY FACTOR V INHIBITION**  
Yesim Dargaud\* (FR), Theo Lindhout, Rob J Wagenvoord, Elisabetta Castoldi, Tilman Hackeng, Christine M Trzeciak, Coenraad H Hemker
- P-MO-528** **MOLECULAR CHARACTERIZATION OF A NEW COMBINED FACTOR V AND FACTOR VII DEFICIENCY AND REVIEW OF THE LITERATURE**  
Michael Daskalakis\* (DE), Julia Driesen, Anna Pavlova, Johannes Oldenburg, Meike Burger, Ulrich Geisen, Juergen Heinz
- P-MO-529** **FIRST REPORT OF A PATIENT WITH SEVERE FACTOR X DEFICIENCY RESULTING FROM TWO HOMOZYGOUS FACTOR X MUTATIONS AND LOW BLEEDING TENDENCY**  
Michael Daskalakis\* (DE), Winnie Schroeder, Juliane Najm, Ute Felbor, Barbara Zieger, Meike Burger, Juergen Heinz, Ulrich Geisen

### Acquired coagulation disorders

- P-MO-530** **PATIENTS WITH SEVERE AORTIC VALVE STENOSIS AND IMPAIRED PLATELET FUNCTION BENEFIT FROM PRE-OPERATIVE DESMOPRESSIN INFUSION**  
Barbara Steinlechner (AT), Michael Spannagl, Peter Quehenberger, Petra Zeidler, Bernd Jilma\*



## POSTER PRESENTATIONS

Monday, July 25, 2011

Monday Posters

- P-MO-531 SUCCESSFUL RITUXIMAB-TREATMENT OF TWO PATIENTS WITH ACQUIRED HEMORRHAPHILIA 13 (HEMORRHAGIC ACQUIRED FACTOR 13 DEFICIENCY DUE TO ITS AUTOANTIBODIES)**  
Yasuhiro Nagate\* (JP), Satoru Kosugi, Soichi Nakata, Takeshi Kotake, Toru Kida, Hironori Take, Masayoshi Souri, Shuichi Katagiri, Akitada Ichinose
- P-MO-532 CORRELATION BETWEEN PLATELET ACTIVATION MARKERS AND HMGB1 IN DIC PATIENTS WITH HEMATOLOGIC MALIGNANCY**  
Shinya Fujita\* (JP), Ryotaro Ozasa, Takahisa Nakanishi, Michihiko Miyaji, Shinichiro Mori, Kazuyoshi Ishii, Tomoki Ito, Shosaku Nomura
- P-MO-534 WARFARIN TREATED PATIENTS HAVE INCREASED MORTALITY FOLLOWING CHRONIC SUBDURAL HEMATOMA**  
Israel Gavish\* (IL), Lion Levi, Anatoly Rikier, Daniel Kirshner, Ali Hatib, Menashe Zaaroor, Benjamin Brenner
- P-MO-535 DELAYED DIAGNOSIS OF ACQUIRED HAEMOPHILIA A IN SUBJECTS WITH BLEEDING SYMPTOMS**  
Gabriella Gamba\* (IT), Nadia Montani, Alice Trincherio, Fabio Lodo, Nicola Ghidelli
- P-MO-536 ACQUIRED HAEMOPHILIA A (AHA) IN THREE PATIENTS ON ANTICOAGULANT THERAPY AND PROFUSE BLEEDING: DIAGNOSTIC AND THERAPEUTIC PROBLEMS**  
Gabriella Gamba\* (IT), Nadia Montani, Alice Trincherio, Fabio Lodo, Nicola Ghidelli
- P-MO-537 A CASE OF ACQUIRED HEMOPHILIA WITH SPURIOUSLY ELEVATED ALP MAY BE ASSOCIATED WITH DRUGS**  
Yutaka Komiyama\* (JP), Tomoki Ito, Shosaku Nomura, Yukie Sato, Yoshika Masamichi, Masaki Hiroya, Hakuo Takahashi
- P-MO-538 THE SURVEY OF SUPPORTIVE THERAPY FOR COAGULATION DISORDER DURING L-ASPARAGINASE(L-ASP) THERAPY IN JAPAN**  
Chitose Ogawa\* (JP), Atsushi Manabe, Akira Ohara, Akira Ishiguro
- P-MO-539 DIVERSITY OF UNDERLYING DISORDERS AND VARIETY OF FIRST VISIT CLINICS FOR PATIENTS WITH ACQUIRED HEMOPHILIA: RESULTS FROM SHIZUOKA REGISTRY**  
Chiho Otani\* (JP), Sadahiro Tamashima, Michiaki Koike, Jun Taguchi, Kensuke Naito, Nobuharu Kosugi, Kentarou Misawa, Toshihide Tanaka, Juichi Tanabe, Hiroshi Mouri
- P-MO-540 RECOMBINANT FACTOR VIIA (RFVIIA) USE FOR SURGERY IN ACQUIRED HEMOPHILIA (AH): ANALYSIS FROM THE HEMOPHILIA AND THROMBOSIS RESEARCH SOCIETY (HTRS) REGISTRY**  
Alice Ma\* (US), Craig M. Kessler, Robert Z. Gut, David L. Cooper

### Innovative therapies for hemorrhagic disorders

- P-MO-541 RFVIIA ADMINISTERED AS CONTINUOUS INFUSION DURING SURGERY IN PATIENTS WITH CONGENITAL SEVERE FVII DEFICIENCY**  
Hoa Thi Tuyet Tran\* (NO), Geir Tjonnfjord, Albert Paus, Paal Andre Holme
- P-MO-542 SUCCESSFUL TREATMENT OF HEMOTHORAX AND INTRACRANIAL HEMORRHAGE IN A TAIWANESE HEMOPHILIAC WITH INHIBITORS BY ACTIVATED RECOMBINANT FACTOR VII AND POSITIVE PRESSURE VENTILATION**  
Chia-Yau Chang\* (TW), Ming-Ching Shen, Chung-Che Wu, Chen-Hua Tsai, Jia-Ruey Tsai, Shi-Yi Lin, Ing-Jy Tseng



## POSTER PRESENTATIONS

Monday, July 25, 2011

- P-MO-543 DEVELOPMENT AND USE OF A SURGICAL DATABASE TO STANDARDIZE CARE, ASSESS EFFICACY AND OUTCOMES IN BLEEDING DISORDER PATIENTS: REPORT OF 1184 PROCEDURES FROM A SINGLE CENTER**  
Charles Nakar\* (US), Craig Haddix, Nina Meschino, Jeanne Sagar, Elaine Menshouse, Ivonne Fuentes, Anne Greist, Amy Shapiro
- P-MO-544 PARTIAL PROHEMOSTATIC EFFECT OF TRANSFUSION OF FIBRINOGEN CONCENTRATE REPLACING FRESH FROZEN PLASMA IN MASSIVE HEMORRHAGE**  
Marcus D. Lance\* (NL), M. Ninivaggi, M.A.E. Marcus, K. Hamulyak, E.C.M. van Pampus, H. ten Cate, J.W.M. Heemskerk
- P-MO-545 TREATING ANTICOAGULATION RESISTANCE IN THROMBOTIC HYPODYSFIBRINOGENAEMIA**  
Catherine J Rea\* (UK), Julia Mitchell, Beverley J Hunt
- P-MO-546 IMPROVEMENT OF SPATIAL FIBRIN FORMATION BY THE ANTI-TFPI APTAMER BAX499: CHANGING CLOT SIZE BY TARGETING EXTRINSIC PATHWAY INITIATION**  
Leonid A Parunov\* (RU), Olga A Fadeeva, Ann N Balandina, Natalia P Soshitova, Konstantin G Kopylov, Maria A Kumskova, James C Gilbert, Robert G Schaub, Kathleen E McGinness, Fazoil I Ataullakhanov, Michael A Pantelev
- P-MO-547 LONGATE, A LONG-ACTING LIPOSOMAL FORMULATION OF PLASMA-DERIVED FACTOR VIII - RESULTS OF AN OPEN LABEL PHASE IIIB CLINICAL TRIAL IN ADULT HEMOPHILIA A PATIENTS**  
Moshe Baru\* (IL), Jack Spira, Olga Plyushch, Tatiana Andreeva, Vladimir Zorenko, Nadezhda Zozulya, Irena Velichkol, Rivka Yatuv
- P-MO-548 HAEMOSTASTIC POTENTIAL OF COAGULATION FACTOR CONCENTRATES VS ALLOGENEIC BLOOD PRODUCTS FOLLOWING CARDIAC SURGERY**  
Mariann Tang\* (UK), Per Wierup, Jacob Greisen, Joergen Ingerslev, Benny Soerensen
- P-MO-549 USE OF PROTHROMBIN COMPLEX CONCENTRATE IN PATIENTS WITH ACUTE OR CHRONIC LIVER DISEASE - A SINGLE CENTRE RETROSPECTIVE AUDIT**  
Anja B Drebes\* (UK), Andrew Burroughs, Alex Gatt, Susan Mallett, Edward G. D. Tuddenham, Pratima Chowdary
- P-MO-550 AN ANALOGUE OF FACTOR VIIA IMPROVES WOUND HEALING IN HEMOPHILIA B MICE**  
Maureane Hoffman\* (US), Jacqueline Brock, Mirella Ezban, Dougald M Monroe
- P-MO-551 NEUTRALIZING ANTIBODIES AGAINST ADENO-ASSOCIATED VIRUS EXAMINED PROSPECTIVELY IN PEDIATRIC PATIENTS WITH HEMOPHILIA**  
Paul E Monahan\* (US), Chengwen Li, Nattee Narkbunnam, R. Jude Samulski, Genlin Hu, Aravind Asokan, Marilyn J. Manco-Johnson, Joint Outcome Study Investigators
- P-MO-552 BONE MARROW TRANSPLANTATION CURES HEMOPHILIA A**  
Antonia Follenzi\* (IT), Sanj Raut, Simone Merlin, Rita Sarkar, Sanjeev Gupta
- P-MO-553 THROMBIN ACTIVATION OF PAR-1 ON BOECS RESULTS IN RELEASE OF CYTOKINES THAT LIKELY CONTRIBUTE TO THE IMMUNE RESPONSE IN A CANINE HEMOPHILIA GENE TRANSFER STRATEGY**  
Christine A. Hough\* (CA), Colleen Notley, Nathalie LeBlanc, Margareth C Ozelo, Christine Brown, Carol Hegadorn, Andrea Labelle, David Lillicrap
- P-MO-554 INTRA-ARTICULAR INJECTION OF AUTOLOGOUS MESENCHYMAL STEM CELLS AMELIORATES HEMOPHILIC ARTHROPATHY IN FACTOR VIII-DEFICIENT MICE**  
Yuji Kashiwakura\* (JP), Tsukasa Ohmori, Jun Mimuro, Atsushi Yasumoto, Akira Ishiwata, Asuka Sakata, Seiji Madoiwa, Mokoto Inoue, Momoru Hasegawa, Natsumi Watanabe, Kohei Tatsumi, Kazuo Ohashi, Teruo Okano, Yoichi Sakata





## POSTER PRESENTATIONS

Monday, July 25, 2011

### Atherosclerosis

- P-MO-555 SILENCING THE F11R GENE CONFIRMS THE CRITICAL ROLE OF THE F11 RECEPTOR (F11R/JAM-A) IN PLATELET ADHESION TO INFLAMED ENDOTHELIUM AND IN ATHEROSCLEROSIS.**  
Bani Mekisha Azari\* (US), Jonathan D. Marmor, Moro O. Salifu, Yigal H. Ehrlich, Elizabeth Kornecki, Anna Babinska
- P-MO-556 THE LONG PENTRAXIN 3 (PTX3), A BIOMARKER OF INFLAMMATION, PREDICTS LONG-TERM MORTALITY IN PATIENTS HOSPITALIZED WITH SUSPECTED ACUTE CORONARY SYNDROME**  
Trygve Brugger-Andersen\* (NO), Volker Poenitz, Frederic Kontrny, Harry Staines, Oistein Mjelva, Heidi Grundt, Dennis WT Nilsen
- P-MO-557 ACTIVATED PROTEIN C THERAPY PREVENTS AGAINST COMPLEX ATHEROSCLEROSIS PROGRESSION IN MICE WITH GENETICALLY IMPAIRED ANTICOAGULANT RESPONSE**  
Julian I. Borissoff\* (NL), Sarah T.B.G. Loubele, Sylvia Heeneman, Peter Leenders, Rene van Oerle, Oliver Soehnlein, Karly Hamulyak, Erik A. Biessen, Hartmut Weiler, Charles T. Esmon, Tilman M. Hackeng, Mat J.A.P. Daemen, Henri M.H. Spronk, Hugo ten Cate
- P-MO-558 VITAMIN K-ANTAGONISTS INDUCE A VULNERABLE ATHEROSCLEROTIC PLAQUE PHENOTYPE**  
Leon J Schurgers\* (NL), Martijn Chatrou, Jagat Narula, Leonard Hofstra, Cees Vermeer, Chris P Reutelingsperger
- P-MO-559 SECRETION OF SALUSIN- $\beta$  FROM HUMAN MONOCYTE-DERIVED CELLS AND DEVELOPMENT OF AN ENZYME-LINKED IMMUNOSORBENT ASSAY FOR MEASUREMENT OF SALUSIN- $\beta$  IN HUMAN PLASMA**  
Kazumi Fujimoto\* (JP), Kengo Sato, Masayoshi Shichiri, Takatoshi Koyama
- P-MO-560 THE FACTOR VII-ACTIVATING PROTEASE (FSAP) ENHANCES THE ACTIVITY OF TRANSFORMING GROWTH FACTOR- $\beta$  (TGF- $\beta$ ) FAMILY MEMBERS**  
Elfie Roedel\* (DE), Frank Ploeger, Elisabeth Schwarz, Sandip Kanse
- P-MO-561 CAROTID INTIMA-MEDIA THICKNESS IN PSORIATIC ARTHRITIS: THE EFFECT OF TNF- $\alpha$  BLOCKERS**  
Matteo Nicola Dario Di Minno\* (IT), Anna Russolillo, Salvatore Iervolino, Antonella Tufano, Rosario Peluso, Raffaele Scarpa, Giovanni Di Minno
- P-MO-562 MMP-9 SERUM LEVELS ARE ASSOCIATED WITH CAROTID ATHEROSCLEROSIS PROGRESSION**  
Walter S Speidl\* (AT), Matthias Hoke, Jasmin Amighi, Wolfgang Mlekusch, Alexander Niessner, Gerald Maurer, Renate Koppensteiner, Erich Minar, Johann Wojta, Martin Schillinger
- P-MO-563 PLASMATIC LEUKOCYTE-DERIVED MICROPARTICLES : NEW BIOMARKER FOR PREDICTION OF PLAQUE UNSTABILITY IN ASYMPTOMATIC PATIENTS WITH HIGH-GRADE CAROTID STENOSIS**  
Florence Sabatier\* (FR), Gabrielle Saron-Bartoli, Youssef Bennis, Laurent Arnaud, Michel-Alain Bartoli, Julien Mancini, Romaric Lacroix, Audree Boudes, Marie-Dominique Piercecchi, Emmanuelle Saron, Benjamin Thevenin, Aurelie Leroyer, Christian Squarcioni, Francois Nicoli, Pierre-Edouard Magnan, Francoise Dignat-George, Florence Sabatier
- P-MO-564 CD39 IN ATHEROSCLEROTIC LESION CONTRIBUTES TO THE VASCULAR PLEIOTROPIC EFFECTS OF STATIN**  
Tsunenari Soeda\* (JP), Hiroyuki Kawata, Ji-Hee Sung, Satoshi Somekawa, Masanori Matsumoto, Yoshihiro Fujimura, Shiro Uemura, Yoshihiko Saito



## POSTER PRESENTATIONS

Monday, July 25, 2011

### Endothelial cells

- P-MO-565 SIGNIFICANCE OF ENDOTHELIAL CELL-DERIVED MICROPARTICLES IN TYPE 2 DIABETES MELLITUS**  
Oleksii M. Korzh\* (UA), Elena A. Pavlova, Sergiy V. Krasnokutskiy
- P-MO-566 VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF)-ENHANCED VASCULAR PERMEABILITY VIA VEGF RECEPTOR-2 SELECTIVELY FORM FENESTRAE ULTRASTRUCTURE IN ENDOTHELIUM**  
Yukiko Matsunaga\* (JP), Yasuo Yamazaki, Hidenori Suzuki, Takashi Morita
- P-MO-567 THE PREDICTIVE VALUE OF THE LONG PENTRAXIN 3 (PTX3) FOR HEART FAILURE DEVELOPMENT IN ACUTE CHEST PAIN PATIENTS**  
Trygve Brugger-Andersen\* (NO), Volker Ponitz, Frederic Konzny, Harry Staines, Oistein Mjelva, Heidi Grundt, Dennis Nilsen
- P-MO-568 THE EFFECT OF RADICAL SCAVENGER TO NO RELEASE IN MICROVESSELS**  
Tsutomu Yamashita\* (JP), Kumi Sakamoto, Hiroshi Yamanishi, Junichiro Yamamoto
- P-MO-569 THE EFFECT OF RADICAL SCAVENGER TO LEUKOCYTE ROLLING IN MICROVESSELS**  
Kumi Sakamoto\* (JP), Tsutomu Yamashita, Hiroshi Yamanishi, Junichiro Yamamoto
- P-MO-570 ALTERATIONS OF MARKERS OF INFLAMMATION AND ENDOTHELIAL CELL DAMAGE AFTER CAROTID ENDOARCTERYCTOMY**  
Masako Yamazaki\* (JP), Yoshikazu Okada, Akitsugu Kawashima, Koji Yamaguchi, Taku Yoneyama, Shinichiro Uchiyama
- P-MO-571 VON WILLEBRAND FACTOR (VWF) ANTIGEN AND VWF PRO-PEPTIDE AS BIOMARKERS OF ACUTE LUNG INJURY IN H1N1**  
Simon J Davidson\* (UK), Anne Riddell, Louise Tillyer, Simon J Finney, Jeremy J Cordingley, Mark J Griffiths
- P-MO-572 THE VITAMIN K-DEPENDENT ANTI-COAGULANT FACTOR, PROTEIN S, REGULATES ANGIOGENESIS *IN VITRO* AND *IN VIVO***  
Sylvain Fraineau\* (FR), Michel Philippe, Julie Talbot, Sandip M Kanse, Arnaud Monvoisin, Omar Benzakour
- P-MO-573 PROTEIN KINASE C ISOFORMS IN THE DIVERGENT ENDOTHELIAL SIGNALLING EXERTED BY THROMBIN- AND ACTIVATED PROTEIN C-DEPENDENT ACTIVATION OF PAR-1**  
Yao Yu\* (UK), James TB Crawley, Justin C Mason, David A Lane
- P-MO-574 UREMIC TOXINS ENHANCE ENDOTHELIAL TISSUE FACTOR PRODUCTION**  
Bertrand Gondouin (FR), Claire Cerini, Laetitia Dou, Noemie Jourde Chiche, Raymond Calaf, Ariane Duval Sabatier, Laurent Arnaud, Stephane Poitevin, Stephane Burtey, Françoise Dignat George\*, Philippe Brunet
- P-MO-575 CIRCULATING ENDOTHELIAL CELLS AND ITS POTENTIAL AS A MARKER OF THE VASCULAR CONDITION**  
Manuel Cesar Campos\* (PT), Claudia Torres, Mafalda Fonseca, Ana Santos, Marlene Santos, Marta Goncalves, Sonia Fonseca, Luis Queiroz, Catarina Lau, Marika Antunes, Anjos Teixeira, Rui Matos, Sara Morais, Margarida Lima



## POSTER PRESENTATIONS

Monday, July 25, 2011

Monday Posters

### Inflammatory cells and cytokines

- P-MO-576 THE EFFECT OF PLATELET DERIVED MICROPARTICLES ON GENES IN CELLS OF WHOLE BLOOD AND THP-1 CELLS**  
Bjarne Osterud\* (NO), Trine Lund, Hege Devold
- P-MO-577 THROMBOMODULIN TREATMENT OF DENDRITIC CELLS ALTERS GENE EXPRESSION**  
John Morser\* (US), Masaaki Toda, Daniel Boveda Ruiz, Paloma Gil Bernabe, Corina N. D'Alessandro-Gabazza, Yasushi Miyake, Esteban C. Gabazza
- P-MO-578 RELATIONSHIP BETWEEN ENDOTHELIAL HAEMOSTATIC MARKERS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE**  
Oleksii M. Korzh\* (UA), Elizaveta Lavrova, Elena Pavlova
- P-MO-579 PLASMIN-CLEAVED CHEMERIN, CHEM158K, IS THE DOMINANT CHEMERIN ISOFORM IN INFLAMMATORY CEREBROSPINAL FLUIDS**  
Lei Zhao\* (US), Yasuto Yamaguchi, Shadi Sharif, Xiaoyan Du, Lawrence D. Recht, John M. Morser, Lawrence L.K. Leung
- P-MO-580 EXOGENOUS GLUCOCORTICIDS ATTENUATES HYPERCOAGULABLE STATE AND SYSTEMIC INFLAMMATION IN EXPERIMENTAL HEATSTROKE**  
Chia-Chyuan Liu\* (TW), Yi-Szu Wen, Wen-Yueh Ho, Kuen-Lin Leu, Tsai-Hsiu Yang
- P-MO-581 HIGH PLASMA LEVELS OF S-ADENOSYLHOMOCYSTEINE HAVE INCREASED THE RISK OF HEATSTROKE IN A RAT MODEL**  
Tsai-Hsiu Yang\* (TW), Chau-Chen Yang, Mei-Lin Tsai, Mei-Ying Wang, Chia-Chyuan Liu
- P-MO-582 TWO-SITE PHOSPHORYLATION OF A TRNA SYNTHETASE LINKS CDK5-MTOR-S6K TRIO TO CONTROL OF INFLAMMATORY GENE EXPRESSION**  
Abul Arif\* (US), Paul Fox
- P-MO-583 UROKINASE RECEPTOR (CD87) IS DECREASED AT THE SURFACE OF MONOCYTES OF PATIENTS TREATED BY STATINS AND CORRELATES WITH PLATELET MICROPARTICLES**  
Marc Vasse\* (FR), Dany Bigot, Sylviane Leclerc, Bernard Lenormand
- P-MO-584 EVIDENCE THAT THE THIOL ISOMERASE-BINDING PEPTIDE, MASTOPARAN, INHIBITS SHEAR-INDUCED TGF- $\beta$ 1 ACTIVATION**  
Teresa Brophy\* (US), Jasimuddin Ahamed, Barry S Collier

### Angiogenesis and lymphangiogenesis

- P-MO-586 PLATELETS TRANSPORT THE TUMOR SECRETOME DURING CANCER PROGRESSION AND METASTASIS**  
Bethany A Kerr\* (US), Weiyi Feng, Maria Madajka, N. Patrick McCabe, Tatiana V. Byzova
- P-MO-587 PROANGIOGENIC ACTIVITY OF RECOMBINANT THROMBOMODULIN PROTEINS**  
Guey-Yueh Shi\* (TW), Yu-Ming Cheng, Bi-Ing Chang, Cheng-Hsiang Kuo, Hua-Lin Wu
- P-MO-588 CONDITIONAL ABLATION OF ALPHA6 INTEGRIN SUBUNIT IN MOUSE ENDOTHELIUM REDUCES ANGIOGENESIS**  
Claire Bouvard\* (FR), Adele De Arcangelis, Blandine Dizier, Isabelle Galy-Fauroux, Anne-Marie Fischer, Elisabeth Georges-Labouesse, Dominique Helley
- P-MO-589 THE ROLE OF THROMBOMODULIN AND LEWIS Y ANTIGEN ON VASCULAR ENDOTHELIAL TUBE FORMATION**  
Cheng-Hsiang Kuo\* (TW), Po-Ku Chen, Hua-Lin Wu, Guey-Yueh Shi



## POSTER PRESENTATIONS

Monday, July 25, 2011

- P-MO-590 THE CARCINOEMBRYONIC ANTIGEN (CEA) INDUCES ANGIOGENESIS VIA INTEGRIN B3- DEPENDENT ACTIVATION OF ENDOTHELIAL CELLS**  
Gerald W Prager\* (AT), Kira H Bramswig, Marina Poettler, Fritz Wrba, Christoph C Zielinski
- P-MO-591 PRESERVATION OF RENAL MICROVASCULATURE IN VASCULAR ENDOTHELIAL ENDOTHELIN-1 KNOCK OUT (VEETKO) MICE AFTER KIDNEY FIBROSIS**  
Nur Arfian\* (JP), Noriaki Emoto, Keiko Yagi, Kazuhiko Nakayama, Vita Y. Anggraeni, Hirowati Ali, Dyah S. Mayasari, Eko Purnomo, Dwi A. Nugrahaningsih, Budi A. Hartopo
- P-MO-592 EVALUATION THE ANTIANGIOGENIC EFFECT OF A NOVEL ENDOGENOUS ANTIANGIOGENIC FACTOR**  
Ching-Hu Chung\* (TW)
- P-MO-593 ANALYSIS OF THE CELLULAR RESPONSE AND THE PROTEASE ACTIVITIES IN THE PROCESS OF RECOVERY FROM SCRATCH WOUNDING USING A PERFUSION CELL CULTURE SYSTEM**  
Moyuru Hayashi\* (JP), Motoyuki Shimonaka
- P-MO-594 INTRAMYOCARDIAL INJECTION OF ANG1-1 IMPROVES CARDIAC FUNCTION AFTER MYOCARDIAL INFARCTION IN PIGS**  
Kuan-Chieh Wang\* (TW), Hsieh C.H. Patrick, Shi Guey-Yueh, Lee Fang-Tzu, Chu Ting-Yu, Shih Ya-Yun, Wu Hua-Lin
- P-MO-595 INHIBITORY EFFECTS OF THAN42 ON ANGIOGENESIS INDUCED BY VASCULAR ENDOTHELIAL GROWTH FACTOR**  
Chih-Yuan Tan\* (TW), Tur-Fu Huang
- P-MO-596 BP5250 INHIBITS THE VASCULAR ENDOTHELIAL GROWTH FACTOR INDUCED ANGIOGENESIS AND HIF-1 $\alpha$  EXPRESSION ON ENDOTHELIAL CELLS**  
Kuan-Ting Lin\* (TW), Tur-Fu Huang
- P-MO-597 SIGNIFICANCE OF HRT FAMILY OF TRANSCRIPTION FACTORS IN POSTNATAL ANGIOGENESIS**  
Hisaki Hayashi\* (JP), Masahide Sakabe, Tomoko Ioka, Takashi Morioka, Genki Sato, Ken Inada, Osamu Nakagawa
- P-MO-598 THE ANTHOCYANIN DELPHINIDIN-3-GLUCOSIDE, CONTAINED IN WILD BLUEBERRIES, PROTECTS ENDOTHELIAL CELLS FROM PROANGIOGENIC AND PROTHROMBOTIC STIMULI**  
Marina Marchetti\* (IT), Gaia Bonacina, Erika Diani, Alfonso Vignoli, Patrizia Riso, Marisa Porrini, Anna Falanga
- P-MO-599 TARGETING TUMOR VASCULATURE WITH SIRNA AGAINST BETA 1 INTEGRIN SUBUNIT AND MMP-7**  
Jolanta M. Niewiarowska\* (PL), Tomasz - Wysocki, Magdalena - Wiktorska, Izabela - Sacewicz-Hofman, Olga - Stasikowska, Czeslaw S. Cierniewski

### Structural biology and drug design

- P-MO-600 NEW GENERATION OF ANTITHROMBOTIC COMPOUNDS WITH DUAL - THROMBIN INHIBITORY AND GPIIb/IIIa RECEPTOR ANTAGONISTIC ACTIVITY**  
Janez Ilas\* (SI), Danijel Kikelj
- P-MO-601 TARGETING OF THE TENASE COMPLEX BY RATIONAL DESIGN OF FACTOR VIII- MEMBRANE INTERACTION INHIBITORS**  
Gerry A F Nicolaes\* (NL), Mahesh Kulharia, Olivier Sperandio, Jan Voorberg, Simone Wielders, Bruno O. Villoutreix



## POSTER PRESENTATIONS

Monday, July 25, 2011

Monday Posters

- P-MO-602 DISCOVERY OF BIOLOGICALLY ACTIVE MOLECULES THAT INHIBIT THE FUNCTIONS OF ANTICOAGULANT ACTIVATED PROTEIN C**  
Gerry A F Nicolaes\* (NL), Karin C.A.A. Wildhagen, Olivier Sperandio, Roy Schrijver, Bruno O. Villoutreix
- P-MO-603 THE PERFORMANCES OF MULTI-WAVELENGTH COAGULOMETER ON HEMOLYZED, ICTERIC, AND LIPEMIC SAMPLES. A COMPARATIVE STUDY WITH A MECHANICAL COAGULOMETER**  
Rahajuningsih Dharma Setiabudy\* (ID), Agus Kosasih, Lyana Setiawan
- P-MO-604 PREVENTION OF VENOUS THROMBUS FORMATION IN RABBITS AFTER SINGLE ORAL AND INTRAVENOUS DOSES OF DERMATAN SULPHATE EXTRACTED FROM BOVINE HIDE PROCESSING WASTE**  
Simone Angelique Osborne\* (AU), Paul Masci, Sharon Qianyun Du, Robyn Daniel, Wei Chen, Peter Stockwell, Kerri Tyrrell, Gregory Harper, Kirthi Desilva, Robert Seymour
- P-MO-605 IDENTIFICATION OF FACTOR IX LIGHT CHAIN VARIANTS WITH INCREASED ACTIVITY; V86 SATURATION MUTAGENESIS AND ANALYSIS OF A D85X-V86A-T87X FOCUSED LIBRARY**  
Chandra Patel\* (US), Uwe Gritzan, Xiaqiao Jiang, Ulrich Hapts, Jesper Haaning, John E Murphy, Alan R Brooks
- P-MO-606 CREATION OF TNFR1-SELECTIVE MUTANT TNF WITH ANTAGONISTIC ACTIVITY**  
Haruhiko Kamada\* (JP), Yasuhiro Abe, Kazuya Nagano, Yasuo Tsutsumi, Shin-ichi Tsunoda
- P-MO-607 TISSUE FACTOR TRIGGERED WHOLE BLOOD THROMBOELASTOMETRY AND THROMBIN GENERATION ASSAY IDENTIFY INTER-INDIVIDUAL VARIABILITY OF ANTICOAGULANT RESPONSE TO TREATMENT WITH LMWH.**  
Grigoris Thomas Gerotziafas\* (FR), Mourad Chaari, Mouna Sassi, Galea Vassiliki, Chrysoula Papageorgiou, Hatmi Mohamed, Elalamy Ismail, Meyer Michel Samama
- P-MO-608 1-6 ANHYDRO RING OF ENOXAPARIN IS ESSENTIAL FOR THE DOWN-REGULATION OF FACTOR VIIA GENERATION DURING CLOTTING OF HUMAN PLASMA.**  
Grigoris Thomas Gerotziafas\* (FR), Tahar Chakroun, Andre Uzan, Meyer Michel Samama, Ismail Elalamy
- P-MO-609 COMPARISON OF METHODS FOR THROMBOEMBOLIC RISK ASSESSMENT WITH CLINICAL PERCEPTIONS AND AWARENESS IN REAL LIFE MEDICAL PATIENTS. COMPASS-MED STUDY**  
Grigoris Thomas Gerotziafas\* (FR), Asterios Katsamouis, Athanasios Lioupis, Dimitris Kiskinis, John Tsolakis, Evagelos Tsimogiannis, Anastasios Koukos, Alex Spyropoulos, Vassiliki Galea, Isabelle Debrix, Hela Bacouche, Ismail Elalamy
- P-MO-610 LOVENOX AND ITS GENERICS EXERT DIFFERENT DEGREE OF INHIBITION OF THROMBIN GENERATION IN PLATELET RICH PLASMA. AN ADDITIONAL CRITERION FOR THE EVALUATION OF LMWH BIOSIMILARITY.**  
Grigoris Thomas Gerotziafas\* (FR), Mouna Sassi, Vassiliki Galea, Jawed Fareed, Jeanine Walenga, Ismail Elalamy
- P-MO-611 IN VITRO INHIBITORY EFFECT OF TINZAPARIN AND ENOXAPARIN ON THROMBIN GENERATION TRIGGERED BY OVARIAN ADENOCARCINOMA CELLS IGROV1**  
Vassiliki Galea\* (FR), Mouna Sassi, Grigoris T. Gerotziafas, Elisabeth Mbemba, Mohamed Hatmi, Jean Francois Bernaudin, Ismail Elalamy
- P-MO-612 LOW MOLECULAR WEIGHT HEPARINS TINZAPARIN AND ENOXAPARIN EQUALLY INHIBITED IN VITRO THROMBIN GENERATION TRIGGERED BY PROSTATE CANCER CELL LINE PC3**  
Vassiliki Galea\* (FR), Grigoris T. Gerotziafas, Mohamed Hatmi, Ismail Elalamy



POSTER PRESENTATIONS

Monday, July 25, 2011



**Scientific Program**  
**Tuesday, July 26, 2011**

Tuesday, July 26, 2011

Plenary Lecture

9:45-10:30

Oscar Ratnoff Memorial Lecture

Main Hall

Chairpersons: P. M. Mannucci (IT) and Koji Suzuki (JP)

**Challenge to novel bioactive peptides**

Kenji Kangawa (JP)

PL-TU-001

09:45 – 10:30

Plenary Lecture

17:15-18:00

Sol Sherry Memorial Lecture

Main Hall

Chairpersons: Henri Bounameaux (CH) and Yoichi Sakata (JP)

**Recent progress in anticoagulant therapy: Oral direct inhibitors of thrombin and factor Xa**

Kenneth A. Bauer (US)

PL-TU-002

17:15 – 18:00

State-of-the-Art Lecture

11:00-12:00

Platelet Clinical

Main Hall

Chairpersons: Marco Cattaneo (IT) and Andreas Greinacher (DE)

**Advances in our understanding of the molecular basis of disorders of platelet function**

Alan T. Nurden (FR), Paquita Nurden

SA-TU-001

11:00 – 11:30

**HIT paradigms and paradoxes**

Theodore Earl Warkentin (CA)

SA-TU-002

11:30 – 12:00

von Willebrand Factor and von Willebrand Disease

Annex Hall 1

Chairpersons: Robert R. Montgomery (US) and Yohko Kawai (JP)

**Von Willebrand factor: The complex molecular genetics of a multidomain and multifunctional protein**

Reinhard Schneppenheim (DE), Ulrich Budde

SA-TU-003

11:00 – 11:30

**Biology and physics of von Willebrand factor concatamers**

Timothy A. Springer (US)

SA-TU-004

11:30 – 12:00





Tuesday, July 26, 2011

**Vascular Biology**

**Annex Hall 2**

*Chairpersons: Francoise Dignat-George (FR) and Ikuo Morita (JP)*

**Molecular analysis of blood vessel maturation**

SA-TU-005

*Nobuyuki Takakura (JP)*

11:00 – 11:30

**Tissue specific adult stem cells**

SA-TU-006

*Piero Anversa (US)*

11:30 – 12:00

**Cancer Thrombosis**

**Room A**

*Chairpersons: Michael Greaves (UK) and Yujiro Asada (JP)*

**Tissue factor and cell signaling in cancer progression and thrombosis**

SA-TU-007

*Wolfram Ruf (US), Jennifer Disse, Tatiana Correa Carneiro-Lobo, Naho Yokota, Florence Schaffner*

11:00 – 11:30

**Management of thrombosis in patients with cancer**

SA-TU-008

*Giancarlo Agnelli (IT)*

11:30 – 12:00

**Symposia**

**8:00-9:30**

**Platelet (Basic and Clinical)**

**Main Hall**

**Immune Thrombocytopenia**

*Chairpersons: Cecile Kaplan (FR) and Diane Nugent (US)*

**Pathophysiology of primary immune thrombocytopenia**

SY-TU-001

*Roberto Stasi (UK)*

08:00 – 08:30

**Loss of tolerance and tolerance regain in ITP**

SY-TU-002

*Ming Hou (CN)*

08:30 – 09:00

**TPO mimetics in ITP**

SY-TU-003

*David J. Kuter (US)*

09:00 – 09:30

Tuesday Science



3

Tuesday, July 26, 2011

**VWF/VWD and ADAMTS13**

**Annex Hall 1**

**Pathogenesis of Thrombotic Microangiopathy**

*Chairpersons: Jeroen Eikenboom (NL) and Changgeng Ruan (CN)*

**Von Willebrand factor, ADAMTS13, and thrombotic microangiopathy**

**SY-TU-004**

*J. Evan Sadler (US)*

08:00 – 08:30

**Baboon model of acquired thrombotic thrombocytopenic purpura**

**SY-TU-005**

*Karen Vanhoorelbeke (BE)*

08:30 – 09:00

**Atypical hemolytic uremic syndrome, complement and coagulation**

**SY-TU-006**

*Edward M. Conway (CA)*

09:00 – 09:30

**Vascular Biology**

**Annex Hall 2**

**Inflammation and Atherothrombosis**

*Chairpersons: Kjell S. Sakariassen (IT) and Toshiyuki Ishibashi (JP)*

**New triggering mechanisms of macrophage activation**

**SY-TU-007**

*Masanori Aikawa (US)*

08:00 – 08:30

**Thrombus formation on disrupted plaques**

**SY-TU-008**

*Atsushi Yamashita (JP)*

08:30 – 09:00

**Hematopoietic and non-hematopoietic cell tissue factor**

**SY-TU-009**

*Nigel Mackman (US)*

09:00 – 09:30

**Symposia**

**13:30-15:00**

**Thrombotic Disorders**

**Main Hall**

**Acute Cerebrovascular Syndrome**

*Chairpersons: K.S. Lawrence Wong (HK) and Shinichiro Uchiyama (JP)*

**Epidemiology and registry of TIA in acute setting**

**SY-TU-010**

*Pierre Amarenco (FR)*

13:30 – 14:00

**Microembolic signals and MRI findings in acute TIA patients**

**SY-TU-011**

*K.S. Lawrence Wong (HK)*

14:00 – 14:30



Tuesday, July 26, 2011

**Acute cerebrovascular syndrome (ACVS)**

*J. Donald Easton (US)*

**SY-TU-012**

14:30 – 15:00

**APSTH Genome**

**Annex Hall 1**

**Genomes in Asian and Caucasian**

*Chairpersons: Uri Seligsohn (IL) and Hatem Salem (AU)*

**Genome-wide association study identifies three new susceptibility loci for coronary artery disease in East Asian populations**

**SY-TU-013**

*Jong-Young Lee (KR), Young-Ah Shin, Kwang Joong Kim, Dong-Jik Shin, Kyung Woo Park, Bok-Soo Lee, Mitsuhiro Yokota, Hiroyuki Asano, Masahiro Nakatochi, Tatsuaki Matsubara, Hidetoshi Kitajima, Ken Yamamoto, Bok-Ghee Han, Yangsoo Jang, Hyo-Soo Kim, Jeong Euy Park, Lee Jong-Young*

13:30 – 14:00

**Genome-wide association studies (GWAS) for hematological phenotypes, and possible application of the results to medicine and pharmacology**

**SY-TU-014**

*Naoyuki Kamatani (JP)*

14:00 – 14:30

**The genetic architecture of the pharmacological response to vitamin K antagonists**

**SY-TU-015**

*Pieter H. Reitsma (NL)*

14:30 – 15:00

**Platelet (Basic and Clinical)**

**Annex Hall 2**

**Lysophospholipids in Platelets and Vasculature**

*Chairpersons: Jonathan Gibbins (UK) and Heyu Ni (CA)*

**Metabolism of lysophospholipids in the blood**

**SY-TU-016**

*Yutaka Yatomi (JP)*

13:30 – 14:00

**Lysophospholipids in platelets and the vasculature**

**SY-TU-017**

*Susan S. Smyth (US)*

14:00 – 14:30

**Sphingosine - 1 - phosphate at the vascular/immune nexus**

**SY-TU-018**

*Timothy Hla (US)*

14:30 – 15:00

Tuesday Science



Tuesday, July 26, 2011

Symposia

15:30-17:00

Thrombotic Disorders

Main Hall

**Atherothrombosis and Antithrombotic Therapy**

*Chairpersons: Philippe G. Steg (FR) and Hisao Ogawa (JP)*

**Thrombosis or bleeding in patients with ventricle assist devices and impact on therapy** **SY-TU-019**

*Barbara Zieger (DE)*

15:30 – 16:00

**Antiplatelet therapy in ACS: Will new therapeutic agents translate into better outcomes?** **SY-TU-020**

*Ingo Ahrens (DE)*

16:00 – 16:30

**Clinical impact of aspirin "resistance" on the secondary prevention of atherothrombosis** **SY-TU-021**

*Shigeki Miyata (JP), Akiko Kada, and Kazuyuki Nagatsuka, on behalf of the Study on Profile and GENetic factors of Aspirin Resistance (ProGEAR study)*

16:30 – 17:00

Platelet (Basic and Clinical)

Annex Hall 1

**Platelet Proteomics and Gene Expression**

*Chairpersons: Yotis A. Senis (UK) and Mitsuru Murata (JP)*

**Novel YxxL containing proteins in platelets** **SY-TU-022**

*Steve P. Watson (UK), Yotis A. Senis*

15:30 – 16:00

**New functions of the dynamic platelet proteome** **SY-TU-023**

*Andrew S. Weyrich (US)*

16:00 – 16:30

**Platelet microRNAs** **SY-TU-024**

*Patrick Provost (CA)*

16:30 – 17:00

Fibrinolysis and Proteolysis

Annex Hall 2

**t-PA Mediated Brain Injury**

*Chairpersons: H. Roger Lijnen (BE) and Osamu Matsuo (JP)*

**t-PA mediated brain injury: MMP-dependent and -independent mechanisms** **SY-TU-025**

*Nobuo Nagai (JP), Yasuhiro Suzuki, Kazuo Umemura, Lijnen H. Roger*

15:30 – 16:00



Tuesday, July 26, 2011

**Denatured proteins substitute for fibrin to promote t-PA activity in the brain** **SY-TU-026**

*Robert L. Medcalf (AU), Maithili Sashindranath, Amanda Au, Rachael Jane Borg, Anja Knaupp, Stephen Bottomley, Andre Laval Samson* 16:00 – 16:30

**PDGF-dependent injury in the CNS** **SY-TU-027**

*Daniel A. Lawrence (US)* 16:30 – 17:00

Tuesday Science



## ORAL COMMUNICATIONS

Tuesday, July 26, 2011

### Integrin $\alpha$ IIb $\beta$ 3

Room C-1

*Chairpersons: Alan Nurden (FR) and David Calderwood (US)*

- O-TU-001** **08:00 - 08:15**  
**APOLIPOPROTEIN A-IV IS A NOVEL LIGAND OF PLATELET  $\beta$ 3 INTEGRINS AND AN ENDOGENOUS INHIBITOR OF THROMBOSIS**  
Joseph W Jin\* (CA), Christopher M Spring, Hong Yang, Adili Rehemam, Yiming Wang, Sean Lang, Jina Song, Yan Yang, Marc Andrews, Guangheng Zhu, Pingguo Chen, Phil Connelly, W Sean Davidson, Patrick Tso, Yi-Min She, Terry Cyr, John Freedman, Heyu Ni
- O-TU-002** **08:15 - 08:30**  
**APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) REGULATES IN VIVO THROMBOSIS BY REGULATING BOTH INSIDE-OUT AND OUTSIDE-IN SIGNALING THROUGH PLATELET INTEGRIN  $\alpha$ IIb $\beta$ 3.**  
Meghna U Naik\* (US), Hidinori Ichijo, Ulhas P Naik
- O-TU-003** **08:30 - 08:45**  
**ANTITHROMBOTIC EFFECTS OF SELECTIVELY MODULATING TALIN-INTEGRIN INTERACTIONS IN PLATELETS**  
Brian G Petrich\* (US), Jacob R. Haling, Susan J. Monkley, David R. Critchley
- O-TU-004** **08:45 - 09:00**  
 **$\alpha$ -ACTININ STABILIZES INTEGRINS TO A LOW-AFFINITY LIGAND-BINDING STATE IN RESTING PLATELETS.**  
Seiji Tadokoro\* (JP), Tsuyoshi Nakazawa, Tsuyoshi Kamae, Kazunobu Kiyomizu, Hirokazu Kashiwagi, Shigenori Honda, Yuzuru Kanakura, Yoshiaki Tomiyama
- O-TU-005** **09:00 - 09:15**  
**INTEGRIN  $\alpha$ IIb $\beta$ 3 ACTIVATION AND INTERNALIZATION IN PLATELETS OF SITOSTEROLEMIC MICE.**  
Taisuke Kanaji\* (US), Sachiko Kanaji, Robert R Montgomery, Shailendra B Patel, Peter J Newman
- O-TU-006** **09:15 - 09:30**  
**MITOCHONDRIALLY-MEDIATED PLATELET INTEGRIN  $\alpha$ IIb $\beta$ 3 INACTIVATION LIMITS PLATELET RECRUITMENT AND THROMBUS GROWTH**  
Fang Liu\* (US), Graciela Gamez, Wayne Clemmons, Shawn M Jobe

### Fibrinogen and Other Factors I

Room C-2

*Chairpersons: Jan Rosing (NL) and Laszlo Muszbek (HU)*

- O-TU-007** **08:00 - 08:15**  
**THROMBIN GENERATION, WALL SHEAR RATE, AND GEOMETRY REGULATE FIBRIN ASSEMBLY UNDER FLOW**  
Keith Benjamin Neeves\* (US), Damian A.R. Illing, Scott L Diamond
- O-TU-008** **08:15 - 08:30**  
**EFFECTS OF TOTAL FIBRINOGEN AND FIBRINOGEN  $\gamma$ ' ON THROMBIN GENERATION AND ACTIVITY IN PLASMA**  
Elisabetta Castoldi\* (NL), Shirley Uitte de Willige, Richard J. Dirven, Robert A.S. Ariens, Jan Rosing, Rogier M. Bertina



## ORAL COMMUNICATIONS

Tuesday, July 26, 2011

- |                 |  |                      |
|-----------------|--|----------------------|
| <b>O-TU-009</b> | <b>FIBRINOGEN <math>\gamma'</math> MODULATES CLOT STRUCTURE AND STIFFNESS THROUGH IMPAIRED PROTOFIBRIL FORMATION</b><br>Peter Allan* (UK), Shirley Uitte de Willige, Simon Connell, Robert Ariens  | <b>08:30 - 08:45</b> |
| <b>O-TU-010</b> | <b>NOVEL REGULATORY SEQUENCES IN THE HUMAN FIBRINOGEN GENE CLUSTER</b><br>Richard J Fish* (CH), Alexandre Fort, Silja Vorjohann, Marguerite Neerman-Arbez  | <b>08:45 - 09:00</b> |
| <b>O-TU-011</b> | <b>THE ASSOCIATION BETWEEN PLASMA FIBRINOGEN AND CORONARY HEART DISEASE IN A JAPANESE URBAN COHORT: THE SUITA STUDY</b><br>Yoshihiro Kokubo* (JP), Toshiyuki Miyata, Toshiyuki Sakata, Akira Okamoto, Makoto Watanabe, Yuu Ono, Mariko Banno, Yoshihiro Miyamoto | <b>09:00 - 09:15</b> |
| <b>O-TU-012</b> | <b>THE GENE MUTATIONS AND MECHANISMS OF FACTOR X DEFICIENCY IN THREE CHINESE FAMILIES</b><br>Qiong Chen* (CN), Jiawei Zhou, Qiulan Ding, Jing Dai, Xuefeng Wang, Hongli Wang   | <b>09:15 - 09:30</b> |

### Regulators of Coagulation

Room D

Chairpersons:  and David Lane (UK)

- |                 |   |                      |
|-----------------|---|----------------------|
| <b>O-TU-013</b> | <b>ENDOTHELIAL PROTEIN C RECEPTOR OVEREXPRESSION PROTECTS MICE AGAINST ALLERGIC LUNG INFLAMMATION IN AN ASTHMA MODEL WITH INTRANASAL INOCULATION OF HOUSE DUST MITE EXTRACT.</b><br>Johannes Daan De Boer* (NL), C Van t Veer, FE Van den Boogaard, LM Kager, JJTH Roelofs, JS Van der Zee, CT Esmon, T Van der Poll          | <b>08:00 - 08:15</b> |
| <b>O-TU-014</b> | <b>P-SELECTIN INHIBITION WITH AN ANTI P-SELECTIN APTAMER, ARC5692, THERAPEUTICALLY PROMOTES THROMBUS RESOLUTION</b><br>Jose Antonio Diaz* (US), Christine M Alvarado, Shirley K Wroblewski, Angela E Hawley, Nichole Baker, Patrick Lester, Frank J Londy, Peter K Henke, Robert G Schaub, Thomas W Wakefield, Daniel D Myers | <b>08:15 - 08:30</b> |
| <b>O-TU-015</b> | <b>FACTOR-VII ACTIVATING PROTEASE (FSAP) ACTIVATION IN HUMAN INFLAMMATION: A SENSOR FOR CELL DEATH</b><br>Femke Stephan* (NL), Ingrid Bulder, Jan Hazelzet, Marja Boermeester, Olivier van Till, Tom van der Poll, Walter Wuillemin, Lucien Aarden, Sacha Zeerleder   | <b>08:30 - 08:45</b> |
| <b>O-TU-016</b> | <b>PROTECTIVE ROLE OF ANTITHROMBIN IN MOUSE MODELS OF LIVER INJURY: POSSIBLE IMPLICATION OF THIS SERPIN IN APOPTOSIS</b><br>Jose Antonio Guerrero* (ES), Raul Teruel, Javier Corral, Isabel Arcas, Antonia Minano, Nuria Garcia-Barbera, Irene Martinez-Martinez, Vicente Vicente, Constantino Martinez                       | <b>08:45 - 09:00</b> |

Tuesday Oral



9

## ORAL COMMUNICATIONS

Tuesday, July 26, 2011

O-TU-017

**TICK SALIVARY PROTEIN P23 INHIBITS COAGULATION BY POSTPONING FACTOR V ACTIVATION AND PLAYS A CRUCIAL ROLE IN TICK FEEDING**

Cornelis van 't Veer\* (NL), Kamran Bakhtiari, Erol Fikrig, Sirlei Daffre, Tom van der Poll, Kathleen DePonte, Sukanya Narasimhan, Joost Meijers, Tim Schuijt

09:00 - 09:15

O-TU-018

**ROLE OF THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR IN LIPOPOLYSACCHARIDE-INDUCED ACUTE LUNG INJURY**

Masahiro Naito\* (JP), Osamu Taguchi, Takehiro Takagi, Masaaki Toda, Tetsu Kobayashi, Yasushi Miyake, Daniel Boveda Ruiz, Corina N. D'Alessandro-Gabazza, John Morser, Yoshiyuki Takei, Esteban C. Gabazza

09:15 - 09:30

### Heparin-induced Thrombocytopenia

Room E

*Chairpersons: Yves Gruel (FR) and Beng Chong (AU)*

O-TU-019

**INDUCTION OF TISSUE FACTOR EXPRESSION IN MONOCYTES BY THE PLATELET FACTOR 4/HEPARIN/ANTIBODY COMPLEX IS MEDIATED BY MEK1 AND PERK1/2**

Raj S Kasthuri\* (US), Sam L Glover, Jonas William, Rafal Pawlinski, Gowthami M Arepally, Nigel S Key, Nigel Mackman

08:00 - 08:15

O-TU-020

**ASSOCIATION OF NATURAL ANTI-PLATELET FACTOR 4/HEPARIN ANTIBODIES WITH PERIODONTAL DISEASE**

Andreas Greinacher\* (DE), Birte Holtfreter, Krystin Krauel, Daniela Gaetke, Claudia Weber, Till Ittermann, Sven Hammerschmidt, Thomas Kocher

08:15 - 08:30

O-TU-021

**FLUCTUATIONS IN THE PREVALENCE OF HIT ANTIBODIES DURING THE PERIOD 2004-2011. RELEVANCE TO HEPARIN CONTAMINANTS.**

Jawed Fareed\* (US), Cafer Adiguzel, Debra Hoppensteadt, Walter Jeske, Jeanine Walenga, Vinod Bansal

08:30 - 08:45

O-TU-022

**ANTI-PROTAMINE SULPHATE/PF4 ANTIBODIES CAN ACTIVATE PLATELETS AND MAY CAUSE THROMBOCYTOPENIA IN PATIENTS UNDERGOING CARDIAC SURGERY**

Tamam Bakchoul\* (DE), Astrid Giptner, Annika Krautwurst, Gregor Bein, Sentot Santoso, Jean Amiral, Ulrich J Sachs

08:45 - 09:00

O-TU-023

**SEROCONVERSION OF ANTI-PF4/HEPARIN ANTIBODIES AND ITS ASSOCIATION WITH DEEP VEIN THROMBOSIS IN ORTHOPEDIC SURGERY PATIENTS RECEIVING VARIOUS THROMBOPROPHYLAXIS METHODS**

Kiyoshi Migita (JP), Shigeki Miyata\*, Seiji Bito, Mashio Nakamura, Masanobu Saito, Yuichiro Nakayama, Hiroyuki Akimoto, Tomohiro Matsushita, Shigeru Yamada, Itaru Furuichi, Yoshihiro Sasazaki, Takaaki Tanaka, Mamoru Yoshida, Hironori Kaneko, Isao Abe, Takatomo Mine, Kazuhiko Ihara, Shigeyuki Kuratsu, Masataka Kamei, Satoru Motokawa

09:00 - 09:15





## ORAL COMMUNICATIONS

Tuesday, July 26, 2011

**O-TU-024** **FONDAPARINUX TREATMENT OF ACUTE HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) CONFIRMED BY A POSITIVE SEROTONIN-RELEASE ASSAY (SRA+).** **09:15 - 09:30**  
Theodore Earl Warkentin\* (CA), Menaka Pai, Sam Schulman, Alex C. Spyropoulos, John W. Eikelboom

### Hemophilia: Treatment

Sakura

*Chairpersons: Georges E Rivard and Steven Pipe (US)*

**O-TU-025** **RECOMBINANT FVIII FC FUSION PROTEIN RETAINS NORMAL BIOCHEMICAL PROCOAGULANT ATTRIBUTES.** **08:00 - 08:15**  
Garabet G. Toby\* (US), Stacie Seidel, Robert T. Peters

**O-TU-026** **ENHANCED PHARMACOKINETICS OF FACTOR VIIIA AS A MONOMERIC FC FUSION** **08:15 - 08:30**  
Joe Salas\* (US), Tongyao Liu, Elena Kistanova, Tamera Ashworth, Mark Slein, Ruchita Patel, George Kamphaus, Amy Correia, Alan Bitonti, Susan Dallabrida, Haiyan Jiang, Robert Peters

**O-TU-027** **STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF A RECOMBINANT FVIIIA DRUG CANDIDATE** **08:30 - 08:45**  
Peter L Turecek\* (AT), Katalin Varadi, Susanne Vejda, Ernst Boehm, Hanspeter Rottensteiner, Hans Peter Schwarz, Manfred Reiter, Artur Mitterer, Wolfgang Mundt, Hartmut J Ehrlich, Friedrich Scheifflinger

**O-TU-028** **INHIBITION OF TISSUE FACTOR INHIBITOR BY ARC19499 (BAX499) IMPROVES EX VIVO CLOTTING IN HEMOPHILIA PATIENTS** **08:45 - 09:00**  
Monika Gorczyca (AT), Christoph Male, Ingrid Pabinger, Sylvia Reitter, Paul Knoebl, Kathleen E McGinness, Robert G Schaub, Bernd Jilma\*

**O-TU-029** **MHC CLASS II-PRESENTED PEPTIDE REPERTOIRES DERIVED FROM HUMAN ANTIGEN-PRESENTING CELLS PULSED WITH BLOOD COAGULATION FACTOR VIII.** **09:00 - 09:15**  
Simon Daniel van Haren\* (NL), Eszter Herczenik, Anja ten Brinke, Koen Mertens, Alexander Meijer, Jan Voorberg

**O-TU-030** **RED CELL DERIVED MICROPARTICLES (RMP) AS HEMOSTATIC AGENT TO TREAT BLEEDING DISORDERS: THE MODE OF ACTION OF RMP** **09:15 - 09:30**  
Yeon S Ahn\* (US), Wenche Jy, Max Johansen, Laurence L Horstman

Tuesday Oral



## ORAL COMMUNICATIONS

Tuesday, July 26, 2011

### Pregnancy and Thrombosis I

Room A

*Chairpersons: Ariella Zivelin and Howard Liebman (US)*

- O-TU-031** **08:00 - 08:15**  
**COMPARATIVE OBSERVATIONAL STUDY OF THE THROMBOTIC RISK IN WOMEN WITH AN OBSTETRICAL ANTIPHOSPHOLIPID SYNDROME REVEALED BY PREGNANCY LOSS. THE NOH-APS STUDY.**  
Jean-Christophe Raymond Gris\* (FR), Erick Mercier, Eva Cochery-Nouvellon, Jean-Pierre Balducchi, Pierre Mares, Isabelle Quere, Michel Dautat
- O-TU-032** **08:15 - 08:30**  
**LOW-DOSE ASPIRIN FOR IN VITRO FERTILIZATION: A SYSTEMATIC**  
Francesco Dentali\* (IT), Walter Ageno, Emanuele Rezoagli, Elena Rancan, Alessandro Squizzato, Maurizio Margaglione, Elvira Grandone
- O-TU-033** **08:30 - 08:45**  
**MENORRHAGIA AND HEALTH-RELATED QUALITY OF LIFE IN WOMEN TREATED WITH ORAL ANTICOAGULANTS**  
Emma Stromdahl (SE), Petra Elfvinge, Eva Johansson, Mans Edlund, Margareta Holmstrom\*
- O-TU-034** **08:45 - 09:00**  
**LONG-TERM QUALITY OF LIFE AFTER PREGNANCY RELATED DEEP VEIN THROMBOSIS AND INFLUENCE OF SOCIOECONOMIC FACTORS AND COMORBIDITY**  
Hilde Skuterud Wik\* (NO), Tone Enden, Anne Flem Jacobsen, Per Morten Sandset
- O-TU-035** **09:00 - 09:15**  
**HEPARANASE PROCOAGULANT ACTIVITY IS ELEVATED IN WOMEN TAKING ORAL CONTRACEPTIVES**  
Matan Moshe (IL), Elena Axelman, Benjamin Brenner, Yona Nadir\*
- O-TU-036** **09:15 - 09:30**  
**THROMBOPHILIA, FAMILY HISTORY OF VTE, AND PROGNOSIS OF LIVE BIRTH IN WOMEN WITH RECURRENT MISCARRIAGE**  
Paulien G de Jong\* (NL), Stef P Kaandorp, Mariette Goddijn, Barbara A Hutten, Saskia Middeldorp

### VTE: Basic

Room B-1

*Chairpersons: Iris Mueller (UK) and Naveen Manchanda*

- O-TU-037** **08:00 - 08:15**  
**RETROSPECTIVE SURVEY OF HEMOSTATIC COMPLICATIONS IN 478 PATIENTS UNDERGOING HEMATOPOIETIC STEM-CELL TRANSPLANTATION (HSCT)**  
Yue Han\* (CN), Depei Wu, Luping Hu, Xia Bai, Wei Zhang, Lili Zhou, Aining Sun, Zhaoyue Wang, Changgeng Ruan
- O-TU-038** **08:15 - 08:30**  
**POTENTIAL ROLE FOR LEPTIN AND OTHER INFLAMMATORY CYTOKINES IN BEVACIZUMAB-INDUCED HYPERCOAGULABILITY.**  
Gregory Clayton Connolly\* (US), Charles W Francis, Brian H Smith, Nigel Mackman, Mark B Taubman, Alok A Khorana



## ORAL COMMUNICATIONS

Tuesday, July 26, 2011

- O-TU-039** **ASSOCIATION OF FACTOR XIA WITH INTRAVENOUS IMMUNE GLOBULIN PRODUCTS IMPLICATED IN THROMBOTIC ADVERSE EVENTS: BIOCHEMICAL ROOT CAUSE INVESTIGATION** 08:30 - 08:45  
Mikhail V Ovanesov\* (US), Alexey M Shibeko, Samuel A Woodle, Christine M Anderson, John Hogwood, Helen Barson, Elaine Gray, Dorothy Scott
- O-TU-040** **CIRCULATING MICROPARTICLES IN CARRIERS OF FACTOR V LEIDEN MUTATION.** 08:45 - 09:00  
Elena Campello (IT), Luca Spiezia, Claudia Radu, Andrea Ballin, Patrizia Zerbinati, Sabrina Gavasso, Barry Woodhams\*, Daniela Tormene, Paolo Simioni
- O-TU-041** **AN IMPAIRED PROTEIN S/TFPI PATHWAY IS A STRONG AND INDEPENDENT RISK FACTOR FOR RECURRENT VENOUS THROMBOEMBOLISM IN PATIENTS WITH FIRST UNPROVOKED DEEP VEIN THROMBOSIS** 09:00 - 09:15  
Kristien Winckers\* (NL), Arina J ten Cate-Hoek, Kim C.M.M. Beekers, Petra Erkens, Karly Hamulyak, Hugo ten Cate, Tilman M Hackeng
- O-TU-042** **GENETIC VARIANTS OF F11, STATIN USE AND VENOUS THROMBOSIS IN MEGA** 09:15 - 09:30  
Lance A Bare\* (US), Andre R Arellano, Carmen H Tong, Irene D Bezemer, Willem M Lijfering, James J Devlin, Pieter H Reitsma, Frits R Rosendaal

Tuesday Oral

### Hemostatic Abnormalities in Thrombosis

Room B-2

*Chairpersons: Flora Peyvandi (IT) and YOSHIO UETSUKA (JP)*

- O-TU-043** **THE EFFECT OF THERAPEUTIC ANTICOAGULATION ON THE RISK OF TRAUMATIC LUMBAR PUNCTURES IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA** 08:00 - 08:15  
Leonardo Rodrigues Brandao\* (CA), Laura M. Avila, Furqan Shaik, McCartney Christine, Suzan Williams
- O-TU-044** **DEEP VEIN THROMBOSIS: A UNITED STATES COST MODEL FOR A PREVENTABLE AND COSTLY ADVERSE EVENT** 08:15 - 08:30  
Charles Mahan\* (US), Mark T Holdsworth, Shawn M Welch, Matt E Borrego, Alex C Spyropoulos
- O-TU-045** **IS MAINTENANCE OF ORAL ANTICOAGULANT THERAPY FOR CATHETER ABLATION OF TYPICAL ATRIAL FLUTTER ASSOCIATED WITH LESS BLEEDING AND THROMBOEMBOLIC COMPLICATIONS?** 08:30 - 08:45  
Romain Didier (FR), Gregoire Le Gal\*, Jean-Christophe Cornily, Yves Etienne, Marjaneh Fatemi
- O-TU-046** **PEDIATRIC INFECTIVE ENDOCARDITIS OVER THE LAST 30 YEARS: THROMBOEMBOLIC COMPLICATIONS AND ASSOCIATIONS OF VEGETATION AND HEART FAILURE WITH MORTALITY** 08:45 - 09:00  
Katharina Ellen Thom\* (AT), Ponny Sivaprakasam, Jennifer L. Russel, Suzan Williams, Upton Allen, Leonardo R. Brandao



13

## ORAL COMMUNICATIONS

Tuesday, July 26, 2011

**O-TU-047** **SHIGA TOXIN UPREGULATES TISSUE FACTOR GENE EXPRESSION IN ENDOTHELIUM WHILE REDUCING SECRETION AND CELL-SURFACE ASSOCIATION OF TISSUE FACTOR PATHWAY INHIBITOR** **09:00 - 09:15**  
Eric Franklin Grabowski\* (US), Ming Cheung, Amy Skaria, Rafail I. Kushak, Julie R. Ingelfinger

**O-TU-048** **HEPARIN-INDUCED-THROMBOCYTOPENIA IN CHILDREN: A SYSTEMATIC REVIEW IDENTIFYING LITERATURE GAPS AND PITFALLS** **09:15 - 09:30**  
Leonardo Rodrigues Brandao\* (CA), Vibhuti Shah, Maria L. Avila

### Progenitor Cells and Stem Cells

Room C-1

Chairpersons: [redacted] and [redacted]

**O-TU-049** **METHODOLOGICAL DEVELOPMENT OF A CLONOGENIC ASSAY TO DETERMINE ENDOTHELIAL PROGENITOR CELL POTENTIAL** **13:30 - 13:45**  
Haruchika Masuda\* (JP), Tomoko Shizuno, Toshiya Ishihara, Shunichi Kato, Takayuki Asahara

**O-TU-050** **CLEAVED HIGH MOLECULAR WEIGHT KININOGEN ACCELERATES THE ONSET OF ENDOTHELIAL PROGENITOR CELL SENESCENCE IN VITRO AND IN VIVO** **13:45 - 14:00**  
Jihong Dai\* (CN), Xuemei Zhu, Mervin C. Yoder, Robert W. Colman, Yi Wu

**O-TU-051** **ABSENCE OF CIRCULATING CD34+ ANGIOGENIC MONOCYTE PROGENITORS AFTER ALLOGENEIC AORTIC TRANSPLANTATION STRONGLY CORRELATES WITH VASCULAR REPAIR OF ALLOIMMUNE DAMAGE.** **14:00 - 14:15**  
Daxin Chen\* (UK), Li El Tham, John H McVey, Anthony Dorling

**O-TU-052** **AUGMENTING THE HOMING OF PROGENITOR CELLS WITH BISPECIFIC SINGLE CHAIN ANTIBODIES TARGETING SCA-1 AND THE ACTIVATED GPIIB/IIIa RECEPTOR ON PLATELETS.** **14:15 - 14:30**  
Ingo Ahrens\* (DE), Christoph Hagemeyer, Franco Klingberg, Ephraem Leitner, Kati Viitaniemi, Fu Jia, Nicole Bassler, Christoph Bode, Karlheinz Peter

**O-TU-053** **TWO DISTINCT SUBPOPULATIONS OF ADULT HUMAN CARDIAC STEM CELLS CONTRIBUTE TO THE THERAPEUTIC REGENERATION OF THE FAILING HEART** **14:30 - 14:45**  
Toru Hosoda\* (US)

**O-TU-054** **MESENCHYMAL STEM CELLS POTENTIATE ANGIOGENIC ACTIVITY OF ENDOTHELIAL PROGENITOR CELLS THROUGH UP-REGULATION OF SPHK-1/S1P PATHWAY** **14:45 - 15:00**  
Florence Sabatier\* (FR), Stephane Poitevin, Gabrielle Sarlon-Bartoli, Virginie Albinet, Nathalie Andrieu-Abadie, Daniel Cussac, Angelo Parini, Francoise Dignat-George



## ORAL COMMUNICATIONS

Tuesday, July 26, 2011

### Serine Protease Inhibitors I

Room C-2

Chairpersons: [redacted] and Hiroyuki Takeya 

- |                 |   |                      |
|-----------------|---|----------------------|
| <b>O-TU-055</b> | <b>HUMAN ANTIPLASMIN-PLASMIN INTERACTION: A COMPREHENSIVE STUDY OF THE ANTIPLASMIN C-TERMINUS REGION USING SURFACE PLASMON RESONANCE</b><br>Bernadine G C Lu* (AU), Trifina Sofian, Ruby H P Law, Paul B Coughlin, Anita J Horvath  | <b>13:30 - 13:45</b> |
| <b>O-TU-056</b> | <b>MECHANISM OF INHIBITION OF THE PROTHROMBINASE COMPLEX BY A COVALENT ANTITHROMBIN-HEPARIN CONJUGATE</b><br>Ivan Stevic* (CA), Leslie R Berry, Anthony K.C. Chan   | <b>13:45 - 14:00</b> |
| <b>O-TU-057</b> | <b>WHEN ASSEMBLED INTO THEIR RESPECTIVE ACTIVATION COMPLEXES, FACTORS XA, IXA, AND VIIA ARE DIFFERENTIALLY PROTECTED FROM INHIBITION BY THE ANTITHROMBIN/HEPARIN COMPLEX.</b><br>Calvin H Yeh* (CA), Hashem Alshurafa, James C Fredenburgh, Alan R Stafford, Paul Y Kim, Jeffrey I Weitz  | <b>14:00 - 14:15</b> |
| <b>O-TU-058</b> | <b>INDIVIDUAL ANTICOAGULANT APTAMERS UNIQUELY IMPAIR THROMBIN GENERATION AND HAVE A SYNERGISTIC EFFECT WHEN USED IN COMBINATION</b><br>Kristin Marie Bompiani* (US), Jens Lohmann, James Frederiksen, Bruce A. Sullenger  | <b>14:15 - 14:30</b> |
| <b>O-TU-059</b> | <b>PROTEIN C INHIBITOR (PCI) INTERACTS WITH PHOSPHOINOSITIDES AND MIGHT AFFECT LIPID SIGNALING.</b><br>Felix Wahlmueller* (AT), Barbora Sokolikova, Daniela Rieger, Margarethe Geiger   | <b>14:30 - 14:45</b> |
| <b>O-TU-060</b> | <b><math>\beta</math>-ISOFORM OF ANTITHROMBIN COMPENSATES THE EFFECT OF THE MUTATION IN TYPE II DEFICIENCIES WITH HEPARIN BINDING DEFECT.</b><br>Irene Martinez-Martinez* (ES), Jose Navarro-Fernandez, Alice Ostergaard, Ricardo Gutierrez-Gallego, Jose Padilla, Nataliya Bohdan, Antonia Minano, Cristina Pascual, Constantino Martinez, Maria Eugenia de la Morena-Barrio, Sonia Aguila, Shona Pedersen, Soren Risom Kristensen, Vicente Vicente, Javier Corral | <b>14:45 - 15:00</b> |

Tuesday Oral

### Coagulation Factors: Experimental Models I

Room D

Chairpersons: Katherine High (US) and Ming Shen (TW)

- |                 |   |                      |
|-----------------|---|----------------------|
| <b>O-TU-061</b> | <b>MEASURING THROMBIN GENERATION IN A HETEROGENEOUS SYSTEM AS A FUNCTION OF SPACE AND TIME: A NOVEL APPROACH FOR BASIC AND APPLIED COAGULATION RESEARCH</b><br>Natalia M Dashkevich* (RU), Mikhail V Ovanesov, Mikhail A Pantelev, Fazoil I Ataullakhanov | <b>13:30 - 13:45</b> |
|-----------------|---|----------------------|



15

## ORAL COMMUNICATIONS

Tuesday, July 26, 2011

- O-TU-062** **SPATIAL AND TEMPORAL LOCALIZATION OF SITE-SPECIFICALLY LABELED COAGULATION FACTORS IN THE DEVELOPING THROMBUS IN VIVO** 13:45 - 14:00  
Lacramioara Ivanciu\* (US), Sriram Krishnaswamy, Rodney M Camire
- O-TU-063** **EFFICACY AND POTENTIAL SYSTEMIC COAGULATION BIOMARKERS IN A JOINT INJURY MODEL OF HEMA MICE COMPARING BAY 86-6150 (A MODIFIED HUMAN FVIIIA) TO EPTACOG ALFA [ACTIVATED] OR APCC** 14:00 - 14:15  
Maria Koellnberger\* (US), Cristina Loomis, Perry Liu, Jian-Ming Gu, Ji-Yun Kim, Inge A. Ivens, Cornell Mallari, Derek S. Sim, John E. Murphy, Jesper Haaning
- O-TU-064** **EFFECTS OF RECOMBINANT FVIII IN A VENOUS BLEEDING MODEL IN HAEMOPHILIA A MICE** 14:15 - 14:30  
Brian Lauritzen\* (DK), Anne Engedahl Pastoft, Mirella Ezban, Mikael Tranholm, Jens Lykkesfeldt
- O-TU-065** **IL2/IL2 MAB COMPLEXES INDUCE IN VIVO EXPANSION OF TREG CELLS AND PREVENT ANTI-FVIII ANTIBODY PRODUCTION FOLLOWING FVIII PROTEIN REPLACEMENT THERAPY IN HEMOPHILIA A MICE** 14:30 - 14:45  
Chao-Lien Liu\* (US), Peiqing Ye, Jacqueline Lin, Carol H. Miao
- O-TU-066** **IMMUNE RESPONSE VERSUS TOLERANCE TO FVIII - A NEW APPROACH TO ANSWER BURNING QUESTIONS IN HEMOPHILIA A** 14:45 - 15:00  
Katharina Nora Steinitz\* (AT), Paula Maria van Helden, Brigitte Binder, Ahmad Uddin Rafi, Markus Weiller, Maurus de la Rosa, Hans-Peter Schwarz, Birgit Maria Reipert

### Immune Thrombocytopenia

Room E

*Chairpersons: Yoshitaka Miyakawa (JP) and [REDACTED]*

- O-TU-067** **MESENCHYMAL STEM CELL-MODULATED DENDRITIC CELLS INDUCE PLATELET-SPECIFIC T CELLS ANERGY IN A KLF10-DEPENDENT MANNER IN PRIMARY THROMBOCYTOPENIC PURPURA** 13:30 - 13:45  
Xinguang Liu\* (CN), Ji Ma, Lin Sun, Ming Hou, Jun Peng
- O-TU-068** **EMERGENCE OF POLYCLONAL AUTOANTIBODY RESPONSES TO MULTIPLE PLATELET SURFACE GLYCOPROTEINS IN REGULATORY T CELL-DEFICIENT MICE WITH IMMUNE THROMBOCYTOPENIA.** 13:45 - 14:00  
Tetsuya Nishimoto\* (JP), Takashi Satoh, Elisa Simpson, Heyu Ni, Tsutomu Takeuchi, Masataka Kuwana
- O-TU-069** **GP IIB/IIIa-DEPENDENT COMPLEMENT ACTIVATION IS A COMMON FINDING IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA AND DEPENDS ON ANTIBODY-GLYCOSYLATION STATUS** 14:00 - 14:15  
Tamam Bakchoul\* (DE), Abdulrahim Najaoui, Annika Krautwurst, Katrin Walek, Gregor Bein, Sentot Santoso, Ulrich Sachs



## ORAL COMMUNICATIONS

Tuesday, July 26, 2011

- O-TU-070** **MICRO RNA ANALYSIS IN IMMUNE THROMBOCYTOPENIC PURPURA** **14:15 - 14:30**  
Huiyuan Li\* (CN), Haifeng Zhao, Weiting Du, Renchi Yang
- O-TU-071** **LOW-AVIDITY ANTI-HPA-1A ALLOANTIBODIES ARE CAPABLE OF ANTIGEN-POSITIVE PLATELET DESTRUCTION IN THE NOD/SCID MOUSE MODEL OF ALLOIMMUNE THROMBOCYTOPENIA** **14:30 - 14:45**  
Tamam Bakchoul\* (DE), Sebastian Kubiak, Annika Krautwurst, Gregor Bein, Ulrich Sachs, Sentot Santoso
- O-TU-072** **ANTI HPA-1A ALLOIMMUNIZATION AND PREGNANCY: PREDICTION OF THE FETAL STATUS AND RESPONSE TO IVIG THERAPY** **14:45 - 15:00**  
Gerald Bertrand\* (FR), Corinne Martageix, Moustapha Drame, Cecile Kaplan

### Hemophilia: Innovative Therapy I

Sakura

*Chairpersons: Erik Berntorp (SE) and Alok Srivastava*

- O-TU-073** **PHARMACOKINETICS AND SAFETY OF RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIII FC) IN A PHASE 1/2A TRIAL IN PREVIOUSLY TREATED PATIENTS (PTPS) WITH SEVERE HEMOPHILIA A** **13:30 - 13:45**  
Jerry Powell\* (US), N C Josephson, D Quon, M V Ragni, G Cheng, B McKinney, Haiyan Jiang, Lian Li, Jennifer Dumont, Jaya Goyal, Jurg Sommer, Alvin Luk, Glenn F Pierce
- O-TU-074** **SAFETY AND PHARMACOKINETIC PROPERTIES OF GLYCOPEGYLATED RECOMBINANT FACTOR IX: A FIRST HUMAN DOSE TRIAL IN PATIENTS WITH HAEMOPHILIA B** **13:45 - 14:00**  
Claude Negrier\* (FR), Karin Knobe, Andreas Tiede, Paul Giangrande, Judi Moss
- O-TU-075** **SYNTHETIC PEPTIDES DISCOVERED BY PHAGE DISPLAY ENHANCE THE ACTIVITY OF HFIXA IN FUNCTIONAL COAGULATION ASSAYS.** **14:00 - 14:15**  
Karina Thorn\* (US), Garo Toby, Ku-chuan Hsiao, Stacie Seidel, Ryan Donnelly, Swapnil Rakhe, Cara Fraley, Alan Bitonti, Robert Peters, Adam Mezo
- O-TU-076** **APTAMER BAX499, A POTENT AND SPECIFIC INHIBITOR OF TFPI, CORRECTS HEMOSTASIS PARAMETERS OF HEMOPHILIC BLOOD** **14:15 - 14:30**  
Shenbagapriya P\* (IN), Nair Sukesh Chandran, Devadarshini Mercy, Abraham Aby, Mathews Vikram, Srivastava Alok
- O-TU-077** **SOLULIN INCREASES CLOT STABILITY IN WHOLE BLOOD FROM INDIVIDUALS WITH HEMOPHILIA A OR B** **14:30 - 14:45**  
Jonathan H Foley\* (US), Catherine J Rea, Karl Uwe Petersen, Michael E Nesheim, Benny Sorensen

Tuesday Oral



17

## ORAL COMMUNICATIONS

Tuesday, July 26, 2011

- O-TU-078** **TARGETING FACTOR VIIA TO PLATELET RECEPTORS RESULTS IN ENHANCED ACTIVITY** **14:45 - 15:00**  
Joe Salas\* (US), Tamera Ashworth, Elena Kistanova, Ruchita Patel, Paul Sakorafas, Bob Pape, Adam Mezo, Susan Dallabrida, Haiyan Jiang, Robert Peters

### Anticoagulation Therapy

Room A

*Chairpersons: Masahiro Yasaka (JP) and Nicholas Smith (US)*

- O-TU-079** **ADHERENCE TO 2008 ACCP GUIDELINES FOR PERIOPERATIVE MANAGEMENT OF ANTICOAGULATION RESULTS IN DECREASED BLEEDING COMPLICATIONS: A SINGLE CENTER EXPERIENCE** **13:30 - 13:45**  
Maria T DeSancho\* (US), John Chapin, Svetoslava Bardarova
- O-TU-080** **MAJOR BLEEDING DURING VITAMIN K ANTAGONIST TREATMENT: THE INFLUENCE OF THYROID HORMONE** **13:45 - 14:00**  
Jan Debeij\* (NL), Suzanne C Cannegieter, Bregje van Zaane, Anton PS van Zanten, Frits R Rosendaal, Victor EA Gerdes, Pieter H Reitsma, Olaf M Dekkers
- O-TU-081** **VITAMIN K ANTAGONIST THERAPY (VKA): EMPOWARMENT; EDMONTON PEDIATRIC WARFARIN SELF-MANAGEMENT** **14:00 - 14:15**  
Mary Elisabeth Bauman\* (CA), Aisha Bruce, Satvinder Kaur, Michelle Bauman, M Patricia Massicotte
- O-TU-082** **INTER-INDIVIDUAL VARIABILITY IN WARFARIN DOSE REQUIREMENT IN CHILDREN CAN BE EXPLAINED BY VKORC1 AND CYP2C9 GENOTYPE AND PATIENT CHARACTERISTICS** **14:15 - 14:30**  
Tina T Biss\* (UK), Peter J Avery, Leonardo R Brandao, Elizabeth A Chalmers, Michael D Williams, John D Grainger, Julian BS Leathart, John P Hanley, Ann K Daly, Farhad Kamali
- O-TU-083** **PATIENT SELF MANAGEMENT OF WARFARIN: MEASUREMENT OF QUALITY OF LIFE IN CHILDREN/FAMILIES** **14:30 - 14:45**  
Aiko MD Bruce\* (CA), M Patricia Massicotte, Mary Bauman
- O-TU-084** **PHARMACOGENETIC EXPERT DOSING STRATEGIES (PEDS) FOR WARFARIN** **14:45 - 15:00**  
Lisa Bomgaars\* (US), M P Massicotte, Courtney Thornburg, Leslie Raffini, Shannon Saldana, Eve Surcobe, Mary Bauman, Emma Jones, Alexander Vinks, Brian Gage





# ORAL COMMUNICATIONS

Tuesday, July 26, 2011

Diagnosis and Treatment for VWD and TTP

Room B-1

Chairpersons: [redacted] and Johanna Kremer Hovinga (CH)

- |                 |  |                      |
|-----------------|--|----------------------|
| <b>O-TU-085</b> | <b>IN VIVO CHARACTERIZATION OF THE ANTI-THROMBOTIC EFFECT OF ANTIBODIES INHIBITING BINDING OF VON WILLEBRAND FACTOR TO COLLAGENS OR TO PLATELET GLYCOPROTEIN IIB/IIIa</b><br>Cecile V Denis* (FR), Ana-Maria Navarrete, Isabelle Marx, Peter J Lenting, Olivier D Christophe, Cecile V Denis   | <b>13:30 - 13:45</b> |
| <b>O-TU-086</b> | <b>RECOMBINANT HUMAN VON WILLEBRAND FACTOR-PLASMA FREE MANUFACTURED: FIRST-IN-HUMAN STUDY EVALUATING PHARMACOKINETICS, DEMONSTRATING SAFETY AND TOLERABILITY IN SEVERE VWD</b><br>Piero M Mannucci (IT), Christine L Kempton, Michael A Laffan, Edward H Romond, Amy Shapiro, Ingvild Birschmann, Margaret V Ragni, Joan C Gill, Thynn Thynn Yee, Robert Klamroth, Sandor Fritsch, Peter L Turecek, Bruce M Ewenstein, Tobias M Suiter*, Baxter BioScience rVWF Study Team | <b>13:45 - 14:00</b> |
| <b>O-TU-087</b> | <b>FIRST ASSAY TO ACCURATELY DETERMINE ADAMTS13-VWF COMPLEXES IN PLASMA</b><br>Hendrik B Feys* (BE), Aaron Peace, Emanuele Barbato, Hans Deckmyn, Jozef Bartunek, Karen Vanhoorelbeke  | <b>14:00 - 14:15</b> |
| <b>O-TU-088</b> | <b>A NOVEL ASSAY SPECIFICALLY DETECTING VON WILLEBRAND FACTOR (VWF) CLEAVED IN THE A2 DOMAIN - INCREASED CLEAVED VWF IN RESPONSE TO ENDOTHELIAL PERTURBATION IN HEALTH AND DISEASE</b><br>Ester C Lowenberg* (NL), Bert-Jan H van den Born, Marcel Levi, Philip G de Groot, J A Lisman, Frank W Leebeek, Jeroen Eikenboom, Rob Fijnheer, Rosemarijn Renckens, Eva de Wee, Joost CM Meijers   | <b>14:15 - 14:30</b> |
| <b>O-TU-089</b> | <b>IDENTIFICATION OF A SMALL MOLECULE THAT MODULATES THE VON WILLEBRAND FACTOR - PLATELET GLYCOPROTEIN IB INTERACTION</b><br>Katleen Broos* (BE), Mieke Trekels, Jonas Demeulemeester, Rani A Jose, Wim De Borggraeve, Marc De Maeyer, Karen Vanhoorelbeke, Hans Deckmyn   | <b>14:30 - 14:45</b> |
| <b>O-TU-090</b> | <b>THE ANTITHROMBOTIC EFFECT OF THE FUCOIDAN OF <i>LESSONIA VADOSA</i>: A STRONG INHIBITOR OF THE PLATELET GLYCOPROTEIN IB RECEPTOR - VON WILLEBRAND FACTOR INTERACTION</b><br>Katleen Broos* (BE), Wim De Borggraeve, Aline Vandenbulcke, Nele Vandeputte, Karen De Ceunynck, Nancy P Chandia, Betty Y Matsuhira, Karen Vanhoorelbeke, Hans Deckmyn   | <b>14:45 - 15:00</b> |

Tuesday Oral



## ORAL COMMUNICATIONS

Tuesday, July 26, 2011

### Antiphospholipid Syndrome: Basic

Room B-2

Chairpersons: Vittorio Pengo and Eiji Matsuura (JP)

O-TU-091

13:30 - 13:45

#### C5 INHIBITOR REV576 AMELIORATES IN VIVO EFFECTS OF ANTIPHOSPHOLIPID ANTIBODIES.

Ana Laura Carrera-Marin (US), Ana Laura Carrera-Marin, Zurina Romay-Penabad, Wynne Weston-Davis, Samuel Machin, Hannah Cohen, Silvia S Pierangeli\*

O-TU-092

13:45 - 14:00

#### C6-DEFICIENT MICE ARE PROTECTED FROM THE PATHOGENIC EFFECTS OF ANTIPHOSPHOLIPID ANTIBODIES.

Ana Laura Carrera-Marin (US), Zurina Romay-Penabad, Renan Aguilar-Valenzuela, Silvia S Pierangeli\*

O-TU-093

14:00 - 14:15

#### ANTI-DOMAIN I ANTIBODIES HAVE A PROTHROMBOTIC CHARACTER ON COAGULATION BY INHIBITING THE ANTICOAGULANT EFFECT OF BETA2GPI

Bas de Laat\* (NL), Gwen van Os, Marisa Ninivaggi, Cetin Agar, Philip de Groot, Coen Hemker, Theo Lindhout, Joost Meijers

O-TU-094

14:15 - 14:30

#### MIR-19B AND MIR-20A AS REGULATORS OF TISSUE FACTOR EXPRESSION IN MONOCYTES FROM PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME

Raul Teruel\* (ES), Carlos Perez-Sanchez, Javier Corral, Maria Teresa Herranz, Virginia Perez-Andreu, Encarnacion Saiz, Nuria Garcia-Barbera, Jesus Lozano, Irene Martinez-Martinez, Vanesa Roldan, Vicente Vicente, Chari Lopez-Pedrer, Constantino Martinez

O-TU-095

14:30 - 14:45

#### ROLE FOR TOLL-LIKE RECEPTOR 2 AND CD14 IN THE ACTIVATION OF HUMAN MONOCYTES AND ENDOTHELIAL CELLS BY ANTIPHOSPHOLIPID ANTIBODIES

Nathalie Satta (CH), Egbert KO Kruihof\*, Celine Fickentscher, Sylvie Dunoyer-Geindre, Francoise Boehlen, Guido Reber, Danielle Burger, Philippe de Moerloose

O-TU-096

14:45 - 15:00

#### CD39 OVER EXPRESSION PROTECTS IN A MURINE MODEL OF ANTIPHOSPHOLIPID ANTIBODY-INDUCED MISCARRIAGES

Harshal Nandurkar\* (AU), Anushka Samudra, Anup Sharma, Xiang-Ming Zhang, Carly Selan, Karen Dwyer, Anthony d'Apice, Peter Cowan

### Platelets: Experimental Models

Room C-1

Chairpersons: S. Massberg and Lawrence Brass (US)

O-TU-097

15:30 - 15:45

#### CALDAG-GEFI IN THROMBOSIS AND HEMOSTASIS

Stolla Moritz\* (US), Lucia Stefanini, R. Claire Roden, Massiel Chavez, Jessica Hirsch, Teshell Greene, Timothy D. Ouellette, Michael P. Reilly, Steven E. McKenzie, Mortimer Poncz, Donna S. Woulfe, Wolfgang Bergmeier



## ORAL COMMUNICATIONS

Tuesday, July 26, 2011

- |                 |   |                      |
|-----------------|---|----------------------|
| <b>O-TU-098</b> | <b>SELECTIVE BLOCKADE OF THE A1 DOMAIN OF VON WILLEBRAND FACTOR (VWF), PREVENTS ISCHEMIC STROKE IN THE GUINEA PIG: COMPARISON WITH THE THROMBOLYTIC RTPA.</b><br>Stefania Momi* (IT), Michela Tantucci, Maarten Van Roy, Hans Ulrichs, Josephin Holz, Paolo Gresele | <b>15:45 - 16:00</b> |
| <b>O-TU-099</b> | <b>ACTIVATED FACTOR XII ENHANCES THROMBUS FORMATION INDEPENDENT OF ITS ROLE IN COAGULATION</b><br>Coen Maas* (NL), Rolf T Urbanus, Sabine C den Hartogh, Cees Weeterings, S AE Sebastian, Philip G de Groot   | <b>16:00 - 16:15</b> |
| <b>O-TU-100</b> | <b>IMPORTANCE OF THROMBIN-ACTIVATION OF PLATELETS IN REGULATING LEUKOCYTE RECRUITMENT TO SITES OF VASCULAR INJURY</b><br>Zane Kaplan* (AU), Mehran Ghasemzadeh, Imala Alwis, Yuping Yuan, Erik Westein, Shaun P. Jackson  | <b>16:15 - 16:30</b> |
| <b>O-TU-101</b> | <b>ENOS INDEPENDENT PLATELET INHIBITION BY ATORVASTATIN</b><br>Ran Ni* (CA), Tal Peleg, Peter L Gross   | <b>16:30 - 16:45</b> |
| <b>O-TU-102</b> | <b>INVERSE ROLE OF PULSATILE BLOOD FLOW ON THROMBUS GROWTH UNDER PHYSIOLOGICAL AND DISTURBED RHEOLOGICAL CONDITIONS</b><br>Pierre Mangin* (FR), Eric Maurer, Mathieu Schaff, Jean-Pierre Cazenave, Christian Gachet, Francois Lanza, Pierre H Mangin                | <b>16:45 - 17:00</b> |

Tuesday Oral

### Plasminogen Activation System: Basic

Room C-2

*Chairpersons: Taiichiro Seki (JP) and Colin Longstaff (UK)*

- |                 |   |                      |
|-----------------|---|----------------------|
| <b>O-TU-103</b> | <b>A NEW PAI-1 INHIBITOR AND ITS CRYSTAL STRUCTURE IN COMPLEX WITH PAI-1</b><br>Zhonghui Lin* (CN), Zebin Hong, Lihong Hu, Mingdong Huang   | <b>15:30 - 15:45</b> |
| <b>O-TU-104</b> | <b>THE EFFECTS OF MUTATIONS OF RESIDUES LYS42, LYS43, AND LYS44 OF TAFI ON ITS ACTIVATION BY THROMBIN-THROMBOMODULIN</b><br>Chengliang Wu* (CA), Ann Gils, Paul Declerck, Michael E Nesheim   | <b>15:45 - 16:00</b> |
| <b>O-TU-105</b> | <b>SPECIFIC TAFIA INHIBITING NANOBODIES AS PROFIBRINOLYTIC TOOLS AND DISCOVERY OF A NEW TAFIA CONFORMATION</b><br>Maarten Hendrickx* (BE), Anais De Winter, Karlien Buelens, Griet Compennolle, Gholamreza Hassanzadeh-Ghassabeh, Serge Muyldermans, Ann Gils, Paul J. Declerck | <b>16:00 - 16:15</b> |
| <b>O-TU-106</b> | <b>EPIGENETIC CONTROL OF TISSUE-TYPE PLASMINOGEN ACTIVATOR SYNTHESIS IN HUMAN ENDOTHELIAL CELLS</b><br>Egbert KO Kruithof* (CH), Sylvie Dunoyer-Geindre   | <b>16:15 - 16:30</b> |



21

## ORAL COMMUNICATIONS

Tuesday, July 26, 2011

**O-TU-107** **16:30 - 16:45**

**SUSCEPTIBILITY OF HUMAN TAFI-TRANSGENIC MICE TO STREPTOCOCCUS PYOGENES**

Mercedes Valls-Seron\* (NL), Stefan R Havik, Heiko Herwald, Philip G de Groot, Joost CM Meijers

**O-TU-108** **16:45 - 17:00**

**PLASMINOGEN ACTIVATOR INHIBITOR TYPE I CONTRIBUTES TO PROTECTIVE IMMUNITY DURING EXPERIMENTAL GRAM-NEGATIVE SEPSIS (MELIOIDOSIS)**

Liesbeth M Kager\* (NL), W. Joost Wiersinga, Joris J Roelofs, Joost C Meijers, Cornelis Van 't Veer, Tom Van der Poll

### Tissue Factor and Factor VII

Room D

*Chairpersons: Philip Hogg (AU) and Wolfram Ruf (US)*

**O-TU-109** **15:30 - 15:45**

**MURINE ALTERNATIVELY SPLICED TISSUE FACTOR IS NOT SUFFICIENT FOR EMBRYONIC DEVELOPMENT AND DOES NOT TRIGGER COAGULATION**

Susanna HM Sluka\* (CH), Alexander Akhmedov, Johannes Vogel, Thomas F Luscher, Felix C Tanner

**O-TU-110** **15:45 - 16:00**

**CRITICAL LENGTH OF THE LINKER BETWEEN THE EGF-LIKE DOMAINS IN FACTOR VIIA ESSENTIAL FOR PRODUCTIVE, HIGH-AFFINITY INTERACTION WITH TISSUE FACTOR**

Egon Persson\* (DK), Ole Hvilsted Olsen

**O-TU-111** **16:00 - 16:15**

**COAGULATION FACTOR VII EXPRESSION CORRELATES WITH TUMOR MIGRATION AND INVASIVENESS IN HUMAN HEPATOCELLULAR CARCINOMA**

Chih Che Lin\* (TW), Hsiang-Jen Yang, Li-Yu Chen, Chih-Chi Wang, Toshiaki Nakano, Shigeru Goto, Kuang-Den Chen, Chao-Long Chen

**O-TU-112** **16:15 - 16:30**

**FACTOR VII ACTIVATING PROTEASE (FSAP) PROMOTES PROTEOLYSIS AND INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR (TFPI)**

Sandip M Kanse\* (DE), Paul J Declerck, Wolfram Ruf, George Broze, Michael Etscheid

**O-TU-113** **16:30 - 16:45**

**A MONOCLONAL ANTI-TFPI-ANTIBODY, MAB 2021, REDUCES AN ONGOING BLEEDING IN HAEMOPHILIC RABBITS WITH A SIMILAR EFFECT AS RFVIIA**

Brian Lauritzen\* (DK), Ida Hilden, Brit Binow Sorensen

**O-TU-114** **16:45 - 17:00**

**BAY 86-6150, A NOVEL RECOMBINANT FACTOR VIIA VARIANT, HAS A SIGNIFICANTLY HIGHER THERAPEUTIC INDEX THAN EPTACOG ALFA (ACTIVATED) IN RABBIT BLEEDING AND THROMBOSIS MODELS**

Derek S. Sim\* (US), Maria Koellnberger, Jian-Ming Gu, Claus Bornaes, Michael Kragh, Susanne K Clausen, John E. Murphy, Jesper Haaning



## ORAL COMMUNICATIONS

Tuesday, July 26, 2011

### Endothelial Cells

Room E

Chairpersons: Asrar B Malik and Joji Ando



- |                 |   |                      |
|-----------------|---|----------------------|
| <b>O-TU-115</b> | <b>UROKINASE PLASMINOGEN ACTIVATOR INDUCES PULMONARY MICROVASCULAR ENDOTHELIAL PERMEABILITY THROUGH LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN - DEPENDENT ENOS ACTIVATION</b><br>Anastasia M. Makarova* (US), Tatiana V Lebedeva, Abd Al-Roof Higazi, Douglas B Cines, Victoria V Stepanova  | <b>15:30 - 15:45</b> |
| <b>O-TU-116</b> | <b>TARGETING ENA/VASP ACTIVITY IN ENDOTHELIAL CELLS AND IN VESSELS <i>IN VIVO</i></b><br>Stefanie Seifert* (SE), Renne Thomas   | <b>15:45 - 16:00</b> |
| <b>O-TU-117</b> | <b>THIOREDOXIN RESTORES EXOCYTOSIS BY DENITROSYLATING N-ETHYLMALEIMIDE SENSITIVE FACTOR.</b><br>Takashi Ito* (JP), Ikuro Maruyama, Charles J Lowenstein   | <b>16:00 - 16:15</b> |
| <b>O-TU-118</b> | <b>GAP JUNCTION PROTEIN, CONNEXIN32 REGULATES EXPRESSION OF TISSUE FACTOR AND INFLAMMATORY CYTOKINES IN THE ENDOTHELIAL CELLS</b><br>Okamoto Takayuki* (JP), Tatsuya Hayashi, Koji Suzuki   | <b>16:15 - 16:30</b> |
| <b>O-TU-119</b> | <b>OSTEOPROTEGERIN, A NEW ACTOR IN VASCULOGENESIS, STIMULATES ENDOTHELIAL COLONY-FORMING CELLS PROPERTIES</b><br>Zahia Benslimane-Ahmim (FR), Dominique Heymann, Blandine Dizier, Anna Lokajczyk, Regis Brion, Françoise Grelac, David M Smadja, Isabelle Galy-Fauroux, Sylvia Collic-Jouault, Anne Marie Fischer, Catherine Boisson-Vidal* | <b>16:30 - 16:45</b> |
| <b>O-TU-120</b> | <b>PARADOXICAL INVOLVEMENT OF THE ENDOTHELIAL MINERALOCORTICOID RECEPTOR IN PLATELET ACTIVATION AND VASCULAR THROMBOSIS IN MOUSE</b><br>Jeremy Lagrange* (FR), Celine Fassot-Lucht, Aurelie Nguyen Dinh Cat, Patrick Lacolley, Frederic Jaisser, Veronique Regnault   | <b>16:45 - 17:00</b> |

Tuesday Oral

### Hemophilia: Inhibitor Development

Sakura

Chairpersons: Seiji Madoiwa (JP) and



- |                 |   |                      |
|-----------------|---|----------------------|
| <b>O-TU-121</b> | <b>THE DEVELOPMENT OF INHIBITORY ANTIBODY TO THERAPEUTIC FACTOR VIII IN SEVERE HEMOPHILIA A IS ASSOCIATED WITH MICROSATELLITE POLYMORPHISM IN HMOX1 PROMOTER</b><br>Yohann Repesse* (FR), Jordan Dimitrov, Surya Dasgupta, Elika Farrokhi, Catherine Costa, Anna Pavlova, Annie Borel Derlon, Roselyne D'Oiron, Johannes Oldenburg, Srinivas Kaveri, Sebastien Lacroix-Desmazes | <b>15:30 - 15:45</b> |
|-----------------|---|----------------------|



23

## ORAL COMMUNICATIONS

Tuesday, July 26, 2011

- O-TU-122** **BLOCKAGE OF FACTOR VIII UPTAKE BY DENDRITIC CELLS RESULTS IN REDUCED ANTIBODY RESPONSES IN A MOUSE MODEL OF HAEMOPHILIA A** 15:45 - 16:00  
Aleksandra Wroblewska\* (NL), Simon D. van Haren, Eszter Herczenik, Alexander B. Meijer, Anja ten Brinke, Jan Voorberg
- O-TU-123** **F8 GENE MUTATION TYPE AND INHIBITOR DEVELOPMENT IN PATIENTS WITH SEVERE HEMOPHILIA A: PRELIMINARY RESULTS OF A SYSTEMATIC REVIEW AND META-ANALYSIS** 16:00 - 16:15  
Samantha C Gouw\* (NL), H Marijke van den Berg, Jan Astermark, Johannes Oldenburg, Maurizio Margaglione, Arthur R Thompson, Jorien Boekhorst, Connie H Miller, Philip G de Groot, Johanna G van der Bom
- O-TU-124** **SEVENFOLD RISK FOR INHIBITORS IN MILD/MODERATE HEMOPHILIA A WITH FACTOR VIII MISSENSE MUTATIONS IN TWO DISTINCT REGIONS** 16:15 - 16:30  
Corien Eckhardt\* (NL), Alice S. van Velzen, Marjolein Peters, Nina Streefkerk, Jan Astermark, Johannes Oldenburg, Kathelijne Peerlinck, Charles R.M. Hay, Pieter-Willem Kamphuisen, Elena Santagostino, Johanna G. van der Bom, Karin Fijnvandraat
- O-TU-125** **MONITORING INHIBITOR DEVELOPMENT IN HAEMOPHILIA: 2-YEAR RESULTS OF EUHASS.** 16:30 - 16:45  
Kathelijn Fischer\* (NL), Mike Makris, Gabriele Callizzani, Charles Hay, Christopher Ludlam, Thierry Lambert, Riitta Lassila, Piero Mannucci
- O-TU-126** **INHIBITOR DEVELOPMENT IN MILD AND MODERATE HEMOPHILIA A SEEMS TO BE ASSOCIATED WITH AN INCREASED MORTALITY RISK** 16:45 - 17:00  
Corien Eckhardt\* (NL), Alice S. van Velzen, Marjolein Peters, Jan Astermark, Rainer Schwaab, Kathelijne Peerlinck, Charles R.M. Hay, Pieter-Willem Kamphuisen, Maria Elisa Mancuso, Johanna G. van der Bom, Karin Fijnvandraat

### Thrombotic Disorders: Clinical Trials I

Room A

Chairpersons: Ramon Corbalan and Alok Khorana (US)

- O-TU-127** **RANDOMIZED COMPARISON OF THE DAWN AC COMPUTER PROGRAM AND A SIMPLE MANUAL NOMOGRAM FOR QUALITY OF WARFARIN DOSING** 15:30 - 15:45  
Robby Nieuwlaat\* (CA), Alex C Spyropoulos, Lowiek Hubers, Alexander Stehouwer, Harriette G Van Spall, John W Eikelboom, Sam Schulman, Stuart J Connolly
- O-TU-128** **THE EFFECT OF POLYMORPHISMS OF VKORC1 C1173T ON THE PERCENTAGE OF TIME THE INR IS WITHIN THE THERAPEUTIC RANGE IN PATIENTS USING VITAMIN K ANTAGONISTS** 15:45 - 16:00  
Edward P.A. Gebuis\* (NL), Frits R. Rosendaal, Erik van Meegen, Felix J.M. van der Meer



## ORAL COMMUNICATIONS

Tuesday, July 26, 2011

O-TU-129

16:00 - 16:15

**INTERMITTENT PNEUMATIC COMPRESSION TO PREVENT VENOUS THROMBOEMBOLISM IN PATIENTS HOSPITALIZED IN INTENSIVE MEDICAL CARE UNITS WITH HIGH RISK OF BLEEDING: A RANDOMIZED TRIAL**

Karine Lacut\* (FR), Aurelien Delluc, Philippe Vignon, Pierre-Francois Dequin, D Benzekri-Lefevre, Anne Renault, Nicolas Paleiron, Audrey Imbert, D Chatellier, V Gissot, G Lheritier, V Aboynans, Luc Bressollette

O-TU-130

16:15 - 16:30

**A RANDOMIZED CONTROLLED TRIAL COMPARING ASPIRIN WITH DALTEPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM FOLLOWING TOTAL HIP ARTHROPLASTY**

David Robert Anderson\* (CA), Michael Dunbar, Pascal-Andre Venitolli, Susan Kahn, Etienne Belzile, Eric Bohm, William Fisher, Peter Gross, Paul Kim, Wade Gofton, Stephen MacDonald, Stephane Pelet, Mark Crowther, Susan Pleasance, Marc Rodger, Philip Wells, Michael Kovacs, Pantelis Andreou

O-TU-131

16:30 - 16:45

**THE IMPACT OF RENAL FUNCTION ON OPTIONS FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS FOLLOWING MAJOR ORTHOPEDIC SURGERY: INSIGHTS FROM A RANDOMIZED TRIAL**

Amir K Jaffer\* (US), Andrew Shorr, Bengt I Eriksson, Michael Kurz

O-TU-132

16:45 - 17:00

**INTERNATIONAL REGISTRY ON SPLANCHNIC VEIN THROMBOSIS: DESCRIPTION OF THE STUDY POPULATION**

Walter Ageno\* (IT), Sam Schulman, Nicoletta Riva, Soo-Mee Bang, Maria Teresa Sartori, Jan Beyer, Giovanni Barillari, Elvira Grandone, Alessandra Malato, Rita Santoro, Rita Duce, Ida Martinelli, Daniela Poli, Adriano Alatri, Peter Verhamme, Peter W Kamphuisen, Doyeun Oh, Cecilia Becattini, Eugenio Bucherini, Francesco Dentali, Study Investigators IRSVT

### VTE: Laboratory Tests I

Room B-1

Chairpersons: Alexander Gallus (AU) and Henry Watson



O-TU-133

15:30 - 15:45

**DIAGNOSTIC SAFETY OF A STRUCTURED ALGORITHM WITH USE OF CLINICAL DECISION RULE, D-DIMER AND CT SCAN FOR CLINICALLY SUSPECTED RECURRENT PULMONARY EMBOLISM**

Inge C.M. Mos\* (NL), Renee A. Douma, Petra M.G. Erkens, Tessa A.C. Nizet, Marc F. Durian, Marcel M.M. Hovens, Anja A. van Houten, Herman M.A. Hofstee, Judith Kooiman, Frederikus A. Klok, Hugo ten Cate, Erik F. Ullmann, Harry R. Buller, Pieter W. Kamphuisen, Menno V. Huisman

O-TU-134

15:45 - 16:00

**AGE-ADJUSTED D-DIMER CUT-OFF VALUE INCREASES THE NUMBER OF OLDER PATIENTS IN WHOM DEEP VEIN THROMBOSIS CAN BE SAFELY EXCLUDED**

Renee A Douma\* (NL), Nadine S Gibson, Roger E.G. Schutgens, Shannon M Bates, Arnaud Perrier, Cristina Legnani, Douwe H Biesma, Jeffrey S Ginsberg, Henri Bounameaux, Gualtiero Palareti, Marc Carrier, Gregoire le Gal, Pieter W Kamphuisen, Marc Righini

Tuesday Oral



25

## ORAL COMMUNICATIONS

Tuesday, July 26, 2011

O-TU-135

16:00 - 16:15

**DIAGNOSTIC ACCURACY OF UNENHANCED AND GADOLINIUM-ENHANCED MAGNETIC RESONANCE IMAGING FOR ACUTE PULMONARY EMBOLISM DIAGNOSIS: RESULTS OF THE "IRM-EP" STUDY**

Olivier Sanchez\* (FR), Marie-Pierre Revel, Sophie Couchon, Benjamin Planquette, Anne Hernigou, Ralph Niarra, Catherine Lefort, Gilles Chatellier, Guy Meyer

O-TU-136

16:15 - 16:30

**MAJOR ILLNESSES AND RISK OF VENOUS THROMBOSIS: RELATION WITH ESTABLISHED ACQUIRED CAUSES OF THROMBOSIS AND CHANGES IN THE COAGULATION SYSTEM**

Gurbey Ocaak\* (NL), Carla Y. Vossen, Marion Verduijn, Karlijn J. van Stralen, Friedo W. Dekker, Frits R. Rosendaal, Willem M. Lijfering

O-TU-137

16:30 - 16:45

**A PROGNOSTIC MODEL FOR SHORT TERM ADVERSE EVENTS IN NORMOTENSIVE PATIENTS WITH PULMONARY EMBOLISM**

Mariette Agterof (NL), Roger EG Schutgens\*, Nouredinne Moumli, Rene Eijkemans, Rene van der Griend, Ellen Tromp, Douwe Biesma

O-TU-138

16:45 - 17:00

**IN PATIENTS WITH INHERITED THROMBOPHILIA THE ABO GROUP AND VWF LEVELS CONTRIBUTE BOTH INDEPENDANTLY TO THE RISK OF VENOUS THROMBOSIS: A RETROSPECTIVE STUDY OF 1774 SUBJECTS**

William Cohen (FR), Christel Castelli, Sophie Bouvet, Dominique Brunet, Marie-Christine Barthelet, Marie-Francoise Aillaud, Marie-Christine Alessi, Geraldine Lavigne-Lissalde, Pierre Emmanuel Morange\*

### ADAMTS 13

Room B-2

Chairpersons: Jing-fei Dong (US) and Agnes Veyradie 

O-TU-139

15:30 - 15:45

**ADAMTS-13 BOUND TO GPIB CLEAVES A1A2A3 DOMAIN OF VWF**

Andrea Artoni\* (IT), Rossana Lombardi, Inmaculada Garcia-Oya, Luciano Baronciani, Flora Peyvandi

O-TU-140

15:45 - 16:00

**VWF PROTEOLYSIS BY ADAMTS13 IS DEPENDENT ON COOPERATION BETWEEN THE ADAMTS13 CYSTEINE-RICH DOMAIN LOOP Q456-Q478 AND THE SPACER DOMAIN.**

Rens de Groot\* (UK), Joon-Yeol Ryu, Matthew Jaring, Brenda Marianne Luken, David Anthony Lane, James Thomas Blick Crawley

O-TU-141

16:00 - 16:15

**C-TYPE LECTIN RECEPTORS PROMOTE THE UPTAKE OF ADAMTS13 BY DENDRITIC CELLS**

Nicoletta Sorvillo\* (NL), Wouter Pos, Rob Fijnheer, Eszter Herczenik, Jan Voorberg

O-TU-142

16:15 - 16:30

**ADAMTS13 CONTAINS TWO BINDING SITES FOR VWF THAT COORDINATE ENZYME-SUBSTRATE INTERACTION: AN ATOMIC FORCE MICROSCOPY STUDY**

Jiangguo Lin\* (US), Tao Wu, Miguel A. Cruz, Jing-fei Dong, Cheng Zhu





## ORAL COMMUNICATIONS

Tuesday, July 26, 2011

**O-TU-143**

**ADAMTS13 BINDS TO VON WILLEBRAND FACTOR MULTIMERS IN SOLUTION VIA THE EIGHTH THROMBOSPONDIN-1 REPEAT**

Hendrik B Feys\* (BE), Karen Deceunynck, Aline Vandembulcke, Elaine M Majerus, Lisa A Westfield, Hans Deckmyn, Evan Sadler, Karen Vanhoorelbeke

16:30 - 16:45

**O-TU-144**

**LOCAL STRETCHING OF VWF STRINGS IS A TRIGGER FOR ADAMTS13 MEDIATED PROTEOLYSIS**

Karen E De Ceunynck\* (BE), Susana Rocha, Hendrik B Feys, Simon F De Meyer, Hans Deckmyn, Hiroshi Uji-i, Johan Hofkens, Karen Vanhoorelbeke

16:45 - 17:00



Tuesday Ora



27

## POSTER PRESENTATIONS

Tuesday, July 26, 2011

### Signal transduction of platelet activation

- P-TU-001**    **TRANSLOCATION OF FIBRIN AND MYOSIN INTO PLATELET MEMBRANE RAFTS IS AN IMPORTANT PROCESS FOR CLOT RETRACTION VIA A FUNCTIONAL PROPERTY OF GPIIb/IIIa**  
Kohji Kasahara\* (JP), Mizuho Kaneda, Toshiaki Miki, Kazuko Iida, Hidenori Suzuki, Yuta Hara, Motoyuki Shimonaka, Morio Arai, Toshihide Kobayashi, Akitada Ichinose, Naomasa Yamamoto
- P-TU-002**    **EVIDENCE FOR A ROLE FOR THE OPEN CANALICULAR SYSTEM IN GENERATING PERICELLULAR CA<sup>2+</sup> SIGNALS IN HUMAN PLATELETS.**  
Alan George Scott Harper\* (UK), Nicholas Pugh, Richard W. Farndale, Stewart O. Sage
- P-TU-003**    **CALCIUM ACTS UPSTREAM OF MITOCHONDRIAL EVENTS TO REGULATE PLATELET PS EXPOSURE**  
Choo Hyojung\* (US), Talib Saafir, Mary Wagner, Shawn Jobe
- P-TU-004**    **QUANTITATIVE AND TIME RESOLVED HIGH-THROUGHPUT ANALYSIS OF ADP INDUCED TYROSINE PHOSPHORYLATION IN PLATELETS**  
Jorg Geiger\* (DE), Ulrich Walter, Hardy Schweigel, Peter Nollau, Rene Zahedi, Albert Sickmann
- P-TU-005**    **IN VITRO PHARMACOKINETICS OF DIETARY FLAVONOIDS ON PLATELET FUNCTION**  
Jonathan Gibbins\* (UK), Bernice Wright, Julie A Lovegrove
- P-TU-006**    **MOLECULAR MECHANISMS INVOLVED IN PLATELET ACTIVATION MEDIATED BY GALECTIN-1**  
Mirta Ana Schattner\* (AR), M A Romaniuk, M J Laponi, A Carestia, S Negrotto, R Benzadon, M V Tribulatti, G A Rabinovich
- P-TU-007**    **MTOR AND S6K1 DRIVE RAC1-MEDIATED PLATELET SPREADING AND PLATELET AGGREGATION**  
Joseph E Aslan\* (US), Garth W Tormoen, Cassandra P. Loren, Jiaqing Pang, Owen JT McCarty
- P-TU-008**    **ROLE OF THE CALDAG-GEFI/RAP1 SIGNALING MODULE IN ITAM-DEPENDENT PLATELET ACTIVATION**  
Lucia Stefanini\* (US), Yacine Boulaftali, Timothy D. Ouellette, Michael Holinstat, Laurent Desire, Bertrand Leblond, Patrick Andre, Pamela B. Conley, Wolfgang Bergmeier
- P-TU-009**    **INCREASED PLATELET ACTIVATION AND THROMBOSIS IN TRANSGENIC MICE OVEREXPRESSING CONSTITUTIVELY ACTIVE P2Y<sub>12</sub> RECEPTOR**  
Yan Zhang\* (CN), Jianqin Ye, Liang Hu, Zhichao Fan, Si Zhang, Yan Yan, Xunbin Wei, Satya P. Kunapuli, Zhongren Ding
- P-TU-010**    **THE ROLE OF 14-3-3ζ IN PLATELET GLYCOPROTEIN IBα-VON WILLEBRAND FACTOR INTERACTION-INDUCED SIGNALING**  
Kesheng Dai\* (CN), Zhang Weilin, Liu Jun, Zhao Lili, Du Juan, Sun Ruichen, Yan Rong, Ruan Changgeng

### Biology of platelets

- P-TU-011**    **PLATELET CYCLIC AMP REGULATION - MATHEMATICAL MODELING AND EXPERIMENTAL VERIFICATION**  
Jorg Geiger\* (DE), Gaby Wangorsch, Marcus Dittrich, Thomas Dandekar, Katharina Hubertus, Ulrich Walter



## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-012 GALECTINS DIFFERENTIALLY REGULATE THE RELEASE OF PLATELET-DERIVED ANGIOGENIC MOLECULES**  
Mirta Ana Schattner\* (AR), J Etulain, S Negrotto, M A Romaniuk, D O Croci, V Cattaneo, O Campetella, G A Rabinovich
- P-TU-013 REQUIREMENTS FOR MEMBRANE ATTACK COMPLEX FORMATION AND ANAPHYLATOXINS BINDING ON COLLAGEN-ACTIVATED PLATELETS**  
Arnaud Bonnefoy\* (CA), Catherine Martel, Sylvie Cointe, Pascal Maurice, Said Matar, Marta Ghitescu, Pierre Theroux
- P-TU-014 PYK2 DOWNSTREAM OF G<sub>12/13</sub> IS AN IMPORTANT FUNCTIONAL TYROSINE KINASE IN REGULATION OF PLATELET FUNCTIONAL RESPONSES**  
Soochong Kim\* (US), Jianguo Jin, Lina Cipolla, Gianni Guidetti, Mitsuhiro Okigaki, Mauro Torti, Satya P. Kunapuli
- P-TU-015 ROLE OF ENDOGENOUS GALECTIN-1 IN REGULATION OF THE HEMOSTATIC PROCESSES**  
Mirta Ana Schattner\* (AR), M A Romaniuk, M J Laponi, J Etulain, A Carestia, D O Croci, G A Rabinovich
- P-TU-016 CONTACT- AND AGONIST-REGULATED PLATELET MICROVESICULATION**  
Yanjun Zhang (CN), Xi Yang, Xiao Liu, Li Liu, Zhou Zhou, Jing-fei Dong\*, Jianning Zhang
- P-TU-017 PLATELETS PARTICIPATION IN HOST DEFENSE: THE ROLE OF PLATELET MEMBRANE RECEPTORS IN PLATELET INTERACTION WITH FOREIGN PARTICLES**  
Elena M Gupalo\* (RU), Cynthia Kuk, Mohammad Qadura, Liudmila I Buryachkovskaya, Maha Othman
- P-TU-018 SER559 OF GLYCOPROTEIN IB $\alpha$  IS PHOSPHORYLATED BY PROTEIN KINASE A WHICH REPRESENTS A MECHANISM FOR REGULATING VWF-GLYCOPROTEIN IB-IX INTERACTION**  
Kesheng Dai\* (CN), Zhang Weilin, Liu Guanglei, Yuan Yanhong, Zhao Lili, Yan Rong, Liao Yi, Ruan Changgeng
- P-TU-019 DIFFERENTIAL EFFECTS OF PLATELET-DERIVED MATRIX METALLOPROTEINASES ON THROMBUS FORMATION AND COLLAGEN MATRIX DEGRADATION**  
Judith M.E.M. Cosemans\* (NL), Marion A.H. Feijge, Romy M.W. Kremers, Paola E.J. van der Meijden, Jason L. Johnson, Johan W.M. Heemskerk
- P-TU-020 INCREASED CONCENTRATIONS OF PLATELET DERIVED MICROPARTICLES WITH A CIRCADIAN RHYTHM IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE**  
Christina Christersson\* (SE), Bertil Lindahl, Agneta Siegbahn

### Integrins and other glycoproteins

- P-TU-021 THROMBOXANE A<sub>2</sub> GENERATED BY INTERACTION OF PLATELETS WITH IMMOBILIZED FIBRINOGEN REGULATES EARLY PLATELET SPREADING AND LAMELLIPODIA FORMATION**  
Jianguo Jin\* (US), Madalina Tuluc, Satya P. Kunapuli
- P-TU-022 HYDROGEN SULPHIDE (H<sub>2</sub>S) INHIBITS HUMAN PLATELET ACTIVATION THROUGH AN INSIDE-OUT INTEGRIN  $\alpha$ IIb $\beta$ 3 SIGNALING PATHWAY.**  
Emilse Bermejo\* (AR), Daniel Alberto Saenz, Maria Fabiana Alberto, Maria Angela Lazzari, Ruth Estela Rosenstein

Tuesday Poster



29

## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-023 LENTIVIRAL GENE RESCUE OF GPIIb $\beta$  IN A BERNARD-SOULIER MOUSE MODEL TO EVALUATE ITS FUNCTION IN CIRCULATING PLATELETS.**  
Francois Lanza\* (FR), Catherine Strassel, Anne Bull, Sylvie Moog, Monique Freund, Anita Eckly, Anne Dubart-Kupperschmitt, Catherine Leon, Christian Gachet, Francois Lanza
- P-TU-024 A MACROMOLECULAR MACHINE CONTROLS INTEGRIN ACTIVATION**  
Yan-Qing Ma\* (US), Jun Yang, Kamila Bledzka, Dhanuja Perera, Jun Qin, Edward F Plow
- P-TU-025 DISSOCIATION BETWEEN CLOT RETRACTION AND FIBRIN BINDING BY ALPHAIIIBETA3: DEPENDENCE ON ACTIVE CONFORMATION OR PRESENCE OF FREE THIOLS**  
Ronit Mor-Cohen (IL), Nurit Rosenberg\*, Olga Romanenko, Uri Seligsohn, Judith Lahav
- P-TU-026 PLATELET RECEPTORS IN THROMBUS FORMATION ON SPOTTED MICROARRAY SURFACES**  
Susanne Maria de Witt\* (NL), Moniek M.E Lamers, Reyhan Nergiz, Frauke Swieringa, Erik Westein, Judith M.E.M Cosemans, Johan W.M Heemskerk
- P-TU-027 HYDROPHOBIC INTERACTIONS REGULATE INTEGRIN ALPHA 2 I DOMAIN**  
Samir W Hamaia\* (UK), D G Bihan, R Stone, S Farrow, V Bolanos-Garcia, R W Farndale
- P-TU-028 ROLE OF ILK-PINCH-PARVIN COMPLEX IN SUPPORTING FUNCTIONAL EXPRESSION OF INTEGRIN**  
Shigenori Honda\* (JP), Hiroko Shirohani-Ikejima, Yasuyuki Matsuda, Seiji Tadokoro, Yoshiaki Tomiyama, Toshiyuki Miyata
- P-TU-029 MUTATIONAL INHIBITION OF TALIN ROD BINDING TO INTEGRIN  $\beta$ 3 IDENTIFIES FOCAL ADHESIONS IN WHICH MUTANT  $\beta$ 3 IS LINKED TO THE ACTIN CYTOSKELETON VIA  $\alpha$ -ACTININ.**  
Nelly Kieffer\* (CN), Xiao Dong Xi, Yue Zhang, Yong Kui Kong, Ming Hui Lin
- P-TU-030 PLATELET AGGREGATION MEDIATED VIA EITHER  $\alpha$ IIb $\beta$ 3 OR GPIIb LEADS TO CYTOSKELETON ASSOCIATION OF BOTH OF THE RECEPTORS**  
Naphtali Savion\* (IL), Ivan Budnik, Boris Shenkman
- P-TU-031 REGULATION OF INTEGRIN CLOSURE IN PROCOAGULANT PLATELETS**  
Nadine J.A. Mattheij\* (NL), Karen Gilio, Roger van Kruchten, Marion A.H. Feijge, Edouard M. Bevers, Shawn M. Jobe, Judith M.E.M Cosemans, Johan W.M. Heemskerk

### Platelet receptors

- P-TU-032 CROSSTALK BETWEEN P2X1 AND P2Y1 RECEPTORS STIMULATES SYNERGISTIC CALCIUM RESPONSES AND PROMOTES ADP-MEDIATED PLATELET AGGREGATION.**  
Sarah Jones\* (UK), Christopher Moore, Michael Emerson, Catherine Leon, Christian Gachet, Richard Evans, Martyn Mahaut-Smith
- P-TU-033 *ESCHERICHIA COLI*-INDUCED PLATELET AGGREGATION**  
Dermot Cox\* (IE), Roisin Moriarty, Alysia Cox, Niamh Farrelly, Michael King, Stephen Smith
- P-TU-034 COOPERATIVE CALCIUM SIGNALING MEDIATED BY GLYCOPROTEINS (GP)IIb-IX-V, GPVI AND INTEGRIN  $\alpha$ <sub>2</sub> $\beta$ <sub>1</sub> DURING PLATELET ADHESION TO COLLAGEN UNDER FLOW**  
Maria Rita Cozzi\* (IT), Monica Battiston, Mario Mazzucato, Martine Jandrot-Perrus, Zaverio M. Ruggeri, Luigi De Marco
- P-TU-035 CLONING OF PLATELET GLYCOPROTEIN IB-IX OF RHESUS MONKEY (MACACA MULATTA) AND COMPARISON WITH HUMAN GLYCOPROTEIN IB-IX**  
Younan Chen\* (CN), Jianlin Qiao, Yang Shen, Yanrong Lu, Jingqiu Cheng



## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-036 PLATELET GLYCOPROTEIN VI ACTIVITY IN RHESUS MONKEY MODELS OF INSULIN-CONTROLLED OR UNCONTROLLED DIABETES MELLITUS**  
Lu Yanrong\* (CN), Yang Shen, Jane Arthur, Younan Chen, Elizabeth Gardiner, Robert Andrews, Jingqiu Cheng
- P-TU-037 TWO-SITE MECHANISM OF  $\alpha$ -THROMBIN BINDING TO PLATELET GLYCOPROTEIN IB $\alpha$**   
Alessandro Zarpellon\* (US), Antonella Zampolli, James Roberts, Richard McClintock, Grazia Loredana Mendolicchio, Zaverio Ruggeri
- P-TU-038 MODE OF ACTION OF P2Y12 ANTAGONISTS AS INHIBITORS OF PLATELET FUNCTION**  
Jacqueline Glenn\* (UK), David Espinosa Iyu, Ann E White, Susan C Fox, Hans van Giezen, Sven Nylander, Stan Heptinstall
- P-TU-039 MEASUREMENT OF HUMAN PLATELET GLYCOPROTEIN VI (GPVI) BY FLOW CYTOMETRY AND EFFECTS OF PATHOLOGICAL SHEAR ON GPVI LEVELS**  
Chee W Tan\* (AU), Marie-Christine Morel-Kopp, Mohammad Al-Tamimi, Jing Jing, Elizabeth Gardiner, Christopher Ward, Robert Andrews
- P-TU-040 LARGE-SCALE SCREENING FOR EXTRACELLULAR PROTEIN INTERACTIONS INVOLVED IN PLATELET AGGREGATION**  
Yi Sun\* (UK), Gavin Wright

### Megakaryocytes and thrombopoiesis

- P-TU-041 ALPHA-LINOLENIC ACID INCREASES PLATELET SURVIVAL BY REDUCING PLATELET ACTIVATION AND INHIBITS P38 AND ERK PHOSPHORYLATION**  
Simona Stivala\* (CH), Christine Lohmann, Eric Holy, Christian Matter, Thomas Luescher, Juerg Beer
- P-TU-042 TRANSIENT ACTIVATION OF C-MYC EXPRESSION IS CRITICAL FOR EFFICIENT PLATELET GENERATION FROM HUMAN INDUCED PLURIPOTENT STEM CELLS**  
Naoya Takayama\* (JP), Satoshi Nishimura, Sou Nakamura, Takafumi Shimizu, Ryoko Ohnishi, Hiroshi Endo, Tomoyuki Yamaguchi, Makoto Otsu, Ken Nishimura, Mahito Nakanishi, Akira Sawaguchi, Ryoza Nagai, Kazutoshi Takahashi, Shinya Yamanaka, Hiromitsu Nakauchi, Koji Eto
- P-TU-043 ANGIOGENIC GROWTH FACTOR 1 (AGGF1) IS EXPRESSED IN HUMAN BONE MARROW MEGAKARYOCYTES**  
Victoria S Hahn-Stromberg\* (SE), Alia Shamikh, Maria Astrom
- P-TU-044 DEFECTIVE MEGAKARYOCYTOPOIESIS AND PRO-PLATELET FORMATION IN A NOVEL GLANZMANN VARIANT MACROTHROMBOCYTOPENIA**  
Loredana Bury\* (IT), Alessandro Malara, Paolo Gresele, Alessandra Balduini
- P-TU-045 RHOA DEFICIENCY RESULTS IN MISLOCALIZATION OF MEGAKARYOCYTES AND REDUCED PLATELET PRODUCTION IN VIVO**  
Irina Pleines\* (DE), Ina Hagedorn, Jolanda van Hengel, Georg Krohne, Cord Brakebusch, Bernhard Nieswandt
- P-TU-046 MEGAKARYOCYTES POSSESS FUNCTIONAL APOPTOTIC PATHWAYS THAT MUST BE RESTRAINED IN ORDER TO SURVIVE AND PRODUCE PLATELETS**  
Emma Charlotte Josefsson\* (AU), Chloe James, Deborah Burnett, Marlyse A Debrincat, Katya J Henley, Rachael Lane, Kelly L Rogers, Mark R Dowling, Michael J White, Elizabeth A Kruse, Sarah Ellis, Cassandra J Vandenberg, Kylie D Mason, Lorraine A O'Reilly, Paquita Nurden, Donald Metcalf, Andrew W Roberts, Andreas Strasser, David CS Huang, Benjamin T Kile

Tuesday Poster



31

## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-047 EFFECTS OF WARFARIN AND VITAMIN K IN PS SYNTHESIS BY MEGAKARYOCYTE CULTURES**  
Claudia Maria Radu\* (IT), Cristiana Bulato, Sabrina Gavasso, Luca Spiezia, Paolo Simioni
- P-TU-048 QUININE-INDUCED THROMBOCYTOPENIA: DRUG-DEPENDENT ANTIBODIES INHIBIT MEGAKARYOCYTE AND PROPLATELET PRODUCTION**  
Jose S Perdomo\* (AU), Feng Yan, Zohra Ahmadi, Xing-Mai Jiang, Beng H Chong

### Rheology of platelets

- P-TU-049 ANTITHROMBOTIC PROPERTIES OF PRAVASTATIN REDUCING INTRA-THROMBUS FIBRIN DEPOSITION UNDER HIGH SHEAR BLOOD FLOW CONDITIONS**  
Mitsuhiko Sugimoto\* (JP), Masaaki Hamada, Hideto Matsui, Masaaki Doi, Yasunori Matsunari, Hidetada Fukushima, Kenji Nishio, Akira Yoshioka, Midori Shima
- P-TU-050 EFFECTS OF PATHOGEN REDUCTION TECHNOLOGY TREATMENT ON PLATELET FUNCTIONS**  
Chikahiro Terada\* (JP), Hitoshi Okazaki, Masahiro Satake, Kenji Tadokoro
- P-TU-051 MATRIX METALLOPROTEINASE (MMP)-2 ENHANCES PLATELET DEPOSITION UNDER FLOW CONDITIONS**  
Paolo Gresele\* (IT), Viviana Appolloni, Giuseppe Guglielmini, Emanuela Falcinelli, Philip De Groot, Luigi De Marco, Paolo Gresele
- P-TU-052 PATIENTS WITH SICKLE CELL DISEASE HAVE INCREASED PLASMA LEVELS OF TOTAL AND ACTIVE TGF- $\beta$ 1**  
Jasimuddin Ahamed\* (US), Patricia Shi, Andreas Mauer, Barry S Collier

### Experimental models

- P-TU-053 LC231306, A NOVEL ANTIPLATELET AGENT, INHIBITS ARTERIAL THROMBOSIS THROUGH SELECTIVE BLOCKADE OF PLATELET P2Y<sub>12</sub> RECEPTORS**  
Hee Dong Park\* (KR), Jung Gyu Park, Tae Hun Kim, Ahn Young Ha
- P-TU-054 COMPARISON OF PLATELET AGGREGATION DURING HIBERNATION AND NON-HIBERNATION IN SCANDINAVIAN BROWN BEARS (URSUS ARCTOS)**  
Karin A H Arinell (SE), Kjeld Christensen\*, Johan Josefsson, Jon M Arnemo, Alina Evans, Ole Frobert
- P-TU-055 PROGRESSION OF DIABETES AND ALTERED HAEMOSTATIC VARIABLES IN A NEW TYPE 2 DIABETIC RAT MODEL**  
Fumitoshi Asai\* (JP), Norihiko Hirai, Noriyuki Kaji, Mitsuyuki Shirai, Ito Katsuaki
- P-TU-056 EFFECT OF HEPARIN: PMX60056 COMPLEXES ON PLATELET AGGREGATION INDUCED BY ADP OF HIT ANTIBODY**  
Walter Jeske\* (US), Eric McAllister, Jeanine Walenga, Michelle Paulus, Jawed Fareed
- P-TU-057 EFFICACY OF CILOSTAZOL FOR PREVENTING THE OCCURRENCES OF CEREBRAL INFARCTION DUE TO THE DISTURBANCE OF CEREBRAL VENOUS CIRCULATION IN RAT TWO-VEIN OCCLUSION (2VO) MODEL**  
Daisuke Wajima\* (JP), Ichiro Nakagawa, Yasuhiro Takeshima, Hiroyuki Nakase
- P-TU-058 THE DIRECT FACTOR XA INHIBITOR RIVAROXABAN REDUCES PLATELET ACTIVATION IN CONGESTIVE HEART FAILURE BY ATTENUATING SECONDARY ADP-MEDIATED AGGREGATION**  
Andreas Schaefer\* (DE), Ulrike Flierl, Jan Micka, Daniela Fraccarollo, Johann Bauersachs



## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-059 DETECTION OF THROMBOEMBOLISM WITH <sup>99m</sup>Tc-LABELED F(AB)<sub>2</sub> FRAGMENT OF ANTI-GPIIIa CHIMERIC MONOCLONAL ANTIBODY IN DOGS**  
Shundong Ji\* (CN), Wei Fang, Ningzheng Dong, Zuoxiang He, Changgeng Ruan
- P-TU-060 PRODUCTION AND APPLICATION OF MONOCLONAL ANTIBODY TO THROMBIN-ACTIVATED PLATELETS**  
Sawitree Chiampanichayakul\* (TH), Nungruthai Nimnuch, Patsara Lekawipat
- P-TU-061 PHOSPHOLIPASE A2 AND PLATELET AGGREGATION INHIBITOR FROM AGKISTRODON BLOMHOFFI USURIENSIS VENOM**  
Nataliia Burlova-Vasilieva\* (UA), Olexiy Savchuk, Ludmila Ostapchenko
- P-TU-062 DEVELOPMENT OF PLATELET CELL SIMULATOR IMPLEMENTING THE FUNCTION OF RELEASE REACTION**  
Yohei Nanazawa\* (JP), Noriko Tamura, Shinya Goto, Yasuhiro Sunaga, Takashi Koyama, Hideo Yokota
- P-TU-063 THROMBOCYTOPENIA IMPAIRS HOST DEFENSE AND SURVIVAL DURING MURINE *STREPTOCOCCUS PNEUMONIAE* PNEUMONIA**  
Floor E. van den Boogaard\* (NL), Marcel Schouten, Cornelis van 't Veer, Tom van der Poll
- P-TU-064 DEVELOPMENT OF A MOUSE MODEL TO STUDY HUMAN PLATELET FUNCTION *IN VIVO*.**  
Lisa-Marie Holbrook\* (UK), Christopher Moore, Michael Emerson
- P-TU-065 THE COMPLEX RELATION OF THROMBUS GROWTH TO WALL SHEAR RATES UP TO 100,000 1/S**  
David N KU\* (US), David L. Bark, Andrea Para

### ITP

- P-TU-066 RISKS OF POSTOPERATIVE MORTALITY AND COMPLICATIONS AMONG SURGICAL PATIENTS WITH PURPURA: A POPULATION-BASED STUDY**  
Chien-Chang Liao\* (TW), Ta-Liang Chen
- P-TU-067 CTLA-4-IG CORRECTS ABNORMAL INDOLEAMINE 2,3-DIOXYGENASE-MEDIATED TRYPTOPHAN CATABOLISM IN DENDRITIC CELLS FROM IMMUNE THROMBOCYTOPENIA**  
yan shi\* (CN), chunyan wang, xiaojuan zhu, xiaoyuan dong, jun peng, heyu ni, ming hou
- P-TU-068 DEXAMETHASONE VS STANDARD PREDNISONE IN PATIENTS WITH CHRONIC ITP: RESULTS AND PREFERENCES**  
Maria E Mingot\* (ES), Dana Diaz-Canales, Laura Gonzalez-Diaz, Anabel Heiniger-Mazo
- P-TU-069 CD72 GENE EXPRESSION IN IMMUNE THROMBOCYTOPENIA**  
Hu ZHOU\* (CN), Aiping QI, Huiyuan LI, Li MA, Jianhui XU, Feng XUE, Shihong LU, Qinjun ZHAO, Zeping ZHOU, Renchi YANG
- P-TU-070 SPLENECTOMY, RITUXIMAB AND ROMIPLOSTIM IN CHRONIC ITP: EFFICACY AND SAFETY PROFILE.**  
Maria E Mingot\* (ES), Dana Diaz-Canales, Maria Rosario Prieto-Bonilla, Alejandro Contento, Alicia Bailen-Garcia, Anabel Heiniger-Mazo

Tuesday Poster



33

## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-071 IDENTIFICATION OF EPITOPES AND CRITICAL RESIDUES FOR BINDING OF PLATELET-ASSOCIATED ANTI-GPIIB/IIIa AUTOANTIBODIES IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA**  
Kazunobu Kiyomizu\* (JP), Hirokazu Kashiwagi, Tsuyoshi Nakazawa, Tsuyoshi Kamae, Seiji Tadokoro, Shigenori Honda, Yuzuru Kanakura, Yoshiaki Tomiyama
- P-TU-072 PERCENTAGE OF CD56+ LYMPHOCYTES THAT PREDICTS THE RESPONSE TO STEROID TREATMENT IN PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIA PURPURA**  
YI-FENG WU\* (TW), Tso-Fu Wang, Sung-Chao Chu, Kuan-Po Huang, Michael R. Loken, Ruey-Ho Kao
- P-TU-073 LOW-DOSE RITUXIMAB TREATMENT IN CHINESE PATIENTS WITH IMMUNE THROMBOCYTOPENIA**  
Hong-mei Wang\* (CN), Tao Sui, Yanhui Yang, Zeping Zhou, Xiaofan Liu, Yongze Liu, Lei Zhang, Renchi Yang
- P-TU-074 CONTRIBUTIONS OF TRAIL MEDIATED MEGAKARYOCYTE APOPTOSIS TO IMPAIRED MEGAKARYOCYTE AND PLATELET PRODUCTION IN IMMUNE THROMBOCYTOPENIA**  
Lei Yang\* (CN), Lin Wang, Chunhong Zhao, Xiaojuan Zhu, Yu Hou, Jun Peng, Ming Hou

### HIT

- P-TU-075 ORDERING OF HEPARIN-PF4 ANTIBODY TESTS AND TREATMENT OF HEPARIN INDUCED THROMBOCYTOPENIA IN THE INTENSIVE CARE UNIT**  
Matthew A Wanat\* (US), Kalliopi Fitousis, Jeffrey Hall, Lawrence Rice
- P-TU-076 PROFILING OF HEPARIN-INDUCED THROMBOCYTOPENIA ANTIBODY TITER IN PATIENTS WITH AND WITHOUT DIABETES**  
M. Margaret Prechel\* (US), Josefina L. Diaz, Mary Ann Emanuele, Nicholas V. Emanuele, Jeanine M. Walenga
- P-TU-077 PREVALENCE OF ANTI-HEPARIN PLATELET FACTOR 4 ANTIBODIES IN PATIENTS WITH DISSEMINATED INTRAVASCULAR COAGULATION**  
Jawed Fareed\* (US), Josephine Cunanan, Walter Jeske, Debra Hoppensteadt, Harry Messmore
- P-TU-078 PREVALENCE OF HIT ANTIBODIES IN HIP FRACTURE PATIENTS UNDERGOING ORTHOPAEDIC SURGERY AND THEIR RELEVANCE TO SERUM AMYLOID A**  
Jawed Fareed\* (US), Justin Griffin, Evangelos Litinas, Indermohan Thethi, Debra Hoppensteadt, Michael Lassen, William Hopkinson, Rakesh Wahi
- P-TU-079 PLATELET WASHING BY BSA-SEPHAROSE GEL FILTRATION IS A PRACTICAL METHOD TO ISOLATE PLATELETS FOR THE SEROTONIN RELEASE ASSAY**  
Nana Kwasi Sono-Koree\* (US), Ronda A Crist, George M Rodgers, Kristi J Smock
- P-TU-080 HIGH-PRESSURE LIQUID CHROMATOGRAPHY IS A ROBUST METHOD FOR PERFORMING THE SEROTONIN RELEASE ASSAY AND CORRELATES WELL WITH THE RADIOACTIVITY METHOD**  
Nana Kwasi Sono-Koree\* (US), Ronda A Crist, Elizabeth A Frank, George M Rodgers, Kristi J Smock
- P-TU-081 DIFFERENTIAL IMMUNOGENIC RESPONSE OF BRANDED AND GENERIC VERSIONS OF LMWH**  
Eduardo Ramacciotti\* (US), Marise Gomes, Jeanine Walenga, Debra Hoppensteadt, Gundu Rao, Helena Nader, Walter Jeske, Jawed Fareed





## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-082 PERIOPERATIVE VENOUS THROMBOEMBOLISM PROPHYLAXIS IN PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT): THE DESIRUDIN EXPERIENCE**  
Jerrold H Levy\* (US), Michael A Kurz, Andreas Koster
- P-TU-083 VALIDATION OF MONOSPECIFIC ELISA TEST AS A SCREENING TEST FOR HEPARIN INDUCED THROMBOCYTOPENIA COMPARE TO OTHER IMMUNOLOGICAL AND FUNCTIONAL ASSAYS**  
Tarek Owaidah\* (SA), Rasheed Nasr, Tarek Owaidah
- P-TU-084 THE FREQUENCY OF RENAL IMPAIRMENT IN PATIENTS SUSPECTED OF HEPARIN INDUCED THROMBOCYTOPENIA SYNDROME (HIT)**  
Philip Young-III Choi\* (AU), Beng Hock Chong, Max Fu, Rosalie Gemmell
- P-TU-085 ARTERIAL THROMBOEMBOLECTOMY AND INTRAOPERATIVE ANTICOAGULATION IN THE SETTING OF HEPARIN-INDUCED THROMBOCYTOPENIA (HIT).**  
Theodore Earl Warkentin\* (CA), Menaka Pai
- P-TU-086 RISKS OF IVC FILTERS IN THE SETTING OF HEPARIN-INDUCED THROMBOCYTOPENIA**  
Moonjung Jung (US), John J McCarthy, Kelty R Baker, Lawrence Rice\*

### Antiplatelet therapy

- P-TU-087 ASPIRIN AM OR PM? : A RANDOMIZED CROSS-OVER TRIAL**  
Tobias Bonten\* (NL), JD Snoep, WJ Assendelft, V van der Meer, JJ Zwaginga, FR Rosendaal, HCJ Eikenboom, JG van der Borm
- P-TU-088 ACETYLSALICYLIC ACID THERAPY: INFLUENCE OF METFORMIN USE ON URINARY 11-DEHYDRO THROMBOXANE B2 LEVELS.**  
Maria das Gracas Carvalho\* (BR), Lillian Harboe Goncalves, Luci Maria Sant'Ana Dusse, Ana Paula Fernandes, Karina Braga Gomes, Marcos Vinicius Ferreira Silva, Geralda de Fatima Guerra Lages, Flavia Komatsuzaki, Marinez Oliveira Sousa, Adriana Aparecida Bosco
- P-TU-089 HEAD-TO-HEAD COMPARISON OF CLOPIDOGREL EFFICACY IN STENTED PATIENTS WITH DIABETES MELLITUS, METABOLIC SYNDROME, OR NONE**  
Nadine Aizenberg\* (FR), Florence Tubach, Gregory Ducrocq, Helene Abergel, Marina Esposito Farese, Marie-Genevieve Huisse, Gabriel Philippe Steg, Laurent Feldman
- P-TU-090 IN VITRO THIENOPYRIDINES' EFFECTS ON PLATELET PROCOAGULANT ACTIVITY:RFVIIA ALONE OR WITH ADP OFFSETS THROMBIN GENERATION INHIBITION MEDIATED BY PRASUGREL'S ACTIVE METABOLITE**  
Jerrold H Levy\* (US), Fania Szlam, Heezoo Kim, Satoru Ogawa, Joseph A Jakubowski, Atsuhiko Sugidachi, Kenichi A Tanaka
- P-TU-091 CONSISTENT AND POTENT PLATELET INHIBITION OF PRASUGREL IRRESPECTIVE OF CYP2C19 POLYMORPHISM IN JAPANESE PATIENTS WITH CORONARY ARTERY DISEASE**  
Masakatsu Nishikawa\* (JP), Takaaki Isshiki, Hisao Ogawa, Takeshi Kimura, Hiroyoshi Yokoi, Shinsuke Nanto, Morimasa Takayama, Kazuo Kitagawa, Shunichi Miyazaki, Hideki Origasa, Kazuhiro Sase, Kazuo Umemura, Yasuo Ikeda, Tetsu Yamaguchi
- P-TU-092 DIFFERENTIAL PREVALENCE AND PHARMACODYNAMIC IMPACT OF CYP2C19 POLYMORPHISMS IN 3 MAJOR ASIAN ETHNICITIES**  
Mark Y Chan\* (SG), Karen Tan, Qian Hui Phua, Huay Cheem Tan, Arthur Mark Richards, Pei Tee Huan, Evelyn Koay

Tuesday Poster



35

## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-093 PREVALENCE AND RISK FACTORS FOR ASPIRIN RESISTANCE IN PATIENTS WITH POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA**  
Yingyong Chinthammitr\* (TH), Jane Jianthanakanon, Yupa Nakkinkun, Bundarika Suwanawiboon, Theera Ruchutrakool
- P-TU-094 DUAL ANTIPLATELET THERAPY FOR TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) - IS IT A RIGHT CHOICE?**  
Janina M Stepinska\* (PL), Katarzyna Czerwinska, Adam Witkowski, Maciej Dabrowski, Marek Banaszewski, Piotr Michalek, Zbigniew Chmielak, Krzysztof Kusmierski, Tomasz Hryniewiecki, Marcin Demkow
- P-TU-095 PRACTICAL USE AND LIMITATIONS OF ADP AGGREGATION TESTING TO PREDICT CARDIOVASCULAR EVENTS: DESIGN AND PRELIMINARY RESULTS OF A META-ANALYSIS ON INDIVIDUAL PATIENTS DATA**  
Jean-Luc Reny\* (CH), Pierre Fontana, Pascale Fabbro-Peray, Silvy Laporte, Joshem Wouter van Werkum, JM Ten Berg, Tobias Geisler, M Gawas, Paul A Gurbel, Marie-Christine Alessi, Thomas Cuisset, Gerald Yong, Dominick Angiolillo, Gianluca Campo, Christophe Combescure
- P-TU-096 DYNAMIC RESPONSE TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROME, CLINICAL AND PROGNOSTIC IMPLICATIONS**  
Galia Spectre\* (IL), Morris Mosseri, Nader M. Abdelrahman, Elinor Briskin, Atilla Bulut, Sasa Loncar, David Varon, Ronny Alcalai
- P-TU-097 ASPIRIN RESISTANCE IN NEUROVASCULAR DISEASES**  
Martin Valis\* (CZ), Dagmar Krajickova, Jaroslav Maly, Radovan Maly, Ilona Fatorova, Lenka Strmiskova, Pavel Semerak
- P-TU-098 DISTINCTIVE ASPIRIN EFFECT ON THE ARACHIDONIC ACID PATHWAY, OXIDATIVE STRESS, NITRIC OXIDE METABOLITES AND P-SELECTIN IN DIABETES MELLITUS**  
Luis R Lopez\* (US), Ivana Muncy, Eiji Matsuura, Joana Batuca, Kirk Guyer, Ignacio Garcia De La Torre, Paul RJ Ames
- P-TU-099 THE ACTIVE METABOLITE OF PRASUGREL AUGMENTS GPIIB-IIIa ANTAGONIST INHIBITION OF PLATELET ACTIVATION AND AGGREGATION: COMPLEMENTARY ROLES FOR INHIBITION OF P2Y<sub>12</sub> AND GPIIB-IIIa**  
Andrew L Frelinger\* (US), Joseph A Jakubowski, Atsuhiko Sugidachi, Marc R Barnard, Alan D Michelson
- P-TU-100 ONE DAILY ASPIRIN IS ENOUGH TO SUPPRESS PLATELET SECRETION WITHOUT INDUCING A COMPLETE INHIBITION OF AGGREGATION IN PATIENTS WITH CARDIOVASCULAR RISK.**  
Alejandro Berkovits\* (CL), Monica Acevedo, Olga Panes, Carolina Valenzuela, Carlos Barria, Marcelo Carrasco, Diego Mezzano

### Inherited and acquired platelet disorders

- P-TU-101 TREATMENT OPTIONS FOR GLANZMANN'S THROMBASTHENIA IN PAKISTAN.**  
Munira Borhany\* (PK), Tahir Shamsi, Zain Pahore, Arshi Naz, Tasneem Farzana, Saqib Ansari, Muhammad Nadeem
- P-TU-102 RECOMBINANT FACTOR VIIa (RFVIIa) USE IN GLANZMANN'S THROMBASTHENIA (GT) AND OTHER PLATELET DISORDERS (OPDS): HEMOPHILIA AND THROMBOSIS RESEARCH SOCIETY (HTRS) REGISTRY DATA**  
Meera Chitlur\* (US), Nadia Ewing, Eric H. Kraut, David L. Cooper



## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-103 IMPAIRED PLATELET AGGREGATION TO ADP IN A NORMAL P2Y1 AND P2Y12 RECEPTORS**  
Eusni R M Tohit\* (MY)
- P-TU-104 ACQUIRED BERNARD-SOULIER SYNDROME/GLANZMANN'S THROMBASTHENIA CAUSED BY AUTOANTIBODIES AGAINST GPIB AND GPIIB/IIIA**  
Naomasa Yamamoto\* (JP), Toshihiro Ito, Naoki Akiu, Takaji Wakita
- P-TU-105 ROLE OF FLOWCYTOMETRIC ANALYSIS OF CD 41 IN GLANZMANN'S THROMBASTHENIA**  
Shanthala Devi Aladahalli Mallappa\* (IN), Vanamala Anand Alwar, Parimala Puttaiah, Sitalakshmi Subramanian, Karuna Rameshkumar
- P-TU-106 PREVALENCE OF PLATELET AGGREGATION DEFECTS IN WOMEN WITH AND WITHOUT MENORRHAGIA**  
H. Marieke Knol\* (NL), Andre B Mulder, Hanneke C Kluin-Nelemans, Ate van der Zee, Dick B Bogchelman, Meijer Karina
- P-TU-107 ABNORMAL PLATELET FUNCTIONS IN TWO PATIENTS WITH FILAMIN A MUTATIONS**  
Jean-Philippe Raymond Rosa\* (FR), Marijke Bryckaert, Eliane Berrou, Frederic Adam, Marilyne Lebret, Alexandre Kauskot, Martine Jandrot-Perrus, Jean-Philippe Rosa, Cyril Goizet, Alan T Nurden, Paquita Nurden
- P-TU-108 A NOVEL HOMOZYOUS MISSENSE MUTATION IN THE P2RY12 GENE RESULTS IN DEFECTIVE ADP-MEDIATED PLATELET ACTIVATION IN A PATIENT SUFFERING FROM A CHRONIC BLEEDING DISORDER.**  
Aine N McCormick\* (UK), Y M Patel, A N McCormick, M Mitchell, J Maloney, S K Austin
- P-TU-109 AQUAGLYCEROPORIN 7 IS INVOLVED IN PLATELET DENSE GRANULE SECRETION: A STUDY IN PATIENTS WITH HYPERGLYCEROLURIA HOMOZYOUS FOR G264V**  
Christophe V Goubau\* (BE), Jaak Jaeken, Elena Levtchenko, Chantal Thys, Michela Di Michele, Geert Martens, Erik Gerlo, Christel Van Geet, Kathleen Freson
- P-TU-110 IDENTIFICATION OF 25 NOVEL MUTATIONS IN 25 PATIENTS WITH GLANZMANN'S THROMBASTHENIA**  
Ziqiang Yu\* (CN), Qingya Cui, Jian Su, Xiaojuan Zhao, Yunwen Bu, Xia Bai, Changgeng Ruan

### Laboratory tests

- P-TU-111 PLATELET GENE POLYMORPHISMS RELATED TO ACUTE MYOCARDIAL INFARCTION IN YOUNG PATIENTS**  
Jana Ulehlova\* (CZ), Ludek Slavik, Vera Krcova, Jan Galuszka, Jan Vaclavik
- P-TU-112 VALIDATION OF A NOVEL ELISA-BASED VASP ASSAY FOR MONITORING ACTIVITY OF P2Y12 ANTAGONISTS IN WHOLE BLOOD**  
Tomoko Motomura\* (JP), Naoyuki Tajima, Fumie Maruyama, Atsuhiko Sugidachi
- P-TU-113 LACK OF CLINICAL PREDICTIVENESS OF SIX MAJOR PLATELET FUNCTION TESTS USED TO ASSESS ASPIRIN RESPONSE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE**  
Marie Lordkipanidze\* (UK), Jean G. Diodati, Erick Schampaert, Donald A. Palisaitis, Chantal Pharand
- P-TU-114 IMPACT OF NOCTURIA ON PLATELET AGGREGABILITY IN ELDERLY PATIENTS WITHOUT CARDIOVASCULAR DISEASE**  
Shoko Uematsu\* (JP), Tomohiro Kurihara, Kenichi Mitani, Yoshio Kimura, Satoshi Murasaki, Haruhisa Noda

Tuesday Poster



37

## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-115 PLATELET FUNCTION IN PATIENTS WITH A LEFT VENTRICULAR ASSIST DEVICE**  
Michael Ashbrook\* (US), Jeffrey Schwatz, Alain Heroux, Vicki Escalante, Walter Jeske, Jeanine Walenga, Mamdouh Bakhos
- P-TU-116 IS POSTPRANDIAL PLATELET ACTIVATION RELATED TO INSULIN RATHER THAN GLUCOSE LEVELS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS?**  
Galia Spectre\* (SE), Claes-Goran Ostenson, Nailin Li, Maud Daleskog, Ragnhild Stalesen, Paul Hjemdahl
- P-TU-117 CENTRIFUGATION SPEED AFFECTS LIGHT TRANSMISSION AGGREGOMETRY RESULTS.**  
Michael A Nardi\* (US), Michael Merolla, Jeffrey S Berger
- P-TU-118 EFFECT OF LOW DOSE OMEGA-3 (N-3) ON PLATELET FUNCTION**  
Brad McEwen\* (AU), Marie-Christine Morel-Kopp, Walter Chen, Geoffrey H Tofler, Christopher M Ward
- P-TU-119 THE POTENTIAL VALUE OF IMPEDANCE AGGREGOMETRY, PLATELET FUNCTION ANALYSER AND BLEEDING TIME TO ASSESS THE BLEEDING RISK IN RENAL BIOPSY**  
Paul Verhezen\* (NL), K Hamulyak, M Mullens, M Christiaans, Y Henskens
- P-TU-120 NO EVIDENCE OF PLATELET ACTIVATION IN PATIENTS WITH ATRIAL FIBRILLATION WHO ARE TREATED WITH DABIGATRAN: A SUBSTUDY OF THE RELY TRIAL**  
John Eikelboom\* (CA), J Oldgren, P Reilly, S Yusuf, L Wallentin, M Ezekowitz, S J Connolly
- P-TU-121 THROMBOELASTOGRAPHY (TEG) : A MARKER OF PLATELET HYPERCOAGULABILITY IN TE PATIENTS WITHOUT CYTOREDUCTIVE THERAPY**  
Claudine Caron\* (FR), Mathieu Wemeau, Anne Bauters, Emmanuelle Jeanpierre, Antoine Tournays, Christophe Zawadzki, Nathalie Trillot, Brigitte Jude, Nathalie Cambier

### Extrinsic pathway of coagulation

- P-TU-122 THE IMPACT OF FLOW ON THE PRESENTATIONS OF FACTOR XA AND THROMBIN**  
Laura M Haynes\* (US), Yves C Dubief, Kenneth G Mann
- P-TU-123 CHARACTERIZATION OF TUMOR-DERIVED CIRCULATING TISSUE FACTOR IN AN ORTHOTOPIC MODEL OF HUMAN PANCREATIC CANCER**  
Monica Davila\* (US), Evgeny Ozhegov, Liza Robles, John Francis, Vladimir Y Bogdanov, Ali Amirkhosravi
- P-TU-124 TFPI ANTAGONIST APTAMER BAX499 IS A PROCOAGULANT IN VITRO AND IN VIVO**  
Kathleen McGinness\* (US), Emily K. Waters, Ryan M. Genga, Michael C. Schwartz, Jennifer A. Nelson, Robert G. Schaub, Karen A. Olson, Jeffrey C Kurz
- P-TU-125 THE PROCOAGULANT ACTIVITY OF BAX513 CORRELATES WITH THE PLASMA LEVEL OF FULL-LENGTH TISSUE FACTOR PATHWAY INHIBITOR (TFPI)**  
Michael Dockal\* (AT), S. Knappe, M. Palige, K. Panholzer-Riedrich, A. Kolm, R. Hartmann, M. Gorczyca, B. Jilma, F Scheifflinger
- P-TU-126 FACTOR VII DEFICIENCY: EVIDENCE THAT IN MINOR SURGERY ONE-DAY REPLACEMENT THERAPY IS SUFFICIENT**  
Guglielmo Mariani\* (IT), Alberto Dolce, Jorgen Ingerslev, Angelika Batorova, Mariasanta Napolitano, Jean Francois Schved, Giovanni Di Minno, Gunter Auerswald, Muriel Giansilly-Blazot, Aronis Sofia, Sergio Siragusa, Arlet Ruiz de Saez, Annarita Tagliaferri



## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-127 FUCOIDAN EFFICIENTLY IMPROVES THROMBOELASTOGRAPHIC COAGULATION PARAMETERS IN AN EX VIVO MODEL OF HEMOPHILIC GUINEA PIGS**  
Michael Dockal\* (AT), W. Hoellriegl, S. Knappe, K. Michalkova, D. E. Verdino, A. Schviz, M. Resch, H. Ehrlich, E. M. Muchitsch, H. P. Schwarz, F. Scheifflinger
- P-TU-128 INHIBITION OF CELL-ASSOCIATED TISSUE FACTOR PATHWAY INHIBITOR (TFPI) INCREASES FACTOR VIIA-TF DEPENDENT FACTOR X ACTIVATION**  
Michael Dockal\* (AT), R. Pachlinger, A. Baldin-Stoyanova, F. Knofl, R. Hartmann, A. Backovic, H. Ehrlich, F. Scheifflinger
- P-TU-129 IMPROVEMENT OF HEMOSTASIS IN HEMOPHILIA BY PEPTIDES INHIBITING TISSUE FACTOR PATHWAY INHIBITOR**  
Michael Dockal\* (AT), R. Hartmann, T. Polakowski, F. Osterkamp, W. Kammlander, E. Panholzer, A. Kolm, C. Redl, H. Ehrlich, F. Scheifflinger
- P-TU-130 HIGH PLASMA LEVELS OF ENDOGENOUS TISSUE FACTOR PATHWAY INHIBITOR STRONGLY CORRELATE WITH POOR BLOOD CLOTTING WHEN FACTOR VIII IS INHIBITED**  
Michael Dockal\* (AT), M. Gorczyca, K. Panholzer-Riedrich, S. Knappe, M. Palige, H. Ehrlich, F. Scheifflinger, B. Jilma
- P-TU-131 IDENTIFICATION OF A FACTOR VA HEAVY CHAIN BINDING SITE IN THE FRAGMENT 2 DOMAIN OF PROTHROMBIN**  
Joanne E. Berridge\* (CA), Nicole Brufatto, Feng Ni, Michael Nesheim
- P-TU-132 CHARACTERIZATION OF AN APTAMER INHIBITOR OF TFPI: A NOVEL THERAPEUTIC STRATEGY IN HEMOPHILIA**  
Nigel S Key\* (US), Jen-Yea Chang, Pichika Chantrathammachart, Kathleen McGinness, James C Gilbert, Robert G Schaub, Dougal M Monroe
- P-TU-133 PURIFICATION, STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF A NOVEL ANTICOAGULANT THREE-FINGER TOXIN FROM THE VENOM OF NAJA SIAMENSIS (INDOCHINESE BLACK SPITTING COBRA)**  
Mohamed AS Nazir\* (SG), R Manjunatha Kini
- P-TU-134 A NOVEL EXTRINSIC TENASE COMPLEX INHIBITOR FROM THE VENOM OF HEMACHATUS HAEMACHATUS (AFRICAN RINGHALS COBRA)**  
Girish Vallerinteavide Mavelli\* (SG), R Manjunatha Kini
- P-TU-135 HAEMOSTASIS AND ANGIOGENESIS IN PLACENTAE FROM THROMBOPHILIC WOMEN WITH PREVIOUS ADVERSE OUTCOMES TREATED WITH LOW MOLECULAR WEIGHT HEPARIN (LMWH).**  
Elvira Grandone\* (IT), Elena Chinni, Donatella Colaizzo, Giovanni Luca Tiscia, Patrizia Vergura, Giovanni Favuzzi, Michela Sarno, Giovanna D'andrea, Maurizio Margaglione
- P-TU-136 ALTERATIONS IN COAGULATION AND FIBRINOLYSIS AFTER LEVOTHYROXINE EXPOSURE IN HEALTHY VOLUNTEERS: A CONTROLLED RANDOMIZED CROSSOVER STUDY**  
Bregje van Zaane\* (NL), Alessandro Squizzato, Jan Debeij, Dekkers M Olaf, Joost CM Meijers, Anton P van Zanten, Harry R Buller, Victor EA Gerdes, Suzanne C Cannegieter, Dees PM Brandjes
- P-TU-137 BLOCKING OF TISSUE FACTOR PATHWAY INHIBITOR (TFPI) WITH MAB 2021 PROMOTES THROMBIN GENERATION IN FVIII DEFICIENT PLASMA**  
Lars Christian Petersen\* (DK), Ida Hilden, Soeren E. Bjoern, Brit B. Soerensen

Tuesday Poster



39

## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-138 MODERATE PLASMA DILUTION BY ARTIFICIAL PLASMA SUBSTITUTING SOLUTIONS INTENSIFIES COAGULATION IN VITRO**  
Elena I Sinauridze\* (RU), Alexander S Gorbatenko
- P-TU-139 PRETHROMBIN-1, THE GLA-DOMAINLESS PROTHROMBIN INTERMEDIATE, IS ACTIVATED EFFICIENTLY TO THROMBIN BY PROTHROMBINASE ASSEMBLED ON THE ACTIVATED PLATELET SURFACE.**  
Paula B Tracy\* (US), Francis Ayombil, Jay R Silveira, Jeremy P Wood

### Intrinsic pathway of coagulation

- P-TU-140 GENETIC DIAGNOSIS OF A PEDIGREE WITH INHERITED COAGULATION FACTOR V DEFICIENCY**  
Zhou Rong-Fu\* (CN), Jian Ouyang, Lu Chen, Xiao-yan Shao, Jing-Yan Xu
- P-TU-141 PARTIAL VERSUS COMPLETE FACTOR VIII INHIBITION IN A MOUSE MODEL OF VENOUS THROMBOSIS**  
Jan Emmerechts\* (BE), Thomas Vanassche, Serena Loyen, Ingrid Van Linthout, Alexandre Kauskot, Clive Long, Marc Jacquemin, Marc Hoylaerts, Peter Verhamme
- P-TU-142 DEVELOPMENT AND COMPARISON OF THE GAIN-OF-FUNCTION FACTOR IX VARIANTS.**  
Shu-Jhu Yang\* (TW), Chung-Yang Kao, Chia-Ni Lin, I-Shing Yu, Mi-Hua Tao, Hua-Lin Wu, Guey-Yueh Shi, Po-Ku Chen, Shu-Rung Lin, Yung-Li Yang, Ming-Ching Shen, Shu-Wha Lin
- P-TU-143 INHIBITION OF THROMBIN GENERATION USING ANTIBODIES AGAINST COAGULATION FACTOR XI**  
Maurits Leonard van Montfoort\* (NL), Jakob Arnoud Marquart, Kamran Bakhtiari, Erik Hack, Joost Meijers
- P-TU-144 TWENTY-YEAR FOLLOW-UP OF OUR PATIENTS WITH HEMOPHILIA A**  
Zafer Salcioglu\* (TR), Arzu Akcay, Nuray Aktay Ayaz, Hulya Sayilan Sen, Gonul Aydogan, Deniz Tugcu, Ferhan Akici, Zafer Baslar
- P-TU-145 A PATIENT COMBINED HEMOPHILIA A AND TYPE 1 VON WILLEBRAND'S DISEASE**  
Huanhuan Qin\* (CN)
- P-TU-146 PHARMACOKINETICS OF ACTIVATED RECOMBINANT FACTOR IX ALBUMIN FUSION PROTEINS**  
Hubert J Metzner\* (DE), Thomas Weimer, Sabine Zollner, Wiegand Lang, Carsten Horn, Jochen Mueller-Cohrs, Gerhard Dickneite, Stefan Schulte
- P-TU-147 SHEAR STRESS TRIGGERS THE UPTAKE OF FACTOR VIII-VON WILLEBRAND FACTOR COMPLEX BY PRIMARY HUMAN MACROPHAGES**  
Lydia Castro\* (NL), Ilze Dienava, Eszter Herczenik, Koen Mertens, Alexander B. Meijer
- P-TU-149 HEALTH-RELATED QUALITY OF LIFE OF CONGENITAL HEMOPHILIA PATIENTS WITH INHIBITORS (CHWI): MEASUREMENT WITH DISEASE-SPECIFIC INSTRUMENTS (HAEMO-QOL, HAEM-A-QOL)**  
Tami Wisniewski\* (US), Allison Petrilla, Mitch DeKoven, Won Chan Lee, Natalia Holot, David L Cooper, Sylvia von Mackensen
- P-TU-150 ILE290THR. A NOVEL VARIANT AT THE FXI HOMODIMER INTERFACE ASSOCIATED WITH AN ASSAY-SPECIFIC FXI:C DISCREPANCY.**  
Marian Hill\* (UK), Charlotte Grimley, Nigel Brooks, Jonas Emsley, Gerry Dolan



## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-151 PATIENT/CAREGIVER PERCEIVED BENEFITS AND BARRIERS TO ELECTIVE ORTHOPEDIC SURGERY (EOS) IN PATIENTS WITH CONGENITAL HEMOPHILIA WITH INHIBITORS**  
Mitch DeKoven (US), Tami Wisniewski\*, Allison Petrilla, Natalia Holot, Won Chan Lee, David L Cooper
- P-TU-152 COMPARISON OF GLYCOSYLATION PROFILES IN VARIOUS RECOMBINANT FVIII PRODUCTS AND THE EFFECT OF B-DOMAIN DELETION**  
Maria C Van Walderveen\* (CA), Leslie R Berry, Anthony K C Chan
- P-TU-153 EVALUATION OF THE SAFETY AND EFFICACY OF RECOMBINANT FACTOR IX (NONACOG ALFA) IN MINIMALLY TREATED AND PREVIOUSLY TREATED CHINESE PATIENTS WITH HEMOPHILIA B**  
Yang Renchi\* (CN), Yongqiang Zhao, Xuefeng Wang, Jing Sun, Jie Jin, Depei Wu, Robert Charnigo, Amanda O'Brien, Pablo Rendo, Zheng Zhong
- P-TU-154 EVALUATION OF THE SAFETY AND EFFICACY OF RECOMBINANT FACTOR VIII (MOROCTOCOG ALFA [AF-CC]) IN MINIMALLY TREATED AND PREVIOUSLY TREATED CHINESE PATIENTS WITH HEMOPHILIA A**  
Yang Renchi\* (CN), Yongqiang Zhao, Xuefeng Wang, Jing Sun, Jie Jin, Depei Wu, Robert Charnigo, Amanda O'Brien, Carl Kollmer, Pablo Rendo, Zheng Zhong
- P-TU-155 A MULTICENTER, OPEN-LABEL STUDY TO COMPARE ON-DEMAND TREATMENT WITH TWO PROPHYLAXIS REGIMENS OF RECOMBINANT COAGULATION FACTOR IX IN SUBJECTS WITH HEMOPHILIA B**  
Leonard A Valentino\* (US), Olga Plushch, Luminita Rusen, Tatyana Andreeva, Ivo Elezovic, Robert Charnigo, James Baumann, Carl Kollmler, Lynne Smith, Pablo Rendo

Tuesday Poster

### Anticoagulant pathway

- P-TU-157 EMPIRICAL VALIDATION OF A MATHEMATICAL MODEL OF THE PROTEIN C PATHWAY**  
Maria Cristina Bravo\* (US), Thomas Orfeo, Kenneth G. Mann, Stephen J. Everse
- P-TU-158 AGE-RELATED DIFFERENCES IN THE AMOUNT OF LATENT ANTITHROMBIN IN PLASMA**  
Chantal Attard\* (AU), Wala'a Al-sanie, Paul Monagle, Vera Ignjatovic
- P-TU-159 RIVAROXABAN RESPONSE IN CHILDREN**  
Chantal Attard\* (AU), Paul Monagle, Vera Ignjatovic
- P-TU-160 AGE-RELATED DIFFERENCES IN BINDING OF HEPARIN TO PLASMA PROTEINS**  
Chantal Attard\* (AU), Paul Monagle, Vera Ignjatovic
- P-TU-161 PROSPECTIVE COMPARISON OF A FIXED VERSUS VARIABLE DOSING REGIMEN OF PROTHROMBIN COMPLEX CONCENTRATE TO COUNTERACT VITAMIN K ANTAGONIST THERAPY IN 255 BLEEDING EMERGENCIES**  
Nakisa Khorsand\* (NL), Nic J.G.M Veeger, Jeroen Heidt, Renier M van Hest, Karina Meijer
- P-TU-162 IN VITRO SEMULOPARIN ACTIVITY IN DIFFERENT COAGULATION TESTS**  
Meyer M Samama\* (FR), Celine Guinet, Lena Le Flem
- P-TU-163 THE PHARMACOKINETICS OF YM150, AN ORAL DIRECT FACTOR XA INHIBITOR ARE NOT AFFECTED TO A CLINICALLY RELEVANT DEGREE BY STRONG INHIBITION OR INDUCTION OF CYP3A4 AND P-GP**  
Marten Heeringa\* (NL), Dorien Groenendaal, Gregory Strabach, Alberto Garcia-Hernandez, Takeshi Kadokura, Roelof Mol, Charlotte Eltink, Hartmut Heinzerling



## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-164 CO-ADMINISTRATION OF YM150, AN ORAL DIRECT FACTOR XA INHIBITOR, WITH ACETYLSALICYLIC ACID, CLOPIDOGREL AND NAPROXEN: NO EVIDENCE OF CLINICALLY RELEVANT INTERACTIONS**  
Marten Heeringa\* (NL), Dorien Groenendaal, Gregory Strabach, Alberto Garcia-Hernandez, James Dickinson, Charlotte Eltink, Roelof Mol, Takeshi Kadokura, Ronny Renfurm, Hartmut Heinzerling
- P-TU-165 A COMPREHENSIVE APPROACH TOWARDS AUTOMATED ANTI-IIA AND ANTI-XA TESTING OF UNFRACTIONATED HEPARIN**  
Patrick Neil Shaklee\* (US), Kimberly Jeanne Reinke
- P-TU-166 PROTEIN C IN CHILDREN WITH EARLY COMPLICATION AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELLS TRANSPLANTATION**  
Dawid Szepecht\* (PL), Jolanta Kurosz, Jerzy Jaworski, Aleksandra Regdos, Krystyna Zawilska, Jacek Wachowiak
- P-TU-167 PERCEPTIONS ABOUT "RAPID" WARFARIN REVERSAL TO REDUCE THE INTERNATIONAL NORMALIZED RATIO WITH FRESH FROZEN PLASMA: A DOUBLE-BLINDED SURVEY OF U.S. TRAUMA CENTERS**  
Jerrold H Levy\* (US), Jeffrey Petrozzino, Chris Jones, Jan Hoesche
- P-TU-168 ACTIVATED PROTEIN C UPREGULATES PROCOAGULANT TISSUE FACTOR ACTIVITY ON ENDOTHELIAL CELLS BY SHEDDING TFPI'S KUNITZ 1 DOMAIN**  
Reto A Schuepbach\* (CH), Kara Velez, Matthias Riewald
- P-TU-169 EFFECT OF ENDOTOXIN AND INFLAMMATORY CYTOKINES ON PROTEIN S AND C4B-BINDING EXPRESSIONS IN THE LIVER HEPG2 CELLS**  
Tatsuya Hayashi\* (JP), Chiemi Kato, Takako Mori, Kakunoshin Yoshida, Nobuyuki Akita, Takayuki Okamoto, Junji Nishioka, Koji Suzuki
- P-TU-170 COAGULATION PROFILE OF EP217609, A NEW NEUTRALIZABLE ANTICOAGULANT FOR EXTRACORPOREAL CIRCULATION DURING CARDIAC SURGERY**  
Maurice PETITOU\* (FR), Richard Swanson, Steven T Olson

### Serine protease inhibitors

- P-TU-171 NO RELEVANT INTERACTIONS BETWEEN THE ORAL FACTOR XA INHIBITOR YM150 AND ANTITHROMBIN *IN VITRO***  
Seiji Kaku\* (JP), Yoshiyuki Iwatsuki, Toshiyuki Funatsu
- P-TU-172 COMBINED EFFECTS OF YM150, ASPIRIN, AND CLOPIDOGREL ON COAGULATION PARAMETERS, PLATELET AGGREGATION, AND BLEEDING TIME AFTER ORAL ADMINISTRATION TO RATS**  
Yoshiyuki Iwatsuki\* (JP), Toshiyuki Funatsu, Seiji Kaku
- P-TU-173 THE DETERMINATION OF RIVAROXABAN IS NOT INFLUENCED IN CHROMOGENIC SUBSTRATE ASSAYS USING PLASMA FROM PATIENTS TREATED WITH WARFARIN**  
Job Harenberg\* (DE), Sandra Erdle, Christina Giese, Svetlana Marx, Roland Kraemer
- P-TU-174 EFFECT OF DABIGATRAN ON PROTHROMBIN TIME ASSAYS USING DIFFERENT THROMBOPLASTIN TIME REAGENTS**  
Job Harenberg\* (DE), Christina Giese, Svetlana Marx, Christel Weiss, Roland Kraemer
- P-TU-175 INFLUENCE OF PROTAMINE SULFATE ON ANTITHROMBIN ACTIVITY OF SULFATED CELLULOSE FROM *POPULUS TREMULA* WOOD.**  
Elena Y Savchik\* (RU), Nataliya N Drozd, Svetlana A Kuznetsova, Vladimir A Makarov, Vladimir A Levdanskiy, Boris Kuznetsov





## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-176 EFFECT OF DABIGATRAN SPIKED TO HUMAN PLASMA ON VARIOUS ACTIVATED PARTIAL THROMBOPLASTIN TIME METHODS**  
Job Harenberg\* (DE), Christina Giese, Svetlana Marx, Christel Weiss, Roland Kraemer
- P-TU-177 INFLUENCE OF RIVAROXABAN ON DIFFERENT ACTIVATED PARTIAL THROMBOPLASTIN TIME ASSAYS**  
Job Harenberg\* (DE), Christina Giese, Sandra Erdle, Svetlana Marx, Christel Weiss, Roland Kraemer
- P-TU-178 EFFECT OF RIVAROXABAN ON FACTOR XA SENSITIVE CHROMOGENIC SUBSTRATE ASSAYS**  
Job Harenberg\* (DE), Christina Giese, Svetlana Marx, Christel Weiss, Roland Kraemer
- P-TU-179 ANALYSIS OF ADDITIVE EFFECTS OF RIVAROXABAN ADDED TO PLASMA OF PATIENTS TREATED WITH VITAMIN-K ANTAGONISTS**  
Job Harenberg\* (DE), Christina Giese, Svetlana Marx, Christel Weiss, Roland Kraemer
- P-TU-180 ENHANCED INHIBITION OF PLATELET-PROTHROMBINASE BY COVALENT ANTITHROMBIN-HEPARIN COMPLEX**  
Ivan Stevic\* (CA), Howard H. Chan, Leslie R. Berry, Anthony K.C. Chan
- P-TU-181 INVOLVEMENT OF ALPHA2-ANTIPLASMIN IN AGE-RELATED COGNITIVE DECLINE**  
Eri Kawashita\* (JP), Yosuke Kanno, Haruka Asayama, Kiyotaka Okada, Shigeru Ueshima, Osamu Matsuo, Hiroyuki Matsuno
- P-TU-182 CHANGES OF PLASMA ANTITHROMBIN LEVELS IN PATIENTS WITH MULTIPLE MYELOMA**  
Zhou Rong-Fu\* (CN), Jian Ouyang, Ping Li

Tuesday Poster

### Structural biology and drug design

- P-TU-183 FULLY GAMMA-CARBOXYLATED TRUNCATED COAGULATION FACTOR VII (FVII) VARIANTS CAN BE SECRETED IN HIGHER YIELDS THAN WILD-TYPE FVII**  
Gert Bolt\* (DK), Jais Rose Bjelke, Jens Jacob Hansen, Thomas Steenstrup, Claus Kristensen
- P-TU-184 IDENTIFICATION OF A NOVEL DELETION IN F13A AT RNA LEVEL IN A CHINESE HEREDITARY COAGULATION FACTOR XIII DEFICIENCY FAMILY**  
Wangwei Cai\* (CN), Qiuling Ma
- P-TU-185 INFLUENCE OF PAMAM G3 DENDRIMERS ON BLOOD PLATELETS ACTIVATION**  
Cezary W Watala\* (PL), Katarzyna Maczynska, Kamil Karolczak, Stefan Miskiewicz
- P-TU-186 LMWH CAN IMPROVE THE OUTCOME OF ART PROCEDURES**  
Corrado Lodigiani\* (IT), Pierpaolo DiMicco, Paola Ferrazzi, Luca Libre, Michela Benigna, Franco Polatti, Paolo Emanuele Levi Setti, Lidia Luciana Rota, Benjamin Brenner
- P-TU-187 STRUCTURAL CHARACTERIZATION OF PLASMA-DERIVED (BETAFACT) AND RECOMBINANT (BENEFIX) COAGULATION FACTOR IX USING MASS SPECTROMETRY**  
Guillaume CHEVREUX\* (FR), Valegh FAID, Nolwenn TILLY, Nicolas BIHOREAU
- P-TU-188 STRUCTURAL BASIS OF FACTOR V RECOGNITION BY RUSSELL'S VIPER VENOM PROTEINASE RVV-V**  
Daisuke Nakayama\* (JP), Youssef Ben Ammar, Soichi Takeda
- P-TU-189 WHOLE BLOOD CELLS ENHANCE CLOT RESISTANCE TO LYSIS: IMPROVEMENT BY RIVAROXABAN A FACTOR XA INHIBITOR**  
Remi Varin\* (FR), Shahsoltan Mirshahi, Pezhman Mirshahi, Christophe Klein, Jean Chidiac, Elisabeth Perzborn, Genevieve Contant, Massoud Mirshahi, Claudine Soria, Jeannette Soria



43

## POSTER PRESENTATIONS

Tuesday, July 26, 2011

**P-TU-190 ENDOPLASMIC RETICULUM STRESS, CELL CYCLE REGULATION AND SURVIVAL PATHWAYS MAY BE INVOLVED IN THE MECHANISM OF ACTION OF AMBLYOMIN-X, A NEW TICK KUNITZ TYPE INHIBITOR**

Ana Marisa Chudzinski-Tavassi\* (BR), Simone Michaela Simons, Katia Luciano Pereira Morais, Carolina Maria Berra, Claudiana Lameu, Sandra Alves Barreto

### Exogenous hemostatic factors

**P-TU-191 LONG TERM FOLLOW UP OF SECONDARY PROPHYLAXIS WITH RFVIII IN HAEMOPHILIA PATIENTS WITH INHIBITORS**

Oscar Walter Torres\* (AR), Patricia Do Nascimento, Guillermo Arbesu, Sandra Borchichi, Anabel Buceta

**P-TU-192 ANTITHROMBIN CONCENTRATE USE IN PAEDIATRIC PRACTICE**

Christina Kozul (AU), Fiona Newall\*, Paul Monagle, Vera Ignjatovic

**P-TU-193 VON WILLEBRAND FACTOR ANTIGEN, PROCOAGULANT FACTOR VIII AND ACQUIRED RESISTANCE OF ACTIVATED PROTEIN C IN PATIENTS WITH MULTIPLE MYELOMA**

Emilia Flochova\* (SK), J. Ivankova, P. Kubisz, K. Masarova

**P-TU-194 BIOSTATE - SWIFT PROGRAM**

Toby L Simon\* (US), A Skotnicki, T Lissitchkov, E Buevich, T Chernova, A Dmoszynska, L Gercheva, S Goranov, A Hellmann, J Kloczko, A Klukowska, K Kuliczkowski, V Mamonov, S Stankovic, K Zawilska, Darryl Maher

**P-TU-195 UPDATE OF A LONG-TERM PHARMACOVIGILANCE PROJECT: REC. FVIII-FS FOR THE TREATMENT OF HEMOPHILIA A**

Johannes Oldenburg (DE), Pia Petrini, Albert Faradji, Ingrid Pabinger, Mathias Juers\*, Claudia Zacharias, Harald Lenk

**P-TU-196 ANALYSIS OF FACTOR VII ACTIVATING PROTEASE (FSAP) EXPRESSION IN THE MOUSE.**

Silke Leiting\* (DE), Lars Muhl, Audrey A. C. Cleuren, Ralf Weiskirchen, Sandip M. Kanse

**P-TU-197 LIQUID PLASMA BANK: TOWARDS A TIMELY SUPPLY IN BLEEDING EMERGENCIES**

Gregor Hron\* (DE), Sarah Kellner, Thomas Thiele, Matthias Nauck, Christina Wasner, Antje Wessel, Andreas Greinacher, Kathleen Selleng

**P-TU-198 CLINICAL STUDY OF A NEW FACTANE CONCENTRATION (200 IU/ML): RECOVERY AND SAFETY RESULTS**

Herve Chambost\* (FR), Anne Lienhart, Pierre Chamouni, Jenny Goudemand, Natalie Stieltjes, Anne-Lise Voyer, Claudine Caron, Martine Vidal, Celine Henriet, Francoise Bridey

**P-TU-199 FIVE-YEAR POST-MARKETING SURVEILLANCE OF HAEMOPHILIA B PATIENT RECEIVING A FACTOR IX CONCENTRATE: FINAL RESULTS.**

Herve Chambost\* (FR), Jenny Goudemand, Marie-Elisabeth Briquel, Annie Borel-Derlon, Group Post-Marketing Study, Anne-Cecile Jaffry, Francoise Bridey, Catherine Chatelanaz, Celine Henriet

**P-TU-201 FULL-LENGTH RECOMBINANT FACTOR VIII (FL-RFVIII): IS IT SAFER?**

Louis M Aledort\* (US), Roberta J Navickis, Mahlon M Wilkes

**P-TU-202 PRECLINICAL MODELS SHOW REDUCED IMMUNOGENICITY OF PEGYLATED RECOMBINANT HUMAN FVIII RELATIVE TO UNMODIFIED FVIII**

Jesper Haaning\* (US), Thomas A. McDonald, Ruprecht Zierz, John E. Murphy, Inge A Ivens



## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-203 SAFETY OF HIGH MOLECULAR WEIGHT POLYETHYLENE GLYCOL (PEG) IN HEMOPHILIA THERAPY**  
Jesper Haaning\* (US), Thomas A. McDonald, John E. Murphy, Inge A. Ivens
- P-TU-204 SUBGROUP ANALYSES OF ANNUALIZED NUMBER OF BLEEDS WITH THREE-TIMES-PER-WEEK PROPHYLAXIS WITH RFVIII-FS**  
Shadan Lalezari\* (IL), Antonio Coppola, Judith Lin, Monika Maas Enriquez

### Fibrinogen and other factors

- P-TU-205 IDENTIFICATION OF MURINOGLOBULIN-1 (MUG1) AS A STAT5-REGULATED INHIBITOR OF FIBRINOPEPTIDE B RELEASE**  
Sarah M Nordstrom\* (US), Brian A Holliday, Jennifer L Tran, Brandon C Sos, Susan T Lord, Ethan J Weiss
- P-TU-206 MARKEDLY SHORTENED HALF-LIFE OF THE ADMINISTERED FACTOR XIII (FXIII) CONCENTRATES DURING FIRST REPLACEMENT THERAPY IN A NEWBORN WITH SEVERE CONGENITAL FXIII DEFICIENCY**  
Noriko Fujii\* (JP), Masayoshi Souri, Midori Shima, Chihiro Tomoyasu, Kenichi Isoda, Akitada Ichinose
- P-TU-207 SSRI AND HEMOSTASIS IN HEMATOLOGICAL MALIGNANCIES PATIENTS**  
Dmitry E Vybornykh\* (RU), Evdokiya S Urnova
- P-TU-208 THOMBIN GENERATION TEST AND GENETIC ANALYSIS IN 17 PATIENTS WITH HYPOFIBRINOGENEMIA ASSOCIATED WITH THROMBOSIS.**  
Claire Flaujac (FR), Nadia Abakarim, Philippe De Mazancourt, Jacqueline Conard\*, Genevieve Plu Bureau, Michaela Fontenay, Marie Helene Horellou
- P-TU-209 BATROXOBIN AND THROMBIN BIND TO DISTINCT SITES ON FIBRINOGEN AND FIBRIN**  
Trang T Vu\* (CA), Alan R Stafford, Beverley A Leslie, James C Fredenburgh, Paul Y Kim, Jeffrey I Weitz
- P-TU-210 TOWARD A COMPLETE MODEL OF FIBRINOGEN IN SOLUTION**  
Barbara Cardinali\* (US), Anna Aprile, Aldo Profumo, Patrice Vachette, Patrick England, Bertrand Raynal, Manfred Roessle, Javier Perez, Niels Volkmann, Susan T Lord, Mattia Rocco
- P-TU-211 DILUTIONAL COAGULOPATHY - THE HAEMOSTATIC EFFECT OF VARIOUS SOURCES OF FIBRINOGEN**  
John Laurie\* (UK), Christian Fenger-Eriksen, Kirsten Christiansen, Benny Sorensen, Catherine Rea
- P-TU-212 CHARACTERIZING THE KINETIC ACTIVATION OF ZYMOGEN FXIII: THE ROLE OF FIBRINOGEN AND OF THROMBIN EXOSITE I**  
Barbara Cardinali\* (US), Brian A Holliday, Susan T Lord
- P-TU-213 THE INHIBITOR FORMATION DURING PRIMARY PROPHYLAXIS THERAPY IN HAEMOPHILIA WITH LOW DOSE AND LOW INTENSITY : RESULTS OF A CENTER FROM TURKEY**  
Tiraje Tulin Celkan\* (TR), Nihal Ozdemir, Gulen Tuysuz
- P-TU-214 HEPARINS-INDUCED MODIFICATION OF THE NANOSTRUCTURE OF FIBRIN CLOT**  
Benoit Polack\* (FR), Chrsitelle Yeromonahos, Raphael Marlu, Francois Caton
- P-TU-215 FACTOR XIII ACTIVATION PEPTIDE - A NOVEL COMPETITIVE THROMBIN INHIBITOR?**  
Verena Schroeder\* (CH), Hans P Kohler

Tuesday Poster



45

## POSTER PRESENTATIONS

Tuesday, July 26, 2011

**P-TU-216 DIFFERENTIAL METHYLATION OF CPGS ACROSS THE FIBRINOGEN GENE CLUSTER CORRELATED WITH FIBRINOGEN EXPRESSION**

Richard J Fish\* (CH), Silja Vorjohann, Corinne DiSanza, Marguerite Neerman-Arbez

### Laboratory tests

**P-TU-217 COMPARISON OF SENSITIVITY TO LUPUS ANTICOAGULANT (LA) ON APTT REAGENT: EFFECT OF SILICA AND ELLAGIC ACID AS ACTIVATOR**

Osamu Kumano\* (JP), Masahiro Ieko, Sumiyoshi Naito, Mika Yoshida, Nobuhiko Takahashi

**P-TU-218 CONCENTRATION-ACTIVITY RELATIONSHIP OF UNFRACTIONATED HEPARIN OR EP217609 BEFORE CARDIAC SURGERY**

Eric Neuhart\* (FR), Pierre Gueret, Pascal Menestret, Jeffrey Spencer, Helen Ridgway, Chantal Krezel

**P-TU-219 EFFECTS OF GABEXATE MESILATE ON RATS WITH LIPOPOLYSACCHARIDE-INDUCED DISSEMINATED INTRAVASCULAR COAGULATION**

Chin-Chen Wu\* (TW), Hsin-Jung Tsai, Mei-Huei Liao, Wen-Jinn Liaw

**P-TU-220 EVALUATION OF THE PERFORMANCE OF A NEW IN VITRO PROTHROMBIN TIME REAGENT**

Pere Domenech\* (ES), Elena Rossello, Begona Alonso, Mariona Bono, Virginia Montanini

**P-TU-221 EVALUATION OF THE DG-APC REAGENT KIT ON Q HEMOSTASIS ANALYZER**

Ingrid V Hrachovinova\* (CZ), Magda Zemanova, Hana Novotna, Frantisek Marecek

**P-TU-222 VALIDATION OF NEW AVAILABLE LIQUID CHROMOGENIC ASSAYS FOR ANTI XA ACTIVITY IN HUMAN CITRATED PLASMA**

Peter Quehenberger\* (AT), Johann Bartko, Sabine Belik, Ulrike Wallner, Oswald Wagner

**P-TU-223 EVALUATION OF METHODS FOR POTENCY TESTING OF PEGYLATED FVIII (PEG-FVIII, BAY 94-9027)**

Lilley Leong\* (US), Vince Evans, Philip Ramsey, Liang Tang, John E. Murphy, Heiner Apeler, Timothy Myles, Jesper Haaning

**P-TU-224 DISCREPANCIES IN INTERNATIONAL NORMALIZED RATIO RESULTS BETWEEN INSTRUMENTS; THE EFFECT OF COAGULATION FACTORS**

Una Oervim Soelvik (NO), Thomas Helge Roeraas, Per Hyltoft Petersen, Grete Monsen, Anne Vegard Stavelin\*, Sverre Sandberg

**P-TU-225 ANTITHROMBIN MUTATIONS IN THROMBOSIS PATIENTS CAUSING DIFFERENT RESULTS IN FUNCTIONAL ANTITHROMBIN TESTING**

Ronald Fischer\* (DE), Matthias Philipps, Kathrin Heidinger, Anna Pavlova, Johannes Oldenburg, Bettina Kemkes-Matthes

**P-TU-226 EVALUATION OF THE PERFORMANCE CHARACTERISTICS OF A NEW HUMAN THROMBIN LIQUID REAGENT FOR FIBRINOGEN DETERMINATION**

Pere Domenech\* (ES), Elena Rossello, Emma Camacho, Mariona Bono, Virginia Montanini

**P-TU-227 HOW IS EXTERNAL QUALITY ASSESSMENT OF POINT-OF-CARE INR TESTING PERFORMED IN EUROPE?**

Anne Stavelin\* (NO), Dianne Kitchen, Piet Meijer, Sverre Sandberg

**P-TU-228 SOLUBLE TISSUE FACTOR-BASED FVIIA ASSAY FOR BAY 86-6150, A RECOMBINANT FVIIA VARIANT IN CLINICAL DEVELOPMENT**

Junliang Pan\* (US), Ji-Yun Kim, Timothy Myles, Edward Blank, John E. Murphy, Jesper Haaning



## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-229** **“IN VITRO” RESPONSE OF DABIGATRAN AND RIVAROXABAN ON THROMBIN GENERATION (CAT) AND FIBRIN FORMATION (ROTEM)**  
Meyer M Samama\* (FR), Celine Guinet, Lena Le Flem, Grigoris Gerotziafas
- P-TU-230** **DIFFERENCES BETWEEN ONE STAGE CLOTTING AND CHROMOGENIC FACTOR VIII ASSAY RESULTS**  
An K Stroobants\* (NL), Erik-Jan van den Dool, Bianca Bakker, Marion Heckman, Pieter-Willem Kamphuisen, Auguste Sturk
- P-TU-231** **EXCLUSION OF HERITABLE PROTEIN C AND PROTEIN S DEFICIENCY IN PATIENTS WITH AN ELEVATED INR**  
Artur Jerzy Szkotak\* (CA)
- P-TU-232** **EVALUATION OF AN EXTERNAL QUALITY ASSESSMENT MATERIAL FOR D-DIMER POINT OF CARE TESTING KITS**  
Dianne Kitchen\* (UK), Shelene Munroe- Peart, Steve Kitchen, Ian Jennings, Tim Woods, Isobel Walker
- P-TU-233** **A QUALITY CONTROL SYSTEM FOR INR PORTABLE MONITORS**  
Sophie Testa\* (IT), Oriana Paoletti, Laura Bassi, Anke Zimmermann, Anna Cogrossi, Nika Delpero, Elisabetta Spotti, Emilia Cancellieri
- P-TU-234** **NANOFILTRATION STEP EFFECTIVELY REMOVES TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY (TSE) MODEL AGENTS DURING HIGH PURITY FACTOR IX PRODUCTION PROCESS**  
Salvador Grancha\* (ES), Magdalena Otegui, Francisco J Belda, Jose M Diez, Santiago Caballero, Rodrigo Gajardo, Juan I Jorquera
- P-TU-235** **POST-ITI HAEMOPHILIA A PATIENTS BLEED BECAUSE OF THE PRESENCE OF LOW TITRE INHIBITORS**  
Myriam Dardikh\* (NL), Thilo Albert, Robert Polenewen, Roos Masereeuw, Johannes Oldenburg, Britta Laros-van Gorkom, Irena Novakova, Waander van Heerde, Bert Verbruggen
- P-TU-236** **DETERMINATION OF HUMAN ANTITHROMBIN IN MICE PLASMA BY ELISA**  
Maria Isabel Bravo\* (ES), Patricia Sabella, Juan I. Jorquera
- P-TU-237** **EVALUATION OF A NEW CONTROL MATERIAL FOR PROTHROMBIN TIME FOR POINT-OF-CARE INSTRUMENTS**  
Kerstin M Gustafsson\* (SE), Tomas L Lindahl
- P-TU-238** **ELECTIVE MAJOR ORTHOPEDIC SURGERY IN A HIGH RESPONDER INHIBITOR HAEMOPHILIA A PATIENT: LABORATORY APPROACH CONTROL WITH THROMBELASTOGRAPHY (TEG) ASSAY**  
Manuela Carvalho (PT), Graca Oliveira, Manuela Reis, Carla Monteiro, Luis Manuel Cunha-Ribeiro\*
- P-TU-239** **EVALUATION OF TWO ELISA SCREENING TESTS FOR DETECTION OF ANTI-FACTOR VIII INHIBITORY ANTIBODIES**  
Christophe Nougier\* (FR), Frederic Sobas, Christine Vinciguerra, Claude Negrier
- P-TU-240** **INTER-PATIENT VARIATION WITH DIFFERENT CONCENTRATES USING A QUANTITATIVE FVIII BINDING ASSAY**  
Kampta Sukhu\* (UK), Paul Giangrande, Jane Needham, Savita Rangarajan, Peter Collins
- P-TU-241** **THE USE OF THROMBIN GENERATION ASSAY IN PLASMA AND WHOLE BLOOD FOR THE EVALUATION OF COAGULABILITY IN PATIENTS WITH DIFFERENT STAGES OF LIVER DISEASE**  
Enriqueta Coll (US), Enriqueta Coll, Elona Rrapo\*, Nikolaos Prysopoulos, Liza Robles-Carrillo, Megan Hatfield, Alane Drexler, Ali Amirkhosravi, Eduardo Reyes, Kristin Rathmann, John Francis

Tuesday Poster



47

## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-242 FIBRINOLYTIC EFFECTS OF FACTOR XIII INHIBITION ARE POTENTIATED BY TISSUE PLASMINOGEN ACTIVATOR**  
Jerrold H Levy\* (US), Fania Szlam, Heezoo Kim, Kenichi Tanaka, Satoru Ogawa, Martin Hils, Ralf Pasternack, Jerrold H Levy
- P-TU-243 PROINFLAMMATORY CYTOKINES GENE POLYMORPHISM AND SUSCEPTIBILITY TO VENOUS THROMBOEMBOLISM IN THE POPULATION OF THE NORTH-WESTERN REGION OF RUSSIA**  
Anastasia Polyakova\* (RU), Yulia S Drizhun, Michael N Blinov, Natalia B Saltykova, Veronika M Shmeleva, Sergey I Kapustin
- P-TU-244 MARKERS OF HYPERCOAGULABILITY ARE INCREASED IN SEVERE OBESITY AND RELATE BOTH TO BMI AND VISCERAL ADIPOSITY AS DETERMINED BY SINGLE SLICE CT**  
Paradzai Boniface Chitongo\* (UK), Lara Roberts, Raj Patel, Lisa Yang, Rebecca Lyall, Richard Luxton, Simon Aylwin, Roopen Arya
- P-TU-245 EVALUATION OF ELISA FACTOR VIII ANTIBODY SCREENING ASSAY COMPARED TO CLOTTING BASED BETHESDA INHIBITOR ASSAY**  
Jane Needham\* (UK), Helen Lewis, Savita Rangarajan

### Experimental models

- P-TU-246 PROLONGED SERUM HALF-LIFE OF A RECOMBINANT FUSION PROTEIN LINKING ACTIVATED COAGULATION FACTOR VII WITH ALBUMIN (RVIIA-FP) IN DIFFERENT PRECLINICAL SPECIES**  
Gerhard Dickneite\* (DE), Sabine Zollner, Thomas Weimer, Stefan Schmidbauer, Elmar Raquet, Jochen Mueller-Cohrs, Ingo Pragst, Stefan Schulte
- P-TU-247 MEASUREMENT OF THROMBIN GENERATION IN PLASMA FROM SEVEN LABORATORY ANIMAL SPECIES**  
Michael Dockal\* (AT), R. Hartmann, E. Panholzer, S. Till, S. Reutterer, H. Ehrlich, W. Hoellriegl, E. M. Muchitsch, F. Scheiflinger
- P-TU-248 ANTIHEMOSTATIC EFFECT OF A PROTEOLYTIC FRACTION FROM *CARICA CANDAMARCENSIS* LATEX ON WISTAR RATS PLASMA, *IN VITRO***  
Maria das Gracas Carvalho\* (BR), Rogerio Pereira Bilheiro, Carlos Edmundo Salas Bravo, Miriam Teresa Paz Lopes
- P-TU-249 THE ANTITHROMBOTIC ACTIVITY OF EP224283, A NEUTRALIZABLE DUAL FACTOR XA INHIBITOR/ $\alpha$ IIb $\beta$ 3 ANTAGONIST, EXCEEDS THAT OF THE CO-ADMINISTRATED PARENT COMPOUNDS**  
Beatrice Hechler\* (FR), Monique Freund, Ghina Alame, Cecile Leguay, Sebastien Gaertner, Jean-Pierre Cazenave, Maurice Petitou, Christian Gachet
- P-TU-250 COMPARATIVE STUDIES ON THE GENERIC VERSIONS OF ENOXAPARIN**  
Jawed Fareed\* (US), Indermohan Thethi, Walter Jeske, Evangelos Litinas, Josephine Cunanan, Debra Hoppensteadt, Jeanine Walenga
- P-TU-251 A STANDARDIZED FVIII DEPENDENT TAIL BLEEDING MODEL IN FVIII -/- MICE**  
Gary J Jesmok\* (US), Philip Scuderi, Walter Faison, Kyle Landskroner
- P-TU-252 CROSS REACTIVITY OF NATURAL HIRUDIN COMPARED TO THE RECOMBINANT HIRUDINS WITH SHEEP ANTI HIRUDIN ANTIBODY**  
Vijaya Paramatmuni\* (US), Debra Hoppensteadt, Evangelos Litinas, Nasir Saddeghi, Jawed Fareed



## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-253 EVALUATION OF PROTHROMBIN COMPLEX CONCENTRATE AND RECOMBINANT ACTIVATED FACTOR VII TO REVERSE FONDAPARINUX IN A RABBIT MODEL**  
Anne Godier\* (FR), Bernard Le Bonniec, Marion Durand, Anne Marie Fischer, Joseph Emmerich, Thomas Lecompte, Charles Marc Samama
- P-TU-254 A BAYESIAN APPROACH FOR QUALITY CONTROL IN FACTOR VIII CLOTTING ASSAY: DEFICIENT PLASMA QUALITY IMPACTS HEMOPHILIA MANAGEMENT**  
Frederic Sobas\* (FR), Panagiotis Tsiamyrtzis, Anne Lienhart, Christophe Nougier, Claude Negrier
- P-TU-255 THE INHIBITION OF LUNG METASTASIS BY INACTIVATION OF COAGULATION ACTIVITY MAY LEAD TO DISSEMINATION OF TUMOR CELLS**  
Kunihiro Asanuma\* (JP), Nobuyuki Akita, Takayuki Okamoto, Tatsuya Hayashi, Tomoaki Yoshikawa, Kakunoshin Yoshida, Yumiko Asanuma, Akihiko Matsumine, Atsumasa Uchida, Akihiro Sudo, Koji Suzuki
- P-TU-256 EVALUATION OF PROTHROMBIN COMPLEX CONCENTRATE, RECOMBINANT ACTIVATED FACTOR VII AND FIBRINOGEN CONCENTRATE TO REVERSE RIVAROXABAN IN A RABBIT MODEL**  
Anne Godier\* (FR), Anastasia Miclot, Bernard Le Bonniec, Marion Durand, Joseph Emmerich, Anne Marie Fischer, Thomas Lecompte, Charles Marc Samama
- P-TU-257 EVALUATION OF HEMOSTATIC DISTURBANCES CAUSED BY ADULT AND YOUNG *BOTHRUPS JARARACA* SNAKE VENOMS AND NEUTRALIZATION BY SPECIFIC ANTIVENIN**  
Luana V. Senise\* (BR), Marcio Y. Yano, Marcelo L. Santoro, Ida S. Sano-Martins

Tuesday Poster

### Plasminogen activator inhibitors

- P-TU-258 IMPAIRED TNF SIGNALLING REVEALED THE ROLE OF KUPFFER CELLS IN LIVER PAI-1 AND GLUCOSE PRODUCTION**  
Ilse Scroyen\* (FR), Delphine Bastelica, Odile Georgelin, Monique Verdier, Nico Van Rooijen, Franck Peiretti, Marie-Christine Alessi
- P-TU-259 HAEMOSTATIC DISEQUILIBRIUM: THE MISSING LINK BETWEEN GADOLINIUM AND NEPHROGENIC SYSTEMIC FIBROSIS?**  
Ilse Scroyen\* (FR), Delphine Bastelica, Jean-Francois Landrier, Odile Georgelin, Monique Verdier, Nico Van Rooijen, Franck Peiretti, Marie-Christine Alessi
- P-TU-260 SPONTANEOUS PLASMA CLOT LYSIS TIME ASSAY REVEALED THE IMPORTANCE OF "COAGULATION-ASSOCIATED ENHANCEMENT OF FIBRINOLYSIS"**  
Tetsumei Urano\* (JP), Tomasz Brzoska, Yuko Suzuki
- P-TU-261 RELATIONSHIPS OF PAI-1 4G/5G POLYMORPHISM AND CONVENTIONAL RISK FACTORS FOR CORONARY ARTERY DISEASE WITH THE SEVERITY OF CORONARY STENOSIS**  
Chutima Rattanawan\* (TH), Nantarat Komanasin, Nongnuch Settatsatian, Chatri Settatsatian, Upa Kukongviriyapan, Pongsak Intharapetch, Sutthittep Duangsorn, Kasem Tantipanichteerakul, Vichai Senthong
- P-TU-262 INITIATION OF INSULIN THERAPY AMELIORATES FIBRINOLYSIS IN TYPE 2 DIABETES**  
Bregtje Annelieke Lemkes\* (NL), J.Hans DeVries, Max Nieuwdorp, Ricardo DeGroot, Joost B.L. Hoekstra, Joost C.M. Meijers, Frits Holleman
- P-TU-263 SUPPRESSIVE ACTIONS OF FUCOIDAN ON LIPID DROPLET FORMATION AND PLASMINOGEN ACTIVATOR INHIBITOR-1 EXPRESSION IN ADIPOCYTES**  
Akira Hayashi\* (JP), Yuwna Yakura, Makoto Taniguchi, Akinori Tomita, Hiroyuki Takeya



49

## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-264 REGULATION OF LEUKOTRIENE PRODUCTION AND PLASMINOGEN ACTIVATOR INHIBITOR-1 EXPRESSION IN ADIPOSE TISSUE**  
Akira Hayashi\* (JP), Makoto Taniguchi, Yuwna Yakura, Jyunya Miyabara, Harumi Yamamoto, Yasunori Kozutsumi, Toshiro Okazaki, Hiroyuki Takeya

### New thrombolytic agents and drug design

- P-TU-265 FACTORS CRITICAL FOR THE EFFICACY OF DIRECT THROMBOLYTICS**  
Valery Novokhatny\* (US), Dean Chamberlain, John Bromirski, Jennifer Nixon, Philip Scuderi, Stephen R. Petteway, Jr
- P-TU-266 COMPARISON OF PLASMIN WITH RT-PA IN LYSIS OF CEREBRAL THROMBOEMBOLI RETRIEVED FROM PATIENTS WITH ACUTE ISCHEMIC STROKE**  
Victor J Marder\* (US), Ales J Blinc, Theresa Gruber, Gregor Tratar, Miso Sabovic, Sidney Starkman, Reza Jahan, Gary Duckwiler, Fernando Vinuela, Satoshi Tateshima, David Liebeskind, Bruce Ovbiagele, Letisha Ali, Doojin Kim, Nestor Gonzalez, Paul M Vespa, Jeffrey L Saver
- P-TU-267 ENCAPSULATION OF STREPTOKINASE WITH INERT FILLER IN POLYETHYLENE GLYCOL (PEG) SHELLS**  
Roza B Aisina\* (RU), Mikhail Y Levashov, Lilia I Mukhametova, Anastasia S Medvedeva, Sergei D Varfolomeyev
- P-TU-268 SPECIFICITY AND IMMUNOCHEMICAL PROPERTIES OF NATTOKINASE**  
Hiroyuki Sumi\* (JP), Sawa Naito, Chieko Yatagai, Etsuo Yoshida, Tadanori Ohsugi, Yasuhide Yanagisawa, Josuke Saito, Masugi Maruyama
- P-TU-269 ELASTASE ACTIVITY AND ELASTATINAL INHIBITION OF NATTOKINASE**  
Hiroyuki Sumi\* (JP), Sawa Naito, Josuke Saito, Masugi Maruyama
- P-TU-270 A FAVORABLE OUTCOME OF DISSEMINATED INTRAVASCULAR COAGULATION IN CHILDREN USING RECOMBINANT THROMBOMODULIN**  
Hiroshi Yagasaki\* (JP), Maiko Kato, Hiroyuki Shichino, Motoaki Chin, Hideo Mugishima
- P-TU-271 OPTIMIZATION TECHNOLOGY FOR OBTAINING THROMBIN-LIKE ENZYME FROM AGKISTRODON BLOMHOFFII USSURIENSIS VENOM FOR INDUSTRIAL SCALING OPTION**  
Bolor Buyanbadrakh\* (MN), Sumiya Byambasuren, Punsaldulam Dashnyam
- P-TU-272 DEVELOPMENT OF THE NEW DRUG DELIVERY SYSTEM FOR THROMBOLYSIS WITH ULTRASOUND IN ACUTE CORONARY SYNDROME**  
Hiroyuki Kawata\* (JP), Tsunenari Soeda, Ji-Hee Sung, Yoshiko Uesugi, Yasuhiko Tabata, Kiyotaka Umaki, Keiji Kato, Yoshihiko Saito
- P-TU-273 MULTIFUNCTIONAL METALLOPROTEINASE FROM VIPERA LEBETINA VENOM**  
Ene Siigur\* (EE), Katrin Trummal, Mari Samel, Kylli Tonismagi, Heiki Vija, Juhan Subbi, Juri Siigur
- P-TU-274 OPTIMIZATION OF MODIFIED RECOMBINANT ALBUMINS THAT SPEED CLOT LYSIS BY COMPETING FOR CROSSLINKING OF ANTIPLASMIN**  
William P Sheffield\* (CA), Louise J Eltringham-Smith
- P-TU-275 POTENTIATION OF PLASMIN ACTIVITY BY ENZAMIN, AN EXTRACT OF METABOLITE FROM *BACILLUS SUBTILIS* AK AND *LACTOBACILLUS* IN VITRO AND IN VIVO**  
Yukinori Tamura\* (JP), Kiyotaka Okada, Naoyuki Kawao, Masato Yano, Shigeru Ueshima, Nobuo Nagai, Osamu Matsuo





## POSTER PRESENTATIONS

Tuesday, July 26, 2011

### Laboratory tests

- P-TU-276 DURATION OF POST-OPERATIVE FIBRINOLYSIS AFTER MAJOR HIP OR KNEE SURGERY: A BIOLOGICAL FOLLOW-UP STUDY**  
Nadia Rosencher\* (FR), Loren Bellamy, Antonia Blanie, Yarad Rhayem, Claire Flaujac, Michaella Fontenay
- P-TU-277 MONITORING HEMOSTASIS WITH OVERALL HEMOSTATIC POTENTIAL (OHP) ASSAY DURING LENALIDOMIDE AND DEXAMETHASONE (LEN/DEX) THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (R-MM)**  
Jennifer L Curnow\* (AU), Caroline Reddel, Kate Burbury, Peter Gambill, Amanda Choo, Judith Trotman, Kevin Lynch, Hang Quach, H Miles Prince, David Westerman, Jennifer Curnow
- P-TU-278 STUDY UTILISING A NEW BIOMARKER (GEL POINT) TO DETERMINE AT WHAT STAGE FIBRINOLYSIS MODIFIES CLOT DEVELOPMENT AND STRUCTURE**  
Matthew James Lawrence\* (UK), Sophia Stanford, Karl M Hawkins, Simon Davidson, P Rhodri Williams, Phillip Adrian Evans
- P-TU-279 ANALYSIS OF THROMBOLYSIS PROCESS IN PLASMA WITH TWO D-DIMER ORIGINAL QUANTITY KITS**  
Yasuo Magari\* (JP), Tomoharu Okazaki
- P-TU-280 CROTALUS DURISSUS ACCIDENT: CHANGES IN NATURAL ANTICOAGULATION AND FIBRINOLYTIC SYSTEMS**  
Luciana Moreira Lima\* (BR), Maria das Gracas Carvalho, Luci Maria Santanna Dusse, Carlos FS Amaral
- P-TU-281 DIAGNOSIS OF NONOVERT DISSEMINATED INTRAVASCULAR COAGULATION USING CRITERIA FROM THE INTERNATIONAL SOCIETY ON THROMBOSIS AND HEMOSTASIS WITH REJECTING NEGATIVE SCORES**  
Jonghwa Lee\* (KR), Jawoo Song
- P-TU-282 CLOT LYSIS TIME IN PLATELET-RICH PLASMA: METHOD ASSESSMENT, RESPONSE TO TRANEXAMIC ACID AND COMPARISON WITH THE ASSAY IN PLATELET-POOR PLASMA**  
Panés Olga\* (CL), Oslando Padilla, Claudia G Saez, Alejandro Berkovits, Jaime Pereira, Diego Mezzano
- P-TU-283 AN ATTENUATED FIBRINOLYTIC PROFILE IS ASSOCIATED WITH RISK OF A FIRST MYOCARDIAL INFARCTION AS MEASURED USING A GLOBAL HAEMOSTATIC ASSAY**  
Shu He\* (SE), Karin Leander, Margareta Blomback, Hakan Wallen
- P-TU-284 PROLONGED CLOT LYSIS TIME (CLT) IN PRP AND PPP IN HYPERCHOLESTEROLEMIA (HYPERCH): PROTECTIVE EFFECT OF HDL-CHOLESTEROL AND PARTIAL CORRECTION BY ATORVASTATIN**  
Diego Mezzano\* (CL), Monica Acevedo, Valeria Matus, Alejandro Berkovits, Jaime Pereira, Olga Panes

### Deep vein thrombosis and pulmonary embolism

- P-TU-285 VENOUS THROMBOEMBOLISM IN NEUROSURGERY PATIENTS**  
Kerry Hitos\* (AU), John P Fletcher
- P-TU-286 ACCURACY OF WELLS SCORING IN PREDICTION OF DEEP VEIN THROMBOSIS**  
Malgorzata Dybowska (PL), Witold Z Tomkowski\*, Renata Gralec, Janusz Burakowski, Adam Jozwik, Pawel Kuca

Tuesday Poster



51

## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-287 RISK FACTORS, ANTITHROMBOTIC TREATMENT AND OUTCOME IN RETINAL VEIN OCCLUSION: AN AGE-RELATED PROSPECTIVE COHORT STUDY**  
Maria Teresa Sartori\* (IT), Sofia Barbar, Annalisa Dona', Stefano Piermarocchi, Elisabetta Pilotto, Graziella Saggiolato, Andrea Ballin, Paolo Prandoni
- P-TU-288 PREVENTION OF THROMBOEMBOLIC EVENTS IN TRAUMATOLOGIC SURGERY: A META-ANALYSIS OF RANDOMIZED TRIALS**  
Celine Chapelle\* (FR), Nadia Rosencher, Paul Zufferey, Patrick Mismetti, Michel Cucherat, Silvy Laporte
- P-TU-289 BODY HEIGHT AS A RISK FACTOR FOR RECURRENT VENOUS THROMBOSIS**  
Linda E Flinterman\* (NL), Astrid Hylckama Vlieg, Frits R Rosendaal, Suzanne C Cannegieter
- P-TU-290 EFFICACY AND SAFETY OF THERAPEUTIC DOSAGES OF LOW-MOLECULAR WEIGHT HEPARIN IN HIGH-RISK PATIENTS UNDERGOING MAJOR ORTHOPAEDIC SURGERY**  
Jan Beyer-Westendorf\* (DE), Lars Donath, Joerg Luetzner, Sebastian Werth, Norbert Weiss
- P-TU-291 A PROSPECTIVE STUDY ON VENOUS THROMBOEMBOLISM FOLLOWING SPINAL SURGERY: USE OF THROMBOPROPHYLAXIS AND ASSOCIATED BLEEDING COMPLICATIONS**  
Kerry Hitos\* (AU), James Rogers, Gavin Soo, Andrew Cree, Mark Dexter, Gordon Dandie, Charles New, Michael Fearnside, John Cummine, Brian Owler, John P Fletcher
- P-TU-292 ALGORITHM FOR THE MANAGEMENT OF PORTAL VEIN THROMBOSIS: A PROSPECTIVE STUDY IN PATIENTS WITH LIVER CIRRHOSIS**  
Maria Teresa Sartori\* (IT), Marco Senzolo, Valeria Rossetto, Patrizia Burra, Umberto Cillo, Patrizia Boccagni, Paolo Gasparini, Emmanuel Tsochatzis, Paolo Simioni, Andrew K. Burroughs
- P-TU-293 STATIN USE AND FIRST VENOUS THROMBOSIS RISK: A SUBGROUP ANALYSIS WITHIN THE MEGA STUDY INTO CLINICAL UTILITY AND MECHANISM**  
Willem M Lijfering\* (NL), Astrid van Hylckama Vlieg, Frits Rosendaal, Frits Cannegieter
- P-TU-294 RISK OF VENOUS THROMBOSIS ASSOCIATED WITH COAGULATION FACTOR VIII AND ITS INTERRELATIONSHIP WITH OTHER PROCOAGULANT AND ENVIRONMENTAL RISK FACTORS**  
Willem M Lijfering\* (NL), Frits Rosendaal, Pieter Reitsma, Suzanne Cannegieter
- P-TU-295 THE ASSOCIATION OF CONCOMITANT USE OF ESTROGEN HORMONES AND STATINS AND THE RISK OF VENOUS THROMBOSIS**  
Astrid van Hylckama Vlieg\* (NL), Nicholas L. Smith, Willem M. Lijfering, Frits R. Rosendaal, Bruce M. Psaty
- P-TU-296 IMPLEMENTATION OF A VENOUS THROMBOEMBOLISM (VTE) RISK ASSESSMENT TOOL TO IMPROVE INPATIENT THROMBOPROPHYLAXIS**  
Gunjan Varma\* (UK), Sarah Mills, Charles Gutteridge, Peter MacCallum
- P-TU-297 THE INCIDENCE OF VENOUS THROMBOEMBOLISM (VTE) IN EAST LONDON**  
James Uprichard\* (UK), K Boomla, S Mills, C Gutteridge, P K MacCallum
- P-TU-298 ANATOMICAL LOCATION OF THROMBI AND A COMPARISON OF THROMBUS LENGTH AS A MARKER OF EXTENSIVENESS IN PATIENTS WITH PULMONARY EMBOLI VERSUS DEEP-VEIN THROMBOSIS**  
Kirsten van Langevelde\* (NL), S. C. Cannegieter, P. W.J. Vincken, C. J. van Rooden, F. R. Rosendaal, A. Sramek
- P-TU-299 EFFICACY AND SAFETY OF VTE PROPHYLAXIS WITH FONDAPARINUX OR LOW-MOLECULAR WEIGHT HEPARIN IN A LARGE COHORT OF CONSECUTIVE PATIENTS UNDERGOING MAJOR ORTHOPAEDIC SURGERY**  
Jan Beyer-Westendorf\* (DE), Lars Donath, Sebastian Werth, Joerg Luetzner, Norbert Weiss



## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-300 VENOUS THROMBOEMBOLISM VALIDATION STUDY OF THE IMPROVE RISK ASSESSMENT MODELS IN THE MEDICAL PATIENT (VTE-VALOURR)**  
Charles Mahan\* (US), Yang Liu, James D Douketis, Alexander GG Turpie, Alexander C Spyropoulos
- P-TU-301 FONDAPARINUX FOR ISOLATED SUPERFICIAL-VEIN THROMBOSIS OF THE LEGS: A COST-EFFECTIVENESS ANALYSIS**  
Marc Blondon\* (CH), Marc Righini, Henri Bounameaux, David L Veenstra
- P-TU-302 SHOULD PATIENTS WITH SUSPECTED NON-MASSIVE PULMONARY EMBOLISM RECEIVE ANTICOAGULATION PRIOR TO THE DEFINITE DIAGNOSIS ? A DECISION ANALYSIS**  
Marc Blondon\* (CH), Gregoire Le Gal, Drahomir Aujesky, Marc Righini, Arnaud Perrier
- P-TU-303 VENOUS THROMBOEMBOLISM (VTE) IS A RARE COMPLICATION WITHOUT APPARENT RISK FACTORS IN JAPANESE MYELOMA PATIENTS TREATED WITH THALIDOMIDE**  
Atsushi Kato\* (JP), Keiichiro Hattori, Michiro Mikoshiba, Hina Takano, Minoru Nakane
- P-TU-304 MOLECULAR ANALYSIS OF THE PHENOTYPES AND GENOTYPES IN TWO CHINESE FAMILIES WITH INHERITED ANTITHROMBIN DEFIDENCY**  
Yan Xia\* (CN)
- P-TU-305 EVALUATION OF THE RISK FACTORS OF VENOUS THROMBOEMBOLISM IN JAPANESE SURGICAL AND NON-SURGICAL PATIENTS USING ELECTRONIC PATIENT DATABASE**  
Masato Sakon\* (JP), Yoshihiko Maehara, Takao Kobayashi, Norimasa Seo, Hiroshi Kobayashi, Toru Shimazui, Yasushi Ozeki
- P-TU-306 WARFARIN INTERACTIONS: A COMPARATIVE EVALUATION OF THREE DIFFERENT COMPENDIA AND A PACKAGE INSERT**  
Daniel Dias Ribeiro\* (BR), Maria Auxiliadora Parreiras Martins, Paula Perdigao Starling Carlos, Vandack Nobre, Cibele Comini Cesar, Manoel Otavio Costa Rocha, Antonio Luiz Pinho Ribeiro
- P-TU-307 RISK OF VENOUS THROMBOSIS FOR COMMON INFECTIOUS AND INFLAMMATORY DISEASES: A CASE-CONTROL STUDY**  
Daniel Dias Ribeiro\* (BR), Willem Lijfering, Astrid Van Hylckama Vlieg, Frits Rosendaal, Suzanne Cannegieter
- P-TU-308 GIESSEN THROMBOPHILIA STUDY: LIPOPROTEIN (A) IN VENOUS THROMBOEMBOLISM**  
Bettina Kemkes-Matthes\* (DE), Anette Kirsch-Altena, Angela Korb-Bangang, Kathrin Heidinger, Ronald Fischer
- P-TU-309 GIESSEN THROMBOPHILIA STUDY: FACTOR VIII:C IN VENOUS THROMBOEMBOLISM**  
Bettina Kemkes-Matthes\* (DE), Anette Kirsch-Altena, Kathrin Heidinger, Ronald Fischer
- P-TU-310 LIPID LOWERING DRUGS AND THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM**  
Aurelien Delluc\* (FR), Emmanuelle Le Moigne, Cecile Tromeur, Frederic Rolland, Francis Couturaud, Gregoire Le Gal, Dominique Mottier, Karine Lacut
- P-TU-311 CORRELATION BETWEEN CLINICAL SUSPICION AND BIOLOGICAL DIAGNOSIS OF HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) : EXPERIENCE FROM A SINGLE CENTER**  
Amparo Santamaria\* (ES), Albert Esquirol, Amparo Santamaria, Montserrat Borrell, Dolores Llobet, Cristina Vallve, Veronica Orantes, Jordi Fontcuberta
- P-TU-312 COMPETING RISK OF ATHEROSCLEROTIC RISK FACTORS FOR ARTERIAL AND VENOUS THROMBOSIS IN A GENERAL POPULATION. THE TROMSO STUDY 1994-2007**  
Sigrid Kufaaas Braekkan\* (NO), Erin M. Hald, Ellisiv B. Mathiesen, Inger Njolstad, Tom Wilsgaard, Frits R. Rosendaal, John-Bjarne Hansen

Tuesday Poster



53

## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-313 REPEATED NT-PROBNP TESTING AND RISK FOR ADVERSE CLINICAL OUTCOME AFTER ACUTE PULMONARY EMBOLISM**  
Wendy Zondag\* (NL), Mariette Agterof, Roger Schutgens, Olaf Dekkers, Douwe Biesma, Menno Huisman
- P-TU-314 RIGHT VENTRICULAR DYSFUNCTION IN PATIENTS WITH PULMONARY EMBOLISM TREATED AT HOME OR IN THE HOSPITAL**  
Wendy Zondag\* (NL), Birgitta I. Hiddinga, Geert Labots, Lies M. A. Vingerhoets, Lucia J.M. Kroft, Menno V. Huisman
- P-TU-315 VENOUS THROMBOEMBOLISM IN PATIENTS WITH DEMENTIA**  
Adriana Visona\* (IT), Manuel Jesus Nunez, Joan Carles Villalba, Ernesto Cebrian, Luciano Lopez-Jimenez, Marta Nunez, Tali-Anne Szwebel, Jose Manuel Luque, Maria Jesus Jaras, Manuel Monreal, and the RIETE INVESTIGATORS
- P-TU-316 SEASONAL VARIATION OF VENOUS THROMBOSIS: A CONSECUTIVE CASE SERIES WITHIN THE MEGA AND TROMSO STUDY**  
Daniel Dias Ribeiro\* (BR), Sigrid K Braekkan, Willem M Lijfering, Ellen E Brodin, Frits R Rosendaal, John-Bjarne Hansen
- P-TU-317 THE IMPLEMENTATION OF THE PADUA PREDICTIVE SCORE HAS THE POTENTIAL TO INCREASE THE RATE OF VTE PROPHYLAXIS IN HIGH-RISK MEDICAL PATIENTS**  
Valeria Rossetto\* (IT), Sofia Barbar, Alessandra Ferrari, Daniela Tormene, Antonio Pagnan, Paolo Prandoni
- P-TU-319 FOUR DIFFERENT CLINICAL DECISION RULES IN THE DIAGNOSTIC WORK-UP OF PE IN PATIENTS WITH A MALIGNANCY**  
Josien van Es\* (NL), I. C.M. Mos, R. A. Douma, P. M.G. Erkens, T. A.C. Nizet, M. Durian, A. A. van Houten, H. M.A. van Hofstee, K. A. Boomars, E. F. Ullmann, H. R. Buller, M. V. Huisman, P. W. Kamphuisen
- P-TU-320 A CLINICAL AUDIT INTO THE USE OF A VENOUS THROMBOEMBOLISM RISK ASSESSMENT TOOL IN A LARGE TERTIARY REFERRAL HOSPITAL IN NORTHERN IRELAND**  
Daniel Gerard O'Callaghan\* (UK), Claire Corrigan, Gary Benson
- P-TU-321 EFFECT OF LOW ALBUMIN ON AVAILABLE MONITORING METHODS FOR THERAPEUTIC UNFRACTIONATED HEPARIN THERAPY**  
Oxana Tcherniantchouk\* (US), Ali Reza Rejali, Sylvia Martin Stone
- P-TU-322 ARTERIAL AND VENOUS THROMBOSIS IN DIALYSIS PATIENTS**  
Gurbey Ocak\* (NL), Carla Y. Vossen, Joris I. Rotmans, Willem M. Lijfering, Frits R. Rosendaal, Karien J. Parlevliet, Ray T. Krediet, Els W. Boeschoten, Friedo W. Dekker, Marion Verduijn
- P-TU-323 RISK FACTORS FOR POST-DISCHARGE BLEEDING IN US MEDICALLY ILL PATIENTS AT RISK OF VENOUS THROMBOEMBOLISM (VTE)**  
Charles Mahan\* (US), Winslow Klaskala, Maxine Fisher, An-Chen Fu, Larry E Fields, Roger Mills, Judith J Stephenson, Tom Wasser, Joseph Singer, Alex C Spyropoulos
- P-TU-324 SEVERITY OF ILLNESS STRONGLY PREDICTS DEVELOPMENT OF VENOUS THROMBOEMBOLISM IN HOSPITALIZED MEDICAL PATIENTS WITHOUT CANCER**  
Richard H White\* (US), Beate Danielsen, Daniel J Tancredi, Calvin H Hirsch, Jeffrey Schein, Larry E Fields, CV Damaraju, Monika Raut, Scott Kaatz
- P-TU-325 AUTOPSY RATES AND THE INCIDENCE OF PULMONARY EMBOLISM: AN UNDERCOUNT**  
John A Heit (US), Kent R Bailey, Tanya M Petterson\*, Aneel A Ashrani, Daniel J Crusan, Cynthia L Leibson



## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-326 THE PREVALENCE OF VARIOUS CLINICAL MANIFESTATIONS OF VENOUS THROMBOEMBOLISM IN THE GROUP OF 441 PATIENTS**  
Jana Hirmerova\* (CZ), Jitka Seidlerova
- P-TU-327 DIAGNOSIS OF HEPARIN INDUCED THROMBOCYTOPENIA WITH WHOLE BLOOD PLATELET AGGREGATION TEST AND ELISA ANTI PF4 HEPARIN TEST**  
Mariette D Lepine-Martin\* (CA), Annie Lacroix, Patrice Beauregard, Jean Dufresne, Line Delisle, Rami Kotb, Hans Knecht, Richard Leblanc, Carole St-Onge
- P-TU-328 EFFECT OF RACE/ETHNICITY ON THE RISK OF ACUTE VENOUS THROMBOEMBOLISM (VTE) DURING MEDICAL HOSPITALIZATION AND AFTER HOSPITAL DISCHARGE**  
Richard H White\* (US), Beate Danielsen, Daniel J Tancredi, Calvin H Hirsch, Jeffrey Schein, Larry Fields, CV Dajamaru, Monika Raut, Scott Kaatz
- P-TU-329 COMPARATIVE EFFECTIVENESS OF LOW MOLECULAR WEIGHT HEPARIN (LMWH) PROPHYLAXIS IN MORBIDLY OBESE AND LESS OBESE PATIENTS UNDERGOING TOTAL KNEE ARTHROPLASTY (TKA)**  
Richard H White\* (US), Banafsheh Sadeghi, Amy Strater, Laurie Hensley, Julie Cerese, Greg Maynard, Patrick S Romano
- P-TU-330 FREQUENCY OF ARTERIOVENOUS THROMBOSIS IN END STAGE RENAL DISEASE PATIENTS**  
Munira Borhany\* (PK), Tahir Shamsi, Arshi Naz, Zafar Mirza Naqi, Syed Anwar Naqvi, Rizvi Adibul Hassan
- P-TU-331 TRANSFUSIONS, BLEEDINGS, AND PREVENTION OF VENOUS THROMBOEMBOLISM WITH ENOXAPARIN OR FONDAPARINUX IN REAL-LIFE PRACTICE**  
Philippe Girard\* (FR), Joelle Demaria, Raffaele Caliandro, Daniele Girard, Alice De Sanctis, Jean-Baptiste Stern
- P-TU-332 MDCT-DETECTED EMBOLIC BURDEN AND CLINICAL OUTCOME IN PATIENTS WITH ACUTE PULMONARY EMBOLISM**  
Cecilia Becattini\* (IT), Maria Cristina Vedovati, Marthe Schreuder, Luca Masotti, Piotr Pruszczyk, Franco Casazza, Aldo Salvi, Stefano Grifoni, Anna Carugati, Stavros Konstantinides, Pieter Kamphuisen, Michele Duranti, Giancarlo Agnelli
- P-TU-333 THYROID DISEASE, ANTITHYROID OR THYREOMIMETIC AGENTS, AND THE RISK OF PULMONARY EMBOLISM**  
Bregje van Zaane\* (NL), Alessandro Squizzato, Sara Biere-Rafi, Patrick C Souverein, Dees PM Brandjes, Harry R Buller, Victor EA Gerdes, Antonius de Boer
- P-TU-334 TWO NOVEL MUTATIONS IN TWO UNRELATED SUBJECTS WITH HEREDITARY PROTEIN S DEFICIENCY**  
Zhifang Xing\* (CN)
- P-TU-335 A RARE SPLICING MUTATION IN PROS1 GENE OF KOREAN PATIENT WITH TYPE I HEREDITARY PROTEIN S DEFICIENCY**  
Jonghyeon Choi (KR), Duck Jin Hong\*, Seung Jun Choi, Hee-Jin Kim, Myung Hee Chang, Sue Jung Kim, Jaewoo Song, Jong Rak Choi, Jong-Ha Yoo

### Genetic determinants and epidemiology

- P-TU-336 INTRA-INDIVIDUAL VARIABILITY IN STEADY PATIENTS ON LONG-TERM ACENOCOUMAROL THERAPY**  
Virginia Perez-Andreu\* (ES), Vanessa Roldan, Javier Corral, JR Gonzalez-Porras, F Ferrando, F Lopez Fernandez, Cristina Pascual, Nuria Garcia-Barbera, Jordi Fontcuberta, Vicente Vicente Garcia, Rocio Gonzalez-Conejero

Tuesday Poster



55

## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-337 GENETIC DETERMINANTS OF PLATELET COUNTS AND IMMATURE PLATELET FRACTION (IPF). RESULTS FROM THE GAIT PROGRAM**  
Nuria Pujol-Moix\* (ES), Anna Brichs, Miquel Vazquez-Santiago, Angel Martinez-Perez, Josep F Nomdedeu, Ramon Ayats, Jordi Fontcuberta, Joan Carles Souto, Jose Manuel Soria
- P-TU-338 GENETIC DETERMINANTS OF BLOOD CELL COUNTS AND RETICULOCYTE COUNTS. RESULTS FROM THE GAIT PROGRAM**  
Nuria Pujol-Moix\* (ES), Anna Brichs, Joan Carles Souto, Leonor Rib, Ramon Ayats, Jordi Fontcuberta, Josep F Nomdedeu, Jose Manuel Soria
- P-TU-339 CEREBRAL VENOUS THROMBOSIS: RISK FACTORS**  
Antonella Tufano\* (IT), Mirko Di Capua, Matteo Nicola Dario Di Minno, Anna Guida, Anna Maria Cerbone, Giovanni Di Minno
- P-TU-340 PHENOTYPIC AND GENOTYPIC CHARACTERIZATION OF "ATYPICAL" MUTATIONS OF THE PROTHROMBIN GENE IN 23 PATIENTS**  
Claire Flaujac (FR), Sophie Lobies, Olivier Kosmider, Etienne Audureau, Jacqueline Conard\*, Marie-Helene Horellou, Michaela Fontenay
- P-TU-341 INHERITED THROMBOPHILIA AND THROMBOSIS IN GEORGIAN POPULATION**  
Nugzar SH. Pargalava\* (GE), Nino A. Pirtskhelani, Nugzar Sh. Pargalava, Mamuka G. Bokuchava, Nino Kochiashvili
- P-TU-342 FAMILY HISTORY OF MYOCARDIAL INFARCTION AS A RISK FACTOR FOR VENOUS THROMBOEMBOLISM AMONG WHITES AND BLACKS**  
Fatima Donia Mili\* (US), W. Craig Hooper, Cathy Lally, Harland Austin
- P-TU-343 INFLAMMATION AND RISK OF COGNITIVE DECLINE IN BLACK AND WHITE AMERICANS IN THE REASONS FOR GEOGRAPHIC AND RACIAL DIFFERENCES IN STROKE (REGARDS) STUDY**  
Sarah Gillett\* (US), Leslie A McLure, Virginia G Wadley, Stephen P Glasser, Virginia J Howard, Brett M Kissela, Frederick W Unverzagt, Nancy S Jenny, Mary Cushman
- P-TU-344 CYP2C9 POLYMORPHISM IN NORMAL SAUDI INDIVIDUALS AND PATIENTS WITH VENOUS THROMBOSIS AND THOSE REQUIRING LOW DOSE WARFARIN - A PROSPECTIVE STUDY**  
Jalal Saour\* (SA), Atia Sheereen, Basil Saour, Layla Mammo
- P-TU-345 INHERITED THROMBOPHILIA IN NORMAL SAUDIS AND THOSE WITH VENOUS THROMBOSIS-THE SAUDI THROMBOSIS AND FAMILIAL THROMBOPHILIA REGISTRY**  
Jalal Saour\* (SA), Atia Sheereen, Tanya Saour, Mohammed Shoukri, Layla Mammo
- P-TU-346 PROTHROMBIN MUTATION GENE (G-A 20210) IN THROMBOPHILIC PATIENTS AND GENERAL POPULATION**  
Jan Stasko\* (SK), Peter Kubisz, Juraj Chudej, Daniela Kotulicova, Radoslava Camajova, Lenka Bartosova, Ivana Plamenova, Juraj Sokol
- P-TU-347 ANTITHROMBIN DEFICIENCY: A CLINICAL AND GENETIC STUDY OF NINE TAIWANESE PATIENTS**  
Yeu-Chin Chen\* (TW), Shin-Nan Cheng, Hu Shu-Hsia, Yiang Amy
- P-TU-348 ASSOCIATION OF P-SELECTIN GENE POLYMORPHISMS WITH ARTERIAL ISCHEMIC STROKE IN CHILDREN**  
Desiree Coen Herak\* (HR), Marina Pavic, Margareta Radic Antolic, Jasna Lenicek Krleza, Renata Zrinski Topic, Slavica Dodig, Renata Zadro



## POSTER PRESENTATIONS

Tuesday, July 26, 2011

### Antiphospholipid syndrome

- P-TU-349 THE 4G/5G POLYMORPHISM OF THE PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI-1) GENE AND THROMBOSIS IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME**  
Lilia I Mukhametova\* (RU), Dmitrii A Gulin, Rosa B Aisina, Tat'yana M Reshetnyak, Ekaterina V Ostryakova, Natalia V Seredavkina, Natalia L Patrusheva, L I Patrushev, E N Aleksandrova, Karina B Gershkovich
- P-TU-350 THE SIGNIFICANCE OF PHOSPHATIDYLSERINE (PHS) AS PREDICTOR OF ANTIPHOSPHOLIPID SYNDROME (APS)**  
Tarek Owaidah\* (SA), Haeethm Khogeer
- P-TU-351 ANTIPHOSPHOLIPID ANTIBODIES AND THE ANTIPHOSPHOLIPID SYNDROME IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS**  
Katia M Taouli\* (DZ), Rawda Sari, El Hadj Kendouci, Omar Boudghene Stambouli, Jean Francois Schved
- P-TU-352 PHOSPHATIDYLSERINE-DEPENDENT ANTIPROTHROMBIN ANTIBODIES (APS/PT) IS A USEFUL PREDICTIVE MARKER OF THROMBOSIS IN PATIENTS WITH AUTOIMMUNE DISEASES**  
Kotaro Otomo\* (JP), Olga Amengual, Tatsuya Atsumi, Yuichiro Fujieda, Masaru Kato, Tetsuya Horita, Shinsuke Yasuda, Walter Binder, Takao Koike
- P-TU-353 EXPERIENCE WITH THE SAPPORO CRITERIA FOR THE ANTIPHOSPHOLIPID SYNDROME (APS) IN A PUBLIC CITY HOSPITAL**  
Michael A Nardi\* (US), Fauzia Beig, Margaret Karpatkin
- P-TU-354 EVALUATION OF DIFFERENT ASSAYS AND METHODS FOR INTERPRETATION OF RESULTS FOR LUPUS ANTICOAGULANT (LA) TESTING, ACCORDING TO 2009 SSC/ISTH GUIDELINES**  
Elizabeth M Duncan\* (AU), Oi-Lin Lee, Olivia Yacoub, Simon McRae
- P-TU-355 DISCRIMINATION OF A LUPUS ANTICOAGULANT CAUSED BY ANTIPHOSPHOLIPID ANTIBODIES OR RIVAROXABAN USING TAIPAN VENOM TIME**  
Gwendolyn Margaretha van Os\* (NL), Bas de Laat, Pieter Willem Kamphuisen, Joost C. Meijers, Philip G. de Groot
- P-TU-356 EVOLUTIONARY CONSERVATION OF  $\beta_2$ -GLYCOPROTEIN I IN VERTEBRATES**  
Cetin Agar\* (NL), Phillip G. de Groot, Arnoud J. Marquart, Joost C.M. Meijers
- P-TU-357 EVALUATION OF LUPUS ANTICOAGULANTS DETECTION BY PHOTO-OPTICAL AND MECHANICAL COAGULOMETERS**  
Napaporn Archararit\* (TH), Kacharin Aryurachai, Bubpha Rachakom, Pantep Angchaisuksiri, Suporn Chuncharunee
- P-TU-358 PREVALENCE AND LABORATORY IDENTIFICATION OF LUPUS ANTICOAGULANTS IN THAI PATIENTS**  
Kacharin Aryurachai\* (TH), Napaporn Archararit, Bubpha Rachakom, Pantep Angchaisuksiri, Suporn Chuncharunee
- P-TU-359 RESIDUAL VENOUS THROMBOSIS AS A MARKER OF ATHEROSCLEROSIS DEVELOPMENT IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME**  
Witold Z Tomkowski\* (PL), Bogdan Hajduk, Grzegorz Malek, Pawel Kuca, Malgorzata Dybowska, Malgorzata Sobieszczanska - Malek, Martyna Meissner, Witold Tomkowski
- P-TU-360 OUTCOME OF KIDNEY TRANSPLANTATION IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES: A CASE SERIES**  
Karen A Breen\* (UK), K Sriharan, J Olsburgh, BJ Hunt

Tuesday Poster



57

## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-361 ANTITHROMBOTIC EFFECTS OF HYDROXYCHLOROQUINE IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES AND SYSTEMIC LUPUS ERYTHEMATOSUS**  
Karen A Breen\* (UK), K Parmar, BJ Hunt

### Disseminated intravascular coagulation

- P-TU-362 DYSREGULATION OF INFLAMMATORY AND HEMOSTATIC MARKERS IN DISSEMINATED INTRAVASCULAR COAGULATION**  
Debra A Hoppensteadt\* (US), Josephine Cunanan, Cafer Adiguzel, Jawed Fareed, Inder Kaul
- P-TU-363 THE CLINICAL FEATURES AND GOOD OUTCOMES OF 35 DISSEMINATED INTRAVASCULAR COAGULATION (DIC) CASES TREATED WITH RECOMBINANT HUMAN SOLUBLE THROMBOMODULIN (RTM)**  
Noriaki Kawano\* (JP), Shuro Yoshida, Nobuyuki Ono, Daisuke Himeji, Naoko Ikeda, Ikuo Kikuchi, Kiyoshi Yamashita, Akira Ueda
- P-TU-364 SPATIAL CLOT GROWTH CAN PREDICT PROTHROMBOTIC CHANGES OF COAGULATION STATE IN SEPSIS**  
Natalya P Soshitova\* (RU), Sergey S Karamzin, Anna N Balandina, Olga A Fadeeva, Anna V Kretchetova, Gennadiy M Galstian, Mikhail A Panteleev, Fazoil I Ataullakhanov
- P-TU-365 THE ROLE OF DIC IN "EARLY" SEPSIS DEVELOPMENT IN SEVERE BURNED M.V. PRESNYAKOVA NIZHNY NOVGOROD RESEARCH INSTITUTE OF TRAUMATOLOGY AND ORTHOPEDICS NIZHNY NOVGOROD, RUSSIA**  
Marina Vladimirovna Presnyakova\* (RU)
- P-TU-366 INCREASED LEVELS OF HISTONE IN HUMAN PLASMA IN SEPTIC PATIENTS WITH DIC**  
Kazuo Kawasugi\* (JP), Tadashi Yamamoto, Ryouyusuke Shirasaki, Haruko Tashiro, Nobu Akiyama, Naoki Shirafuji
- P-TU-367 ON THE CLASSIFICATION OF ACUTE DIC SYNDROME**  
Nadezda A. Vorobyeva\* (RU)
- P-TU-368 DEGRADATION OF CROSS-LINKED FIBRIN BY LEUKOCYTE ELASTASE AS ALTERNATIVE PATHWAY FOR PLASMIN-MEDIATED FIBRINOLYSIS IN SEPSIS-INDUCED DISSEMINATED INTRAVASCULAR COAGULATION**  
Seiji Madoiwa\* (JP), Hideyuki Tanaka, Yutaka Nagahama, Yuji Kashiwakura, Asuka Sakata, Atsushi Yasumoto, Tsukasa Ohmori, Jun Mimuro, Yoichi Sakata
- P-TU-369 POST MARKETING SURVEILLANCE OF THE SAFETY AND EFFECTIVENESS OF THROMBOMODULIN ALFA IN JAPANESE PATIENTS WITH DIC**  
Tatsuhiko Kuroda\* (JP), Yoichi Sakata, Hoyu Takahashi, Hajime Tsuji, Jun Mimuro, Yutaka Eguchi, Isao Kitajima, Tadashi Matsushita
- P-TU-370 ISTH DIC SCORE: INTEREST OF PLATELET ACTIVATION MARKERS IN ICU PATIENTS**  
Barry J Woodhams\* (FR), Philippe Cauchie, Sandra Ollieuz, Barry Woodhams, Mariette Adam, Karim Zouaoui Boudjeltia, Nadine Deschepper, Charles Cauchie, Patrick Biston
- P-TU-371 RECOMBINANT THROMBOMODULIN IMPROVES PROGRESSION OF COAGULOPATHY AND ORGAN INJURY BY INHIBITING HIGH MOBILITY GROUP BOX 1 PROTEIN IN SEVERE ACUTE PANCREATITIS**  
Toshihisa Tamura\* (JP), Kohji Okamoto, Masaru Nagato, Noritaka Minagawa, Aiichirou Higure, Koji Yamaguchi





## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-372 THERAPEUTIC EFFECT OF RECOMBINANT THROMBOMODULIN ON THE HEMOSTATIC AND INFLAMMATORY RESPONSE IN PATIENTS WITH SEPTIC DIC**  
Noritaka Yada\* (JP), Kenji Nishio, Keisuke Takano, Hideki Asai, Tomoo Watanabe, Tadahiko Seki, Tooru Ueyama, Hidetada Hukushima, Yasuyuki Urizono, Tomoaki Hata, Kazuo Okuchi
- P-TU-373 ENHANCED HOST DEFENSE TO E. COLI BY INHIBITION OF COAGULATION IS ASSOCIATED WITH INCREASED TNF PRODUCTION, DECREASED MKP-1 EXPRESSION AND INCREASED P38 PHOSPHORYLATION**  
Cornelis van 't Veer\* (NL), Keizer Veer, Kelly Maijoor, Nigel Mackman, Danielle Kruijswijk, Petra van den Pangaart, Tom van der Poll
- P-TU-374 EFFICACY OF THE COMBINED THERAPY WITH RECOMBINANT HUMAN SOLUBLE THROMBOMODULIN AND ANTITHROMBIN IN SEPTIC DIC PATIENTS**  
Taisuke Kitamura\* (JP), Hiroyasu Ishikura, Akira Murai, Junichi Tanaka, Takeshi Nishida, Daiki Ohta, Takanori Kamitani, Takehiro Umemura, Tomoko Sugimura, Kunihiro Matsuo
- P-TU-375 PROTECTIVE EFFECTS OF RECOMBINANT HUMAN SOLUBLE THROMBOMODULIN ON ISCHEMIA-REPERFUSION INJURY OF RAT LIVER WERE MEDIATED BY HIGH MOBILITY GROUP BOX 1 PROTEIN**  
Kohji Okamoto\* (JP), Toshihisa Tamura, Masaru Nagato, Aiichirou Higure, Koji Yamaguchi
- P-TU-376 EFFICACY OF RECOMBINANT THROMBOMODULIN IN SEPTIC DISSEMINATED INTRAVASCULAR COAGULATION REFRACTORY TO ANTITHROMBIN CONCENTRATE ANALYZED BY MOLECULAR MARKERS**  
Yutaka Eguchi\* (JP)

Tuesday Poster

### Pregnancy, hormones, women's issues

- P-TU-377 CLINICAL CHARACTERISTICS OF WOMEN WHO EXPERIENCE VENOUS THROMBOEMBOLISM DURING COMBINED ORAL CONTRACEPTIVE USE**  
Elizabeth Femma van Vlijmen\* (NL), Nic Veeger, Marieke Knol, Vladimir Tichelaar, Anja Makelburg, Hanneke Kluin-Nelemans, Karina Meijer
- P-TU-378 THE TEAM PROJECT: SPANISH REGISTRY OF THROMBOEMBOLIC DISEASE (TD) IN WOMEN RELATED WITH SPECIAL CLINICAL SETTINGS**  
Amparo Santamaria\* (ES), Dolores Tassies, Oscar Martinez, Javier Rodriguez-Martorell, Im Ramirez, M Lecumberri, M Casellas, Mj Gutierrez-Pimentel, Pilar Llamas, Ana Redondo-Izal
- P-TU-379 STRATEGIES FOR THROMBOEMBOLISM PREVENTION IN PREGNANCY : INTEGRATION BETWEEN HOSPITAL AND PRIMARY HEALTH CARE UNITS**  
Sophie Testa\* (IT), Oriana Paoletti, Enrica Ronca, Alberto Rigolli, Emilia Cancellieri, Anke Zimmermann, Deborah Mammoliti, Aldo Riccardi
- P-TU-380 INCREASED LEVELS OF SEX HORMONE BINDING GLOBULIN IN ASSOCIATION WITH VENOUS THROMBOSIS**  
Bernardine H Stegeman\* (NL), Hans L Vos, Frans M Helmerhorst, Astrid Van Hylckama Vlieg, Pieter H Reitsma, Frits R Rosendaal
- P-TU-381 ANTI XA LEVELS IN PREGNANT WOMEN OF DIFFERENT WEIGHTS RECEIVING ENOXAPARIN THROMBOPROPHYLAXIS DURING PREGNANCY**  
Karen A Breen\* (UK), K Bramham, K Parmar, S Robinson, C Nelson-Piercy, BJ Hunt
- P-TU-382 DOES LONG-TERM PROPHYLAXIS INFLUENCE THE BONE MINERAL DENSITY OF PREGNANT WOMEN?**  
Zdenka Hajsmanova\* (CZ), Jitka Slechtova



59

## POSTER PRESENTATIONS

Tuesday, July 26, 2011

**P-TU-383 ELEVATED LIPOPROTEINE (A) LEVELS AND THE HPA1-B ALLELE OF THE PLATELET INTEGRIN ALPHAIIA-BETA3 ARE RISK DETERMINANTS OF SEVERE INTRAUTERINE GROWTH RESTRICTION (IUGR)**

Andrea Gerhardt\* (DE), Heimo Beneke, Ruediger E. Scharf, Rainer B. Zotz

**P-TU-384 FREQUENCY OF F V LEIDEN MUTATION IN 600 FEMALES WITH VENOUS THROMBOEMBOLISM IN ASSOCIATION WITH ORAL CONTRACEPTIVE USE**

Petr Dulicek\* (CZ), Jaroslav Maly, Martin Beranek

**P-TU-385 THROMBOSIS AND PREGNANCY IN HEREDITARY THROMBOPHILIAS**

Ivo Elezovic\* (RS), Darko Antic, Predrag Miljic, Valentina Djordjevic, Ljudmila Stojanovic, Olivera Markovic, Mirjana Kovac

**P-TU-386 THROMBOPHILIA, INFLAMMATION IN PREGNANT PATIENTS WITH METABOLIC SYNDROME**

Tatiana B Radulovich (RU), Ekaterina B Perederyaeva, Alexander D Makatsariya\*

**P-TU-387 PREGNANCY-RELATED ISCHEMIC STROKE: A COHORT STUDY**

Elvira Grandone\* (IT), Giovanni Luca Tiscia, Donatella Colaizzo, Filomena Cappucci, Vincenzo Inchingolo, Carlo Vigna, Lucia Fischetti, Patrizia Vergura, Maurizio Margaglione

**P-TU-388 FIBRIN MONOMER (FM) LEVELS IN PREGNANT PATIENTS PRESENTING WITH SYMPTOMS OF DEEP VEIN THROMBOSIS (DVT)**

Marilyn A Johnston\* (CA), Mala Rupwate, JS Ginsberg, WS Chan

**P-TU-389 TISSUE FACTOR DEPENDENT AND INDEPENDENT THROMBIN GENERATION ACROSS PREGNANCY**

Kelley Carmelite Wulfkuhle\* (US), Saulius Butenas, Ira Bernstein, Kathleen Brummel-Ziedins

**P-TU-390 A PILOT AUDIT OF THROMBOPROPHYLAXIS COMPLIANCE WITH LOW MOLECULAR WEIGHT HEPARIN IN PREGNANCY**

Gillian N Pike\* (UK), Miranda Hobson, Elizabeth Hay, Michael Nash, Charles Hay, Louise Byrd

**P-TU-391 A PILOT AUDIT OF THROMBOPROPHYLAXIS COMPLIANCE WITH GRADUATED COMPRESSION STOCKINGS IN PREGNANCY**

Gillian N Pike\* (UK), Miranda Hobson, Elizabeth Hay, Michael Nash, Charles Hay, Louise Byrd

**P-TU-392 INFLUENCE OF HYPERPROLACTINEMIA TREATMENT ON HEMOSTATIC SYSTEM ACTIVITY**

Gorana Mitic\* (RS), Milica Medic-Stojanoska, Dragan T. Spasic, Nikola Curuc, Igor M. Mitic

### Cancer and thrombosis

**P-TU-393 PROCOAGULANT ACTIVITY OF INTRAVASCULAR TISSUE FACTOR IS DEPENDENT ON CARRIER BURDEN**

Garth William Tormoen\* (US), Andras Gruber, Owen JT McCarty

**P-TU-394 LONG-TERM CLINICAL OUTCOME OF INCIDENTALLY DIAGNOSED PULMONARY EMBOLISM IN PATIENTS WITH MALIGNANCY**

Paul L den Exter\* (NL), Jose Hooijer, Olaf M Dekkers, Menno V Huisman

**P-TU-395 DETECTION OF CIRCULATING HEPARIN IN CANCER PATIENTS AFTER PORT FLUSH OF INDWELLING VENOUS ACCESS DEVICES: IMPLICATIONS FOR BEVACIZUMAB ASSOCIATED PLATELET ACTIVATION**

Ali Amirkhosravi\* (US), Todd Meyer, Meghan Hatfield, Hina Desai, Mildred Amaya, Alane Drexler, Glenn Bigsby IV, Eduardo Reyes, John Barranco, Kristin Rathman, John Francis



## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-396 D-DIMER LEVEL IN PEDIATRIC PATIENTS WITH SOLID AND HEMATOLOGIC MALIGNANCIES, SHIRAZ, SOUTHERN IRAN**  
Mehran Karimi\* (IR), Nasrin Saki, Forugh Saki, Mohammad Reza Saki
- P-TU-397 ALTERATIONS OF HEMOSTATIC PARAMETERS IN THE EARLY DEVELOPMENT OF ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION RELATED COMPLICATIONS**  
Yue Han\* (CN), Depei Wu, Li Zhu, Luping Hu, Lili Zhou, Yongya Ren, Wei Zhang, Xiaojin Wu, Xiaohui Hu, Xiang Zhang, Aining Sun, Zhaoyue Wang, Changgeng Ruan
- P-TU-398 HYDROXYUREA REDUCES THROMBIN GENERATION (TG)**  
Claudine Caron\* (FR), Mathieu Wemeau, Nathalie Cambier, Emmanuelle Jeanpierre, Antoine Tournoys, Christophe Zawadzki, Nathalie Trillot, Brigitte Jude, Anne Bauters
- P-TU-399 THROMBOTIC COMPLICATIONS IN ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A REPORT OF 40 PATIENTS**  
Mahdia Saidi\* (DZ), Fatema Zohra Soltani, Mounira Bitam, Rabah Chafai, Fatiha Belhadri, Nadjoua Saidane
- P-TU-400 EXTERNAL VALIDATION OF THE MODIFIED OTTAWA RULE FOR RISK STRATIFICATION OF RECURRENT VENOUS THROMBOEMBOLISM IN CANCER PATIENTS**  
Aurelien Delluc\* (FR), Xavier Savary, Mikael Le Henaff, Emmanuelle Le Moigne, Karine Lacut, Dominique Mottier, Gregoire Le Gal
- P-TU-401 MICROPARTICLE TISSUE FACTOR ACTIVITY IS INCREASED IN CANCER PATIENTS PRIOR TO THE DEVELOPMENT OF VENOUS THROMBOEMBOLISM**  
Ankie Kleinjan\* (NL), Frederiek F. van Doormaal, Rene J. Berckmans, Nigel Mackman, David A. Manly, Pieter W. Kamphuisen, Dick J. Richel, Harry R. Buller, Auguste Sturk, Rienk Nieuwland
- P-TU-402 PRO-THROMBOTIC INDICES AND INVASIVE-ANGIOGENIC PROPERTIES OF BLOOD FROM PANCREATIC CANCER (PC) PATIENTS IMPROVE AFTER CANCER RESECTION: A PROSPECTIVE CONTROLLED STUDY**  
Hussein H Jassim Echrich\* (UK), Leigh Madden, John Greenman, Kevin Wedgwood, Downmitra Dasgupta, Anthony Maraveyas
- P-TU-403 OUTCOME AND CHARACTERISTICS OF CANCER PATIENTS WITH INCIDENTAL PE MANAGED UNDER A SPECIALISED CARE PATHWAY PROTOCOL**  
Georgios Bozas\* (UK), June Palmer, Ged Avery, Anthony Maraveyas
- P-TU-404 SOME ASPECTS OF HEMOSTASIS IN MELANOMA**  
Nadezda A. Vorobyeva\* (RU), Maria N. Smirnova
- P-TU-405 PROPHYLAXIS AND TREATMENT STRATEGIES OF VENOUS THROMBOEMBOLISM IN HEMATOLOGICAL MALIGNANCIES AMONG HEMATOLOGISTS AND ONCOLOGISTS IN THE NETHERLANDS: A NATIONAL SURVEY**  
Marielle MJBGM Beckers\* (NL), Bart J Biemond, Hans-Martin Otten, Pieter-Willem Kamphuisen
- P-TU-406 EFFECT OF PREVENTIVE ANTITHROMBOTIC MEASURES ON THROMBOTIC RISK IN ADULT PATIENTS TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA**  
Mandy Nicole Lauw\* (NL), Bronno Van der Holt, Saskia Middeldorp, Bart J Biemond

Tuesday Poster



61

## POSTER PRESENTATIONS

Tuesday, July 26, 2011

### Pediatric thrombosis

- P-TU-407 ASSESSMENT OF FUNCTIONAL FIBRINOLYSIS IN NEONATES USING MODIFIED THROMBOELASTOMETRY**  
Gili Kenet\* (IL), Rakefet Sidlik, Tzipora Strauss, Boris Shenkman, Ilya Tamarin, Aharon Lubetsky, Jacob Kuint, Uri Martinowitz
- P-TU-408 ABNORMALITY OF GLOBAL FIBRINOLYTIC ACTIVITY AND EXCESS OF PAI-1 LEVEL IN CHILDREN WITH THROMBOEMBOLISM**  
Rungrote Natesirinilkul\* (TH), Werasak Sasanakul, Ampaiwan Chuansumrit, Pragywan Kadekasam, Anannit Visudibhan, Pakawan Wongwerawattanakoon, Nongnuch Sirachainan
- P-TU-409 THE CYP4F2 V433M POLYMORPHISM DOES NOT CORRELATE WITH VITAMIN K ANTAGONIST DOSING IN A PEDIATRIC POPULATION**  
Lesley G Mitchell\* (CA), Kevin Dietrich, Ulrike Nowak-Gottl, Daria Schaffranek, Noha Sharaf Eldin, Yutaka Yasui, Christof Geisen
- P-TU-410 ORAL ANTICOAGULANT THERAPY IN CHILDREN: THE DUTCH EXPERIENCE**  
Cornelia Helena van Ommen\* (NL), Jamie Kornet, Odette D.M. Paauwe-Insinger, Anke H.H. van Geest-Daalderop, Marjolein Peters
- P-TU-411 PHENPROCOUMON AND ACENOCOUMAROL TREATMENT IN PEDIATRIC PATIENTS**  
Cornelia Helena van Ommen\* (NL), Nienke Spoor, Felix J.M. van der Meer, Barbara A. Hutten, Frans Smiers
- P-TU-412 CRITICALLY ILL CHILDREN WITH H1N1 INFLUENZA AND STAPHYLOCOCCUS AUREUS COINFECTION ARE AT A GREATER RISK FOR DEVELOPING DISSEMINATED INTRAVASCULAR COAGULATION (DIC)**  
Trung Chanh Nguyen\* (US), Ursula G Kyle, Nancy Jaimon, M. Hossein Tcharmtchi, Fong W Lam, Jun Teruya, Jorge A Coss-Bu, Laura Loftis
- P-TU-413 HYPERCOAGULATION PANEL IN PEDIATRIC SETTING. - IS IT WARRANTED?**  
Jun Teruya\* (US), Ozlem Bilen, Maha Mohamed, Eiman Hussein, Lisa Bomgaars
- P-TU-414 QUALITY OF LIFE ASSESSMENT OF CHILDREN REQUIRING LONG-TERM ORAL ANTICOAGULANT THERAPY**  
Sophie Jones\* (AU), Paul Monagle, Elizabeth Manias, Aisha Bruce, Fiona Newall
- P-TU-415 COUMARIN-INDUCED SKIN NECROSIS ASSOCIATED WITH A RARE THROMBOPHILIC COMBINATION DEFECT IN A 14-YEAR-OLD GIRL**  
Holger Seidel\* (DE), Hans-Jurgen Laws, Sebastian Weinspach, Luise Weiss, Arndt Borkhardt, Mariana Santos, Till Hoffmann, Barbara Bomke, Rudiger E Scharf
- P-TU-416 CEREBRAL SINOVENOUS THROMBOSIS (CSVT) IN CHILDREN BEYOND NEONATAL PERIOD**  
Helen Pergantou\* (GR), Maria Avgeri, Vasilis Hatziantoniou, Panagiota Xafaki, Helen Platokouki
- P-TU-417 INCIDENCE OF INFECTIOUS, THROMBOTIC AND SUBSEQUENT POST-THROMBOTIC COMPLICATIONS AFTER FEMORAL VEIN CATHETERIZATION IN A PAEDIATRIC INTENSIVE CARE UNIT**  
Cornelia Helena van Ommen\* (NL), Jeanine J. Sol, Aukje Betlem, Majorie de Neef, Anne Smets, Hennie Knoester
- P-TU-418 THROMBIN GENERATION TEST TO ASSESS THE HAEMOSTATIC POTENTIAL OF CHILDREN DURING TREATMENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)**  
Anne Claire Demulder\* (BE), Laurence Rozen, Denis Noubouossie, France Debaugnies, Sophie Huybrechts, Phu Quoc Le, Alina Ferster



## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-419 HEPARIN INDUCED SKIN NECROSIS IN A CHILD IN THE ABSENCE OF MEASURABLE HIT ANTIBODIES**  
Yaser Diab\* (CA), Suzan Williams, Leonardo Brandao, Veerle Labarque, Frederico Xavier, Darlene Castle, Paul Thorner, Elena Pope, Walter Kahr
- P-TU-420 ENDOTHELIAL CELL INJURY: A POSSIBLE PATHOGENESIS OF THROMBOSIS IN IRON DEFICIENCY ANEMIA**  
Pornchanok Iamsirirak\* (TH), Ampaiwan Chuansumrit, Werasak Sasanakul, Praguaywan Kadegasem, Pakawan Wongwerawattanakorn, Nongnuch Sirachainan

### Arterial vascular diseases

- P-TU-421 ACTIVATION MARKERS OF THROMBOGENESIS AND ENDOTHELIAL DYSFUNCTION IN END STAGE RENAL DISEASE**  
Vinod Bansal\* (US), Korosh Shareain, Debra Hoppensteadt, Evangelos Litinas, Jawed Fareed
- P-TU-422 D-DIMER IS AN INDEPENDENT PREDICTOR OF MORTALITY AT LONG-TERM FOLLOW-UP IN PATIENTS WITH SUSPECTED ACUTE CORONARY SYNDROME**  
Trygve Brugger-Andersen\* (NO), Volker Poenitz, Patrycja Naesgaard, Harry Staines, Heidi Grundt, Dennis WT Nilsen
- P-TU-424 PROPORTION OF PLATELETS, FIBRIN, AND RED BLOOD CELLS DIFFERS IN CARDIOEMBOLIC AND ATHEROTHROMBOTIC THROMBI**  
Yuichiro Sato\* (JP), Hatsue Ueda, Kinta Hatakeyama, Atsushi Yamashita, Yujiro Asada
- P-TU-425 THE RELATIONSHIP BETWEEN VENOUS THROMBOSIS AND SUBSEQUENT ARTERIAL CARDIOVASCULAR DISEASE: CAUSAL OR MEDIATED BY COMMON ETIOLOGIC FACTORS?**  
Rachel E.J. Roach\* (NL), Willem M. Lijfering, Linda E. Flinterman, Frits R. Rosendaal, Suzanne C. Cannegieter
- P-TU-426 STATINS FOR ACUTE ISCHEMIC STROKE: A COCHRANE META-ANALYSIS**  
Alessandro Squizzato\* (IT), Erica Romualdi, Francesco Dentali, Walter Ageno
- P-TU-427 WARFARIN USE AND RISK OF CORONARY ARTERY CALCIFICATION**  
Robert G Lerner\* (US), Arunabh Sekhri, Chandrasekar Palaniswamy, Wilbert S. Aronow, Sreedhar Adapa, Chul Ahn, Tarunjit Singh, Albert J. DeLuca
- P-TU-428 HAEMOSTATIC VARIABLES AND RISK OF PERIPHERAL ARTERIAL DISEASE AND ITS COMPLICATIONS: SYSTEMATIC REVIEW**  
Olivia Wu\* (UK), Gordon Lowe
- P-TU-429 PLASMA LEVELS OF FVII-ACTIVATING PROTEASE (FSAP) IN ISCHEMIC STROKE**  
Ellen Hanson\* (SE), Sandip M Kanse, Amit Joshi, Katarina Jood, Christian Blomstrand, Christina Jern
- P-TU-430 BIOCHEMICAL AND HEMOSTATIC BIOMARKERS FOR PREDICTING CORONARY ARTERY DISEASE**  
Maria das Gracas Carvalho\* (BR), Luciana Moreira Lima, Daniela Rezende Garcia Junqueira, Marinez Oliveira Sousa
- P-TU-431 USE OF HUMAN PLACENTA-DERIVED MESENCHYMAL STEM CELLS TO TREAT CRITICAL LIMB ISCHEMIA**  
Zhong Chao Han\* (CN), Zhi Bo Han, Jian Hua Li, Jun Hong Jia, Guang Sheng Zhuo

Tuesday Poster



63

## POSTER PRESENTATIONS

Tuesday, July 26, 2011

### Clinical trials and registries

- P-TU-432 SOLUBLE TISSUE FACTOR IN PRIMARY HIV INFECTION**  
Beverley J Hunt\* (UK), Elizabeth Hamlyn, Kiran Parmar, Stephen Hickling, John Frater, Rodney Phillips, Myra McClure, Sarah Fidler
- P-TU-433 LOW ACHIEVEMENT OF TARGET INTERNATIONAL NORMALIZED RATIO IN PATIENTS TAKING WARFARIN EVEN IN A SPECIALIST CLINIC:A STUDY IN OMANI PATIENTS AND REVIEW OF LITERATURE**  
Chao Hung Ho\* (OM), David Gravell
- P-TU-434 HIT ANTIBODY SEROPOSITIVITY DOES NOT PREDICT THROMBOEMBOLIC EVENTS AFTER CARDIAC SURGERY**  
Ian Welsby\* (US), Thomas Ortel, David Kong, Elizabeth Krakow, Nicole Whitlach, John Heit, Eliot C Williams, Shahar Bar Yosef, Susan Martinelli
- P-TU-435 IMMEDIATELY STARTED LEG COMPRESSION IN ACUTE DEEP VEIN THROMBOSIS: A DOUBLE-EDGED INTERVENTION**  
Werner Blaettler\* (CH), Horst E Gerlach, Felix Amsler, Irene K Blaettler, Iris Baumgartner
- P-TU-436 A CONTROLLED COHORT STUDY ON THE USE AND SAFETY OF LOW MOLECULAR WEIGHT HEPARIN DURING PREGNANCY**  
Paeivi Johanna Galambosi\* (FI), Veli-Matti Ulander, Risto Juhani Kaaja
- P-TU-438 VITAMIN K ANTAGONIST DOSING METHODS AND INDIVIDUAL PATIENT QUALITY OF INR CONTROL IN THE INTERNATIONAL ACTIVE W ANTICOAGULATION STUDY**  
Robby Nieuwlaat\* (CA), Jennifer Ng, Stuart J Connolly
- P-TU-439 FOUR WEEKS VERSUS TWELVE WEEKS DOSING INTERVAL FOR STABLE PATIENTS ON WARFARIN: A RANDOMIZED TRIAL**  
Sam Schulman\* (CA), Sameer Parpia, Clare Stewart, Lisa Rudd-Scott, Jim Julian, Mark Levine
- P-TU-440 DETERMINATION OF PROTHROMBIN TIME INTERNATIONAL NORMALIZED RATIO BY PORTABLE DEVICE (COAGUCHECK XS) UNDERGOING ANTICOAGULANT THERAPY PATIENTS**  
Hidehiko Iwahashi\* (JP), Mitsue Iwahashi

### Health service and outcomes

- P-TU-441 HOW DO CLINICIANS MONITOR TREATMENT WITH VITAMIN K ANTAGONISTS: AN INTERNATIONAL SURVEY**  
Ann-Helen Kristoffersen\* (NO), Geir Thue, Eva Ajzner, Neree Claes, Mujdat Aytakin, Andrea Rita Horvath, Kaja Kallion, Steve Kitchen, Marge Kutt, Piet Meijer, Mathias Muller, Elisabeth Nilsson, Carmen Perich, Inger Plum, Carmen Ricos, Dunja Rogic, Joseph Watine, Sverre Sandberg
- P-TU-442 PREVALENCE OF THROMBOPHILIA IN PATIENTS WITH RETINAL VASCULAR OCCLUSIONS**  
Maria T DeSancho\* (US), John Chapin, Karen Sue Carlson, Karen Powell-Boone
- P-TU-443 MONITORING INTRA-OPERATIVE ANTICOAGULATION WITH ACTIVATED CLOTTING TIME IN A PATIENT WITH ANTIPHOSPHOLIPID ANTIBODIES AND A PROLONGED ACTIVATED PARTIAL THROMBOPLASTIN TIME**  
Maria T DeSancho\* (US), John Chapin, Mikhail Roshal, Barbara Hempstead, William Debois



## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-444 THE STOP (STOP SMOKING THERAPY FOR ONTARIO PATIENTS) STUDY: EFFECTIVENESS OF MAILED NICOTINE REPLACEMENT TO MOTIVATED SMOKERS**  
Peter L Selby\* (CA), Laurie Zawertailo, Susan Bondy, Rosa Dragonetti
- P-TU-445 NEW LATEX-BASED ASSAY FOR THE DETECTION OF ANTI PF4-HEPARIN ANTIBODIES ON AUTOMATED COAGULOMETERS USEFUL IN THE DIAGNOSIS OF HEPARIN-INDUCED THROMBOCYTOPENIA (HIT)**  
Lourdes Davalos\* (ES), Encarna Ingles, Miquel Sales
- P-TU-446 SYSTEMATIC EVALUATION OF THE PERFORMANCE OF A PORTABLE MONITOR OF PROTHROMBIN TIME IN PATIENTS WITH SUPRATHERAPEUTIC INR LEVELS**  
Erich de Paula\* (BR), Marina Pereira Colella, Maiara Marx Luz Fiusa, Tania Fatima Gomes Siegl Machado, Sueli Custodio, Fernanda Andrade Orsi, Joyce Maria Annichino-Bizzacchi
- P-TU-447 RISK MANAGEMENT PLAN (RMP) FOR NEW ANTICOAGULANTS IN FRANCE: FIRST RESULTS WITH DABIGATRAN ETEXILATE (PRADAXA)**  
Agnes Lillo Le Louet\* (FR), Christine Le Beller, Herve Le Louet
- P-TU-448 ORAKAY IS AS EFFECTIVE AS KONAKION (PHYTOMENADIONE) IN THE CORRECTION OF SUPRATHERAPEUTIC INRS IN PATIENTS RECEIVING WARFARIN ANTICOAGULATION**  
Rhona M Maclean\* (UK), James W Taylor, Stuart Rollings, Linda Carver, Joost vanVeen
- P-TU-449 AN EVALUATION OF THE QUALITY OF ORAL ANTICOAGULATION MANAGEMENT IN AN OUTPATIENT PHARMACIST-ASSISTED CLINIC**  
Ming Chai Kong\* (SG), Yi Feng Lai, Mei Huey Fiona Tee, Heng Joo Ng, Lai Heng Lee

Tuesday Poster

### von Willebrand disease

- P-TU-450 STRUCTURE-FUNCTIONAL RELATIONSHIP OF 4 NOVEL MISSENSE MUTATIONS IN VWF GENE PREDICTED BY MOLECULAR MODELLING**  
Arijit Biswas\* (DE), Hamideh Yadegari, Driesen Julia, Pavlova Anna, Oldenburg Johannes
- P-TU-451 FIRST RESULTS OF A LONG-TERM PHARMACOVIGILANCE WITH PLASMA DERIVED VON-WILLEBRAND-FACTOR/FACTOR VIII CONCENTRATE**  
Manuela Krause (DE), Michael Varvenne, Rainer B Zotz, Claudia Niekrens, Ute Scholz, Andrea Gerhardt, Bettina Kemkes-Matthes, Beate Krammer-Steiner, Mathias Juers\*, Claudia Zacharias, Guenter Auerswald
- P-TU-452 CONCURRENCE OF TYPE II VON WILLEBRAND DISEASE AND SEVERE HEMOPHILIA B IN A TAIWANESE: A CASE REPORT AND REVIEW OF LITERATURE**  
Chia-Yau Chang\* (TW), Chen-Hua Tsai, Jia-ruey Tsai, Geng-Chang Yeh, Ing-Jy Tseng
- P-TU-453 MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION (MLPA) SCREENING OF THE VWF GENE: IDENTIFICATION OF 3 NOVEL DELETIONS AND A CAUTIONARY OBSERVATION**  
Bimal D M Theophilus\* (UK), Lesley M Baugh, Andrea M Guilliat, Jonathan T Wilde, Jayashree Motwani, Michael D Williams
- P-TU-454 LABORATORY, MULTIMERIC AND MOLECULAR CHARACTERISATION OF VON WILLEBRAND DISEASE IN THE SOUTH MORAVIAN POPULATION (CZECH REPUBLIC): THE BRNO-VWD STUDY**  
Alain Peter Gadisseur\* (BE), Petr Smejkal, Inge Vangenechten, O Zapletal, Fatima Bouddount, J Zavrelova, J Blatny, M Penka, JJ Michiels



## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-455 UTILITY OF VON WILLEBRAND FACTOR COLLAGEN BINDING ASSAYS (VWF:CB) WITH TYPE VI COLLAGEN IN THE DIAGNOSIS OF VWD**  
Veronica H Flood (US), Sandra L Haberichter, Kenneth D Friedman, Steven R Lentz, Raymond G Hoffmann, Joan Cox Gill, Robert R Montgomery\*
- P-TU-456 INTRACRANIAL HEMORRHAGE IN VON WILLEBRAND DISEASE: A REPORT ON 6 PEDIATRIC CASES**  
Veerle Labarque\* (CA), Ann Marie Stain, Victor Blanchette, Walter H. Kahr, Manuel D. Carcao
- P-TU-457 TYPE 2B VON WILLEBRAND DISEASE: ONE CENTER EXPERIENCE (DEPARTMENT OF HEMATOLOGY, JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE, KRAKOW, POLAND)**  
Joanna Zdziarska (PL), Teresa Iwaniec, Beata Mazurek, Jolanta Ras, Jacek Musial\*, Aleksander Bartlomiej Skotnicki
- P-TU-458 CASE REPORT: VON WILLEBRAND FACTOR INHIBITOR IN A FIVE YEAR OLD GIRL WITH TYPE III VWD AND RESPONSE TO ITI**  
Natasha M Wiles\* (UK), Julia Spires, Gary Moore, James Maloney, Jayanthi Alamelu
- P-TU-459 THE CONDENSED MCMDM1-VWD BLEEDING QUESTIONNAIRE: UTILITY AS A DIAGNOSTIC TOOL IN THE HEMATOLOGY CLINIC**  
Shannon Jackson (CA), Man-Chiu Poon, Julie Grabell, David Lillcrap, Paula D James\*
- P-TU-460 THROMBOELASTOGRAPHY REFLECTS VARIATIONS OF HAEMOSTATIC PATTERN IN TYPE 2B VON WILLEBRAND DISEASE PATIENTS WITH R1306W MUTATION**  
Mazen Toukh\* (CA), Anne Angelillo-Scherrer, Maha Othman
- P-TU-461 HETEROGENEITY OF THE CLINICAL, LABORATORY AND MOLECULAR MARKERS OF VWD TYPE 3: RESULTS FROM THE RETROSPECTIVE/PROSPECTIVE STUDIES ON 122/52 ITALIAN PATIENTS**  
Augusto B Federici\* (IT), Paolo Bucciarelli, Giancarlo Castaman, Emily Oliovecchio, Alfonso Iorio, Pier M Mannucci
- P-TU-462 19 NOVEL MUTATIONS IN VWF GENE CAUSING VON WILLEBRAND DISEASE IN 17 CHINESE PEDIGREES**  
Huanhuan Qin\* (CN)

### ADAMTS13

- P-TU-463 A NEW ADAMTS13 MISSENSE MUTATION (A4085T) IN THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) DIAGNOSED IN PREGNANCY**  
Julio C Calderazzo Pereyra\* (AR), Ana C Kempfer, Yanina P Powazniak, Ileana R Lopez, Analia Sanchez-Luceros, Maria A Lazzari
- P-TU-464 ALTERATIONS OF VON WILLEBRAND FACTOR ANTIGEN AND ADAMTS13 ACTIVITY IN PATIENTS WITH CANCER**  
Xia Bai\* (CN), Yue Han, Luping Hu, Xiaohui Hu, Changgeng Ruan
- P-TU-465 NEUTROPHIL OXIDANTS INACTIVATE ADAMTS13**  
Xiaoyun Fu\* (US), Yi Wang, Junmei Chen, Minhua Ling, Thomas Jordan, Jose A Lopez, Dominic W Chung, Xiaoyun Fu
- P-TU-466 ADAMTS13 ANTIGEN LEVELS VARY IN PERIPHERAL VERSUS INFARCT-RELATED CORONARY BLOOD IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION**  
Hendrik B Feys\* (BE), Aaron Peace, Fabio Mangiacapra, Micaela Conte, Luigi Di Serafino, Yiannis Ntarladimas, Olivier Muller, Argyrios Ntalianis, Etienne Puymirat, Karen Dierickx, Len Delrue, Jozef Bartunek, Karen Vanhoorelbeke, Emanuele Barbato





## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-467 VON WILLEBRAND FACTOR AND ADAMTS13: A CANDIDATE COUPLE FOR PREECLAMPSIA PATHOPHYSIOLOGY**  
Alain Stepanian\* (FR), Marie Cohen-Moatti, Thibaut Sanglier, Paulette Legendre, Nejma Ameziane, Vassilis Tsatsaris, Laurent Mandelbrot, Dominique De Prost, Agnes Veyradier
- P-TU-468 VON WILLEBRAND FACTOR O-LINKED GLYCANS INFLUENCE ITS INTERACTION WITH ADAMTS13**  
Agata Nowak\* (UK), Thomas McKinnon, Hughes Jenny, Mike Laffan
- P-TU-469 E. COLI DERIVED VON WILLEBRAND FACTOR-A2 DOMAIN FRAGMENTS QUANTIFY PLASMA ADAMTS13 ACTIVITY IN FRET AND FLOW CYTOMETRY BASED ASSAYS**  
Sriram Neelamegham\* (US), Shobhit Gogia, Kannayakanahalli M Dayananda
- P-TU-470 PROBING THE DETERMINANTS OF VWF SUBSTRATE SPECIFICITY FOR ADAMTS13 BY M13 FILAMENTOUS PHAGE DISPLAY**  
Colin Kretz\* (US), Karl Desch, David Ginsburg
- P-TU-471 SUBSTRATE SUITABILITY EVALUATION OF HUMAN RECOMBINANT ADAMTS13 WITH VON WILLEBRAND FACTOR FROM DIFFERENT MAMMALIAN SPECIES**  
Barbara Plaimauer\* (AT), Claudia Kitzler, Gabriele Mohr, Peter L. Turecek, Hanspeter Rottensteiner, Friedrich Scheiflinger
- P-TU-472 DEVELOPMENT OF A MANUFACTURING PROCESS FOR RADAMTS13**  
Friedrich Scheiflinger\* (AT), Christa Mayer, Christian Fiedler, Leopold Grillberger, Meinhard Hasslacher, Martin Kaliwoda, Wilfried Woehrer, Manfred Reiter, Artur Mitterer, Wolfgang Mundt
- P-TU-473 ADAMTS13 SINGLE-NUCLEOTIDE POLYMORPHISMS IN GEOGRAPHICALLY-DIVERSE POPULATIONS**  
Benjamin Kim\* (US), Kevin R. Viel, Victor J. Marder, Tom E. Howard
- P-TU-474 TRANSITIONS OF PLASMA VWF PROPEPTIDE, VWF AND ADAMTS13 IN PATIENTS WITH SEPTIC DIC**  
Hidetada Fukushima\* (JP), Kenji Nishio, Kazuo Okuchi, Ayami Isonishi, Masanori Matsumoto, Yoshihiro Fujimura, Keisuke Takano, Hideki Asai, Tomoo Watanabe, Shingo Ito, Tadahiko Seki, Yasuyuki Urizono, Michiaki Hata, Masaaki Doi, Yasuaki Shida, Hideto Matsui, Mitsuhiro Sugimoto

### Experimental models

- P-TU-475 THE ASSAY OF VON WILLEBRAND FACTOR (VWF) PROPEPTIDE TO ANTIGEN RATIO (VWFPP/VWF) IDENTIFIES A REDUCED VWF SURVIVAL PHENOTYPE IN MICE**  
Paula M Jacobi\* (US), Ashley L Gehrand, Scot A Fahs, Robert R Montgomery, Jill M Johnsen, Sandra L Haberichter
- P-TU-477 IMAGING ANALYSIS OF THE INTERACTION BETWEEN UNUSUALLY LARGE VON-WILLEBRAND FACTOR MULTIMERS AND PLATELETS ON VASCULAR ENDOTHELIAL CELLS IN LIVING ANIMALS**  
Tomasz Brzoska\* (JP), Miroslaw Rybaltowski, Yuko Suzuki, Hideo Mogami, Iwona Chlebinska, Aki Tanaka, Fumiaki Banno, Toshiyuki Miyata, Tetsumei Urano

Tuesday Poster



67

## POSTER PRESENTATIONS

Tuesday, July 26, 2011

### Hemophilia

- P-TU-478 MALIGNANCIES IN ITALIAN HEMOPHILIA PATIENTS**  
Annarita Tagliaferri (IT), Caterina Di Perna, Cristina Santoro, Piercarla Schinco, Rita Santoro, Gina Rossetti\*, Antonio Coppola, Massimo Morfini, Giancarlo Castaman, Francesco Antonio Scaraggi, Samantha Pasca, Silvia Macchi, Lelia Valdre', Ezio Zanon, Marialuisa Serino, Marisanta Napolitano, Isabella Cantori, Annachiara Giuffrida, Grazia Delios, Paolo Radossi, Massimo Franchini
- P-TU-479 ACUTE PROMYELOYTIC LEUKEMIA (APL) IN A 3.5-YEARS-OLD CHILD WITH SEVERE HEMOPHILIA A: DIAGNOSTIC ISSUES AND COAGULOPATHY TREATMENT CHALLENGE**  
Manuela Carvalho (PT), Manuela Reis, Carla Monteiro, Victor Costa, Maria Joao Milheiro, Alzira Carvalhais, Luis Manuel Cunha-Ribeiro\*
- P-TU-480 IMPLEMENTATION OF A TELEMETRIC SMARTPHONE APPLICATION FOR IMPROVED SURVEILLANCE OF HEMOPHILIA HOME TREATMENT**  
Andreas Roesch\* (DE), David Schmoltdt, Wolfgang Mondorf, Hartmut Pollmann
- P-TU-481 SCREENING HEMOPHILIA IN THE WEST OF ALGERIA AND DIFFERENTIAL DIAGNOSIS BETWEEN HEMOPHILIA A AND WILLEBRAND'S DISEASE**  
Driss Benlaldj\* (DZ), Khedidja Moulasserdoun, Chakib Rahal, Fatima Seghier
- P-TU-482 AWARENESS OF CARRIER STATUS AS A RESULT OF GENETIC COUNSELING IMPROVES HEMOPHILIA PATIENT CARE**  
F.van Herrewegen\* (NL), M.A. Legdeur, C. Valk, Ommen C.H. van, I.B. Mathijssen, M. Peters
- P-TU-483 MLPA ASSAY IN HAEMOPHILIA: A SECOND-LINE TEST IN GENE MUTATION DETECTION**  
Giuseppe Tagariello\* (IT), Roberta Salviato, Donata Belvini, Federica Pierobon, Roberta Callegari, Nilla Maschio, Paolo Radossi, Renzo Risato, Roberto Sartori, Cristina Tassinari
- P-TU-484 BODY WEIGHT AND FAT MASS INDEX AS STRONG PREDICTORS OF IN VIVO FACTOR VIII RECOVERY IN ADULTS WITH HEMOPHILIA A**  
Severine Henrard\* (BE), Cedric Hermans, Niko Speybroeck
- P-TU-485 ESTABLISHMENT OF THE CDC HEMOPHILIA A MUTATION PROJECT (CHAMP) TO PROVIDE STANDARDIZED F8 MUTATION DATABASES**  
Connie H Miller\* (US), Amanda Payne, Fiona Kelly, J. Michael Soucie, W. Craig Hooper
- P-TU-486 HYPOCOAGULABILITY DOES NOT PROTECT AGAINST ATHEROSCLEROSIS IN HEMOPHILIA A PATIENTS WITH OBESITY**  
Sara Biere-Rafi\* (NL), Attie Tuinenburg, Bas Haak, Marjolijn Peters, Eric De Groot, Peter Verhamme, Kathelijne Peerlinck, Frank Visseren, Marieke Kruip, Britta Laros-van Gorkom, Harry Buller, Victor Gerdes, Roger Schutgens, Pieter Kamphuisen
- P-TU-487 THE AGE AT DIAGNOSIS OF HEMOPHILIA. SITUATION IN BOSNIA AND HERZEGOVINA**  
Jelica Samardzic Predojevic\* (BA), Edo Hasanbegovic, Biljana Banjac
- P-TU-488 INTERLEUKIN-28B (IL28B) POLYMORPHISM AS PREDICTOR OF SUSTAINED VIROLOGICAL RESPONSE AFTER ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C IN PATIENTS WITH HEMOPHILIA**  
Maria Elisa Mancuso\* (IT), Alessio Aghemo, Elena Santagostino, Maria Grazia Rumi, Raffaele Bruno, Massimo Colombo, Pier Mannuccio Mannucci
- P-TU-489 TRANSIENT ELASTOGRAPHY (FIBROSCAN) AS A TOOL TO ASSESS LIVER FIBROSIS IN PATIENTS WITH HEMOPHILIA AND CHRONIC HEPATITIS C**  
Maria Elisa Mancuso\* (IT), Alessio Aghemo, Gianmaria Prati, Maria Grazia Rumi, Elena Santagostino, Massimo Colombo



## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-490    PRENATAL DIAGNOSIS FOR HAEMOPHILIA AT CASTELFRANCO VENETO: A 15 YEAR EXPERIENCE IN MOLECULAR DIAGNOSIS**  
Giuseppe Tagariello\* (IT), Donata Belvini, Roberta Salviato, Federica Pierobon, Barbara Callegari, Nilla Maschio, Paolo Radossi, Renzo Risato, Roberto Sartori, Cristina Tassinari
- P-TU-491    CORONARY ARTERY CALCIFICATION IN HEMOPHILIA A: NO EVIDENCE FOR A PROTECTIVE EFFECT OF FACTOR VIII DEFICIENCY ON ATHEROSCLEROSIS**  
Attie Tuinenburg\* (NL), Annemarieke Rutten, Maryam Kavousi, Frank W.G. Leebeek, Paula F. Ypma, Britta A.P. Laros-van Gorkom, Marten R. Nijziel, Pieter W. Kamphuisen, Evelien P. Mauser-Bunschoten, Goris Roosendaal, Douwe H. Biesma, Aad van der Lugt, Albert Hofman, Jacqueline C.M. Witteman, Michiel L. Bots, Roger E.G. Schutgens
- P-TU-492    30-YEARS´ EXPERIENCE OF PRENATAL DIAGNOSIS OF HAEMOPHILIA IN SWEDEN**  
Annika Martensson (SE), Ulf Tedgard, Rolf Ljung\*
- P-TU-493    HIGH FREQUENCY OF ASYMPTOMATIC THROMBOSIS ASSOCIATED WITH CENTRAL VENOUS LINES IN CHILDREN WITH HAEMOPHILIA**  
Olof Rask (SE), Ola Bjorgell, Cecilia Wattsgard, Rolf Ljung\*
- P-TU-494    A BASIC MRI SCALE FOR HEMOPHILIC ARTHROPATHY FROM THE INTERNATIONAL PROPHYLAXIS STUDY GROUP (IPSG)**  
B Lundin (SE), M Manco-Johnson, SF Miller, R Moineddin, D Ignas, Rolf Ljung\*, AL Dunn, GE Rivard, P Babyn, SN Keshava, S Gibikote, V Blanchette, A Doria
- P-TU-495    IMPAIRED MICROVASCULAR ENDOTHELIAL FUNCTION IN ADULT MALES WITH HEMOPHILIA**  
Shannon Claire Jackson\* (CA), Morna Brown, Carol Spitzer, Leah Odiaman, Marinda Fung, Todd J. Anderson, Man-Chiu Poon
- P-TU-496    ABNORMAL DYNAMIC PLATELET AGGREGATION IN HAEMOPHILIA A FOLLOWING TISSUE FACTOR INITIATED ENDOGENOUSLY GENERATED THROMBIN STIMULATION**  
Maria Sander Jensen\* (DK), Ole Halfdan Larsen, Kirsten Christiansen, Christian Fenger-Eriksen, Jorgen Ingerslev, Benny Sorensen
- P-TU-497    EFFECTIVENESS OF HAEMOPHILIA MEDICATION THERAPY ADHERENCE CLINIC (HMTAC) IN IMPROVING TREATMENT ADHERENCE USING A MODIFIED VERITAS-PRN SCORE**  
Shu Ping Wong\* (MY), Jameela Sathar, Adibah Md Shariff, Yeok Siew Lim
- P-TU-498    DOES HAEMOPHILIA A PROTECT AGAINST LIVER FIBROSIS IN AN EXPERIMENTAL MODEL?**  
Stephane L Eeckhoudt\* (BE), Isabelle Leclercq, Cedric Hermans, Dominique Latinne, Yves Horsmans
- P-TU-499    INHIBITORS IN HEMOPHILIA B: THE ITALIAN EXPERIENCE**  
Giuseppe Tagariello\* (IT), Giancarlo Castaman, Maria Messina, Massimo Morfini, Angiola Rocino, Antonio Scaraggi, Pier Mannuccio Mannucci
- P-TU-500    CONSTRUCTION OF NONSENSE-MUTATED EUKARYOTIC EXPRESSION VECTORS OF FACTOR IX GENE AND ITS EXPRESSION**  
linhua Yang\* (CN), Xin Nie, Yuan Zhang

Tuesday Poster



69

## POSTER PRESENTATIONS

Tuesday, July 26, 2011

### Hemophilia therapy

- P-TU-501 PHARMACOKINETIC AND DYNAMIC PROPERTIES OF RECOMBINANT VS. PLASMA DERIVED FIX IN PATIENTS WITH HAEMOPHILIA B : A PROSPECTIVE CROSS-OVER STUDY**  
Jayanthi Alamelu\* (UK), Benny Sorensen, Savita Rangarajan
- P-TU-502 THE POST-AUTHORIZATION SAFETY SURVEILLANCE (PASS) PROGRAM CONFIRMED ACTUAL CLINICAL SAFETY AND EFFICACY OF RECOMBINANT PLASMA/ALBUMIN-FREE METHOD FACTOR VIII IN JAPAN**  
Katsuyuki Fukutake\* (JP), Hideji Hanabusa, Masashi Taki, Tadashi Matsushita, Midori Shima, Akira Shirahata, The Advate PASS Study Group
- P-TU-503 RFVIIA-ANALOGUE AND RFVIIA ENHANCE CLOT STABILITY MORE THAN FVIII IN HAEMOPHILIA A**  
Catherine J Rea\* (UK), Mirella Ezban, Jonathan H Foley, Benny Sorensen
- P-TU-504 INCREASED HAEMOSTATIC EFFECT OF HIGH DOSE RFVIIA COMPARED TO PD-APCC IN A TREATMENT-REFRACTORY PATIENT WITH HAEMOPHILIA A AND INHIBITORS**  
Catherine J Rea\* (UK), David Bevan, Benny Sorensen
- P-TU-505 MEDICO-ECONOMIC AND QUALITY OF LIFE STUDY OF REPLACEMENT THERAPY FOR HAEMOPHILIA B IN FRANCE: THE EQOFIX STUDY**  
Benoit Polack\* (FR), Thierry Calvez, Segolene Claeysens, Herve Chambost, Annie Derlon, Jenny Goudemand, Chantal Rothschild, Marie-Christine Woronoff-Lemsi
- P-TU-506 SECONDARY PROPHYLAXIS IS MANDATORY IN ADULT/ELDER HEMOPHILIACS HIV-WITH NEOPLASMAS UNDERGOING TO CHEMOTHERAPY AND/OR RADIOTHERAPY**  
Margaret Musso\* (IT), Anna Musso, Luca Maugeri, Luciano Messina
- P-TU-507 LIVER DISEASE DAMAGE PROGRESSION AND HEPATOCARCINOMA OCCURRENCE IN HCV+/HBV+/HIV- HEMOPHILIACS DESPITE LASTING HCV/HBV VIRUS REPLICATION ABSENCES AFTER ANTIVIRAL THERAPIES**  
Margaret Musso\* (IT), Anna Musso, Luca Maugeri, Roberto Musso
- P-TU-508 TRANEXAMIC ACID WITHOUT PROPHYLACTIC FACTOR REPLACEMENT FOR PREVENTION OF BLEEDING IN PATIENTS WITH HEREDITARY BLEEDING DISORDERS UNDERGOING ELECTIVE ENDOSCOPY: A PILOT STUDY**  
Amanda Davis\* (AU), Alison Street, Huyen Tran, Megan Walsh, Penny McCarthy, Chun Fong, Gregor Brown, Stuart Roberts
- P-TU-509 CONSEQUENCES OF SWITCHING FROM PROPHYLACTIC TREATMENT TO ON-DEMAND TREATMENT IN LATE TEENS AND EARLY ADULTS WITH SEVERE HEMOPHILIA A**  
Marilyn J Manco-Johnson\* (US), Joann Sanders, Nadia Ewing
- P-TU-510 CLINICAL EXPERIENCE OF PREVIOUSLY UNTREATED PATIENTS WITH ANTIHEMOPHILIC FACTOR (RECOMBINANT), PLASMA/ALBUMIN-FREE METHOD FROM POST-AUTHORIZATION SAFETY SURVEILLANCE IN JAPAN**  
Masashi Taki\* (JP), Hideji Hanabusa, Katsuyuki Fukutake, Tadashi Matsushita, Midori Shima, Akira Shirahata, Study Group the Advate PASS
- P-TU-511 PROSPECTIVE ADVATE IMMUNE TOLERANCE REGISTRY (PAIR) IN JAPANESE HEMOPHILIA A PATIENTS WITH INHIBITORS: AN INTERIM REPORT**  
Tadashi Matsushita\* (JP), Hideji Hanabusa, Katsuyuki Fukutake, Masashi Taki, Midori Shima, Akira Shirahata, Study Group the Advate PASS



## POSTER PRESENTATIONS

Tuesday, July 26, 2011

### Inhibitors: pathogenesis, prevention and treatment

- P-TU-512 IMPACT OF POLYMORPHISMS IN GENES INVOLVED IN AUTOIMMUNE DISEASE ON INHIBITOR DEVELOPMENT IN CHINESE PATIENTS WITH HAEMOPHILIA A**  
Yeling Lu\* (CN), Xuefeng Wang, Qiulan Ding, Jing Dai, Hongli Wang, Xiaodong Xi
- P-TU-513 DID RITUXIMAB (ANTI-CD20) INFLUENCE THE OUTCOME OF LATE IMMUNE TOLERANCE INDUCTION (ITI) IN AN ADULT WITH SEVERE HEMOPHILIA A (HA) AND HIGH-RESPONDER INHIBITOR?**  
Albert Faradji\* (FR), Lelia Grunebaum, Dominique Desprez, Veronica Goldbarg, Geraldine Lavigne-Lissalde, Anne Dory, Anne Cecile Gerout, Natacha Chilintseva-Natorov, Alice Eischen, Olivier Feugeas, Patrick Karcher
- P-TU-513 DID RITUXIMAB (ANTI-CD20) INFLUENCE THE OUTCOME OF LATE IMMUNE TOLERANCE INDUCTION (ITI) IN AN ADULT WITH SEVERE HEMOPHILIA A (HA) AND HIGH-RESPONDER INHIBITOR?**  
ALBERT FARADJI\* (FR), Lelia Grunebaum, Dominique Desprez, Veronica Goldbarg, Geraldine Lavigne-Lissalde, Anne Dory, Anne Cecile Gerout, Natacha Chilintseva-Natorov, Alice Eischen, Olivier Feugeas, Patrick Karcher
- P-TU-514 COMPARISON OF THE EFFICACY OF TWO RECOMBINANT FACTOR VIIA AGENTS**  
Gennady M Galstyan\* (RU), Vladimir Yu Zorenko, Tatyana Yu Polyanskaya, Magomed Sampiev, Tatyana Severova, Nadezhda Konyashina, Irina Gribkova, Elena Orel, Vladimir Gorodetsky
- P-TU-515 SUCCESSFUL IMMUNOTOLERANCE INDUCTION IN 2 BOYS WITH HAEMOPHILIA B AND INHIBITOR**  
Anna Klukowska\* (PL), Pawel Laguna, Beata Waleszkiewicz-Majewska
- P-TU-516 COAGIL-VII APPLICATION IN ORTHOPEDIC SURGERY IN INHIBITOR HEMOPHILIA A PATIENTS**  
Vladimir Zorenko\* (RU), Tatiana Polianskaya, G. Galstian, M. Sampiev, T. Severova, N. Koniashina, E. Orel, I. Gribkova, M. Aleksanian
- P-TU-517 EVALUATION OF DIFFERENT REGIMENS OF RECOMBINANT ACTIVATED FACTOR VIIA ON BLEEDING AND PAIN RESOLUTION IN PATIENTS WITH HAEMOPHILIA AND INHIBITORS**  
Peter Salaj\* (CZ), Miroslav Penka, Petra Ovesna
- P-TU-518 SAFETY OF EXPOSURE TO RECOMBINANT ACTIVATED FVII (RFVIIA) DOSES IN PATIENTS WITH CONGENITAL HEMOPHILIA WITH INHIBITORS (CHWI) TO FACTORS VIII OR IX**  
Amy D Shapiro\* (US), Ellis J. Neufeld, Victor S. Blanchette, Herve Chambost, David L. Cooper
- P-TU-519 RECOMBINANT FVIIA (RFVIIA) USE FOR SURGERY IN CONGENITAL HEMOPHILIA WITH INHIBITORS (CHWI) PATIENTS: DATA FROM THE HEMOPHILIA AND THROMBOSIS RESEARCH SOCIETY (HTRS) REGISTRY**  
Ellis Neufeld\* (US), Kapil Saxena, David L. Cooper
- P-TU-520 BYPASS THERAPY EXPERIENCE IN ROUTINE CLINICAL MANAGEMENT: A POST-AUTHORIZATION SAFETY STUDY (PASS) WITH ANTI INHIBITOR COAGULATION COMPLEX (AICC)**  
Allison Quaglino\* (US), Manfred Pirck, Wing-Yen Wong, Gerald Spotts, Robert P Numerof
- P-TU-521 POTENTIAL IMPACT OF THE AVAILABILITY OF A LARGER NOVOSEVEN® (RFVIIA) VIAL SIZE IN THE TREATMENT OF ACUTE BLEED EPISODES IN PATIENTS WITH HAEMOPHILIA**  
Paulo Andre Palhares de Miranda\* (CH), Kathryn Starzyk

Tuesday Poster



71

## POSTER PRESENTATIONS

Tuesday, July 26, 2011

### Inherited coagulation disorders (except for von Willebrand disease)

- P-TU-522 A CASE OF FACTOR FIVE DEFICIENCY ASSOCIATED WITH GONADAL AGENESIS**  
Valizadeh Nasim\* (IR), Nasser Jahanbakhsh
- P-TU-523 RECOMBINANT FACTOR VIIA (RFVIIA) TREATMENT OF BLEEDING IN CONGENITAL FACTOR VII DEFICIENCY (C7D): ANALYSIS FROM THE HEMOPHILIA AND THROMBOSIS RESEARCH SOCIETY (HTRS) REGISTRY**  
Kapil Saxena\* (US), Ellis J. Neufeld, Eric H. Kraut, David L. Cooper
- P-TU-524 MOLECULAR ANALYSIS OF TWO NOVEL MUTATIONS IN A CHINESE PEDIGREE WITH HEREDITARY FVII DEFICIENCY**  
Zhifang Xing\* (CN), Xuefeng Wang
- P-TU-525 NOVEL MUTATIONS AND THEIR STRUCTURAL ANALYSIS IN 20 UNRELATED FAMILIES WITH INHERITED FACTOR VII DEFICIENCY SEEN IN TAIWAN**  
Hsiang Chun Liu\* (TW), Ming Ching Shen, Ching Yeh Lin, Bo Do Lin, Wei Tsay, Shyuann Yuh Lin, Su Feng Kuo, Jen Shiou Lin, Mei Hua Hong
- P-TU-526 IS A PROLONGED PTT, CAUSED BY A DEFICIENCY OF FACTOR XII, HMWK- OR PREKALLIKREIN, ASSOCIATED WITH A HEMORRHAGIC DIATHESIS?**  
Sonja R Alesci\* (DE), Kofler D Stefan, Genet Asmelash, Wolfgang Miesbach
- P-TU-527 ASSESSING BLEEDING IN RARE BLEEDING DISORDERS (RBDS) WITH BLEEDING SCORE: RESULTS FROM THE EUROPEAN NETWORK OF RARE BLEEDING DISORDERS (EN-RBD)**  
Roberta Palla\* (IT), Marzia Menegatti, Simona Maria Siboni, Claudia Mistretta, Alain Gadisseur, Muriel Giansily-Blaizot, Susan Halimeh, Lidija Kitanovski, Danijela Mikovic, Nihal Ozdemir, Helen Pergantou, Flora Peyvandi
- P-TU-528 STRUCTURE-FUNCTIONAL RELATIONSHIP OF 5 NOVEL MISSENSE MUTATIONS IN F13A GENE PREDICTED BY MOLECULAR MODELLING**  
Arijit Biswas\* (DE), Vytautas Ivaskevicius, Anne Thomas, Johannes Oldenburg
- P-TU-529 ESTABLISHING THE CAUSATIVITY FOR ISOLATED HETEROZYGOUS MUTATIONS IN F13A AND F13B GENES BY *IN VITRO* EXPRESSION**  
Anne Thomas\* (DE), Arijit Biswas, Vytautas Ivaskevicius, Johannes Oldenburg
- P-TU-530 CONCURRENCE OF CLASSIC TYPE EHLERS-DANLOS SYNDROME AND MODERATE HEMOPHILIA A IN A TAIWANESE: A CASE REPORT**  
Chia-Yau Chang\* (TW), Chang Chia-Yau, Chen-Hua Tsai, Jia-ruey Tsai, Geng-Chang Yeh, Ing-Jy Tseng
- P-TU-531 SEVERE FACTOR V DEFICIENCY ASSOCIATED WITH A HOMOZYGOUS F5 DEEP-INTRONIC SPLICING MUTATION**  
Elisabetta Castoldi\* (NL), Connie Duckers, Claudia Radu, Cristiana Bulato, Luca Spiezia, Valeria Rossetto, Giuseppe Tagariello, Jan Rosing, Paolo Simioni

### Acquired coagulation disorders

- P-TU-532 TREATMENT OF ACUTE BLEEDS IN ACQUIRED HEMOPHILIA WITH RECOMBINANT FACTOR VIIA (RFVIIA): AN UPDATED ANALYSIS FROM THE HEMOPHILIA AND THROMBOSIS RESEARCH SOCIETY (HTRS) REGISTRY**  
Alice Ma\* (US), Craig M. Kessler, Robert Z. Gut, David L. Cooper



## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-533 HYPOFIBRINOGENEMIA AND CRYOPRECIPITATE USE IN ON-PUMP CARDIAC SURGERY**  
Jerome Teitel\* (CA), Gail Rockman, C David Mazer, Katerina Pavenski
- P-TU-534 THE EFFECT OF HYDROXYETHYL STARCH PLASMA EXPANDER ON WHOLE BLOOD PLATELET FUNCTION**  
Christian Fenger-Eriksen\* (DK), Else Toennesen, David Bevan, Joergen Ingerslev, Benny Soerensen
- P-TU-535 OVERCOMING BARRIERS TO RAPID DIAGNOSIS OF BLEEDING DISORDERS AND ACQUIRED HEMOPHILIA (AH) BY HEALTH CARE PRACTITIONERS (HCP): THE COAGS UNCOMPLICATED IPHONE APPLICATION**  
Craig M Kessler (US), Ellinor I. Peerschke, Gretchen Eberhart, Robert Z. Gut, David L. Cooper\*
- P-TU-536 PERINATAL INTRAVENTRICULAR HEMORRHAGE(IVH) RELATED TO MATERNAL WARFARIN**  
Patcharee Komvilaisak\* (TH), Pakaphan Kiatchoosakun, Junya Jirapradittha, Amnat Kitkhuandee, Suda Vannaprasaht
- P-TU-537 CLINICAL ANALYSIS OF 42 PATIENTS WITH ACQUIRED DEFICIENCY OF VITAMIN K-DEPENDENT COAGULATION FACTORS**  
Hai Fei Chen\* (CN), Tian Qin Wu, Ling Juan Jin, Jie Qing Tang, Hong Shi Shen, Zheng Yang Li, Jing Jing Zhu, Long Mei Qin, Zi Qiang Yu, Zhao Yue Wang
- P-TU-538 LR AND HEXTEND RESUSCITATION ON COAGULATION FOLLOWING TISSUE INJURY AND SEVERE HEMORRHAGE IN PIGS**  
Wenjun Z Martini\* (US), Douglas Cortez, Shavaughn Colvin, Jill Sondeen, Michael Dubick, Lorne Blackbourne
- P-TU-539 REPEATED ADMINISTRATION OF LOW DOSE MONOCLONAL ANTICD20 ANTIBODY RITUXIMAB (RTX) IN REFRACTORY ACQUIRED HEMOPHILIA A (AHA): A CASE REPORT**  
Regina - Pileckyte\* (LT), Neringa Gailiute, Ligita Malciute, Audrone Drungiene, Laimonas Griskevicius
- P-TU-540 DISSEMINATED INTRAVASCULAR COAGULATION IN NEWLY DIAGNOSED ACUTE LEUKEMIA: PREVALENCE AND IMPACT**  
Theera Ruchutrakool\* (TH), Saranya Pongudom, Yupa Nakkinkun, Bundarika Suwanwiboon, Yingyong Chinthammitr, Surapol Issaragrisil
- P-TU-541 SAFETY AND EFFICACY OF PROTHROMBIN COMPLEX CONCENTRATES IN THE EMERGENCY REVERSAL OF WARFARIN COAGULOPATHY**  
Ammar Hussain Majeed\* (SE), Anna Eelde, Margareta Holmstrom, Sam Schulman
- P-TU-542 PATHOGENESIS OF SYSTEMIC HEMOSTATIC DISTURBANCES IN *BOTHROPS JARARACA* ENVENOMATION IN RATS**  
Karine Miki Yamashita\* (BR), Marcelo Larami Santoro
- P-TU-543 THE USE OF RECOMBINANT FACTOR VIIA IN WARFARIN PATIENTS WITH TRAUMATIC BRAIN INJURY**  
Emma DeLoughery\* (US), Thomas DeLoughery

### Experimental models

- P-TU-544 DOES FIBRINOGEN REPLACEMENT INCREASE THE RISK OF VASCULAR OCCLUSION AFTER CARDIAC SURGERY?**  
Kenichi Tanaka\* (US), Satoru Ogawa, Fania Szlam, Jerrold H Levy, Tomoko Ohnishi, Kazuya Hosokawa

Tuesday Poster



73

## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-545 PROTHROMBIN COMPLEX CONCENTRATE (PCC) INCREASES SURVIVAL BY REDUCING BLOOD LOSS, ASSOCIATED WITH ENHANCED THROMBIN GENERATION IN A PIG MODEL OF BLUNT LIVER INJURY**  
Henri M H Spronk\* (NL), Oliver Grottke, T Braunschweig, Rene van Oerle, Hugo ten Cate, R Rossaint, Henri M.H. Spronk
- P-TU-546 EXPERIMENTAL ACUTE TRAUMATIC COAGULOPATHY IS DUE TO SYSTEMIC ACTIVATION OF PROTEIN C DURING HYPOPERFUSION**  
Daniel Frith\* (UK), Maria Lima Baptista, Mitchell Cohen, Rupert Pearse, Chris Thiemermann, Karim Brohi
- P-TU-547 STREPTOCOCCUS MUTANS, A PATHOGEN OF DENTAL CARIES, AGGRAVATES CEREBRAL HEMORRHAGE BY ITS CELL-SURFACE COLLAGEN-BINDING PROTEIN**  
Kazuya Hokamura\* (JP), Koichiro Wada, Kazuhiko Nakano, Min Thura, Takashi Ooshima, Kazuo Umemura

### Atherosclerosis

- P-TU-548 INTERLEUKIN-33 INDUCES UROKINASE-TYPE PLASMINOGEN ACTIVATOR AND PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 IN HUMAN ENDOTHELIAL CELLS IN VITRO**  
Svitlana Demyanets\* (AT), Stefan Stojkovic, Christoph Kaun, Gerald Maurer, Kurt Huber, Johann Wojta
- P-TU-549 DIMINISHED NEUTROPHIL INTRAPLAQUE RECRUITMENT IN RESPONSE TO GENETICALLY IMPOSED HYPOPROTHROMBINEMIA RESULTS IN ATHEROSCLEROTIC PLAQUE STABILITY IN HYPERLIPIDEMIC MICE**  
Julian I. Borissov\* (NL), Sarah T.B.G. Loubele, Sylvia Heeneman, Peter Leenders, Rene van Oerle, Karly Hamulyak, Erik A. Biessen, Jay L. Degen, Tilman M. Hackeng, Mat J.A.P. Daemen, Henri M.H. Spronk, Hugo ten Cate
- P-TU-550 MONOMERIC C-REACTIVE PROTEIN IMPAIRS ENDOTHELIAL PROGENITOR CELL FUNCTION AND DIFFERENTIATION VIA UP-REGULATION OF INTERFERONE ALPHA RESPONSIVE GENES**  
Ingo Ahrens\* (DE), Helena Domeij, Steffen Eisenhardt, Madlin Albrecht, Denijal Topcic, Ephraem Leitner, Jeremy Jowett, Martha Lappas, Izhak Haviv, Christoph Bode, Karlheinz Peter
- P-TU-551 THE EFFECT OF ELASTIN AND FIBULIN-5 GENE EXPRESSIONS IN CAROTID ARTERY DISEASE DEVELOPMENT**  
Mehmet Kurtoglu\* (TR), Emre Sivrikoz, Umit Zeybek, Arzu Ergen, Ozlem Timirci, Murat Aksoy
- P-TU-552 EFFECT OF ATORVASTATIN ON INFLAMMATORY MARKERS, NITRIC OXIDE METABOLITES AND CAROTID INTIMA MEDIA THICKNESS IN SYSTEMIC LUPUS ERYTHEMATOSUS. A PLACEBO CONTROLLED STUDY**  
Paul Richard Julian Ames\* (UK), Kathrina Benita Sokoll, Helen Mavlyer, Joana Batuca, Luis Lopez, Paul Emery
- P-TU-553 EFFECT OF BETAINE ON TISSUE FACTOR EXPRESSION IN ACTIVATED HUMAN ENDOTHELIAL CELLS: A NEW PATHWAY OF VASCULAR PROTECTION**  
Emanuela Napoleone (IT), Antonella Cutrone, Daniela Cugino, Iolanda Santimone, Licia Iacoviello, Enzo Grossi, Giovanni de Gaetano, Maria Benedetta Donati, Roberto Lorenzet\*
- P-TU-554 DOWNREGULATION OF TISSUE FACTOR EXPRESSION IN HUMAN MONONUCLEAR CELLS AND MACROPHAGES BY CONJUGATED LINOLEIC ACID ISOMERS**  
Antonella Cutrone (IT), Emanuela Napoleone, Giulia Colavecchia, Daniela Cugino, Licia Iacoviello, Giovanni de Gaetano, Orina Belton, Maria Benedetta Donati, Roberto Lorenzet\*





## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-555 MOLECULAR AND CELLULAR COMPONENTS OF HUMAN CAROTID ARTERY ATHEROSCLEROTIC PLAQUES RELEVANT FOR THROMBUS FORMATION**  
Patrizia Marchese\* (US), Patrizia Marchese, Chiara Foglieni, Andras Gruber, Zaverio M. Ruggeri
- P-TU-556 HISTOPATHOLOGICAL DIFFERENCES BETWEEN PTX3 AND CRP IN CORONARY ATHEROSCLEROTIC PLAQUE**  
Yunosuke Matsuura\* (JP), Kinta Hatakeyama, Takuroh Imamura, Yoshisato Shibata, Tatsuhiko Kodama, Kazuo Kitamura, Yujiro Asada
- P-TU-557 SELECTIVE DISRUPTION OF THE CD40L/MAC-1 INTERACTION BY A SMALL PEPTIDE INHIBITOR MIMICKING THE EQLKSKTL MOTIF ATTENUATES INFLAMMATION AND ATHEROGENESIS IN MICE**  
Andreas Zirlik\* (DE), Dennis Wolf, Ansgar Wiedemann, Jan David Hohmann, Nicole Bassler, Peter Libby, Karlheinz Peter, Christoph Bode

### Endothelial cells

- P-TU-558 STANDARDIZATION OF MICROPARTICLE MEASUREMENT BY FLOW CYTOMETRY**  
Shosaku Nomura\* (JP), Norihito Inami, Shinya Fujita, Ryotaro Ozasa, Shuji Higashi, Yutaka Nagai
- P-TU-559 CLOPIDOGREL INDUCED INHIBITION OF PLATELET REACTIVITY PREDICT ENDOTHELIAL INJURY DURING PERCUTANEOUS CORONARY ANGIOPLASTY**  
Florence Sabatier\* (FR), Karim Harhour, Laurent Bonello, Florence Sabatier, Laurence Camoin-Jau, Laurent Arnaud, Karine Baumstarck-Barrau, Omar Ait-Mokhtar, Francois Roubille, Christophe Piot, Nathalie Lesavre, Franck Paganelli, Francoise Dignat-George
- P-TU-560 NICOTINAMIDE AND 1-METHYLNICOTINAMIDE PRESENT LOW VASODILATING ACTIVITY. FUNCTIONAL AND IN VITRO STUDIES**  
Cezary W Watala\* (PL), Tomasz Przygodzki, Piotr Kazmierczak
- P-TU-561 EXPOSURE TO CARBON NANOPARTICLES INDUCES UPREGULATION OF FACTOR VIII PRODUCTION BY HUMAN PULMONARY MICROVASCULAR ENDOTHELIAL CELLS**  
Tina Shahani\* (BE), Jan Emmerechts, Sophie Deckx, Marc Hoylaerts, Marc Jacquemin
- P-TU-562 THE INTERACTION OF CD146/MCAM WITH GALECTIN-1 IS INVOLVED IN THE CONTROL OF ENDOTHELIAL CELL APOPTOSIS**  
Francoise Dignat-George\* (FR), Nathalie Jouve, Nicolas Despoix, Marion Espeli, Karim Fallague, Nathalie Bardin, Marcel Blot-Chabaud, Laurent Gauthier, Frederic Vely, Claudine Schiff, Aurelie Leroyer
- P-TU-563 IMPAIRED MICROVASCULAR FUNCTION DURING ATORVASTATIN THERAPY IN PATIENTS WITH TYPE 1 DIABETES**  
Sara Tehrani\* (SE), Fariborz Mobarrez, Aleksandra Antovic, Per-Eric Lins, Ulf Adamson, Peter Henriksson, Hakan Wallen, Gun Jorneskog
- P-TU-564 IDENTIFICATION OF SOLUBLE-FORM EXTRACELLULAR TIE-2 WITH FULL FUNCTIONAL DOMAINS: INVOLVEMENT OF TIMP-INSENSITIVE ADAM9 IN ITS PRODUCTION IN ENDOTHELIAL CELLS**  
Mitsuho Onimaru\* (JP), Yoshikazu Yonemitsu, Hanako Suzuki, Katsuo Sueishi
- P-TU-565 KRINGLE1-5 OF PLASMINOGEN MEDIATES ANTIANGIOGENESIS BY ACTIVATION OF PKA AND DOWNREGULATES THROMBOMODULIN EXPRESSION**  
Chia-Fong Cho\* (TW), Hua-Lin Wu, Guey-Yueh Shi

Tuesday Poster



75

## POSTER PRESENTATIONS

Tuesday, July 26, 2011

- P-TU-566 PAI-1 AND PAI-2 INHIBIT PROTEASOME ACTIVITY FAVORING PROAPOPTOTIC SIGNALING IN ENDOTHELIAL CELLS**  
Joanna M Boncela\* (PL), Izabela Papiewska-Pajak, Patrycja Przygodzka, Elzbieta Wyroba, Czeslaw S Cierniewski
- P-TU-567 INVOLVEMENT OF NALP3 INFLAMMASOME AND NFKAPPAB IN THE DEVELOPMENT OF ENDOTHELIAL DYSFUNCTION IN ADVANCED CHRONIC KIDNEY DISEASE: PROTECTIVE ROLE OF ANTIOXIDANT MOLECULES**  
Carolina Caballo\* (ES), Marta Palomo, Aleix Cases, Patricia Molina, Manel Vera, Xavier Bosch, Gines Escolar, Maribel Diaz-Ricart
- P-TU-568 CIRCULATING ENDOTHELIAL CELLS AND ENDOTHELIAL PROGENITOR CELLS IN ACUTE MYOCARDIAL INFARCTION: CORRELATION WITH PLASMA VASCULAR MARKERS**  
Maribel Diaz-Ricart\* (ES), Ander Regueiro, Marta Palomo, Isaac Subirana, Joan Vila, Juan Sanchis, Susana Novella, Ana Oliveras, Gines Escolar, Jaume Roquer, Magda Heras

### Inflammatory cells and cytokines

- P-TU-569 THE INHIBITORY EFFECTS OF DISINTEGRIN, RHODOSTOMIN, ON THE ACTIVATION OF TOLL-LIKE RECEPTOR 2**  
Chun-Chieh Hsu\* (TW), Tur-Fu Huang
- P-TU-570 STRESS-INDUCED ADIPOSE INFLAMMATION PROMOTES A PROCOAGULANT STATE AND IMPAIRS INSULIN SENSITIVITY BY ADIPOCYTE-DERIVED MONOCYTE CHEMOATTRACTANT PROTEIN-1**  
Yasuhiro Uchida\* (JP), Kyosuke Takeshita, Koji Yamamoto, Ryosuke Kikuchi, Takayuki Nakayama, Tadashi Matsushita, Hideo Nakamura, Tetsuhito Kojima, Toyooki Murohara
- P-TU-571 RECOMBINANT CD93 SUPPRESSES INFLAMMATORY RESPONSES IN EXPERIMENTAL INFLAMMATORY MODELS**  
Yuan-Chung Kao\* (TW), Shi Guey-Yueh, Hsu Hsin-I, Wu Hua-Lin
- P-TU-572 POTENT INHIBITION OF SUPEROXIDE ANION PRODUCTION IN ACTIVATED HUMAN NEUTROPHILS BY A SMALL CHEMICAL COMPOUND, HTL-9807**  
Hwang Tsong-Long\* (TW), Yann-Ili Leu
- P-TU-573 EVALUATION OF THE EFFECTS OF THE COMBINED TP AND 5-HT2 RECEPTOR ANTAGONIST NAFTIDROFURYL IN THE RAT POST-ISCHEMIC KIDNEY**  
Virginie Voisin\* (BE), Vanessa Colombaro, Laetitia Giordano, Isabelle Habsch, Lucie Burette, Francois Mullier, Jean-Michel Dogne, Nathalie Caron
- P-TU-574 SOLUBLE TWEAK PLASMA LEVELS AS A NOVEL BIOMARKER OF ENDOTHELIAL FUNCTION IN PREVALENT ORTHOTOPIC HEART TRANSPLANT RECIPIENTS**  
Jolanta Malyszko\* (PL), Piotr Przybylowski, Jacek Malyszko, Mysliwiec Michal
- P-TU-575 TRAIL IS A MARKER OF KIDNEY FUNCTION AND INFLAMMATION IN HEART AND KIDNEY TRANSPLANT RECIPIENTS**  
Jolanta Malyszko\* (PL), Piotr Przybylowski, Jacek Stanislaw Malyszko, Ewa Koc-Zorawska, Jerzy Sadowski, Michal Mysliwiec
- P-TU-576 CXCR4 ANTAGONISM IS EQUALLY EFFECTIVE AS SIROLIMUS IN REDUCING NEOINTIMA FORMATION AFTER ARTERIAL INJURY WITHOUT IMPAIRING RE-ENDOTHELIALIZATION**  
Karim Hamesch\* (DE), Pallavi Subramanian, Xiaofeng Li, Anna Thiemann, Kathrin Heyll, Klaus Dembowski, Eric Chevalier, Christian Weber, Andreas Schober



## POSTER PRESENTATIONS

Tuesday, July 26, 2011

**P-TU-577 EFFECT OF RIVAROXABAN ON THROMBIN-INDUCED PRO-INFLAMMATORY GENE EXPRESSION IN HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS**

Peter Ellinghaus\* (DE), Volker Laux, Elisabeth Perzborn

### Redox status

**P-TU-579 INTRACELLULAR REDOX HOMEOSTASIS IS DEPENDENT ON VITAMIN K AND THE VKORC1 HOMOLOGUE VKORC1L1**

Matthias Watzka\* (DE), Matthias Watzka, Philipp Westhofen, Milka Marinova, Moritz Hass, Gregor Kirfel, Jens Mueller, Nancy Blaurock, Carville G Bevans, Johannes Oldenburg

### Progenitor cells and stem cells

**P-TU-581 INHIBITION OF TISSUE FACTOR ON CD34+ALPHA(A)-SMA+ CELLS IS ASSOCIATED WITH REDUCED ANGIOPOIETIN-DEPENDENT CXCR4 EXPRESSION AND REPAIR AFTER ENDOVASCULAR INJURY**

Daxin Chen\* (UK), Li El Tham, John H McVey, Anthony Dorling

**P-TU-582 TISSUE FACTOR- AND ANGIOPOIETIN-DEPENDENT CROSS-TALK BETWEEN CD34+ALPHA(A)-SMA+ AND CD34+CD31+ CELLS SUPPORTS EARLY RECRUITMENT OF ENDOTHELIAL CELLS AFTER ENDOLUMINAL INJURY**

Daxin Chen\* (UK), Li El Tham, John H McVey, Anthony Dorling

**P-TU-583 TISSUE FACTOR PATHWAY INHIBITOR-DEPENDENT CHANGES IN ANGIOPOIETIN EXPRESSION BY CD34+ ALPHA-SMOOTH MUSCLE ACTIN (A-SMA)+PROGENITORS ASSOCIATED WITH ENDOVASCULAR REPAIR**

Daxin Chen\* (UK), Li El Tham, John H McVey, Anthony Dorling

**P-TU-584 LACK OF TISSUE FACTOR- AND ANGIOPOIETIN-DEPENDENT CXCL12 EXPRESSION BY CD34+ALPHA-SMOOTH MUSCLE ACTIN (A-SMA)+CELLS ASSOCIATES WITH REPAIR AFTER ENDOVASCULAR INJURY**

Daxin Chen\* (UK), Li El Tham, John H McVey, Anthony Dorling

**P-TU-585 INVOLVEMENT OF THE ANTIMICROBIAL PEPTIDE LL-37 (CAMP) IN THE DIFFERENTIATION OF CORD BLOOD DERIVED CD34+ CELLS INTO ENDOTHELIAL PROGENITOR CELLS**

Ingo Ahrens\* (DE), Helena Domeij, Denijal Topcic, Izhak Haviv, Alex Agrotis, Ephraem Leitner, Jeremy Jowett, Martha Lappas, Christoph Bode, Karlheinz Peter

**P-TU-586 ADMA INDUCES ENDOTHELIAL PROGENITOR CELLS APOPTOSIS BY P38/JNK MAPK SIGNALING PATHWAYS**

Shilong Xiong\* (CN), Wang Qian, Zheng Lei, Bao Jie, Cai Zhen

**P-TU-587 THE METABOLIC SYNDROME INDUCES APOPTOSIS IN BONE MARROW CELLS AND DECREASES THEIR PROLIFERATIVE CAPACITIES**

Sophie Susen\* (FR), Matthieu Barthelemy, Madjid Tagzrit, Alexandre Ung, Joke Breyne, Delphine Corseaux, Philippe Marchetti, Brigitte Jude, Eric Van Belle, Frederic Mouquet

**P-TU-588 HUMAN BONE MARROW RESIDENT STEM/PROGENITOR CELLS AND STATIN THERAPY IN PATIENTS WITH CORONARY ARTERY DISEASE**

Olena Dotsenko\* (UK), Qingbo Xu, Marjan Jahangiri

Tuesday Poster



77

## POSTER PRESENTATIONS

Tuesday, July 26, 2011

### Imaging technologies

- P-TU-589 THE ASSESSMENT METHOD OF TISSUE FACTOR PATHWAY INITIATION ACTIVITY--- PLASMA RECALCIFICATION TIME DIFFERENCE RATIO**  
Xiaofan He\* (CN), Jing Hu, Hongjian Wang, Bangtao Li, Xudong Tang, Zhhibin Wen, Shilin He
- P-TU-590 SEQUENTIAL MAGNETIC RESONANCE SIGNAL CHANGE OF VENOUS THROMBUS RELATES TO ORGANIZING PROCESSES AND THROMBOLYTIC RESPONSES IN RABBITS**  
Yasuyoshi Kuroiwa\* (JP), Atsushi Yamashita, Tosiaki Miyati, Eiji Furukoji, Misaki Takahashi, Toshiya Azuma, Hiroshi Sugimura, Taketoshi Asanuma, Shozo Tamura, Keiichi Kawai, Yuijro Asada
- P-TU-591 ULTRASOUND IN THE EVALUATION OF HAEMOPHILIC ARTHROPATHY OF ANKLES AND KNEES: A NEW TOOL IN HAEMOPHILIA CARE**  
Alessandro Gringeri\* (IT), Myrvete Muca-Perja, Lucia Mangiafico, Silvia Riva, Beata Maria Grochowska, Francesco Fusco, Debora Mago
- P-TU-592 PERFORMANCE CHARACTERISTICS OF THE THE ENHANCED HEPARIN INSENSITIVE ALERE INRATIO(R)/INRATIO(R)2 PT/INR MONITORING SYSTEM**  
Grace DeSantis\* (US), Mae Zhang, Kari Kalvelage, Anne Lacorte, Elena Garcia, Ken Kupfer, Rick SanGeorge
- P-TU-593 IMAGING SPATIAL DYNAMICS OF FIBRIN CLOT FORMATION: POSSIBILITIES FOR DETECTION OF PROTHROMBOTIC AND BLEEDING TENDENCIES**  
Mikhail A Panteleev\* (RU), Anna N Balandina, Vladimir M Emelianenko, Olga A Fadeeva, Gennadii M Galstian, Sergey S Karamzin, Elena N Lipets, Natalia P Soshitova, Ivan D Tarandovskii, Fazoil I Ataulakhanov
- P-TU-594 ARFI ULTRASOUND FOR IN VIVO MONITORING OF SOFT-TISSUE BLEEDING AND HEMOSTASIS IN A DOG MODEL OF HEMOPHILIA**  
Mallory Renee Scola\* (US), Timothy C Nichols, Melissa C Caughey, Elizabeth P Merricks, Robin A Raymer, Paris Margaritis, Katherine A High, Caterina M Gallippi
- P-TU-595 PREDICTION OF THE EVOLUTION OF ABDOMINAL AORTIC ANEURYSM ON A ANIMAL MODEL BY PET-CT**  
Ziad Touat\* (BE), Pierre Drion, Jean-Francois Monville, Geoff Warnock, Betty Nutsgens, Alain Colige, Alain Cyclotron Research Center, ULG, Belgium Plenevaux, Olivier Defraigne, Natzi Sakalihan
- P-TU-596 OPTICAL COHERENCE TOMOGRAPHY AS A NOVEL TOOL FOR DIFFERENTIAL DIAGNOSIS OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION FROM PULMONARY ARTERIAL HYPERTENSION**  
Nobuhiro Yaoita\* (JP), Shunsuke Tatebe, Yoshihiro Fukumoto, Hisanori Horiuchi, Hiroaki Shimokawa
- P-TU-597 2-D DIGE AS A NOVEL ANALYTICAL TOOL TO ANALYZE THE STRUCTURE OF RECOMBINANT FVIII AND ITS PEGYLATED VARIANTS**  
Hanspeter Rottensteiner\* (AT), Christina Monetti, Herbert Gritsch, Alfred Weber, Friedrich Scheiflinger, Peter L. Turecek
- P-TU-598 COST IMPLICATIONS OF POTENTIAL DIFFERENCES IN FVIII PRODUCT HALF-LIVES IN A SWEDISH SOCIETY SETTING**  
Flemming Lund Axelsen\* (CH), Alec Miners
- P-TU-600 DIAGNOSTIC OPTICAL COMPOSITE COMPLEX FOR IN VIVO IMAGING OF PLATELETS**  
Irina Vasilenko\* (RU), Vladislav Metelin, Irina Kastrikina, Olga Lopyreva, Marina Nalgieva, Roman Lifenko, Benjamin Agadzhanjan, Irina Ivanyuta



## POSTER PRESENTATIONS

Tuesday, July 26, 2011

**P-TU-601 PREDICTION OF PERIPROCEDURAL ISCHEMIC COMPLICATION IN CAROTID ARTERY STENTING WITH FILTER EMBOLIC PROTECTION DEVICE BY USING MAGNETIC RESONANCE (MR) PLAQUE IMAGING**

Kimihiko Kichikawa\* (JP), Katsutoshi Takayama, Hiroyuki Nakagawa, Kaoru Miyouchinn, Toshiaki Taoka, Masahiko Sakamoto, Takeshi Wada, Shinichiro Kurokawa

Tuesday Poster



79

**Scientific Program**  
**Wednesday, July 27, 2011**

Wednesday, July 27, 2011

**Presidential Symposium**

**11:15-12:45**

**Historical Perspective and Future Direction**

**Main Hall**

*Chairpersons: Yasuo Ikeda (JP) and Frits R. Rosendaal (NL)*

**Historical perspective and future direction in platelet research**

PS-WE-001

*Barry S. Coller (US)*

11:15 – 11:45

**Historical perspective and future direction of coagulation research**

PS-WE-002

*Hidehiko Saito (JP), Tadashi Matsushita, Tetsuhito Kojima*

11:45 – 12:15

**Historical perspective and future direction of fibrinolysis research:**

**The re-discovery of plasmin**

PS-WE-003

*Victor J. Marder (US)*

12:15 – 12:45

**State-of-the-Art Lecture**

**9:45-10:45**

**Atherothrombosis**

**Main Hall**

*Chairpersons: Anna Falanga (IT) and Shinya Goto (JP)*

**Atherothrombosis and the role of antiplatelet therapy**

SA-WE-001

*Philippe G. Steg (FR)*

09:45 – 10:15

**Improving reperfusion therapy for acute ischemic stroke**

SA-WE-002

*Jeffrey L. Saver (US)*

10:15 – 10:45

**Platelet Activation**

**Annex Hall 1**

*Chairpersons: Kenneth J. Clemetson (CH) and Mitsuhiro Sugimoto (JP)*

**Novel platelet activation receptor CLEC-2: From discovery to prospects**

SA-WE-003

*Katsue Suzuki-Inoue (JP), Osamu Inoue, Yukio Ozaki*

09:45 – 10:15

**Platelet adhesion and activation mechanisms in arterial thrombosis and ischemic stroke**

SA-WE-004

*Bernhard Nieswandt (DE), Pleines Irina, Bender Markus*

10:15 – 10:45



Wednesday, July 27, 2011

**Genetics in Thrombosis**

**Annex Hall 2**

*Chairpersons: Willem H. Ouwehand (UK) and Toshiyuki Miyata (JP)*

**Discovery of novel platelet aggregation and platelet function loci through genome-wide studies**

SA-WE-005

*Andrew D. Johnson (US)*

09:45 – 10:15

**Lessons from genome-wide association studies in venous thrombosis**

SA-WE-006

*Pierre-Emmanuel Morange (FR), Tregouet David-Alexandre*

10:15 – 10:45

**Hemorrhagic and Thrombotic Disorders in Women**

**Room A**

*Chairpersons: Nigel Key (US) and Takao Kobayashi (JP)*

**Women with inherited bleeding disorders**

SA-WE-007

*Flora Peyvandi (IT), Isabella Garagiola, Marzia Menegatti*

09:45 – 10:15

**Antithrombotic treatment for recurrent pregnancy loss?**

SA-WE-008

*Ian A. Greer (UK)*

10:15 – 10:45

**Symposia**

**8:00-9:30**

**Thrombotic Disorders**

**Main Hall**

**Venous Thromboembolism Prophylaxis**

*Chairpersons: Meyer-Michel Samama (FR) and Masato Sakon (JP)*

**Thromboprophylaxis in surgical patients: How reliable are clinical trials?**

SY-WE-001

*Ajay Kakkar (UK)*

08:00 – 08:30

**Direct factor Xa and thrombin inhibitors: Clinical trial update**

SY-WE-002

*Alexander G. G. Turpie (CA)*

08:30 – 09:00

**Preventing VTE in non-surgical patients**

SY-WE-003

*Alexander Stephen Gallus (AU)*

09:00 – 09:30

Wednesday Science



3



Wednesday, July 27, 2011

**Platelet (Basic and Clinical)**

**Annex Hall 1**

**Platelets Beyond Hemostasis**

*Chairpersons: Guy A. Zimmerman (US) and Paul Harrison (UK)*

**Platelets: Multi-talents in vascular biology**

**SY-WE-004**

*Steffen Massberg (DE)*

08:00 – 08:30

**Platelet signaling and the regulation of lymphatic vascular development**

**SY-WE-005**

*Mark L. Kahn (US)*

08:30 – 09:00

**The functions of platelets and platelet microparticles in inflammatory arthritis**

**SY-WE-006**

*Eric Boillard (CA), Nathalie Cloutier, Richard Farndale, Brisson Alain*

09:00 – 09:30

**Coagulation Factors and Inhibitors**

**Annex Hall 2**

**Coagulation Initiation and Amplification**

*Chairpersons: Bjarne Østerud (NO) and Pantep Angchaisuksiri (TH)*

**Alternatively spliced tissue factor: A physiological or pathological phenomenon?**

**SY-WE-007**

*Henri H. Versteeg (NL)*

08:00 – 08:30

**Factor IX-Triple, an improvement upon natural factor IX for treating hemophilia B?**

**SY-WE-008**

*Shu-Wha Lin (TW), Chung-Yang Kao, Chia-Ni Lin*

08:30 – 09:00

**Prothrombinase activation**

**SY-WE-009**

*Sriram Krishnaswamy (US)*

09:00 – 09:30



# ORAL COMMUNICATIONS

Wednesday, July 27, 2011

## Innovation and Technology

Room C-1

*Chairpersons: Jian Chun Chen and Masaru Ishii (JP)*

- |                 |  |                      |
|-----------------|--|----------------------|
| <b>O-WE-001</b> | <b>NOVEL SINGLE-CHAIN ANTIBODY-TARGETED MICROBUBBLES FOR DETECTION OF ARTERIAL THROMBOSIS VIA CONTRAST ENHANCED ULTRASOUND</b><br>Xiaowei Wang* (AU), Christoph E Hagemeyer, Fu Jia, Ephraem Leitner, Ingo Ahrens, Karlheinz Peter   | <b>08:00 - 08:15</b> |
| <b>O-WE-002</b> | <b>DEVELOPMENT OF A QUANTITATIVE DIFFERENTIAL INTERFERENCE CONTRAST-BASED REFRACTOMETRY METHOD FOR THE CHARACTERIZATION OF RARE BLOOD CELL SUBPOPULATIONS</b><br>Owen J McCarty* (US), Steven Jacques, Kevin Phillips  | <b>08:15 - 08:30</b> |
| <b>O-WE-003</b> | <b>TISSUE FACTOR-TRIGGERED PROCOAGULANT ACTIVITY OF MESENCHYMAL STEM CELLS</b><br>Kohei Tatsumi* (JP), Kazuo Ohashi, Yoshinori Matsubara, Ayako Kohori, Hiroshi Kakidachi, Akihiro Horii, Teruo Okano  | <b>08:30 - 08:45</b> |
| <b>O-WE-004</b> | <b>A QUANTUM DOT APPROACH TO PLATELET SIGNALING</b><br>Joseph E Aslan* (US), Thomas Jacob, Owen JT McCarty, Tania Q Vu   | <b>08:45 - 09:00</b> |
| <b>O-WE-005</b> | <b>NONINVASIVE PRENATAL DIAGNOSIS OF HEMOPHILIA BY MICROFLUIDICS DIGITAL PCR ANALYSIS OF MATERNAL PLASMA DNA</b><br>Rezan A Kadir* (UK), Nancy B. Y. Tsui, Allen Chan, Claudia Chi, Gillian Mellars, Edward G Tuddenham, Tak Y Leung, Tze K Lau, Rossa W K. Chiu, Dennis Y M Lo                                      | <b>09:00 - 09:15</b> |
| <b>O-WE-006</b> | <b>PLATELET BEHAVIOR ON VON WILLEBRAND FACTOR UNDER ARTERIAL FLUID SHEAR DIFFERS BETWEEN HEALTHY INDIVIDUALS AND PATIENTS WITH CARDIOVASCULAR DISEASE ON DUAL ANTIPLATELET THERAPY</b><br>Gerardene R Meade* (IE), Sinead O'Brien* (IE), Martin Somers, Gail Plunkett, Colm McAtamney, Antonio J Ricco, Dermot Kenny | <b>09:15 - 09:30</b> |

Wednesday Oral

## Fibrinogen and Other Factors II

Room C-2

*Chairpersons: Yoshihiro Kokubo (JP) and [REDACTED]*

- |                 |   |                      |
|-----------------|---|----------------------|
| <b>O-WE-007</b> | <b>QUANTITATIVE MONITORING OF CLOT FORMATION AND FXIII ACTIVITY IN REAL TIME USING MURINE IN VIVO MODEL OF THROMBOSIS</b><br>Majid Ali* (UK), Richard Pease, Victoria Ridger, Gareth Howells, Peter Grant, Robert Ariens, Helen Philippou | <b>08:00 - 08:15</b> |
|-----------------|---|----------------------|



## ORAL COMMUNICATIONS

Wednesday, July 27, 2011

- O-WE-008** **08:15 - 08:30**  
**THE RECENTLY DISCOVERED INTRON K NT29576C>G FACTOR XIII B SUBUNIT GENE POLYMORPHISM DECREASES THE RISK OF MYOCARDIAL INFARCTION AND FACTOR XIII LEVEL IN YOUNG ADULTS**  
Laszlo Muszbek\* (HU), Zoltan A Mezei, Zsuzsanna Bereczky, Laszlo Balogh, Eva Katona, Istvan Edes
- O-WE-009** **08:30 - 08:45**  
**INHIBITION OF STAPHYLOTHROMBIN BY DABIGATRAN REDUCES STAPHYLOCOCCUS AUREUS ADHESION TO CATHETER AND OTHER FOREIGN SURFACES IN VITRO AND ABSCESS VOLUME IN VIVO**  
Thomas Vanassche\* (BE), Willy E Peetermans, Jan Verhaegen, Joanne van Ryn, Marc F Hoylaerts, Peter Verhamme
- O-WE-010** **08:45 - 09:00**  
**A NEW, SAFE AND EFFECTIVE RECOMBINANT PROPHYLACTIC TREATMENT FOR PATIENTS WITH CONGENITAL FXIII-A SUBUNIT DEFICIENCY**  
Manuel Carcao\* (CA), Aida Inbal, Johannes Oldenburg, Anders Rosholm, Ramin Tehrani, Diane Nugent
- O-WE-011** **09:00 - 09:15**  
**ARTIFICIAL PLASMA SUBSTITUTING SOLUTIONS (PSSS) DON'T WORSEN THROMBIN-FIBRINOGEN AND FACTOR XIII-FIBRIN POLYMER INTERACTIONS**  
Elena I Sinauridze\* (RU), Irina V Gribkova
- O-WE-012** **09:15 - 09:30**  
**GENDER DIFFERENCES IN FIBRIN NETWORK IN TYPE 2 DIABETES: A STUDY OF CLOT STRUCTURE CHARACTERISTICS AND ASSOCIATIONS WITH VASCULAR AND CARDIOMETABOLIC PARAMETERS**  
Katharina Hess\* (DE), Saad H Alzahrani, Jackie F Price, Mark WJ Strachan, Paul D Baxter, Richard Cubbon, Fladia Phoenix, Toby Gamlen, Nikolaus Marx, Peter J Grant, Ramzi Ajjan

### Coagulation Factors: Experimental Models II

Room D

*Chairpersons: Hans Deckmyn (BE) and Hidemi Ishii (JP)*

- O-WE-013** **08:00 - 08:15**  
**EP217609, A NOVEL NEUTRALIZABLE ANTICOAGULANT IN CARDIOPULMONARY BYPASS**  
Eric Neuhart\* (FR), Yves Fromes, Pierre Gueret, Chantal Krezel, Maurice Petitou
- O-WE-014** **08:15 - 08:30**  
**ANTI-APOPTOTIC EFFECT OF ACTIVATED PROTEIN C DURING GLUTAMATE-TOXICITY: MOLECULAR MECHANISM**  
Lyubov Gorbacheva\* (RU), Irina Savinkova, Vsevolod Pinelis, Schin'ichi Ishiwata, Georg Reiser, Svetlana Strukova
- O-WE-015** **08:30 - 08:45**  
**PROTECTIVE ROLE OF PROTEIN S IN LIVER FIBROSIS**  
Rumi Moroka\* (JP), Paloma Gil Bernabe, Corina D'Alessandro-Gabazza, Daniel Boveda Ruiz, Masaaki Toda, Yasushi Miyake, Atsushi Yasukawa, Masahiro Naito, Takehiro Takagi, Motoh Iwasa, Osamu Taguchi, John Morser, Yoshiyuki Takei, Esteban C Gabazza



## ORAL COMMUNICATIONS

Wednesday, July 27, 2011

- O-WE-016** **THROMBIN-THROMBOMODULIN INTERACTIONS ARE AN IMPORTANT DETERMINANT OF METASTATIC POTENTIAL** **08:45 - 09:00**  
Netanel Horowitz\* (US), Elizabeth A Blevins, Whitney M Miller, Ashley R Perry, Kathryn E Talmage, Eric S Mullins, Brett Monia, Jay L Degen, Joseph S Palumbo
- O-WE-017** **ROLE OF PDI IN THROMBUS FORMATION AND FIBRIN GENERATION IN A COLLAGEN INDUCED PATHWAY** **09:00 - 09:15**  
Dolores Bellido Martin\* (US), Lola Bellido-Martin, Bruce Furie, Barbara Furie
- O-WE-018** **DIAGNOSIS, MECHANISM AND THERAPY OF HEREDITARY ANGIOEDEMA TYPE III** **09:15 - 09:30**  
Jenny Bjorkqvist\* (SE), Felicitas Mueller, Sabine Wilhelm, Sven Cichon, Markus Nothen, Thomas Renne

### Atherosclerosis and Atherothrombosis

Room E

Chairpersons: Shinichiro Kurosawa (US) and Henri M. Spronk (NL)

- O-WE-019** **FACTOR SEVEN ACTIVATING PROTEASE (FSAP) INHIBITS THE ACTIVITY OF PLATELET DERIVED GROWTH FACTOR-BB (PDGF-BB) IN VITRO AND IN VIVO** **08:00 - 08:15**  
Sandip M Kanse\* (DE), Jan-Marcus Daniel, Karin Hersemeyer, David M Kaetzel, Daniel Sedding
- O-WE-020** **THE ROLE OF THE EXTRACELLULAR RNA/RNASE SYSTEM IN CARDIOVASCULAR DISEASE AND INFLAMMATION** **08:15 - 08:30**  
Klaus T Preissner\* (DE), Silvia Fischer, Christiane Thoelen, Tobias Grantzow, Nicole Kral, Julia Gansler, Thomas Weimer, Markus Sperandio, Elisabeth Deindl, Daniel Sedding
- O-WE-021** **BM-573 INHIBITS THE EARLY ATHEROSCLEROTIC LESIONS IN APO E DEFICIENT MICE BY BLOCKING TP RECEPTORS AND THROMBOXANE SYNTHASE** **08:30 - 08:45**  
Celine Cherdon\* (BE), Stephanie Rolin, Julien Hanson, Annie Ooms, Laurent de Leval, Pierre Drion, Carine Michiels, Bernard Pirotte, Francois Mullier, Natzi Sakalihassan, Jean-Olivier Defraigne, Jean-Michel Dogne
- O-WE-022** **ADMINISTRATION OF ORAL DABIGATRAN ETEXILATE SUBSTANTIALLY COUNTERACTS INFLAMMATION AND ENHANCES PLAQUE STABILITY IN A HYPERCOAGULABLE MODEL OF AGGRESSIVE ATHEROSCLEROSIS** **08:45 - 09:00**  
Julian I. Borissoff\* (NL), Sarah T.B.G. Loubele, Sylvia Heeneman, Peter Leenders, Rene van Oerle, Oliver Soehnlein, Karly Hamulyak, Erik A. Biessen, Hartmut Weiler, Joanne van Ryn, Tilman M. Hackeng, Mat J.A.P. Daemen, Henri M.H. Spronk, Hugo ten Cate

Wednesday Oral



7

## ORAL COMMUNICATIONS

Wednesday, July 27, 2011

**O-WE-023** **09:00 - 09:15**

**INNATE IMMUNE RESPONSE THROUGH TLR4 IS ASSOCIATED WITH PLATELET ACTIVATION AND INFLAMMATION IN PATIENTS WITH ACUTE CORONARY SYNDROME**

Kagari M Murasaki\* (JP), Hisako Omori, Yoshio Uetsuka, Nobuhisa Hagiwara

**O-WE-024** **09:15 - 09:30**

**INTEGRIN MAC-1 FACILITATES THE ANTI-INFLAMMATORY ACTIVITY OF ACTIVATED PROTEIN C**

Li Zhang\* (US), Chunzhang Cao, Yamei Gao, Yang Li, Toni M Antalis, Francis J Castellino

### Hemophilia: Inhibitor Treatment

Sakura

*Chairpersons: Elena Santagostino (IT) and Claude Negrier (FR)*

**O-WE-025** **08:00 - 08:15**

**UPDATE ON THE IMMUNE TOLERANCE AND ECONOMICS RETROSPECTIVE REGISTRY (ITER) OF PATIENTS WITH HAEMOPHILIA A (HA) AND FACTOR VIII INHIBITORS**

Alessandro Gringeri\* (IT), Angiola Rocino, Jan Astermark, Maria Joao Diniz, Karin Fijnvandraat, Robert Klamroth, Geraldine Lavigne-Lissalde, Thierry Lambert, Maria Fernanda Lopez-Fernandez, Massimo Morfini, Carmen Altisent, EHTSB Members

**O-WE-026** **08:15 - 08:30**

**COST OF IMMUNE TOLERANCE INDUCTION IN HAEMOPHILIA A PATIENTS: RESULTS FROM THE ITER STUDY**

Alessandro Gringeri\* (IT), Luciana Scalone, Lorenzo Giovanni Mantovani, Angiola Rocino, Carmen Altisent, Jan Astermark, Maria Joao Diniz, Karin Fijnvandraat, Robert Klamroth, Thierry Lambert, Geraldine Lavigne-Lissalde, Maria Fernanda Lopez Fernandez, Massimo Morfini, EHTSB Members

**O-WE-027** **08:30 - 08:45**

**EFFECTIVENESS AND SAFETY OF SECONDARY PROPHYLAXIS WITH RFVIIA IN HAEMOPHILIA PATIENTS WITH INHIBITORS: RESULTS FROM THE PRO-PACT OBSERVATIONAL STUDY**

Victor S Blanchette\* (CA), Elena Santagostino, Massimo Morfini, Guenter K Auerswald, Thierry Lambert, Victor Jimenez-Yuste, Guy Young

**O-WE-028** **08:45 - 09:00**

**SURGERY IN HAEMOPHILIA PATIENTS WITH INHIBITORS TO FVIII/FIX: THE NORWEGIAN SINGLE CENTRE STUDY**

Pal Andre Holme\* (NO), Hoa Thi Tyet Tran, Albert Paus, Geir E Tjonnfjord

**O-WE-029** **09:00 - 09:15**

**CLINICAL AND LABORATORY RESULTS FROM ADEPTTM 1, A PHASE 2 TRIAL INVESTIGATING THE USE OF RECOMBINANT ACTIVATED FVII ANALOGUE IN CONGENITAL HAEMOPHILIA PATIENTS WITH INHIBITORS**

Erich de Paula\* (BR), Kaan Kavakli, Johnny Mahlangu, Yasmin Ayob, Steven R. Lentz, Massimo Morfini, Laszlo Nemes, Silva Zupancic Salek, Midori Shima, Jerzy Windyga, Silke Ehrenforth, Henning Friis Andersen, Ampaiwan Chuansumrit, on behalf of 1804 (adeptTM 1) Investigators



## ORAL COMMUNICATIONS

Wednesday, July 27, 2011

O-WE-030

09:15 - 09:30

**CLINICAL PHARMACOLOGICAL STUDY OF A PLASMA-DERIVED FACTOR VIIA AND FACTOR X MIXTURE (MC710) IN HAEMOPHILIA PATIENTS WITH INHIBITORS - PHASE I TRIAL -**

Tadashi Matsushita\* (JP), Akira Shirahata, Katsuyuki Fukutake, Jun-ichi Mimaya, Junki Takamatsu, Midori Shima, Hideji Hanabusa, Hideyuki Takedani, Yoshifumi Takashima, Akio Tawa, Satoshi Higasa, Noboru Takata, Michio Sakai, Kiyoshi Kawakami, Yasuo Ohashi, Hidehiko Saito

**Antiphospholipid Syndrome: Clinical**

**Room A**

*Chairpersons: Tatsuya Atsumi (JP) and Philip de Groot (NL)*

O-WE-031

08:00 - 08:15

**OBSERVATIONAL STUDY OF THE VARIOUS ANTIPHOSPHOLIPID ANTIBODIES-RELATED DEEP VENOUS THROMBOTIC RISK IN WOMEN WITH AN OBSTETRICAL ANTIPHOSPHOLIPID SYNDROME**

Jean-Christophe Raymond Gris\* (FR), Erik Mercier, Eva Cochery-Nouvellon, Jean-Pierre Balducchi, Pierre Mares, Isabelle Quere, Michel Dauzat

O-WE-032

08:15 - 08:30

**IMPACT OF PERSISTENT ANTIPHOSPHOLIPID ANTIBODIES ON SYMPTOMATIC THROMBOEMBOLISM IN CHILDREN: A SYSTEMATIC REVIEW & META-ANALYSIS [OBSERVATIONAL STUDIES]**

Ulrike Nowak-Gottl\* (DE), Gili Kenet, Mariana Bonduel, Anthony Chan, Neil A Goldenberg, Susanne Holzhauser, Alfonso Iorio, Janna Journeykake, Ralf Junker, Christoph Male, Patricia Masicotte, Paul Monagle, Heleen C Van Ommen, Leslie Raffini, Paolo Simioni, Guy Young

O-WE-033

08:30 - 08:45

**THROMBOGENIC EFFECTS OF ANTIPHOSPHOLIPID ANTIBODIES ARE AMELIORATED IN TISSUE FACTOR DEFICIENT MICE**

Zurina Romay-Penabad (US), Ana Laura Carrera-Marin, Nigel Mackman, Silvia S Pierangeli\*

O-WE-034

08:45 - 09:00

**PREDOMINANT PREVALENCE OF STROKE IN JAPANESE PATIENTS WITH THE ANTIPHOSPHOLIPID SYNDROME**

Yuichiro Fujieda\* (JP), Tatsuya Atsumi, Kotaro Otomo, Masaru Kato, Kenji Oku, Olga Amegual, Shinsuke Yasuda, Tetsuya Horita, Takao Koike

O-WE-035

09:00 - 09:15

**DEVELOPMENT OF AUTO-ANTIBODIES AGAINST  $\beta$ 2-GLYCOPROTEIN I IN MICE**

Gwendolyn Margaretha van Os\* (NL), Joost M Meijers, Cetin Agar, Mercedes Valls Seron, Arnoud Marquart, Per Akesson, Rolf T Urbanus, Ron H Derksen, Heiko Herwald, Matthias Morgelin, Philip G. de Groot

O-WE-036

09:15 - 09:30

**$\beta$ 2-GLYCOPROTEIN I: A NOVEL COMPONENT OF INNATE IMMUNITY**

Cetin Agar\* (NL), Philip G de Groot, Matthias Morgelin, Stephanie D.D.C. Monk, Gwendolyn M.A. van Os, Johannes H.M. Levels, Bas de Laat, Rolf T Urbanus, Heiko Herwald, Tom van der Poll, Joost C.M. Meijers

Wednesday Oral




9

## ORAL COMMUNICATIONS

Wednesday, July 27, 2011

### Microparticles

Room B-1

Chairpersons: Shosaku Nomura (JP) and Benjamin Brenner 

- O-WE-037** **MICROPARTICLE-ASSOCIATED TISSUE FACTOR ACTIVITY IN PANCREATIC- AND BRAIN CANCER PATIENTS: IMPACT ON THROMBOSIS RISK AND SURVIVAL** 08:00 - 08:15  
Johannes Thaler\* (AT), Cihan Ay, Rogier M. Bertina, Silvia Koder, Alexandra Kaider, Marosi Christine, Gabriela Kornek, Christoph Zielinski, Ingrid Pabinger
- O-WE-038** **CHARACTERIZATION OF THE PROCOAGULANT ACTIVITY OF TWO DIFFERENT MICROPARTICLE SPECIES** 08:15 - 08:30  
Ludwig Traby\* (AT), Marietta Kollars, Khalid Shoumariyeh, Ansgar Weltermann, Paul Alexander Kyrle, Sabine Eichinger, Daniel Lechner
- O-WE-039** **PHOSPHATIDYLSERINE EXTERNALIZATION AND ITS VESICULATION IN GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY** 08:30 - 08:45  
Duangdao Nantakomol\* (TH), Attakorn Palasuwan, Suphan Soogarun, Supantitra Chanprasert, Pornlada Nuchnoi
- O-WE-040** **LABEL-FREE DISTINCTION BETWEEN PLATELET AND ERYTHROCYTE MICROPARTICLES BY RAMAN MICROSCOPY** 08:45 - 09:00  
Edwin van der Pol\* (NL), C M Hau, C Otto, A Sturk, T G van Leeuwen, R Nieuwland
- O-WE-041** **REDUCTION OF PRO-COAGULANT PHOSPHOLIPID AND PLATELET ACTIVATION DURING TISSUE ISCHEMIA AND REPERFUSION IN UPPER LIMB TRAUMA** 09:00 - 09:15  
Ross Ian Baker\* (AU), M Wenk, Elizabeth Gardiner, James Thom, Tomas Corcoran
- O-WE-042** **IMPROVEMENT OF MICROPARTICLE DETECTION USING A NEW HIGH-SENSITIVITY ROUTINE FLOW CYTOMETER: EXPLORING THE HIDDEN PART OF THE ICEBERG** 09:15 - 09:30  
Stephane Robert\* (FR), Romaric Lacroix, Philippe Poncelet, Jennifer Wischhusen, Karim Harhour, Tarik Bouriche, Jose Sampol, Francoise Dignat-George

### Plasminogen Activation System: Tissue Remodeling

Room B-2

Chairpersons: HIROYUKI MATSUNO (JP) and Johan Wojta

- O-WE-043** **LAP DEGRADATES: A NOVEL BLOOD BIOMARKER OF PLASMA KALLIKREIN-DEPENDENT TGF- $\beta$  ACTIVATION REFLECTING EARLY STAGE OF THE LIVER FIBROGENESIS** 08:00 - 08:15  
Soichi Kojima\* (JP)



## ORAL COMMUNICATIONS

Wednesday, July 27, 2011

**O-WE-044**

**UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR) REGULATES ANGIOGENESIS VIA DIRECT INTERACTION WITH LOW DENSITY LIPOPROTEIN RECEPTOR (LDLR-) LIKE PROTEIN IN ENDOTHELIAL CELLS**

Rene Novotny (AT), Matthias Unseld, Marina Poettler, Wacława Kalinowska, Margarethe Geiger, Christoph Zielinski, Gerald Prager\*

08:15 - 08:30

**O-WE-045**

**THE EXPRESSION OF ANNEXIN II IN APL CELLS AND ITS ROLE IN THE FIBRINOLYTIC ACTIVITY IN PATIENTS WITH APL**

Zhaoyue Wang\* (CN), Yanhui Liu, Miao Jiang, Lan Dai, Wei Zhang

08:30 - 08:45

**O-WE-046**

**IDENTIFICATION OF NOVEL PLASMINOGEN RECEPTOR ON HEPATOCYTES**

Taiichiro Seki\* (JP), Mayuko Arima, Nobuaki Okumura, Hiromi Shigematsu, Kasumi Ishii, Takashi Hosono, Jun Ogihara, Toyohiko Ariga

08:45 - 09:00

**O-WE-047**

**TAFI DEFICIENCY ACCELERATES LIVER DAMAGE IN MURINE MODELS OF CHRONIC AND ACUTE LIVER FAILURE**

Greg Hugenholtz\* (NL), Jelle Adelmeijer, Robert J Porte, Joost CM Meijers, Ton Lisman

09:00 - 09:15

**O-WE-048**

**ENDOGENOUS ALPHA-2-ANTIPLASMIN IS PROTECTIVE DURING SEVERE GRAM-NEGATIVE SEPSIS (MELIOIDOSIS)**

Liesbeth M Kager\* (NL), Gavin CKW Koh, W Joost Wiersinga, Joris J Roelofs, Joost C Meijers, Cornelis Van 't Veer, Tom Van der Poll

09:15 - 09:30

Wednesday Oral





## POSTER PRESENTATIONS

Wednesday, July 27, 2011

### Signal transduction of platelet activation

- P-WE-001 FORMATION OF A PROCOAGULANT PROTEIN COAT ON THE SURFACE OF THE PHOSPHATIDYLSERINE-EXPOSING PLATELETS BY TRANSGLUTAMINASES**  
Vladimir N Kolyadko\* (RU), Yana N Kotova, Fazoil I Ataulakhanov, Mikhail A Panteleev
- P-WE-002 A ROLE FOR SHIP1 IN PLATELET INTERNAL CONTRACTION**  
Marie-Pierre Gratacap\* (FR), Sonia Severin, Alessandra Consonni, Gaetan Chicanne, Sophie Allart, Monique Plantavid, Bernard Payrastre
- P-WE-003 IDENTIFICATION OF SIGNAL TRANSDUCTION PATHWAYS INVOLVED IN THE FORMATION OF PLATELET SUBPOPULATIONS DURING ACTIVATION**  
Nikolay N Topalov\* (RU), Yana N Kotova, Sergey A Vasil`ev, Mikgail A Panteleev
- P-WE-004 EXOGENOUS PDI MEDIATES INTEGRIN-DEPENDENT ADHESION BOTH AS A CHAPERONE-LIKE ACTIVITY AND AS AN OXIDOREDUCTASE**  
Vera Sheptovitzky (IL), Nurit Rosenberg, Ronit Mor-Cohen, Judith Lahav\*
- P-WE-005 PROTEIN KINASE C $\delta$  MEDIATES THE ACTIVATION OF PROTEIN KINASE D2 IN PLATELETS**  
Dheeraj Bhavanasri\* (US), Soochong Kim, Larry E Goldfinger, Satya P Kunapuli
- P-WE-006 INTRODUCTION OF THE CRGT PEPTIDE INTO PLATELET CYTOPLASM LEADS TO THE DISSOCIATION OF C-SRC FROM THE INTEGRIN  $\beta$ 3 TAIL WITHOUT AFFECTING ITS BASAL KINASE ACTIVITY**  
Jiansong Huang\* (CN), Xiaodong Xi, Nelly Kieffer, Yulan Zhou, Lanlan Tao, Yongkui Kong, Xiaofeng Shi
- P-WE-007 A LACK OF REGULATOR OF G-PROTEIN SIGNALING 2 (RGS2) IN MICE DOES NOT AFFECT THROMBUS FORMATION AT SITES OF VASCULAR INJURY**  
Fumiaki Banno\* (JP), Takahiro Nojiri, Sachiko Matsumoto, Kei Kamide, Naoki Mochizuki, Toshiyuki Miyata
- P-WE-008 PYK2 IS PREREQUISITE FOR GPVI-INDUCED PLATELET ROS PRODUCTION, BUT NOT AGGREGATION**  
Tony Gerard Walsh\* (IE), Naadiya Carrim, Pat Metharom, Michael C Berndt
- P-WE-009 THE ROLE OF THE MOLECULAR TARGET OF RAPAMYCIN COMPLEX (MTORC)2 IN AKT REGULATION IN HUMAN PLATELETS**  
Ingeborg Hers\* (UK), Roger W Hunter, Samantha F Moore
- P-WE-010 INTERNALIZATION OF TISSUE FACTOR BY PLATELETS PROMOTES REVERSIBLE CYTOSKELETAL ASSEMBLY THROUGH ACTIVATION OF RHOA AND PI3-KINASE. EFFECTS OF INHIBITORY STRATEGIES**  
Irene Lopez-Vilchez\* (ES), Maribel Diaz-Ricart, Ana M Galan, Merce Roque, Patricia Molina, James G White, Gines Escolar
- P-WE-011 GLUTATHIONE REGULATES STORE-OPERATED CALCIUM ENTRY BY REMODELING ACTIN CYTOSKELETON IN HUMAN PLATELETS**  
Ekaterina V Shamova\* (BY), Marina A Osipenko, Mihail V Goltayev, Irina V Gorudko, Sergey N Cherenkevich



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

### Biology of platelets

- P-WE-012 ROLE OF INNATE IMMUNE RECEPTORS, TLR2 AND IL1R1, IN MODULATING THE EFFECTS OF OBESITY ON MEGAKRYOCYTES AND PLATELETS**  
Lea M Beaulieu\* (US), Rebecca Iafrati, Selim Tanriverdi, Bahadir Ercan, Olga Vitseva, Kahraman Tanriverdi, Jane E Freedman
- P-WE-013 IDENTIFICATION OF A BIDIRECTIONAL LEUKOCYTE CONVEYANCE MECHANISM AT SITES OF VASCULAR INJURY**  
Yuping Yuan\* (AU), Ghasemzadeh Mehran, Alwis Imala, Schoenwaelder M Simone, Nesbitt S Warwick, Westein Erik, Kaplan Zane, Jackson P Shaun
- P-WE-014 ROLE OF PLASMA FIBRONECTIN IN THROMBOSIS AND HEMOSTASIS: EVIDENCE FOR THE FIBRIN-DEPENDENT AND -INDEPENDENT PATHWAYS**  
Yiming Wang\* (CA), Adili Rehemani, Jalil Kalantari, Wuxun Jin, Peter Gross, Margaret Rand, John Freedman, Heyu Ni
- P-WE-015 PLATELET ACTIVATION IS NEGATIVELY REGULATED BY THE MOLECULAR INTERACTION OF PLATELET SURFACE CD226 WITH CD112 EXPRESSED ON ENDOTHELIAL CELLS**  
Yukinori Kozuma\* (JP), Haruhiko Ninomiya, Kazuko Shibuya, Akira Shibuya, Hiroshi Kojima
- P-WE-016 LOW CONCENTRATION DETERGENT SCLEROSANTS INDUCE PLATELET ACTIVATION BUT INHIBIT AGGREGATION IN VITRO**  
Kurosh Parsi\* (AU), Anne Pilotelle, David E Connor, Joyce Low, David D.F. Ma, Joanne E Joseph
- P-WE-017 RELEASE REACTION OF BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) THROUGH PAR1 ACTIVATION AND ITS TWO DISTINCT POOLS IN HUMAN PLATELETS**  
Shogo Tamura\* (JP), Hidenori Suzuki, Yuji Hirowatari, Ayumi Nagasawa, Masanao Hatase, Tetsuya Tsunematsu, Kazuhiko Matsuno, Seiichi Kobayashi, Takanori Moriyama
- P-WE-018 INDIRECT PLATELET RECRUITMENT BY STAPHYLOCOCCUS AUREUS THROUGH STAPHYLOCOAGULASE-MEDIATED FIBRIN**  
Thomas Vanassche\* (BE), Katrien Cludts, Serena Loyen, Marc F Hoylaerts, Peter Verhamme
- P-WE-019 EXTRACELLULAR PROTEIN DISULFIDE ISOMERASE REGULATES THROMBIN-INDUCED THROMBIN BURST ON THE PLATELET SURFACE VIA MODULATION OF COAGULATION FACTOR BINDING**  
Kerstin Jurk\* (DE), Judith Lahav, Beate E. Kehrel
- P-WE-020 ACTIVATED PLATELETS MODULATE TISSUE REGENERATION BY PROMOTING ANGIOGENESIS AND RETINOL METABOLISM, AND SUPPRESSING INFLAMMATION**  
Rima Dardik\* (IL), Livia Theodor
- P-WE-021 HUMAN ALPHA-DEFENSINS ACTIVATE PLATELETS**  
Anne Bertling\* (DE), Meike Horn, Martin F. Brodde, Anja Mueller, Joachim Roth, Christina Stuerzel, Christine Heilmann, Georg Peters, Kerstin Jurk, Beate E. Kehrel

### Integrins and other glycoproteins

- P-WE-022 IMPAIRED ANGIOGENESIS CONTRIBUTES TO PATHOGENESIS OF FETAL AND NEONATAL IMMUNE THROMBOCYTOPENIA**  
Sean Lang\* (CA), Hong Yang, Shelley Boyd, Pingguo Chen, Xu Zhao, Conglei Li, Siavash Piran, Guangheng Zhu, John Freedman, Heyu Ni



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-023 IMPACT OF PLASMA LIGANDS ON CELL ADHESION AND ON OUTSIDE-IN SIGNALING IN HEK293 CELLS TRANSFECTED WITH THE POLYMORPHIC PLATELET INTEGRIN ALPHAIIIB BETA3**  
Marianna Gyenes\* (DE), Abdel El-Khattouti, Volker R. Stoldt, Ruediger E. Scharf
- P-WE-024 PLATELET INTEGRIN  $\alpha$ IIb $\beta$ 3: POLYMORPHIC VARIANTS DISPLAY DIFFERENT RECEPTOR ACTIVATION STATES**  
Abdelouahid El-Khattouti\* (DE), Volker R. Stoldt, Benjamin Chahem, Rudiger E. Scharf
- P-WE-025 LOW-CONCENTRATED COATING OF RGD-LIGANDS MODULATES ADHESION OF HPA-1B/1B PLATELETS UNDER HIGH SHEAR RATES**  
Volker R. Stoldt\* (DE), Saskia Schlesinger, Ruediger E. Scharf
- P-WE-026 UNFOLDING OF FIBRONECTIN BY PLATELET  $\beta$ 3 INTEGRINS UNDER STATIC AND FLOW CONDITIONS**  
Khon Chan Huynh\* (DE), Ruediger E. Scharf, Volker R. Stoldt
- P-WE-027 KINETICS, THERMODYNAMICS AND THE MECHANISM OF SINGLE-MOLECULE INTERACTIONS OF THE PLATELET INTEGRIN  $\alpha$ IIb $\beta$ 3 WITH CYCLIC RGD AND THE FIBRIN(OGEN)  $\gamma$ C-DODECAPEPTIDE**  
Rustem I Litvinov\* (US), Valeri Barsegov, Olga Kononova, Paul C Billings, Craig Streu, Joel S Bennett, John W Weisel
- P-WE-028 ROLE OF THE FIBRIN(OGEN)  $\alpha$  CHAIN RGD MOTIFS AND THE  $\gamma$ A/ $\gamma'$  CHAIN POLYMORPHISM IN  $\alpha$ IIb $\beta$ 3-FIBRIN INTERACTIONS**  
Rustem I Litvinov\* (US), David H Farrell, John W Weisel, Joel S Bennett
- P-WE-029 THE EFFECT OF STIR-SPEED ON GPVI-DEPENDENT PLATELET AGGREGATION**  
Philip DM Leadbeater\* (UK), Richard W Farndale, Jane A Mitchell, Timothy D Warner
- P-WE-030 ANALYSIS OF PLATELET RECEPTOR EXPRESSION IN ITP**  
Huy Tran\* (AU), Jian Lin Qiao, Mu Fi-tjen, Robert K Andrews, Elizabeth E Gardiner
- P-WE-031 SEPARATION OF THE TWO EXTRACELLULAR TAILS IS REQUIRED TO PROPAGATE ACTIVATION SIGNALS INITIATED IN THE CYTOPLASMIC TAILS OF  $\alpha$ IIb $\beta$ 3 INTEGRIN**  
Tetsuji Kamata\* (JP), Makoto Handa, Yohko Kawai, Yasuo Ikeda
- P-WE-032 PROTEOME ANALYSIS AND BIOLOGICAL CHARACTERIZATION OF NOVEL RHOH EFFECTORS**  
Akira Katsumi\* (JP), Marina Takasu, Miki Kobayashi, Norio Kaneda, Tadashi Matsushita, Tetsuhito Kojima, Tomoki Naoe, Kozo Kaibuchi

### Platelets as drug targets

- P-WE-033 HEPARIN-INDUCED THROMBOCYTOPENIA AND THROMBOSIS - A NEW EMERGING THERAPEUTIC STRATEGY**  
Jaa Y New\* (AU), Jose Sail Perdomo, Xing-Mai Jiang, Beng H Chong
- P-WE-034 ASPIRIN DOES NOT AUGMENT INHIBITION OF HUMAN PLATELET RESPONSES TO THROMBIN IN THE PRESENCE OF P2Y<sub>12</sub> ANTAGONISM**  
Frederick Ofosu\* (CA), Mehar Raja, Matthew Chong, Joseph Jakubowski, Atsuniro Sugidachi
- P-WE-035 P2Y<sub>12</sub> ANTAGONISM PROVIDES MORE EFFECTIVE INHIBITION OF PLATELET RESPONSES TO THROMBIN THAN PAR-1 OR PAR-4 ANTAGONISM**  
Frederick Ofosu\* (CA), Kenneth Nkonge, Matthew Chong, Joseph Jakubowski, Atsuhiro Sugidachi



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-036 A SELECTIVE PHOSPHODIESTERASE 3 INHIBITOR, K-134, SUPPRESSES VWF-GPIB//IX-MEDIATED PLATELET THROMBUS FORMATION VIA ELEVATION OF INTRACELLULAR CAMP BUT NOT CGMP LEVEL**  
Hideo Yoshida\* (JP), Yosuke Okamura, Naohide Watanabe, Souhei Tanabe, Yasuo Ikeda, Makoto Handa
- P-WE-037 DOSE-DEPENDENT EFFECTS OF PRASUGREL ON ADP- AND COLLAGEN-INDUCED PLATELET AGGREGATION ON A BACKGROUND OF ASPIRIN IN MINIATURE PIGS**  
Kousaku Ohno\* (JP), Atsuyuki Tomizawa, Joseph A Jakubowski, Atsuhiko Sugidachi
- P-WE-038 COMPARISON OF PRASUGREL AND TICAGRELOR ON ANTIPLATELET, ANTITHROMBOTIC AND ANTIHAEMOSTATIC ACTIONS IN RATS**  
Atsuyuki Tomizawa\* (JP), Kousaku Ohno, Joseph A Jakubowski, Atsuhiko Sugidachi
- P-WE-039 *IN VITRO* EFFECTS OF PRASUGREL'S ACTIVE METABOLITE ON A NOVEL ELISA-BASED WHOLE BLOOD VASP ASSAY**  
Shinji Yamaguchi\* (JP), Kousaku Ohno, Joseph A Jakubowski, Atsuyuki Tomizawa, Atsuhiko Sugidachi
- P-WE-040 MITOCHONDRIAL DYSFUNCTION AND THROMBOSIS: PLATELET STIMULATION BY THE CITRIC ACID CYCLE INTERMEDIATE SUCCINATE AS A POTENTIAL CAUSE OF CLOPIDOGREL AND ASPIRIN RESISTANCE**  
Florian Langer\* (DE), Brigitte Spath, Arne Hansen, Carsten Bokemeyer
- P-WE-041 FLAVONOLS IMPROVE BLOOD FLOW IN A MODEL OF ACUTE ARTERIAL THROMBOSIS**  
Sapha Mosawy\* (AU), Owen L Woodman, Matthew D Linden
- P-WE-042 QUERCETIN AND 3', 4'- DIHYDROXYFLAVONOL INHIBIT PLATELET FUNCTION IN VITRO**  
Sapha Mosawy\* (AU), Owen L Woodman, Matthew D Linden
- P-WE-043 ENDOCANNABINOIDS AND CANNABIS SATIVA USE INHIBIT HUMAN PLATELET FUNCTION**  
Valentina De Angelis\* (NL), Coen Maas, Flip G. de Groot, Rolf T. Urbanus, Mark Roest
- P-WE-044 LOW CONCENTRATIONS OF DABIGATRAN PREVENT THROMBIN-MEDIATED PLATELET AGGREGATION AND PARTIALLY INHIBIT PAR-1 AND PAR-4 ACTIVATION**  
Frederick Ofosu\* (CA), Yingqi Song, Hina Bhakta

### Novel methodologies

- P-WE-045 THE RELATIONSHIP OF LIGHT TRANSMISSION AGGREGOMETRY AND FLOW CYTOMETRY TO PLATELET COUNT IN PLATELET FUNCTION TESTING**  
Gillian Clare Lowe\* (UK), Ban B Dawood, William A Lester, Jonathan T Wilde, Steve P Watson
- P-WE-046 A NOVEL, COLORIMETRIC PLATELET ACTIVATION ASSAY FOR DIAGNOSIS OF HEPARIN INDUCED THROMBOCYTOPENIA (HIT)**  
M. Margaret Prechel\* (US), Vicki Escalante, Amanda F. Drenth, Jeanine M. Walenga
- P-WE-047 NEW SENSITIVE MARKERS OF PLATELET'S REACTIVITY IN CLOPIDOGREL TREATED PATIENTS: RESULTS OF FLOW CYTOMETRY AND GENETIC ANALYSIS**  
Olga V Sirotkina\* (RU), Anastasiya B Laskovets, Nataliya A Bogankova, Larisa B Gaykovaya, Tatiana V Vavilova
- P-WE-048 LOW ANGLE LIGHT SCATTERING ANALYZER: A NOVEL METHOD FOR QUANTITATIVE CHARACTERIZATION OF HUMAN PLATELET RECEPTOR FUNCTIONS**  
Jorg Geiger\* (DE), Igor Mindukshev, Igor Krivchenko, Stepan Gambaryan, Anna Kobsar, Anna Rukoyatkina, Ulrich Walter

Wednesday Posters



15

## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-049** **IMMOBILISED METAL AFFINITY CHROMATOGRAPHY (PROTEIN IMAC) AS A METHOD TO ENRICH FOR LOW ABUNDANCE PROTEINS IN RESTING AND GPVI-STIMULATED PLATELETS**  
Ronald Geoffrey Stanley\* (UK), Bernice Wright, William Kaiser, Jonathan Gibbins
- P-WE-050** **ANALYSIS OF PROTEIN NETWORKS IN RESTING AND COLLAGEN RECEPTOR (GPVI)-STIMULATED PLATELET SUB-PROTEOMES**  
Ronald Geoffrey Stanley\* (UK), Bernice Wright, William Kaiser, Jonathan Gibbins
- P-WE-051** **QUANTIFICATION OF PLATELET MRNA FROM HIGHLY PURIFIED PLATELETS REVEALS SIGNIFICANT EXPRESSION OF COMPONENTS OF THE INNATE IMMUNE SYSTEM IN PLATELETS**  
Ingo Ahrens\* (DE), Madlin Albrecht, Christoph Bode, Karlheinz Peter
- P-WE-052** **THE SIGNIFICANCE OF LEUKOCYTE-PLATELET AGGREGATES FORMATION BY PLATELET ACTIVATION**  
Ayumi Nagasawa\* (JP), Shogo Tamura, Kouji Hayasaka, Takanori Moriyama, Kazuhiko Matsuno
- P-WE-053** **PROPORTION AND MORPHOMETRIC PARAMETERS OF LARGE PLATELETS AND SMALL PLATELETS IN HEALTHY PEOPLE**  
Elizaveta Vlasova\* (RU), Irina Vasilenko
- P-WE-054** **MEASUREMENT OF VASP-PHOSPHORYLATION USING A NEW ASSAY BASED ON BEAD TECHNOLOGY**  
Jacqueline Glenn\* (UK), Jackie Glenn, Kiren Dhillon, Natalia Dovlatova, Sue Fox, Stan Heptinstall
- P-WE-055** **FIRST COMPARISON STUDY FOR THE INFLUENCES OF TICAGRELOR AND CLOPIDOGREL ADMINISTRATION ON PLATELET-FIBRIN CLOT STRENGTH MEASURED BY THROMBELASTOGRAPHY**  
Young-Hoon Jeong\* (US)

### ITP

- P-WE-056** **AUTOANTIBODY TO PLATELET GPIB/IX IS A PREDICTIVE FACTOR FOR POOR RESPONSE TO INTRAVENOUS IMMUNOGLOBULIN IN ADULTS WITH SEVERE IMMUNE THROMBOCYTOPENIA**  
Jun Peng\* (CN), Shi-hui Ma, Xi-min Liu, Rui-rong Xu, Cheng-shan Guo, Heyui Ni, Ming Hou
- P-WE-057** **NEUTRALIZING TH17 CYTOKINES SUPPRESSES IMMUNE DISORDERS IN IMMUNE THROMBOCYTOPENIA**  
Yu Hu\* (CN), Daoxin Ma, Shuang Yu, Ji Ma, Yanan Min, Ming Hou
- P-WE-058** **ELEVATED TC17 AND ITS CORRELATION WITH TH17 IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA**  
Daoxin Ma\* (CN), Yu Hu, Ming Hou
- P-WE-059** **EFFECT OF SPLENECTOMY ON THE INCIDENCE OF VENOUS THROMBOEMBOLISM (VTE) AND SEPSIS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP)**  
Ted Wun\* (US), Soames Boyle, Ann Brunson, Richard White
- P-WE-060** **THE USE OF PLATELET ASSOCIATED IGG (PAIGG) BY FLOW CYTOMETRY IN THE DIAGNOSIS OF IMMUNE THROMBOCYTOPENIA**  
Theera Ruchutrakool\* (TH), Siriporn Leelatanapipat, Yupa Nakkinkun, Bundarika Suwanwiboon, Yingyong Chinthammitr, Wanchai Wanachiwawin



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-061 THE CLINICAL SIGNIFICANCE OF DETECTION OF IMMUNE INDEX IN THE PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA**  
Jianfang Chen\* (CN), Linhua Yang, Junqing Liu, Lixian Chang, Jianjun Feng
- P-WE-062 EFFECTS OF CD70 AND CD11A IN IMMUNE THROMBOCYTOPENIA PATIENTS**  
Li Ma\* (CN), Zeping Zhou, Hongmei Wang, Aiping Qi, Hu Zhou, Huiyuan Li, Hairong Jia, Renchi Yang
- P-WE-063 INCREASED DNA METHYLTRANSFERASE CONTRIBUTE TO CD70 PROMOTER HYPOMETHYLATION AND OVER EXPRESSION OF CD70 IN ITP**  
Li Ma\* (CN), Renchi Yang, Zeping Zhou, Hu Zhou, Hongmei Wang, Huiyuan Li
- P-WE-064 OUTCOMES IN IMMUNE THROMBOCYTOPENIA (ITP): A RETROSPECTIVE AUDIT ON A SINGLE TERTIARY REFERRAL CENTRE**  
Philip Young-III Choi\* (AU), Beng Hock Chong
- P-WE-065 EFFIECTIVE CHILDREN TREATMENT SUFFER FROM ITP WITH INTRAVENOUS IMMUNOGLOBULIN**  
Pavel Svirin\* (RU), E.V Ageenkova, V.Y Petrov, E.K. Donyush, G.I Soskov, E.A. Yatcenko, V.V. Vdovin

### HIT

- P-WE-066 HEPARIN INDUCED THROMBOCYTOPENIA IN INTENSIVE CARE UNIT PATIENTS WITH DISSEMINATED INTRAVASCULAR COAGULATION**  
Borae G Park\* (KR), Seongsoo Jang, Hyoeun Shim, Chan-Jeoung Park, Hyun-Sook Chi, Sang-Bum Hong
- P-WE-067 FREQUENCY OF ANTI-HEPARIN-PF4 COMPLEX ANTIBODIES (HIT ANTIBODIES) IN PATIENTS UNDERGOING ON CHRONIC INTERMITTENT HEMODIALYSIS**  
Chiara Adele Elena Novelli\* (IT), Benedetto Morelli, Nicoletta Erba, Vanessa Proserpio, Vincenzo Toschi, Corrado Turri, Carlo Maria Guastoni
- P-WE-068 PF4-HEPARIN ANTIBODIES IN PATIENTS UNDERGOING EXTRACORPOREAL CIRCULATION CARDIAC SURGERY (ECCS)**  
Nicoletta Erba\* (IT), Vanessa Proserpio, Amando Gamba, Chiara Novelli, Benedetto Morelli, Vincenzo Toschi
- P-WE-069 PLATELET MICROPARTICLE GENERATION ASSAY: A VALUABLE ALTERNATIVE TO 14C-SRA FOR HEPARIN-INDUCED THROMBOCYTOPENIA DIAGNOSIS**  
Francois Mullier\* (BE), Nicolas Bailly, Yvan Cornet, Severine Robert, Jean-Claude Osselaer, Christian Chatelain, Ismail Elalamy, Jean-Michel Dogne, Bernard Chatelain
- P-WE-070 IDENTIFYING PATIENT- AND TREATMENT-RELATED FACTORS RELATED TO AMPUTATION RISK IN CASES OF HEPARIN-INDUCED THROMBOCYTOPENIA TREATED WITH ARGATROBAN**  
Sylvia Katharina Haas\* (DE), Bruce E Lewis
- P-WE-071 NOT ALL EIA-TESTS TO DETECT HEPARIN/PLATELET FACTOR 4 (H/PF4)-ANTIBODIES ARE EQUAL - MORE CONFUSION AFTER COMPARISON OF FOUR COMMERCIALY AVAILABLE ASSAYS**  
Frauke Bergmann\* (DE), Christiane Bruns, Andreas Czwalinna, Annette Klemens, Siegfried Krell, Burghard Arndt, Helga Dalluegge-Tamm, Arndt Groening



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-072 THROMBIN GENERATION TO DIAGNOSE DANAPAROID CROSS REACTIVITY IN HIT PATIENTS**  
Brigitte Tardy-Poncet\* (FR), Michele Piot, Patrick Mismetti, Lydia Campos, Olivier Garraud, Herve Decousus, Bernard Tardy
- P-WE-073 HEPARIN-INDUCED THROMBOCYTOPENIA AS A RESULT OF CROSS-REACTIVE ANTIBODIES IN THE SETTING OF BACTERIAL INFECTIONS**  
Prapti A Patel\* (US), Melody Smith, Jonathan Dowell, Eugene Frenkel, Ravi Sarode, Yu Min Shen
- P-WE-074 EXPERTS' OPINION OR SEROTONIN RELEASE ASSAY AS GOLD STANDARD FOR THE DIAGNOSIS OF HEPARIN INDUCED THROMBOCYTOPENIA (HIT)?**  
Bernard Tardy\* (FR), Emilie Presles, Madjid Akrou, Emmanuel De Maistre, Thomas Lecompte, Brigitte Tardy-Poncet
- P-WE-075 AGREEMENT BETWEEN LOCAL EXPERT OPINION, AN INDEPENDENT EXPERT COMMITTEE AND SRA RESULTS ABOUT HIT DIAGNOSIS: FIRST RESULTS OF AN INTERNATIONAL MULTICENTRIC PROSPECTIVE STUDY**  
Thomas Lecompte (FR), Bernard Tardy\*, Madjid Akrou, Emilie Presles, Claire Pouplard, Martine Alhenc-Gelas, Philippe Nguyen, Ismail Elalamy, Andreas Greinacher, Emmanuel De Maistre, Marie-Helene Horellou, Brigitte Tardy-Poncet
- P-WE-076 LEPIRUDIN USE AND LABORATORY MONITORING IN PATIENTS ON CHRONIC HAEMODIALYSIS WITH A HISTORY OF TYPE II HEPARIN-INDUCED THROMBOCYTOPENIA (HIT)**  
Chee W Tan\* (AU), Christopher Ward, Margaret Aboud, Timothy Pianta

### Antiplatelet therapy

- P-WE-077 NON COMPLIANCE AND ASPIRIN RESISTANCE IN ACUTE STROKE: A PILOT STUDY**  
Mauro Silingardi\* (IT), Maria Cristina Leone, Annalisa Pilia, Attilia Pizzini, Dimitriy Arioli, Sofia Chiatamone-Ranieri, Nerina Bonacini, Maria Grazia Bonini, Luigi Vecchia, Ido Iori
- P-WE-078 POINT-OF-CARE ASSESSMENT AFTER CLOPIDOGREL TREATMENT PREDICTS CLINICAL OUTCOMES OF PATIENTS WITH CARDIOVASCULAR DISEASE: A META-ANALYSIS OF 6 STUDIES**  
Yusuke Yamaguchi\* (JP), Takayuki Abe, Yuji Sato, Takanori Moriki, Mitsuru Murata
- P-WE-079 CYCLOOXYGENASE-1(COX-1)- DEPENDENT AND COX-1-INDEPENDENT PLATELET REACTIVITY IN ASPIRIN-TREATED PATIENTS WITH ACUTE CEREBRAL STROKE OR TIA**  
Maria Teresa Santos\* (ES), Aida Lago, Antonio Moscardo, Belen Cortina, Ana LaTorre, Vera Parkhutik, Jose Tembl, Juana Valles
- P-WE-080 USE OF PLATELET P-SELECTIN TO MONITOR P2Y12 BLOCKADE IN CARDIAC PATIENTS**  
Yanushi Dullewe Wijeyeratne\* (UK), Andrew Johnson, Jane May, Sue Fox, Robert Henderson, Stan Heptinstall
- P-WE-081 IS ASPIRIN AN ANTIFIBRINOLYTIC DRUG? ANTICOAGULANT EFFECT IS ASSOCIATED WITH PROLONGED CLOT LYSIS TIME IN PLATELET-RICH PLASMA OF OLDER**  
Alejandro Berkovits\* (CL), Diego Mezzano, Monica Acevedo, Carolina Valenzuela, Carlos Barria, Marcelo Carrasco, Olga Panes
- P-WE-082 CLOPIDOGREL DEGRADATION BY ESTERASES IS A MAJOR CONTRIBUTOR TO THE ATTENUATED RESPONSE TO CLOPIDOGREL OBSERVED IN SUBJECTS WHO ARE LOW RESPONDERS**  
Ludovic Drouet\* (FR), Natacha Berge, Claire Bal dit Sollier



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-083 NATURAL HISTORY OF HIGH ON TREATMENT PLATELET REACTIVITY BY ADP IN PATIENTS WITH ACS UNDERGOING PCI**  
Rossella Marcucci\* (IT), Rita Paniccia, Anna Maria Gori, Alessia Fabbri, Emilia Antonucci, Giulia Casola, Niccolo' Maggini, Marco Miranda, Betti Giusti, Gian Franco Gensini, Rosanna Abbate
- P-WE-084 HIGH-ON CLOPIDOGREL PLATELET REACTIVITY IS A DETERMINANT OF 1-YEAR MORTALITY IN ACUTE CORONARY SYNDROME PATIENTS: DATA FROM AMI-FLORENCE 2 STUDY**  
Rossella Marcucci\* (IT), Anna Maria Gori, Rita Paniccia, Betti Giusti, Antonella Cordisco, Daniela Balzi, Alessandro Barchielli, Nazario Carrabba, Serafina Valente, Cristina Giglioli, Rosanna Abbate, Gian Franco Gensini
- P-WE-085 HIGH-ON TREATMENT PLATELET REACTIVITY BY DIFFERENT STIMULI IS A DETERMINANT OF 1 YEAR MORTALITY IN ACUTE CORONARY SYNDROME PATIENTS: DATA FROM AMI-FLORENCE 2 STUDY**  
Rossella Marcucci\* (IT), Anna Maria Gori, Rita Paniccia, Betti Giusti, Antonella Cordisco, Daniela Balzi, Alessandro Barchielli, Serafina Valente, Cristina Giglioli, Rosanna Abbate, Gian Franco Gensini
- P-WE-086 MONITORING OF PLATELET FUNCTION IN PATIENTS WITH CEREBRAL ARTERY ANEURYSMS UNDERGOING ENDOVASCULAR TREATMENT WITH STENTS: A REVIEW OF 56 CASES**  
Rossella Marcucci\* (IT), Rita Paniccia, Arturo Consoli, Niccolo' Maggini, Marco Miranda, Emilia Antonucci, Giulia Casola, Rosanna Abbate, Gian Franco Gensini, Salvatore Mangiafico
- P-WE-087 THROMBIN GENERATION AND PROCOAGULANT MICROPARTICULES IN PATIENTS WITH CONORNARY SYNDROME UNDER DOUBLE ANTIPLATELET THERAPY**  
Concepcion Brocal\* (ES), Emma Lopez, Ana Mauricio, Pascual Marco, Santiago Heras, Juan Miguel Ruiz, Vicente Arrarte
- P-WE-088 TIME-RELATED CHANGES OF THE SENSITIVITY TO ANTI-PLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME AFTER PERCUTANEOUS CORONARY INTERVENTION**  
Krystyna Maria Zawilska\* (PL), Maria Jamrozek-Jedlinska, Malgorzata Duszynska, Ireneusz Jedlinski, Marek Slomczynski
- P-WE-089 PGE2 INHIBITS THROMBOGENESIS VIA THE EP4 RECEPTOR IN A PROTEIN KINASE C MEDIATED PATHWAY**  
Sonia Philipose\* (AT), Rufina Schuligoi, Akos Heinemann

### Inherited and acquired platelet disorders

- P-WE-090 GLANZMANN'S THROMBASTHENIA DOES NOT PROTECT FROM SEVERE CORONARY DISEASE**  
Susana Sara Meschengieser\* (AR), Analia Sanchez Luceros, Emilse Bermejo, Maria Fabiana Alberto, Maria Angela Lazzari
- P-WE-091 DESCRIPTION OF SEVEN NOVEL MUTATIONS IN  $\alpha$ IIb AND  $\beta$ 3 GENES IN 21 CHINESE PEDIGREES WITH GLANZMANN THROMBASTHENIA**  
Huanhuan Qin\* (CN)
- P-WE-092 PROSPECTIVE VALIDATION OF THE CONDENSED MCMDM1-VWD BLEEDING QUESTIONNAIRE FOR PLATELET FUNCTION DISORDERS**  
Paula D James\* (CA), Mackenzie Bowman, Julie Grabell, Louise Dwyre, Dilys Rapson





## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-093 GLYCOPROTEIN IB-IX-V AND EFFECT OF RECOMBINANT FACTOR VIIA - A WHOLE BLOOD STUDY FROM BERNARD-SOULIER PATIENTS AND THEIR RELATIVES**  
Ole Halfdan Larsen\* (DK), Pall T Onundarson, Brynja R Gudmundsdottir, Hekla Sigmundsdottir, Kirsten Christiansen, Brynjar Vidarsson, Jorgen Ingerslev, Benny Sorensen
- P-WE-094 THROMBOCYTOSIS IN CANCER IS ASSOCIATED WITH PLATELET ACTIVATION AND A PRO-ANGIOGENIC STATE**  
Alok A Khorana\* (US), Gregory Connolly, Brian H. Smith, Nigel Mackman, Richard P. Phipps, Mark Taubman, Charles W. Francis
- P-WE-095 PLATELET ACTIVATION IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA**  
Hans-Heinrich Wolf\* (DE), Monique Cernota, Angelika Fruehauf, Ursula Wolf-Jacobs
- P-WE-096 CARDIOVASCULAR RISK IN PATIENTS WITH FIRST EPISODE OF SCHIZOPHRENIA**  
Jiri Masopust\* (CZ), Radovan Maly, Dita Kalnicka, Jan Bazant, Ctirad Andrys, Ladislav Hosak
- P-WE-097 ACQUIRED PLATELET DYSFUNCTION WITH EOSINOPHILIA PRESENTING AS SUBGALEAL HEMATOMA**  
Piti Techavichit\* (TH), Darintr Sosothikul, Panya Seksarn

### Laboratory tests

- P-WE-098 EVALUATION OF WHOLE BLOOD LUMIAGGREGOMETRY AS A TOOL FOR DIAGNOSIS OF PLATELET DYSFUNCTION IN PAEDIATRIC PATIENTS**  
A N McCormick (UK), J Alamelu
- P-WE-099 SOLUBLE CD40 LIGAND AND CD40 LIGAND/PLATELET RATIO ARE PREDICTORS OF VENTRICULAR FUNCTION AND ADVERSE CLINICAL OUTCOME AMONG ACUTE CORONARY SYNDROME PATIENTS**  
Putrika P.R. Gharini\* (ID), Anggoro B Hartopo, Budi Y Setianto
- P-WE-100 DIAGNOSIS OF GLANZMANN'S THROMBASTHENIA USING THE WHOLE BLOOD IMPEDENCE MUTIPLATE ANALYZER**  
Tarek Owaidah\* (SA), Abdulmajeed Albanyan, Abdulrahman Almusa
- P-WE-101 PNEUMATIC TUBE TRANSPORT OF PLATELET CONCENTRATES DOES NOT AFFECT IN VITRO PLATELET FUNCTION**  
Yvonne Henskens\* (NL), Marcus Lance, Rene Van Oerle, Maurice Theunissen, Marco Marcus
- P-WE-102 PLASMA AND WHOLE BLOOD SEROTONIN LEVELS IN PATIENTS WITH ABDOMINAL AORTIC ANEURYSM AND PERIPHERAL ARTERIAL DISEASE MEASURED BY AN IMPROVED HPLC METHOD**  
Hirofumi Sugawara\* (JP), Akira Sato, Hitoshi Goto, Munetaka Hashimoto, Daijiro Akamatsu, Takuya Shimizu, Tsutomu Zukeran, Fukashi Serizawa, Ken Tsuchida, Susumu Satomi, Yuji Hirowatari
- P-WE-103 COMPARISON OF VENOUS AND ARTERIAL BLOOD SAMPLING FOR THE ASSESSMENT OF PLATELET AGGREGATION WITH WHOLE BLOOD IMPEDANCE AGGREGOMETRY**  
Sam Kafian\* (SE), Fariborz Mobarrez, Majid Kalani, Hakan Wallen, Bassem A. Samad
- P-WE-104 PLATELET FUNCTION IN TRAUMA PATIENTS**  
Cristina Solomon\* (AT), Herbert Schoechl
- P-WE-105 A NOVEL PLATELET STABILIZING FORMULA MAINTAINS FUNCTIONAL WHOLE BLOOD AGGREGATION RESPONSES OVER PROLONGED SPECIMEN STORAGE**  
Keith Moskowitz\* (US), Pia Guinto, Daniel J. Marchiarullo, Craig A. Gelfand



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

**P-WE-106    COMPARING PLATELET AGGREGOMETRY BY CHRONLOG 560VS AGREGOMETER WITH SYSMEX CS2000I COAGULOMETER**

Shenbagapriya P\* (IN), Inbakumar David, Kavitha ML, Srivastava Alok, Nair Sukesh Chandran

**P-WE-107    PLATELET REACTIVITY IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE USING ASPIRIN: CORRELATION BETWEEN DIFFERENT TESTS AND ASSOCIATION WITH SUBJECT CHARACTERISTICS**

Jaapjan D. Snoep (NL), Jaap Jan Zwaginga, Jeroen CJ Eikenboom, Mark Roest, Carlo Patrono, Bianca Rocca, Davide Pocaterra, Frits R Rosendaal, Johanna G van der Bom\*

**P-WE-108    THE PROFILE OF PLATELET MICROPARTICLES (PMP) IN ACUTE CORONARY SYNDROME (ACS) PATIENTS AT SARDJITO HOSPITAL YOGYAKARTA INDONESIA**

Ira Puspitawati\* (ID), Anggoro Budi Hartopo, Elizabeth-Henny Herningtyas

### New antiplatelet agents

**P-WE-109    EFFECTS OF P2Y1 RECEPTOR ANTAGONISM ON THE REACTIVITY OF PLATELETS FROM PATIENTS WITH STABLE CORONARY ARTERY DISEASE USING ASPIRIN AND CLOPIDOGREL**

Arnaud Bonnefoy\* (CA), Benoit Labarthe, Judith Babin, Pierre Theroux, Marijke Bryckaert

**P-WE-110    PURIFICATION AND CHARACTERIZATION OF PLATELET AGGREGATION INHIBITOR FROM AGGKISTRODON BLOMHOFFII BREVICAUDUS**

Punsaldulam Dashnyam Chimgeen\* (MN), Sumiya Byambasuren Otgontaj, Bolor Buyanbadrakh, Khongorzul Odgerel

**P-WE-111    DISCOVERY OF AN ORALLY AVAILABLE PAR-1 ANTAGONIST**

Sunkyung Lee\* (KR), Chul-Min Park, Jong-Whan Song, Dong-Chul Lim, Woo-Young Cho

### Extrinsic pathway of coagulation

**P-WE-112    FACTOR VIIA-ANTITHROMBIN COMPLEXES PLASMA LEVELS IN HEALTHY SUBJECTS**

Luca Spiezia (IT), Maria Bon, Elena Campello, Sabrina Gavasso, Barry Woodhams\*, Paolo Simioni

**P-WE-113    FACTOR VIIA-ANTITHROMBIN COMPLEXES PLASMA LEVELS IN PREECLAMPTIC WOMEN**

Luca Spiezia (IT), Fabio Dalla Valle, Cristiana Bulato, Sabrina Gavasso, Silvia Visentin, Erich Cosmi, Barry Woodhams\*, Paolo Simioni

**P-WE-116    THE EXPRESSION OF TISSUE FACTOR RELEASED FROM ACUTE MYELOBLASTIC LEUKEMIA CELLS**

Yi Fang\* (CN), Jiayi Cai, Jihua Zhong, Hua Zhong, Hairong Wang, Fangyuan Chen

**P-WE-117    LYSO-SULFATIDE BINDS FACTOR XA OUTSIDE OF THE GLA DOMAIN AND POTENTLY INHIBITS THROMBIN GENERATION**

Subramanian Yegneswaran (US), Yajnavalka Banerjee, Jose Fernandez\*, Hiroshi Deguchi, John Griffin

**P-WE-118    FACTOR VIIA-ANTITHROMBIN COMPLEXES IN CHILDREN WITH ISCHEMIC STROKE**

Luca Spiezia (IT), Elena Campello, Chiara Gentilomo, Sabrina Gavasso, Barry Woodhams\*, Anna Maria Laverda, Paolo Simioni

**P-WE-119    BALANCE BETWEEN FACTOR VII COMPETITION FOR TISSUE FACTOR AND FACTOR VII ACTIVATION DETERMINES INITIATION AND PROPAGATION OF BLOOD COAGULATION**

Alexey M Shibeko\* (US), Samuel A Woodle, Timothy K Lee, Mikhail V Ovanesov

Wednesday Posters



21

## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-120 THE TIMED UP AND GO TEST CORRELATED STRONGLY WITH OTHER JOINT SCORES IN A HEALTH OUTCOME STUDY COMPARING A COHORT OF AFFECTED MALES WITH MILD HEMOPHILIA A WITH THEIR SIBLINGS**  
Mary-Frances Scully\* (CA), Andrea Hann, Aicha Traore, Ya-Gang Xie, Brendan Barrett
- P-WE-121 CONFIRMATION OF THE QUALITY OF PLASMA DERIVED FVIIA/FX MIXTURE AGENT (MC710) BY THE VALIDATED ASSAYS**  
Teruhisa Nakashima\* (JP), Kazuhiko Tomokiyo, Yasushi Nakatomi, Hiroki Miyazaki, Eisuke Takami, Manami Tsuji, Sayaka Oonishi-Kanakuri, Emiko Kusumoto, Ai Takaki-Kakisaka, Asami Shindome, Tatsuya Araki, Takayoshi Hamamoto, Tomohiro Nakagaki
- P-WE-122 CONGENITAL COAGULATION FACTOR VII DEFICIENCY: A CLINICAL AND GENETIC STUDY OF FIVE TAIWANESE PATIENTS**  
Nan Shin Cheng\* (TW), Yeu Chin Chen
- P-WE-123 BLEEDING SCORE RESULTS IN A HEALTH OUTCOME STUDY COMPARING AFFECTED MALES WITH MILD HEMOPHILIA A AND THEIR MUTATION NEGATIVE RELATIVES**  
Mary-Frances Scully\* (CA), Aicha Traore, Brendan Barrett, Ya-Gang Xie
- P-WE-124 CHARACTERISATION OF VWF INTERACTION, COFACTOR ACTIVITY AND RATES OF ACTIVATION AND INACTIVATION OF A SELECTIVELY 40K O-GLYCOPEGYLATED RECOMBINANT FACTOR VIII (N8-GP)**  
Kristoffer Winther Balling\* (DK), Egon Persson, Ida Hilden, Marianne Kjalke, Eva HN Olsen, Henning R Stennicke
- P-WE-125 EFFECT OF NON-SYNONYMOUS POLYMORPHISMS ON COAGULATION FACTOR VII**  
Shu-wen W. Chen (FR), Muriel Giansily-Blaizot, Jean-Luc Pellequer\*
- P-WE-126 INHIBITION OF TFPI EFFICIENTLY IMPROVES HEMOSTASIS IN HEMOPHILIC MICE**  
Werner Hoellriegel\* (AT), Michael Dockal, Alexandra Schiviz, John Philip Lawo, Dagmar Verdino, Peter Leidenmuehler, Hans-Peter Schwarz, Hartmut Ehrlich, Rudolf Hartmann, Eva-Maria Muchitsch, Friedrich Scheifflinger
- P-WE-127 COST-EFFECTIVENESS OF PROTHROMBIN COMPLEX (OCTAPLEX™) USAGE IN AN EMERGENCY ROOM**  
Manuel Quintana\* (ES), Santiago Perez-Cachafeiro, Sara Fabra-Cadenas, Alberto Borobia
- P-WE-128 DOWNREGULATION OF THE PROCOAGULANT POTENTIAL OF HUMAN BREAST CARCINOMA CELLS BY INHIBITION OF THE RENIN-ANGIOTENSIN SYSTEM**  
Emanuela Napoleone (IT), Antonella Cutrone, Daniela Cugino, Concetta Amore, Angelomaria Di Santo, Licia Iacoviello, Giovanni de Gaetano, Maria Benedetta Donati, Roberto Lorenzet\*

### Intrinsic pathway of coagulation

- P-WE-129 A PRELIMINARY MOLECULAR STUDY MAY EXPLAIN THE LOW FREQUENCY OF SEVER HEMOPHILIACS A WITH INHIBITORS IN TUNISIA**  
Hejer Elmahmoudi\* (TN), Houssein Khodjet-el-Khil, Kaouther Zahra, Dorothe Pellechia, Christine Vinciguerra, Belkis Meddeb, Amel Elgaaied Ben Ammar, Emna Gouider
- P-WE-130 BLOCKING THE INTRINSIC PATHWAY OF COAGULATION WITH RNA APTAMERS**  
Becky Woodruff\* (US), Juliana Layzer, Bruce Sullenger



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-131 RECOMBINANT FVIII FC FUSION PROTEIN IS FULLY ACTIVE IN TREATING ACUTE INJURY AND DEMONSTRATES PROLONGED PROPHYLACTIC EFFICACY IN HEMOPHILIA A MICE**  
Tongyao Liu\* (US), Xin Zhang, Douglas Drager, Todd Hoehn, Jennifer Dumont, Glenn Pierce, Haiyan Jiang
- P-WE-132 THE FIRST REPORT OF THE SAUDI NATIONAL SCREENING PROGRAM FOR FACTOR VIII AND IX HEMOPHILIA INHIBITORS**  
Tarek Owaidah\* (SA), Abdulkareem Al Momeen
- P-WE-133 SIGNIFICANCE OF MISSENSE MUTATIONS WITHIN THE *FACTOR 8* GENE FOR INHIBITOR FORMATION**  
Rainer Schwaab\* (DE), Anna Pavlova, Thilo Albert, Johannes Oldenburg
- P-WE-134 FACTOR XII DEPLETION PROTECTS AGAINST THE DEVELOPMENT OF PULMONARY FIBROSIS**  
Malgorzata Wygrecka\* (DE), Ewa Jablonska, Thomas Renne, Andreas Guenther, Philipp Markart, Klaus T Preissner
- P-WE-135 INTERIM RESULTS OF THE USEFULNESS OF PRIMARY PROPHYLAXIS IN HEMOPHILIA PATIENTS AT OUR HEMOPHILIA CENTER**  
Chiai Nagae\* (JP), Tomoko Ashikaga, Atsuki Yamashita, Shinji Muto, Kaoru Kikkawa, Kimie Yoshikawa, Satoshi Yamazaki, Masashi Taki
- P-WE-136 THE HEMOPHILIA INHIBITOR GENETICS STUDY (HIGS): IMMUNE TOLERANCE INDUCTION (ITI) THERAPY AND OUTCOME**  
Jan Astermark\* (SE), Erika Menius, Sharyne Donfield, Erik Berntorp
- P-WE-137 LONG-TERM INTERMITTENT USE OF RITUXIMAB TO CONTROL INHIBITORS IN CONGENITAL SEVERE HEMOPHILIA A**  
M Dawn Goodyear\* (CA), John K Wu, Man-Chiu Poon
- P-WE-138 MICROPARTICLES GENERATE THROMBIN IN A FACTOR XII-DEPENDENT MANNER**  
Paola Van der Meijden\* (NL), Muriel Van Schilfgaarde, Rene Van Oerle, Felicitas Muller, Thomas Renne, Hugo Ten Cate, Henri Spronk
- P-WE-139 DEMOGRAPHIC ANALYSES AND JOINTS STATUS OF PATIENTS WITH HEMOPHILIA A, B AND VON WILLEBRAND DISEASE**  
Sefika Selvi\* (TR), Feride Duru, Emel Ozyurek, Canan Albayrak, Davut Albayrak, Berna Tander, Tunc Fisgin
- P-WE-140 EFFECTS OF A FVIII INHIBITOR TB-402 ON COAGULATION: REVERSIBILITY WITH PROCOAGULANTS**  
Clive J Long\* (BE), Peter Verhamme, Jan Emmerechts, Marc Hoylaerts, Marc Jacquemin, Peter Giesen
- P-WE-141 FACTOR VIII-HYDROLYZING MONOCLONAL ANTIBODIES IN PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA**  
Ankit Mahendra\* (FR), Frederic Davi, Sebastien Andre, Cyril Plainchais, Ivan Peyron, Jordan Dimitrov, Alain Friboulet, Srinivas Kaveri, Sebastien Lacroix-Desmazes
- P-WE-143 ELEVATED SERUM AMYLOID A IS ASSOCIATED WITH BLOOD COAGULABILITY AND WITH VENOUS THROMBOEMBOLISM**  
Hiroshi Deguchi\* (US), Darlene J Elias, Silvia Navarro, Espana Francisco, John H Griffin
- P-WE-144 COAGULATION VELOCITY AND ACCELERATION CORRELATE WITH CLINICAL PHENOTYPE OF PATIENTS WITH ACQUIRED FACTOR V INHIBITORS**  
Tomoko Matsumoto\* (JP), Keiji Nogami, Kenichi Ogiwara, Nobuyuki Tsujii, Midori Shima

Wednesday Posters



23

## POSTER PRESENTATIONS

Wednesday, July 27, 2011

**P-WE-145 ELEVATED PLASMA LEVELS OF FACTOR VIII ENHANCE THROMBUS FORMATION THOUGH EXCESS THROMBIN GENERATION IN RABBIT JUGULAR VEIN**

Chihiro Sugita\* (JP), Atsushi Yamashita, Shuntaro Matsuda, Sayaka Goto Moriguchi, Tomoko Matsumoto, Osamu Inoue, Takashi Iwakiri, Yunosuke Matsuura, Midori Shima, Yujiro Asada

### Contact phase activation

**P-WE-146 ACTIVATED FACTOR XII TYPE A INDEPENDENTLY PREDICTS LONG TERM MORTALITY WITHIN SEVEN YEARS FOLLOW UP IN PATIENTS ADMITTED WITH SUSPECTED ACUTE CORONARY SYNDROME**

Volker Poenitz\* (NO), Trygve Bruegger-Andersen, Heidi Grundt, Patrycja Naesgaard, Harry Staines, Dennis Winston Trygve Nilsen

**P-WE-147 THE PREVALENCE OF THE PLASMINOGEN ACTIVATOR INHIBITOR-1 GENE 4G/5G POLYMORPHISM IN PATIENTS WITH CHRONIC VENOUS LEG ULCERATION**

Adam Wiszniewski\* (PL), Ksenia Bykowska, Piotr Szopinski

**P-WE-148 CATHETER THROMBOSIS WITH FONDAPARINUX IS PREVENTED BY THROMBIN INHIBITION *IN VITRO* AND IN RABBITS**

Jonathan W Yau\* (CA), Alan R Stafford, Peng Liao, James C Fredenburgh, Robin Roberts, Jeffrey I Weitz

**P-WE-149 SMALL HAIRPIN-STRUCTURED NUCLEIC ACIDS PROMOTE COAGULATION**

Julia Gansler\* (DE), Miriam Jaax, Andreas Greinacher, Klaus T. Preissner, Silvia Fischer

**P-WE-151 HIGH MOLECULAR WEIGHT KININOGEN AND THE RISK OF MYOCARDIAL INFARCTION AND ISCHAEMIC STROKE IN YOUNG WOMEN: RESULTS FROM THE RATIO CASE-CONTROL STUDY**

Bob Siegerink\* (NL), A Algra, Frits Rosendaal

**P-WE-152 INHIBITING POLYPHOSPHATE AS A NOVEL ANTITHROMBOTIC/ANTI-INFLAMMATORY STRATEGY**

Sharon H Choi\* (US), Julie N.R. Collins, Stephanie A. Smith, Brian C. Cooley, James H. Morrissey

**P-WE-153 GLYCO-PEGYLATION OF FVIII REDUCES CELLULAR UPTAKE IN THE LIVER, BUT DOES NOT ALTER *IN VIVO* DISTRIBUTION**

Rupa Shree Appa\* (DK), Cristina Ionica Oie, Jesper Boggild Kristensen, Carsten Behrens, Charlotte Gudme, Marianne Kjalke, Baard Smedsrod, Henrik Agersoe, Henning Stennicke

### Anticoagulant pathway

**P-WE-154 URINARY PROTHROMBIN FRAGMENTS (F1+2) AS A DIAGNOSTIC TOOL FOR VENOUS THROMBO-EMBOLISM AND MYOCARDIAL INFARCTION; A PILOT STUDY**

Josien van Es\* (NL), Sara Rafi, Mohamed Ahdi, Pieter W. Kamphuisen, Joost C.M. Meijers, Victor E.A. Gerdes

**P-WE-155 DECREASED FREE PROTEIN S LEVELS AND VENOUS THROMBOSIS IN THE ACUTE SETTING, A CASE-CONTROL STUDY**

Rene Mulder\* (NL), Vladimir Y.I.G. Tichelaar, Willem M. Lijfering, Andre M Mulder, Karina Meijer

**P-WE-156 ANTITHROMBOTIC AGENTS PURIFIED FROM AGKISTRODON BLOMHOFFII BREVICAUDUS**

Sumiya Byambasuren Otgontaj\* (MN), Bolor Buyanbadrakh, Khongorzul Odgerel, Punsaldulam Dashnyam Chimgeen



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-157 GENOME-WIDE ASSOCIATION STUDY (GWAS) FOR DISCOVERY OF GENES MODULATING ANTITHROMBIN ACTIVITY. ROLE OF *LARGE*, AN N-ACETYLGUCOSAMINYLTRANSFERASE.**  
Maria Eugenia de la Morena-Barrio\* (ES), Alfonso Buil, Ana Isabel Anton, Antonia Minano, Juan Carlo Souto, Irene Martinez-Martinez, Ricardo Gutierrez-Gallego, Jose Navarro-Fernandez, Sonia Aguila, Vicente Vicente, Jordi Fontcuberta, Jose Manuel Soria, Javier Corral
- P-WE-158 CHARACTERISTICS OF FIBRIN FORMATION AND CLOT STABILITY IN INDIVIDUALS PREDISPOSED TO THROMBOSIS**  
Jonathan H Foley\* (US), Lauren Ferris, Kathleen Brummel-Ziedins
- P-WE-159 DIRECT COMPARISON OF THE PHARMACOKINETICS AND PHARMACODYNAMICS OF APIXABAN AND RIVAROXABAN**  
Charles Frost\* (US), Yan Song, Yu Chen Barrett, Jessie Wang, Tong Li, Frank LaCreta
- P-WE-160 THE CHOICE OF THERAPY IN THE ACENOCOUMAROL OVERDOSE IS INDEPENDENT AND ILLNESS SEVERITY DEPENDENT**  
Manuel Quintana\* (ES), Alberto Borobia, Sara Fabra, Ana Martinez Virto, Marcelino Sanchez Casado
- P-WE-161 PMX-60056 KINETICS IN REVERSAL OF HEPARIN AND LMWH ANTICOAGULATION**  
Ronald Eric McAllister\* (US), Richard Scott, Bozena Korczak
- P-WE-162 PMX-60056 RAPIDLY REVERSES LOW-MOLECULAR-WEIGHT HEPARIN (LMWH) TINZAPARIN ANTICOAGULATION IN MAN**  
Ronald Eric McAllister\* (US), Richard Scott, Bozena Korczak
- P-WE-163 REVERSAL OF SURGICAL DOSES OF HEPARIN BY PMX-60056 IS PREDICTABLE AND SAFE**  
Ronald Eric McAllister\* (US), Richard Scott, Bozena Korczak
- P-WE-164 PATIENTS WITH MUTATIONS IN VKORC1: A CHALLENGING PROBLEM IN CLINICAL PRACTICE**  
Johannes Oldenburg\* (DE), Christof Geisen, Carville Bevans, Erhard Seifried, Matthias Watzka
- P-WE-165 GENERATION OF KNOCK-IN MICE CARRYING A K196E POINT MUTATION IN PROTEIN S**  
Fumiaki Banno\* (JP), Toshiyuki Kita, Hiroji Yanamoto, Koichi Kokame, Koji Iihara, Toshiyuki Miyata
- P-WE-166 PROTEIN S AND C4BBP MUTATIONAL SCREENING IN ATYPICAL HAEMOLYIC URAEMIC SYNDROME PATIENTS**  
Jorine S Koenderman\* (NL), Dineke Westra, Elena B Volokhina, Pieter H Reitsma, Lambertus P Van den Heuvel
- P-WE-167 HIGH ACTIVATED PROTEIN C LEVELS ATTENUATE ALLERGIC LUNG INFLAMMATION IN A MURINE ASTHMA MODEL USING INTRANASAL INOCULATION OF HOUSE DUST MITE EXTRACT**  
Johannes Daan De Boer\* (NL), C Van t Veer, M Schouten, J Yang, JJTH Roelofs, JS Van der Zee, BH Ishermann, T Van der Poll
- P-WE-168 THE INFLUENCE OF UNFRACTIONATED HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARIN ON VASCULAR ENDOTHELIUM AND PLATELETS IN PATIENTS WITH CHRONIC RENAL FAILURE UNDERGOING HEMODIALYSIS**  
Elizaveta Vlasova\* (RU), Irina Vasilenko, Vera Samoylenko, Vladimir Suslov

Wednesday Posters



25

## POSTER PRESENTATIONS

Wednesday, July 27, 2011

### Serine protease inhibitors

- P-WE-169 CHANGES OF LEVELS OF FIBRINOGEN, D-DIMER AND ANTITHROMBIN IN PATIENTS WITH HEMATOLOGICAL MALIGNANCY**  
Zhou Rong-Fu\* (CN), Jian Ouyang, Ping Li, Jing-yan Xu, Bing Chen, Yong-gong Yang, Qi-guo Zhang, Xiao-yan Shao
- P-WE-170 COMPARISON OF THE ANTICOAGULANT EFFECTS IN PLASMA SAMPLES SPIKED WITH DABIGATRAN AND RIVAROXABAN**  
Job Harenberg\* (DE), Christina Giese, Svetlana Marx, Roland Kraemer
- P-WE-171 THE ACTION MECHANISM OF DIRECT THROMBIN INHIBITORS DURING COAGULATION**  
Robert Johan Wagenvoord\* (NL), Rob Wagenvoord, Coen Hemker
- P-WE-172 PREVALENCE OF HEREDITARY ANTITHROMBIN DEFICIENCY HIGHER THAN ESTIMATED?**  
Ronald Fischer\* (DE), Dominik Eisenburger, Kathrin Heidinger, Bettina Kemkes-Matthes
- P-WE-173 SIX NOVEL PROTEIN C MUTATIONS CAUSING HEREDITARY PROTEIN C DEFICIENCY**  
Ronald Fischer\* (DE), Bettina Kemkes-Matthes, Anna Pavlova, Johannes Oldenburg, Hanna Mellage
- P-WE-174 EFFECTS OF MDCO-2010 ON ACTIVATED CLOTTING TIME IN BLOOD OBTAINED FROM PATIENTS UNDERGOING CARDIOPULMONARY BYPASS**  
Heezoo Kim\* (KR), Fania Szlam, Kenichi Tanaka, Satoru Ogawa, Andreas van de Loch, Jerrold H Levy
- P-WE-175 INHIBITION OF COAGULATION FACTORS BY COVALENT ANTITHROMBIN-HEPARIN IN THE PRESENCE OF ENDOTHELIUM**  
Helen M. Atkinson\* (CA), Leslie R. Berry, Anthony K. C. Chan
- P-WE-176 COMPARISON OF THE EFFECTS OF EDOXABAN, AN ORAL FACTOR XA INHIBITOR, AND OTHER ANTICOAGULANTS ON THROMBIN GENERATION**  
Jeanne Mendell\* (US), Yan Li, Meyer Michel Samama, Abdel-Baset Halim, SaeHeum Song, Francois Depasse, Satoshi Kunitada
- P-WE-177 INHIBITION OF THROMBIN GENERATION BY EDOXABAN**  
Jeanne Mendell\* (US), Meyer Michel Samama, Yan Li, Abdel-Baset Halim, SaeHeum Song, Francois Depasse, Guinet Celine, Satoshi Kunitada
- P-WE-178 PROTEIN C INHIBITOR INHIBITS TUMOR CELL GROWTH, BUT PROMOTES TUMOR CELL METASTASIS BY ITS PROCOAGULANT PROPERTIES *IN VIVO***  
Nobuyuki Akita\* (JP), Kakunoshin Yoshida, Takayuki Okamoto, Junji Nishioka, Tatsuya Hayashi, Koji Suzuki
- P-WE-179 BLEEDING IS A RARE MANIFESTATION IN PATIENT WITH LUPUS ANTICOAGULATION IN CHILDREN**  
Patcharee Komvilaisak\* (TH), Arunee Jetsrisuparb, Surapon Wiangnon
- P-WE-180 REVERSAL OF DABIGATRAN USING RECOMBINANT ACTIVATED FACTOR VII AND ACTIVATED PROTHROMBIN COMPLEX CONCENTRATES IN THROMBOELASTOGRAPHY ASSAY**  
Howard H.W. Chan\* (CA), Helen M Atkinson, Mykhaylo Goncharenko, Leslie R. Berry, Anthony K.C. Chan



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

### Exogenous hemostatic factors

- P-WE-181 ESPP, AN EXTRACELLULAR SERINE PROTEASE FROM ENTEROHEMORRHAGIC *E. COLI*, INDUCES COAGULOPATHY IN HUMAN PLASMA AND FIBRINOLYSIS IN WHOLE BLOOD**  
Shekeeb Khan\* (CA), Kuo H. M. Kevin, Elena Brnjac, Margaret L. Rand, Emil F. Pai, Alden E. Chesney
- P-WE-182 FACTORS AFFECTING WARFARIN THERAPY IN CHILDREN FOLLOWING THE FONTAN PROCEDURE**  
Elizabeth Crone\* (AU), Nabby Saliba, Elizabeth Hume, Swapna George, Sophie Jones, Fiona Newall
- P-WE-183 COMPARISON OF IN VIVO RECOVERY OF RECOMBINANT FACTOR IX AND PLASMA DERIVED FACTOR IX IN PREVIOUSLY TREATED JAPANESE HEMOPHILIA B PATIENTS**  
Atsuki Yamashita\* (JP), Chiai Nagae, Tomoko Ashikaga, Shinji Muto, Satoshi Yamazaki, Shigenobu Takayama, Masashi Taki
- P-WE-184 PHENOTYPES OF ALLO- AND AUTO-IMMUNE ANTIBODY RESPONSES TO FVIII CHARACTERIZED BY SURFACE PLASMON RESONANCE**  
Kenneth B Lewis\* (US), Phuong-Cac T Nguyen, Colette Norby-Slycord, Tom E Howard, Nigel S Key, Kathleen P Pratt
- P-WE-185 DIFFERENTIAL PROTEIN COMPOSITION AND CATALYTIC ACTIVITY OF SERINE PROTEASES AFFECTING HEMOSTASIS FROM THREE SOUTH AMERICAN REAR-FANGED SNAKE VENOMS**  
Marcelo Larami Santoro\* (BR), Stephen P Mackessy, Maria E Peichoto
- P-WE-186 DENTAL EXTRACTIONS IN ANTICOAGULATED PATIENTS- COMPARISON OF LOCAL HAEMOSTATIC MODALITIES WITH AND WITHOUT SUTURING**  
Branislav Bajkin (RS), Nebojsa Rajic\*
- P-WE-187 SUPPRESSION OF LONGSTANDING, REFRACTORY INHIBITORY ANTIBODIES TO FVIII OR FIX IN ADULT PATIENTS WITH SEVERE HEMOPHILIA A (HA) OR B (HB) USING RITUXIMAB**  
Adam Giermasz\* (US), Darcy Phelan, Susan Karp, Patrick F. Fogarty
- P-WE-188 CLINICAL EXPERIENCE IN A WAR SETTING OF A UNIVERSAL FREEZE DRIED PLASMA**  
Sylvain Ausset\* (FR), Jean-Louis Daban, Anne-Virginie Deshayes, Anne Godier, Anne Sailliol
- P-WE-189 ESTIMATED VIAL REDUCTION WITH THE AVAILABILITY OF NEW FACTOR VIII DOSAGE STRENGTHS**  
Joshua Davin Epstein\* (US), David Suggitt
- P-WE-190 INTERACTION OF VARIOUS RECOMBINANT FVIII CONCENTRATES WITH VON WILLEBRAND FACTOR**  
Daniele Pillitteri\* (DE), Thomas Scholz, Manuela Krause, Ann-Kathrin Pilgrim, Carl Kirchmaier
- P-WE-191 ESTIMATED PATIENT BENEFITS OF REDUCING FACTOR VIII RECONSTITUTION VOLUMES**  
Joshua Davin Epstein\* (US), Jacquelyn Lam
- P-WE-192 OCTANATE SHOWS LOW INHIBITOR INCIDENCE IN TREATMENT OF PREVIOUSLY UNTREATED PATIENTS WITH HAEMOPHILIA A**  
Anna Klukowska\* (PL), Vladimir Komrska, Martina Jansen, Peter Laguna

Wednesday Posters



27



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

**P-WE-193 CLONING AND CHARACTERIZATION OF FACTOR V AND FACTOR X ACTIVATORS FROM *VIPERA URSINII RENARDI* VENOM**

Inn-Ho Tsai\* (TW), Xin-Hong Yu, Hong-Sen Chen

**P-WE-194 IMMUNE TOLERANCE THERAPY (ITI) IN CHILDREN WITH FVIII INHIBITORS: PROGRESS REPORT**

Vladimir Vdovin\* (RU), Pavel Svirin, Ekaterina Shiller, Tatiana Andreeva, Nina Klimova, Natalia Osmulskaya, Andrey Momot, Andrey Mamaev, Irina Blazhievich, Ekaterina Smirnova, Ludmila Okladnikova

### Fibrinogen and other factors

**P-WE-195 MOLECULAR MODELING STUDY ON THE STRUCTURAL AND DYNAMIC PROPERTIES OF COAGULATION FACTOR XIII IN ITS ACTIVE AND INACTIVE CONFORMATIONS**

Istvan Komaromi\* (HU), Laszlo Muszbek

**P-WE-196 CONGENITAL AFIBRINOGENEMIA DUE TO MATERNAL ISODISOMY OF CHROMOSOME 4 CONTAINING A NOVEL TRP293STOP MUTATION IN FIBRINOGEN B $\beta$ -CHAIN GENE**

Qi OuYang\* (CN), Qiulan Ding, Xuefeng Wang, Hongli Wang, Xiaodong Xi

**P-WE-197 RESEARCH OF PHENOTYPE AND GENOTYPE IN THREE CHINESE PEDIGREES WITH INHERITED DYSFIBRINOGENEMIA**

Qi OuYang\* (CN), Qiulan Ding, Xuefeng Wang, Hongli Wang, Xiaodong Xi

**P-WE-198 COMPARISON OF THE FIBTEM AND FUNCTIONAL FIBRINOGEN ASSAYS USING THE ROTEM AND TEG DEVICES**

Cristina Solomon\* (AT), Niels Rahe-Meyer, Herbert Schoechl

**P-WE-199 FACTOR XIII IMPROVES PLATELET ADHESION TO FIBRINOGEN BY PROTEIN DISULFIDE ISOMERASE-MEDIATED ACTIVITY**

Judith Lahav\* (IL), Ariela Tvito, Zsuzsa Bagoly, Aida Inbal

**P-WE-200 HAEMOSTATIC THERAPY IN CORONARY ARTERY BYPASS GRAFT PATIENTS WITH DECREASED PLATELET FUNCTION: COMPARISON OF FIBRINOGEN CONCENTRATE WITH ALLOGENEIC BLOOD PRODUCTS**

Cristina Solomon\* (AT), Herbert Schoechl, Alexander Hanke, Andreas Calatzis, Christian Hagl, Kenichi Tanaka, Niels Rahe-Meyer

**P-WE-201 PROCOAGULANT PHOSPHOLIPIDS CLOTTING TIME IN NORMAL PREGNANCY AND PREECLAMPSIA**

Luca Spiezia (IT), Elena Campello, Maria Bon, Sabrina Gavasso, Silvia Visentin, Erich Cosmi, Barry Woodhams\*, Paolo Simioni

**P-WE-202 SPECIFIC PROTEOLYTIC CLEAVAGE OF REELIN BY COAGULATION FACTOR X**

Wei-Lien Tseng\* (TW), Yen-Shu Huang, Chia-Chun Huang, Chun-Fang Yeh, Tzu-Hsuan Chen, Ju-Chien Cheng, Ching-Ping Tseng

**P-WE-203 A CHILD WITH CONGENITAL FACTOR X DEFICIENCY**

Kun Soo Lee\* (KR), Ye Jee Shim

**P-WE-204 TWO NOVEL MUTATIONS OF THE FIBRINOGEN GENE IN TWO UNRELATED AFIBRINOGENEMIC PATIENTS**

Elvira Grandone\* (IT), Lucia Fischetti, Filomena Cappucci, Rossana Santacroce, Fiorenza Soli, Giovanni Favuzzi, Cristina Legnani, Giovanni Luca Tiscia, Maria Antonietta Rizzo, Gualtiero Palareti, Maurizio Margaglione



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-205 LEVELS OF FIBRINOGEN AND THROMBOELASTOMETRY FIBRIN POLYMERISATION FOLLOWING TREATMENT WITH DESMOPRESSIN (DDAVP)**  
Benny Sorensen\* (UK), Gary Moore, Gerald Hochleitner, Christian Fenger-Eriksen

### Laboratory tests

- P-WE-206 EVALUATION OF ASSAY METHODOLOGY ON EFFECTIVE MANAGEMENT OF REPLACEMENT THERAPY IN HAEMOPHILIA B**  
Jane Needham\* (UK), Jayanthi Alamelu, Helen Lewis, Savita Rangarajan
- P-WE-207 CHARACTERIZATION OF PROS1 MUTATION-NEGATIVE HEREDITARY PROTEIN S DEFICIENCY**  
Rene Mulder\* (NL), Min Ki ten Kate, Hugo ten Cate, Henri M.H. Spronk, Hanneke C. Kluin-Nelemans, Andre B. Mulder
- P-WE-208 ACQUIRED INHIBITOR TO FACTOR XII IN PATIENT WITH SERONEGATIVE RHEUMATOID ARTHRITIS**  
Darko Antic\* (RS), Ivo Elezovic, Predrag Miljic, Mirjana Mitrovic, Maja Zlatanovic
- P-WE-209 COMPARISON OF FACTOR ASSAY OPTICAL AND MECHANICAL DETECTION SYSTEMS ON THE DESTINY MAX COAGULATION ANALYSER**  
Jane Needham\* (UK), Helen Lewis, Savita Rangarajan
- P-WE-210 HERITABLE THROMBOPHILIA TESTING AT A PUBLIC TEACHING HOSPITAL**  
Gabriela Mainetti\* (AR), Maria Eugenia Pagliaro, Corina Naymark, Laura Fischer, Ines Engelberguer, Roxana Zarate, Ricardo Hermes, Beatriz Grand
- P-WE-211 PROSPECTIVE AUDIT OF UNFRACTIONATED HEPARIN (UFH) THERAPY IN INFANTS AND CHILDREN IN PAEDIATRIC INTENSIVE CARE UNIT (PICU)**  
Syarul Hafiz Mohd Shah\* (AU), Paul Monagle, Robyn Summerhayes, Sophie Jones, Fiona Newall
- P-WE-212 COMPARISON BETWEEN ELISA BASED TEST FOR DETECTION OF FACTOR VIII ANTIBODIES SCREEN AND STANDARD BETHESDA**  
Tarek Owaidah\* (SA), Rasheed Nasr, Abdulkareem Al Moomn
- P-WE-213 PLASMA CONCENTRATIONS OF TOTAL PROTEIN S ANTIGEN ARE NOT RELATED WITH BODY FAT MASS BUT WITH TRIGLYCERIDE LEVELS IN OBESE JAPANESE WOMEN**  
Maiko Ueda\* (JP), Eri Nakazono, Tomohide Tsuda, Xiu Ri Jin, Shuji Nakano, Hiroko Tsuda
- P-WE-215 EFFECT OF RAMADAN FASTING ON INTERNATIONAL NORMALIZED RATIO AMONG PATIENTS TREATED BY ORAL ANTICOAGULANT**  
Faouzi Addad\* (TN), Majdi Amami, Rym Chrigui, Nadia Hammami, Samira Chine, Afef Ben Halima, Ikram Kamoun, Sadok Yahlaoui, Salem Kachboura
- P-WE-216 ANTIPHOSPHOLIPID ANTIBODIES PRE AND POST ENZYME REPLACEMENT TREATMENT IN ANDERSON FABRY PATIENTS FROM ARGENTINA**  
Pablo Alberto Martinez\* (AR), Mario Aggio, Paula Rozenfeld
- P-WE-217 EVALUATION OF ROTEM AND TEG FOR ASSESSING ANTICOAGULATION WITH WARFARIN**  
Despoina Adamidou\* (UK), Pratima Chowdary, Saman Aghighi, Paul Priest, Lida Moghaddam, Anne Riddell
- P-WE-218 RIVAROXABAN INTERFERES WITH FACTOR VIII MEASUREMENTS**  
Vladimir Tichelaar\* (NL), Hanneke C. Kluin-Nelemans, J. Hendrik Nijland, Karina Meijer, Andre B. Mulder

Wednesday Posters



29

## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-219 DEVELOPMENTAL CHANGES OF COMMON COAGULATION PARAMETERS MEASURED ON SYMEX CA-1500 ANALYZER**  
Inge M Appel\* (NL), Tineke Henniphof, Carla van Kessel-Bakvis, Rolinda Stigter, Auke Beishuizen
- P-WE-220 IN VITRO AND IN VIVO THROMBIN GENERATION IN DEVELOPMENTAL HAEMOSTASIS: ETP VERSUS F1+2 AND TAT**  
Inge M Appel\* (NL), Tineke Henniphof, Carla van Kessel-Bakvis, Rolinda Stigter, Auke Beishuizen
- P-WE-221 FORMATION OF THE SECOND PEAK IN PLATELET-RICH PLASMA THROMBIN GENERATION CURVE IS LINKED WITH PHOSPHATIDYLSERINE EXPRESSION DURING PLATELET ACTIVATION**  
Ivan Dmitrievitch Tarandovskiy\* (RU), Mikhail Panteleev, Elena Sinauridze, Nikolai Topalov, Elena Artemenko, Nadejda Podoplelova, Fazoil Ataulakhanov
- P-WE-222 PAEDIATRIC REFERENCE LEVELS FOR TEG AND ROTEM: THE YOUNGER THE FASTER AND STRONGER THE CLOT**  
Inge M Appel\* (NL), Andreas Machotta, Bart Grimminck, Johan Geerts, Sander Talman, Rolinda Stigter, Marjon H Cnossen, Auke Beishuizen
- P-WE-223 THROMBOELASTOGRAPHY AND THROMBOELASTOMETRY IN PAEDIATRICS: COMPARISON OF HAEMOSCOPE TEG AND TEM ROTEM**  
Inge M Appel\* (NL), Tineke Henniphof, Carla van Kessel-Bakvis, Rolinda Stigter, Auke Beishuizen
- P-WE-224 PRP THROMBIN GENERATION (TG) IN PATIENTS ON ORAL ANTICOAGULATION WITH WARFARIN: INFLUENCE OF TISSUE FACTOR (TF) CONCENTRATION AND CORN TRYPSIN INHIBITOR (CTI)**  
Despoina Adamidou\* (UK), Anne Riddell, Saman Aghighi, Shaila Bates, Pratima Chowdary
- P-WE-225 INCREASED HEPARANASE PROCOAGULANT ACTIVITY IN ORTHOPEDIC SURGERY PATIENTS RECEIVING PROPHYLACTIC DOSE OF ENOXAPARIN**  
Eli Peled (IL), Alexie Robitzki, Elena Axelman, Doron Norman, Benjamin Brenner, Yona Nadir\*
- P-WE-226 CLINICHAEMATOLOGICAL PROFILE OF PATIENTS WITH FACTOR VIII: C INHIBITORS**  
Sitalakshmi Subramanian\* (IN), Karuna Rameshkumar, Cecil Reuben Ross, Vanamala Anand Alwar, Shanthala Devi AM, Parimala Puttaiah
- P-WE-227 ROLE OF ANTITHROMBIN, PROTEIN C AND PROTEIN S DEFICIENCY ON INCIDENCE OF SYMPTOMATIC THROMBOSIS IN CHILDREN AND THEIR RELATIVES: A MULTICENTER EUROPEAN COHORT STUDY**  
Susanne Holzhauer (DE), Kristin Jochmans, Gili Kenet, Ralf Knoefler, Rosemarie Schobess, Ulrike Nowak-Gottl\*
- P-WE-228 THROMBIN GENERATION TEST IN NEONATES**  
Martin Prochazka\* (CZ), Jana Prochazkova, Veronika Lattova, Ludek Slavik, Jana Ulehlova, Radovan Pilka
- P-WE-229 IMMUNE TOLERANCE INDUCTION TO ERADICATE INHIBITORS IN VENEZUELAN HEMOPHILIA A PATIENTS: A PRELIMINARY REPORT**  
Apsara V Boadas de Sanchez\* (VE), Luisa N Hernandez, Mercedes E Mijares, Marion M Echenagucia, Norma B de Bosch, Arlette V Ruiz-Saez
- P-WE-230 THE REFERENCE RANGES OF D-DIMER LEVELS ARE DIFFERENT IN PREGNANT WOMEN USING VARIOUS D-DIMER ASSAYS**  
Petr Kessler\* (CZ), Roman Petrik, Hynek Poul, Maria Kusnierova, Gabriel Horkay



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-231 SUCCESSFUL CONSERVATIVE TREATMENT OF RECURRENT INTRACRANIAL HEMORRHAGE IN INFANT WITH CONGENITAL FVII DEFICIENCY**  
Dragan Micic\* (RS), Milena Jovic, Olivera Serbic, Kuzmanovic Milos
- P-WE-232 EFFECT OF NOISE GENERATED BY MICROPLATE READER ON THE PERFORMANCE OF THE THROMBIN GENERATION TEST**  
Samuel Woodle\* (US), Dominique T Monteil, Mikhail V Ovanesov
- P-WE-233 OPTIMIZATION OF A THROMBIN GENERATION TEST FOR THE ANALYSIS OF FACTOR XIA CONTAMINATION IN IMMUNOGLOBULINS**  
Samuel Woodle\* (US), Alexey M Shibeko, Mikhail V Ovanesov
- P-WE-234 INTERPRETATION AND SIGNIFICANCE OF ANTI-FVIII ANTIBODIES DETECTED BY ELISA AND WESTERN BLOTTING**  
Satoshi Yamazaki\* (JP), Shigenobu Takayama, Tomoko Ashikaga, Atsuki Yamashita, Shinji Muto, Chiai Nagae, Masashi Taki
- P-WE-235 THE ACTIVATED PARTIAL THROMBOPLASTIN TIME IN PREKALLIKREIN DEFICIENCY VARIES WIDELY WITH REAGENT TYPE, ACTIVATION TIME AND CLOT DETECTION PRINCIPLE: A CASE REPORT**  
Geoffrey Kershaw\* (AU), Diane Zebeljan
- P-WE-236 EVALUATION OF NOVEL TOTAL PROTEIN S ASSAY SYSTEM FOR SCREENING OF PROTEIN S TYPE II DEFICIENCY**  
Tomohide Tsuda\* (JP), Xiuri Jin, Hiroko Tsuda, Eriko Morishita, Takao Kobayashi, Naotaka Hamasaki
- P-WE-237 DEVELOPMENT OF A NEW QUANTITATIVE TOTAL PROTEIN S ASSAY SYSTEM FOR SCREENING OF PROTEIN S TYPE II DEFICIENCY**  
Xiuri Jin\* (JP), Tomohide Tsuda, Hiroko Tsuda, Masahiro Ieko, Tomoko Adachi, Naotaka Hamasaki

### Experimental models

- P-WE-238 THE ROLE OF THROMBOMODULIN IN SEPSIS CAUSED BY BURKHOLDERIA PSEUDOMALLEI**  
Liesbeth M Kager\* (NL), W Joost Wiersinga, Gavin CKW Koh, Joris J Roelofs, Joost C Meijers, Edward M Conway, Hartmut Weiler, Cornelis Van 't Veer, Tom Van der Poll
- P-WE-239 EVALUATION OF SEPSIS OUTCOMES IN MICE MODELS OF HEMOPHILIA A AND B**  
Erich de Paula\* (BR), Suley Mara Chaddad Vancine, Susan Kelly Picoli-Quaino, Devanira Souza Paixao Costa, Silmara Aparecida Lima Montalvao, Margareth Castro Ozelo, Joyce Maria Annichino-Bizzacchi
- P-WE-240 ACTIVATION OF PROTEASE ACTIVATED RECEPTOR-2 IMPAIRS HOST DEFENSE DURING MURINE *STREPTOCOCCUS PNEUMONIAE* PNEUMONIA BY A MECHANISM INDEPENDENT OF TISSUE FACTOR/FACTOR VIIA**  
Floor E. van den Boogaard\* (NL), Marcel Schouten, Xanthe Brands, Marcus J. Schultz, Cornelis van 't Veer, Tom van der Poll
- P-WE-241 MAINTENANCE AND BREAK OF IMMUNE TOLERANCE IN A NEW MOUSE MODEL THAT IS IMMUNOLOGICALLY TOLERANT TO NATIVE HUMAN FACTOR VIIA**  
Christine Lenk\* (AT), Sabine Unterthurner, Gerhard Antoine, Markus Weiller, Rafi Uddin Ahmad, Maurus de la Rosa, Hans-Peter Schwarz, Birgit Maria Reipert



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-242 MAST CELLS PLAY AN UNFAVORABLE ROLE DURING MURINE *STREPTOCOCCUS PNEUMONIAE* PNEUMONIA**  
Floor E. van den Boogaard\* (NL), Xanthe Brands, Joris J.T.H. Roelofs, Cornelis van 't Veer, Tom van der Poll
- P-WE-243 ANTI-HAEMOPHILIC FACTOR (FACTOR VIII) AND THROMBIN GENERATION IN CAMEL PLASMA - A COMPARATIVE STUDY WITH HUMANS**  
Abdel Galil M Abdel Gadir\* (SA), Al Momen M Abdul Karim, Abdulqader A Alhaider, Brooks Catalfamo Brooks, James L Catalfamo, Ahmed A Al Haidari
- P-WE-244 THROMBIN GENERATION TEST (TGT), A POWERFUL EX VIVO SCREENING TOOL TO PREDICT IN VIVO ANTITHROMBOTIC EFFICACY: APPLICATION TO COUMARINS TARGETING THROMBIN**  
Severine Robert\* (BE), Raphael Frederick, Philippe Devel, Francois Mullier, Bernard Chatelain, Bernard Masereel, Lionel Pochet, Jean-Michel Dogne
- P-WE-245 PROTECTIVE EFFECT OF THROMBOMODULIN IN A MURINE MODEL OF ALLERGEN-INDUCED ASTHMA**  
Takehiro Takagi\* (JP), Osamu Taguchi, Masahiro Naito, Masaaki Toda, Tetsu Kobayashi, Yasushi Miyake, Daniel Boveda, Corina N D'Alessandro-Gabazza, John Morser, Esteban C Gabazza
- P-WE-246 ANTICOAGULANT AND FIBRINOLYTIC EFFECTS OF GLYPROLINES IN CONDITIONS OF IMMOBILIZATION STRESS**  
Marina E Grigorjeva\* (RU), Ludmila A Lyapina
- P-WE-247 MODELLING AND SIMULATION OF REDISTRIBUTION OF DABIGATRAN AFTER ELIMINATION BY HEMODIALYSIS IN PATIENTS WITH END STAGE RENAL DISEASE**  
Karl-Heinz Liesenfeld (DE), T. Lehr, V. Moschetti, S. Formella\*, A. Clemens, A. Staab, S. Haertter
- P-WE-248 ACTIVATED PROTEIN C MODULATES EPCR AND PAR1 EXPRESSION IN NEURONS AT EXITOTOXICITY**  
Irina Savinkova\* (RU), Lubov Gorbacheva, Vsevolod Pinelis, Svetlana Strukova, Georg Reiser
- P-WE-248\* ACTIVATED PROTEIN C MODULATES MAST CELL FUNCTIONS AND SURVIVAL AT INFLAMMATION**  
Svetlana Strukova\* (RU), Aleksey Piskunov, Anna Rusanova, Lubov Gorbacheva, Fumi Ono, Shin'ichi Ishiwata

### TAFI

- P-WE-249 DETERMINATION OF COAGULATION AND FIBRINOLYSIS MARKERS UPON ANTI-TAFI TREATMENT IN A MOUSE THROMBOEMBOLISM MODEL**  
Ellen Vercauteren\* (BE), Jan Emmerechts, Miet Peeters, Marc F Hoylaerts, Paul J Declerck, Ann Gils
- P-WE-250 CLONING AND CHARACTERIZATION OF AN ANTIBODY-BASED INHIBITOR OF TAFI**  
Tine L Wyseure\* (BE), E. Vercauteren, A. Gils, P.J. Declerck
- P-WE-251 REGULATION OF THE SURVIVAL AND APOPTOSIS SIGNALS WITH TAFI IN THE PRIMARY CULTURED RAT HEPATOCYTES**  
Kasumi Ishii\* (JP), Nobuaki Okumura, Mayuko Arima, Ai Hashizume, Keiichi Akiyama, Takashi Hosono, Taiichiro Seki, Toyohiko Ariga
- P-WE-252 ANTIFIBRINOLYTIC ACTIVITY OF THROMBIN AND TAFIA GENERATED OUTSIDE THE CLOT. DO ANTICOAGULANTS ENHANCE CLOT LYSIS?**  
Mario Colucci\* (IT), Francesca Incampo, Cosimo Carrieri, Laura La Grasta, Nicola Semeraro



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-253 PROFIBRINOLYTIC ACTIVITY OF DIFFERENT ANTICOAGULANTS IN BLOOD. RELATION WITH CLOTTING INHIBITION AND INFLUENCE OF PLATELETS**  
Mario Colucci\* (IT), Cosimo Carrieri, Francesca Incampo, Rita Galasso, Nicola Semeraro
- P-WE-254 REPRESSION OF THROMBIN-ACTIVABLE FIBRINOLYSIS INHIBITOR (TAFI) EXPRESSION BY NOBILETIN IN HUMAN HEPATOMA HEPG2 CELLS**  
Kimihiko Takada\* (JP), Toru Seike, Tomoyuki Sasaki, Yutaka Masuda, Hidemi Ishii
- P-WE-256 TAFI ACTIVATION, FIBRINOLYSIS AND THROMBIN GENERATION IN HEMOPHILIA A CASES BEFORE AND AFTER TREATMENT WITH FVIII OR RECOMBINANT FVIIA**  
Norma de Bosch\* (VE), Belsy Guerrero, Maria Lucia D'Errico, Apsara Boadas, Arlette Ruiz-Saez, Zoila Carvajal, Ana Maria Salazar, Norma de Bosch

### PA system in CNS

- P-WE-257 TISSUE-TYPE PLASMINOGEN ACTIVATOR TRANSIENTLY ENHANCED THE PERMEABILITY OF BLOOD BRAIN BARRIER IN ISCHEMIA**  
Yasuhiro Suzuki\* (JP), Nobuo Nagai, Kazuo Umemura

### PA system in immunity and inflammation

- P-WE-258 THE ROLE OF CHYMASE, A NOVEL FIBRINOLYSIS ENZYME, IN ADIPOSE TISSUE**  
Misako Kikuzawa\* (JP), Tomohiro Ando, Yuri Shimamura, Shouta Nonaka, Kanako Okuyama, Shinichi Kenzaki, Hitomi Sekine, Takashi Hosono, Taiichiro Seki, Toyohiko Ariga
- P-WE-259 IMPAIRED ACCUMULATION OF MACROPHAGES AND ABSENCE OF THEIR PHENOTYPE HETEROGENEITY DURING LIVER REPAIR IN UROKINASE-DEFICIENT MICE**  
Naoyuki Kawao\* (JP), Nobuo Nagai, Yukinori Tamura, Katsumi Okumoto, Kiyotaka Okada, Masato Yano, Yasuhiro Suzuki, Kazuo Umemura, Shigeru Ueshima, Osamu Matsuo

### Experimental models

- P-WE-260 MECHANISM OF THE ANTITHROMBOTIC EFFECT OF AN APPLE VARIETY INVOLVES ENHANCEMENT OF ENDOGENOUS FIBRINOLYTIC ACTIVITY**  
Junichiro Yamamoto\* (JP), Mai Morishita, Aki Naemura, Kanae Hyodo, Yuko Tsuda, Yoshio Okada, Kiyotaka Okada, Osamu Matsuo
- P-WE-261 CALORIC RESTRICTION OF OBESE MICE IMPROVES ADIPOSITY, INFLAMMATION AND METABOLIC PROFILE**  
Matthias Van Hul\* (BE), Bianca Hemmeryckx, Henri Roger Lijnen
- P-WE-263 A SIMPLE FIRST-LINE SCREENING METHOD FOR THE EVALUATION OF THROMBOLYTICS BY INTRAVITAL MICROSCOPY**  
Benoit Ho-Tin-Noe\* (FR), Yacine Boulaftali, Lamia Lamrani, Marie-Catherine Paoli, Marie-Christine Bouton, Martine Jandrot-Perrus
- P-WE-264 REAL TIME IMAGING OF PLASMINOGEN BINDING TO PLATELET-RICH MICROTHROMBUS IN VIVO**  
Tetsumei Urano\* (JP), Aki Tanaka, Yuko Suzuki, Tomasz Brzoska, Hideo Mogami



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

### Deep vein thrombosis and pulmonary embolism

- P-WE-265 THE AGE-ADJUSTED D-DIMER SAFELY EXCLUDES A HIGH NUMBER OF PULMONARY EMBOLISMS IN COMBINATION WITH FOUR DIFFERENT CLINICAL DECISION RULES**  
Josien van Es\* (NL), I. C.M. Mos, R. A. Douma, M. G. P., T. A.C. Nizet, M. Durian, A. A. van Houten, H. M.A. Hofstee, H. Ten Cate, E. F. Ullmann, H. R. Buller, M. V. Huisman, P. W. Kamphuisen
- P-WE-266 CLINICAL AND ECONOMIC BURDEN OF VENOUS THROMBOEMBOLISM AMONG U.S. AMBULATORY CANCER PATIENTS UNDERGOING CHEMOTHERAPY**  
Jay Lin\* (US), Alok Khorana, Meul Dalal, Gregory Connolly
- P-WE-267 LONG TERM OUTCOME IN PATIENTS WITH SUPERFICIAL VEIN THROMBOSIS OF THE LEGS TREATED WITH THERAPEUTIC DOSES OF LOW MOLECULAR WEIGHT HEPARIN**  
Monika Stalc\* (SI), Tjasa Vizintin Cuderman, Matija Kozak, Nina Vene
- P-WE-268 IMPROVED PERFORMANCE OF HEMOSIL D-DIMER HS500 ASSAY TO RULE OUT VENOUS THROMBOEMBOLISM IN ELDERLY OUT-PATIENTS WITH LOW AND INTERMEDIATE PTP USING AGE-ADJUSTED CUT-OFF VALUES**  
Pierre A Toulon\* (FR), Christina Legnani, Dimitrios Scarvelis, Jogin R Wu, Gualtiero Palaretti
- P-WE-269 PERIOPERATIVE HEPARIN BRIDGING IN PATIENTS RECEIVING ORAL ANTICOAGULATION: META-ANALYSIS OF BLEEDING AND THROMBOEMBOLIC RATES**  
Deborah Siegal\* (CA), Jovana Yudin, Wendy Lim, Scott Kaatz, James D. Douketis, Alex C. Spyropoulos
- P-WE-270 PREVALENCE OF SYMPTOMATIC VENOUS THROMBOEMBOLISM IN MEDICAL IN-PATIENTS AT SIRIRAJ HOSPITAL**  
Yingyong Chinthamittr\* (TH), Busakorn Sae-aeng, Harutaya Kasayanan, Bundarika Suwanwiboon, Theera Ruchutrakool
- P-WE-271 SAFE EXCLUSION OF PULMONARY EMBOLISM USING THE WELLS RULE AND A POINT-OF-CARE OR LABORATORY BASED D-DIMER TEST IN PRIMARY CARE: A DIAGNOSTIC VALIDATION STUDY**  
Geert-Jan Geersing\* (NL), Petra Erkens, Wim Lucassen, Harry Buller, Arno Hoes, Ruud Oudega, Martin Prins, Henri Stoffers, Hugo ten Cate, Henk van Weert, Karel Moons
- P-WE-272 ATTITUDES TOWARDS AND PRACTICE OF VENOUS THROMBOEMBOLISM PREVENTION IN GENERAL INTERNAL MEDICINE WARDS- A PAN-EUROPEAN SURVEY**  
Moshe Vardi\* (IL), Lorenzo Dagna, Michal Haran, Roger W Duckit
- P-WE-273 THROMBOELASTOGRAPHY MONITORS HYPERCOAGULABILITY FOLLOWING CPAP TREATMENT IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA**  
Mazen Toukh\* (CA), Effie J Pereira, Bani J Falcon, Christina Liak, Marina Lerner, Wilma M Hopman, Steve Iscoe, Michael F Fitzpatrick, Maha Othman
- P-WE-274 PREVALENCE AND INDICATORS OF DEEP VEIN THROMBOSIS IN FEMALE MEDICAL PATIENTS WITH IMMOBILIZATION ON ADMISSION IN HOSPITAL**  
Koichi Sato\* (DE), Kazuhiko Hanzawa, Takeshi Okamoto, Roland Hetzer, Jun-ichi Hayashi
- P-WE-275 STICKERS IN MEDICAL RECORDS AS A TOOL TO REMEMBER THE IMPORTANCE OF VENOUS THROMBOEMBOLISM PROPHYLAXIS**  
Beatriz Eugenia Grand\* (AR), Bernabe Demaria, Julio Hammoe, Ramiro Gutierrez, Oscar Mando



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-276 GENETIC ASSOCIATIONS OF PULMONARY EMBOLISM AMONG THOSE WITH A DEEP VEIN THROMBOSIS**  
Nicholas L Smith\* (US), Marine Germain, Weihong Tang, Martina Teichert, Guillaume Pare, Mary Cushman, William Cohen, Pierre Morange, Aaron Folsom, Lynda Rose, Daniel I Chasman, Edwin T. Bovill, David-Alexandre Tregouet, Saonli Basu, Bruno Stricker, Paul Ridker
- P-WE-277 IS THROMBIN GENERATION AT THE TIME OF AN ACUTE THROMBOEMBOLIC EPISODE A PREDICTOR OF RECURRENCE RISK? THE LINKOPING STUDY ON THROMBOSIS (LIST) - A 7-YEAR FOLLOW-UP**  
Roza Chairati\* (SE), Cecilia Jennersjo, Tomas Lindahl
- P-WE-278 HOW ARE THROMBIN GENERATION AND THROMBOSIS RECURRENCE RATES AFFECTED BY AGE AND GENDER? THE LINKOPING STUDY ON THROMBOSIS (LIST) - A 7 YEAR FOLLOW-UP**  
Roza Chairati\* (SE), Cecilia Jennersjo, Tomas L Lindahl
- P-WE-279 INCIDENCE OF VENOUS THROMBOEMBOLISM IN PSYCHIATRIC UNITS**  
Karine Lacut\* (FR), Aurelien Delluc, Stephanie Montavon, Olivier Canceil, Marc Carpentier, Luc Bressollette, Sylvie Etienne, Michel Walter, Jean-Pierre Olie, Dominique Mottier
- P-WE-280 MEASUREMENT OF FVIII LEVELS OVER TIME IN CONSECUTIVE PATIENTS AFTER DEEP VEIN THROMBOSIS**  
Arina J ten Cate-Hoek\* (NL), K Hamulyak, P Verheezzen, H ten Cate
- P-WE-281 IS THE PREDICTIVE QUALITY OF D-DIMER FOR THE RECURRENCE OF THROMBOSIS TIME DEPENDENT?**  
Arina J ten Cate-Hoek\* (NL), P Erkens, K Hamulyak, P Verhezen, H ten Cate
- P-WE-282 INCIDENCE AND PATTERNS OF VENOUS THROMBOEMBOLIC EVENTS AMONG HOSPITALIZED MEDICAL PATIENTS IN A TERTIARY SINGAPORE INSTITUTION**  
Hein Than\* (SG), Heng Joo Ng, Ying Hua Leong, Lai Heng Lee
- P-WE-283 MANAGEMENT AND ASSESSMENT OF PREOPERATIVE PULMONARY EMBOLISM IN THE JAPANESE ACADEMIC MEDICAL CENTER**  
Chikao Yasuda\* (JP), Mitsugu Taniguchi, Masao Akagi, Kiyotaka Okada, Shigeru Ueshima, Osamu Matsuo, Eizaburoh Ishimaru, Ryuji Kajikawa, Yasutaka Shiokawa, Yoshifumi Takeyama, Kiyotaka Okuno, Hitoshi Shiozaki
- P-WE-284 THE INCIDENCE OF DEEP VEIN THROMBOSIS AFTER RESECTION OF MUSCULOSKELETAL TUMOR**  
Toshio Yamaguchi\* (JP), Akihiko Matsumine, Tokuzen Shi, Rui Niimi, Tomoki Nakamura, Takao Matsubara, Kunihiro Asanuma, Masahiro Hasegawa, Akihiro Sudo
- P-WE-285 PROGNOSTIC CLINICAL PREDICTION RULES FOR IDENTIFYING LOW-RISK PULMONARY EMBOLISM: A SYSTEMATIC REVIEW AND META-ANALYSIS**  
Alessandro Squizzato\* (IT), Marco Donadini, Luca Galli, Francesco Dentali, Walter Ageno
- P-WE-286 DISTRIBUTION OF DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN THE ELDERLY**  
Marissa Josephina Engbers\* (NL), Jeanet Blom, Mary Cushman, Frits Rosendaal, Astrid van Hylckama Vlieg
- P-WE-287 CLINICAL RELEVANCE OF COMPRESSION ULTRASONOGRAPHY IN CASE OF SYMPTOMATIC ISOLATED SUPERFICIAL VEIN THROMBOSIS OF LOWER LIMBS**  
Jean-Philippe Galanaud\* (FR), Isabelle Quere, Alain Leizerovicz, Jean-Philippe Galanaud, Emilie Presles, Francois Becker, Marie-Therese Barrellier, Gilles Desprairies, Herve Guenneguez, Patrick Mismetti, Anne Vinel, Herve Decousus





## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-288 RECURRENT VENOUS THROMBOSIS AND POST-THROMBOTIC SYNDROME AFTER CATHETER-DIRECTED THROMBOLYSIS IN ILEOFEMORAL DEEP VENOUS THROMBOSIS (DVT)**  
Waleed Ghanima\* (NO), Ingrid Wiig Kleven, Tone Enden, Antonio Rosales, Hilde Skuterud Wik, Paal Andre Holme, Per Morten Sandset
- P-WE-289 EARLY PROGNOSIS OF SYMPTOMATIC ISOLATED SUPERFICIAL-VEIN THROMBOSIS IN THE REAL LIFE: A POOLED ANALYSIS OF OBSERVATIONAL STUDIES**  
Jean-Philippe Galanaud\* (FR), Isabelle Quere, Celine Genty, Emilie Presles, Jean-Luc Bosson, Herve Decousus, Alain Leizerovicz
- P-WE-290 D-DIMER AND PULMONARY EMBOLISM SEVERITY INDEX IN RELATION TO RIGHT VENTRICULAR FUNCTION**  
Marten Soderberg\* (SE), Riikka Rydman, Marten Soderberg, Flemming Larsen, Mahbulul Alam, Kenneth Caidahl
- P-WE-291 FRAILTY AND VENOUS STASIS AS RISK FACTORS OF VENOUS THROMBOSIS IN THE ELDERLY**  
Marissa Josephina Engbers\* (NL), Jeanet Blom, Mary Cushman, Frits Rosendaal, Astrid van Hylckama Vlieg
- P-WE-292 PERFORMANCE OF FOUR CLINICAL DECISION RULES IN THE DIAGNOSTIC MANAGEMENT OF ACUTE PULMONARY EMBOLISM; THE PROMETHEUS DIAGNOSTIC ACCURACY STUDY**  
Inge C.M. Mos\* (NL), Renee A. Douma, Petra M.G. Erkens, Tessa A.C. Nizet, Marc F. Durian, Marcel M.M. Hovens, Anja A. van Houten, Herman M.A. Hofstee, Frederikus A. Klok, Hugo ten Cate, Erik F. Ullmann, Harry R. Buller, Pieter W. Kamphuisen, Menno V. Huisman
- P-WE-293 CONGESTION AND INFLAMMATION ASSOCIATED CALF COMPARTMENT SYNDROME IN ACUTE PROXIMAL DEEP VENOUS THROMBOSIS ASSESSED WITH MAGNETIC RESONANCE TOMOGRAPHY**  
Hong H Keo\* (CH), Torsten Willenberg, Werner Blaettler
- P-WE-294 EVALUATING THE USE OF NEGATIVE D-DIMER AND LOW WELLS SCORE IN EXCLUDING ABOVE KNEE DEEP VENOUS THROMBOSIS IN AN OUTPATIENT POPULATION AT A MAJOR LONDON TEACHING HOSPITAL**  
Shirish G Prabhudesai\* (UK), Anshul Rastogi, Sean Platton, David Mcclinton, Deirdre Norris, Louise Bowles, Peter K MacCallum, Emma Friedman
- P-WE-295 HEALTH RELATED QUALITY OF LIFE (HRQOL) AFTER CATHETER-DIRECTED THROMBOLYSIS IN DEEP VENOUS THROMBOSIS (DVT) - A CASE CONTROL STUDY**  
Waleed Ghanima\* (NO), Hilde Skuterud Wik, Kleven Wiig Ingrid, Tone Enden, Per Morten Sandset
- P-WE-296 METABOLIC SYNDROME IS ASSOCIATED WITH UNPROVOKED VENOUS THROMBOEMBOLISM: A PATIENT-LEVEL META-ANALYSIS**  
Walter Ageno\* (IT), Matteo ND Di Minno, Cihan Ay, Moon J Jang, Ingrid Pabinger, Doyeun Oh, Giovanni Di Minno, Alessandro Squizzato, Francesco Dentali
- P-WE-297 DIFFERENTIAL INHIBITION OF FIBRINOKINETICS BY UNFRACTIONATED HEPARINS AND DEPOLYMERIZED HEPARINS**  
Angel L Gray\* (US), Josephine Cunanan, Debra Hoppensteadt, Jawed Fareed
- P-WE-298 RESEARCH OF THE RELATIONSHIP BETWEEN PHENOTYPE AND GENOTYPE IN THREE CHINESE PEDIGREES WITH INHERITED ANTITHROMBIN DEFICIENCY**  
Qi OuYang\* (CN), Qiulan Ding, Xuefeng Wang, Hongli Wang, Xiaodong Xi



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-299 HIGH PREVALENCE OF LATE SYMPTOMS AFTER PULMONARY EMBOLISM IN PATIENTS WITH NORMAL ECHOCARDIOGRAPHY AND PULMONARY FUNCTION TESTS**  
Anja B.U. Makelburg\* (NL), Georges D. Nossent, Elke S. Hoendermis, Adrienne H. Brouwers, Nic J.G.M. Veeger, Hanneke C. Kluin-Nelemans, Meijer Karina
- P-WE-300 RISK FACTORS OF VENOUS THROMBOEMBOLISM AT THE PATIENTS NEEDY IN PLANNED HIP OR KNEE REPLACEMENT**  
Svetlana A. Bozhkova\* (RU), Rashid M Tikhilov, Evgenia L Nesenyuk, Anatoliy V Yarmilko, Alexandr V Stoyanov, Anatoliy V Sementkovskiy
- P-WE-301 PRODUCT ASSOCIATED VARIATION IN GENERIC ENOXAPARIN. POTENTIAL CLINICAL IMPLICATIONS.**  
Jawed Fareed\* (US), Debra Hoppensteadt, Walter Jeske, Angel Gray, Jeanine Walenga, Evi Kalodiki, Indermohan Thethi, Rakesh Wahi
- P-WE-302 LIPID PARAMETERS MIGHT INFLUENCE VTE EXTENSION**  
Thomas Gary\* (AT), Klara Belaj, Franz Hafner, Harald Froehlich, Ernst Pilger, Marianne Brodmann
- P-WE-303 MARKERS OF THROMBOGENESIS IN PATIENTS WITH ACUTE PSYCHOSIS**  
Jiri Masopust\* (CZ), Radovan Maly, Ctirad Andrys, Martin Valis, Jan Bazant, Ladislav Hosak
- P-WE-305 COMPARISON OF 5 D-DIMER REAGENTS AND APPLICATION OF AN AGE ADJUSTED CUT-OFF FOR THE DIAGNOSIS OF VTE IN EMERGENCY DEPARTMENT**  
Francois Mullier\* (BE), Dominique Vanpee, Jacques Jamart, Eric Dubuc, Yvan Cornet, Christian Chatelain, Jean-Michel Dogne, Bernard Chatelain
- P-WE-306 PLASMA D-DIMER TESTING FOLLOWED BY ULTRASONOGRAPHY FOR PREDICTING VENOUS THROMBOEMBOLISM IN PATIENTS WITH GYNECOLOGIC DISEASE**  
Haruta Shoji\* (JP), Ryuji Kawaguchi, Yasuhito Tanase, Akira Nagai, Shozo Yoshida, Naoto Furukawa, Yoshihiko Yamada, Hidekazu Oi, Toshiko Hirai, Hiroshi Kobayashi
- P-WE-307 EFFECTS OF INTERMITTANT PNEUMATIC COMPRESSION DEVICES**  
Mehmet Kurtoglu\* (TR), Alper Ozturk, Emre Sivrikoz, Hakan Yanar, Murat Aksoy
- P-WE-308 EXAMINATION OF THE DEEP VEIN THROMBOSIS BY LAPAROSCOPIC SURGERY**  
Kazuteru Komuro\* (JP), Noriko Yokoyama, Hiromitsu Doumen, Yoshitsugu Nakanishi, Nozomu Iwashiro, Masanori Ohara, Masanori Ishizaka, Kaoru Komuro, Kazuya Yonezawa
- P-WE-309 EXAMINATION OF THE DEEP VEIN THROMBOSIS BY SURGERY**  
Noriko Yokoyama\* (JP), Kazuteru Komuro, Kaoru Komuro, Hiromitsu Doumen, Yoshitsugu Nakanishi, Nozomu Iwashiro, Masanori Ohara, Masanori Ishizaka, Kazuya Yonezawa
- P-WE-310 ACTIVATION OF HAEMOSTASIS IN PATIENTS WITH NEWLY DIAGNOSED OF PSYCHOSIS BEFORE AND DURING ANTIPSYCHOTIC TREATMENT: MATCHED CASE-CONTROL ANTRE STUDY**  
Radovan Maly\* (CZ), Jiri Masopust, Ctirad Andrys, Dita Kalnicka, Jan Bazant, Ladislav Hosak
- P-WE-311 THE IMPACT OF A VENOUS THROMBOEMBOLISM RISK ASSESSMENT TOOL ON USAGE OF LOW MOLECULAR WEIGHT HEPARIN AND INCIDENCE OF PULMONARY EMBOLISM IN A LARGE ORTHOPAEDIC HOSPITAL**  
Claire Corrigan\* (UK), Daniel O'Callaghan, Cathy Jack, Gary Benson
- P-WE-312 PLATELET INTEGRIN BETA-3 DELETION OR PHARMACOLOGIC BLOCKADE AUGMENTS FIBRIN IN LARGE-VEIN THROMBOSIS**  
Brian C. Cooley\* (US)

Wednesday Posters



37

## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-313 BIOCHEMICAL DETERMINANTS OF ANTI-XA AND APTT DISCORDANCE FOR UFH MONITORING**  
Clifford Takemoto\* (US), Kenneth Shercock, Peggy Kraus, Dana Moore, Peter Greene, David Thiemann, Brent Petty, Redonda Miller, Michael Streiff, Thomas Kickler
- P-WE-314 HYPOBARIC HYPOXIA INDUCES HYPERCOAGULABLE STATE: ROLE OF INFLAMMATION AND ENDOTHELIAL DYSFUNCTION**  
Gausal Azam Khan\* (IN), Garg Itri, Indranil Biswas, Bandana Singh, Pawan Agarwal
- P-WE-315 RISK OF RECURRENT VENOUS THROMBOSIS ASSOCIATED WITH ELEVATED D-DIMER LEVELS**  
Astrid van Hylckama Vlieg\* (NL), Caroline A. Baglin, Roger Luddington, Frits R. Rosendaal, Trevor P. Baglin
- P-WE-316 POTENTIAL INTERACTIONS BETWEEN BLOOD TYPE AND THROMBOGENIC LIFESTYLE FACTORS. A DANISH FOLLOW-UP STUDY**  
El-Galaly Tarec\* (DK), Kim Overvad, Soeren Risom Kristensen, Rudi Steffensen, Marianne Tang Severinsen
- P-WE-317 FATAL PULMONARY EMBOLISM (PE), AS AN OUTCOME FROM HOSPITAL ACQUIRED THROMBOSIS (HAT): A SINGLE CENTRE EXPERIENCE**  
Yin M Thi\* (UK), Monica Beauchamp, Timothy JC Nokes
- P-WE-318 MYELOPROLIFERATIVE DISORDERS IN PATIENTS WITH ACUTE PORTAL, MESENTERIC OR SPLENIC VEIN THROMBOSES**  
Andrea Buchmuller-Cordier\* (FR), Karine Rivron-Guillot, Silvy Laporte, Beatrice Trombert-Paviot, Herve Decousus

### Genetic determinants and epidemiology

- P-WE-319 FACTOR XIII VAL34LEU POLYMORPHISM AND SUSCEPTIBILITY TO VENOUS THROMBOEMBOLISM IN NORTH-WESTERN RUSSIA**  
Sergey Igorevich Kapustin\* (RU), Yulia Semenovna Drizhun, Lyudmila Ivanovna Filanovskaya, Viktor Dmitrievich Kargin, Lyudmila Petrovna Papayan, Michail Nikolaevich Blinov
- P-WE-320 FREQUENCY OF FACTOR V LEIDEN AND PROTHROMBIN MUTATION IN TESTED SAMPLES FOR THROMBOPHILIA AND CONCORDANCE OF FUNCTIONAL AND MOLECULAR TESTS FOR FACTOR V LEIDEN MUTATION**  
Abdulaziz alshaiikh (SA), Tarek Owaidah\*
- P-WE-321 THE JAK2 V617F MUTATION REPRESENTS A GENDER-RELATED SUSCEPTIBILITY ALLELE FOR SPLANCHNIC VENOUS THROMBOSIS**  
Elvira Grandone\* (IT), Donatella Colaizzo, Giovanni Luca Tiscia, Patrizia Vergura, Gennaro Vecchione, Filomena Cappucci, Valeria Bafunno, Maurizio Margaglione
- P-WE-322 FACTOR V LEIDEN AND SLOVAK POPULATION**  
Peter Kubisz\* (SK), Jan Stasko, Ivana Plamenova, Lenka Bartosova, Juraj Chudej, Pavol Holly, Peter Chudy
- P-WE-323 GENOME WIDE ASSOCIATION STUDY IDENTIFIES NOVEL SUSCEPTIBILITY GENES FOR PEDIATRIC STROKE AT THE INTERFACE BETWEEN VASCULAR BIOLOGY AND COAGULATION**  
Monika Stoll\* (DE), Ulrike Nowak-Goettl, Milan Hiersche, Christoph Preuss, Frank Ruehle, Anika Sietmann, Thomas Niederstadt, Karin Kurnik



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-324 THE INFLUENCE OF ABO BLOOD GROUP GENOTYPES AND THE INTERACTION OF NON-O BLOOD GROUP WITH THE FACTOR V LEIDEN AND PROTHROMBIN 20210A MUTATIONS ON VTE RISK**  
Olivia Wu\* (UK), Peter Clark
- P-WE-325 PRIORITIZED-GWAS BASED ON LINKAGE INFORMATION IDENTIFIES NOVEL PUTATIVE LOCI INFLUENCING FACTOR XII PLASMA LEVELS**  
France Gagnon\* (CA), Apostolos Dimitromanolakis, Guillemette Antoni, Angel Martinez, Nicholas Greliche, Alfonso Buil, Jose Manuel Soria, Pierre Emmanuel Morange, Philip Wells, David Alexandre Tregouet, Lei Sun
- P-WE-326 GENETIC RISK FACTORS FOR RECURRENT VENOUS THROMBOSIS**  
Linda E Flinterman\* (NL), Astrid Hylckama Vlieg, Lance A Bare, Suzanne C Cannegieter, Andre R Arellano, Pieter H Reitsma, James J Devlin, Frits R Rosendaal
- P-WE-327 NEW CANDIDATE LOCI MODULATING VWF AND FVIII PLASMA LEVELS: RESULTS FROM A META-ANALYSIS OF THREE GWAS IN SELECTED SAMPLES**  
Tiphaine Oudot-Mellakh (FR), Guillemette Antoni, Apostolos Dimitromanolakis, Marine Germain, William Cohen, Philip Wells, Mark Lathrop, David-Alexandre Tregouet, France Gagnon, Pierre-Emmanuel Morange\*
- P-WE-328 THE IMPACT OF FAMILY HISTORY OF VENOUS THROMBOEMBOLISM, FACTOR V LEIDEN AND PROTHROMBIN 20210G>A MUTATIONS, AND ACQUIRED RISK FACTORS ON THE RISK OF VENOUS THROMBOEMBOLISM**  
Fatima Donia Mili\* (US), W. Craig Hooper, Cathy Lally, Harland Austin
- P-WE-329 ARE FACTOR V LEIDEN AND PROTHROMBIN MUTATION RISK FACTORS FOR ARTERIAL THROMBOTIC EVENTS?**  
Manuel Cesar Campos\* (PT), Maria Coutinho, Ana Spinola, Eugenia Cruz, Sara Morais, Monica Pereira, Rui Matos, Norival Pinho, Nilza Seidi, Margarida Miranda

### Antiphospholipid syndrome

- P-WE-330 MARKERS OF ENDOTHELIAL ANGIOGENIC DYSFUNCTION IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES**  
Karen A Breen\* (UK), K Parmar, BJ Hunt
- P-WE-331 ANTIPHOSPHOLIPID ANTIBODIES IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA RECEIVING ECULIZUMAB**  
Dominique Helley\* (FR), Luc Darnige, Regis Peffault de Latour, Laurence Zemori, Gerard Socie, Anne-Marie Fischer
- P-WE-332 SUPERFICIAL VENOUS THROMBOSIS PREDICTS THROMBOEMBOLIC EVENTS IN LUPUS AND ANTIPHOSPHOLIPID PATIENTS. A PROSPECTIVE COHORT STUDY.**  
Stephane Zuily\* (FR), Veronique Regnault, Francis Guillemin, Pierre Kaminsky, Thomas Lecompte, Denis Wahl
- P-WE-333 RETINAL VEIN OCCLUSION IN ASSOCIATION WITH PERSISTENT ANTIPHOSPHOLIPID ANTIBODIES: A SINGLE CENTRE CASE SERIES**  
John Laurie\* (UK), Karen Breen, Beverley J Hunt
- P-WE-334 EVALUATION OF THE CRITERIA FOR LUPUS ANTICOAGULANT DETECTION. MA NARDI AND M KARPATKIN. DEPARTMENTS OF PEDIATRICS AND PATHOLOGY. BELLEVUE-NYU MEDICAL CENTER. NY, NY, USA.**  
Michael A Nardi\* (US), Margaret Karpatkin

Wednesday Posters



39

## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-335 PRIMARY ANTIPHOSPHOLIPID SYNDROME AND RENAL VASCULAR DISEASE**  
Jitka Slechtova\* (CZ), Zdenka Hajsmanova, Pavla Sigutova
- P-WE-336 MONITORING DISEASE ACTIVITY AND RESPONSE TO THERAPY IN CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME**  
Michiel Coppens\* (NL), Erik Jan Van den Dool, Joost C.M. Meijers, An K Stroobants, Bert Jan Van den Born
- P-WE-337 PROLONGED CLINICAL OBSERVATION OF A GROUP OF PATIENTS WITH ASYMPTOMATIC ANTIPHOSPHOLIPID ANTIBODIES**  
Krystyna Maria Zawilska\* (PL), Agata Maria Lehmann-Kopydlowska
- P-WE-338 ELEVATED CYTOKINE AND CHEMOKINE LEVELS IN ANTIPHOSPHOLIPID ANTIBODY (APL)-POSITIVE PATIENTS**  
Vijaya Murthy (US), Shraddha Jatwani, Laura Aline Martinez-Martinez, Renan Aguilar-Valenzuela, Ellis Doan, Elizabeth Papalardo, Joann Vega, Emilio B Gonzalez, Douk Erkan, Silvia S Pierangeli\*
- P-WE-339 STUDIES OF MICROPARTICLES IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME (APS)**  
Anna Vikerfors (SE), Fariborz Mobarrez\*, Katarina Bremme, Margareta Holmstrom, Anna Agren, Anna Eelde, Maria Bruzelius, Aleksandra Antovic, Hakan Wallen, Elisabet Svenungsson
- P-WE-340 A SINGLE CENTRE EVALUATION OF MORTALITY PREDICTORS IN THROMBOTIC PRIMARY ANTIPHOSPHOLIPID SYNDROME**  
Paul Richard Julian Ames\* (UK), Luigi Iannaccone, Antonio Ciampa, Catello Tommasino, Vincenzo Brancaccio
- P-WE-341 LUPUS ANTICOAGULANT IN WOMEN WITH OBSTETRIC COMPLICATIONS: PERSISTENCE OF RESULTS BETWEEN SAMPLES**  
Andrea Laura Avigliano\* (AR), Maria Cecilia Goni, Juan Carlos Galli, Beatriz Eugenia Grand
- P-WE-342 AUTOANTIBODIES TO THE COMPLEX OF PS/PT IN 67 FINNISH PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES**  
Marja Kaarina Puurunen\* (FI), Kustaa Lehtonen, Petra Makkonen, Kaija Javela

### Pregnancy, hormones, women's issues

- P-WE-343 THE INCIDENCE OF HEMORRHAGIC AND THROMBOEMBOLIC COMPLICATIONS OF THERAPEUTIC AND PROPHYLACTIC LOW MOLECULAR WEIGHT HEPARIN REGIMEN DURING PREGNANCY**  
Gorana Mitic\* (RS), Mirjana Kovac, Pavica Radovic, Aleksandra Novakov-Mikic
- P-WE-344 THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR ANTIGEN AND MICROPARTICLES' PROCOAGULANT ACTIVITY DURING PREGNANCY IN HEALTHY WOMEN AND WOMEN WITH AUTOIMMUNE DISEASES**  
Magdalena Celinska-Lowenhoff\* (PL), Teresa Iwaniec, Anna Wojtowicz, Magdalena Pulka, Jacek Musial
- P-WE-345 THROMBOPHILIA AND PLACENTAL ABRUPTION**  
Olga Panfilova\* (RU), Natalia Makatsaria, Marina Kiria
- P-WE-346 HEMOSTATIC AND LIPID PROFILE OF PATIENTS WITH HYPERTHYROIDISM BEFORE AND AFTER TREATMENT**  
Ana Paula Fernandes\* (BR), Michelle Aparecida Borges, Pedro Wesley Rosario, Luci Maria Sant' Ana Dusse, Kathryn Fontana Rodrigues, Maria das Gracias Carvalho



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-347 THROMBOPHILIA AND COMPLICATIONS OF MULTIPLE AND SINGLE PREGNANCY AFTER IVF**  
Natalia Makatsaria\* (RU), Olga Panfilova, Marina Kiria
- P-WE-348 MORPHOFUNCTIONAL FEATURES OF THROMBOCYTES IN THE FIRST TRIMESTER OF THE PREGNANCY COMPLICATED WITH DIABETES TYPE 1**  
Irina A Burenkova (RU), Irina M Ordiyants\*, Mikhail B Tamarkin, Irina A Vasilenko
- P-WE-349 PATHOGENESIS AND PROPHYLAXIS OF PROSTHETIC VALVE THROMBOSIS DURING PREGNANCY**  
Alexander D. Makatsaria\* (RU), Svetlana V. Akinshina, Viktoria O. Bitzadze, Vyacheslav B. Nemyrovskiy, Nestor T. Meskhi
- P-WE-350 ROLE OF HAEMOSTATIC DISORDERS DETECTION IN WOMEN WITH HISTORY OF ISCHEMIC STROKE FOR PREGNANCY MANAGEMENT**  
Svetlana V. Akinshina\* (RU), Alexander D. Makatsaria, Viktoria O. Bitzadze, Seda M. Baimuradova, Vyacheslav B. Nemirovskiy
- P-WE-351 PREVENTION OF RECURRENT THROMBOTIC AND THROMBOEMBOLIC COMPLICATIONS DURING PREGNANCY**  
Svetlana V. Akinshina\* (RU), Alexander D. Makatsaria
- P-WE-352 PATHOGENETIC PROPHYLAXIS OF RECURRENT ANTENATAL FETAL DEATH AND BIRTH DEFECTS IN PARENTS WITH GENETICALLY DETERMINED HYPERHOMOCYSTEINEMIA**  
Viktoria O. Bitsadze\* (RU), Inna N, Talalaeva, Alexander D. Makatsaria
- P-WE-353 PATHOGENETIC PROPHYLACTIC STRATEGY IN WOMEN WITH THROMBOPHILIA AND HISTORY OF PREECLAMPSIA IN FUTURE PREGNANCY**  
Viktoria O. Bitsadze\* (RU), Alexander D. Makatsaria, Seda M. Baimuradova, Svetlana V. Akinshina
- P-WE-354 F XIII AND PLATELETS IN PREGNANCY**  
Annelie Siegemund\* (DE), Elena Mirson, Thomas Siegemund, Ute Scholz
- P-WE-355 LATE OBSTETRIC MORBIDITY IN WOMEN WITH AND WITHOUT INHERITED OR ACQUIRED THROMBOPHILIA: MANAGEMENT AND OUTCOMES**  
Anja B Drebes\* (UK), Asma Khalil, Patrick O'Brien, Hannah Cohen
- P-WE-356 THE UTILITY OF THE WELLS CLINICAL PREDICTION MODEL AND VENTILATION-PERFUSION SCANNING FOR PULMONARY EMBOLISM IN PREGNANCY**  
Briony A Cutts\* (AU), Huyen Tran, Eileen Merriman, Dee Nandurkar, Geoffrey Soo
- P-WE-357 VASCULAR ENDOTHELIAL GROWTH FACTOR GENE POLYMORPHISMS IN SPONTANEOUSLY ABORTED EMBRYOS**  
Young Joo Jeon (KR), Ji Hyang Kim, Soo Yeon Kim, KyuBeom Kwack, Tae Ki Yoon, Dong Hee Choi, Nam Keun Kim\*
- P-WE-358 HORMONAL THERAPY (HT) ASSOCIATED THROMBOEMBOLISM. RETROSPECTIVE ANALYSIS OF 81 CASES AND LONG TERM FOLLOW UP, EXPERIENCE FROM A SINGLE CENTER**  
Emmanuel Papadakis\* (GR), Anastasia Spyrou, Eleni Gatsa, Konstantina Tsimirika, Konstantinos Loukidis, Elissavet Georgiou, Smaragda Efraimidou, Parthena Kapali, Anna Kioumi, Ioannis Korantzis, Georgia Papaioannou
- P-WE-359 THROMBIN GENERATION PROFILES AND ASSOCIATION WITH OBESITY AND INFLAMMATION IN WOMEN WITH VTE**  
Kristina Sonnev\* (SE), Svetlana Tchaikovski, Margareta Holmstrom, Katarina Bremme, Jan Rosing, Gerd Larfars



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

**P-WE-360 HAPLOTYPE-BASED ASSOCIATION OF ACE, AT1R, AND AGT POLYMORPHISMS IN RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM GENES IN IDIOPATHIC RECURRENT SPONTANEOUS ABORTIONS**

Yi Seul Choi (KR), Hwang Kwon, Young Joo Jeon, Tae Ki Yoon, Dong Hee Choi, Doyeun Oh, Nam Keun Kim\*

### Atrial fibrillation and thrombosis

**P-WE-361 UNDERUSE OF ORAL ANTICOAGULANTS IN ISCHEMIC STROKE PATIENTS WITH ATRIAL FIBRILLATION**

Birsen Ince\* (TR), Gulcin Benbir, Feray Bolukbasi

**P-WE-362 INFLUENCE OF CARDIAC FUNCTION ON THE HEMOSTATIC STATUS OF PATIENTS WITH CARDIOEMBOLIC STROKE UNDERGOING ANTICOAGULANT THERAPY**

Takehiko Nagao\* (JP), Hideki Takubo, Yasuo Katayama, Shin-ichiro Uchiyama

**P-WE-363 RACE/ETHNICITY BUT NOT SOCIOECONOMIC STATUS IS A STRONG AND INDEPENDENT RISK FACTOR FOR INCIDENT ATRIAL FIBRILLATION IN WOMEN**

David Conen\* (CH), Julie E Buring, Brendan M Everett, Michelle A Albert, Christine M Albert

**P-WE-364 CHRONIC KIDNEY DISEASE IN PATIENTS WITH ATRIAL FIBRILLATION; A DIFFICULTY FOR THE TREATMENT WITH THE NEW ORAL ANTITHROMBOTIC AGENTS?**

Judith Kooiman\* (NL), Wilke van de Peppel, Felix JM van der Meer, M V Huisman

**P-WE-365 BRIDGING LOW MOLECULAR WEIGHT HEPARIN DURING WARFARIN INITIATION IN PATIENTS WITH ATRIAL FIBRILLATION**

Scott Kaatz\* (US), Abdallah Kobeissy, Geoffrey D Barnes, Xiaokui Gu, Leaden Hickman, Steven Almany, Jay Kozlowski, Dennis Besley, Marcella Novakosky, Thomas Leyden, James B Froehlich

**P-WE-366 EFFECT OF AMIODARONE ON THE TIME IN THERAPEUTIC INR RANGE FOR PATIENTS INITIATED ON WARFARIN, RESULTS OF THE MICHIGAN ANTICOAGULATION QUALITY IMPROVEMENT INITIATIVE (MAQI2)**

Scott Kaatz\* (US), Abdallah Kobeissy, Geoffrey D Barnes, Xiaokui Gu, Leaden Hickman, Steven Almany, Jay Kozlowski, Dennis Besley, Marcella Novakosky, Thomas Leyden, James B Froehlich

**P-WE-367 CAN THE CHADS2 SCORE PREDICT POSTOPERATIVE STROKE RISK IN PATIENTS WITH CHRONIC ATRIAL FIBRILLATION WHO ARE HAVING ELECTIVE NON-CARDIAC SURGERY?**

Scott Kaatz\* (US), James D Douketis, Richard H White, Hong Zhou

**P-WE-368 BRIDGE TRIAL: BRIDGING ANTICOAGULATION IN PATIENTS WHO REQUIRE TEMPORARY INTERRUPTION OF WARFARIN FOR ELECTIVE SURGERY/PROCEDURE: DESIGN, RATIONALE AND CLINICAL IMPLICATIONS**

Alex Spyropoulos (CA), James Douketis\*, Scott Kaatz, Tom Ortel

### Cancer and thrombosis

**P-WE-369 DISCUSSION OF THE CORRELATION BETWEEN JAK2V617F MUTATION AND THROMBOEMBOLISM IN MYELOPROLIFERATIVE NEOPLASM PATIENTS**

Liang Xia\* (CN), Jing-sheng Wu, Kai-yang Ding, Qing-shub Zeng, Xiao-yan Cai, Wei-bo Zhu, Lin-lin Wu, Xin Liu, Hui-zhi Yang



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-370 A THROMBOELASTOGRAPHY STUDY TO EVALUATE THE EFFECT OF THROMBOCYTOPENIA ON CLOT FORMATION IN THE PRESENCE OF UNFRACTIONATED HEPARIN**  
Lih Yeen Tan\* (CA), Mohammed S. Almakadi, Anthony K.C. Chan, Howard H.W. Chan
- P-WE-371 THE INCIDENCE AND PROGNOSTIC IMPLICATIONS OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH COLORECTAL CANCER**  
Keun-Wook Lee\* (KR), Seyoun Choi, Soo-Mee Bang, Jeong-Ok Lee, Yu Jung Kim, Jee Hyun Kim, Duck-Woo Kim, Sung-Bum Kang, Jong Seok Lee
- P-WE-372 ANTICOAGULANT THERAPY IN PATIENTS WITH THROMBOCYTOPENIA: A SYSTEMATIC REVIEW OF CASE SERIES IN MEDICAL LITERATURE**  
Mohammed Almakadi\* (CA), Anthony K.C. Chan, Howard H.W. Chan
- P-WE-373 INCIDENCE OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH COLORECTAL CANCER UNDERGOING LAPAROSCOPIC SURGERY**  
Cecilia Becattini\* (IT), Maria Cristina Vedovati, Fabio Rondelli, Michela Boncompagni, Giuseppe Camporese, Enrico Mariani, Giovanni Natalini, Giancarlo Agnelli
- P-WE-374 THE CPS DISC CENTRIFUGE: A NEW ORIGINAL METHOD TO DETECT MICROPARTICLES (MPS)**  
Julie Hardij\* (BE), Jorge Mejia, Damien Gheldof, Emilie Varin, Carine Michiels, Francois Mullier, Stephane Lucas, Bernard Chatelain, Jean-Michel Dogne
- P-WE-375 THROMBOTIC COMPLICATIONS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)**  
Monica S Martinez\* (AR), Alejandra Costa, Fernanda Cuello, Virginia Schuttemberg, Liliana Alba, Marcela Aznar, Ramiro Fernandez, Sandra Formisano, Sandra Arguello, Sergio Gomez, Luis Pistaccio, Alcira Fynn
- P-WE-376 CHARACTERISTICS OF CANCER ASSOCIATED AND NON-CANCER ASSOCIATED VENOUS THROMBOEMBOLISM (VTE) AMONG ADULTS OBTAINING CARE AT US THROMBOSIS AND HEMOSTASIS CENTERS**  
Claire S Philipp\* (US), Imran Khan, Ambarina Faiz, Michele G Beckman, Kristy M Kenney, Paula Bockenstedt, John A Heit, Roshni Kulkarni, Marilyn Manco-Johnson, Stephan Moll, Thomas L Ortel
- P-WE-377 THE APPLICATION OF CLINICAL VARIABLES AND MODELS TO PREDICT PULMONARY EMBOLISM (PE) IN CANCER PATIENTS. A COMPREHENSIVE CANCER CENTER EXPERIENCE.**  
Hikmat N. Abdel-Razeq\* (JO), Asem H Mansour, Yousef M Ismael, Rim N Turfa, Mahmoud A Abu Nasser, Hussain A Abu Ali
- P-WE-378 A NATION-WIDE ANALYSIS OF VENOUS THROMBOEMBOLISM IN 497,180 CANCER PATIENTS WITH THE DEVELOPMENT AND VALIDATION OF A RISK-STRATIFICATION SCORING SYSTEM**  
Yuan-Bin Yu\* (TW), Jyh-Pyng Gau, Chun-Yu Liu, Muh-Hwa Yang, Shu-Chiung Chiang, Hui-Chi Hsu, Ying-Chung Hong, Liang-Tsai Hsiao, Jin-Hwang Liu, Tzeon-Jye Chiou, Po-Min Chen, Tzong-Shyuan Lee, Li-Fang Chou, Cheng-Hwai Tzeng, Tzeng-Ji Chen
- P-WE-379 A MODIFIED KHORANA RISK SCORE MODEL FOR VENOUS THROMBOEMBOLISM IN AMBULATORY CANCER PATIENTS RECEIVING CHEMOTHERAPY: THE PROTECT SCORE**  
Melina Verso\* (IT), Giancarlo Agnelli, Roberto LaBianca, Giampietro Gasparini, Sandro Barni, Erminio Bonizzoni, Matteo Brighenti, Mario Mandala, Fausto Petrelli, Carlo Bianchini, Tania Perrone

Wednesday Posters



43



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-380 NOVEL THROMBOGENIC BIOMARKERS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (R-MM) TREATED WITH LENALIDOMIDE (LEN) AND DEXAMETHASONE (DEX) THERAPY**  
Kate L Burbury\* (AU), Peter Gambell, Amanda Choo, Caroline Reddel, Kevin Lynch, H Miles Prince, Hang Quach, Simon Harrison, David Ritchie, Jennifer Curnow, David Westerman
- P-WE-381 ANTICOAGULANT PROPERTIES OF CURCUMIN**  
Severine Robert\* (BE), Philippe Devel, Francois Mullier, Bernard Chatelain, Lionel Pochet, Fabian Priem, Jean-Michel Dogne
- P-WE-382 MICROPARTICLE-ASSOCIATED TISSUE FACTOR ACTIVITY, VENOUS THROMBOSIS AND POOR SURVIVAL IN PANCREATIC CANCER PATIENTS**  
Patricia Garcia Rodriguez\* (NL), Margot E Tesselaar, Fred P Romijn, Irma K van der Linden, Rogier M Bertina, Susanne Osanto

### Pediatric thrombosis

- P-WE-383 THROMBOSIS IN NEWBORNS WITH HOMOZYGOUS ANTITHROMBIN DEFICIENCY**  
Katarina Zervan\* (AT), Katharina Thom, Christine Mannhalter, Christoph Male
- P-WE-384 A PREDICTION MODEL FOR THROMBOSIS RISK IN CHILDHOOD CANCER PATIENTS**  
Lesley G Mitchell\* (CA), Jacqueline Halton, Maria Spavor, Evelyn Sharek, Sara Israels, Kevin Dietrich, Cheri Roberts, Sharon Abish, Qu Liu, Yutaka Yasui
- P-WE-385 RISK FACTORS FOR THE DEVELOPMENT OF IN-HOSPITAL VENOUS THROMBOEMBOLISM IN CHILDREN: A CASE-CONTROL STUDY EMPLOYING DIAGNOSTIC VALIDATION**  
Brian R Branchford\* (US), Peter Mourani, Lalit Bajaj, Marilyn Manco-Johnson, Michael Wang, Neil Goldenberg
- P-WE-386 THROMBOSIS IN THAI INFANTS AND CHILDREN: 5 YEARS PROSPECTIVE COHORT STUDY**  
Darintr Sosohtikul\* (TH), Piti Techavichit, Yodkwan Aphikulchatkit, Viroj Pongpanlert, Panya Seksarn
- P-WE-387 COMPARISON OF BONE MINERAL DENSITY IN POST-FONTAN CHILDREN: ASPIRIN VS. WARFARIN**  
Chengde Pham\* (AU), Paul Monagle, Fergus Cameron, Sue Kantor, Fiona Newall
- P-WE-388 NON-HAEMATOLOGICAL EFFECTS OF UNFRACTIONATED HEPARIN IN NEONATES**  
Fiona Newall\* (AU), Eliza Mertyn, Paul Monagle
- P-WE-389 INBORN PROTEIN C DEFICIENCY CASE IN NEWBORN**  
Nadezda A. Vorobyeva\* (RU), Alyona I. Vorobyeva, Elena V. Tsyganova, Andrei I. Lobanov, Tatyana A. Kosix, Petr A. Lavrinov
- P-WE-390 INTRACARDIAC THROMBOSIS IN NEONATES. CASE REPORTS.**  
Pavel Svirin\* (RU), A.Y. Perepyolkina, I.I. Ryumina, I.V. Orlovskaya, N.V. Yevteeva, V.V. Vdovin
- P-WE-391 EFFECTIVE TREATMENT OF BOY WITH EXTRAHEPATIC PORTAL HYPERTENSION AND RECURRENT THROMBOSIS OF PORTAL-SYSTEMIC SHUNT WITH PROTEIN C. CASE REPORT.**  
Pavel Svirin\* (RU), L.E. Larina, G.A. Sukhanova, Y.V. Averianova, V.V. Vdovin
- P-WE-392 BODY MASS INDEX AND THROMBOEMBOLISM IN CHILDREN WITH HEMATOLOGICAL MALIGNANCIES**  
Ruta Tuckuviene\* (DK), Trishana Nayiager, Anthony Chan, Uma Athale



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-393 CONTINUOUS INTRAVENOUS ENOXAPARIN THERAPY IN TREATMENT OF SEVERE ARTERIAL AND VENOUS THROMBOTIC COMPLICATIONS IN PEDIATRIC AND ADULT PATIENTS**  
Hans-Joerg Hertfelder\* (DE), Beatrix Wiebe, Christian Rabe, Frauke Verrel, Eckfried Hoebert, Martin Schneider, Michael Ehlen, Tilmann Sauerbruch, Peter Bartmann, Johannes Oldenburg, Andreas Mueller
- P-WE-394 CENTRAL VENOUS LINE RELATED NON-OCCLUSIVE THROMBOSIS IN CHILDREN-DO WE HAVE TO TREAT?**  
Suzan Williams\* (CA), Viola van Eimeren, Leo Brandao, Walter Kahr
- P-WE-395 THE FIRST NATIONAL SURVEY OF PEDIATRIC THROMBOEMBOLISM IN JAPAN**  
Akira Ishiguro\* (JP), Masashi Taki, Atsushi Manabe, Chitose Ogawa, Midori Shima
- P-WE-396 VALIDATION OF THE SCORING SYSTEM FOR THE KIDCLOT PAC QL; A NOVEL APPROACH**  
Aiko MD Bruce\* (CA), M Patricia Massicotte, Mary Bauman

### Microparticles

- P-WE-397 MICROPARTICLES CARRY ACTIVE TISSUE FACTOR AND FIBRINOLYTIC FACTORS IN ACUTE PROMYELOCYTIC LEUKEMIA AND ARE MOSTLY DERIVED FROM MYELOID CELLS**  
Hau C Kwaan\* (US), Eduardo M Rego, Brandon McMahon, Ivy Weiss, James Marvin
- P-WE-398 NEUTROPHILS AS WELL AS MONOCYTES PHAGOCYTOSE PLATELET REMNANTS AND DAMAGED ENDOTHELIAL CELLS IN PATIENTS WITH ACUTE CORONARY SYNDROME**  
Mathie Leers\* (NL), Jeffrey Keuren, Mark Huts, Hans Kragten, Asiong Jie
- P-WE-399 INCREASED LEVELS OF MONOCYTE AND ENDOTHELIAL DERIVED MICROPARTICLES EXPRESSING TISSUE FACTOR AND ALTERED FIBRIN NETWORK IN PATIENTS WITH GRAVES' DISEASE**  
Fariborz Mobarrez\* (SE), Mirna Abraham-Nordling, Inger Friberg, Aleksandra Antovic, Gun Jorneskog, Hakan Wallen
- P-WE-400 TISSUE-FACTOR BEARING, GLIAL AND ENDOTHELIAL DERIVED MICROPARTICLES IN PATIENTS WITH GLIOBLASTOMA MULTIFORME: A POSSIBLE CONTRIBUTION TO A PROTHROMBOTIC STATE**  
Maria Teresa Sartori\* (IT), Alessandro Della Puppa, Andrea Ballin, Claudia Maria Radu, Graziella Saggiorato, Elena Campello, Luca Spiezia, Domenico d'Avella, Giuseppe Cella, Paolo Simioni
- P-WE-401 PROCOAGULANT ACTIVITY OF MICROPARTICLES IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES**  
Karen A Breen\* (UK), K Parmar, BJ Hunt
- P-WE-402 MODULATION OF CIRCULATING MICROPARTICLE LEVEL ANALYSIS IN ELDERLY PATIENTS WITH ACUTE HIP FRACTURE TREATED WITH HEPARINS**  
Jawed Fareed\* (US), Humza Azam, Evangelos Litinas, William Hopkinson, Debra Hoppensteadt, Michael Lassen, Rakesh Wah
- P-WE-403 STAPHYLOCOCCUS AUREUS ACCELERATES THROMBIN GENERATION THROUGH INCREASED TISSUE FACTOR AND MICROPARTICLES IN WHOLE BLOOD**  
Zechariah Gideon Franks\* (US), Robert C Campbell, Guy A Zimmerman, Andrew S Weyrich, Matthew T Rondina

Wednesday Posters



45

## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-404 REQUIREMENT OF SEVERAL TECHNIQUES TO STUDY TISSUE-FACTOR BEARING MICROPARTICLES IN THROMBOSIS ASSOCIATED WITH BREAST CANCER**  
Francois Mullier\* (BE), Emilie Varin, Damien Gheldof, Julie Hardij, Severine Robert, Nicolas Bailly, Philippe Devel, Chantal Doyen, Christian Chatelain, Carine Michiels, Bernard Chatelain, Jean-Michel Dogne
- P-WE-405 PROCOAGULANT MICROPARTICLES AND THROMBIN GENERATION IN TRAUMA**  
Barbara AL Owen\* (US), Myung S Park, Robert S Litwiller, Claude Deschamps, Michael G Sarr
- P-WE-406 CELLULAR ORIGIN AND PROCOAGULANT ACTIVITY OF TISSUE FACTOR-EXPOSING MICROPARTICLES IN CANCER PATIENTS**  
Ankie Kleinjan\* (NL), Rene J. Berckmans, Anita N. Boing, Auguste Sturk, Harry R. Buller, Pieter W. Kamphuisen, Rienk Nieuwland

### Arterial vascular diseases

- P-WE-408 THE SPLEEN AS PROTECTOR AGAINST THE DEVELOPMENT OF CARDIOVASCULAR EVENTS AFTER TREATMENT OF HODGKIN LYMPHOMA**  
Hilde A.M. Kooistra\* (NL), J. C. Kluin-Nelemans, M. A.E. van der Kaaij
- P-WE-409 SERUM URIC ACID, BUT NOT RS7442295 POLYMORPHISM OF SCL2A9 GENE, PREDICTS TOTAL AND CARDIOVASCULAR MORTALITY IN SEVERE CORONARY ARTERY DISEASE**  
Nicola Martinelli\* (IT), Letizia Consoli, Laura Annarumma, Giovanni Malerba, Francesca Pizzolo, Simonetta Friso, Thomas Illig, Pier Franco Pignatti, Roberto Corrocher, Domenico Girelli, Oliviero Olivieri
- P-WE-410 PLATELET P-SELECTIN IS ASSOCIATED WITH TISSUE FACTOR EXPRESSION IN PLATELET-MONOCYTE AGGREGATES IN PATIENTS WITH PULMONARY HYPERTENSION**  
Christina Christersson\* (SE), Gerhard Wikstrom, Agneta Siegbahn
- P-WE-411 DELAYED INITIATION BUT PROLONGED THROMBIN GENERATION IN ACUTE ISCHEMIC STROKE**  
Ross Ian Baker\* (AU), Grace Gilmore, Rosa Szollosi, Matthew Cooper, James Thom, Graeme Hankey
- P-WE-412 INVESTIGATION ON THE RELATIONSHIP OF PROLACTIN LEVELS AND ARTERIAL THROMBOTIC DISEASE**  
Ning Tang\* (CN), Huijun Li, Jing Peng, Biyu Zhang
- P-WE-413 THALASSEMIA TRAIT AND ARTERIAL THROMBOEMBOLIC EVENTS: A SYSTEMATIC REVIEW AND A META-ANALYSIS OF THE LITERATURE**  
Francesco Dentali\* (IT), Erica Romualdi, Walter Ageno, Maria D Cappellini, Pier Mannuccio Mannucci
- P-WE-414 ROSUVASTATIN DECREASES SERUM LEVELS OF OXIDIZED LOW-DENSITY LIPOPROTEIN/BETA2-GLYCOPROTEIN I COMPLEX THROUGH THE NITRIC OXIDE PATHWAY IN DIABETES MELLITUS**  
Luis R Lopez\* (US), Eiji Matsuura, Joana Batuca, Ignacio Garcia De La Torre, Paul RJ Ames
- P-WE-415 CEREBRAL THROMBOEMBOLIC EVENTS IN PATIENTS WITH BETA-THALASSEMIA: A SYSTEMATIC-REVIEW**  
Mehran Karimi\* (IR), Sezaneh Haghpahanah



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

**P-WE-416 ASSOCIATION BETWEEN KINASE INSERT DOMAIN-CONTAINING RECEPTOR (KDR) GENE POLYMORPHISM AND HAPLOTYPES AND ISCHEMIC STROKE**

Nam Keun Kim\* (KR), Seung-Hun Oh, Kyung Tae Min, Young Joo Jeon, Hyun Sook Kim, Eun Kyung Park, Doyeun Oh, Ok Joon Kim, Hyun Seok Kim

**P-WE-417 GENETIC POLYMORPHISMS OF ENDOTHELIN-RELATED GENES ASSOCIATED WITH RISK OF CHRONIC KIDNEY DISEASE IN JAPANESE HYPERTENSIVES**

Mariko Banno\* (JP), Kei Kamide, Takeshi Horio, Toshiyuki Miyata, Yuhei Kawano

### Clinical trials and registries

**P-WE-418 A PHASE II STUDY OF ECUZUMAB IN PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) RECEIVING CHRONIC PLASMA EXCHANGE/INFUSION: INTERIM ANALYSIS**

Christoph Licht\* (CA), Petra Muus, Christophe Legendre, Kenneth Douglas, Maryvonne Hourmant, Yehsou Delmas, Maria Herthelius, Antonella Trivelli, Timothy Goodship, Camille Bedrosian, Chantal Loirat

**P-WE-419 ECUZUMAB IS EFFECTIVE IN PATIENTS RESISTANT TO PLASMA EXCHANGE/INFUSION WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)**

Camille Bedrosian\* (US), Sunil Babu, Richard Furman, Neil Sheerin, David Cohen, Osama Gaber, Frank Eitner, Yehsou Delmas, Chantal Loirat, Larry Greenbaum, Lothar Zimmerhackl, Christophe Legendre

**P-WE-420 CHARACTERISING VTE RISK, PROPHYLAXIS USE AND EXTENDED PROPHYLAXIS NEED IN HOSPITALISED VERSUS OUTPATIENT MEDICAL PATIENTS (STATUS REGISTRY)**

Sylvia Katharina Haas\* (DE), Knut Kroger, Vera Regitz-Zagrosek, Sebastian M Schellong, Rainer B Zotz, Carsten Kienitz

**P-WE-421 EVALUATION OF A SIMPLIFIED CLINICAL DECISION RULE (I-DVT) IN PATIENTS WITH A SUSPECTED ACUTE DEEP VEIN THROMBOSIS**

Melanie Tan\* (NL), Gerben C. Mol, Antonio Iglesias del Sol, Olaf M Dekkers, Frederikus A Klok, Marcel A van de Ree, Menno V Huisman

**P-WE-422 VENOUS THROMBOEMBOLISM RISK IN THE ACUTE OUTPATIENT CARE SETTING: RESULTS OF THE SURVEY FROM THE PROFIL STUDY IN POLAND**

Wojciech J. Sydor\* (PL), Jacek Musial, Grzegorz Oszkinis, Piotr Pruszczyk, Jerzy Windyga

**P-WE-423 ELECTRONIC ALERT DOES NOT INCREASE THE THROMBOPROPHYLAXIS USE IN THE ACUTE OUTPATIENT CARE SETTING: RESULTS OF THE PROFIL STUDY**

Wojciech Juliusz Sydor\* (PL), Jacek Musial, Grzegorz Oszkinis, Piotr Pruszczyk, Jerzy Windyga

**P-WE-424 META-EMBOL: A WEB-BASED APPLICATION PROVIDING DYNAMIC INTERACTIVE SYSTEMATIC REVIEWS AND META-ANALYSES OF CLINICAL TRIALS IN THE THROMBOSIS FIELD**

Silvy Laporte\* (FR), Celine Chapelle, Laurent Bertoletti, Michel Cucherat, Paul Zufferey, Carine Labruyere, Patrick Mismetti, Collaborators Meta-Embol

**P-WE-425 GUIDELINES FOR VENOUS THROMBOEMBOLISM (VTE) PREVENTION IN HOSPITALISED MEDICAL PATIENTS: A VALIDATION STUDY PILOT**

Nicola Helen Chapman\* (AU), Marissa N Lassere, Mary Clarke, Beng Hock Chong

Wednesday Posters



47

## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-426 VITAMIN K ANTAGONISTS (VKA) AND DRUG INTERACTIONS: A MULTICENTER PHARMACOVIGILANCE SYSTEM (FARMAMICO)**  
Sophie Testa\* (IT), Roberto Del Bono, Daria Bettoni, Giuliana Martini, Volpi Roberta, Oriana Paoletti, Anke Zimmermann, Catia Barosi, Anna Falanga, Simona Pedrini, Maria Bertoli, Lidia Rota, Emilia Lelli, D. Paganotti
- P-WE-427 IMPACT OF PHARMACOKINETIC (*CYP2C9*) AND PHARMACODYNAMIC (*VKORC1*, *GGCX*, *CALU*, *EPHX1*, *F7*, *PROC*) GENE VARIANTS ON PHENPROCOUMON THERAPY**  
Christof Geisen\* (DE), Beate Luxembourg, Matthias Watzka, Katja Sittinger, K. Schneider, Stefan W Toennes, Milka Marinova, Nicolas von Ahsen, Edelgard Lindhoff-Last, Erhard Seifried, Johannes Oldenburg

### Post-thrombotic syndrome

- P-WE-428 INFLAMMATION AND PERIPHERAL VEIN DISEASE: THE SAN DIEGO POPULATION STUDY**  
Mary Cushman\* (US), Peter W Callas, Julie O Denenberg, Michael H Criqui
- P-WE-429 ERYTHROCYTE DERIVED MICROPARTICLES AND PROCOAGULANT PHOSPHOLIPIDS INDUCE ACCELERATION OF THROMBIN GENERATION IN PATIENTS WITH STEADY STATE SICKLE CELL ANEMIA**  
Grigoris Gerotziafas (FR), Mourad Chaari, Patrick Van Dreden, Barry Woodhams\*, Francois Lionel, Robert Giro, Vasso Galea, Ismail Elalamy
- P-WE-430 EARLY USE OF COMPRESSION STOCKINGS FOLLOWING DEEP VEIN THROMBOSIS IS ASSOCIATED WITH REDUCED EARLY INCIDENCE OF POST-THROMBOTIC SYNDROME AND IMPROVED QUALITY OF LIFE**  
Lara N Roberts\* (UK), Raj K Patel, Lynda Bonner, Roopen Arya
- P-WE-431 INDIVIDUALLY TAILORED ELASTIC COMPRESSION THERAPY AND POST THROMBOTIC SYNDROME, A RANDOMIZED MULTICENTRE TRIAL (IDEAL DVT STUDY)**  
Arina J ten Cate-Hoek\* (NL), M Joore, K Hamulyak, J Veraert, M H Prins, H ten Cate

### Innovative therapies for thrombotic disorders

- P-WE-432 CROSS REACTIVITY OF RABBIT ANTI-RECOTHROM (HUMAN RECOMBINANT THROMBIN) WITH MOLECULAR VARIANTS OF HUMAN THROMBIN AND BOVINE THROMBIN PREPARATIONS**  
Nasir Sadeghi\* (US), He Zhu, Debra Hoppensteadt, Indermohan Thethi, Rakesh Wahi, Jawed Fareed
- P-WE-433 LASER-INDUCED SELECTIVE THROMBOLYSIS WITHOUT VESSEL DAMAGE IN THE RAT THROMBOSIS MODELS**  
Yuji Matsumoto\* (JP), Daisuke Yamashita, Yutaka Yamashita, Yoshiyuki Shimizu, Hiroyuki Okada, Teiji Nakayama, Kazuya Hokamura, Ayami Hori, Kazuo Umemura
- P-WE-434 THE INFLUENCE OF CARVEDILOL VERSUS METOPROLOL ON SYMPATHETIC ACTIVITY AND HEMOSTASIS IN PATIENTS WITH HEART FAILURE**  
Olav R De Peuter\* (NL), Wouter E Kok, Hein J Verberne, Bas van den Bogaard, Jasper Truijen, Marianna C Schaap, Rienk Nieuwland, Joost C Meijers, J A Verheul, C A De Groot, Ad Bakx, G A Somsen, Lizzy M Brewster, Harry R Buller, Pieter W Kamphuisen



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-435 REVERSAL OF RIVAROXABAN AND DABIGATRAN BY PROTHROMBIN COMPLEX CONCENTRATE: A RANDOMIZED, PLACEBO-CONTROLLED, CROSS-OVER STUDY IN HEALTHY SUBJECTS**  
Elise S Eerenberg\* (NL), Pieter W Kamphuisen, Meertien K Sijpkens, Joost CM Meijers, Harry R Buller, Marcel Levi
- P-WE-436 HIGH-DENSITY LIPOPROTEIN ACCELERATES DEGRADATION OF A BLOOD CLOT AS MEASURED BY THROMBOELASTOGRAPHY**  
Simone Talens\* (NL), Frank W.G. Leebeek, Dick C. Rijken
- P-WE-437 THE EFFECT OF RIVAROXABAN: A NEW FXA INHIBITOR ON ROUTINE HAEMOSTASIS ASSAYS**  
Lucy Hawkins (FR), Lucia Rugeri, Christophe Nougier, Christine Vinciguerra\*, Claude Negrier, Yesim Dargaud
- P-WE-438 THE EFFECT OF TOTAL HIP AND KNEE REPLACEMENT SURGERY AND DABIGATRAN ON THROMBIN GENERATION**  
Laura Green\* (UK), Andrew S Lawrie, Rahul Patel, Robert CM Stephens, Ian J Mackie, Andy Chitolie, Fares S Haddad, Samuel J Machin
- P-WE-439 INHALATIONAL USE OF ANTITHROMBOTIC AGENTS: EVIDENCE FOR USE**  
Kate Monagle\* (AU), Eliza Merten, Michele Hepponstall, Paul Monagle, Fiona Newall
- P-WE-440 ORAL, DIRECT FACTOR XA INHIBITOR FOR THROMBOPROPHYLAXIS AFTER TOTAL HIP REPLACEMENT**  
Maria Hulikova\* (SK), Ivan Stasko, Stefan Hulik, Janka Hulikova
- P-WE-441 EGF1-EGFP PROTEIN-CONJUGATED PEG-PLGA NANOPARTICLES ALLOW GENE DELIVERY INTO CEREBRAL INFARCTION REGIONS VIA INTRAVENOUS ADMINISTRATION**  
Wei Shi\* (CN), Yu Hu, Heng Mei, Jun Deng, Huafang Wang, Tao Guo, Chen Chen, Bo Zhang, Zhiqing Pang, Xinguo Jiang, Xuxia Wang, Hao Lei
- P-WE-442 ONSET OF PURPURA FULMINANS AND RAPID RESOLUTION OF SYMPTOMS BY ADMINISTERING PROTEIN C CONCENTRATE IN A HOMOZYGOUS PROTEIN C DEFICIENT PATIENT WITH ORAL ANTICOAGULATION**  
Hans-Joerg Hertfelder\* (DE), Derya Sivritas, Elke Odenthal, Rainer Woitas, Marcus Gorschluerer, Johannes Oldenburg
- P-WE-443 REVERSAL OF ANTICOAGULANT PROPERTIES OF ANTIXA AND ANTI IIA ANTICOAGULANT BY NON SPECIFIC HAEMOSTATIC DRUGS: AN EX VIVO STUDY IN HEALTHY VOLUNTEERS**  
Gilles Pernod\* (FR), Raphael Marlu, Adeline Paris, Enkelejda Hodaj, Pierre Albaladejo, Benoit Polack, Jean Luc Crackowski
- P-WE-444 ECULIZUMAB (ECU) THERAPY FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) IN PEDIATRIC PATIENTS: EFFICACY AND SAFETY OUTCOMES FROM A RETROSPECTIVE STUDY**  
Ralph Gruppo\* (US), N Rodig, R Vilalta, J Hernandez, J Camacho Diaz, A-L Lapeyraque, J Sherwinter, O Fremont, V Baudouin, GD Simonetti, C Langman
- P-WE-445 CALIBRATED CLOTTING AND CHROMOGENIC METHODS FOR MEASURING DABIGATRAN IN PLASMA**  
Marie PEYRAFITTE\* (FR), Joachim STANGIER, Jean AMIRAL

Wednesday Posters



49

## POSTER PRESENTATIONS

Wednesday, July 27, 2011

### von Willebrand factor

- P-WE-446 INFLUENCE OF ABH ANTIGEN ON CLEARANCE OF VON WILLEBRAND FACTOR IN VIVO**  
Dafna Groeneveld\* (NL), Ronella Wiegers, Pieter Reitsma, Jeroen Eikenboom
- P-WE-447 LIVER AND SPLEEN MACROPHAGE DEPLETION INCREASES THE PLASMA HALF-LIFE OF VON WILLEBRAND FACTOR**  
Dafna Groeneveld\* (NL), Bart van Vlijmen, Ka Lei Cheung, Ronella Wiegers, Pieter Reitsma, Jeroen Eikenboom
- P-WE-448 INFLUENCE OF ABH ANTIGEN ON CLEARANCE OF VON WILLEBRAND FACTOR IN MICE**  
Dafna Groeneveld\* (NL), Bart van Vlijmen, Ka Lei Cheung, Pieter Reitsma, Jeroen Eikenboom
- P-WE-449 REASSIGNMENT OF THE MODULAR ARCHITECTURE OF VON WILLEBRAND FACTOR: NOVEL STRUCTURAL INSIGHTS INTO THE NON-A REPEAT REGION REVEALING THE MAJOR FVIII BINDING REGION**  
Nuha Shiltagh\* (UK), D. Flemming Hansen, Keith Gomez, Stephen J Perkins, Edward GD Tuddenham
- P-WE-450 COMPREHENSIVE GENETIC STUDY OF TYPE 2 VON WILLEBRAND DISEASE IN IRANIAN PATIENTS**  
Maryam Rassoulzadegan\* (IR), Mohammad Jazebi, Shirin Ravanbod, Said Enayat, Ghasem Rastegar Lari, Fereydoun Ala
- P-WE-451 ESTABLISHMENT OF VON WILLEBRAND FACTOR STRINGS IN A NON-ENDOTHELIAL SYSTEM**  
Jiong-Wei Wang\* (NL), Karine M Valentijn, Jack A Valentijn, Biewke Dragt, Jan Voorberg, Pieter H Reitsma, Jeroen Eikenboom
- P-WE-452 DYNAMIC CHANGES IN VON WILLEBRAND FACTOR MULTIMERS REFLECT THE SEVERITY OF OBSTRUCTIVE SLEEP APNEA**  
Noriko Koyama\* (JP), Masanori Matsumoto, Shinji Tamaki, Masanori Yoshikawa, Yoshihiro Fujimura, Hiroshi Kimura
- P-WE-453 CONVERSION OF VON WILLEBRAND FACTOR INTO ITS GLYCOPROTEIN IB-BINDING CONFORMATION INDUCES BINDING AND UPTAKE BY MACROPHAGES**  
Bas de Laat\* (NL), Y.P. Wu, B. Zhang, S.F. Chen, Y.T. Wang, G.Y. Li, H.Q. Gao, Ph.G. de Groot
- P-WE-454 PRE-CLINICAL TESTING OF HUMAN RECOMBINANT VON WILLEBRAND FACTOR: ADAMTS13 CLEAVAGE CAPACITY IN ANIMALS AS CRITERION FOR SPECIES SUITABILITY**  
Eva Maria Muchitsch\* (AT), Barbara Dietrich, Hanspeter Rottensteiner, Wilfried Auer, Herbert Gritsch, Hartmut Ehrlich, Peter Turecek, Friedrich Scheiflinger, Hans Peter Schwarz
- P-WE-455 FUNCTIONAL IN VIVO ANALYSIS OF VON WILLEBRAND FACTOR O-GLYCOSYLATIONS**  
Cecile V Denis\* (FR), Idinath Badirou, Julie Rayes, Paulette Legendre, Peter J Lenting, Olivier D Christophe, Cecile V Denis
- P-WE-456 GALECTINS INFLUENCE VON WILLEBRAND FACTOR STRING ASSEMBLY AT THE ENDOTHELIAL SURFACE**  
Peter Lenting\* (FR), Beatrijs D Oortwijn, Soline Odouard, Philip G de Groot, Cecile V Denis



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

### von Willebrand disease

- P-WE-457 THE DIAGNOSIS AND MANAGEMENT OF VON WILLEBRAND DISEASE (VWD) ASSOCIATED ANGIODYSPLASIA**  
Michael Makris\* (UK), Augusto Federici, Thynn T Yee, Tom Abshire, Eric Berntorp, Pier M Mannucci
- P-WE-458 IDENTIFICATION AND FUNCTIONAL STUDIES OF A NOVEL VON WILLEBRAND FACTOR MUTATION IN A FAMILY WITH TYPE 2A VON WILLEBRAND DISEASE**  
Jing Dong\* (CN), Xiaojuan Zhao, Qingyu Wu, Changgeng Ruan, Ningzheng Dong
- P-WE-459 USE OF RECOMBINANT FACTOR VIIA PLUS CONTINUOUS INFUSION OF RECOMBINANT FACTOR VIII IN THE HEMOSTASIS OF TYPE 3 VON WILLEBRAND DISEASE WITH ANAPHYLACTIC ANTI-VWF INHIBITOR**  
Nobuaki Suzuki\* (JP), Naomi Sanda, Tadashi Matsushita, Tetsuhito Kojima, Koji Yamamoto, Akira Katsumi, Kanji Hirashima, Youko Kajjura, Mayumi Takatsu, Tomoki Naoe
- P-WE-460 RESPONSE TO DESMOPRESSIN IN VON WILLEBRAND DISEASE MONITORED BY PFA-100**  
Teresa Agata Iwaniec\* (PL), Joanna Zdziarska, Zbigniew Walter, Aleksander Skotnicki, Jacek Musial
- P-WE-461 IDENTIFICATION OF THE ELUSIVE MUTATION CAUSING THE HISTORICAL VON WILLEBRAND DISEASE TYPE IIC MIAMI**  
Reinhard Schneppenheim\* (DE), Marlies Ledford-Kraemer, Jean-Maurice Lavergne, Rolf Marschalek, Robert Montgomery, Tobias Obser, Florian Oyen, J. Evan Sadler, Sonja Schneppenheim, Ulrich Budde
- P-WE-462 LONG-TERM SECONDARY PROPHYLAXIS FACTOR REPLACEMENT THERAPY WITH WILATE IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH VON WILLEBRAND DISEASE**  
Susan Halimeh\* (DE), Anne Kruempel, Hannelore Rott, Ulrich Budde, Britta Faeser, Ulrike Nowak-Goettl
- P-WE-463 THALIDOMIDE PLUS VWF/FVIII PROPHYLAXIS AS A SUCCESSFUL TREATMENT FOR REPEATED INTESTINAL BLEEDING IN A PATIENT WITH VON WILLEBRAND DISEASE.**  
Alexander Wild\* (SK), Erika Cellarova, Vladislav Volek, Viera Stulajterova, Elena Balintova, Anna Vallova
- P-WE-464 STANDARDIZED BLEEDING SCORING SYSTEM AND PLATELET FUNCTION ANALYZER IN DIAGNOSIS OF PATIENTS WITH VON WILLEBRAND DISEASE: A SURVEY FROM A SINGLE CENTRE (THE BRNO-VWD STUDY)**  
Petr Smejkal\* (CZ), Ondrej Zapletal, Alain Gadisseur, Inge Vangenechten, Jirina Zavrelova, Jan Blatny, Jan Jacques Michiels, Miroslav Penka
- P-WE-465 GENOTYPE-PHENOTYPE CORRELATION IN VON WILLEBRAND DISEASE**  
Hamideh Yadegari\* (DE), Julia Driesen, Anna Pavlova, Helena Dermer, Inga Schuering, Hans-Joerg Hertfelder, Johannes Oldenburg
- P-WE-466 EFFICACY AND SAFETY EVALUATION IN CHILDREN WITH VWD FOLLOWING PRODUCT SWITCH TO A NEW GENERATION HIGH PURITY, DOUBLE VIRUS INACTIVATED VWF/ FVIII CONCENTRATE**  
Kate Khair\* (UK), Mary Mathias, Ri Liesner





## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-467 GYNECOLOGICAL & OBSTETRICAL EVENTS FROM A FRENCH POST -MARKETING SURVEY OF A VON WILLEBRAND FACTOR CONCENTRATE WITH A LOW FACTOR VIII CONTENT**  
Annie Borel-Derlon\* (FR), Jenny Goudemand, Catherine Boyer-Neumann, Segolene Claeysens, Marie-Anne Bertrand, Group Post-Marketing Study, Celine Henriet, Catherine Chatelanaz, Francoise Bridey
- P-WE-468 PREGNANCY IN PLATELET-TYPE VWD: A CASE SERIES**  
David O'Connor\* (UK), Will Lester, Sara Willoughby, Jonathan T Wilde
- P-WE-469 MANAGEMENT OF JOINT REPLACEMENT SURGERY WITH A VON WILLEBRAND FACTOR PRODUCT WITH A LOW FVIII CONTENT IN VON WILLEBRAND DISEASE PATIENTS**  
Annie Borel-Derlon\* (FR), Augusto.B Federici, Jenny Goudemand, Valerie Roussel-Robert, Group Post-Marketing Study, Catherine Chatelanaz, Celine Henriet, Francoise Bridey
- P-WE-470 CHARACTERISATION OF VON WILLEBRAND FACTOR A1 DOMAIN MUTANTS 1416N AND I1416T: APPLICATION OF FLOW-BASED PLATELET ADHESION ASSAYS**  
Thomas McKinnon\* (UK), Agata Nowak, Anna Goyder, Anne Riddell, Mike Laffan, Carolyn Millar

### TTP and related disorders

- P-WE-473 TREATMENT OF THROMBOTIC THROMBOCYTOPENIC PURPURA AND HEMOLYTIC UREMIC SYNDROME IN SERBIA: CLINICAL EXPERIENCE WITH 28 PATIENTS**  
Dragica A Vucelic\* (RS), Danijela Mikovic, Nebojsa Savic, Zoran Rajic, Slobodan Obradovic, Dragana Jevtic
- P-WE-474 SURVIVAL, RELAPSE AND OUTCOME IN PATIENTS WITH IDIOPATHIC THROMBOTIC THROMBOCYTOPENIC PURPURA: A SINGLE CENTER EXPERIENCE**  
Marc Heizmann\* (CH), Johanna A. Kremer Hovinga, Ramona O. Merki, Mario J. Bargetzi
- P-WE-475 ANTI-ADAMTS13 INHIBITOR BOOSTING WITH PLASMA EXCHANGE IN ACQUIRED TTP: CHARACTERIZATION OF INHIBITORS AND EFFICIENT TREATMENT WITH RITUXIMAB**  
Ayami Isonishi\* (JP), Barbara Plaimauer, Friedrich Scheiflinger, Kenji Nishio, Mitsuhiro Uchiba, Yuji Yonemura, Masanori Matsumoto, Yoshihiro Fujimura
- P-WE-476 ESTIMATED PATIENT NUMBER OF CONGENITAL ATYPICAL HUS WITHIN A TMA PATIENT REGISTRY ACROSS JAPAN: A REGISTRY OF NARA MEDICAL UNIVERSITY**  
Masaki Hayakawa\* (JP), Masanori Matsumoto, Yoko Yoshida, Ayami Isonishi, Seiji Kato, Yoshihiro Fujimura
- P-WE-477 SIZE OF VWF MULTIMERS, MODULATED BY THERAPEUTIC REGIMENS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION, DETERMINE AN ADVERSE REACTION TO BLEEDING OR THROMBOTIC MICROANGIOPATHY**  
Masanori Matsumoto\* (JP), Kayo Yamada, Keiko Nakayama, Ayami Isonishi, Masaki Hayakawa, Masami Inoue, Keisei Kawa, Yoshihiro Fujimura
- P-WE-478 MEASURING ADAMTS-13 ACTIVITY: A COMPARISON OF FRET AND ELISA METHODS USING THREE COMMERCIALY AVAILABLE KITS**  
Ronda Crist\* (US), Nana K Sono-Koree, George M Rodgers, Kristi J Smock

### Laboratory tests

- P-WE-479 PERFORMANCE OF A NEW AUTOMATED VON WILLEBRAND FACTOR ACTIVITY ASSAY BASED ON GPIIb/IIIa BINDING\***  
Juergen Patzke\* (DE), Heidrun Muth, Matthias Wilkens, Reinhard Schneppenheim



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-480 THE EVALUATION OF A NEW VWF:CB KIT FOR QUANTITATIVE DETERMINATION OF VWF ACTIVITY FOR THE DIAGNOSIS OF VWD.**  
Kampta Sukhu\* (UK), Rhiannon Marr, James Beavis, David Keeling
- P-WE-481 CDNA CLONING AND EXPRESSION OF BOTROCETIN-LIKE PROTEIN**  
Taei Matsui\* (JP), Taei Matsui, Yukiyo Suzuki, Fumio Matsushita, Jiharu Hamako, Izumi Furuta, Youhei Nashimoto, Masanori Matsumoto, Yoshihiko Sakurai, Yoshihiro Fujimura
- P-WE-482 ADAPTATION OF THE VON WILLEBRAND FACTOR RISTOCETIN COFACTOR ASSAY (VWF:RCO) ON AN AUTOMATED COAGULATION ANALYZER USING AN IMMUNOLOGICAL TEST PRINCIPLE**  
Vanessa Chan\* (CA), William Brien, Cindy Ing
- P-WE-483 HIGH THROUGHPUT DETECTION OF VON WILLEBRAND'S DISEASE USING A NEW COAGULATION ANALYSER**  
Andrew S Lawrie\* (UK), Maria Teresa Canciani, Jessica Iseppi, Ian J Mackie, Samuel J Machin, Flora Peyvandi
- P-WE-484 VWF PROPEPTIDE - A USEFUL MARKER IN PATIENTS WITH VON WILLEBRAND DISEASE?**  
Annelie Siegemund\* (DE), Natalie Adam, Ute Scholz
- P-WE-485 AUTOMATED VON WILLEBRAND FACTOR RISTOCETIN COFACTOR ASSAY ON THE SYMEX CS2000I COAGULOMETER.**  
Shenbagapriya P\* (IN), Inbakumar David, kavitha ML, Srivastava Alok, Nair Sukesh Chandran

### Hemophilia

- P-WE-486 EFFECTIVENESS OF HAEMOPHILIA MEDICATION THERAPY ADHERENCE CLINIC (HMTAC) IN IMPROVING HOME-TREATMENT KNOWLEDGE IN A TERTIARY HOSPITAL**  
Shu Ping Wong\* (MY), Adibah Md Shariff, Jameela Sathar, Yeok Siew Lim
- P-WE-487 HIGH DOSAGE PROPHYLACTIC TREATMENT OF SEVERE PATIENTS WITH HAEMOPHILIA B**  
Olga Plyusch\* (RU), Maria Kumskova, Irina Velichko
- P-WE-488 QUALITY OF LIFE IN ADULT PATIENTS WITH HAEMOPHILIA. A SINGLE CENTRE EXPERIENCE FROM SWEDEN**  
Karin Lindvall\* (SE), Erik Berntorp, Sylvia von Mackensen
- P-WE-489 A FOUNDER EFFECT OF THE FACTOR 8 GENE TYR1680PHE MUTATION IN 52 PATIENTS WITH MODERATE SEVERE HAEMOPHILIA A**  
Anna Pavlova\* (DE), Laura Heinen, Philipp Westhofen, Benaz Pezeshkpoor, Simone Hasenmueller, Johannes Oldenburg
- P-WE-490 MORTALITY AND CAUSES OF DEATH AMONG HAEMOPHILIA PATIENTS IN THE WESTERN DANISH POPULATION**  
Peter Noerkjaer Laursen\* (DK), Catherine Rea, Benny Sorensen, Jorgen Ingerslev
- P-WE-491 HERO, AN INTERNATIONAL INITIATIVE EXPLORING UNMET PSYCHOSOCIAL NEEDS IN HAEMOPHILIA: CHARACTERISTICS OF A QUANTITATIVE SURVEY TARGETING 1200 SUBJECTS IN 12 COUNTRIES**  
Alfonso Iorio\* (CA), Felipe Querol, Angela Forsyth, Frederica Cassis

Wednesday Posters



53

## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-492 HERO - AN INTERNATIONAL INITIATIVE EXPLORING UNMET PSYCHOSOCIAL NEEDS IN HAEMOPHILIA: RESULTS FROM A QUALITATIVE SURVEY TARGETING 150 SUBJECTS IN 7 COUNTRIES**  
Alfonso Iorio\* (CA), Frederica Cassis, Felipe Querol, Angela Forsyth
- P-WE-493 PSYCHOSOCIAL ASPECTS OF LIVING WITH HAEMOPHILIA: THE HERO PROJECT AND A NARRATIVE REVIEW OF THE PUBLISHED LITERATURE**  
Alfonso Iorio\* (CA), Angela Forsyth, Frederica Cassis, Felipe Querol
- P-WE-494 SPORADIC SEVERE HEMOPHILIA B IN NEW-BORN CHILD: STILL NOW A MISLEADING AND BELATED DIAGNOSIS.**  
Margaret Musso\* (IT), Anna Musso, Luca Maugeri, Luciano Messina, Roberto Musso
- P-WE-495 OUTCOMES OF MENTORED FELLOWSHIP TRAINING IN HEMOSTASIS/THROMBOSIS: FINDINGS FROM A NESTED CASE-CONTROL SURVEY STUDY OF THE NHF-BAXTER CLINICAL FELLOWSHIP, 2002-2010**  
Neil Goldenberg\* (US), Rebecca Kruse-Jarres, Neil Frick, Steven W Pipe, Leissing A Cindy, Craig M Kessler
- P-WE-496 EVALUATION OF A POPULATION PHARMACOKINETIC MODEL OF A RECOMBINANT FVIII (ADVATE) IN PATIENTS WITH HEMOPHILIA A USING EXTERNAL DATA**  
MyungShin Oh\* (US), Sven Bjorkman, Phillip Schroth, Sandor Fritsch, Peter W Collins, Kathelijjn Fischer, Victor S Blanchette, Kathleen Casey, Gerald D Spotts, Bruce M Ewenstein
- P-WE-497 PROFILE OF HEMOPHILIA IN MANADO**  
Stefanus Gunawan\* (ID), Juliawaty Salim, Max Mantik, Carel Eckmann, Anjo Veerman, Eveline Mauser-Bunschoten
- P-WE-498 ILIOPSOAS HEMATOMA IN PATIENTS WITH HEMOPHILIA: RESULTS FROM ONE BRAZILIAN CENTER.**  
Paula R Villaca\* (BR), Elbio A D'Amico, Jorge DA Carneiro, Erica Okasaki, Audrey K.Z. Valim, Eliane P.N. Sandoval, Dalton A.F. Chamone
- P-WE-499 VALIDATION OF THREE-DIMENSIONAL GAIT ANALYSIS FOR THE ASSESSMENT OF HEMOPHILIC LOWER LIMBS ARTHROPATHY**  
Sebastien Lobet\* (BE), Cedric Hermans, Christine Detrembleur
- P-WE-500 TWO DE NOVO FACTOR VIII MUTATIONS IN THE FAMILY OF AN ISOLATED HAEMOPHILIA A PATIENT**  
Zoey Kapsimali\* (GR), Anna Pavlova, Helen Pergantou, Eftychia Adamtziki, Johannes Oldenburg, Helen Platokouki
- P-WE-501 TREATMENT OF HAEMOPHILIA IN AUSTRIA: DATA FROM THE AUSTRIAN HAEMOPHILIA REGISTRY**  
Sylvia Kepa\* (AT), Sylvia Elisabeth Reitter, Werner Streif, Stefan Oberbichler, Christoph Male, Wolfgang Muntean, Ingrid Pabinger-Fasching
- P-WE-502 HOW DOES TRANSITION FROM ADOLESCENCE TO ADULTHOOD IMPACT ON THE HEALTH-RELATED QUALITY OF LIFE OF HAEMOPHILIA PATIENTS. RESULTS OF THE HYQOL-EUROPE STUDY**  
Sylvia von Mackensen\* (DE), Robert Klamroth, Alessandro Gringeri
- P-WE-503 MILD AND MODERATE HAEMOPHILIA A IN POLAND**  
Beata Baran\* (PL), Anna Pavlova, Ewa Stefanska-Windyga, Johannes Oldenburg, Jerzy Windyga
- P-WE-504 TREATMENT METHODS OF HAEMOPHILIA IN RUSSIAN FEDERATION**  
Olga Plyusch\* (RU), L. M. Kudryavceva



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-505 COMPREHENSIVE CARE FOR HEMOPHILIA IN SHIZUOKA CHILDREN'S HOSPITAL**  
Yasuo Horikoshi\* (JP), Taemi Ogura, Eriko Kakazu, Yasuko Abe, Nobuhiro Watanabe, Kazuko Kudo, Takashima Yoshihumi, Jun-ichi Mimaya
- P-WE-506 DISTRIBUTION OF N9-GP, A GLYCOPEGYLATED RECOMBINANT FIX DERIVATIVE - DETERMINED BY QUANTITATIVE WHOLE BODY RADIOGRAPHY (QWBA) AND IMMUNOHISTOCHEMICAL (IHC) STAINING.**  
Estelle Watson\* (DK), Jette Nowack, Lene Hansen, Mikael Tranholm, Phil Fernyhough, Hanne Kjaer Offenber
- P-WE-507 A RECURRENT F8 MUTATION (R2016W) IN A COHORT OF ITALIAN HAEMOPHILIA A PATIENTS: EVIDENCE FOR A FOUNDER EFFECT**  
Flora Peyvandi\* (IT), Mimosa Mortarino, Isabella Garagiola, Maria Elisa Mancuso, Elena Santagostino

### Hemophilia therapy

- P-WE-508 THE GREAT IMPORTANCE OF LOCAL BLEEDING CONTROL MEASURES IN PATIENTS WITH HEMOPHILIA AND INHIBITORS**  
Nebojsa Rajic\* (RS), Stevan Popovic, Aleksandar Savic, Ivanka Savic, Ivana Urosevic, Ivana Milosevic, Goran Marusic, Milan Popov, Aleksandar Knezevic, Branislav Bajkin
- P-WE-509 NEW APPROACH FOR PROPHYLACTIC TREATMENT OF SEVERE ADULT PATIENTS WITH HAEMOPHILIA A**  
Olga Plyusch\* (RU), Maria Kumskova, Konstantine Kopylov, Irina Velichko
- P-WE-510 VARIABLE ACTIVATION KINETICS OF DIFFERENT RECOMBINANT FULL LENGTH AND B DOMAIN DELETED FACTOR VIII CONCENTRATES**  
Anna Pavlova\* (DE), Saskia Pahl, Jens Mueller, Holger Brondke, Johannes Oldenburg
- P-WE-511 FACTOR XIII AS A HAEMOSTATIC AGENT IN SEVERE HAEMOPHILIA**  
Catherine J Rea\* (UK), Benny Sorensen
- P-WE-512 DOSING DECISIONS IN SEVERE HEMOPHILIA A: CAN WE AIM LOWER? FVIII USE IN A COHORT OF CANADIAN PATIENTS IN 2009.**  
Cecily Bos\* (CA), Anthony Chan, Kathryn Webert, Irwin Walker, Theresa Almonte, Kay Decker, Rebecca Goldsmith, Karen Strike, Linda Waterhouse
- P-WE-513 AN ANALYSIS OF FACTORS AFFECTING THE INCIDENCE OF INHIBITOR FORMATION IN PATIENTS WITH CONGENITAL HAEMOPHILIA IN JAPAN**  
Akira Shirahata (JP), Katsuyuki Fukutake, Satoshi Higasa, Junichi Mimaya, Toshiaki Oka, Midori Shima\*, Junki Takamatsu, Masashi Taki, Maiko Taneichi, Akira Yoshioka
- P-WE-514 ON-DEMAND TREATMENT OF BLEEDS IN HEMOPHILIA PATIENTS WITH INHIBITORS: STRATEGIES FOR SECURING AND MAINTAINING PREDICTABLE EFFICACY WITH RECOMBINANT ACTIVATED FACTOR VII**  
Benny Sorensen\* (UK), Yesim Dargaud, Gili Kenet, Jeanne Lusher, Andrew D Mumford, Steven Pipe, Andreas Tiede
- P-WE-515 BIOEQUIVALENCE OF B-DOMAIN DELETED AND PLASMA DERIVED FVIII CONCENTRATES**  
Massimo Morfini (IT), Alfonso Iorio\*, Maria Gabriella Mazzucconi, Sandro Cinotti, Ezio Zanon, E Paladino, Emanuela Marchesini, Cristina Santoro

Wednesday Posters



55

## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-516 PERIOPERATIVE HEMOSTATIC MANAGEMENT FOR COARCTATION OF AORTA IN AN EARLY INFANT WITH SEVERE HAEMOPHILIA A**  
Shoko Furukawa\* (JP), Hiroyuki Yoshizawa, Kenichi Ogiwara, Keiji Nogami, Katsumi Nishiya, Ichiro Tanaka, Yoshiro Yoshikawa, Midori Shima
- P-WE-517 PROCOAGULANT EFFECT OF TRANEXAMIC ACID WITH MINIMAL UROKINASE ON *EX VIVO* HUMAN HAEMOPHILIA MODEL UNDER BLOOD FLOW.**  
Kenichi Ogiwara\* (JP), Keiji Nogami, Kazuya Hosokawa, Tomoko Matsumoto, Midori Shima
- P-WE-518 BAXTER'S RECOMBINANT FACTOR VIIA: COMPARATIVE PRECLINICAL IMMUNOGENICITY ASSESSMENT USING NOVEL MOUSE MODELS**  
Frank Horling\* (AT), Christine Lenk, Raffi Uddin Ahmad, Markus Weiller, Maria Schuster, Hans-Peter Schwarz, Birgit M Reipert

### Inhibitors: pathogenesis, prevention and treatment

- P-WE-519 INTRACRANIAL BLEEDING IN PATIENTS WITH HAEMOPHILIA AND INHIBITORS**  
Maria Jose Paloma\* (ES), Victor Jimenez-Yuste, Maria Fernanda Lopez-Fernandez, Carmen Altisent, Ana Rosa Cid, Ramiro Nunez, Inmaculada Soto, Eva Mingot, Manuel Prieto, Carmen Sedano
- P-WE-520 REAL WORLD OUTCOMES ASSOCIATED WITH THE TREATMENT OF ACUTE BLEEDS WITH RFVIIA IN HAEMOPHILIA PATIENTS WITH INHIBITORS: RESULTS FROM THE INTERNATIONAL ONE REGISTRY**  
Elena Santagostino\* (IT), Herve Chambost, Kaan Kavakli, Mike Laffan, for the Steering Committee of the ONE Registry
- P-WE-521 SCREENING OF FVIII INHIBITORS IN HAEMOPHILIA A PATIENTS USING THE MODIFIED BETHESDA ASSAY IN THE WEST OF ALGERIA**  
Driss Benlaldj\* (DZ), Khedidja Moulasserdoun, Chakib Rahal, Fatima Seghier
- P-WE-522 INSIGHT IN TREATMENT OF INHIBITORS IN MILD AND MODERATE HAEMOPHILIA A**  
Alice S. van Velzen\* (NL), Alice S. van Velzen, Corien L. Eckhardt, Daniel P. Hart, Marjolein Peters, Johanna G. van der Bom, Thynn T. Yee, Karin Fijnvandraat
- P-WE-523 A SYSTEMATIC REVIEW AND META-ANALYSIS COMPARING THE EFFICACY OF BYPASSING AGENTS IN HAEMOPHILIA PATIENTS WITH INHIBITORS**  
Zheng-Yi Zhou\* (US), Joel W Hay
- P-WE-524 RISK FACTORS FOR INHIBITOR DEVELOPMENT IN PATIENTS WITH HAEMOPHILIA A: THE ROLE OF FACTOR VIII (FVIII) PRODUCT TYPE.**  
Maria Elisa Mancuso\* (IT), Pier Mannuccio Mannucci, Angiola Rocino, Isabella Garagiola, Annarita Tagliaferri, Caterina Di Perna, Elena Santagostino
- P-WE-525 TREATMENT OF PEOPLE WITH HAEMOPHILIA AND INHIBITORS IN MACEDONIA**  
Rumjana Apostolovska\* (MK), Violeta Dejanova, Violeta Neceva, Ivanka Nikoloska
- P-WE-526 SURGICAL INTERVENTIONS WITH FEIBA (SURF): AN INTERNATIONAL REGISTRY-BASED ANALYSIS OF SURGERY IN HAEMOPHILIA PATIENTS WITH INHIBITORY ANTIBODIES**  
Claude Negrier\* (FR), Murielle Pousse, Robert Numerof, Darby Stephens, Wing Yen Wong, Fariba Baghaei, Thynn Yee



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-527 INHIBITORS IN SEVERE HAEMOPHILIA A INCREASE ABOVE THE AGE OF 60 YEARS BUT ARE REDUCED BY HIV: A 20 YEAR FOLLOW UP STUDY FROM UK HAEMOPHILIA CENTRE DOCTORS' ORGANISATION**  
Peter W Collins\* (UK), Benjamin Palmer, Elizabeth Chalmers, Ri Liesner, Rhona Maclean, Savita Rajaragan, Michael Williams, Charles RM Hay
- P-WE-528 FACTOR VIII SUPPLEMENTATION IMPROVES HEMOPHILIA A THROMBIN GENERATION IN THE PRESENCE OF FVIII INHIBITORS AND RECOMBINANT FACTOR VIIA**  
Shannon L Meeks\* (US), Bagirath Gangadharan, Christopher B. Doering
- P-WE-529 THE FREQUENCY OF INHIBITORS IN HAEMOPHILIA A PATIENTS INCREASES IN SWEDEN**  
Frida Holmberg (SE), Pia Petrini, Rolf Ljung\*

### Inherited coagulation disorders (except for von Willebrand disease)

- P-WE-530 BLEEDING RISKS ASSOCIATED WITH INHERITED PLATELET DISORDERS: RESULTS FROM A PROSPECTIVE COHORT STUDY**  
Menaka Pai\* (CA), Grace Wang, Yang Liu, Emmy Arnold, Richard J. Cook, Kathryn E. Webert, Nancy M. Heddle, Catherine P.M. Hayward
- P-WE-531 A PROSPECTIVE COHORT STUDY OF BLEEDING SYMPTOMS AMONG PERSONS REFERRED TO HEMATOLOGISTS WHO ARE DIAGNOSED WITH OR EXCLUDED OF HAVING BLEEDING DISORDERS**  
Menaka Pai\* (CA), Grace Wang, Yang Liu, Emmy Arnold, Richard J. Cook, Kathryn E. Webert, Nancy M. Heddle, Catherine P.M. Hayward
- P-WE-532 THE MOLECULAR MECHANISM OF THE INHERITED FACTOR XII DEFICIENCY IN TWO UNRELATED FAMILIES**  
Zhifang Xing\* (CN)
- P-WE-533 A RETROSPECTIVE ANALYSIS OF 157 SURGICAL PROCEDURES PERFORMED WITHOUT REPLACEMENT THERAPY IN 83 FACTOR VII-DEFICIENT PATIENTS**  
Muriel Giansily-Blaizot\* (FR), Thibaut Mura, Fatma Benlakhel, Jean-Francois Schved, F S Group
- P-WE-534 PHE283LEU IN F11 IS ASSOCIATED WITH VARIABILITY OF FACTOR XI CLOTTING ACTIVITY IN DEFICIENT PATIENTS.**  
Despoina Adamidou\* (UK), Keith Gomez
- P-WE-535 FACTOR V DEFICIENCY DUE TO A FV P190S HOMOZYGOUS MUTATION, BUT NO BLEEDING TENDENCY**  
Keiko Shinozawa\* (JP), Kazuhisa Maeda, Kagehiro Amano, Masahiro Abe, Hiroshi Inaba, Katsuyuki Fukutake
- P-WE-536 TWO NOVEL MUTATIONS IN THE PROTHROMBIN GENE IDENTIFIED IN A PATIENT WITH COMPOUND HETEROZYGOUS TYPE 1/2 PROTHROMBIN DEFICIENCY, PRESENTING WITH A UMBILICAL CORD BLEEDING**  
Natasja Dors\* (NL), Daan van de Kerkhof, P Reitsma, Jacqueline van Sluijs, Feiko Halbertsma, Philip Kuijper
- P-WE-537 TWO CASES OF FACTOR V DEFICIENCIES CAUSED BY NOVEL MUTATIONS**  
Sue Jung Kim\* (KR), Kim Yoonjung, Song Jaewoo



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

### Acquired coagulation disorders

- P-WE-538 BITES BY YOUNG *BOTHROPS JARARACA* SNAKES PROVOKE MORE SEVERE HEMOSTATIC DISTURBANCES THAN THOSE INFLICTED BY ADULT SNAKES**  
Marcelo Larami Santoro\* (BR), Ida S Sano-Martins, Ceila MS Malaque, Hui W Fan
- P-WE-539 VARIABLE EFFICACY OF FONDAPARINUX AND RIVAROXABAN IN THE TREATMENT OF INTRAVASCULAR COAGULOPATHY ASSOCIATED WITH LARGE CONGENITAL VENOUS MALFORMATION**  
Jean-Baptiste Valentin\* (FR), Benedicte Delahousse, Denis Herbreteau, Ludovic Drouet, Yves Gruel
- P-WE-540 EFFICACY AND SAFETY OF PROTHROMBIN COMPLEX CONCENTRATE AND VITAMIN K IN A COHORT OF 76 PATIENTS WITH ANTICOAGULATION-RELATED ACUTE INTRACRANIAL HEMORRHAGE**  
Berardino Pollio\* (IT), Grazia Delios, Giorgia Matta, Gabriella Tomei, Marco Tucciarone, Gabriele Aitoro, Piercarla Schinco, Mauro Girotto
- P-WE-541 POTENTIAL BLEEDING LESIONS IN MULTIPLE TRAUMA. A PILOT STUDY**  
Manuel Quintana\* (ES), Milagros Marti, Sara Fabra, Isabel Casado, Inmaculada Pinilla, Ana Martinez Virto
- P-WE-542 EPIDEMIOLOGY OF ALLOGENEIC BLOOD TRANSFUSION IN THE EMERGENCY ROOM: A PILOT STUDY**  
Manuel Quintana\* (ES), Alberto Borobia, Sara Fabra, Begona Reche, N Medrano, H Tong, Ana Martinez
- P-WE-543 ARE WE DOING WELL THE ALLOGENEIC BLOOD TRANSFUSION IN EMERGENCY ROOM?.**  
Manuel Quintana\* (ES), Sara Fabra, Alberto Borobia, Begona Reche, Itziar Pozuelo, Camino Guallar, Pablo Millan, Ana Martinez Virto
- P-WE-544 A MAJOR HAEMORRHAGE PROTOCOL IMPROVES BLOOD PRODUCT ADMINISTRATION AND WASTAGE COMPARED TO TRADITIONAL MASSIVE TRANSFUSION PROTOCOLS**  
Sirat Khan\* (UK), Karim Brohi, Ross Davenport, Imran Raza, Joanna Manson, Anita West, Henry De'Ath, Catherine Spoors, Shubha Allard, Daniel Hart
- P-WE-545 LYOPHILISATION PRESERVE GLOBAL HEMOSTATIC CAPACITIES OF FRENCH FREEZED DRIED PLASMA**  
Sophie Susen\* (FR), Christophe Martinaud, Corinne Civadier, Anne Godier, Sylain Ausset, Anne Virginie Deshayes, Anne Saillol
- P-WE-546 OXIDATIVE MODIFICATION OF FIBRINOGEN DURING TRAUMATIC SHOCK: A PILOT STUDY**  
Nathan J White\* (US), Dominic Chung, Xiaoyun Fu, Jason Newton, Kevin Ward, Jose A Lopez
- P-WE-547 DILUTIONAL COAGULOPATHY FOLLOWING BLOOD TRANSFUSION IN TRAUMA**  
Imran Raza\* (UK), Ross Davenport, Karim Brohi, Claire Rourke, Sean Platton, Sirat Khan, Henry De'Ath, Catherine Spoors, Joanna Manson
- P-WE-548 SERIAL CHANGES IN CLOT STABILITY FOLLOWING CARDIAC SURGERY USING TRANEXAMIC ACID**  
Mariann Tang\* (UK), Kirsten Christiansen, Joergen Ingerslev, Jacob Greisen, Vibeke Hjortdal, Benny Soerensen



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

**P-WE-549 ENHANCED THROMBIN GENERATION IN CIRRHOTICS WITH COAGULOPATHY AND VARICEAL BLEEDING**

Paul Harrison\* (UK), Vipul Jairath, Amber Raja, Simon Stanworth, Jane Collier, Mike Murphy, Ellie Barnes

### Hemorrhagic disorders in children

**P-WE-550 COMPARISON BETWEEN THROMBOELASTOGRAPHY AND CONVENTIONAL CLOTTING TESTS AFTER CARDIO-PULMONARY BYPASS SURGERY (CPB) IN A PAEDIATRIC INTENSIVE CARE UNIT**

Simon J Davidson\* (UK), Judith Pekelharing, Duncan Macrae, Anke Furck

**P-WE-551 MILD VERSUS SEVERE HAEMOPHILIA A: THE DILEMMA OF AN UNDERESTIMATED DISEASE**

Christoph Bidlingmaier\* (DE), Susanne Knorr, Martin Olivieri, Karin Kurnik

**P-WE-552 IDENTIFICATION OF CHILDREN WITH SIGNIFICANT EPISTAXIS: COMPARISON OF THE KATSANIS ET AL EPISTAXIS SCORING SYSTEM AND THE PEDIATRIC BLEEDING QUESTIONNAIRE EPISTAXIS SCORE**

Catherine I Segbefia\* (GH), Tina T Biss, Dewi S Clark, Paula D James, Victor S Blanchette, Margaret L Rand

**P-WE-553 PROSPECTIVE VALIDATION OF TWO BLEEDING SCORES IN ONE HUNDRED CHILDREN INCLUDING THEIR FAMILIES**

Christoph Bidlingmaier\* (DE), Martin Olivieri, Ulrich Budde, Karin Kurnik

**P-WE-554 BODY CONTACT IN CHILDHOOD PHYSICAL ACTIVITY: RECOMMENDATIONS FOR CHILDREN PRONE TO BLEEDING INJURIES**

Leonardo Rodrigues Brandao\* (CA), Patricia E Longmuir, LiAnn Yap, Carolyn Bravo, Ban Lee, Brian W McCrindle, Leonardo R Brandao

**P-WE-555 RATIONALE FOR TAILORED PROPHYLAXIS WITH RECOMBINANT FVIIA IN SEVERE CONGENITAL FACTOR VII DEFICIENCY**

Amir Kuperman\* (IL), Tami Livnat, Andrei Braester, Nickol Amar, Gili Kenet

**P-WE-556 PERIPHERALLY INSERTED CENTRAL CATHETERS (PICC) IN CHILDREN WITH INHERITED BLEEDING DISORDERS: EXPERIENCE OF A SINGLE ITALIAN COMPREHENSIVE HEMOPHILIA CENTER**

Berardino Pollio\* (IT), Maria Messina, Roberto Albani, Cristina Mesiti, Mauro Pagliarino

**P-WE-557 THE LUPUS ANTICOAGULANT HYPOPROTHROMBINEMIA SYNDROME (LAHPS): A RARE BLEEDING DISORDER SEEN MOSTLY IN CHILDREN.**

Jonathan M Ducore\* (US), Brian Gablehouse, Douglas Taylor

**P-WE-558 THE ROLE OF THE HEMATOLOGIST IN THE ASSESSMENT OF HEMOSTASIS IN CHILDREN WITH SUSPECTED MALTREATMENT**

Lesleigh Selina Abbott\* (CA), Eileen McBride, Steven Bellemare, Amy Ornstein, Colleen O'Connell, Victoria Price

**P-WE-559 UTILITY OF THE PAEDIATRIC BLEEDING QUESTIONNAIRE AS A SCREENING TOOL IN CHILDREN REFERRED FOR EVALUATION OF A POSSIBLE BLEEDING DISORDER.**

Jeremy David Robertson\* (AU), Rebecca Mary Smith

**P-WE-560 THE BLOOD COAGULATION SYSTEM IN VERY LOW BIRTH WEIGHT INFANTS WITH HEMORRHAGIC MANIFESTATIONS IN THE EARLY NEONATAL PERIOD**

Leyla Alieva\* (RU), Albert Antonov, Alexander Mishchenko

Wednesday Posters



59



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-561 LOW RATE OF INHIBITORS IN PEDIATRIC COHORT OF INHERITED FACTOR DEFICIENCIES FROM 1990S TO 2010S**  
Phu-Quoc LE\* (BE), Caroline La, Thomas Reygaerts, Anne Demulder, Lambert Leenders, Catherine Heijmans, Sophie Huybrechts, Alina Ferster
- P-WE-562 ALGERIAN REGISTRY OF HEMOPHILIA : THE UPDATE STATUS**  
YASMINA BERKOUK-REDJIMI\* (DZ), HAKIM BRAHIMI, KARIMA WAFIA CHENNOUKH, MERIEM BENSADOK, FATIMA BENMEGHERBI, MERIEM FADILA BELHANI
- P-WE-563 COMBINED BLEEDING DISORDERS: EXPERIENCE AT A SINGLE HAEMOPHILIA TREATMENT CENTRE**  
Jayashree Motwani\* (UK), Bimal DM Theophilus, Andrea M Guillatt, Michael D Williams
- P-WE-564 CHALLENGES IN TREATING CHILDREN WITH SEVERE BLEEDING DISORDERS AND SEVERE AUTISM: A SINGLE CENTRE EXPERIENCE**  
Jayashree Motwani\* (UK), Dianne Marshall, Priscilla Nyatunga, Shaun Emitt, Leah Denver, Michael Williams

### Laboratory tests

- P-WE-565 PERIOPERATIVE POSSIBILITIES OF ROTATION THROMBELASTOMETRY METHOD TO PREDICT THE NECESSITY OF BLOOD PRODUCT TRANSFUSION DURING LIVER TRANSPLANTATION**  
Assya Georgieva Stancheva\* (BG), Lubomir Dimitrov Spassov
- P-WE-566 KAOLIN, USED TO TRIGGER COAGULATION IN THROMBIN GENERATION TEST, INCREASES SENSITIVITY OF THE METHOD IN HEMOPHILIA PATIENTS**  
Irina V Gribkova\* (RU), Gennady Galstyan, Elena Sinauridze
- P-WE-567 A NOVEL QUICK POINT OF CARE TEST OF COAGULATION FACTOR XIII ACTIVITY BASED ON CLOT RETRACTION IN HUMANS**  
Makoto Kaneko\* (JP), Nobuko Kanno, Akiko Suzuki, Ryoko Tanaka, Masayoshi Souri, Yutaka Yatomi, Akitada Ichinose
- P-WE-568 REPLICATION STUDY OF PRIOR GWAS CANDIDATE GENES/LOCI FOR CORONARY ARTERY DISEASES IN THE GENETIC ISOLATED NEWFOUNDLAND AND LABRADOR POPULATION**  
Ya-Gang Xie\* (CA), Jianxun Cui, Edward Randell, James Renouf, Shuo Li, Angela Pope, Guang Sun, Wayne Gulliver, Bruce Sussex, Fei-Yu Han
- P-WE-569 ANALYSIS OF FLAER BINDING WITH WBC BY FLOW CYTOMETRY**  
Mingqing Zhu\* (CN), Wenhong Shen, Li Chen, Lan Dai, Changgeng Ruan
- P-WE-570 ELEVATED INTERLEUKIN-27 ENHANCES TH1 CELL POLARIZATION AND THE PRODUCTION OF PROINFLAMMATORY CYTOKINES IN IMMUNE THROMBOCYTOPENIC PURPURA**  
Huiyuan Li\* (CN), Donglei Zhang, Jianping Li, Renchi Yang
- P-WE-571 ROTATION THROMBOELASTOMETRY FOR A RAPID ASSESSMENT OF PLASMA FIBRINOGEN DURING CARDIOPULMONARY BYPASS SURGERY**  
Satoru Ogawa\* (US), Fania Szlam, Jerrold H Levy, Kenichi A Tanaka
- P-WE-572 THROMBOELASTOGRAPHIC CHANGES IN HEMODIALYSIS AND PERITONEAL DIALYSIS PATIENTS**  
Amir Kuperman\* (IL), Andrei Braester, Kamal Hassan



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

- P-WE-573 ASSESSMENT OF THROMBIN GENERATION IN THE PRESENCE OF PLATELET PRE- AND POST CARDIAC SURGERY AND ITS RELATION WITH BLEEDING POST-OPERATIVELY**  
Raed Al Dieri\* (NL), Yvonne Bosch, Hugo Ten Cate, Bas Mochtar, H Coen Hemker
- P-WE-574 PREDICTION OF BLEEDING TENDENCIES IN HEMOPHILIA A PATIENTS ON PROPHYLACTIC TREATMENT USING A NOVEL REACTION-DIFFUSION ASSAY OF HEMOSTASIS**  
Anna N Balandina\* (RU), Mariya A Kumskova, Konstantin G Kopylov, Sergey S Karamzin, Olga A Fadeeva, Mikhail A Panteleev, Yuri V Zorenko, Olga P Plyushch, Fazoil I Ataullakhanov
- P-WE-575 EVALUATION OF A NOVEL FLOW CHAMBER SYSTEM TO ASSESS CLOT FORMATION IN FACTOR VIII-DEFICIENT MICE**  
Satoru Ogawa\* (US), Fania Szlam, Tomoko Ohnishi, Kazuya Hosokawa, Tanaka A Kenichi

### Atherothrombosis

- P-WE-576 INDUCTION OF CYTOKINE EXPRESSION IN NKT CELLS BY S1P: IMPLICATIONS FOR INSULIN RESISTANCE AND ATHEROTHROMBOSIS**  
Shiori Ito\* (JP), Keiko Koike, Soichiro Iwaki, Kazuya Iwabuchi, Ryunosuke Ohkawa, Yutaka Yatomi, Satoshi Fujii
- P-WE-577 BMP-2 INHIBITS TF EXPRESSION IN ACTIVATED HUMAN MONONUCLEAR CELLS VIA DOWNREGULATION OF ERK1/2 AND P38, BUT NOT JNK SIGNALING PATHWAYS**  
Mikhail Sovershaev (NO), Timofey Sovershaev, Elena Egorina, John-Bjarne Hansen\*
- P-WE-578 INCREASED EXPRESSION OF TF IN BMP-7-TREATED HUMAN MONONUCLEAR CELLS DEPENDS ON ACTIVATION OF P38 AND ERK1/2 SIGNALING PATHWAYS**  
Elena Egorina\* (NO), Timofey Sovershaev, Birgit Svensson, Mikhail Sovershaev, John-Bjarne Hansen
- P-WE-579 BMP-7-INDUCED TF EXPRESSION IN HUMAN MONONUCLEAR CELLS IS ASSOCIATED WITH INCREASED NF-KB, BUT NOT AP-1 TRANSCRIPTIONAL ACTIVITY**  
Mikhail Sovershaev (NO), Elena Egorina, Timofey Sovershaev, John-Bjarne Hansen\*
- P-WE-580 RELATIONSHIP BETWEEN OXIDATIVE STRESS, ENDOTHELIAL INJURY AND COAGULATION ACTIVATION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE**  
Oleksii M. Korzh\* (UA), Sergiy Krasnokutskiy, Elizaveta Lavrova
- P-WE-581 HUMAN C-REACTIVE PROTEIN ENHANCES THROMBUS FORMATION AFTER NEOINTIMAL BALLOON INJURY IN TRANSGENIC RABBITS**  
Shuntaro Matsuda\* (JP), Atsushi Yamashita, Yuichiro Sato, Shuji Kitajima, Tomonari Koike, Fan Jiangling, Yujiro Asada
- P-WE-582 EVEN MILD HYPERGLYCEMIA DISTURBS VASCULAR HOMEOSTASIS IN HUMANS**  
Bregtje Annelieke Lemkes\* (NL), Sarah E. Siegelaar, Max Nieuwdorp, Wim Kulik, Joost B.L. Hoekstra, Joost C.M. Meijers, Frits Holleman
- P-WE-583 VASCULAR ENDOTHELIAL GROWTH FACTOR AS THROMBOSIS RISK MARKER IN POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA PATIENTS**  
Sry Suryani Widjaja\* (ID), Stephen L KOH, Karmel Tambunan, Evelyn Koay
- P-WE-584 CD39 GENE-ELUTING STENT PREVENTS SUBACUTE IN-STENT THROMBOSIS IN INJURED ARTERY**  
Hiroyuki Kawata\* (JP), Yasuhiro Takemoto, Soeda Tsunenari, Ji-Hee Sung, Masanori Matsumoto, Yoshihiro Fujimura, Yasuhiko Tabata, Yoshihiko Saito

Wednesday Posters



61

## POSTER PRESENTATIONS

Wednesday, July 27, 2011

### Endothelial cells

- P-WE-585 THROMBOMODULIN PROMOTES CELL MIGRATION THROUGH INTEGRATED PLASMINOGEN ACTIVATION SYSTEM ON CELL SURFACE**  
Po-Ku Chen\* (TW), Bi-Ing Chang, Guey-Yueh Shi, Hua-Lin Wu
- P-WE-586 THE ENDOTHELIAL P2Y1 RECEPTOR PLAYS A ROLE IN TNF $\alpha$ -INDUCED RECRUITMENT OF LEUKOCYTES TO HUMAN CORONARY ARTERY ENDOTHELIAL CELLS UNDER FLOW CONDITIONS**  
Murielle Zerr\* (FR), Beatrice Hechler, Jean-Pierre Cazenave, Pierre Mangin, Christian Gachet
- P-WE-587 AUTOCRINE EFFECTS OF VASCULAR ENDOTHELIAL GROWTH FACTOR-D (VEGF-D) ON ENDOTHELIAL CELLS AFTER TRANSDUCTION WITH ADENOVIRUS VECTOR (AD-VEGF-D $\Delta$ N $\Delta$ C)**  
Izabela J Papiewska-Pajak\* (PL), Wiktor Koziolkiewicz, Anna Kozaczuk, Joanna Boncela, Emilia Stec-Martyna, Czeslaw Cierniewski
- P-WE-588 RENAL AND URINARY LEVELS OF EPCR CORRELATE WITH ACUTE RENAL ALLOGRAFT REJECTION**  
Lionel Lattenist\* (NL), Jesper Kers, Ineke J ten Berge, Sandrine Florquin, Joris J Roelofs
- P-WE-589 E-SELECTIN, L-SELECTIN AND COAGULATION ACTIVATION IN MYELOID LEUKEMIA PATIENTS WITH LEUKOCYTOSIS**  
Lugyanti - Sukrisman\* (ID), Karmel Lidow Tambunan
- P-WE-590 ENDOTHELIAL MICROPARTICLES AS MARKERS FOR ENDOTHELIAL DYSFUNCTION: DO PLASMA LIPIDS INTERFERE?**  
Sabrina van Ierssel\* (BE), Vicky Y Hoymans, Emeline M Van Craenenbroeck, Viggo F Van Tendeloo, Viviane M Conraads, Philippe G Jorens
- P-WE-591 PORCINE ENDOTHELIAL CELLS TRANSGENIC FOR HUMAN ENDOTHELIAL PROTEIN C RECEPTOR AND/OR THROMBOMODULIN GENERATE DIFFERENT LEVELS OF HUMAN ACTIVATED PROTEIN C**  
Cristiana Bulato\* (IT), Claudia Maria Radu, Sabrina Gavasso, Luca Spiezia, Cesare Galli, Emanuele Cozzi, Paolo Simioni
- P-WE-592 ENDOTHELIAL PROTEIN C RECEPTOR PLAYS AN IMPORTANT ROLE IN PROTEIN C ACTIVATION BY ENDOTHELIAL CELLS IN XENOGRAFTS**  
Claudia Maria Radu\* (IT), Cristiana Bulato, Sabrina Gavasso, Luca Spiezia, Cesare Galli, Emanuele Cozzi, Paolo Simioni
- P-WE-593 PROTECTIVE EFFECT OF DEFIBROTIDE ON ACTIVATED ENDOTHELIUM: MECHANISM FOR PREVENTION OF ACUTE GVHD**  
Simona Somaini\* (IT), Maria Distaso, Jawed Fareed, Debra Hoppensteadt, Massimo Iacobelli, Cinara Echert
- P-WE-594 RAB27A IS NOT A NEGATIVE REGULATOR OF WPB EXOCYTOSIS IN POST-CONFLUENT CULTURED ENDOTHELIAL CELLS**  
Ruben Bierings\* (UK), Robert Rowlands, Nicola Hellen, Bijal Patel, Laura Knipe, Lindsay Hewlett, Tom Carter, Matthew Hannah



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

### Smooth muscle cells

- P-WE-595 SILENCING OF THE F11R GENE REVEALS A ROLE FOR F11R/JAM-A IN THE MIGRATION OF INFLAMED VASCULAR SMOOTH MUSCLE CELLS IN ATHEROSCLEROSIS**  
Bani Mekisha Azari\* (US), Jonathan D. Marmur, Moro O. Salifu, Yigal H. Ehrlich, Elizabeth Kornecki, Anna Babinska
- P-WE-596 ADMISSION LEVEL OF PREGNANCY-ASSOCIATED PLASMA PROTEIN A PREDICTS LONG TERM MORTALITY WITHIN SEVEN YEARS FOLLOW UP IN PATIENTS ADMITTED WITH SUSPECTED ACUTE CORONARY SYNDROME**  
Volker Poenitz\* (NO), Trygve Bruegger-Andersen, Heidi Grundt, Oistein Mjelva, Harry Staines, Dennis Winston Trygve Nielsen
- P-WE-597 BUTEIN INHIBITS PDGF-INDUCED RESTENOSIS AFTER PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY**  
Yen-Nien Chen\* (TW), Tur-Fu Huang, Ching-Hu Chung

### Hemodynamics and shear stress

- P-WE-598 CORONARY MICROVASCULAR DYSFUNCTION DUE TO ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA: THE MISSING PIECE OF THE PUZZLE OF THEIR INCREASED CARDIOVASCULAR RISK?**  
Giuseppe Cella\* (IT), Francesco Tona, Giulia Famoso, Andrea Ballin, Elena Osto, Sabino Iliceto, Graziella Saggiorato
- P-WE-599 VOLUME REPLACEMENT RESUSCITATES IN HEATSTROKE RATS BY RESTORING HOMEOSTATIC FUNCTION AND REDUCING VITAL ORGANS DAMAGE**  
Kuen-Bor Chen\* (TW), Mei-Fen Shih, Wu-Tien Huang, Hsin-Mao Tsai, Tsai-Hsiu Yang, Chia-Chyuan Liu
- P-WE-600 RHEOLOGICAL AND MICROSTRUCTURAL STUDIES OF INCIPIENT CLOTS FORMED UNDER "IN-VIVO" CONDITIONS**  
Karl Hawkins\* (UK), Matthew Lawrence, Rhodri Williams, Ahmed Sowedan, Nafiseh Badiei, Adrian Evans

### Genomics and proteomics

- P-WE-601 PROTEINCHIP ARRAY PROFILING OF MOLECULAR VARIANTS OF HIRUDINS USING SURFACE ENHANCED LASER DESORPTION IONIZATION (SELDI) TECHNIQUE.**  
Vijaya Paramatmuni\* (US), Rahul Biljani, Evangelos Litinas, Nasir Saddeghi, Walter Jeske, Debra Hoppensteadt, Jawed Fareed
- P-WE-602 TOWARDS PLATELET-SPECIFIC RNA INTERFERENCE**  
Tim Thijs\* (BE), Katleen Broos, Isabelle I Salles, Stefaan Soenen, Aline Vandenbulcke, Jose A Lopez, Karen Vanhoorelbeke, Hans Deckmyn
- P-WE-603 DOES ABO BLOOD GROUP INCREASE THE RATE OF RECURRENT EVENTS AFTER INITIAL TREATMENT FOR A FIRST UNPROVOKED VENOUS THROMBOEMBOLISM (VTE) EVENT? REVERSE COHORT SUBGROUP ANALYSIS**  
Esteban Gandara\* (CA), Michael J. Kovacs, Susan Kahn, Phil Wells, David A. Anderson, Susan Solymoss, Gregoire Le Gal, Isabelle Chagnon, Mark A. Crowther, Nicole Langlois, Arnaud Perrier, Richard A. White, Marc Carrier, Nancy Carson, Julian Little, Tim Ramsay, Marc A Rodger



## POSTER PRESENTATIONS

Wednesday, July 27, 2011

**P-WE-604    MULTIPLEXED NEXT-GENERATION DNA SEQUENCING OF THE HEMOSTATIC EXOME IN DEEP VEIN THROMBOSIS**

Luca A Lotta\* (IT), Mark Wang, Jin Yu, Fuli Yu, Ida Martinelli, Serena Passamonti, Dario Consonni, Emanuela Pappalardo, Marzia Menegatti, Steve E Scherer, Yu-Ye Wen, Robin T Varghese, Dannyae Lee, Cindy Lin, Walker Hale IV, Jeffrey G Reid, Donna M Muzny, Pier Mannuccio Mannucci, Richard A Gibbs, Flora Peyvandi

**P-WE-605    A CUSTOM TILING EXPRESSION MICROARRAY AS A NOVEL APPROACH TO STUDY A CORONARY ARTERY DISEASE GENETIC RISK LOCUS**

Fiona R Green\* (UK), Lesley D Beeton, Pritilata Chivers, Theodosios Kyriakou, Anuj Goel, John Peden



**Scientific Program**  
**Thursday, July 28, 2011**

Thursday, July 28, 2011

Plenary Lecture

9:45-10:30

**Kenneth M. Brinkhous Memorial Lecture**

Main Hall

*Chairpersons: Michael Berndt (IE) and Yoshiaki Tomiyama (JP)*

**Molecular mechanism of inside-out integrin regulation**

PL-TH-001

*Mark H. Ginsberg (US), Feng Ye, Chungo Kim*

09:45 – 10:30

Plenary Lecture

13:30-14:15

**Wright-Schulte Memorial Lecture**

Main Hall

*Chairpersons: Pieter H. Reitsma (NL) and Takehiko Koide (JP)*

**Serpin structure, function and dysfunction**

PL-TH-002

*James A. Huntington (UK)*

13:30 – 14:15

State-of-the-Art Lecture

11:00-12:00

**Hemophilia**

Main Hall

*Chairpersons: David Lillicrap (CA) and Katsuyuki Fukutake (JP)*

**Immune tolerance induction in hemophilia: Evidence and the way forward**

SA-TH-001

*Donna Marie DiMichele (US)*

11:00 – 11:30

**Management of acquired haemophilia a**

SA-TH-002

*Peter W. Collins (UK)*

11:30 – 12:00

**Platelet and Vascular Wall**

Annex Hall 1

*Chairpersons: Gerhard Johnson (US) and Ryozi Nagai (JP)*

**Discovery of the cardiovascular system: From galen to william harvey**

SA-TH-003

*William C. Aird (US)*

11:00 – 11:30

**How platelets safeguard vascular integrity**

SA-TH-004

*Denisa D. Wagner (US)*

11:30 – 12:00



Thursday, July 28, 2011

**Coagulation Activation**

**Annex Hall 2**

*Chairpersons: Ton Lisman (NL) and Takashi Morita (JP)*

**Toxins in thrombosis and hemostasis: Potential beyond imagination**

SA-TH-005

*Manjunatha R. Kini (SG)*

11:00 – 11:30

**Nanoscale studies of protein-membrane interactions in blood clotting**

SA-TH-006

*James H. Morrissey (US), E. Tajkhorshid, C.M. Rienstra*

11:30 – 12:00

**Congenital and Acquired Thrombotic Disorders**

**Room A**

*Chairpersons: Bernhard Lämmle (CH) and Seonyang Park (KR)*

**Molecular pathophysiology of the antiphospholipid syndrome: The role of oxidative posttranslational modification of beta 2 glycoprotein I**

SA-TH-007

*Steven Krillis (AU), Freda Passam, Bill Giannakopoulos, Peyman Mirarabshahi*

11:00 – 11:30

**Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan**

SA-TH-008

*Yoshihiro Fujimura (JP), Masanori Matsumoto, Ayami Isonishi, Hideo Yagi, Koichi Kokame, Kenji Soejima, Mitsuru Murata, Toshiyuki Miyata*

11:30 – 12:00

**Symposia**

**8:00-9:30**

**Thrombotic Disorders**

**Main Hall**

**Pathogenesis, Diagnosis and Treatment of Septic DIC**

*Chairpersons: Hidesaku Asakura (JP), Doyeun Oh (KR)*

**Pathogenesis, diagnosis and treatment of septic DIC**

SY-TH-001

*William K. Hoots (US)*

08:00 – 08:30

**New approach to diagnosing DIC**

SY-TH-002

*Cheng-Hock Toh (UK)*

08:30 – 09:00

**New strategy for treatment of septic DIC**

SY-TH-003

*Satoshi Gando (JP)*

09:00 – 09:30

Thursday Science



3



Thursday, July 28, 2011

**Platelet (Basic and Clinical)**

**Annex Hall 1**

**Mechanisms of Platelet Adhesive Function**

*Chairpersons: Edward F. Plow (US) and Makoto Handa (JP)*

**Integrin cytoskeletal interactions**

*David A. Calderwood (US)*

**SY-TH-004**

08:00 – 08:30

**STIM1 and Orai in calcium-dependent platelet activation and thrombosis**

*Wolfgang Bergmeier (US)*

**SY-TH-005**

08:30 – 09:00

**Genetic analysis of integrin signaling in mice**

*Markus Moser (DE)*

**SY-TH-006**

09:00 – 09:30

**Coagulation Factors and Inhibitors**

**Annex Hall 2**

**Structural Biology in Thrombosis**

*Chairpersons: Soichi Takeda (JP) and Philip Hogg (AU)*

**Structural basis for ADAMTS13 function**

*Masashi Akiyama (JP), Daisuke Nakayama, Soichi Takeda, Toshiyuki Miyata*

**SY-TH-007**

08:00 – 08:30

**Crystal structure and function of VKOR and its redox partner**

*Weikai Li (US), Li Weikai, Sol Schulman, Tom Rapoport, Jon Beckwith, Dana Boyd, Melinda Wang, Rachel Dutton*

**SY-TH-008**

08:30 – 09:00

**Structural origins of clot and thrombus mechanical properties**

*John W. Weisel (US)*

**SY-TH-009**

09:00 – 09:30

**Symposia**

**14:30-16:00**

**VWF/VWD and ADAMTS13**

**Main Hall**

**Function and Dysfunction of von Willebrand Factor**

*Chairpersons: Ian R. Peake (UK) and Augusto B. Federici (IT)*

**von Willebrand factor and  $\alpha$ -thrombin at the cross-road of hemostasis and thrombosis**

*Zaverio M. Ruggeri (US)*

**SY-TH-010**

14:30 – 15:00



Thursday, July 28, 2011

**Genetic basis of type 1 von Willebrand disease**

*Ian R. Peake (UK)*

**SY-TH-011**

15:00 – 15:30

**Functional analysis of von willebrand factor (VWF) using VWF knockout mice**

*Cecile V. Denis (FR)*

**SY-TH-012**

15:30 – 16:00

**Hemorrhagic Disorders**

**Annex Hall 1**

**Molecular Mechanisms of Coagulation Disorders**

*Chairpersons: Hugo Ten Cate (NL) and Tetsuhito Kojima (JP)*

**Genetic mechanisms of the royal disease**

*Evgeny I. Rogaev (US)*

**SY-TH-013**

14:30 – 15:00

**Molecular mechanisms of factor VII deficiency and variants**

*Mirko Pinotti (IT), Francesco Bernardi*

**SY-TH-014**

15:00 – 15:30

**Diverse molecular mechanisms of congenital and acquired factor XIII/13 deficiency and its newly proposed biological functions**

*Akitada Ichinose (JP)*

**SY-TH-015**

15:30 – 16:00

**Vascular Biology**

**Annex Hall 2**

**Angiogenesis and Vasculogenesis**

*Chairpersons: Toshio Suda (JP) and William C. Aird (US)*

**The ins and outs of VEGF signaling**

*Luisa Iruela-Arispe (US)*

**SY-TH-016**

14:30 – 15:00

**Control of angiogenesis and vascular homeostasis through the angiopoietin/tie system**

*Hellmut G. Augustin (DE)*

**SY-TH-017**

15:00 – 15:30

**Regulation of TGF-beta signaling and vascular diseases**

*Kohei Miyazono (JP)*

**SY-TH-018**

15:30 – 16:00

Thursday Science



Thursday, July 28, 2011

**Symposia**

**16:15-17:45**

**Coagulation Factors and Inhibitors**

**Main Hall**

**Protein C System**

*Chairpersons: Tilman Hackeng (NL) and Yongqiang Zhao (CN)*

**Reevaluation of the role of HDL in the anticoagulant protein C system**

**SY-TH-019**

*Björn Dahlbäck (SE)*

16:15 – 16:45

**Protein S deficient mice**

**SY-TH-020**

*Anne Angelillo-Scherrer (CH), Francois Saller, Sara Calzavarini*

16:45 – 17:15

**Therapeutic efficacy of activated protein C in murine endotoxemia**

**SY-TH-021**

*Hartmut Weiler (US), Edward Kerschen, Irene Hernandez, John H. Griffin,  
Jose A. Fernandez*

17:15 – 17:45

**Fibrinolysis and Proteolysis**

**Annex Hall 1**

**Plasminogen Activation and Its Modulation**

*Chairpersons: Nuala Booth (UK) and Tetsumei Urano (JP)*

**Plasminogen receptors and their regulation on macrophages**

**SY-TH-022**

*Edward F. Plow (US), Riku Das*

16:15 – 16:45

**Unique secretory mechanism of t-PA and the expression of fibrinolytic activity on vascular endothelial cells**

**SY-TH-023**

*Yuko Suzuki (JP), Tetsumei Urano*

16:45 – 17:15

**Targeting TAFI/TAFIa through different pathways: In vitro and in vivo evaluation**

**SY-TH-024**

*Paul J. Declerck (BE), Ann Gils*

17:15 – 17:45

**Late Breaking Clinical Research**

**Annex Hall 2**

**Late Breaking Clinical Research**

*Chairpersons: Yasuo Ikeda (JP) and Sam Schulman (CA)*

**Sixty-eight genetic loci uncover new gene functions in hematopoiesis and platelet formation**

**SY-TH-025**

*Willem Hendrik Ouwehand (UK), Christian Gieger, Nicole Soranzo*

16:15 – 16:45



Thursday, July 28, 2011

**High residual platelet reactivity assessed with specific and global tests in the ADRIE study: Comparative predictive values for the recurrence of ischemic events** **SY-TH-026**

*Jean-Luc Reny (CH), Philippe Berdague, Christophe Combescure, Severine Nolli, Isabelle Barazer, Pascale Fabbro-Peray, Jean-Francois Schved, Henri Bounameaux, Francois Mach, Philippe de Moerloose, Pierre Fontana*

16:45 – 17:15

**First results of the phase II TITAN trial: Anti-von willebrand factor nanobody as adjunctive treatment for patients with acquired thrombotic thrombocytopenic purpura** **SY-TH-027**

*Flora Peyvandi (IT), Dimitri A. Breems, Paul Kncubl, Caroline De Man, Ka Lung Wu, Christophe Lyssens, Josefin-Beate Holz*

17:15 – 17:45

Thursday Science



7

## ORAL COMMUNICATIONS

Thursday, July 28, 2011

### Inherited Platelet Disorders

Room C-1

Chairpersons: Catherine Hayward (CA) and 

- O-TH-001** **MEGAKARYOCYTE AND PLATELET ABNORMALITIES RESULTING FROM CONGENITAL DEFECTS IN FILAMIN A DELINEATE A NOVEL PHENOTYPE OF CONGENITAL THROMBOCYTOPENIA**  
Paquita Nurden\* (FR), Najet Debili, Marijke Bryckaert, Ibtissam Youlyouz-Marfak, Isabelle Coupry, Caroline Rooryck, Jean-Marie Daniel Lamaziere, Anne-Cecile Pons, Chloe James, Alan Nurden, Cyril Goizet  
**08:00 - 08:15**
- O-TH-002** **THE FRENCH MYH9 SYNDROME COHORT: PHENOTYPE, GENOTYPE AND EPIDEMIOLOGICAL ASPECTS. ON BEHALF OF THE NATIONAL FRENCH REFERENCE CENTER ON INHERITED PLATELET DISORDERS (CRPP).**  
Nicole SCHLEGEL\* (FR), Beatrice SAPOSNIK, Sylvie BINARD, Odile FENNETEAU, Alan NURDEN, Paquita NURDEN, Nicole SCHLEGEL  
**08:15 - 08:30**
- O-TH-003** **TWO NEW MUTATIONS IN THE LYST/CHS1 GENE IN PATIENTS WITH CHEDIAK-HIGASHI SYNDROME. FIRST CASE OF A MISSENSE MUTATION IN A CASE OF SEVERE CHILDHOOD CHEDIAK-HIGASHI**  
Ana I Anton\* (ES), I Sanchez-Guiu, J Navarro-Fernandez, JL Fuster, JM Couselo, C Martinez, V Vicente, J Rivera, ML Lozano  
**08:30 - 08:45**
- O-TH-004** **A NEW MUTATION IN THE FERMT3 GENE CAUSES THE ABSENCE OF KINDLIN-3 IN PLATELETS AND LEUKOCYTES : CONSEQUENCES ON INTEGRIN DEPENDENT AND INDEPENDENT ADHESION.**  
Matthias Canault\* (FR), Phillipe Robert, Charlotte Grosdidier, Catherine Farnarier, Nurden T Alan, Vincent Barlogis, Pierre Bongrand, Anne Pierres, Herve Chambost, Marie-Christine Alessi  
**08:45 - 09:00**
- O-TH-005** **COMMON SIGNALING PATHWAYS INVOLVING PI3K BETA IN THE REGULATION OF PLATELET INHIBITION VIA GS IN SUBJECTS WITH NORMAL OR ALTERED GS FUNCTION**  
Frauke Swieringa\* (NL), Marion A.H. Feijge, Yvonne M.C. Henskens, Connie T Schrandt-Stumpel, Estela Rubio-Gozalbo, Paola E Van der Meijden, Irene M.L.W. Keularts, Johan W.M. Heemskerk  
**09:00 - 09:15**
- O-TH-006** **ROLE OF TMEM16F IN AGONIST-INDUCED BUT NOT APOPTOSIS-INDUCED PHOSPHATIDYLSERINE EXPOSURE IN SCOTT PLATELETS**  
Roger van Kruchten\* (NL), Roger van Kruchten, Jef L. N. Wolfs, Marion A. H. Feijge, Nadine J. A. Mattheij, Peter Collins, Johan W. M. Heemskerk, Edouard M. Bevers  
**09:15 - 09:30**



## ORAL COMMUNICATIONS

Thursday, July 28, 2011

### Serine Protease Inhibitors II

Room C-2

*Chairpersons: Margarethe Geiger (AT) and Masayoshi Souri (JP)*

- O-TH-007** **PROTEIN Z-DEPENDENT PROTEASE INHIBITOR AND PROTEIN Z INCREASE IN NORMAL PREGNANCIES BUT NOT IN PATIENTS WITH UNEXPLAINED RECURRENT MISCARRIAGE** **08:00 - 08:15**  
Mayumi Sugiura-Ogasawara\* (JP), Masayoshi Souri, Shigeru Saito, Betinna Kemkes-Matthes, Joost C.M. Meijers, Akitada Ichinose
- O-TH-008** **DISCREPANCY IN RESULTS OF ANTITHROMBIN ACTIVITY USING FIVE DIFFERENT COMMERCIALLY AVAILABLE METHODS - CLINICAL IMPLICATIONS IN DETECTING AT DEFICIENCY** **08:15 - 08:30**  
Marja Kaarina Puurunen\* (FI), Sari Engelbarth, Kaija Javele
- O-TH-009** **HOW CONTROL OF THROMBIN BY SERPINS IN VERTEBRATES AROSE** **08:30 - 08:45**  
Hermann Ragg\* (DE), Yunjie Wang
- O-TH-010** **STABLE OVEREXPRESSION OF TFPI IN BREAST CANCER CELLS CHANGES THE EXPRESSION OF MRNAS AND MICRORNAS INVOLVED IN IMMUNE RESPONSE AND CANCER DEVELOPMENT** **08:45 - 09:00**  
Benedicte Stavik\* (NO), Grethe Skretting, Marit Sletten, Ole Kristoffer Olstad, Per Morten Sandset, Nina Iversen
- O-TH-011** **RETENTION OF THROMBIN INHIBITORY ACTIVITY BY RECOMBINANT SERPINS EXPRESSED AS INTEGRAL MEMBRANE PROTEINS TETHERED TO THE SURFACE OF MAMMALIAN CELLS** **09:00 - 09:15**  
William P Sheffield\* (CA), Richard F Gierczak, Jason S Sutherland, Varsha Bhakta, Lisa J Toltl, Patricia C Liaw
- O-TH-012** **EFFECT OF PROTEIN C INHIBITOR ON LIPOPOLYSACCHARIDE-INDUCED VASCULAR PERMEABILITY** **09:15 - 09:30**  
Tomoaki Yoshikawa\* (AL), Yoshinori Saito, Tatsuya Hayashi, Tatsuya Kurata, Junji Nishioka, Takayuki Okamoto, Akita Nobuyuki, Asanuma Kunihiko, Sudo Akihiro, Uchida Atsumasa

### Coagulation Factors I

Room D

*Chairpersons: [REDACTED] and Jun Mizuguchi (JP)*

- O-TH-013** **HYPERGLYCOSYLATED FACTOR IX VARIANTS WITH IMPROVED PHARMACOKINETIC PROPERTIES IN ANIMALS** **08:00 - 08:15**  
Alan Brooks\* (US), Chandra Patel, Xiaoqiao Jiang, Eric Blasko, Liang Tang, Derek S. Sim, Rick Feldman, Xiao-Yan Zhao, Uwe Gritzan, Ulrich Haupts, Heiner Apeler, Jesper Haaning, John E. Murphy
- O-TH-014** **BAY86-6150, A NOVEL RECOMBINANT FACTOR VIIA VARIANT, HAS A HIGHER THERAPEUTIC INDEX THAN WILDTYPE RFVIIA IN MURINE HEMOPHILIA A THROMBOSIS AND BLEEDING MODELS** **08:15 - 08:30**  
Derek S. Sim\* (US), Cornell Mallari, Perry Liu, Cristina Loomis, Maria Koellnberger, John E. Murphy, Jesper Haaning

Thursday Oral



9

## ORAL COMMUNICATIONS

Thursday, July 28, 2011

- O-TH-015** **PEGYLATION OF FVIII RESULTS IN REDUCED UPTAKE BY HUMAN DENDRITIC CELLS AND A SIGNIFICANT REDUCTION IN HUMAN FVIII-SPECIFIC T-CELL RESPONSE IN VITRO** **08:30 - 08:45**  
John E. Murphy\* (US), Xie Jinger, Pedro Paz, Marc Jacquemin, Renaud Lavendhomme, Jesper Haaning, Fred Aswad
- O-TH-016** **EFFICACY AND SAFETY OF PROPHYLAXIS WITH ONCE-WEEKLY BAY 79-4980 VERSUS 3-TIMES-WEEKLY RFVIII-FS: A RANDOMIZED, ACTIVE-CONTROLLED, DOUBLE-BLIND STUDY** **08:45 - 09:00**  
Jerry Powell\* (US), Jorgen Ingerslev, Monika Maas Enriquez, Uri Martinowitz
- O-TH-017** **EFFECT OF THE EXTRACELLULAR RNA IN THE ANTICOAGULANT FUNCTION OF ANTITHROMBIN** **09:00 - 09:15**  
Jose Navarro-Fernandez\* (ES), Irene Martinez-Martinez, Horacio Perez-Sanchez, Antonia Minano, Nataliya Bohdan, Maria Eugenia de la Morena-Barrio, Sonia Aguila, Vicente Vicente, Javier Corral
- O-TH-018** **RESVERATROL, A PHYTOESTROGEN FOUND IN RED WINE, DOWN-REGULATES PROTEIN S EXPRESSION IN HEPG2 CELLS** **09:15 - 09:30**  
Hiroko Tsuda\* (JP), Yoshie Hiroto, Kana Tadokoro, Tomohide Tsuda, Eri Nakazono, Keizo Ohnaka, Ryoichi Takayanagi, Naotaka Hamasaki

### Platelets as Drug Targets

Room E

Chairpersons: Garrett A Fitzgerald and DD Wagner



- O-TH-019** **STORE-OPERATED CALCIUM ENTRY AS A POTENTIAL TARGET TO SUPPRESS ARTERIAL THROMBUS FORMATION** **08:00 - 08:15**  
Roger van Kruchten\* (NL), Attila Braun, Marion A. H. Feijge, David E. Schmidt, Peter Kraft, Guido Stoll, Marijke J. E. Kuijpers, Edouard M. Bevers, Bernhard Nieswandt, Johan W. M. Heemskerk
- O-TH-020** **A SMALL MOLECULE INHIBITOR OF PROTEIN DISULFIDE ISOMERASE INHIBITS THROMBUS FORMATION IN A MOUSE LASER-INDUCED THROMBOSIS MODEL** **08:15 - 08:30**  
Reema Jasuja\* (US), freda passam, daniel kennedy, sarah kim, james R dilks, bruce furie, barbara c furie, R flaumenhaft
- O-TH-021** **DIANNEXIN, A HOMODIMER OF ANNEXIN A5 (A5), BINDS PHOSPHATIDYL SERINE (PS) WITH HIGH AFFINITY AND IS A POTENT INHIBITOR OF ARTERIAL THROMBOSIS IN MICE** **08:30 - 08:45**  
Margaret L Rand\* (CA), Alan Stafford, Ran Ni, Hong Wang, Anthony C Allison, Jeffrey I Weitz, Peter L Gross
- O-TH-022** **ADENOSINE DERIVED FROM ADP CAN CONTRIBUTE TO INHIBITION OF PLATELET AGGREGATION IN THE PRESENCE OF A P2Y12 ANTAGONIST** **08:45 - 09:00**  
Jacqueline Glenn\* (UK), David Espinosa Iyu, Ann White, Susan Fox, Stan Heptinstall



## ORAL COMMUNICATIONS

Thursday, July 28, 2011

O-TH-023

**INTERACTION BETWEEN IMPAIRED THROMBIN GENERATION AND IMPAIRED THROMBIN-INDUCED PLATELET ACTIVATION IN MOUSE MODELS OF HEMOSTASIS AND THROMBOSIS.**

Tovo David\* (US), Cherry L Concengo, Daniel Ha, Ivo Cornelissen, Shaun R Coughlin

09:00 - 09:15

O-TH-024

**DEVELOPMENT OF ANTITHROMBOTIC ALLOSTERIC MODULATORS OF PAR1**

Louisa Dowal\* (US), Derek Sim, James Dilks, Lynn VerPlank, Price Blair, Sarah Beaudry, Bradley Denker, Georgios Koukos, Athan Kuliopoulos, Daniel Smith, Albert Mairuhu, Joseph Negri, Chris Dockendorff, Lawrence MacPherson, Michelle Palmer, Stuart Scheiber, Robert Flaumenhaft

09:15 - 09:30

### Hemophilia: Pathophysiology

Sakura

*Chairpersons: Aida Inbal (IL) and Kathleen P (US)*

O-TH-025

**UP-REGULATION OF PLATELET ACTIVATION IN HEMOPHILIA A**

Esther Ruth van Bladel\* (NL), Mark Roest, Philip G. de Groot, Roger E.G. Schutgens

08:00 - 08:15

O-TH-026

**HEME REDUCES PRO-COAGULANT ACTIVITY OF FACTOR VIII**

Jordan D Dimitrov\* (FR), Yohann Repesse, Ivan Peyron, Elika Farrokhi Moshai, Laurent Kiger, Michael C Marden, Srinivas V Kaveri, Sebastien Lacroix-Desmazes

08:15 - 08:30

O-TH-027

**USE OF A CALIBRATED AUTOMATED THROMBIN GENERATION ASSAY TO QUANTIFY ACCURATELY FACTOR VIII LEVELS IN SEVERE AND MODERATE HAEMOPHILIA A**

Marisa Ninivaggi\* (NL), Yesim Dargaud, Coenraad H. Hemker, Theo Lindhout

08:30 - 08:45

O-TH-028

**HEPATIC CLEARANCE OF B-DOMAINLESS FACTOR VIII DOES NOT REQUIRE ITS PRIOR ACTIVATION TO FACTOR VIIIa**

Dudley Strickland\* (US), Mary Migliorini, Ernest T Parker, Pete Lollar

08:45 - 09:00

O-TH-029

**UPTAKE OF BLOOD COAGULATION FACTOR VIII BY DENDRITIC CELLS IS MEDIATED VIA ITS C1 DOMAIN**

Eszter Herczenik\* (NL), Simon D. van Haren, Aleksandra Wroblewska, Alexander B. Meijer, Luisa Martinez-Pomares, Anja ten Brinke, Jan Voorberg

09:00 - 09:15

O-TH-030

**LARGE SCALE SEQUENCING OF THE F8 GENE USING A HIGH DENSITY OLIGONUCLEOTIDE ARRAY**

Pamala Kanagasabapathy\* (UK), Keith Gomez, John H McVEY

09:15 - 09:30

Thursday Oral



11



## ORAL COMMUNICATIONS

Thursday, July 28, 2011

### Thrombotic Disorders: Clinical Trials II

Room A

Chairpersons: Clive Kearon and Yukihiro Koretsune



- O-TH-031** **APIXABAN VERSUS ENOXAPARIN AFTER KNEE OR HIP SURGERY: EFFICACY AND SAFETY IN KEY CLINICAL SUBGROUPS**  
Graham F. Pineo\* (CA), Alex Gallus, Gary Raskob, Luz Margarita Ramirez, Robert Wright, Dalei Chen, Michael Rud Lassen  
08:00 - 08:15
- O-TH-032** **RANDOMIZED, OPEN-LABEL, DOSE-RANGING STUDY OF DABIGATRAN, A NOVEL, ORAL, DIRECT THROMBIN INHIBITOR, IN ELECTIVE PCI. (THE D-FINE STUDY)**  
Frank W G Leebeek\* (NL), Moniek P. de Maat, Russell Jones, Linda van Campen, Jeffrey Friedman, Paul Reilly, Pascal Vranckx  
08:15 - 08:30
- O-TH-033** **DABIGATRAN OR WARFARIN FOR EXTENDED MAINTENANCE THERAPY OF VENOUS THROMBOEMBOLISM**  
Sam Schulman\* (CA), Henry Eriksson, Samuel Zachary Goldhaber, Ajay K. Lord Kakkar, Clive Kearon, Anne Mathilde Kvamme, Patrick Mismetti, Sebastian Schellong, Janet Schnee  
08:30 - 08:45
- O-TH-034** **A MULTICENTRE, RANDOMISED, DOUBLE-BLIND CLINICAL TRIAL TO EVALUATE BEMIPARIN SODIUM VS UNFRACTIONATED HEPARIN AS BRIDGING THERAPY FOR AMBULATORY SURGERY: "BERTA" STUDY.**  
AMPARO SANTAMARIA\* (ES), A. UGARRIZA, C. MUNOZ, I. DE DIEGO, F. LOPEZ, JAVIER MARTINEZ-GONZALEZ, JORDI FONTCUBERTA  
08:45 - 09:00
- O-TH-035** **TIME TO REACH THERAPEUTIC ANTICOAGULATION FOR POST-OPERATIVE ORTHOPEDIC PROPHYLAXIS, RESULTS OF THE MICHIGAN ANTICOAGULATION QUALITY IMPROVEMENT INITIATIVE (MAQI2)**  
Scott Kaatz\* (US), Vlad Golgotiu, Geoffrey D Barnes, Xiaokui Gu, Jay Kozlowski, Steven L Almany, Dennis Besley, Paul Ponstein  
09:00 - 09:15
- O-TH-036** **PERSISTENT REDUCTION OF ADAMTS13 ACTIVITY IN ACUTE ISCHEMIC STROKE WHICH IS INDEPENDENT OF VWF LEVELS AND ADAMTS13 INHIBITOR**  
Ross Ian Baker\* (AU), James Thom, Quintin Hughes, Barbara Plaimauer, Fritz Scheiflinger, Hanspeter Rottensteiner, Graeme Hankey  
09:15 - 09:30

### VTE: Laboratory Tests II

Room B-1

Chairpersons: Theodore Warkentin (CA) and

- O-TH-037** **DOES THE PULMONARY EMBOLISM SEVERITY INDEX ACCURATELY IDENTIFY LOW RISK PATIENTS ELIGIBLE FOR OUTPATIENT TREATMENT?**  
Petra MG Erkens\* (NL), Esteban Gandara, Phil Wells, Alex Yi-Hao Shen, Gauruv Bose, Gregoire Le Gal, Marc Rodger, Martin H Prins, Marc Carrier  
08:00 - 08:15



## ORAL COMMUNICATIONS

Thursday, July 28, 2011

- O-TH-038** **THE ROLE OF MULTIPLE BIOMARKERS IN THE DIAGNOSIS OF PULMONARY EMBOLISM** **08:15 - 08:30**  
Kerstin Hogg\* (CA), Edward Hinchliffe, Shonagh Haslam, Fiona Lecky
- O-TH-039** **THROMBIN GENERATION IN PATIENTS WITH SPLANCNIC VEIN THROMBOSIS WITH AND WITHOUT CIRRHOSIS.** **08:30 - 08:45**  
Valeria Rossetto\* (IT), Marco Senzolo, Maria Teresa Sartori, Krissia Rodriguez, Mariangela Fadin, Patrizia Zerbinati, Sabrina Gavasso, Patrizia Burra, Paolo Simioni
- O-TH-040** **TARGETED GENE SEQUENCING OF THE PROTEIN C AND EPCR GENES IN A LARGE POPULATION OF PATIENTS WITH UNPROVOKED VENOUS THROMBOEMBOLISM** **08:45 - 09:00**  
Dhruva J. Dwivedi\* (CA), Cynthia Wu, Laura Pepler, Zakhar Lysov, John Wayne, Jim Julian, Clive Kearon, Patricia Liaw
- O-TH-041** **FV LEIDEN PSEUDO-HOMOZYGOTES HAVE A MORE PRONOUNCED HYPERCOAGULABLE STATE THAN HOMOZYGOTES DUE TO LOW PLASMA TFPI LEVELS** **09:00 - 09:15**  
Connie Duckers (NL), Paolo Simioni, Daniela Tormene, Sara Carraro, Jan Rosing, Elisabetta Castoldi\*
- O-TH-042** **RECURRENT VENOUS THROMBOEMBOLISM IS ASSOCIATED WITH FACTOR V LEIDEN MUTATION** **09:15 - 09:30**  
Signy Vala Sveinsdottir\* (SE), Ymir Saemundsson, Nazim Isma, Anders Gottsater, Peter J. Svensson

### Von Willebrand Factor

Room B-2

*Chairpersons: Jan Voorberg (NL) and Jim Crawley (UK)*

- O-TH-043** **SIGLEC-5 MODULATES PLASMA LEVELS OF THE FACTOR VIII-VON WILLEBRAND FACTOR COMPLEX** **08:00 - 08:15**  
Peter Lenting\* (FR), Julie Pegon, Cecile V Denis, Soline Odouard, Caterina Casari, Olivier D Christophe
- O-TH-044** **PLATELET CAPTURE UNDER VERY HIGH SHEAR BY CONTOURED VWF NETS** **08:15 - 08:30**  
David N KU\* (US), Peter Wellings
- O-TH-045** **GENOME-WIDE ASSOCIATION STUDIES IDENTIFY NEW DETERMINANTS OF LOW VON WILLEBRAND FACTOR PLASMA LEVELS** **08:30 - 08:45**  
Janine E. van Loon\* (NL), Janine van Loon, Weihong Tang, Ming-Huei Chen, David Strachan, Stella Trompet, Caroline Hayward, Nicholas L. Smith, Moniek P.M. de Maat

Thursday Oral



13

## ORAL COMMUNICATIONS

Thursday, July 28, 2011

- O-TH-046** **PLATELET-DERIVED VON WILLEBRAND FACTOR GLYCOSYLATION MEDIATES RESISTANCE TO ADAMTS13 PROTEOLYSIS** 08:45 - 09:00  
Rachel Therese McGrath\* (IE), Maartje van den Biggelaar, Barry Byrne, Emily McRae, Orla Rawley, Richard O'Kennedy, Jan Voorberg, James S O'Donnell
- O-TH-047** **MACROPHAGE LRP1 IS INVOLVED IN THE CLEARANCE OF VON WILLEBRAND FACTOR** 09:00 - 09:15  
Peter Lenting\* (FR), Ghasem Ratergarlari, Julie Pegon, Soline Odouard, Anna-Maria Navarette, Caterina Casari, Nathalie Saint-Lu, Olivier D Christophe, Cecile V Denis
- O-TH-048** **O-LINKED GLYCANS MEDIATE THE INTERACTION OF VON WILLEBRAND FACTOR WITH PLATELET RECEPTOR GLYCOPROTEIN IB UNDER SHEAR CONDITIONS** 09:15 - 09:30  
Agata Nowak\* (UK), Mike Laffan, Thomas Mckinnon

### Platelet Signaling II

Room C-1

*Chairpersons: Mark Kahn and Wolfgang Bergmeier (US)*

- O-TH-049** **STIM1 DEFICIENCY RESULTS IN IMPAIRED PLATELET PROCOAGULANT ACTIVITY AND PROTECTION FROM ARTERIAL THROMBOSIS** 14:30 - 14:45  
Firdos Ahmad\* (US), Lucia Stefanini, Timothy Daniel Ouellette, Teshell Greene, Stefan Feske, Wolfgang Bergmeier
- O-TH-050** **THE ROLE OF THE FOCAL ADHESION KINASE PYK2 IN PLATELET ACTIVATION** 14:45 - 15:00  
Ilaria Canobbio\* (IT), Lina Cipolla, Alessandra Consonni, Gianni Guidetti, Stefania Momi, Barbara Oliviero, Marco Falasca, Mitsui Okigaki, Cesare Balduini, Paolo Gresele, Mauro Torti
- O-TH-051** **THE TYROSINE KINASE PYK2 MEDIATES THE CROSS-TALK BETWEEN PLATELET INTEGRINS  $\alpha 2\beta 1$  AND  $\alpha IIB\beta 3$ .** 15:00 - 15:15  
Gianni F Guidetti\* (IT), Alessandra Consonni, Lina Cipolla, Ilaria Canobbio, Elisa Ciralo, Emilio Hirsch, Marco Falasca, Mitsuhiko Okigaki, Cesare Balduini, Mauro Torti
- O-TH-052** **TYROSINE PHOSPHORYLATED C-CBL REGULATES PLATELET FUNCTIONAL RESPONSES MEDIATED BY OUTSIDE-IN SIGNALING** 15:15 - 15:30  
Claudia Lorena Buitrago\* (US), Wallace Langdon, Archana Sanjay, Satya Kunapuli
- O-TH-053** **JAM-A PROTECTS FROM THROMBOSIS BY ATTENUATING C-SRC ACTIVATION BY RECRUITING CSK TO THE INTEGRIN  $\alpha IIB\beta 3$  AND SUPPRESSES OUTSIDE-IN SIGNALING IN PLATELETS** 15:30 - 15:45  
Meghna U Naik\* (US), Ulhas P Naik



## ORAL COMMUNICATIONS

Thursday, July 28, 2011

**O-TH-054** **PAIRWISE AGONIST SCANNING OF HUMAN PLATELETS REVEALS THE HIGH-DIMENSIONAL CALCIUM RESPONSE TO COMBINATORIAL MEDIATORS OF THROMBOSIS** **15:45 - 16:00**  
Scott L Diamond\* (US), Manash Chatterjee, Jeremy Purvis, Matt Flamm

**Contact Phase Activation** **Room C-2**

*Chairpersons:* and Martijn FBG Gebbink



**O-TH-055** **FUNCTIONS OF PLASMA KALLIKREIN FOR THROMBOSIS AND VASCULAR LEAKAGE *IN VIVO*** **14:30 - 14:45**  
Coen Maas\* (SE), Chris Oschatz, Thomas Renne

**O-TH-056** **FACTOR XII INTERACTION WITH PHOSPHATIDYLSERINE MEDIATES THE PROCOAGULANT ACTIVITY OF APOPTOTIC CELLS AND THEIR CLEARANCE** **14:45 - 15:00**  
Aizhen Yang\* (CN), Xuemei Zhu, Xuefeng Wang, Qiulan Ding, Raymond B. Birge, Yi Wu, Robert W. Colman

**O-TH-057** **DISTINCT FUNCTIONS OF EXTRINSIC AND INTRINSIC COAGULATION PATHWAYS IN THROMBUS FORMATION ON RUPTURED PLAQUES *IN VIVO* AND *IN VITRO*** **15:00 - 15:15**  
Judith M.E.M. Cosemans\* (NL), Marijke J.E. Kuijpers, Paola E.J. van der Meijden, Nadine J.A. Mattheij, Johan W.M. Heemskerk

**O-TH-058** **MAST CELL-HEPARIN INCREASES VASCULAR PERMEABILITY *IN VIVO* BY CONTACT SYSTEM-DRIVEN BRADYKININ FORMATION** **15:15 - 15:30**  
Chris Tina Oschatz\* (SE), Coen Maas, Jenny Bjorkqvist, Werner Mueller-Esterl, Walter A. Wuillemin, Thomas Renne

**O-TH-059** **MECHANISM AND THERAPY OF FAT EMBOLISM** **15:30 - 15:45**  
Felicitas E Mueller\* (SE), Paolo Parini, Robert Flaumenhaft, Thomas Renne

**O-TH-060** **COAGULATION FACTOR XIa INFLUENCES HUMAN FIBRIN CLOT STRUCTURE INDEPENDENT OF ADDITIONAL THROMBIN GENERATION** **15:45 - 16:00**  
Joke Konings\* (NL), Jose WP Govers-Riemslog, Helen Philippou, Nicola J Mutch, Julian I Borissoff, Sumitra Mohan, Guido Tans, Hugo Ten Cate, Robert AS Ariens

**Protein C** **Room D**

*Chairpersons:* Mitsuhiro Uchiba (JP) and Fernandez Jose (US)

**O-TH-061** **ZYMOGEN PROTEIN C AS A PROTECTIVE MODULATOR OF TUMOR PROGRESSION IN MURINE MODELS** **14:30 - 14:45**  
Valder R Arruda\* (US), Geerte Van Sluis, Paris Margaritis, Jenna Mauer, Armida Faella, Shangzhen Zhou, Katherine A High, C. Arnold Spek

Thursday Oral



15

## ORAL COMMUNICATIONS

Thursday, July 28, 2011

- O-TH-062** **HIGH-DENSITY LIPOPROTEIN ENHANCES ACTIVATED PROTEIN C CYTOPROTECTIVE SIGNALING ON ENDOTHELIAL CELLS** 14:45 - 15:00  
Fionnuala Ni Ainle\* (IE), Jennifer A. Johnson, Eimear M. Gleeson, Bridget-Ann Kenny, James S. O'Donnell, Roger J.S. Preston
- O-TH-063** **DISCRETE REGIONS OF THE FACTOR V B DOMAIN PROTECTS THE PROCOFACTOR FROM INACTIVATION BY ACTIVATED PROTEIN C** 15:00 - 15:15  
Haerin Kim\* (US), Laura Castellano, Mettine H.A. Bos, Rodney M. Camire
- O-TH-064** **ANTICOAGULANT ACTIVATED PROTEIN C SUPPRESSES OSTEOCLAST DIFFERENTIATION VIA ENDOTHELIAL PROTEIN C RECEPTOR** 15:15 - 15:30  
Kakunoshin Yoshida\* (JP), Takayuki Okamoto, Kunihiro Asanuma, Tatsuya Hayashi, Koji Suzuki, Atsumasa Uchida, Akihiro Sudo
- O-TH-065** **INHIBITION OF THROMBIN FORMATION BY ACTIVE SITE MUTATED ACTIVATED PROTEIN C \*** 15:30 - 15:45  
Gerry A F Nicolaes\* (NL), Karin C.A.A. Wildhagen, Kenneth Segers, B. Dahlback, Jan Rosing, Paul E. Bock
- O-TH-066** **SPECIFICITY OF ACTIVATED PROTEIN C (APC)-MEDIATED PROTEASE RECEPTOR 3 (PAR3) PROTEOLYSIS PROVIDES A MOLECULAR EXPLANATION FOR DIVERGENT PATTERNS FOR APC VS THROMBIN SIGNALING** 15:45 - 16:00  
Laurent O Mosnier\* (US)

### Laboratory Tests in Platelet Function

Room E

Chairpersons: Robert Andrews (AU) and Jonathan Miller 

- O-TH-067** **SPONTANEOUS PLATELET AGGREGATION IN PATIENTS WITH ACUTE CORONARY SYNDROME CORRELATES WITH RECURRENT THROMBOTIC EVENTS AND THE LEVEL OF VWF** 14:30 - 14:45  
Natalia Dovlatova\* (UK), Natalia Dovlatova, Julia Lange, Mark Thomas, Jane May, Stan Heptinstall
- O-TH-068** **MEASUREMENT OF PLATELET ADENOSINE TRIPHOSPHATE RELEASE UNEXPECTEDLY NORMALIZES AGGREGATION FINDINGS IN SOME SUBJECTS, INCLUDING PERSONS WITH QUEBEC PLATELET DISORDER** 14:45 - 15:00  
Catherine P M Hayward\* (CA), Karen Ann Moffat, Jean Francois Castilloux, Jodi Seecharan, Cormier Anik, Georges Etienne Rivard
- O-TH-069** **INSIGHTS ON THE MECHANISM OF PLATELET INHIBITION BY OMEGA-3 POLYUNSATURATED FATTY ACIDS. RESULTS OF THE LEAP TRIAL.** 15:00 - 15:15  
Joseph S Rossi\* (US), Mauricio G Cohen, Alison Motsinger, Allison Dupont, Regina Bowling, Jennifer Garbarino, Don Gabriel



## ORAL COMMUNICATIONS

Thursday, July 28, 2011

- O-TH-070** **P-SELECTIN IS ASSOCIATED WITH SUBSEQUENT ATHEROTHROMBOTIC EVENTS IN PATIENTS WITH RECENT ACUTE CORONARY SYNDROMES TREATED WITH CLOPIDOGREL** 15:15 - 15:30  
Mark Thomas\* (UK), Yanushi Wijeyeratne, Jane May, Sue Fox, Stan Heptinstall
- O-TH-071** **PATIENTS WITH RHEUMATOID ARTHRITIS HAVE A DECREASED RESPONSE TO COLLAGEN INDUCED PLATELET AGGREGATION AND INCREASED PLASMA LEVELS OF SOLUBLE GPVI.** 15:30 - 15:45  
Eimear Dunne\* (IE), Paul MacMullan, Michael C Berndt, Robert K Andrews, Elizabeth E Gardiner, Geraldine McCarthy, Dermot Kenny
- O-TH-072** **THROMBIN BINDING TO PLATELETS OF YOUNG PATIENTS WITH A HISTORY OF ACUTE MYOCARDIAL INFARCTION** 15:45 - 16:00  
Grazia Loredana Mendolicchio\* (IT), Monica Bacci, Dennis Zavalloni, Lidia Rota, Zaverio Marcello Ruggeri

### Hemophilia: Clinical Study

Sakura

Chairpersons: [REDACTED] and Alessandro Gringeri (IT)

- O-TH-073** **SWEDISH VERSUS DUTCH PROPHYLACTIC STRATEGY FOR HEMOPHILIA: DIFFERENCE IN OUTCOME IS SMALL BUT COST-DIFFERENCE IS LARGE** 14:30 - 14:45  
Kathelijn Fischer\* (NL), Katarina Steen-Carlsson, Pia Petrini, Margareta Holmstrom, Rolf Ljung, Erik Berntorp
- O-TH-074** **FIRST ANALYSIS OF 10-YEAR TREND IN NATIONAL FACTOR CONCENTRATES USAGE IN HEMOPHILIA: DATA FROM THE CANADIAN HEMOPHILIA ASSESSMENT AND RESOURCE MANAGEMENT SYSTEM.** 14:45 - 15:00  
Aicha N Traore\* (CA), Anthony K. C. Chan, Kathryn E. Webert, Nancy Heddle, Bruce Ritchie, Jean St-Louis, Irwin Walker
- O-TH-075** **QUALITY OF LIFE OF CHILDREN WITH HEMOPHILIA A UNDERGOING PROPHYLAXIS OR EPISODIC TREATMENT: RESULTS FROM THE ESPRIT STUDY** 15:00 - 15:15  
Sylvia von Mackensen\* (DE), Silvia Riva, Francesco Fusco, Lorenzo Mantovani, Alessandro Gringeri
- O-TH-076** **PRACTICE PATTERNS OF CANADIAN CHILDREN AND ADULTS WITH HEMOPHILIA A (HA) WHO ARE ON PROPHYLACTIC HOME INFUSION OF FACTOR VIII (FVIII)** 15:15 - 15:30  
Jerome Teitel\* (CA), Victor Blanchehte, Dorine Belliveau
- O-TH-077** **DIFFERENCIES IN THE CARE OF CHILDREN WITH HAEMOPHILIA IN EUROPE** 15:30 - 15:45  
Rolf Ljung\* (SE), Alessandro Gringeri, Laszlo Nemes, Margit Serban, Karin Berger, Wolfgang Schramm

Thursday Oral



17

## ORAL COMMUNICATIONS

Thursday, July 28, 2011

**O-TH-078** **LIFE-LONG PROPHYLAXIS IN A LARGE COHORT OF ADULT PATIENTS WITH SEVERE HAEMOPHILIA SHOWS A BENEFICIAL EFFECT ON ORTHOPAEDIC OUTCOMES AND QUALITY OF LIFE.** 15:45 - 16:00  
Mohammed Khawaji\* (SE), Jan Astermark, Erik Berntorp

### Thrombotic Disorders: Clinical II

Room A

Chairpersons: *stev*  *is (AU) and* 

**O-TH-079** **MORTALITY DUE TO PULMONARY EMBOLISM, MYOCARDIAL INFARCTION, AND STROKE AMONG PATIENTS STARTING DIALYSIS** 14:30 - 14:45  
Gurbey Ocak\* (NL), Karlijn J. van Stralen, Marion Verduijn, Friedo W. Dekker, Kitty J. Jager

**O-TH-080** **<DIV ALIGN=JUSTIFY>ENHANCED ENDOGENOUS THROMBIN POTENTIAL IS ASSOCIATED WITH THE SEVERITY OF CORONARY ATHEROSCLEROSIS</DIV ALIGN=JUSTIFY>** 14:45 - 15:00  
Julian I. Borissoff\* (NL), Julian I. Borissoff\*, Ivo A.P.G. Joosen\*, Mathijs O. Versteulen, Henri M.H. Spronk, Hugo ten Cate, Leonard Hofstra

**O-TH-081** **BLEEDING RISK IN VERY OLD PATIENTS ON VKA TREATMENT: RESULTS OF A PROSPECTIVE COLLABORATIVE STUDY** 15:00 - 15:15  
Daniela Poli\* (IT), Emilia Antonucci, Elisa Grifoni, Leonardo Di Gennaro, Anna Falanga, Pietro Falco, Marco Valerio Grasso, Francesco Marongiu, Simona Pedrini, Pasquale Pignatelli, Scortechini Rita Anna, Sophie Testa, Walter Ageno, Gualtiero Palareti

**O-TH-082** **INFLUENCE OF NON-GENETIC AND GENETIC FACTORS ON THE MAINTENANCE DOSE IN ELDERLY INPATIENTS ON FLUINDIONE, A NON-COUMARIN VITAMIN K ANTAGONIST** 15:15 - 15:30  
Virginie SIGURET (FR), Caroline MOREAU, Charlotte DEVERLIE, Eric PAUTAS, Marion ANDRO, Karine LACUT, Franck LEBOURGEOIS, Isabelle PEYRON, Jean-Louis GOLMARD, Joseph EMMERICH\*, Marie-Anne LORIOT, Isabelle GOUIN-THIBAUT

**O-TH-083** **SAFETY AND TOLERABILITY OF THE ORAL FACTOR XA INHIBITOR, YM150 VERSUS WARFARIN IN 1297 PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: A DOSE CONFIRMATION STUDY (OPAL-2)** 15:30 - 15:45  
Gregory YH Lip\* (UK), Jonathan L Halperin, Palle Petersen, George M Rodgers, Ronny W Renfurm

**O-TH-084** **ATRIAL FIBRILLATION RESULTS IN THE GENERATION OF UNIQUE BIOMARKERS AS STUDIED BY PROTEINCHIP AND BIOCHIP ARRAY TECHNIQUES** 15:45 - 16:00  
Debra A Hoppensteadt\* (US), Bruce Lewis, Indermohan Thethi, Josephine Cunanan, Evangelos Litinas, Rakesh Wahi, Jawed Fareed



## ORAL COMMUNICATIONS

Thursday, July 28, 2011

### VTE: Risk Factors II

Room B-1

Chairpersons: Fred Anderson (US) and Sergio Coccheri



O-TH-085

14:30 - 14:45

**NT-PRO-BNP LEVELS IN PATIENTS WITH ACUTE PULMONARY EMBOLISM ARE CORRELATED TO RIGHT AND NOT LEFT VENTRICULAR VOLUME AND FUNCTION**

Sharif M Pasha\* (NL), Noortje Van Der Bijl, Frederik A Klok, Albert De Roos, Lucia JM Kroft, Menno V Huisman

O-TH-086

14:45 - 15:00

**COMPARATIVE EFFECTIVENESS OF THROMBOPROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS ACROSS THE US ACUTE HOSPITAL SETTING**

Wei Huang\* (US), Frederick A Anderson, Alexander T Cohen

O-TH-087

15:00 - 15:15

**VENOUS THROMBOEMBOLISM (VTE): DISEASE BURDEN AND OUTCOMES - VTE EPIDEMIOLOGY GROUP (VEG) STUDY**

Carlos Martinez\* (DE), Stephan Rietbrock, Luke Bamber, Alexander T Cohen

O-TH-088

15:15 - 15:30

**RISK FACTORS FOR VENOUS THROMBOEMBOLISM (VTE) IN SURGICAL PATIENTS IN THE VTE EPIDEMIOLOGY GROUP (VEG) STUDY**

Carlos Martinez\* (DE), Stephan Rietbrock, Alexander T Cohen

O-TH-089

15:30 - 15:45

**RISK FACTORS FOR VENOUS THROMBOEMBOLISM (VTE) IN MEDICAL PATIENTS IN THE VTE EPIDEMIOLOGY GROUP (VEG) STUDY**

Alexander T Cohen\* (UK), Stephan Rietbrock, Carlos Martinez

O-TH-090

15:45 - 16:00

**SAFE EXCLUSION OF DEEP VEIN THROMBOSIS IN PRIMARY AND SECONDARY CARE USING THE WELLS-RULE; A LARGE INDIVIDUAL PATIENT DATA META-ANALYSIS**

Geert-Jan Geersing\* (NL), Peter Zuithoff, Clive Kearon, David Anderson, Johan Elf, Shannon Bates, Arno Hoes, Kristel Janssen, Roderik Kraaijenhagen, Ruud Oudega, Roger Schutgens, Scott Stevens, Phil Wells, Karel Moons

### Pregnancy and Thrombosis II

Room B-2

Chairpersons: Grégoire LE GAL (FR) and Per-Morten Sandset (NO)

O-TH-091

14:30 - 14:45

**LOW MOLECULAR WEIGHT HEPARIN FOR THE SECONDARY PREVENTION OF PLACENTAL-MEDIATED PREGNANCY COMPLICATIONS: A SYSTEMATIC REVIEW AND META ANALYSIS.**

Marc Alan Rodger\* (CA), Jean-Christophe Gris, Evelyne Rey, Marc Carrier, Gregoire Le Gal

Thursday Oral



19



## ORAL COMMUNICATIONS

Thursday, July 28, 2011

- O-TH-092** **PREGNANCY RELATED VENOUS THROMBOSIS IS ASSOCIATED WITH REDUCED SENSITIVITY TO ACTIVATED PROTEIN C IN THE ABSENCE OF THE FACTOR V LEIDEN POLYMORPHISM** 14:45 - 15:00  
Astrid Bergrem\* (NO), Astrid Bergrem, Anders E.A Dahm, Anne Flem Jacobsen, Marie-Christine Mowinckel, Leiv Sandvik, Per Morten Sandset
- O-TH-093** **WOMEN WITH FACTOR V LEIDEN MUTATION AND UNEXPLAINED RECURRENT MISCARRIAGE HAVE A SHORTER TIME TO PREGNANCY THAN NON-CARRIERS; AN EVOLUTIONARY ADVANTAGE?** 15:00 - 15:15  
Thijs E van Mens\* (NL), Stef P Kaandorp, Mariette Goddijn, Barbara A Hutten, Saskia Middeldorp
- O-TH-094** **GENETIC VARIABILITY OF LXRβ GENE MIGHT CONTRIBUTE TO PREECLAMPSIA** 15:15 - 15:30  
Jean-Christophe Raymond Gris\* (FR), Kevin Mouzat, Erick Mercier, Anne Polge, Alexandre Evrard, Jean-Marc A. Lobaccaro, Jean-Paul Brouillet, Serge Lumbroso
- O-TH-095** **ENOXAPARIN FOR THE SECONDARY PREVENTION OF PLACENTAL VASCULAR COMPLICATIONS IN WOMEN WITH PREVIOUS SEVERE PRE-ECLAMPSIA: THE PILOT RANDOMISED CONTROLLED NOH-PE STUDY.** 15:30 - 15:45  
Jean-Christophe Raymond Gris\* (FR), Celine Chauleur, Pierre Mares, Eva Nouvellon, Eric Mercier, Sylvie Bouvier, Isabelle Quere, Jean-Yves Lefrant, Bassam Haddad, Michel Dauzat
- O-TH-096** **ATTENUATION OF THROMBIN SIGNALING, BUT NOT PLATELET AGGREGATION, RESCUES FETAL LOSS IN A MURINE MODEL OF FACTOR V LEIDEN -ASSOCIATED PLACENTAL FAILURE.** 15:45 - 16:00  
Rashmi Sood\* (US), Magarya S Waitara, Jianzhang An, Michelle Bordas, Brian G Petrich

### Platelet Granules

Room C-1

Chairpersons: [REDACTED] and Joseph Italiano (US)

- O-TH-097** **LOSS OF PIKFYVE IN MURINE PLATELETS LEADS TO ABERRANT PLATELET GRANULE BIOGENESIS AND A PLEOMORPHIC PHENOTYPE WITH MULTIORGAN FAILURE** 16:15 - 16:30  
Sang Hee Min\* (US), Aae Suzuki, Liang Zhao, Lurong Lian, Sidney W Whiteheart, Michael S Marks, John Choi, Charles S Abrams
- O-TH-098** **THE PF4-VARIANT CHEMOKINE CXCL4L1 AND PF4 ARE STORED IN MEGAKARYOCYTE ALPHA GRANULES VIA THE SAME PATHWAY** 16:30 - 16:45  
Jean-Philippe Raymond Rosa\* (FR), AMINE BAZAA, ESSID HELA, ODILE ISSERTIAL, LEBRET MARILYNE, ANNE DUBART-KUPPERSCHMITT, JEAN-PHILIPPE ROSA
- O-TH-099** **IMPAIRMENT OF THROMBUS FORMATION IN MUNC13-4 DEFICIENT MICE** 16:45 - 17:00  
Joshua S Savage\* (UK), Olga Konopatskaya, Alastair W Poole



## ORAL COMMUNICATIONS

Thursday, July 28, 2011

- O-TH-100** **MEMBRANE REMODELING DURING PLATELET SPREADING REQUIRES MUNC13-4-DEPENDENT EXOCYTOSIS OF  $\alpha$ -GRANULES EXPRESSING VAMP7** **17:00 - 17:15**  
Robert Flaumenhaft\* (US), Christian G. Peters
- O-TH-101** **INHIBITION OF NEUTROPHIL TRANSMIGRATION BY TREM-LIKE TRANSCRIPT (TLT)-1** **17:15 - 17:30**  
Anthony Valance Washington\* (PR), Jessica Morales, Linette Rivera, Rysienid Hernandez, Karina Villa, James Gattis, Giovanni Ortiz, Michael Gomez, Monica Fernandez, Marilene Martinez, Robert Hunter
- O-TH-102** **MRP4 MEDIATED TRANSPORT IS PART OF THE PHYSIOLOGICAL MECHANISM OF ELIMINATION CYCLIC NUCLEOTIDES FROM HUMAN PLATELETS** **17:30 - 17:45**  
Alessandra Borgognone\* (IT), Fabio Maria Pulcinelli

### Thrombin Generation Test

Room C-2

Chairpersons: [REDACTED] and Joost Meijers (NL)

- O-TH-103** **REGULATION OF THROMBIN GENERATION AND CLOT GROWTH BY MUTANT FACTOR VIII MOLECULES** **16:15 - 16:30**  
Jean-Claude Bordet\* (FR), Mickael Panteleev, Jean-Luc Plantier, Yesim Dargaud, Fazly Ataulakhanov, Claude Negrier
- O-TH-104** **ERYTHROCYTE-DEPENDENT THROMBIN GENERATION IN WHOLE-BLOOD** **16:30 - 16:45**  
Marisa Ninivaggi\* (NL), Rafael Apitz-Castro, Theo Lindhout, Coenraad H. Hemker
- O-TH-105** **RELATION OF BLEEDING TENDENCY IN RARE BLEEDING DISORDERS WITH DEFICIENCIES IN FACTOR II, V, VII, X, XIII, AND FIBRINOGEN AND SIMULTANEOUS THROMBIN AND PLASMIN GENERATION.** **16:45 - 17:00**  
Mark van Geffen\* (NL), Flora Peyvandi, Marzia Menegatti, Arnoud Loof, Paul Lap, Mehran Karimi, Britta Laros-van Gorkom, Paul Brons, Waander van Heerde
- O-TH-106** **THE IMPACT OF VITAMIN K-DEPENDENT PROCOAGULANT PROTEINS ON THROMBIN GENERATION IN A CELL-BASED MODEL OF WARFARIN ANTICOAGULATION** **17:00 - 17:15**  
Yesim Dargaud\* (FR), Maureane Hoffman, Leana LeFrappier, Dougald M Monroe
- O-TH-107** **EFFECT OF LOW DOSE OMEGA-3 ON FIBRIN, THROMBIN AND COAGULATION** **17:15 - 17:30**  
Brad McEwen\* (AU), Marie-Christine Morel-Kopp, Walter Chen, Geoffrey H Tofler, Christopher M Ward

Thursday Oral



21

## ORAL COMMUNICATIONS

Thursday, July 28, 2011

**O-TH-108** 17:30 - 17:45

**REGULATION OF CLOT GROWTH BY FACTOR XI THROUGH THE GENERATION OF THROMBIN INSIDE THE CLOT**

Mikhail V Ovanesov\* (US), Li W William, Fazoil I Ataullakhanov, David Gailani, Alexey M Shibeko

### Coagulation Factors II

Room D

*Chairpersons: Arnold Spek (NL) and Saulius Butenas (US)*

**O-TH-109** 16:15 - 16:30

**ACTIVATED FACTOR X IS A NOVEL REGULATOR OF MONOCYTE TOLL-LIKE RECEPTOR SIGNALING**

Eimear Marie Gleeson\* (IE), Fionnuala Ni Ainle, Bridget-Ann Kenny, James S. O'Donnell, Roger J.S. Preston

**O-TH-110** 16:30 - 16:45

**THE ROLE OF FACTOR V ACTIVATION IN THRESHOLDING BEHAVIOUR IN PROTHROMBIN ACTIVATION BY PROTHROMBINASE**

P. Michael Cook\* (CA), Harry Zhou, Michael E. Nesheim

**O-TH-111** 16:45 - 17:00

**RECOMBINANT FIX FC FUSION PROTEIN IS EFFECTIVE FOR ON-DEMAND TREATMENT WITH SIGNIFICANTLY PROLONGED EFFICACY FOR PROPHYLAXIS IN HEMOPHILIA B MICE**

Tongyao Liu\* (US), Xin Zhang, Susannah Patarroyo-White, Douglas Drager, Glenn Pierce, Haiyan Jiang

**O-TH-112** 17:00 - 17:15

**FACTOR IX-R338L (FIX PADUA) IS AN EFFECTIVE ALTERNATIVE FOR THE TREATMENT OF CANINE SEVERE HEMOPHILIA B.**

Jonathan Douglas Finn\* (US), Timothy Nichols, Paolo Simioni, Nikos Svoronos, Scott N Ashley, Shangzhen Zhou, Katherine A High, Valder R Arruda

**O-TH-113** 17:15 - 17:30

**GENETIC DETERMINANTS OF PLASMA FACTOR VIII ANTIGEN LEVELS: A TARGET GENE SNP ANALYSIS OF THE ARIC COHORT**

Marco Campo (US), Ashley Buchanan, Fuli Yu, Maja Barbalic, Woody Chambliss, Christie Ballantyne, Aaron Folsom, Eric Boerwinkle, Jing-fei Dong\*

**O-TH-114** 17:30 - 17:45

**HISTIDINE-RICH GLYCOPROTEIN BINDS FIBRINOGEN WITH HIGH AFFINITY AND MODULATES THROMBIN BINDING TO THE  $\gamma$ '-CHAIN**

Trang T Vu\* (CA), Alan R Stafford, Beverly A Leslie, James C Fredenburgh, Paul Y Kim, Jeffrey I Weitz

### Angiogenesis and Lymphangiogenesis

Room E

*Chairpersons: Ulhas Naik (US) and Yoshihiko Saito (JP)*

**O-TH-115** 16:15 - 16:30

**JUNCTIONAL ADHESION MOLECULE-A DIFFERENTIALLY REGULATES FGF2- AND VEGF-INDUCED ANGIOGENESIS.**

Meghna U Naik\* (US), Ulhas P Naik



## ORAL COMMUNICATIONS

Thursday, July 28, 2011

- O-TH-116** **THE ROLE OF BREAST CANCER CELLS MICROPARTICLES IN THROMBOGENICITY AND ANGIOGENESIS FOLLOWING CHEMOTHERAPY** 16:30 - 16:45  
Anat Aharon\* (IL), Benjamin Brenner
- O-TH-117** **DISTINCT PLATELET SECRETION AND SURFACE EXPRESSION OF PROANGIOGENIC AND ANTIANGIOGENIC FACTORS UPON DIFFERENT PLATELET STIMULI** 16:45 - 17:00  
Nailin Li\* (SE), Madhumita Chatterjee, Zhangsen Huang, Wei Zhang, Lei Jiang, Kjell Hultenby, Linjing Zhu, Hu Hu, Gunnar P. Nilsson, Nailin Li
- O-TH-118** **PLATELETS REGULATE THE FORMATION OF THE LYMPHATIC VASCULATURE BY MODULATING THE MIGRATORY POTENTIAL OF LYMPHATIC ENDOTHELIAL CELLS** 17:00 - 17:15  
Leyre Navarro-Nunez\* (UK), Leyre Navarro-Nunez, Brenda A Finney, Gerard B Nash, Steve P Watson
- O-TH-119** **ROLE OF ENDOTHELIAL CELL-DERIVED ENDOTHELIN-1 IN THE INTERPLAY BETWEEN FIBROSIS AND LYMPHANGIOGENESIS** 17:15 - 17:30  
Anggoro B Hartopo\* (JP), Noriaki Emoto, Keiko Yagi, Kazuhiko Nakayama, Nur Arfian, Dwi Aris A Nugrahaningsih, Vita Y Anggraeni, Hirowati Ali, Dyah S Mayasari, Eko Purnomo, Ken-ichi Hirata
- O-TH-120** **UROKINASE RECEPTOR (UPAR) MEDIATED INTEGRIN REDISTRIBUTION REPRESENTS A CENTRAL MECHANISM FOR GROWTH FACTOR INDUCED ENDOTHELIAL CELL MIGRATION** 17:30 - 17:45  
Gerald W Prager\* (AT), Matthias Unseld, Johannes Breuss, Bernd R Binder, Christoph C Zielinski

### Hemophilia: Innovative Therapy II

Sakura

Chairpersons: CS Manno and Benny Sorensen



- O-TH-121** **ENHANCED PLATELET BINDING OF A FACTOR VIIIA ANALOG WITH ENHANCED TISSUE FACTOR-INDEPENDENT ACTIVITY** 16:15 - 16:30  
Maureane Hoffman\* (US), Maureane Hoffman, Egon Persson, Mirella Ezban, Dougal M Monroe
- O-TH-122** **PHASE 3 DOSE SETTING FOR N9-GP, A RECOMBINANT FIX DERIVATIVE, IN HAEMOPHILIA B PATIENTS USING EXTRAPOLATIONS OF PHASE 1 DATA WITH POPULATION PHARMACOKINETIC MODELLING** 16:30 - 16:45  
Peter W Collins\* (UK), Peter W Collins, Estelle Watson, Karin Knobe, Andreas Groth, Judi Moss
- O-TH-123** **EVALUATING THE EFFICACY OF A STEM CELL-BASED GENE THERAPY STRATEGY IN A CANINE MODEL OF HEMOPHILIA A.** 16:45 - 17:00  
Margareth C Ozelo\* (BR), Christine Brown, Carol Hegadorn, Andrea Labelle, Morag McMurray, Lori Harpell, Sandra Powell, James F Hulvat, Janine Handforth, Andrew Winterborn, Christine Hough, David Lillicrap

Thursday Oral



23

## ORAL COMMUNICATIONS

Thursday, July 28, 2011

- O-TH-124** **DOSE-DEPENDENT ACTIVATION OF CAPSID-SPECIFIC T CELLS AFTER AAV SEROTYPE 8 VECTOR ADMINISTRATION IN A CLINICAL STUDY FOR HEMOPHILIA B** **17:00 - 17:15**  
Federico Mingozzi\* (US), Mingozzi Federico, Etiena Basner-Tschakarjan, Yifeng Chen, Amit C Nathwani, Edward GD Tuddenham, Cecilia Rosales, Jenny McIntosh, Anne Riddell, Pradip Rustagi, Bertil Glader, Mark A Kay, James Allay, John Coleman, Susan Sleep, John Gray, Ulrike Reiss, Arthur W Nienhuis, Andrew M Davidoff, Katherine A High
- O-TH-125** **INHIBITOR ERADICATION AND VECTOR READMINISTRATION IN A NON-HUMAN PRIMATE MODEL OF AAV-MEDIATED LIVER GENE TRANSFER FOR HEMOPHILIA B** **17:15 - 17:30**  
Federico Mingozzi\* (US), Federico Mingozzi, Yifeng Chen, Shangzhen Zhou, Samuel L Murphy, Mark Metzger, Robert E Donahue, Fraser J Wright, Cynthia J Dunbar, Katherine A High
- O-TH-126** **PROPAGATION AND GENETIC MODIFICATION OF AUTOLOGOUS HEPATOCYTES TOWARD GENE AND CELL THERAPY FOR HEMOPHILIA B** **17:30 - 17:45**  
Kohei Tatsumi\* (JP), Kazuo Ohashi, Chise Tateno, Hiroyuki Nakai, Anja Ehrhardt, Rie Utoh, Katsutoshi Yoshizato, Teruo Okano
- VTE: Risk Factors III** **Room A**
- Chairpersons: Hideo Wada and David Bergqvist (SE)*
- O-TH-127** **CLINICAL HISTORY OF PATIENTS WITH CEREBRAL VEIN THROMBOSIS: RESULTS OF A LARGE MULTICENTER INTERNATIONAL COHORT STUDY** **16:15 - 16:30**  
Francesco Dentali\* (IT), Daniela Poli, Umberto Scoditti, Matteo ND Di Minno, Valerio De Stefano, Sergio Siragusa, Milan Kostal, Gualtiero Palareti, Maria Teresa Sartori, Elvira Grandone, Maria Cristina Vedovati, Dan Witt, Mauro Silingardi, Anna Falanga, Sophie Testa, Giovanni Barillari, Stefano Barco, Marina Bianchi, Emanuele Rezoagli, Walter Ageno
- O-TH-128** **PROTHROMBINEX-VF (PTX-VF) USAGE FOR REVERSAL OF COAGULOPATHY: PROSPECTIVE EVALUATION OF THROMBOGENIC RISK** **16:30 - 16:45**  
Eileen Grace Merriman\* (NZ), Louise Bobbitt, Jacqueline Raynes, Ross Henderson, Hilary Blacklock, Sanjeev Chunilal
- O-TH-129** **EMERGING CONCEPTS: IDENTIFYING, MONITORING AND REDUCING PREVENTABLE MAJOR BLEEDS IN THE HOSPITAL SETTING** **16:45 - 17:00**  
Deborah Caraballo\* (US), Charles E Mahan
- O-TH-130** **ISOLATED DISTAL DEEP-VEIN THROMBOSIS IS NOT A POOR PROVIDER OF VENOUS THROMBOEMBOLIC RECURRENCE** **17:00 - 17:15**  
Jean-Philippe Galanaud\* (FR), Celine Genty, Marie-Antoinette Sevestre, Isabelle Quere, Jean-Luc Bosson



## ORAL COMMUNICATIONS

Thursday, July 28, 2011

- O-TH-131** **CHRONIC KIDNEY DISEASE AND RISK OF VENOUS THROMBOSIS: AN INDICATION FOR THROMBOPROPHYLAXIS?** 17:15 - 17:30  
Gurbey Ocak\* (NL), Willem M. Lijfering, Marion Verduijn, Friedo W. Dekker, Carla Y. Vossen, Frits R. Rosendaal
- O-TH-132** **THE RISK OF VENOUS THROMBOSIS RELATED TO CHRONIC KIDNEY DISEASE IS MEDIATED BY HIGH LEVELS OF FACTOR VIII** 17:30 - 17:45  
Gurbey Ocak\* (NL), Carla Y. Vossen, Marion Verduijn, Friedo W. Dekker, Willem M. Lijfering, Frits R. Rosendaal

### Thromboprophylaxis in Children

Room B-1

Chairpersons: Marilyn Manco-Johnson (US) and [REDACTED]

- O-TH-133** **SUBCUTANEOUS PROTEIN C CONCENTRATE IN THE PROPHYLAXIS OF THROMBOSIS IN SEVERE PROTEIN C DEFICIENCY** 16:15 - 16:30  
Adrian MB Minford (UK), Mary Mathias, Mary Morgan, Michele David, Natividad Gomez Gomez, Wolfgang Behnisch, Martin Olivieri, Ulrike Nowak-Gottl, Hans-Joerg Hertfelder\*, Paul Brons
- O-TH-134** **CHARACTERIZATION OF POST-THROMBOTIC SYNDROME IN CHILDREN WITH CONGENITAL HEART DISEASE: A COMPARISON OF INSTRUMENTS** 16:30 - 16:45  
Leonardo Rodrigues Brandao\* (CA), Cedric Manlhiot, Suzan Williams, Brian C. McCrindle
- O-TH-135** **SAFETY AND EFFICACY OF LOW MOLECULAR WEIGHT HEPARINS IN CHILDREN: A SYSTEMATIC REVIEW OF THE LITERATURE AND META-ANALYSIS OF SINGLE ARM STUDIES** 16:45 - 17:00  
Ulrike Nowak-Gottl\* (DE), Christoph Bidlingmaier, Gili Kenet, Karin Kurnik, Daniela Manner, Prasad Matthew, Ralf Junker, Lesley Mitchell, Anne Katarina Krumpel, Ulrike Nowak-Gottl
- O-TH-136** **PROPHYLACTIC ANTICOAGULATION DECREASES CATHETER-RELATED THROMBOSIS AND OCCLUSION IN CHILDREN WITH HOME PARENTERAL NUTRITION** 17:00 - 17:15  
Cornelia Helena van Ommen\* (NL), Irene L. Vegting, Merit M. Tabbers, Marc A. Benninga, Jim C. Wilde, Mireille J. Serlie
- O-TH-137** **RANDOMIZED CONTROLLED TRIAL COMPARING HIGH-DOSE VERSUS LOW-DOSE HEPARINIZATION PROTOCOLS FOR PROPHYLAXIS OF THROMBOTIC COMPLICATIONS DURING CC IN CHILDREN (HEARTCAT STUDY)** 17:15 - 17:30  
Andreas Hanslik (AT), Erwin Kitzmueller, Katharina Thom, Haumer Markus, Wolfgang Mlekusch, Ulrike Salzer-Muhar, Ina Michel-Bhenke, Christoph Male\*
- O-TH-138** **THROMBOTIC COMPLICATIONS AND THROMBOPROPHYLAXIS IN SINGLE VENTRICLE HEART PALLIATION IN CHILDREN** 17:30 - 17:45  
Leonardo Rodrigues Brandao\* (CA), Cedric Manlhiot, Judith Kwok, Stefan Kegel, Ines B. Menjak, Caitlin L. Carew, Anthony K. Chan, Christopher A. Caldarone, Glen S. Van Arsdell, Brian W. McCrindle

Thursday Oral



25

## ORAL COMMUNICATIONS

Thursday, July 28, 2011

### Thrombotic Disorders: Genetic Determinations and Epidemiology

Room B-2

*Chairpersons: Vicente Vicente (ES) and Mary Cushman (US)*

- O-TH-139** **SOCIAL RISK FACTORS FOR VENOUS THROMBOEMBOLISM (VTE) IN THE VTE EPIDEMIOLOGY GROUP (VEG) STUDY** 16:15 - 16:30  
Alexander T Cohen\* (UK), Stephan Rietbrock, Carlos Martinez
- O-TH-140** **IDENTIFICATION OF BTN2A1 AS A SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION IN JAPANESE INDIVIDUALS BY A GENOME-WIDE ASSOCIATION STUDY** 16:30 - 16:45  
Yoshiji Yamada\* (JP)
- O-TH-141** **EXOME SEQUENCING IDENTIFIES NBEAL2 AS THE CAUSATIVE GENE FOR GRAY PLATELET SYNDROME** 16:45 - 17:00  
Cornelis A Albers\* (UK), Ana Cvejic, Remi Favier, Evelien E Bouwmans, Marie-Christine Alessi, Paul Bertone, Gregory Jordan, Graham Kiddle, Myrto Kostadima, Randy J Read, Botond Sipos, Peter Smethurst, Jonathan Stephens, Katrin Voss, Alan Nurden, Augusto Rendon, Paquita Nurden, Willem H Ouwehand
- O-TH-142** **NOVEL GENETIC DETERMINANTS OF PLASMA VON WILLEBRAND FACTOR AND FIBRINOGEN ANTIGEN LEVELS IN A POPULATION OF HEALTHY SIBLINGS** 17:00 - 17:15  
Karl Desch\* (US), Jun Li, Ayse Bilge Ozel, David Siemieniak, David Ginsburg
- O-TH-143** **HAPLOTYPES IN THE CYP1A2 AND CYP3A4 GENES AND THE RISK OF ORAL CONTRACEPTIVE-ASSOCIATED VENOUS THROMBOSIS** 17:15 - 17:30  
Bernardine H Stegeman\* (NL), Hans L Vos, Frans M Helmerhorst, A Van Hylckama Vlieg, Pieter H Reitsma, Frits R Rosendaal
- O-TH-144** **GENETIC RISK SCORE FROM GWA STUDIES IS STRONGLY ASSOCIATED WITH ANGIOGRAPHICALLY-DEFINED CORONARY ARTERY DISEASE, BUT NOT WITH MORTALITY IN THE SETTING OF SECONDARY PREVENTION** 17:30 - 17:45  
Nicola Martinelli\* (IT), Oliviero Olivieri, Patrizia Guarini, Simonetta Friso, Francesca Pizzolo, Letizia Consoli, Roberta Micaglio, Fabiana Busti, Domenico Girelli



## POSTER PRESENTATIONS

Thursday, July 28, 2011

### Signal transduction of platelet activation

- P-TH-001 REGULATION OF PLATELET FUNCTIONAL AND MECHANICAL PROPERTIES BY NITRIC OXIDE DONORS**  
Volha D Bichan\* (BY), Ekaterina V Shamova, Elizaveta S Drozd, Irina V Gorudko, Sergey A Chizhik, Konstantin B Shumaev, Sergey N Cherehkevich, Anatoliy F Vanin
- P-TH-002 GAS6 RECEPTORS, TYRO3, AXL AND MER, DIFFERENTIALLY PARTICIPATE IN GLYCOPROTEIN VI-MEDIATED PLATELET ACTIVATION**  
Junsong Zhou\* (CN), Lu Wang, Qingxian Lu, Katsue Suzuki-Inoue, Yi Wu, Yukio Ozaki
- P-TH-003 AGONIST-INDUCED PLATELET ACTIVATION IS REGULATED BY ASK1 THROUGH MKK6/P38 KINASE PATHWAY**  
Ulhas P Naik\* (US), Ramya Turaga, Hidinori Ichijo, Meghna U Naik
- P-TH-004 AN RNAI SCREENING TO IDENTIFY THE MOLECULES INVOLVED IN INTEGRIN  $\alpha$ IIb $\beta$ 3 ACTIVATION**  
Yasuyuki Matsuda\* (JP), Shigenori Honda, Toshiyuki Miyata
- P-TH-005 GLUTATHIONE-DEPENDENT PLATELET INTERACTIONS WITH NEUTROPHILS AND TUMOR CELLS**  
Irina Gorudko\* (BY), Ekaterina Shamova, Anna Mukhortova, Luda Shishlo, Sergey Gusev, Oleg Panasenko, Sergey Cherenkevich
- P-TH-006 CHARACTERIZATION OF MYOSIN LIGHT CHAIN ACTIVATION DURING CLOT RETRACTION**  
Christilla Bachelot-Loza\* (FR), Marion Egot, Tristan Mirault, Françoise Grelac, Genevieve Baujat, Dominique Lasne, Christilla Bachelot-Loza
- P-TH-007 DUAL REGULATION OF IN VIVO THROMBOSIS BY POLO-LIKE KINASE 3: SUPPORT AGONIST-INDUCED GRANULAR SECRETION, BUT SUPPRESS OUTSIDE-IN SIGNALING**  
Ulhas P Naik\* (US), Meghna U Naik, Brendan Bachman, John C Kostyak, Wei Dai
- P-TH-008 STAT3 REGULATES COLLAGEN-INDUCED PLATELET AGGREGATION INDEPENDENT OF ITS TRANSCRIPTION FACTOR ACTIVITY**  
Zhou Zhou\* (US), Francisca C. Gushiken, Angela L. Bergeron, Wensheng Sun, Niloufar Aghakasiri, Vinod K. Vijayan, Rolando Rumbaut, Jose A. Lopez, Jing-fei Dong
- P-TH-009 A NOVEL SYK-INDEPENDENT PI-3 KINASE DEPENDENT TYROSINE KINASE PATHWAY LEADING TO FIBRINOGEN ACTIVATION IN PLATELETS**  
Todd M. Getz\* (US), Lorena Buitrago, YingYing Mao, Satya Kunapuli
- P-TH-010 SYK-DEPENDENT AND -INDEPENDENT GENERATION OF REACTIVE OXYGEN SPECIES DOWNSTREAM OF GPVI ENGAGEMENT**  
Jane F Arthur\* (AU), Elizabeth E Gardiner, Jing Jing, Amanda K Davis, Michael C Berndt, Robert K Andrews
- P-TH-011 ROLE OF MITOCHONDRIA IN THE PROCESS OF PLATELET ACTIVATION AND THROMBUS FORMATION UNDER BLOOD FLOW CONDITIONS**  
Noriko Tamura\* (JP), Yohei Nanazawa, Shinya Goto

Thursday Posters



27



## POSTER PRESENTATIONS

Thursday, July 28, 2011

### Biology of platelets

- P-TH-012 STAPHYLOCOCCAL EXTRACELLULAR ADHERENCE PROTEIN (EAP) INDUCES PLATELET ADHESION, AGGLUTINATION, AGGREGATION AND PROCOAGULANT ACTIVITY**  
Anne Bertling\* (DE), Silke Niemann, Muzaffar Hussain, Martin F. Brodde, Silke Pohl, Tina Schifferdecker, Joachim Roth, Kerstin Jurk, Anja Mueller, Georg Peters, Christine Heilmann, Beate E. Kehrel
- P-TH-013 MOLECULAR MECHANISMS INVOLVED IN THE ANTITHROMBOTIC ACTIVITY OF AEGYPTIN, A NOVEL MOSQUITO-DERIVED COLLAGEN-BINDING PROTEIN**  
Daniella M Mizurini\* (BR), Eric Calvo, Ivo M Francischetti, Robson Q Monteiro
- P-TH-015 *IN VIVO* ROLES OF DISABLED-2 (DAB2) IN HAEMOSTASIS AND PLATELET FUNCTION: STUDIES USING A MEGAKARYOCYTE LINEAGE-RESTRICTED DAB2 KNOCKOUT**  
Chien-Ling Huang\* (TW), Chung-Ching Lin, Yao-Wen Chang, Jonathan A. Cooper, Ju-Chien Cheng, Ching-Ping Tseng
- P-TH-016 IN VIVO ACTIVATED PLATELETS EXPRESS CD40L IN HUMANS RESULTING IN ENDOTHELIAL ACTIVATION**  
Paolo Gresele\* (IT), Silvia Giannini, Emanuela Falcinelli, Loredana Bury, Giuseppe Guglielmini, Roberta Rossi, Stefania Momi
- P-TH-017 PLATELET-DERIVED MATRIX METALLOPROTEINASE-2 (MMP-2) REGULATES PLATELET AND LEUKOCYTE MIGRATION THROUGH LUNG TISSUE IN A MURINE MODEL OF ALLERGIC INFLAMMATION**  
Stefania Momi\* (IT), Simon C Pitchford, Clive P Page, Paolo Gresele
- P-TH-018 THE 78 KDA GLUCOSE RESPONSE PROTEIN (GRP78) IS RECRUITED TO THE SURFACE OF ENDOTHELIUM BY INTERACTING WITH THROMBOMODULIN AND IT DEMONSTRATES ANTITHROMBOTIC ACTIVITY**  
Anup Ramashankar Sharma\* (AU), Xiang-Ming Zhang, Carly Selan, Anushka Samudra, Lisa Murray-Segal, Evelyn Salvaris, Belinda Michell, Bruce Kemp, Conway E.D., Yuping Yuan, Anthony d'Apice, Peter Cowan, Harshal Nandurkar
- P-TH-019 OREXIN BUT NOT OBESTATIN OR NEUROPEPTIDE Y INHIBITS ADP INDUCED PLATELET AGGREGATION: IMPACT ON OBESITY RELATED CARDIOVASCULAR DISEASE**  
Hisham S Elbatarny\* (CA), Donald H Maurice
- P-TH-020 EXPRESSION AND LOCALIZATION OF THE MEMBRANE-BINDING AND -DEFORMING PROTEIN, PACSIN 2, IN PLATELETS AND MEGAKARYOCYTES**  
Herve Falet\* (US), Terese Joensson, Antonija Jurak Begonja, John H Hartwig, Herve Falet
- P-TH-021 INTERACTION BETWEEN PLATELETS AND ADAMTS-13**  
Kimberly MacEachern\* (CA), Carlene Lott, Alexander Hamilton, Kayleen Elcich, Maha Othman

### Platelet receptors

- P-TH-022 A CRITICAL ROLE FOR THE ADP RECEPTOR, P2Y<sub>12</sub>, IN *STREPTOCOCCUS ORALIS* INDUCED PLATELET ACTIVATION**  
Dorothea O Tilley\* (IE), Sarah A Maume, Dermot Cox, Albert Smolenski, CW Ian Douglas, Steven W Kerrigan



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-023 GLYCOPROTEIN IB $\alpha$  IS A MECHANORECEPTOR WHICH CLUSTERS UPON COLD STORAGE AND HYDRODYNAMIC FORCE**  
Eelo Gitz\* (NL), Hans Deckmyn, Cornelis A Koekman, Dave J van den Heuvel, Hans C Gerritsen, Jan-Willem Akkerman
- P-TH-024 NOVEL MOLECULAR ASSOCIATION OF ADP PURINERGIC RECEPTOR, P2Y<sub>12</sub> WITH TETRASPANIN SUPERFAMILY MEMBER, CD151 IN HUMAN PLATELETS**  
Fatemeh Moheimani\* (AU), Leonie K Ashman, Mark D Wright, Denise E Jackson
- P-TH-025 THE CX3C CHEMOKINE FRACTALKINE MEDIATES PLATELET ADHESION VIA THE VON WILLEBRAND RECEPTOR GLYCOPROTEIN IB**  
Sascha Meyer dos Santos\* (DE), Ute Klinkhardt, Klaus Scholich, Karen Nelson, Nadejda Monsefi, Hans Deckmyn, Karina Kuczka, Anita Zorn, Sebastian Harder
- P-TH-026 INCREASED PLATELET COUNTS CORRELATE WITH DECREASED FUNCTION OF PLATELET P2Y<sub>12</sub> RECEPTORS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASM**  
Hung Chang\* (TW), Lee-Yung Shih, Po Dunn, Alan D. Michelson, Andrew L. Frelinger, Po-Nan Wang, Ming-Chung Kuo, Tung-Liang Lin, Jin-Hou Wu, Tzung-Chih Tang
- P-TH-027 MODIFICATIONS IN PLATELET BEHAVIOUR IN RESPONSE TO MMP-DIGESTED COLLAGENS**  
Joanna-Marie Howes\* (UK), Nicholas Pugh, Richard W Farndale
- P-TH-028 THE NEW SELECTIVE P2Y<sub>12</sub> ANTAGONIST RADIOLIGAND [3H]PSB-0413 IS A HIGHLY ACCURATE TOOL TO QUANTIFY**  
Christian Gachet\* (FR), Philippe Ohlmann, Anna Lecchi, A El Tayeb, Christa Muller, Marco Cattaneo, Christian Gachet
- P-TH-029 PLATELET GLYCOPROTEIN VI DIMERISATION IS AN ACTIVE PROCESS INDUCING RECEPTOR COMPETENCE**  
Martine Jandrot-Perrus\* (FR), STEPHANE LOYAU, BENEDICTE DUMONT, VERONIQUE OLLIVIER, YACINE BOULAFTALI, LAURENT FELDMAN, NADINE AJZENBERG, MARTINE JANDROT-PERRUS
- P-TH-030 P2Y<sub>12</sub> ANTAGONISTS AND AN EP3 ANTAGONIST PROMOTE THE INHIBITORY EFFECTS OF MODULATORS OF PLATELET AGGREGATION THAT ACT VIA CAMP**  
Jacqueline Glenn\* (UK), David Espinosa Iyu, Ann White, Susan Fox, Natalia Dovlatova, Stan Heptinstall
- P-TH-031 ANALYSIS OF PLATELET FUNCTION AND GPVI REGULATION IN MICE LACKING THE METALLOPROTEINASES ADAM10 AND ADAM17**  
Markus Bender\* (DE), Sebastian Hofmann, David Stegner, Martina Morowski, Peter Kraft, Guido Stoll, Athena Chalaris, Attila Braun, Juergen Scheller, Stefan Rose-John, Bernhard Nieswandt

### Platelets as drug targets

- P-TH-032 THE EFFECT OF TIME ON PLATELET AGGREGATION ASSESSED BY LIGHT TRANSMISSION**  
Philip DM Leadbeater\* (UK), Jane A Mitchell, Timothy D Warner
- P-TH-033 THE EFFECT OF STIR-SPEED AND TIME ON TP-RECEPTOR INDUCED PLATELET AGGREGATION IN THE PRESENCE OF ASPIRIN AND P2Y<sub>12</sub> RECEPTOR BLOCKADE**  
Philip DM Leadbeater\* (UK), Jane A Mitchell, Timothy D Warner
- P-TH-034 PLATELET INHIBITION BY CLOPIDOGREL PROTECTS AGAINST ACUTE KIDNEY INJURY**  
Joris J Roelofs\* (NL), Gwendoline J. Teske, Nike Claessen

Thursday Posters



29

## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-035 ASPIRIN AUGMENTS THE ANTI-PLATELET EFFECTS OF PARTIAL BUT NOT COMPLETE P2Y<sub>12</sub> RECEPTOR BLOCKADE BY TICAGRELOR**  
Nicholas S Kirkby\* (UK), Philip DM Leadbeater, Melissa V Chan, Sven Nylander, Jane A Mitchell, Timothy D Warner
- P-TH-036 SYNERGISTIC INHIBITION OF PLATELET AGGREGATION BY NITRIC OXIDE AND PROSTACYCLIN IS POTENTIATED BY P2Y<sub>12</sub> BLOCKADE**  
Nicholas S Kirkby\* (UK), Rachit Singhal, Jane A Mitchell, Timothy D Warner
- P-TH-037 EFFECT OF PAR1 AND PAR4 AGONISTS ON PLATELET ACTIVITY**  
Liudmila I Buryachkovskaya\* (RU), Svetlana M Strukova, Irina A Uchitel, Alexander B Sumarokov
- P-TH-038 FIBRINOGEN BINDING TO ACTIVATED PLATELETS IN THE PRESENCE OF PLASMA CONCENTRATION OF THE NATURAL LIGAND MAY BE SUFFICIENT TO ALLOW THERAPEUTIC TARGETING**  
Julie A. Oliver\* (US), Evan S. Krystofiak, Linda G. Westrick
- P-TH-039 INHIBITORY EFFECTS OF POLYPEPTIDES DERIVED FROM SNAKE VENOM C-TYPE LECTIN, AGGRETIN, ON TUMOR CELL-INDUCED PLATELET AGGREGATION**  
Chien-Hsin Chang\* (TW), Ching-Hu Chung, Tur-Fu Huang
- P-TH-040 DESTRUCTION OF ACTIVATED PLATELETS WITH FIBRINOGEN-CONJUGATED CORE-SHELL NANOPARTICLES**  
Julie A. Oliver\* (US), Evan S. Krystofiak
- P-TH-041 THAN 40 EXHIBITS ANTIPLATELET ACTIVITY IN VIVO AND EX VIVO**  
Zui-ying Wu\* (TW), Jin-Cherng Lien, Sheng-Chu Kuo, Tur-Fu Huang
- P-TH-042 BETA-NITROSTYRENES INHIBIT PLATELET AGGREGATION CAUSED BY HUMAN BREAST CANCER MDA-MB-231 CELLS**  
Chin-Chung Wu\* (TW), Chien-Kai Wei
- P-TH-043 A NOVEL QUANTITATIVE AND SENSITIVE HIGH THROUGHPUT-READY TECHNIQUE FOR DETECTION OF CYCLIC NUCLEOTIDE MODULATING DRUG EFFECTS**  
Jorg Geiger\* (DE), Katharina Hubertus, Walter Ulrich, Reinhard Schinzel

### Genetics and proteomics of platelets

- P-TH-044 THE TRANSCRIPTION FACTOR MEIS1 MARKS A MEGAKARYOCYTE-SPECIFIC ALTERNATIVE PROMOTER OF THE DNM3 LOCUS AT THE POSITION OF A GWAS SEQUENCE VARIANT FOR PLATELET VOLUME**  
Sylvia Nuernberg (UK), Peter A. Smethurst\*, Rafik Rizkallah, Nicole Soranzo, Augusto Rendon, Willem Ouwehand
- P-TH-045 THE USE OF HIGH RESOLUTION MELTING (HRM) ANALYSIS FOR THE SCREENING OF GENETIC DEFECTS IN GLANZMANN THROMBASTHENIA**  
Xavier Pillois\* (FR), Mathieu Fiore, Roland Heilig, Paquita Nurden, Alan Nurden
- P-TH-046 THE PROTEOME OF PLATELET-DERIVED MICROPARTICLES VARIES DEPENDING ON THE STIMULUS: IMPLICATION OF SIGNALING PROTEINS**  
Angel Garcia\* (ES), Ela Shai, Andres F Parguina, Isaac Rosa, David Varon
- P-TH-047 THROMBIN ACTIVATION ALTERS MRNA SIGNATURE AND PROTEIN SYNTHESIS IN HUMAN PLATELETS**  
Abdimajid Osman\* (SE), Knut Falcker, Tomas L Lindahl



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-048** **PROTEOMIC IDENTIFICATION OF PLATELET SIGNALING PATHWAYS PLAYING A MAJOR ROLE IN ACUTE CORONARY SYNDROME**  
Angel Garcia\* (ES), Andres F Parguina, Lilian Grigorian-Shamajian, Rosa M Agra, Diego Lopez, Isaac Rosa, Jana Alonso, Jose Ramon Gonzalez-Juanatey
- P-TH-049** **ELUCIDATING THE CLEC-2 SIGNALING CASCADE USING A GLOBAL PROTEOMICS APPROACH**  
Angel Garcia\* (ES), Andres F Parguina, Isaac Rosa, Johannes A Eble
- P-TH-050** **NOVEL LOCI INVOLVED ON PLATELET FUNCTION AND PLATELET COUNT IDENTIFIED BY A GWAS PERFORMED IN CHILDREN**  
Jose Antonio Guerrero\* (ES), Jose Rivera, Teresa Quiroga, Angel Martinez-Perez, Ana Isabel Anton, Constantino Martinez, Olga Panes, Vicente Vicente, Diego Mezzano, Jose Manuel Soria, Corral Javier
- P-TH-051** **P-SELECTIN VARIANT THR715PRO IMPAIRS TERMINAL GLYCOSYLATION OF P-SELECTIN**  
Harihara Manikandan Ponniahpillai Subramanian\* (AT), Christine Mannhalter
- P-TH-052** **OLIGOPHRENIN-1 IS PRESENT IN PLATELETS AND REGULATES FILOPODIA FORMATION UPON GPVI STIMULATION**  
Thijs C van Holten\* (NL), Onno B Blijerveld, Rolf T Urbanus, Richard W Farndale, Philip G de Groot, Albert JR Heck, Arjen Scholten, Mark Roest
- P-TH-053** **GENE EXPRESSION WITHIN A THROMBUS: FURTHER REGULATION OF THE HAEMOSTATIC RESPONSE**  
Joy R Wright\* (UK), Cordelia Langford, Nicholas A Watkins, Willem H Ouwehand, Alison H Goodall
- P-TH-054** **PROTEINS INVOLVED IN "STICKY PLATELET SYNDROME" PLATELET ACTIVATION**  
Diana Marli Fries\* (BR), Cristina S.S.S. Silva, Valeria Oliveira, Victor Debbas, Elbio A. DAmico, Teresinha J.C. Neiva, Tania R.F. Rocha
- P-TH-055** **PROTEOMICS PROFILES OF PLATELETS ACCORDING TO HIGH ON TREATMENT PLATELET REACTIVITY AND CARDIOVASCULAR EVENTS (APICE PROJECT)**  
Betti Giusti\* (IT), Claudia Boccardi, Anna Maria Gori, Rossella Marcucci, Silvia Rocchiccioli, Ilaria Romagnuolo, Niccolo' Maggini, David Antonucci, Oberdan Parodi, Lorenzo Citti, Rosanna Abbate
- P-TH-056** **THE SMALL RNA PROFILE OF HUMAN PLATELETS**  
Patrick Provost\* (CA), Helene Ple, Patricia Landry, Ashley Benham, Preethi Gunaratne

### ITP

- P-TH-057** **PREDICTORS FOR RESOLUTION WITHIN 6 MONTHS IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA**  
Shoshana Revel-Vilk\* (IL), Shlomzion Frank, Tal Ben-Ami, Mira Harit, Elisha Waldman, Iris Fried, Aker Memet, Polina Stepenski, Michael Weintraub
- P-TH-058** **FACTORS ASSOCIATED WITH FAVORABLE RESPONSE TO CORTICOSTEROIDS IN THAI PATIENTS DIAGNOSED WITH IMMUNE THROMBOCYTOPENIA**  
Bundarika Suwanawiboon\* (TH), Kritichat Kamjornpreecha, Sirawit Bantornwa, Yingyong Chinthammitr, Theera Ruchutrakool, Wanchai Wanachiwanawin
- P-TH-059** **RITUXIMAB PLUS RECOMBINANT HUMAN THROMBOPOIETIN YIELDS RAPID AND SUSTAINED RESPONSE IN ADULT PATIENTS WITH GLUCOCORTICOID RESISTANT PRIMARY IMMUNE THROMBOCYTOPENIA**  
Xiaoyuan Dong\* (CN), Ming Hou, Jie Li, Jun Peng, Hao Li, Luqun Wang



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-060 A MULTI-CENTRE RETROSPECTIVE ANALYSIS OF RITUXIMAB USE IN IMMUNE THROMBOCYTOPENIA PURPURA (ITP) IN THE REPUBLIC OF IRELAND**  
Denis J O'keeffe\* (IE), Aine Burke, Suzanne Mc Pherson, Mirfan Khan, Yassir Mahdi, Mary Gleeson, Joy Lewis, Jill Mackarel, Janusz Krawczyk, Sahar Khan, Karen Murphy, Brian Hennessy, Catherine Flynn, Philip Murphy, Patrick Thornton, Peter O Gorman, Oonagh Gilligan, Michael O Dwyer, Margaret Murray, Helen Enright, Gerry Crotty
- P-TH-061 REVERSIBLE, RECURRENT, DOSE-DEPENDENT LEUKOERYTHROBLASTOSIS ASSOCIATED WITH USE OF A THROMBOPOIETIN RECEPTOR AGONIST (TPO-RA) IN CHRONIC IMMUNE THROMBOCYTOPENIA (ITP).**  
Adam Giermasz\* (US), Joan Etzell, Patrick F. Fogarty
- P-TH-062 EVALUATION OF PLATELET FUNCTION IN IMMUNE THROMBOCYTOPENIA DURING ELTROMBOPAG TREATMENT**  
Johanna Haselboeck\* (AT), Simon Panzer, Ingrid Pabinger
- P-TH-063 LOW-DOSE INTERFERON-ALPHA THERAPY FOR CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA (ITP) IN CHILDREN**  
Pavel Svirin\* (RU), E.K. Donyush, A.V. Ageenkova, L.E. Larina, A.V. Malkova, V.U. Petrov, G.I. Soskov
- P-TH-064 THE PLATELET COUNT OF PATIENTS WITH THROMBOCYTOPENIA MAY BE UNDERESTIMATED WHEN MEASURED IN EDTA SAMPLES IN ROUTINE LABORATORIES**  
Marco Cattaneo\* (IT), Gian Marco Podda, Mariateresa Pugliano, Eti Alessandra Femia, Anna Maria Mezzasoma, Paolo Gresele, Giovanni Carpani
- P-TH-065 THROMBOPOIETIN RECEPTOR AGONISTS (TPOA) DO NOT CAUSE ACTIVATION OF THE COAGULATION-FIBRINOLYTIC SYSTEM IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP)**  
Waleed Ghanima\* (NO), Sarah Barsam, Per Morten Sandset, Allison Miller, James B Busset

### Antiplatelet therapy

- P-TH-066 ANTITHROMBOTIC EFFECTS OF ASPIRIN BASED ON PLA1/A2 GLYCOPROTEIN IIIA POLYMORPHISM IN PATIENTS WITH CORONARY ARTERY DISEASE**  
Jerzy Dropinski\* (PL), Jerzy Dropinski, Marek Sanak, Bogdan Jakiela, Wojciech Wegrzyn, Andrzej Szczeklik, Jacek Musial
- P-TH-067 RESISTANCE TO CLOPIDOGREL BASED ON PLATELET GLYCOPROTEIN IIIA POLYMORPHISM IN CORONARY ARTERY DISEASE PATIENTS**  
Jerzy Dropinski\* (PL), Marek Sanak, Bogdan Jakiela, Wojciech Wegrzyn, Andrzej Szczeklik, Jacek Musial
- P-TH-068 ADDITIONAL ANTIPLATELET EFFECT OF CLOPIDOGREL IN PATIENTS TREATED WITH ASPIRIN**  
Jerzy Dropinski\* (PL), Bogdan Jakiela, Marek Sanak, Wojciech Wegrzyn, Andrzej Szczeklik, Jacek Musial
- P-TH-069 ASPIRIN TREATED SUBJECTS SHOW ATTENUATED ELECTRON MICROSCOPIC EVIDENCE OF PLATELET ACTIVATION AND A PARALLEL ATTENUATION IN THROMBIN STIMULATED PLATELET ACTIVATION ANTIGENS**  
Mary Rose Cahill\* (IE), Marion Macey, Adrian C Newland
- P-TH-070 THE FIRST DEMONSTRATION OF RACE AND GENDER INFLUENCE ON PLATELET REACTIVITY WITHIN CYP2C19 GENOTYPES**  
Paul Alfred Gurbel\* (US), Kevin P Bliden, Young-Hoon Jeong, Tantry S Tantry



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-071 HIGH POST-TREATMENT PLATELET REACTIVITY AND IMPAIRED CLINICAL PROGNOSIS BUT ADEQUATE RESPONSE TO THIENOPYRIDINE IN ELDERLY PATIENTS WITH UNSTABLE CORONARY DISEASE**  
Marie-Christine Alessi\* (FR), Thomas Cuisset, Jacques Quilici, Charlotte Grosdidier, Laurent Fourcade, Benedicte Gaborit, Mathieu Pankert, William Cohen, Laurent Molines, Marc Lambert, Pierre-Emmanuel Morange, Jean Louis Bonnet
- P-TH-072 INFLUENCE OF GENETIC POLYMORPHISMS ON PLATELET INHIBITION BY ADJUNCTIVE CILOSTAZOL TO CLOPIDOGREL AND CLOPIDOGREL: RESULTS OF THE ACCEL-TRIPLE STUDY**  
Young-Hoon Jeong\* (US), In-Suk Kim, Yongwhi Park, Seong-Eun Yun, Tae Jung Kwon
- P-TH-073 CELLULARITY OF POLYURETHANE SURFACE IN THE POLISH EXTRACORPOREAL VENTRICULAR ASSIST DEVICE IN LONG TERM USAGE**  
Roman Kustosz\* (PL), Magdalena Koscielniak Ziemniak, Karolina Gorka, Artur Kapis, Romuald Wojnicz, Ewa Reichman-Warmusz
- P-TH-074 FIRST COMPARISON OF THROMBELASTOGRAPHY VERSUS LIGHT TRANSMITTANCE AGGREGOMETRY TO DEFINE HIGH PLATELET REACTIVITY**  
Young-Hoon Jeong\* (US), Kevin P. Bliden, Mark J. Antonino, Udaya S. Tantry, Paul A. Gurbel
- P-TH-075 IMPACT OF THE CYTOCHROME P450 2C19\*3 POLYMORPHISM ON PLATELET REACTIVITY AND ADVERSE CLINICAL EVENTS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION**  
Young-Hoon Jeong\* (US), Jin-Sin Koh, Tae Jung Kwon, Yongwhi Park, In-Suk Kim
- P-TH-076 EVALUATION OF BIOEQUIVALENCE OF BISULFATE AND AND BESYLATE CLOPIDOGREL ON THE INHIBITION OF ADP INDUCE PLATELET AGGREGATION IN PATIENTS WITH CORONARY ARTERY DISEASE**  
John Zarifis\* (GR), Cristos Zafiris, George Tsinopoulos, Evangelos Kaltsas, Spyrou Gerou, Ismail Elalamy, Grigoris T. Gerotziafas

### Platelets in transfusion medicine

- P-TH-077 EFFECTS OF *IN-VITRO* ADULT PLATELET TRANSFUSIONS ON NEONATAL HEMOSTASIS**  
Francisca Ferrer-Marin\* (US), Chaitanya Chavda, Michael Lampa, Alan D Michelson, Frelinger III Andrew L., Martha Sola-Visner
- P-TH-078 OPTIMIZATION OF PLATELET-RICH PLASMA PREPARATION METHOD FOR IMPROVEMENT OF ITS QUALITY**  
Saleh Nasiri\* (IR)
- P-TH-079 REAL-TIME QUANTIFICATION OF HPA-1A ANTIBODY IN SERUM OF MOTHERS WITH NEONATAL ALLOIMMUNE THROMBOCYTOPENIA DURING MANAGED PREGNANCIES BY SURFACE PLASMON RESONANCE TECHNIQUE**  
Tamam Bakchoul\* (DE), G Bertrand, S Kubiak, Ulrich Sachs, Gregor Bein, Sentot Santoso, Cecile Kaplan

### Inherited and acquired platelet disorders

- P-TH-080 MOLECULAR GENETIC ANALYSIS AND PLATELET FUNCTION TESTING IN 27 GLANZMANN'S THROMBASTENIA PATIENTS**  
Ann-Kathrin Pilgrim\* (DE), Daniele Pillitteri, Thomas Scholz, Manuela Krause, Carl M Kirchmaier

Thursday Posters



33

## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-081 CLASSIFICATION OF MILD PLATELET-BASED BLEEDING DISORDERS USING LUMI-AGGREGOMETRY**  
Ban B Dawood\* (UK), Jonathan T Wilde, Martina E Daly, Paul Gissen, Mike Makris, Andrew D Mumford, Steve P Watson
- P-TH-082 THROMBOCYTOPENIA AND THE QUESTION OF PLATELET FUNCTION**  
Ingvild Birschmann\* (DE), Judith Schmoekel, Anja Zamow, Arnold Ganser
- P-TH-083 MAY-HEGGLIN ANOMALY DURING PREGNANCY**  
Brwa Ali Hussein\* (UK), Keith Gomez, Rezan Kadir
- P-TH-084 INHERITED THROMBOCYTOPENIA WITH RUNX1 VARIANTS: NEW FRENCH CASES WITH POINT MUTATIONS OR LARGE DELETIONS AND EVIDENCE FOR A DEFECT IN DENSE GRANULES**  
Thomas P Lecompte\* (FR), Veronique Latger-Cannard, Alexandre Bouquet, Christophe Philippe, Claude Preudhomme, Philippe Jonveaux, Thomas Lecompte, Remi Favier
- P-TH-085 HERMANSKY-PUDLAK SYNDROME DURING PREGNANCY**  
Brwa Ali Hussein\* (UK), Keith Gomez, Rezan Kadir
- P-TH-086 TWO NOVEL MISSENSE MUTATIONS IN THE *ITGB3* GENE CHARACTERIZING A COMPOUND HETEROZYGOUS GLANZMANN THROMBASTHENIA (GT) PATIENT**  
Loredana Bury\* (IT), Eva Zetterberg, Teresa Corazzi, Paquita Nurden, Alan T Nurden, Paolo Gresele
- P-TH-087 INTERMITTENT X-LINKED THROMBOCYTOPENIA DUE TO THE P.THR45MET WASP GENE MUTATION**  
Margareth C Ozelo\* (BR), Lucia H Siqueira, Marina P Colella, Mariana Gil, Joyce M Annichino-Bizzacchi, Erich V De Paula, Margareth C Ozelo

### Laboratory tests

- P-TH-089 VALIDATION AND ASSESSMENT OF MEPACRINE TESTING IN DELTA STORAGE POOL DISEASE: A 3-CENTRE STUDY**  
Francois Mullier\* (BE), Veronique Latger-Cannard, Marie Toussaint-Hacquard, Marie-France Hurtaud, Nicolas Bailly, Jean-Michel Dogne, Bernard Chatelain, Thomas Lecompte
- P-TH-090 DIRECT COMPARISON OF DIFFERENT PROCEDURES TO PREPARE PLATELET-RICH PLASMA FOR LIGHT TRANSMISSION AGGREGOMETRY**  
Marco Cattaneo\* (IT), Eti Alessandra Femia, Mariateresa Pugliano, Gian Marco Podda, Klodiana Dosti
- P-TH-091 FLOW CYTOMETRY IDENTIFIES PLATELET DYSFUNCTION IN PATIENTS WITH THROMBOCYTOPENIA AND THROMBOCYTOSIS**  
David E Connor\* (AU), Joanne E Joseph
- P-TH-092 HERITABILITY OF PLATELET-LEUKOCYTE CONJUGATES AND CELL ACTIVATION MARKERS IN FAMILIES WITH AND WITHOUT JUVENILE MYOCARDIAL INFARCTION**  
Chiara Cerletti\* (IT), Francesco Gianfagna, Chiara Tamburrelli, Branislav Vonhout, Marilena Crescente, Benedetta Izzì, Agnieszka Pampuch, Amalia De Curtis, Augusto Di Castelnuovo, Antonella Cutrone, Emanuela Napoleone, Bamidele Tayo, Roberto Lorenzè, Maria Benedetta Donati, Giovanni de Gaetano, Licia Iacoviello, Investigators Moli-family Study
- P-TH-093 IDENTIFICATION OF COMMON DRUGS INTERFERING WITH THE PFA CLOSURE TIME**  
Andreas R. Rechner\* (DE), Anja Borchert, Anette Immel, Annette Merte-Schulz, Norbert Zander



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-094 VARIABILITY OF ADP-INDUCED HUMAN PLATELET AGGREGATION IS REDUCED IN THE PRESENCE OF ASPIRIN**  
Chao-Zong Liu\* (TW), Jia-Ming Weng, Ling-Ya Chang
- P-TH-095 PLATELET FUNCTION IN TRAUMA MEASURED BY MULTIPLE ELECTRODE AGGREGOMETRY**  
Catherine Mary Spoons\* (UK), Ross Davenport, Henry De'Ath, Sirat Khan, Joanna Manson, Imran Raza, Claire Rourke, Per Johansson, Karim Brohi
- P-TH-096 POSSIBLE ROLE OF PLATELET ACTIVATION IN THE CARDIOVASCULAR COMPLICATIONS ASSOCIATED WITH HIV INFECTION: DIFFERENTIAL EFFECTS OF ABACAVIR (ABC) VERSUS TENOFOVIR (TDF)**  
Paolo Gresele\* (IT), Daniela Francisci, Emanuela Falcinelli, Barbara Belfiori, Eleonora Petito, Tiziana Fierro, AnnaMaria Mezzasoma, Franco Baldelli
- P-TH-097 WHITE BLOOD CELL COUNT, SEX AND AGE ARE MAJOR DETERMINANTS OF PLATELET INDICES HETEROGENEITY IN AN ADULT GENERAL POPULATION: RESULTS FROM THE MOLI-SANI PROJECT**  
Chiara Cerletti\* (IT), Iolanda Santimone, Augusto Di Castelnuovo, Amalia De Curtis, Maria Spinelli, Daniela Cugino, Maria Benedetta Donati, Giovanni de Gaetano, Licia Iacoviello, Investigators Moli-sani Project
- P-TH-098 PAK™LX: A NEW LUMINEX®-BASED ASSAY TO DETECT AND IDENTIFY ANTIBODIES TO HUMAN PLATELET ANTIGENS (HPA) IN PATIENT SERUM**  
Rathore Vipul\* (US), Patrick Coghlan, Adrian Fleet, Grant Mraz, Matthew Meyers
- P-TH-099 COMPARING FIVE PLATELET FUNCTION TESTS (PRP AGGREGOMETRY, MULTIPLATE, P-SELECTIN, VERIFYNOW AND BIOCYTEX VASP) DESIGNED TO ASSESS RESPONSES TO ASPIRIN AND P2Y<sub>12</sub> ANTAGONISTS**  
Susan Fox\* (UK), Jane May, Jacqueline Glenn, Andrew Johnson, Ann White, Natalia Dovlatova, David Iyu, Yanushi Wijeyeratne, Stan Heptinstall
- P-TH-100 SEVERE PREECLAMPSIA: PLATELET PARAMETERS ROLE FOR ITS PREDICTION**  
Luci Maria SantAna Dusse\* (BR), Luci Maria Dusse, Leticia Goncalves Freitas, Patricia Nessler Alpoim, Denise Silva Kattah, Maria Graca Carvalho, Karina Braga Gomes

### Extrinsic pathway of coagulation

- P-TH-101 INCREASED EXPRESSION OF TFPI BY SODIUM BUTYRATE INVOLVES THE PI3K AND NF-κB PATHWAYS**  
Grethe Skretting\* (NO), Christiane Filion Myklebust, Nina Iversen, Anders Dahm, Per Morten Sandset
- P-TH-102 THE COAGULANT ACTIVITY OF TISSUE FACTOR DOES NOT REQUIRE ASSOCIATION WITH LIPID RAFTS**  
Guus Sturk\* (NL), Anita Boing, Chi Hau, Jan van Marle, Rienk Nieuwland
- P-TH-103 POSTTRANSLATIONAL MODIFICATIONS AND ACTIVITY OF NATURAL HUMAN TISSUE FACTOR**  
Jolanta T Krudysz-Amblo\* (US), Mark E Jennings II, Dwight E Matthews, Kenneth G Mann, Saulius Butenas
- P-TH-104 ENHANCED THROMBIN GENERATION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): DEPENDENCE ON PLASMA FACTOR COMPOSITION**  
Milosz Jankowski (PL), Anetta Undas\*, Przemyslaw Kaczmarek, Kathleen E Brummel-Ziedins

Thursday Posters



35



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-105 LEPTIN UPREGULATES TISSUE FACTOR EXPRESSION IN THE HUMAN BREAST CANCER CELL LINE MCF7: A POSSIBLE ROLE OF TNF- $\alpha$**   
Emanuela Napoleone (IT), Antonella Cutrone, Maria Carmela Latella, Daniela Cugino, Licia Iacoviello, Giovanni de Gaetano, Maria Benedetta Donati, Roberto Lorenzet\*
- P-TH-106 SUBSTANCE P (SP)-NEUROKININ-1 RECEPTOR (NK-1R) INTERACTION PROMOTES UPREGULATION OF MONOCYTE TISSUE FACTOR (TF)**  
Mohammad Munir Hossain Khan\* (US), Steven D Douglas, Tami Benton
- P-TH-107 SYNERGISTIC AMPLIFICATION OF THROMBIN GENERATION IN PLASMA THROUGH MINIMALLY ACTIVATED EXTRINSIC AND INTRINSIC COAGULATION PATHWAYS**  
Yuichi Kamikubo\* (US), Andrew J Gale, Wolfram Ruf, Zaverio M Ruggeri
- P-TH-108 MOUSE TISSUE FACTOR PROCOAGULANT ACTIVITY IS DEPENDENT ON THE PRESENCE OF THE CYS190-CYS213 ALLOSTERIC DISULFIDE**  
Lisa G van den Hengel\* (NL), Pieter H Reitsma, Henri H Versteeg
- P-TH-109 ALTERNATIVELY SPLICED AND FULL-LENGTH TISSUE FACTOR REVEAL A NON-IDENTICAL RELATIONSHIP TO CLINICOPATHOLOGICAL PARAMETERS IN A LARGE COHORT OF HUMAN BREAST CANCER**  
Yascha W Van den Berg\* (NL), J Sven D Mieog, Esther M De Kruijf, Jiongwei Wang, Anita Sajet, Peter JK Kuppen, Cornelis JH Van de Velde, Pieter H Reitsma, Susanne Osanto, Vladimir Y Bogdanov, Henri H Versteeg
- P-TH-110 SELECTION OF ANTIBODY CLONES INFLUENCE MEASUREMENT OF TISSUE FACTOR EXPRESSION IN BLOOD CELLS**  
Bjarne Osterud\* (NO), Manjunath Goolyam Basavaraj, Jan Ole Olsen, Bjarne Osterud, John-Bjarne Hansen
- P-TH-111 EFFECTS OF HISTAMINE ON TISSUE FACTOR EXPRESSION IN MONOCYTES OF BLOOD**  
Bjarne Osterud\* (NO), Bjarne Osterud, Jan Ole Olsen, Eliana Lakis
- P-TH-112 MALIGNANCY ASSOCIATED ACQUIRED FACTOR VII DEFICIENCY**  
Rhona M Maclean\* (UK), Peter Cooper, Steve Kitchen, Michael Makris
- P-TH-113 TRANSCRIPTION FACTOR NFAT BUT NOT NF- $\kappa$ B IS ESSENTIAL FOR THROMBIN-INDUCED TISSUE FACTOR EXPRESSION**  
Yuwana Yakura\* (JP), Makoto Taniguchi, Kaori Morimoto, Akira Hayashi, Hiroyuki Takeya
- P-TH-114 A REVIEW OF SEVERE FACTOR X DEFICIENCY IN PATIENTS IN THE REPUBLIC OF IRELAND**  
Mary Kavanagh\* (IE), Ann O'Sullivan, Imelda Kelly, Irene Regan, Mary Byrne, Vince Jenkins, Dympna Cawley, James O'Donnell, Beatrice Nolan
- P-TH-115 FACTOR VIIA/ANTITHROMBIN COMPLEXES IN CIRRHOTICS WITH AND WITHOUT PORTAL VEIN THROMBOSIS: A POSSIBLY MARKER OF INCREASED THROMBOTIC RISK?**  
Valeria Rossetto (IT), Luca Spiezia, Sabrina Gavasso, Mariangela Fadin, Elena Campello, Maria Teresa Sartori, Marco Senzolo, Krissia Rodriguez, Barry Woodhams\*, Paolo Simioni
- P-TH-116 KOREAN HEMOPHILIA'S PREVALENCE AND REALITIES**  
Ji-Yoon Kim\* (KR), Kun Soo Lee, Yong-Mook Choi, Tai Ju Hwang, Ki Young Yoo



## POSTER PRESENTATIONS

Thursday, July 28, 2011

### Intrinsic pathway of coagulation

- P-TH-117 ANTIGEN LEVELS OF INTRINSIC COAGULATION PROTEINS AND THE RISK OF MYOCARDIAL INFARCTION AND ISCHAEMIC STROKE IN YOUNG WOMEN: RESULTS FROM THE RATIO CASE-CONTROL STUDY**  
Bob Siegerink\* (NL), A Algra, Frits R Rosendaal
- P-TH-118 ACQUIRED HEMOPHILIA A ASSOCIATED WITH AUTOIMMUNE BULLOUS DISEASE; CHARACTERIZATION OF AUTOANTIBODIES OF TWO CASES AND REVIEW OF THE LITERATURE**  
Koji Miyazaki\* (JP), Shinichi Makita, Takumi Aoki, Mikio Danbara, Masaaki Higashihara
- P-TH-119 MILD CLINICAL PHENOTYPE IN A SEVERE HEMOPHILIA A WITH ARG1781HIS SUBSTITUTION ASSOCIATED WITH INCREASED FACTOR XA GENERATION**  
Koji Yada\* (JP), Keiji Nogami, Kenichi Ogiwara, Masaru Shibata, Midori Shima
- P-TH-120 A SINGLE CENTER CLINICAL SURVEY ON THE TREATMENT OF 24 CASES OF ACQUIRED HEMOPHILIA A : A 2011 UPDATE**  
Ogata Kyoichi\* (JP), Takashi Suzuki, Manabu Otaki, Ikuo Seita, Takashi Muramatsu, Mihoko Yotsumoto, Takeshi Hagiwara, Kagehiro Amano, Katsuyuki Fukutake
- P-TH-121 AGE OF FIRST FACTOR VIII INFUSION DO NOT INFLUENCE THE DEVELOPMENT OF INHIBITORS IN A BRAZILIAN COHORT OF CHILDREN WITH SEVERE HEMOPHILIA A**  
Jorge D Aivazoglou Carneiro\* (BR), Paula Ribeiro Villaca, Eliane P Nobre Sandoval, Dalton A Fischer Chamone, Elbio Antonio D'amico
- P-TH-122 ANTICOAGULANT ACTIVITY AND BEHAVIOR OF FXIIA INHIBITORS**  
Severine Robert\* (BE), Henri M Spronk, Rene van Oerle, Philippe Devel, Francois Mullier, Bernard Chatelain, Lionel Pochet, Hugo ten Cate, Jean-Michel Dogne
- P-TH-123 AGE-DEPENDANT INCREASE OF COAGULATION FACTOR LEVELS IN PATIENTS AND CARRIERS WITH HAEMOPHILIA A, VON WILLEBRAND DISEASE AND CORRELATION TO THE GENE DEFECT AND CO-MORBIDITY**  
Wolfgang Miesbach\* (DE), Christine Delbrueck, Sybille Mueller, Vida Makki, Genet Asmelash, Stefanie Krekeler, Sonja Alesci
- P-TH-124 INTEREST OF FACTOR VIII ACTIVITY/VON WILLEBRAND ANTIGEN RATIO IN THE EARLY DIAGNOSIS OF ACQUIRED HEMOPHILIA A RELAPSE**  
Armelle LEFRANCOIS\* (FR), Julie Graveleau, Armelle Lefrancois, Marc Fouassier, Marianne Sigaud, Mohamed Hamidou, Marc Trossaert
- P-TH-125 ACUTE LEUKEMIA COMPLICATING HEREDITARY COAGULATION FACTOR XII DEFICIENCY CAUSED BY COMPLEX MUTATIONS**  
XU YE\* (CN), YING FENG, XUHONG ZHOU, YIYAN LAI
- P-TH-126 THE EVALUATION OF PROTEIN Z LEVELS OF CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA DURING INDUCTION THERAPY**  
Hale Oren\* (TR), Aydan Cankal, Ozlem Tufekci, Salih Gozmen, Tuba Hilkey Karapinar, Sebnem Yilmaz, Faize Yuksel, Canan Vergin, Gulersu Irken
- P-TH-127 UNUSUAL PATTERN OF HEREDITARY BLEEDING DISORDERS AS REPORTED IN THE NEWFOUNDLAND AND LABRADOR, CANADA, REGISTRY OF RARE BLEEDING DISORDERS**  
Mary-Frances Scully\* (CA), Charlotte Sheppard, Jill MacDonald

Thursday Posters



37

## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-128 ACQUIRED FACTOR VIII INHIBITOR: A PRELIMINARY REPORT OF THREE CASES TREATED WITH AZATHIOPRINE**  
Audrey Kruse Zeinad Valim\* (BR), Erica Okazaki, Paula Ribeiro Villaca, Patricia Lima Junqueira, Dalton Fischer Chamone, Elbio Antonio D'Amico
- P-TH-129 PROPHYLAXIS IN HEMOPHILIA A: A MULTICENTER, OPEN-LABEL, RANDOMIZED, PHASE 4 CLINICAL STUDY OF ANTIHEMOPHILIC FACTOR (RECOMBINANT), PLASMA/ALBUMIN-FREE METHOD (RAHF-PFM)**  
Wing-Yen Wong\* (US), Vasily Mamonov, Andrzej Hellman, Doris Quon, Julian C Desmond, Phillip Schroth, Leonard A Valentino
- P-TH-130 A PAIRED LC-MS/MS UNTARGETED METABOLOMICS INVESTIGATION OF PLASMA FROM PATIENTS ON WARFARIN IDENTIFIES NOVEL PROCOAGULANT PLASMA LIPIDS**  
Hiroshi Deguchi\* (US), Darlene J Elias, Sunia Trauger, Huimin Zhang, Ewa Kalisiak, Gary Siuzdak, John H Griffin
- P-TH-131 THE IMMUNOLOGICAL BASIS OF VARYING F8 INHIBITOR TITERS IN HEMOPHILIA A PATIENTS**  
Han-Mou Tsai\* (US), M. Elaine Eyster, Wenhua Zhou
- P-TH-132 INHIBITOR PROBLEM AND TREATMENT OF BLEEDING EPISODES IN A HEMOPHILIA B PATIENT**  
Osman Alphan Kupesiz\* (TR), Vedat Uygun, Funda Tayfun, Mediha Akcan, Akif Yesilipek

### Contact phase activation

- P-TH-133 REAL TIME VISUALIZATION OF FVIII DISTRIBUTION IN MICE**  
Rupa Shree Appa\* (DK), Ditte Maria Karpf, Lene Hansen, Mikael Kofod Hansen, Henrik Agersoe, Henning Stennicke
- P-TH-134 THE INFLUENCE OF PNEUMATIC TUBE SYSTEM VERSUS MANUAL TRANSPORT ON ACTIVATION OF COAGULATION MEASURED WITH THROMBOELASTOMETRY AND THROMBIN GENERATION**  
Gerhardus J.A.J.M. Kuiper\* (NL), Marcus D. Lance, Matthijs Sloep, Henri M.H. Spronk, Rene Van Oerle, Yvonne M.C. Henkens, Marco A.E. Marcus, Hugo Ten Cate
- P-TH-136 CORN TRYPSIN INHIBITOR COATING ATTENUATES THE PROTHROMBOTIC PROPERTIES OF CORONARY CATHETERS *IN VITRO* AND IN RABBITS**  
Jonathan W Yau\* (CA), Alan R Stafford, Peng Liao, James C Fredenburgh, Robin Roberts, John L Brash, Jeffrey I Weitz
- P-TH-137 DISTINCTIVE CONTACT SYSTEM ACTIVATION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IF PREVIOUS CARDIOVASCULAR DISEASE OR NOT**  
Jennie Back\* (SE), Christian Lood, Graciela Elgue, Anders A Bengtsson, Kristina Nilsson Ekdahl, Bo Nilsson
- P-TH-138 FACTOR V LEIDEN MICE ARE VULNERABLE FOR ISCHEMIC STROKE**  
Toshiyuki Kita\* (JP), Fumiaki Banno, Yukako Nakajo, Hiroji Yanamoto, Koji Iihara, Toshiyuki Miyata
- P-TH-139 SUPPRESSION OF ACUTE PLASMA LEAKAGE IN GUINEA PIGS BY SUBCUTANEOUS ADMINISTRATION OF A NOVEL LOW-MOLECULAR-WEIGHT PLASMA KALLIKREIN INHIBITOR, AS1845069**  
Takeshi Shigenaga\* (JP), Yumiko Moritani, Satomi Nishijima, Yoshimasa Imamura, Kazuhiro Tetsuka



## POSTER PRESENTATIONS

Thursday, July 28, 2011

**P-TH-140 NON-FAMILIAL RECURRENT ANGIOEDEMA CASES EXPLAINED BY A COAGULATION FACTOR XII MUTATION**

Georg Dewald\* (DE), Emel Aygoeren-Pursun, Eva Rusicke, Inmaculada Martinez Saguer, Wolfhart Kreuz

### Anticoagulant pathway

**P-TH-141 THE VITAMIN K-DEPENDENT ANTI-COAGULANT FACTOR, PROTEIN S, REGULATES MERTK-MEDIATED PHAGOCYTOSIS OF APOPTOTIC SUBSTRATE BY SERTOLI CELLS FROM SEMINIFEROUS EPITHELIUM**

Omar Benzakour\* (FR), Marina Yefimova, Nadia Messaddeq, Thomas Harnois, Anais Noblanc, Michel Philippe, Nicolas Bourmeyster, Omar Benzakour

**P-TH-142 ROLE OF THE KUNITZ 1 AND KUNITZ 3 DOMAINS OF TFPI IN THE MECHANISM OF FXA INHIBITION**

Sameera Peraramelli\* (NL), Dennis Suylen, Jan Rosing, Tilman M Hackeng

**P-TH-143 POOR ANTICOAGULANT RESPONSE TO TFPI IN PATIENTS WITH ACQUIRED OR INHERITED PROTEIN S DEFICIENCY**

Brigitte Tardy-Poncet\* (FR), Michele Piot, Dominique Brunet, Celine Chapelle, Pierre Morange, Patrick Mismetti, Herve Decousus, Bernard Tardy

**P-TH-144 C6ORF105-ENCODED PROTEIN REGULATES TFPI- AND ANDROGEN-DEPENDENT ENDOTHELIAL ANTICOAGULANT FUNCTION**

Cristina Lupu\* (US), Hua Zhu, Narcis Ioan Popescu, Jonathan David Wren, Florea Lupu

**P-TH-145 CONTRIBUTION OF THE ACTIVATED PROTEIN C SYSTEM TO THE DYNAMICS OF THROMBIN FORMATION BY HUMAN VASCULAR CELLS AND DERIVED MICROPARTICLES**

Veronique Regnault\* (FR), Rose Said, Thomas Lecompte, Jean-Pierre Max, Huguette Louis, Patrick Lacolley, Denis G Wahl, Veronique Regnault

**P-TH-146 IS IT POSSIBLE TO OBTAIN A TYPICAL HEPARIN FROM BOVINE INTESTINE?**

Roberto Jose Castro Fonseca\* (BR), Ana MF Tovar, Nina VM Capille, Bruno C Vairo, Gustavo RC Santos, Paulo AS Mourao

**P-TH-147 ABSENCE OF PLATELET TISSUE FACTOR PATHWAY INHIBITOR (TFPI) REDUCES BLEEDING IN FVIII DEFICIENT MICE**

Susan A Maroney\* (US), Brian C Cooley, Catherine E Bonesho, Josephine P Ferrel, Lars C Petersen, Alan E Mast

**P-TH-148 IS IT POSSIBLE USING A GLOBAL HEMOSTASIS ASSAY TO MONITOR THERAPY WITH DIRECT THROMBIN INHIBITORS?**

Margareta Blomback\* (SE), Hakan Wallen, Niklas Bark, Shu He

**P-TH-149 THE ANTI-COAGULANT FACTOR PROTEIN S AND ITS STRUCTURAL HOMOLOG GAS6, REGULATE NEURAL STEM CELL PROLIFERATION.**

Omar Benzakour\* (FR), Valerie Coronas, Aurore Gely-Pernot, Arnaud Monvoisin, Pablo Garcia De Frutos, Michel Philippe, Omar Benzakour

**P-TH-150 MOLECULAR BASIS OF ANTITHROMBIN DEFICIENCY. IDENTIFICATION OF 27 NEW MUTATIONS AND ASSOCIATIONS WITH OTHER GENETIC RISK FACTORS**

Consuelo Martinez-Redondo\* (ES), Ana I Anton, Jordi Fontcuberta, Francisco Espana, Natividad Gomez, Maria F Lopez, Pilar Llamas, Carmen De Cos, Ignacio Alberca, Cristina Pascual, Joaquin Martinez, Rosa Maia, Vanessa Roldan, Irene Martinez-Martinez, Antonia Minano, Jose Padilla, Vicente Vicente, Javier Corral



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-151 ANTICOAGULANTS SYSTEM STATE IN MULTIPLE MYELOMA**  
Olga Smirnova\* (RU), E. A. Hait, L. P. Papayan
- P-TH-152 PROTEIN C LEVELS ARE REGULATED BY *EDEM2* INDEPENDENT OF SOLUBLE EPCR LEVELS**  
Carolina Pintao\* (NL), Frits R Rosendaal, Pieter H Reitsma
- P-TH-153 PROTEIN C MUTATION (A267T) RESULTS IN ER RETENTION AND UNFOLDED PROTEIN RESPONSE ACTIVATION**  
Lena Tjeldhorn\* (NO), Nina Iversen, Kirsten Sandvig, Jonas Bergan, Per Morten Sandset, Grethe Skretting
- P-TH-154 EFFECTS OF FLUVASTATIN ON THE EXPRESSION OF TISSUE FACTOR PATHWAY INHIBITOR IN HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS**  
Eriko Morishita\* (JP), Hiroki Torishima, Keiko Maruyama, Akiko Sekiya, Hidesaku Asakura, Shigeki Ohtake
- P-TH-155 TWO CASES OF TYPE I PROTEIN S DEFICIENCY: GENE ANALYSIS AND IN VITRO EXPRESSION STUDIES OF MUTANT PROTEIN S**  
Akiko Sekiya\* (JP), Eriko Morishita, Keiko Maruyama, Itsumi Shimogawara, Yuka Yasumoto, Hidesaku Asakura, Shinji Nakao, Shigeki Ohtake

### Serine protease inhibitors

- P-TH-156 TYPE IIHBS ANTITHROMBIN DEFICIENCY: CLINICAL SYMPTOMS AND LABORATORY DIAGNOSIS**  
Laszlo Muszbek\* (HU), Zsuzsanna Bereczky, Zsolt Olah, Bettina Kovacs, Boda Zoltan
- P-TH-157 GENETIC VARIABILITY AND PROMOTER MUTATIONS IN THE *SERPINC1* GENE: IMPLICATION FOR INTERINDIVIDUAL VARIATIONS OF ANTITHROMBIN DEFICIENCY**  
Maria Eugenia de la Morena-Barrio\* (ES), Ana Isabel Anton, Irene Martinez-Martinez, Jose Padilla, Antonia Minano, Jose Navarro-Fernandez, Lorena Velazquez, Sonia Aguila, Nataliya Bohdan, Vicente Vicente, Javier Corral
- P-TH-158 ANTITHROMBIN KRAKOW: A NOVEL MUTATION LEADING TO TYPE I DEFICIENCY ASSOCIATED WITH PROTHROMBOTIC FIBRIN CLOT PHENOTYPE IN A POLISH FAMILY**  
Magdalena Celinska-Lowenhoff\* (PL), Teresa Iwaniec, Martine Alhenc-Gelas, Jacek Musial, Anetta Undas
- P-TH-159 ELUCIDATING NOVEL UROKINASE-TYPE PLASMINOGEN ACTIVATOR INHIBITORS**  
Emma L Smith\* (UK), Emma Louise Smith, Spencer John, Maryam Abdinejad, Jayakanth Kankanala, Colin W.G. Fishwick, Emma Philippou
- P-TH-160 PROTEIN C INHIBITOR - INTERACTION WITH ENTEROPEPTIDASE AND POSSIBLE FUNCTION IN THE PANCREAS**  
Thomas A. Prohaska\* (AT), Felix Wahlmueller, Margarethe Geiger
- P-TH-161 PROTEIN C INHIBITOR: A BROOMSTICK IN APOPTOTIC CELL CLEARANCE?**  
Daniela Rieger\* (AT), Margarethe Geiger, Margareta Furtmueller, Katrin Einfinger, Sokolikova Barbora
- P-TH-162 PROTEIN C INHIBITOR ON MICROPARTICLES AND ITS POSSIBLE FUNCTIONAL ROLES IN COMPLEMENT ACTIVATION**  
Katrin Einfinger\* (AT), Margarethe Geiger, Margarete Furtmueller, Daniela Rieger, Felix Wahlmueller



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-163 DETECTION OF MUTATIONS IN THE ATIII GENE IN PATIENTS WITH VTE AND ATIII DEFICIENCY**  
Maria Tsaousidou (GR), Zissis Moschidis, Iwanna Anastasopoulou, Anastasia Karafoulidou, Olga Katsarou, Paraskevi Kotsi\*
- P-TH-164 PROTEIN C INHIBITOR (PCI) AND JFC1 INTERACTION IN PROSTATE CELLS**  
Barbora Sokolikova\* (AT), Julia M. Malleier, Bernd R. Binder, Margarethe Geiger
- P-TH-165 STABILITY OF THE BIOTIN MOIETY IN EP217609, A NEW PARENTERAL ANTICOAGULANT NEUTRALIZABLE BY AVIDIN**  
Maurice Petitou\* (FR), Jean Amiral, Chantal Krezel, Eric Neuhart, Maurice Petitou
- P-TH-166 INTRACELLULAR INTERACTION PARTNERS OF PROTEIN C INHIBITOR (PCI)**  
Margareta Furtmueller\* (AT), Johannes Alfred Schmid, Bettina Sarg, Herbert Lindner, Margarethe Geiger

### Structural biology and drug design

- P-TH-167 LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN (LRP) CLUSTER II INTERACTS WITH THE FACTOR (F)VIII LIGHT CHAIN VIA AN EXTENDED SURFACE COMPRISING MULTIPLE LYSINE RESIDUES**  
Maartje van den Biggelaar\* (NL), Carmen van den Zwaan, Koen Mertens, Alexander B Meijer
- P-TH-168 STABILIZATION OF RECOMBINANT HUMAN FIX BY GLYCOPEGYLATION**  
Anders Dybdal Nielsen\* (DK), Lisbeth Palm, Finn Stausholm Nielsen
- P-TH-169 PHARMACODYNAMIC DIFFERENCES OF AN ANTI-FXA ENRICHED ULTRA LOW MOLECULAR WEIGHT HEPARIN, AVE5026 IN COMPARISON TO ENOXAPARIN AND UNFRACTIONATED HEPARIN**  
Debra A Hoppensteadt\* (US), Angel Gray, Evangelos Litinas, Walter Jeske, Jawed Fareed
- P-TH-170 ISOLATION AND FUNCTIONAL CHARACTERIZATION OF A SINGLE CHAIN FORM OF RECOMBINANT FACTOR VIII**  
Lars Thim\* (DK), Louise K Gram, Hermann Pelzer, Helle Knudsen, Kristoffer W Balling, Marianne Kjalke
- P-TH-171 ZINC AND COPPER IONS IN A RECOMBINANT COAGULATION FACTOR FVIII**  
Ole Hvilsted Olsen\* (DK), L.A. Svensson, L. Thim, E.M. Nicolaisen
- P-TH-172 AN OPEN LABEL, NON RANDOMIZED, PROSPECTIVE PHASE IV CLINICAL TRIAL EVALUATING THE IMMUNOGENICITY OF BRANDED ENOXAPARIN VERSUS BIOSIMILARS IN HEALTHY VOLUNTEERS**  
Marise Gomes\* (US), Eduardo Ramacciotti, Debra Hoppensteadt, Jeanine Walenga, Bruce Lewis, Walter Jeske, Indermohan Thethi, Jawed Fareed
- P-TH-173 MOLECULAR MIMICRY IN THE ADULTERATION OF HEPARIN. SCIENTIFIC BASIS FOR THE DEVELOPMENT OF OVERSULFATED CHONDROITIN SULFATE AND RELATED COMPONENTS.**  
Jawed Fareed\* (US), Rakesh Wahi, Indermohan Thethi, Debra Hoppensteadt, Jeanine Walenga, Walter Jeske, Vinod Bansal, Harry Messmore
- P-TH-174 THE TWO DIFFERENT ACTIVATED FORMS OF FXIII, FXIIIa\* AND FXIIIa<sub>o</sub>, HAVE SIMILAR STRUCTURES, CATALYTIC ACTIVITY AND SUBSTRATE SPECIFICITY**  
Lene Hoerlyck\* (DK), Mette Dahl Andersen, Johan Henrik Faber, Gunhild Klarskov Kristiansen, Benedicte Kiehr, Eva H. Norling Olsen

Thursday Posters



41

## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-175 SHOULD GENERIC VERSIONS OF LOW MOLECULAR WEIGHT HEPARINS BE CONSIDERED AS GENERIC OR BIOSIMILAR DRUGS. A REGULATORY DILEMMA.**  
Jawed Fareed\* (US), Walter Jeske, Jeanine M. Walenga, Debra Hoppensteadt, Rakesh Wahi, Russell Hull
- P-TH-176 SERINE PROTEASE GENERATION BY OVERSULAFED CHONDROITIN SULFATE AND CONTAMINANTS IN HEPARIN: CLINICAL IMPLICATIONS**  
Debra A Hoppensteadt\* (US), Jacqueline Champlain, Josephine Cunanan, Hussein Khan, Walter Jeske, Jawed Fareed

### Exogenous hemostatic factors

- P-TH-177 DIFFERENTIAL EFFECTS OF GAS6 AND PROTEIN S IN HUMAN EOSINOPHILS**  
Koa Hosoki\* (JP), Masaaki Toda, Atsushi Yasukawa, Yasushi Miyake, Daniel Boveda, Paloma Gil-Bernabe, Takehiro Takagi, Rumi Morooka, Mizuho Nagao, Corina D'Alessandro-Gabazza, John Morser, Takao Fujisawa, Osamu Taguchi, Esteban Gabazza
- P-TH-178 ECONOMIC ANALYSIS OF AN EARLY PROPHYLAXIS REGIMEN TO REDUCE FVIII INHIBITOR DEVELOPMENT IN PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH SEVERE HAEMOPHILIA A**  
Guenter Auerswald\* (DE), Karin Kurnik, Joshua D Epstein, Roberto Crea, Armin J Reininger
- P-TH-179 IMMUNOSUPPRESSIVE ACTIVITY OF ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE (APCC): A NEW STEP TOWARD THE ERADICATION OF INHIBITORS AGAINST FACTOR VIII?**  
Ihosvany Fernandez-Bello\* (ES), E.G. Arias-Salgado, M. Martin-Salces, M.T. Alvarez-Roman, R. Mendez-Burgos, M. Valencia-Sanchez, L. Casabella-Prieto, V. Jimenez-Yuste, A R.de la Rua, I. Rivas-Pollmar, N. Butta-Coll
- P-TH-180 ITI WITH A VWF/ FVIII CONCENTRATE IN HAEMOPHILIA A PATIENTS WITH INHIBITORS AND A POOR PROGNOSIS FOR ITI SUCCESS: PROGRESS REPORT ON OCTANATE IN THE OBSITI STUDY**  
Nedezhda Zozulya\* (RU), Olga Plyushch, Vladimir Vdovin, Tatiana Andreeva, Pavel Svirin, Tatiana Severova, Ekaterina Shiller, Nina Klimova, Majda Benedik Dolnicar, Francisco Velasco, Manuel Campos, Sara Morais, Carmen Escuriola Ettingshausen, Wolfhart Kreuz
- P-TH-181 THE USE OF A VWF CONTAINING PLASMA DERIVED FVIII PRODUCT (VWF/PD-FVIII) IN HEMOPHILIA A PATIENTS WITH INHIBITORS IN PRIMARY OR RESCUE IMMUNE TOLERANCE INDUCTION (ITI)**  
Victor Jimenez-Yuste\* (ES), Saturnino Haya, Rosario Perez, Lydia Abad-Franch, Ana Rosa Cid, Inmaculada Soto, Carmen Altisent, Ihosvany Fernandez-Bello, Jordi Fontcuberta, Rosario Gonzalez-Boullosa, Montserrat Maicas, Ramiro Nunez, Fernando Ortega, Maria Jose Paloma, Maria Angeles Palomo, Manuel Prieto, Margarita Redondo, Francisco Javier Rodriguez-Martorell, Jose Luis Sastre
- P-TH-182 THE FIRST NATIONAL ANNUAL TENDER FOR FACTOR CONCENTRATES IN MACEDONIA**  
Violeta Dejanova-Ilijevska\* (MK), Rumjana Apostolovska
- P-TH-183 ALLERGIC REACTION AFTER REPLACEMENT THERAPY IN HAEMOPHILIA B PAEDIATRIC PATIENT WITH INHIBITOR TO FACTOR IX**  
Paola Giordano\* (IT), Rosanna Scaraggi, Giuseppe Lassandro, Renato Marino, Domenico De Mattia, Francesco Antonio Scaraggi



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-184**    **SIGNIFICANT IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE WITH PROPHYLAXIS IN SEVERE HEMOPHILIA A: RESULTS FROM THE RAHF-PFM RANDOMIZED, CONTROLLED PROPHYLAXIS STUDY**  
Amy D Shapiro\* (US), Elena Santagostino, Joshua D Epstein, Phillip Schroth, Wing-Yen Wong
- P-TH-185**    **TOWARDS A LIQUID PLASMA BANK. OPTIMAL STORAGE CONDITIONS AND METHYLEN-BLUE PATHOGEN INACTIVATION OF THAWED PLASMA**  
Thomas Thiele\* (DE), Sarah Kellner, Gregor Hron, Christina Wasner, Matthias Nauck, Andreas Greinacher, Kathleen Selleng
- P-TH-186**    **SUBCUTANEOUS DELIVERY OF RFXFC FOR THE TREATMENT OF HEMOPHILIA B**  
Susan M Dallabrida\* (US), Todd D. Hoehn, Li Shuanglian, Douglas Drager, Tongyao Liu, Susannah Patarroyo-White, Nancy Moore, Glenn F. Pierce, Haiyan Jiang
- P-TH-187**    **AN OPTIMIZED LOW VOLUME FACTOR IX PRODUCT CONCEPT SUPPLYING 400 IU/ML**  
Oliver Hegener\* (CH), Lutz Hoffer, Marietta Putz, Gerhard Gruber
- P-TH-188**    **PROCOAGULANT MICROPARTICLES IN THERAPEUTIC PLASMAS**  
Thomas P Lecompte\* (FR), Marie Hacquard, Carole Pellegrini, Lysiane Chevreux, Sylvie Gross, Thierry Schneider
- P-TH-189**    **FACTOR XI CONCENTRATE AS REPLACEMENT THERAPY FOR INHERITED FXI DEFICIENCY: DATA FROM A FRENCH COHORT OF 44 PATIENTS**  
Frederic Bauduer (FR), Emmanuelle De Raucourt, Jenny Goudemand, Catherine Boyer-Neumann, Marc Trossaert, Philippe Beurrier, Group Post-Marketing Study, Françoise Bridey\*, Catherine Chatelanaz, Celine Henriet\*
- P-TH-190**    **LOSAC, THE FIRST HEMOLIN THAT EXHIBITS PROCOAGULANT ACTIVITY THROUGH SELECTIVE FACTOR X PROTEOLYTIC ACTIVATION**  
Ana Marisa Chudzinski-Tavassi\* (BR), Daniel Furlin, Oscar Henrique Pereira Ramos, Andrea Balan, K Konno, Miryam Paola Alvarez Flores

### Fibrinogen and other factors

- P-TH-191**    **IMPACT OF HEMODILUTION WITH CRYSTALLOIDS AND COLLOIDS ON PRIMARY HEMOSTASIS AND COAGULATION PARAMETERS: REVERSION OF THE COAGULOPATHY WITH PLASMA CONCENTRATES**  
Carolina Caballo\* (ES), CAROLINA CABALLO, ANA M. GALAN, MARIBEL DIAZ-RICART, IRENE LOPEZ-VILCHEZ, ARTURO PEREIRA, MIGUEL LOZANO, JOAN CID, JOAN BELTRAN, MISERICORDIA BASORA, GINES ESCOLAR
- P-TH-192**    **A COMPARISON OF RECOMBINANT AND PLASMA-DERIVED HUMAN FIBRINOGEN ON EX-VIVO CLOT FORMATION IN WHOLE BLOOD SAMPLES FROM CARDIAC SURGERY PATIENTS**  
Fariba Baghaei\* (SE), Vladimir Radulovic, Inger Fagerberg Blixter, Susann Samuelsson, Anders Jeppsson
- P-TH-193**    **FAMILIAL FIBRINOGEN DONGHAE: A NOVEL DYSFIBRINOGENEMIA WITH GAMMA ALANINE-367 TO ASPARTATE SUBSTITUTION**  
Eunkyung Park\* (KR), Eunhyoung Jeon, Hee-Jin Kim, Inho Kim, Seonyang Park
- P-TH-194**    **FIBRIN ARCHITECTURE IS ALTERED IN ABDOMINAL AORTIC ANEURYSMS AND CORRELATES WITH ANEURYSM SIZE**  
Cedric Duval\* (UK), Julian D A Scott, Priya Prasad, Daniel Whalley, Andy Kordowicz, Ramzi A Ajjan, Helen Philippou, Robert A S Ariens

Thursday Posters



43



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-195 ON DEMAND THERAPY AFTER ITT FAILURE IN A PATIENT WITH VON WILLEBRAND DISEASE TYPE 3 AND ALLOANTIBODIES**  
Manuela Krause\* (DE), Thomas Scholz, Christoph Koenigs, Daniele Pillitteri, Ann-Kathrin Pilgrimm, Carl Maximilian Kirchmaier, Wolfhard Kreuz
- P-TH-196 FIBRIN NANOMECHANICS: STRUCTURAL UNDERPINNINGS AND UNFOLDING MECHANISM UNDERLYING FORCED ELONGATION OF FIBRIN(OGEN) MONOMERS AND POLYMERS**  
John W Weisel\* (US), Artem Zhmurov, Andre E.X. Brown, Rustem I. Litvinov, Ruxandra I. Dima, Valeri Barsegov, John W. Weisel
- P-TH-197 CLEAVAGE OF FIBRINOGEN FPA BY THROMBIN INDUCES STRUCTURAL CHANGES WITHIN BBETA121-138 REGION OF MOLECULE**  
Eduard Vitalievich Lugovskoy\* (UA), Lesya Petrovna Urvant, Evgeniy Mitrofanovich Makogonenko, Nataliya Eduardovna Lugovskaya, Nikolay Aleksandrovich Pydiura, Tatyana Anatolievna Koshel, Irina Nikolaevna Kolesnikova, Serhey Vasilievich Komisarenko
- P-TH-198 VISFATIN INDUCES TISSUE FACTOR EXPRESSION IN MONOCYTES BY NF-KAPPAB-DEPENDENT PATHWAY**  
Li Jun-ling\* (CN), Shi-long Xiong, Ping Zhou, Wen-hui Zhu, Feng Gao
- P-TH-199 POLYMERIZATION OF THE  $\alpha$ C-DOMAINS IN FIBRIN RESULTS IN THE EXPOSURE OF THEIR CRYPTIC TPA- AND PLASMINOGEN-BINDING SITES**  
Leonid Medved\* (US), Galina Tsurupa, Ariza Mahid
- P-TH-200 CAN HAEMOCOMPLETTAN (A FIBRINOGEN CONCENTRATE) AND/OR FIBROGAMMIN (A FXIII CONCENTRATE) BE USED AS ANTIDOTES TO THE BLEEDING COMPLICATIONS OF ANTITHROMBOTIC THERAPY ?**  
Shu He\* (SE), Hakan Wallen, Bark Niklas, Johnsson Hans, Blomback Margareta
- P-TH-201 PROCOAGULANT PHOSPHOLIPIDS IN PATIENTS WITH LIVER CIRRHOSIS WITH AND WITHOUT PORTAL VEIN THROMBOSIS.**  
Valeria Rossetto (IT), Luca Spiezia, Elena Campello, Sabrina Gavasso, Maria Bon, Marco Senzolo, Krissia Rodriguez, Maria Teresa Sartori, Barry Woodhams\*, Paolo Simioni
- P-TH-202 TISSUE TRANSGLUTAMINASE INHIBITOR IN A PATIENT WITH ACQUIRED FXIII DEFICIENCY**  
Aaron Lubetsky\* (IL), Rima Dardik, Gili Kenet, Ilia Tamarin, Uri Martinowitz

### Laboratory tests

- P-TH-203 PRELIMINARY PERFORMANCE DATA OF A NEW FREE PROTEIN S ANTIGEN ASSAY\***  
Mechthild Merz\* (DE), Andreas Eidam, Edelgard Lindhoff-Last
- P-TH-204 AN INNOVATIVE TOOL TO INVESTIGATE THE IMMUNE RESPONSE DIRECTED AGAINST FVII IN PATIENTS WITH BLOOD COAGULATION DISORDERS TREATED BY RFVIIA**  
Caroline Pfeiffer\* (FR), Geraldine Lavigne-Lissalde, Pauline Logghe, Huseyin Tokgoz, Jean-Luc Pellequer, Jean-Francois Schved, Muriel Giansily-Blaizot,  
. the french group of FVII deficiency
- P-TH-205 MARKERS OF BLOOD CELL ACTIVATION AND COMPLEMENT ACTIVATION IN FACTOR IX CONCENTRATES**  
Martin F Brodde\* (DE), Beate E Kehrel



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-206 MEASUREMENT OF RIVAROXABAN PLASMA CONCENTRATIONS USING CALIBRATORS AND CONTROLS; RESULTS OF THE PROTHROMBIN TIME AND THE ANTI-FACTOR XA CHROMOGENIC ASSAY FIELD TRIALS**  
MEYER MICHEL SAMAMA\* (FR), Genevieve Contant, Elisabeth Perzborn, Celine Guinet, Yves Gourmelin, Lena Le Flem, Jean Luc Martinoli, Francois Depasse, Gabriele Rohde, Theodore E. Spiro
- P-TH-207 EFFECT OF N-ACETYLCYSTEINE ON COAGULATION AND CLOT FORMATION.**  
Carolina Caballo\* (ES), Carolina Caballo, Annabel Blasi, Miguel Lozano, Ana M. Galan, Pilar Taura, Gines Escolar
- P-TH-208 FEATURES OF A NEW CHROMOGENIC KIT FOR DETERMINATION OF FIX ACTIVITY IN PLASMA AND FIX CONCENTRATES.**  
Pia Bryngelhed\* (SE), Per Rosen, Steffen Rosen
- P-TH-209 ACCIDENTAL DIAGNOSIS OF REDUCED FVIII LEVELS IN FEMALES: WHAT DOES IT MEAN?**  
Rima Dardik\* (IL), Ariella Zivelin, Gili Kenet, Shadan Lalezari, Uriel Martinowitz
- P-TH-210 A PATIENT DISCREPANT IN ASSAYS OF FREE PROTEIN S ANTIGEN**  
Kieron P Hickey\* (UK), Kieron Hickey, Peter Cooper, Steve Kitchen, Rhona Maclean
- P-TH-211 ACQUIRED FACTOR V INHIBITOR DEVELOPING IN A PATIENT WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA**  
Minooh Ahmadinejad\* (IR), Nader Roushan, Hassan Abolghasemi
- P-TH-212 THROMBIN GENERATION AND ANTITHROMBOTIC ACTIVITY OF FONDAPARINUX AFTER TOTAL HIP REPLACEMENT**  
Lauri Virtanen\* (FI), Birgitta Salmela, Jari Leinonen, Lotta Joutsu-Korhonen, Riitta Lassila
- P-TH-213 EVALUATION OF THROMBIN GENERATION IN SICKLE CELL PATIENTS AND CORRELATION TO CLINICAL DISEASE**  
Nirmish R Shah\* (US), Marilyn Telen, Thomas Ortel
- P-TH-214 STUDY ON THE METHOD FOR ASSAYING FVIII INHIBITOR TITER USING FVIII CONCENTRATE FOR THE NEUTRALIZATION THERAPY.**  
Tatsuya Araki\* (JP), Kohei Hashimoto, Sayaka Oonishi-Kanakuri, Noriyuki Ishihara, Kazuhiko Tomokiyo, Takayoshi Hamamoto, Tomohiro Nakagaki, Hideji Hanabusa
- P-TH-215 A FILTER SPOT TEST FOR OVERSULFATED CONTAMINANTS IN HEPARIN**  
Helga Szelke\* (DE), Ulrich Warttinger, Annamaria Naggi, Giangiacomo Torri, Job Harenberg, Roland Kraemer
- P-TH-216 ANTICARDIOLIPID ANTIBODIES IN THE REAL WORLD: WHAT IS THE IMPACT OF A CONFIRMATORY TEST AT 12 WEEKS?**  
Jean Devignes (FR), Denis Wahl, Stephane Zuily, Thomas Lecompte\*
- P-TH-217 THE EFFECTS OF VARYING HEMOGLOBIN/HEMATOCRIT AND PLATELET COUNT ON NOVEL THROMBOELASTOGRAPHIC METHODS WHICH ARE SENSITIVE FOR HYPERCOAGULABILITY**  
Richard Har Ko\* (US), Jemily Malvar, Guy Young
- P-TH-218 EVALUATION OF THE COAGULATION ANALYZER CEVERON ALPHA WITH THE NEW OPTIMIZED FLUOROGENIC MODULE FOR STANDARDIZED TGA MEASUREMENT**  
Lieselotte Wagner\* (AT), Viktoria Kaufmann, Jutta Mager, Wolfgang Manak
- P-TH-219 LABORATORY EVALUATION AND MUTATIONAL ANALYSIS OF A COHORT OF PATIENTS WITH ANTITHROMBIN DEFECTS**  
Mary Byrne\* (IE), Carol Ryan, Lisa Preston, Ruth Gilmore, James O'Donnell, Peter V Jenkins

Thursday Posters



45

## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-220** **EVALUATION OF DIRECT THROMBIN INHIBITORS ASSAY FOR MEASURING DABIGATRAN PLASMA CONCENTRATIONS USING CALIBRATOR AND CONTROLS**  
Omid Safa\* (US), Ralph Bottenus, Mark Triscott
- P-TH-221** **THROMBIN GENERATION - EXPERIENCE IN A ONE YEAR OBSERVATION PERIOD UNDER ROUTINE CONDITIONS**  
Annelie Siegemund\* (DE), Thomas Siegemund, Natalie Adam, Ute Scholz
- P-TH-222** **THE RATIO BETWEEN THE ACTIVITIES OF COAGULATION FACTOR XII AND C1 ESTERASE INHIBITOR IN PATIENTS WITH ANGIOEDEMA - UPDATE**  
Georg Moessmer\* (DE)
- P-TH-223** **SIBLINGS WITH HEMOPHILIA A AND INHIBITORS SHOW SIMILAR REACTIVITY WITH FVIII EPITOPES**  
Christoph Koenigs\* (DE), Joerg Kahle, Aleksander Orlowski, Diana Stichel, Nicole Krause, Karin Becker-Peters, Christine Heller, Sharyne Donfield, Erik Berntorp, Wolfhart Kreuz, Jan Astermark
- P-TH-224** **LIQUID ANTI-XA ASSAY: RAPID MONITORING OF XA INHIBITORS**  
Valeri Krougliak\* (US), Chun Kung, Mark Triscott
- P-TH-225** **A NEW LATERAL-FLOW DEVICE IN URINE TO ASSESS COAGULATION ACTIVITY IN PATIENTS WITH OR WITHOUT VENOUS THROMBOEMBOLIC COMPLICATIONS AFTER TOTAL HIP OR KNEE ARTHROPLASTY**  
Lars Carl Borris\* (DK), Morten Breindahl, Michael Rud Lassen, Akos Ferenc Pap, Frank Misselwitz
- P-TH-226** **USE OF PROTEIN C CONCENTRATE IN ADULT PATIENTS WITH CANCER AND DISSEMINATED INTRAVASCULAR COAGULATION**  
ALESSANDRA MALATO\* (IT), Giorgia Saccullo, Clementina Caracciolo, Lucio Lo Coco, Sergio Siragusa
- P-TH-227** **LABORATORY FOLLOW-UP AND CLINICAL MANAGEMENT OF A PATIENT CASE WITH SEVERE BLEEDING COMPLICATION ON DABIGATRAN FOR ATRIAL FIBRILLATION**  
Riitta Lassila\* (FI), E Munsterhjelm, L Joutsu-Korhonen, Elina Armstrong
- P-TH-228** **CIRCADIAN CHANGES IN THROMBOTIC POTENTIAL IN OBSTRUCTIVE SLEEP APNEA (OSA): A RANDOMIZED, PLACEBO-CONTROLLED CROSSOVER STUDY**  
Brad McEwen\* (AU), Marie-Christine Morel-Kopp, Craig Phillips, David Sullivan, Christopher M Ward, Ron Grunstein, Geoffrey H Tofler
- P-TH-229** **COMPARING THROMBIN GENERATION ASSAY WITH ACTIVATED PARTIAL THROMBOPLASTIN TIME FOR MONITORING THERAPY IN A PATIENT WITH ACQUIRED HEMOPHILIA**  
Franco Carmassi\* (IT), Ferdinando De Negri, Alessandra De Serio
- P-TH-230** **CORRELATION BETWEEN HEPARIN DOSE AND CLINICAL MONITORING TEST RESULTS INCLUDING APTT IN PATIENTS TREATED WITH UNFRACTIONATED HEPARIN**  
Sumiyoshi Naito\* (JP), Masahiro Ieko, Mika Yoshida, Nobuhiko Takahashi, Osamu Kumano, Masumi Murakami, Chizuru Morikawa, Shinji Fujita, Yutaka Toyoda, Shigeru Arima
- P-TH-231** **LEVEL OF KNOWLEDGE AMONG TUNISIAN PATIENTS UNDERGOING LONG-TERM ACENOCOUMAROL TREATMENT**  
Faouzi Addad\* (TN), Iella zohr Rezine, Khalil Mahmoudi, Rym Chrigui, nadia Hammami, Samir Chine, Majdi Amami, Sami Gargouri, Afef Ben Halima, Ikram Kamoun, Salem Kachboura
- P-TH-232** **D-DIMER LEVELS AND PREECLAMPSIA: A SYSTEMATIC REVIEW**  
Luci Maria SantAna Dusse\* (BR), Melina Barros Pinheiro, Fernanda Fonseca Coelho, Maria Graca Carvalho, Ana Paula Fernandes, Daniela Rezende Junqueira, Karina Braga Gomes



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-233 COAGULATION ABNORMALITIES IN PATIENTS WITH COLON CANCER OPERATED FOR ACUTE INTRA-ABDOMINAL SEPSIS.**  
Dmitriy Gurzhiy\* (RU), Khizri Ahmedovich Gamzatov
- P-TH-234 REVIEW OF OUT OF HOUR COAGULATION SCREEN REQUESTS IN TWO UNIVERSITY TEACHING HOSPITALS**  
Siamak Arami\* (UK), Charlotte Foley, John Hanley

### Experimental models

- P-TH-235 DIRECT FLUORESCENCE ASSAY FOR THE QUANTIFICATION OF HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARINS IN CLINICAL SAMPLES**  
Helga Szelke (DE), Christina Giese, Roland Kraemer, Job Harenberg\*
- P-TH-236 SEVERE HEMOPHILIA A IN A MALE DOG WITH A C TO T TRANSITION IN EXON 12 OF FACTOR VIII GENE LEADING TO A PREMATURE STOP CODON**  
Timothy Charles Nichols\* (US), Jay N Lozier, Mark T Kloos, Elizabeth P Merricks, Robin A Raymer, Nathaly Lemoine, Dwight Bellinger
- P-TH-237 COMPARISON OF UNFRACTIONATED HEPARIN, ENOXAPARIN, LOW-DOSE AND HIGH-DOSE RIVAROXABAN IN PREVENTING THROMBUS FORMATION ON MECHANICAL HEART VALVES: RESULTS OF AN IN VITRO STUDY**  
Anja Kaeberich\* (DE), Iris Reindl, Uwe Raaz, Lars Maegdefessel, Alexander Vogt, Torsten Linde, Ulrich Steinseifer, Elisabeth Perzborn, Nancy Cook Bruns, Baerbel Hauroeder, Michael Buerke, Karl Werdan, Axel Schlitt
- P-TH-238 LONG-TERM ESTROGEN TREATMENT OF THROMBOSIS PRONE MICE INDUCES A SUSTAINED INCREASE IN THE ENDOGENOUS THROMBIN POTENTIAL WITHOUT AFFECTING THE THROMBOTIC PHENOTYPE**  
Audrey CA Cleuren\* (NL), Rene van Oerle, Hugo ten Cate, Pieter H Reitsma, Henri M Spronk, Bart JM van Vlijmen
- P-TH-239 THROMBOMODULIN MODULATES MATURATION AND ANTIGEN PRESENTATION OF MURINE DENDRITIC CELLS *IN VITRO***  
Masaaki Toda\* (JP), Takehiro Takagi, Osamu Taguchi, Daniel Boveda Ruiz, Paloma Gil Bernabe, Corina N D'Alessandro-Gabazza, Yasushi Miyake, Atsushi Yasukawa, John Morser, Esteban C Gabazza
- P-TH-240 ALLERGEN-INDUCED BRONCHIAL ASTHMA IN THE FACTOR V LEIDEN MOUSE**  
Atsushi Yasukawa\* (JP), Takehiro Takagi, Osamu Taguchi, Masaaki Toda, Daniel Boveda Ruiz, Paloma Gil Bernabe, Corina N D'Alessandro-Gabazza, Yasushi Miyake, John Morser, Esteban C Gabazza
- P-TH-241 THE ROLE OF THROMBIN IN ALLERGIC BRONCHIAL ASTHMA IS MEDIATED BY DENDRITIC CELLS**  
Yasushi Miyake\* (JP), Masaaki Toda, Atsushi Yasukawa, Yuki Matsushima, Corina N Gabazza, Takehiro Takagi, Masahiro Naito, Daniel Boveda Ruiz, Paloma Gil Bernabe, John Morser, Osamu Taguchi, Esteban C Gabazza
- P-TH-242 THE PRINCIPAL RESULTS OF THE INTERNATIONAL IMMUNE TOLERANCE STUDY: EFFICACY AND PREDICTORS OF OUTCOME.**  
Charles RM Hay\* (UK), Donna M DiMichele, and ITI Study Group
- P-TH-243 THE PRINCIPAL RESULTS OF THE INTERNATIONAL IMMUNE TOLAERANCE STUDY: MORBIDITY.**  
Charles RM Hay\* (UK), Donna M DiMichele, and The ITI study Group



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-244 CARBON MONOXIDE-RELEASING MOLECULE-DERIVED CO REGULATES TISSUE FACTOR IN HUMAN ENDOTHELIAL CELLS AND PERIPHERAL BLOOD MONONUCLEAR CELLS**  
keiko maruyama\* (JP), Eriko Morishita, Takeo Yuno, Akiko Sekiya, Hidesaku Asakura, Shigeki Ohtake
- P-TH-245 THE PROTEIN C SYSTEM DOES NOT PLAY A ROLE IN HOST DEFENSE DURING EXPERIMENTAL TUBERCULOSIS**  
Liesbeth M Kager\* (NL), Catharina W Wieland, Alex F De Vos, Joris J Roelofs, Joost CM Meijers, Berend Isermann, Charles T Esmon, Cornelis Van 't Veer, Tom Van der Poll
- P-TH-246 CHARACTERISATION OF BASELINE AND CYTOKINE-STIMULATED ENDOTHELIAL CELL COAGULANT PHENOTYPE AND CORRELATION WITH TISSUE FACTOR AND TISSUE FACTOR PATHWAY INHIBITOR EXPRESSION.**  
Asad Luqmani\* (UK), Mike A Laffan, Ayesha R Khan, Abdullah Alsuliman

### Plasminogen and plasminogen activators

- P-TH-247 HIGH AFFINITY BINDING OF PLASMINOGEN TO FIBRIN IS NOT ESSENTIAL FOR EFFICIENT ACTIVATION BY TISSUE PLASMINOGEN ACTIVATOR**  
Paul Y. Kim\* (CA), Long D. Tieu, Alan R. Stafford, James C. Fredenburgh, Jeffrey I. Weitz
- P-TH-248 IDENTIFICATION OF MOLECULAR TARGET OF SMTF, A CANDIDATE THERAPEUTIC COMPOUND FOR STROKE**  
Eriko Suzuki\* (JP), Naoki Matsumoto, Keiji Hasumi
- P-TH-249 CROSS-EFFECTS OF HYPOTENSIVE AND ANTIFIBRINOLYTIC DRUGS ON THE KEY ENZYMES ACTIVITY OF FIBRINOLYTIC SYSTEM (FS) AND RENIN-ANGIOTENSIN SYSTEM (RAS) IN VITRO**  
Dmitry A Gulin\* (RU), Lilia I Mukhametova, Roza B Aisina, Olga A Kost, Irina I Nikolskaya, Karina B Gershkovich
- P-TH-250 OCCULT ACTIVATION OF FIBRINOLYSIS IN TRAUMA**  
Imran Raza\* (UK), Ross Davenport, Claire Rourke, Sean Platton, Joanna Manson, Catherine Spoons, Henry De'Ath, Sirat Khan, Shuba Allard, Daniel Hart, K John Pasi, Beverley J Hunt, Simon Stanworth, Peter MacCallum, Karim Brohi
- P-TH-251 PLASMINOGEN/PLASMIN MODULATES BONE METABOLISM BY REGULATING THE OSTEOBLAST AND OSTEOCLAST FUNCTION.**  
Yosuke Kanno\* (JP), Eri Kawashita, Kiyotaka Okada, Shigeru Ueshima, Osamu Matsuo, Hiroyuki Matsuno
- P-TH-252 DIABETES-INDUCED POST-TRANSLATIONAL MODIFICATIONS IN PLASMINOGEN ALTER PROTEIN ACTIVITY AND INTERACTION WITH FIBRIN**  
Ramzi A Ajjan\* (UK), Toby Gamlen, Kristina F Standeven, Salihah Mughal, Katharina Hess, Paul Thornalley, Fladia Phoenix, Helen Philippou, Peter J Grant
- P-TH-253 INSIGHTS INTO THE DIFFERENT CONFORMATIONAL FORMS OF PLASMIN(OGEN)**  
Bernadine G C Lu\* (AU), Ruby H P Law, Paul B Coughlin, Anita J Horvath
- P-TH-254 PLASMIN-ANTIPLASMIN COMPLEX IS AN USEFUL MARKER FOR DIAGNOSIS OF AL AMYLOIDOSIS**  
Mitsuhiro Uchiba\* (JP), Hiroyuki Hata, Yuji Yonemura, Mitsuharu Ueda, Hiroaki Mitsuya, Yukio Ando



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-255 ZN<sup>2+</sup> DELAYS GLU- AND LYS-PLASMINOGEN ACTIVATION BY TISSUE PLASMINOGEN ACTIVATOR AND INHIBITS PLASMIN ACTIVITY TOWARD MACROMOLECULAR SUBSTRATES**  
Sultan Chaudhry\* (CA), Paul kim, Alan Stafford, Beverly Leslie, James Fredenburgh, Jeffrey Weitz
- P-TH-256 EFFECT OF FIBRINOGEN ON CELL-STIMULATED ACTIVATION OF PLASMINOGEN**  
Valeryi K Lishko\* (US), Ivan S Yermolenko, Tatiana P Ugarova
- P-TH-257 A NEW SYNTHETIC PEPTIDE (SP) ENHANCES PLASMINOGEN ACTIVATION BY T-PA**  
Kiyotaka Okada\* (JP), Shigeru Ueshima, Hiroyuki Matsuno, Naoyuki Kawao, Yukinori Tamura, Masato Yano, Nobuo Nagai, Osamu Matsuo
- P-TH-258 MODELLING PLASMINOGEN ACTIVATION IN FIBRIN USING VARIANTS OF TISSUE PLASMINOGEN ACTIVATOR**  
Colin Longstaff\* (UK), Craig Thelwell, Marta Silva

### TAFI

- P-TH-259 EVALUATION OF TAFI ACTIVATION IN PLASMAS WITH ABNORMAL THROMBIN GENERATION. ROLE OF PROGRESSIVE DOSIS OF THROMBIN IN THE ASSAY.**  
Maria Lucia D'Errico (VE), Norma de Bosch\*, Apsara Boadas, Carlos Ibarra, Ana Maria Salazar, Arlette Ruiz-Saez, Belsy Guerrero
- P-TH-260 HYPOFIBRINOLYSIS AND THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM: A PROSPECTIVE COHORT STUDY**  
Ludwig Traby\* (AT), Georg Heinze, Marietta Kollars, Lisbeth Eischer, Sabine Eichinger, Paul Alexander Kyrle
- P-TH-261 EFFECT OF ORAL ANTICOAGULANT TREATMENT ON TAFI/TAFIA LEVELS AND CLOT RESISTANCE TO FIBRINOLYSIS**  
Mario Colucci\* (IT), Francesca Incampo, Cosimo Carrieri, Rita Galasso, Francesca Di Serio, Nicola Semeraro
- P-TH-262 ASSOCIATIONS BETWEEN TAFI LEVELS, THE TAFI GENE POLYMORPHISMS AND THE CLOT LYSIS IN DEEP VEINS IN PATIENTS WITH VENOUS THROMBOEMBOLISM IN RUSSIAN POPULATION**  
Natalya Mikhaylovna Vorobyeva\* (RU), Natalya A. Doroshchuk, Zukhra B. Khasanova, Anatoliy B. Dobrovolsky, Elena V. Titaeva, Anton Yu. Postnov, Olga V. Ermolina, Tatyana V. Balakhonova, Alexandr I. Kirienko, Elizaveta P. Panchenko
- P-TH-263 PROTECTIVE ROLE OF THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR IN ALLERGIC BRONCHIAL ASTHMA**  
Daniel Boveda Ruiz\* (JP), Corina N. D'Alessandro-Gabazza, Masaaki Toda, Paloma Gil Bernabe, Yasushi Miyake, Atsushi Yasukawa, Yuki Matsushima, Masahiro Naito, Takehiro Takagi, John Morser, Osamu Taguchi, Esteban C. Gabazza
- P-TH-264 THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR SYSTEM IN CANCER PATIENTS WITH OR WITHOUT VENOUS THROMBOEMBOLISM**  
Claudia Maria Radu (IT), Luca Spiezia, Elena Campello, Cristiana Bulato, Sabrina Gavasso, Fabio Dalla Valle, Sara Carraro, Valeria Ferri, Barry Woodhams\*, Paolo Simioni
- P-TH-265 ACTIVATION OF THE COMPLEMENT SYSTEM IN DIABETIC THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR/APOLIPOPROTEIN-E DOUBLE KNOCKOUT MICE.**  
Paloma Gil Bernabe\* (JP), Corina N. D'Alessandro-Gabazza, Masaaki Toda, Takehiro Takagi, Daniel Boveda Ruiz, Yasushi Miyake, John Morser, Esteban C. Gabazza



## POSTER PRESENTATIONS

Thursday, July 28, 2011

**P-TH-266 HYPofibrinolysis in patients with portal vein thrombosis and liver cirrhosis.**

Valeria Rossetto (IT), Luca Spiezia, Sabrina Gavasso, Patrizia Zerbinati, Elena Campello, Marco Senzolo, Krissia Rodriguez, Maria teresa Sartori, Maria Bon, Barry Woodhams\*, Paolo Simioni

### MMPs

**P-TH-267 MODULATION OF GELATINASES DURING WEIGHT LOSS IN OBESE MICE**

Matthias Van Hul\* (BE), Bianca Hemmeryckx, Henri Roger Lijnen

**P-TH-268 HIGH LEVEL OF MATRIX METALLOPROTEINASE-2 IS RELATED TO THROMBOTIC EVENTS IN PATIENTS WITH STABLE CORONARY DISEASE.**

Andrey Komarov\* (RU), Anatoly Dobrovolsky, Elena Titaeva, Olga Shakmatova, Tatiana Ilyushchenko, Gulara Dzhaliilova, Aleksander Deev, Elisaveta Panchenko

### Deep vein thrombosis and pulmonary embolism

**P-TH-269 INTAKE OF FATTY FISH IS ASSOCIATED WITH LOWER RISK OF VTE. A DANISH FOLLOW-UP STUDY**

Marianne Tang Severinsen\* (DK), Kim Overvad, Erik Berg Schmidt, Soeren Risom Kristensen

**P-TH-270 A NOVEL MISSENSE MUTATION OF FACTOR V (FACTOR V NARA : W1920R) MANIFESTED THROMBOSIS AND DEMONSTRATED A POSITIVE RESULT OF ACTIVATED PROTEIN C RESISTANCE ASSAY**

Keiko Shinozawa\* (JP), Keiji Nogami, Kenji Ogiwara, Tomoko Matsumoto, Kagehiro Amano, Midori Shima, Katsuyuki Fukutake

**P-TH-271 RESULTS OF THROMBOPHILIA SCREENING IN PATIENTS WITH VENOUS THROMBOEMBOLISM IN NORTH WEST RUSSIA.**

Veronika Shmeleva\* (RU), Sergei Kapustin, Michail Blinov, Vera Kobilyanskaya, Ludmila Papayan

**P-TH-272 THE INCIDENCE OF RECURRENT VENOUS THROMBOEMBOLISM IN A DEFINED POPULATION**

Inge C.M. Mos\* (NL), Melanie Tan, Madelief Klinkenberg, Felix J.M. van der Meer, Menno V. Huisman

**P-TH-273 ONYX-3, A DOUBLE-BLIND COMPARISON OF ONCE- OR TWICE-DAILY DOSING WITH YM150 (30 OR 60 MG DAILY) FOR PREVENTING VENOUS THROMBOEMBOLISM AFTER ELECTIVE HIP ARTHROPLASTY**

Bengt I Eriksson\* (SE), Giancarlo Agnelli, Alexander S Gallus, Michael R Lassen, Martin H Prins, Ronny W Renfurum, Alexander GG Turpie

**P-TH-274 PROTEIN S MUTATIONS IN THAI PATIENTS WITH DEEP VEIN THROMBOSIS**

Worawan - Chumpia\* (TH), Pantep Angchaisuksiri, Chatlada Thabthimngam, Yada Moonpijit, Panutas Kritpetcharut

**P-TH-275 DABIGATRAN ETEXILATE IS EFFECTIVE IN OVERWEIGHT AND OBESE PATIENTS - EFFECT OF BODY MASS INDEX (BMI) ON THE EFFICACY OF DABIGATRAN ETEXILATE: A POOLED ANALYSIS**

Bengt I Eriksson\* (SE), Andreas A Kurth, Ola E Dahl, Martin Feuring, Andreas Clemens, Herbert Noack, Stefan Hantel, Richard J Friedman, Michael Huo



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-276 ORAL DABIGATRAN ETEXILATE VERSUS ENOXAPARIN FOR PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP ARTHROPLASTY: A POOLED ANALYSIS OF TWO RANDOMIZED TRIALS**  
Bengt I Eriksson\* (SE), Andreas A Kurth, Ola E Dahl, Andreas Clemens, Janet Schnee, Stefan Hantel, Martin Feuring, Richard J Friedman, Michael Huo
- P-TH-277 RIVAROXABAN: SAFETY, USEFULNESS AND PRACTICAL DETAILS OF DRUG MONITORING.**  
Francois Mullier\* (BE), Jonathan Douxfils, Severine Robert, Philippe Devel, Christian Chatelain, Bernard Chatelain, Jean-Michel Dogne
- P-TH-278 DABIGATRAN: SAFETY, USEFULNESS AND PRACTICAL DETAILS OF DRUG MONITORING.**  
Francois Mullier\* (BE), Jonathan Douxfils, Severine Robert, Philippe Devel, Christian Chatelain, Bernard Chatelain, Jean-Michel Dogne
- P-TH-279 RISK ASSESSMENT FOR RECURRENT VENOUS THROMBOEMBOLISM (VTE) AFTER 6 TO 14 MONTHS OF ANTICOAGULANT TREATMENT**  
Gary E Raskob\* (US), Lensing W.A. Anthonie, Martin H. Prins, Sebastian Schellong, Harry R. Buller
- P-TH-280 ANTICOAGULATION AND BLEEDING: THE EFFECT OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, ACETYLSALICYLIC ACID, OR OTHER PLATELET AGGREGATION INHIBITORS**  
Bruce L Davidson\* (US), Anthonie W.A. Lensing, Benjamin Brenner, Martin H. Prins, Martin Gebel, Martin Homering, Harry R. Buller
- P-TH-281 THE RELATIVE EFFICACY OF RIVAROXABAN VERSUS VITAMIN K ANTAGONISTS (VKA) IN RELATION TO TIME IN THERAPEUTIC RANGE (TTR) IN PATIENTS WITH DEEP VEIN THROMBOSIS (DVT)**  
Martin H Prins\* (NL), Anthonie W.A. Lensing, Phil Wells, Alice Benson, Karina Meijer, Harry R. Buller
- P-TH-282 THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM AND MAJOR BLEEDING IN FRAGILE PATIENTS WITH DEEP VEIN THROMBOSIS**  
Peter Verhamme\* (BE), Anthonie W.A. Lensing, Barry Jacobson, Akos F. Pap, Martin H. Prins, Harry R. Buller
- P-TH-283 ANTICOAGULATION AND BLEEDING: THE EFFECT OF BLOOD PRESSURE**  
Herve Decousus\* (FR), Anthonie W.A. Lensing, Franco Piovella, Martin H. Prins, Akos F. Pap, Harry R. Buller
- P-TH-284 PATIENT-REPORTED TREATMENT SATISFACTION WITH ORAL RIVAROXABAN VERSUS STANDARD THERAPY IN THE TREATMENT OF SYMPTOMATIC DEEP VEIN THROMBOSIS (DVT)**  
Luke Bamber\* (DE), Stefan J. Cano, Donna L. Lamping, Maria Y. Wang, Martin H. Prins, Rupert Bauersachs, Alexander S. Gallus, Anthonie W.A. Lensing
- P-TH-285 INITIATION OF RIVAROXABAN FOLLOWING LOW MOLECULAR WEIGHT HEPARIN FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS**  
Roger M Mills\* (US), Chandrasekhar Rao V. Damaraju, Lisa K Jennings, Peter Wildgoose
- P-TH-286 THE EFFECT OF PRERANDOMIZATION USE OF THERAPEUTIC ANTICOAGULANTS ON THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN PATIENTS WITH DEEP VEIN THROMBOSIS TREATED WITH RIVAROXABAN**  
Martin H Prins\* (NL), Henri Bounameaux, Anthonie Lensing, Akos F. Pap, Harry R. Buller

Thursday Posters



51



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-287 EVALUATION OF AN AGE ADJUSTED D-DIMER TEST CUT-OFF POINT IN PATIENTS WITH CLINICALLY SUSPECTED ACUTE DEEP-VEIN THROMBOSIS**  
Melanie Tan\* (NL), Gerben C Mol, Antonio Iglesias del Sol, Marcel A van de Ree, Menno V Huisman
- P-TH-288 THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM DURING VITAMIN K ANTAGONIST TREATMENT IN RELATION TO TIME IN THERAPEUTIC RANGE IN PATIENTS WITH DEEP VEIN THROMBOSIS**  
Martin H Prins\* (NL), Anthonie W.A. Lensing, Gary E. Raskob, Alexander S. Gallus, Alice Benson, Harry R. Buller
- P-TH-289 ASYMPTOMATIC PULMONARY EMBOLISM AND ITS PROGNOSTIC IMPACT - FINDING FROM RIETE**  
Inna Tzoran\* (IL), G Saharov, V Valdes, J Villalta, A Bura-Riviere, B Brenner, M Monreal
- P-TH-290 IS HYPOTHERMIA BENEFICIAL DURING RESUSCITATION OF MASSIVE PULMONAL EMBOLI? A PORCINE MODEL OF PULMONAL EMBOLI**  
Soren Risom Kristensen\* (DK), Benedict Kjaergaard, Bodil Steen Rasmussen, Susanne de Neergaard
- P-TH-291 PROGNOSTIC VALUE OF D-DIMER IN PATIENTS WITH VENOUS THROMBOEMBOLISM**  
Natalya Mikhaylovna Vorobyeva\* (RU), Anatoliy B. Dobrovolsky, Elena V. Titavaeva, Alexandr I. Kirienko, Elizaveta P. Panchenko
- P-TH-292 PROTEIN S ACTIVITY ASSAYS. TIME FOR LABORATORIES TO FOLLOW NATIONAL GUIDELINES?**  
Ian Jennings\* (UK), Steve Kitchen, Dianne P Kitchen, Timothy AL Woods, Isobel D Walker
- P-TH-293 VARIABILITY IN ANTICOAGULANT DOSING RECOMMENDATIONS; RESULTS FROM PRIMARY AND SECONDARY CARE IN A UK NEQAS FOR BLOOD COAGULATION EXERCISE.**  
Ian Jennings\* (UK), Steve Kitchen, Dianne P Kitchen, Timothy AL Woods, Isobel D Walker
- P-TH-294 ALTERED FIBRIN CLOT PROPERTIES ARE ASSOCIATED WITH RESIDUAL VENOUS THROMBOSIS**  
Anetta Undas\* (PL), Mariola Ciesla-Dul, Tomasz Drazkiewicz, Jerzy Sadowski
- P-TH-295 TRANSPORT OF HEPARIN ACROSS RAT ILEAL MUCOSA IS ENHANCED BY PEYER'S PATCHES**  
Linda Marie Hiebert\* (CA), Bitu Moazed, Linda M Hiebert
- P-TH-296 IS THE PREDICTIVE QUALITY OF TG IN CONSECUTIVE PATIENTS AFTER DVT INCREASED BY REPETITIVE MEASUREMENTS?**  
Arina J ten Cate-Hoek\* (NL), P Erkens, R van Oerle, H.M.H Spronk, H ten Cate
- P-TH-297 STRUCTURAL AND FUNCTIONAL FIBRONECTIN CHANGES MEDIATED BY HOMOCYSTEINE-THIOLACTONE**  
Valeria Genoud\* (AR), Ana Rovetta, Lucia Kordich, Irene Quintana
- P-TH-298 ACUTE AND CHRONIC CARDIAC FINDINGS FOLLOWING PULMONARY EMBOLISM IN CHILDREN: FINDINGS FROM A PROSPECTIVE INCEPTION COHORT STUDY**  
Michael Wang\* (US), Hayley Suzanne Hancock, Katja Gist, Shelley Miyamoto, Marilyn Manco-Johnson, Neil Goldenberg
- P-TH-299 RISK OF RECURRENCE IN PATIENTS WITH PULMONARY EMBOLISM: PREDICTIVE ROLE OF D-DIMER AND OF RESIDUAL PERFUSION DEFECTS ON LUNG SCINTIGRAPHY.**  
Daniela Poli\* (IT), Caterina Cenci, Elisa Grifoni, Emilia Antonucci, Chiara Arcangeli, Domenico Prisco, Rosanna Abbate, Massimo Miniati



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-300 PREDICTIVE FACTORS FOR ASYMPTOMATIC PULMONARY EMBOLISM**  
Anja Boc\* (SI), Alenka Mavri
- P-TH-301 DISTRIBUTION OF THROMBOPHILIC FACTORS IN CHRONIC PORTAL VEIN THROMBOSIS**  
Neila Ben Romdhane\* (TN), Sonia Mahjoub, Houda Kaabi, Hela Baccouche, Nabil Bel Feki, Zeineb Manai, Hmida Slama
- P-TH-302 IN MEDICAL INPATIENTS INCIDENCE AND PROGNOSIS OF ASYMPTOMATIC DISTAL DEEP VEIN THROMBOSIS.THE IMPACT STUDY**  
Gabriele Ciuti\* (IT), Gabriele Ciuti, Elisa Grifoni, Andrea Pavellini, Daniele SOD di Angiologia Righi, Lorenzo Zanasi, Rosanna Abbate, Domenico Prisco, Alberto Moggi Pignone
- P-TH-303 BIOMARKERS IN MORTALITY PREDICTION AFTER VENOUS THROMBOEMBOLISM**  
Kerstin Hogg\* (CA), Edward Hinchliffe, Shonagh Haslam, Esteban Gandara, Fiona Lecky
- P-TH-304 VENOUS THROMBOEMBOLISM FOLLOWING MAJOR SURGERY AND RISK OF RECURRENCE: A POPULATION-BASED COHORT STUDY**  
Vicky Tagalakis\* (CA), Dimple Kondal, Susan Rebecca Kahn
- P-TH-305 PROGNOSTIC VALUE OF MULTIDETECTOR COMPUTED TOMOGRAPHIC PULMONARY ANGIOGRAPHY AND CLINICAL SCORES IN PATIENTS WITH PULMONARY EMBOLISM**  
Suely Meireles Rezende\* (BR), Thiago Horta Soares, Bruna Vilaca de Carvalho, Wanderval Moreira, Cristiane Pena Cabral, Luciano Fagundes de Paula, Marcos de Bastos, Suely Meireles Rezende
- P-TH-306 THROMBOPHILIC MARKERS IN PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH)**  
Angelika Batorova\* (SK), Iveta Simkova, Denisa Jankovicova, Tatiana Prigancova, Anna Morongova
- P-TH-307 "IN VITRO" EFFECT OF ENOXAPARIN ON THROMBIN GENERATION IN PLASMA OF CIRRHOTIC PATIENTS AT DIFFERENT STAGES OF LIVER DISEASE**  
Valeria Rossetto\* (IT), Krissia Rodriguez, Marco Senzolo, Maria Teresa Sartori, Sabrina Gavasso, Mariangela Fadin, Patrizia Zerbinati, Patrizia Burra, Paolo Simioni
- P-TH-308 THE IMPACT OF VENOUS THROMBOEMBOLISM IN CRITICALLY ILL PATIENTS: A META-ANALYSIS OF MAJOR CLINICAL OUTCOMES**  
ALESSANDRA MALATO\* (IT), Francesco Dentali, Francesco Fabbiano, Giorgia Saccullo, Sergio Siragusa
- P-TH-309 REPEATED DOSE ORAL UNFRACTIONATED HEPARIN PREVENTS THROMBOSIS IN A PIG MODEL**  
Linda Marie Hiebert\* (CA), Linda Hiebert, Tilly Ping, Sandra Wice
- P-TH-310 HIGH LEVELS OF THYROXINE INCREASE LEVELS OF COAGULATION FACTORS AND THE RISK OF VENOUS THROMBOSIS: RESULTS OF A LARGE POPULATION-BASED CASE-CONTROL STUDY (MEGA-STUDY)**  
Jan Debeij\* (NL), Bregje van Zaane, Olaf M Dekkers, Johannes WA Smit, Anton PS van Zanten, Dees PM Brandjes, Harry R Buller, Victor EA Gerdes, Frits R Rosendaal, Suzanne C Cannegieter
- P-TH-311 LEVELS OF PROLACTIN IN RELATION TO LEVELS OF COAGULATION FACTORS AND THE RISK OF VENOUS THROMBOSIS: RESULTS OF A LARGE POPULATION-BASED CASE-CONTROL STUDY (MEGA-STUDY)**  
Danka JF Stuijver (NL), Jan Debeij\*, Olaf M Dekkers, Victor EA Gerdes, Frits R Rosendaal, Suzanne C Cannegieter

Thursday Posters



53

## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-312 THE MALMO POLYMORPHISM OF COAGULATION FACTOR IX (FIX) AND THE RISK OF VENOUS THROMBOSIS**  
Cristiana Bulato\* (IT), Elena Campello, Luca Spiezia, Maria Bon, Valeria Rossetto, Patrizia Zerbinati, Mariangela Fadin, Paolo Simioni
- P-TH-313 A COMPARISON OF LOW MOLECULAR WEIGHT, ULTRA LOW MOLECULAR WEIGHT, AND UNFRACTIONATED HEPARINS IN A PURIFIED ANTITHROMBIN SYSTEM**  
Angel L Gray\* (US), Debra Hoppensteadt, Walter Jeske, Jeanine M Walenga, Jawed Fareed
- P-TH-314 PHARMACODYNAMIC DIFFERENCES IN TWO GENERIC BRANDS OF ENOXAPARIN**  
Debra A Hoppensteadt\* (US), Walter Jeske, Jeanine M Walenga, Rakesh Wahi, Indermohan Thethi, Jawed Fareed
- P-TH-315 AGE IS A MAJOR RISK FACTOR OF VENOUS THROMBOEMBOLISM (VTE)**  
Francis Couturaud\* (FR), Nicolas Bizien, Elise Noel Savina, Cecile Tromeur, A Delluc, Dominique Mottier, Christophe Leroyer
- P-TH-316 MANDATORY ELECTRONIC RISK ASSESSMENT MODEL IMPROVES COMPLIANCE WITH GUIDELINES FOR VTE PROPHYLAXIS**  
Hanady R Samaha\* (LB), Nabil A Diab, Mirna C Waked, Nader Wansa, Imad P Hajj
- P-TH-317 FACTOR IX ACTIVITY/ANTIGEN RATIO AND THE RISK OF UNPROVOKED VENOUS THROMBOSIS.**  
Elena Campello\* (IT), Luca Spiezia, Maria Bon, Valeria Rossetto, Sabrina Gavasso, Daniela Tormene, Paolo Simioni
- P-TH-318 ERYTHROCYTE AND PLATELET ADHESIVE PROPERTIES ARE NOT INCREASED IN PATIENTS WITH VTE AFTER AN ACUTE PERIOD OF ANTICOAGULATION**  
Kiara Cristina Senger Zapponi\* (BR), Luis Fernando Bittar, Carla Franco Pentead, Nicola Conran, Erich Vinicios De Paula, Joyce Maria Annichino-Bizzacchi
- P-TH-319 DESCRIPTION OF A COHORT OF PATIENTS WITH THROMBOSIS ASSOCIATED WITH HIV INFECTION IN A COLOMBIAN HOSPITAL**  
Juan Carlos Arrieta\* (CO), Eugenia Lopez, Diana Patricia Giraldo, Luisa Escobar, Maria Fernanda Saldarriaga, James Samir Diaz, Luis Felipe Gomez
- P-TH-320 DESCRIPTION OF A COHORT OF PATIENTS TREATED WITH PHLEGMASIA CERULEA DOLENS TREATED IN A COLOMBIAN HOSPITAL**  
Diana Patricia Giraldo\* (CO), Juan Carlos Arrieta Bechara, Jhon Catano, Paola Arteaga, Juan David Ramirez, Eugenia Lopez

### Genetic determinants and epidemiology

- P-TH-321 DECREASED COMPLEMENT FACTOR H IS ASSOCIATED WITH ENHANCED COMPLEMENT ACTIVATION AND CARDIOVASCULAR RISK IN SOUTH ASIAN RELATIVES OF PATIENTS WITH TYPE 2 DIABETES MELLITUS**  
Victoria R Richardson\* (UK), Somani Riyaz, Kristina F Standeven, Angela M Carter
- P-TH-322 THROMBOPHILIA IN IRANIAN WOMEN WITH PREGNANCY COMPLICATIONS**  
Minoo Ahmadinejad\* (IR), Elham Farhadi, Nooshin Ahmadzadeh, Somaieh Baluch, Kamran Atarodi, Ladan Seyed Mortaz, Zahra Ahmadinejad, Shahin Negari, Mahtab Maghsudlu, Hasan Abolghasemi
- P-TH-323 METHYLENETETRAHYDROFOLATE REDUCTASE (MTHFR) AND THYMIDYLATE SYNTHASE (TS) POLYMORPHISMS IN OSTEOPOROTIC VERTEBRAL COMPRESSION FRACTURE (OVCF) AMONG POSTMENOPAUSAL KOREAN WOMEN**  
Nam Keun Kim\* (KR), Soo Yeon Kim, Young Sun Chung, Seung Ho Hong, Young Joo Jeon, Dong Eun Shin, Dong Ah Shin



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-324 JAK-2 MUTATION IN ESSENTIAL THROMBOCYTOSIS CORRELATES WITH HIGHER HEMOGLOBIN VALUES.**  
Damianos Sotiropoulos\* (GR), Theodoros Marinakis, Panayotis Tsigotis, Michail Iskas, Vasilios Papadopoulos, Emmanouil Papadakis, Emmanouil Spanoudakis, Ioannis Kotsianidis, Anastasia Pouli, Amalia Vassou, Anna Pigaditou, Artemis Balta, Maria Dimou, Maria Kotsopoulou, Haris Matsouka, Ioannis Koratzis, Ioannis Dervenoulas, Nikolaos Anagnostopoulos, Panayotis Panagiotidis, Achilles Anagnostopoulos
- P-TH-325 IMPACT OF OTHER RISK FACTORS ON THE ASSOCIATION OF OBESITY WITH VENOUS THROMBOSIS: THE LONGITUDINAL INVESTIGATION OF THROMBOEMBOLISM ETIOLOGY (LITE) STUDY**  
Mary Cushman\* (US), Ellen S O'Meara, Susan R Heckbert, Neil A Zakai, Aaron R Folsom
- P-TH-326 THE CHROMOSOME 9P21 IS ASSOCIATED WITH ISCHEMIC STROKE IN CHINESE POPULATION**  
Shuo Li (CA), Yuming Xu\*, Hong Zheng, Jianxun Cui, Haizhen Wang, Guang Sun, Wayna Gulliver, Fei-Yu Han, Ya-Gang Xie\*
- P-TH-327 THREE NOVEL 3'END PROTHROMBIN GENE POLYMORPHISMS AND THEIR ASSOCIATION WITH THROMBOPHILIA**  
Valentina Djordjevic\* (RS), Iva Pruner, Mirjana Kovac, Predrag Miljic, Nebojsa Antonijevic, Snezana Kojic, Dragica Radojkovic
- P-TH-328 FACTOR XI POLYMORPHISMS (RS2289252 AND RS2036914) MODULATE FACTOR XI ACTIVITY LEVELS AND APTT RATIO IN THROMBOTIC BUT NOT IN ASYMPTOMATIC WOMEN**  
Barbara Lunghi\* (IT), Michela Cini, Cristina Legnani, Silvia Lorenzi, Gualtiero Palareti, Giovanna Marchetti, Francesco Bernardi
- P-TH-329 COMORBIDITIES DO NOT EXPLAIN THE INCREASED VTE RISK ASSOCIATED WITH RACE AND NON-O BLOOD TYPES**  
Chunhui Fang (US), Hillel W Cohen, Henny H Billett\*
- P-TH-330 ESTABLISHED RISK FACTORS FOR VENOUS THROMBOEMBOLISM AND THEIR RECURRENCE RISK IN A LARGE PANEL OF SMALL THROMBOPHILIA FAMILIES (GIFT STUDY)**  
Marieke C.H. de Visser\* (NL), Rick van Minkelen, Jeroen C.J. Eikenboom, Willem M. Lijfering, Rogier M. Bertina
- P-TH-331 FIBRINOGEN-BETA -249C/T POLYMORPHISM IS A NOVEL GENETIC PREDICTOR FOR RECURRENCE OF DEEP VEIN THROMBOSIS IN RUSSIAN POPULATION**  
Natalya Mikhaylovna Vorobyeva\* (RU), Zukhra B. Khasanova, Natalya A. Doroshchuk, Anton Yu. Postnov, Alexandr I. Kirienko, Elizaveta P. Panchenko
- P-TH-332 CARDIOVASCULAR AND THROMBOPHILIC RISK FACTORS IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION**  
JERZY DROPINSKI\* (PL)
- P-TH-333 THE RISK FOR RECURRENT VENOUS THROMBOEMBOLISM IN CARRIERS OF FACTOR V LEIDEN AND PROTHROMBIN MUTATION**  
Daniela Tormene\* (IT), Sara Carraro, Valeria Ferri, Paolo Simioni
- P-TH-334 SUDDEN SENSORINEURAL HEARING LOSS: A POSSIBLE ROLE OF THROMBOPHILIA AND CARDIOVASCULAR RISK FACTORS**  
Corrado Lodigiani\* (IT), Rosaria Lorusso, Paola Ferrazzi, Luca Libre', Lidia Luciana Rota, Arturo Mario Poletti

Thursday Posters



55

## POSTER PRESENTATIONS

Thursday, July 28, 2011

### Antiphospholipid syndrome

- P-TH-335 CIRCULATING IMMUNOCOMPLEXES CONTAINING  $\beta_2$ -GLYCOPROTEIN I ( $\beta_2$ GPI) IN PATIENTS WITH APS: DETECTION BY MEANS OF HEPARIN (HEP) AFFINITY CHROMATOGRAPHY.**  
Alessandra Banzato\* (IT), Roberta Frasson, Vincenzo De Filippis, Gentian Denas, Seena Jose Padayattil, Amelia Ruffatti, Vittorio Pengo
- P-TH-336 SOLUBLE P-SELECTIN IN PATIENTS WITH THE LUPUS ANTICOAGULANT WITH AND WITHOUT THROMBOSIS**  
Silvia Koder\* (AT), Johanna Haselboeck, Simon Panzer, Ingrid Pabinger
- P-TH-337 ANTIPHOSPHOLIPID ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS IS ASSOCIATED WITH LOW LEVELS OF COMPLEMENT COMPONENTS C3 AND C4**  
Lamya Garabet\* (NO), Inge-Margrethe Gilboe, Marie-Christine Mowinckel, Tom Eirik Mollnes, Per Morten Sandset, Leif Wille, Eva Marie Jacobsen
- P-TH-338 PROTHROMBOTIC ACTIVITY OF PURIFIED ANTI- $\beta_2$ GPI AUTOANTIBODIES IN PATIENTS IS INDEPENDENT OF THEIR PLASMA LEVEL**  
Valerie Proulle\* (US), Richard Furie, Barbara Furie, Bruce Furie
- P-TH-339 INTERNATIONAL MULTICENTRE EVALUATION OF A NEW ASSAY TO DETECT LUPUS ANTICOAGULANTS CAUSED BY ANTI-BETA2-GLYCOPROTEIN AUTOANTIBODIES**  
Bas de Laat\* (NL), R.H.W.M. Derksen, G. Reber, J. Musial, J. Swadzba, B. Bozic, S. Cucnik, V. Regnault, R. Forastiero, B.J. Woodhams, Ph.G. de Groot
- P-TH-340 LUPUS ANTICOAGULANT GUIDELINES: HOW FAR HAVE THESE BEEN ADOPTED BY LABORATORIES?**  
Ian Jennings\* (UK), Steve Kitchen, Dianne P Kitchen, Timothy AL Woods, Isobel D Walker
- P-TH-341 ANTITHROMBIN III LEVEL IN STROKE AT BETHESDA HOSPITAL, YOGYAKARTA, INDONESIA**  
Usi Sukorini\* (ID), Ira Puspitawati, Yohanes Sugiri, Laksmi Asanti
- P-TH-342 AUTOANTIBODIES TO PROTEIN DISULFIDE ISOMERASE (PDI) AS POTENTIAL MEDIATORS OF THE PROTHROMBOTIC PHENOTYPE IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)**  
Narcis Ioan Popescu\* (US), Stan Kamp, Joan T. Merrill, Florea Lupu
- P-TH-343 MYOCARDITIS IN PRIMARY ANTIPHOSPHOLIPID SYNDROME- A CASE REPORT.**  
Antonella Tufano\* (IT), Anna Guida, Matteo Nicola Dario Di Minno, Angela Maria De Gregorio, Anna Cerbone, Ernesto Cimino, Giovanni Di Minno
- P-TH-344 DIAGNOSTIC VALUE OF ANTIPHOSPHATIDYLSERINE ANTIBODIES IN PATIENTS WITH COLLAGENOPATHIES AND/OR CLINICALLY SUSPECTED OF ANTIPHOSPHOLIPID SYNDROME**  
Susana Maria Ouvina\* (AR), Alberto Maneyro, Silvina Lopez Morgan, Santiago Delgado Villalba, Celeste Jagoe, Luis Quiroga, Daniela Antonio, Silvana Cugliari, Layla Noya, Augusto Miroli, Luis Palmer
- P-TH-345 NEW MEASUREMENT METHOD FOR DETECTING LUPUS ANTICOAGULANT WITHOUT INTERFERENCE CAUSED BY WARFARIN THERAPY**  
Chizuru Morikawa\* (JP), Masahiro Ieko, Naito Sumiyoshi, Mika Yoshida, Nobuhiko Takahashi



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-346 IS PLASMA SEPARATED FROM BLOOD BY DOUBLE CENTRIFUGATION USEFUL FOR DETERMINATION OF LUPUS ANTICOAGULANT?**  
Mika Yoshida\* (JP), Masahiro Ieko, Sumiyoshi Naito, Chizuru Morikawa, Osamu Kumano, Masumi Murakami, Nobuhiko Takahashi, Tatsuya Atsumi
- P-TH-347 D-DIMER AND UMBILICAL ARTERY SYSTOLIC-DIASTOLIC RATIO AS ANTEPARTUM MONITORING PARAMETERS IN WOMEN WITH PREGNANCY LOSS FOR THE TIMING OF PROPHYLACTIC ANTICOAGULANTS**  
Tubagus Djumhana Atmakusuma\* (ID), Raden Muharam, Andi Hudono, Fitriyadi Kusumah

### Pregnancy, hormones, women's issues

- P-TH-348 THE ROLES OF THROMBOXANE A2 IN HIGH SALT INDUCED-DEFECT DURING PREGNANCY**  
Chen-Hsueh Pai\* (TW), Ching-Tzu Yen, Shu-Rung Lin, Shu-Wha Lin
- P-TH-349 THE ASSOCIATION OF ANTIPHOSPHOLIPID ANTIBODIES WITH INTRAUTERINE FETAL DEATH: A CASE-CONTROL STUDY**  
Linda Bjork Helgadottir\* (NO), Finn Egil Skjeldestad, Anne Flem Jacobsen, Per Morten Sandset, Eva-Marie Jacobssen
- P-TH-350 THE ASSOCIATION OF INHERITED THROMBOPHILIA AND INTRAUTERINE FETAL DEATH: A CASE-CONTROL STUDY**  
Linda Bjork Helgadottir\* (NO), Finn Egil Skjeldestad, Anne Flem Jacobsen, Per Morten Sandset, Eva-Marie Jacobsen
- P-TH-351 PREVALENCE OF THROMBOPHILIC DEFECTS IN WOMEN WITH ADVERSE PREGNANCY OUTCOMES**  
Minoo Ahmadinejad\* (IR), Ali Rajabi, Kamran Atarodi, Somaie Baluch, Maryam Mohammadi, Seyed Mohammad Reza Tabatabaei, Seyedeh Ladan Seyed Mortaz, Sedigheh Amini Kafi Aabad, Hassan Abolghasemi
- P-TH-352 D-DIMER IN NORMAL PREGNANCY - COMPARISON OF THREE COMMERCIALY AVAILABLE ASSAYS AND DETERMINATION OF REFERENCE VALUES**  
Frauke Bergmann\* (DE), Nadine Pingel, Melanie Mescheder, Florian Guenther, Kathrin Hansmann, Andreas Czwalinna, Christina Platzer, Matthias Koch
- P-TH-353 ASSESSMENT OF ADMA PLASMA LEVELS IN SEVERE PRE-ECLAMPSIA**  
Luci Maria SantAna Dusse\* (BR), Patricia Nessler Alpoim, Lara Carvalho Godoi, Leticia Goncalves Freitas, Melina Barros Pinheiro, Fabiana Kalina Marques, Maria Gracas Carvalho, Ana Paula Fernandes, Karina Braga Gomes
- P-TH-354 ASSESSMENT OF GLU298ASP POLYMORPHISM IN ENDOTHELIAL NITRIC OXIDE SYNTHASE GENE IN SEVERE PRE-ECLAMPSIA**  
Luci Maria SantAna Dusse\* (BR), Patricia Nessler Alpoim, Lara Carvalho Godoi, Melina Barros Pinheiro, Leticia Goncalves Freitas, Fabiana Kalina Marques, Ana Paula Fernandes, Maria Graca Carvalho, Karina Braga Gomes
- P-TH-355 APPLICATION OF LOW MOLECULAR-WEIGHT HEPARIN**  
Elena Vorobiova\* (GE), Nugzar Pargalava, Bokuchava Mamuka, Japaridze Nino
- P-TH-356 IMPACT OF ENOXAPARIN SODIUM ON PUERPERANT'S BLOOD SERUM ENDOTOXIN CONCENTRATION AFTER ABDOMINAL DELIVERY**  
Aleksy V Pyregov\* (RU), Efim M Shifman, Oksana I Shestakova, Igor I Baranov



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-357 SUCCESSFUL MANAGEMENT OF THREE PREGNANCIES IN A PATIENT WITH HOMOZYGOUS PROTEIN C DEFICIENCY AND RECURRENT VENOUS THROMBOEMBOLIC EVENTS**  
Sabine Struve\* (DE)
- P-TH-358 ASSOCIATION BETWEEN MIGRAINE AND BIOLOGICAL THROMBOPHILIA: PRELIMINARY RESULTS OF THE PROMIS STUDY**  
Lorraine Maitrot-Mantelet (FR), Marie-Helene Horellou, Helene Massiou, Anne Gompel, Jacqueline Conard, Genevieve Plu-Bureau\*
- P-TH-359 PREVENTION OF RECURRENT PREECLAMPSIA IN WOMEN WITH THROMBOPHILIA**  
Alexander D. Makatsaria\* (RU), Viktoria O. Bitsadze, Seda M. Baimuradova, Svetlana V. Akinshina
- P-TH-360 RECURRENT FETAL LOSS SYNDROME IN PATIENTS WITH THROMBOPHILIA: PREVENTION IS POSSIBLE**  
Alexander D. Makatsaria\* (RU), Viktoria O. Bitsadze, Seda M. Baimuradova, Svetlana V. Akinshina, Djamilya H. Khizroeva
- P-TH-361 PREVENTION OF RECURRENT ANTENATAL FETAL DEATH AND BIRTH DEFECTS IN PARENTS WITH DEFECTS OF FOLATE METABOLISM AND HYPERHOMOCYSTEINEMIA**  
Alexander D. Makatsaria\* (RU), Viktoria O. Bitsadze, Inna N. Talalaeva, Svetlana V. Akinshina
- P-TH-362 THROMBOSIS RISK SCORE IN PREGNANCY: PRELIMINARY RESULTS FROM A MODEL.**  
Venina Viana Barros\* (BR), Andre Longo De Oliveira, Fernanda Spadotto Baptista, Maria Rita Lemos Bortolotto, Ana Maria Kondo Igai, Regina Schultz, Rossana Vieira Francisco, Roberto Bittar, Marcelo Zugaib
- P-TH-363 THE ROLE OF ANTICOAGULANT PROPHYLAXIS IN REDUCING THE RISK OF IMPLANT FAILURE IN IVF PROCEDURES.**  
Daniela Tormene\* (IT), Sara Carraro, Francesca Vigano, Valeria Ferri, Guido Ambrosini, Paolo Simioni
- P-TH-364 HIGH LEVELS OF LIPOPROTEIN-A (LPA) AND PREGNANCY OUTCOMES**  
Venina Viana Barros\* (BR), Andre Longo Oliveira, Fernanda Spadotto Baptista, Maria Rita Lemos Bortolotto, Ana Maria Kondo Igai, Regina Schultz, Rossana Vieira Francisco, Roberto Eduardo Bittar, Marcelo Zugaib
- P-TH-365 EFFECTIVENESS OF PROPHYLAXIS WITH LOW MOLECULAR WEIGHT HEPARIN DURING PREGNANCY AND POSTPARTUM IN CARRIERS OF ANTITHROMBIN, PROTEIN C AND PROTEIN S DEFICIENCY**  
Daniela Tormene\* (IT), Sara Carraro, Valeria Ferri, Sabrina Gavasso, Paolo Simioni

### Atrial fibrillation and thrombosis

- P-TH-366 TWO YEARS THROMBOSIS SERVICE MAINZ (TDM): THE PATIENT POPULATION OF THE TDM**  
Helmut Schinzel\* (DE), Betina Zeiter, Philipp Wild, Heike Schuhmacher, Irene Kraemer, Thomas Muenzel
- P-TH-367 RESEARCH INTO AGE DEPENDENT INDICATIONS OF VITAMIN K-ANTAGONISTS THERAPY (VKA)**  
Helmut Schinzel\* (DE), Betina Zeiter, Britta Wimmer, Johannes Lotz, Juergen Prochaska, Thomas Muenzel



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-368 PLASMA VON WILLEBRAND FACTOR LEVELS ARE AN INDEPENDENT RISK FACTOR FOR ADVERSE EVENTS, MORTALITY AND MAJOR BLEEDING IN ANTICOAGULATED ATRIAL FIBRILLATION PATIENTS**  
Vanessa Roldan\* (ES), Francisco Marin, Begona Muina, Jose Miguel Torregrosa, Pilar Gallego, Rocio Gonzalez-Conejero, Lip YH Gregory, Vicente Vicente
- P-TH-369 USE OF STATINS AND RECURRENCE OF ATRIAL FIBRILLATION AFTER CATHETER ABLATION OR ELECTRICAL CARDIOVERSION: A SYSTEMATIC REVIEW AND META-ANALYSIS**  
Francesco Dentali\* (IT), Monica Gianni, Alessandro Squizzato, Walter Ageno, Luana Castiglioni, Lorenzo Maroni, Elaine Hylek, Anna Maria Grandi, Achille Venco, Luigina Guasti
- P-TH-370 LOW BLEEDING RISK OF VERY OLD ATRIAL FIBRILLATION WOMEN ON VKA TREATMENT: RESULTS FROM A PROSPECTIVE COLLABORATIVE STUDY. ON BEHALF OF THE AD HOC STUDY GROUP OF FCSA**  
Daniela Poli\* (IT), Emilia Antonucci, Elisa Grifoni, Umberto Carini, Antonio Ciampa, Paolo Da Col, Loreto Galbo, Antonio Insana, Giovanni Nante, Domenico Restifo, Sophie Testa, Walter Ageno, Gualtiero Palareti
- P-TH-371 BLEEDING AND STROKE RISK IN A 'REAL WORLD' PROSPECTIVE PRIMARY PREVENTION COHORT OF ATRIAL FIBRILLATION PATIENTS.**  
Daniela Poli\* (IT), Sophie Testa, Emilia Antonucci, Elisa Grifoni, Oriana Paoletti, Gregory YH Lip
- P-TH-372 IMPACT OF GLOMERULAR FILTRATION ESTIMATE ON BLEEDING RISK IN VERY OLD PATIENTS TREATED WITH VKA: RESULTS OF A PROSPECTIVE COLLABORATIVE STUDY.**  
Daniela Poli\* (IT), Emilia Antonucci, Maria Zanazzi, Elisa Grifoni, Roberto Cappelli, Eugenio Lucherini, Francesco Orlandini, Fabio Pini, Antonietta Piana, Antonietta Piana, Lucia Ruocco, Eros Tiraferri, Sophie Testa, Walter Ageno, Gualtiero Palareti
- P-TH-373 EFFICACY OF THE ORAL FXA INHIBITOR, YM150 ON BIOMARKERS FOR THROMBOGENESIS IN 1297 PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: PHASE IIB DOSE CONFIRMATION STUDY (OPAL-2)**  
George M Rodgers\* (US), Ronny W Renfurm, Jonathan L Halperin, Palle Petersen, Gregory YH Lip
- P-TH-374 EFFICACY OF COMBINED ANTIPLATELET THERAPY IN PREVENTING THROMBOEMBOLISM IN PATIENTS WITH ATRIAL FIBRILLATION**  
Sadjana Lazar Novakovic-Anucin\* (RS), Sanja Gnip, Ljubica Povazan, Visnja Canak, Biljana Vuckovic, Milena Scekic, Pavica Radovic, Predrag Filipov, Gorana Mitic

### Cancer and thrombosis

- P-TH-375 INCREASED THROMBIN GENERATION AND PROCOAGULANT ACTIVITY OF CIRCULATING MICROPARTICLES FROM PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA**  
Marina Marchetti\* (IT), Annamaria Leuzzi, Marina Panova-Noeva, Carmen Julia Tartari, Laura Russo, Alessandro Rambaldi, Guido Finazzi, Tiziano Barbui, Barry Woodhams, Anna Falanga
- P-TH-376 ON THE ACQUISITION OF A PROCOAGULANT PATTERN BY HUMAN GLIOBLASTOMA CELLS**  
Angelica Dutra Oliveira\* (BR), T C Carneiro-Lobo, L G Lima, L Romao, V Moura-Neto, S M Oba-Shinjo, S K Marie, M C Sogayar, R Q Monteiro





## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-377 XA INHIBITOR IS EFFECTIVE IN THE PREVENTION OF POSTOPERATIVE VENOUS THROMBOEMBOLISM - A STUDY OF THE EFFECTIVENESS OF SELECTIVE XA INHIBITOR FONDAPARINUX -**  
Norihito Yoshioka\* (JP), Nao Suzuki, Hiroka Hata, Kimie Murayama, Tatsuru Ohara, Yoshiko Nishigaya, Akiko Tozawa, Kazushige Kiguchi, Bunpei Ishizuka
- P-TH-378 DEVELOPING THE THROMBOPROPHYLAXIS RESEARCH AGENDA IN ADVANCED CANCER: A QUALITATIVE STUDY**  
Simon Ian Robert Noble\* (UK), Annmarie Nelson, Ilora Finlay
- P-TH-379 ASSESSMENT OF PLATELET FUNCTION AND SELECTED PARAMETERS OF COAGULATION IN PATIENTS WITH MULTIPLE MYELOMA BEFORE AND AFTER THALIDOMIDE THERAPY.**  
Krzysztof Chojnowski\* (PL), Marta Robak, Jacek Trelinski
- P-TH-380 SOLUBLE FIBRIN DETERMINATION IN ADVANCED CANCER PATIENTS.**  
Shahsultan Mirshahi\* (FR), Shahsultan Mirshahi, Massoud Mirshahi, Jean Chidiac, Remi Varin, Dalel Azzazene, Eric Pujade-Lauraine, Claudine Soria, Jeannette Soria
- P-TH-381 THE RISK OF CANCER FOLLOWING IDIOPATHIC VENOUS THROMBOEMBOLISM: A POPULATION-BASED COHORT STUDY**  
Vicky Tagalakis\* (CA), Dimple Kondal, Susan Rebecca Kahn
- P-TH-382 VENOUS THROMBOEMBOLISM IN CANCER PATIENTS FOLLOWING MAJOR SURGERY**  
Vicky Tagalakis\* (CA), Thierry Haim Toledano, Dimple Kondal, Susan Rebecca Kahn
- P-TH-383 INCREASED THROMBIN POTENTIAL AND VON WILLEBRAND FACTOR INDICATE THROMBOTIC RISK AFTER LAPAROSCOPIC RADICAL PROSTATECTOMY**  
Jolan Harsfalvi\* (HU), Tibor Flasko, Zsuzsanna Molnar, Zoltan Batta, Matyas Benyo
- P-TH-384 EVALUATION OF THE HAEMOSTATIC STATUS IN PATIENTS WITH PROSTATE CANCER USING THROMBOELASTOGRAPHY AND TISSUE FACTOR- MICROPARTICLES**  
Mazen Toukh\* (CA), Angela Black, Robert D Siemens, Maha Othman
- P-TH-385 JAK2V617F MUTATION AND THROMBOSIS IN THE MYELOPROLIFERATIVE NEOPLASMS**  
Fatih Demirkan\* (TR), Serdar Kalkan, Selda Kahraman, Sunay Tunali, Abdullah Katgi, Ozden Piskin, Mehmet Ali Ozcan, Hayri Guner Ozsan, Bulent Undar
- P-TH-386 DIFFERENTIAL LOCALIZATION OF FULL LENGTH TISSUE FACTOR AND ALTERNATIVELY SPLICED TISSUE FACTOR IN BREAST CANCER CELLS**  
Begum Kocaturk\* (NL), Yascha W van den Berg, Pieter H Reitsma, Vladimir Y Bogdanov, Henri H Versteeg
- P-TH-387 PROTEASE-ACTIVATED RECEPTOR-2 (PAR-2) INDUCES VEGF PRODUCTION THROUGH ERK1/2 PATHWAYS IN HUMAN GLIOBLASTOMA CELL LINES**  
Andrea Mariano Oliveira\* (BR), Angelica Dutra Oliveira, Robson Queiroz Monteiro

### Pediatric thrombosis

- P-TH-388 LONG-TERM OUTCOME OF CHILDHOOD PULMONARY EMBOLISM**  
Suzan Williams\* (CA), Viola van Eimeren, Leonardo Brandao, Walter Kahr
- P-TH-389 A RECENT NATIONAL SURVEY OF NEONATAL THROMBOSIS IN JAPAN. COMPARISON WITH MAILING QUESTIONNAIRES IN 2004**  
Chiharu Kawaguchi\* (JP), Yukihiro Takahashi



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-390 THROMBUS PERSISTENCE AND THROMBOTIC-RELATED COMPLICATIONS AFTER PEDIATRIC CARDIAC SURGERY**  
Leonardo Rodrigues Brandao\* (CA), Cedric Manhlot, Janet A. McMullen, Anthony K. Chan, Suzan Williams, Ben Sivarajan, Steven M. Schwartz, Brian W. McCrindle
- P-TH-391 INHERITED HETEROZYGOUS PROTEIN S DEFICIENCY: A REPORT OF 6 CASES.**  
Piti Techavichit\* (TH), Darintr Sosohtikul, Panya Seksarn
- P-TH-392 INHERITED PROTHROMBOTIC RISK FACTORS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA**  
Turkan Patiroglu\* (TR), Yasemin Altuner Torun, Mehmet Akif Ozdemir, Yusuf Ozkul, Ali Yikilmaz, Musa Karakukcu
- P-TH-393 THROMBOTIC EVENTS IN CHILDREN WITH MALIGNANCIES IN RELATION TO TREATMENT COMPONENTS OF CHEMOTHERAPY**  
Alexandra A Russo\* (DE), Charis von Auer, Nesrin Karabul, Matthias Dittrich, Peter Gutjahr, Inge Scharrer, Joerg Faber
- P-TH-394 PEDIATRIC ANTICOAGULATION: SIMILAR BLEEDING BUT FEWER THROMBOEMBOLIC COMPLICATIONS THAN ADULTS**  
Cameron C Trenor\* (US), Kathy M. Harney, Juliann McSweeney, Alan D. Michelson, Ellis J. Neufeld, Cameron C. Trenor
- P-TH-395 PEDIATRIC HEPARIN-INDUCED THROMBOCYTOPENIA: THE 4T SCORING SYSTEM PREDICTS PATIENTS AT LOW RISK**  
Cameron C Trenor\* (US), Esther A. Obeng, Kathy M. Harney, Ellis J. Neufeld, Cameron C. Trenor
- P-TH-397 INTRACARDIAC THROMBOSIS IN TWO CHILDREN AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**  
Osman Alphan Kupesiz\* (TR), Vedat Uygun, Mediha Akcan, Gulsun Karasu, Volkan Hazar, Mehmet Akif Yesilipek
- P-TH-398 GENETIC AND ACQUIRED RISK FACTORS IN BRAZILIAN CHILDREN AND ADOLESCENTS DIAGNOSED WITH PORTAL VEIN THROMBOSIS (PVT) WITH NO HEPATIC DISEASES**  
Ana Paula Fernandes\* (BR), Priscila Menezes Ferri, Daniel Dias Ribeiro, Eleonora Druve Tavares Fagundes, Karina Braga Gomes, Luci Sant'Ana Dusse, Maria das Gracas Carvalho, Alexandre Rodrigues Ferreira
- P-TH-399 ANTICOAGULATION IN PEDIATRIC PATIENTS WITH THE HEARTMATE II VENTRICULAR ASSIST DEVICE (VAD)**  
Lisa Bomgaars\* (US), Mona Shah, Donald Yee, Jun Teruya, Joe Rossano, David Morales, Donald Mahoney
- P-TH-400 THE ITALIAN REGISTRY OF CHILDHOOD THROMBOSIS (RITI - REGISTRO ITALIANO TROMBOSI INFANTILE) ON BEHALF OF THE GROUP FOR THE ITALIAN REGISTRY OF CHILDHOOD THROMBOSIS (GIRTI)**  
Chiara Gentilomo\* (IT), Paola Saracco, Manuela Agostini, Rossana Bagna, Bianca Bassi, Paola Giordano, Anna Maria Laverda, Angelo Claudio Molinari, Luca Antonio Ramenghi, Paolo Simioni

### Microparticles

- P-TH-401 CORRELATION BETWEEN CD144 POSITIVE MICROPARTICLES AND CD142 POSITIVE MICROPARTICLES IN PATIENTS WHO HAVE UNDERGONE PCI.**  
Yutaka Nagai\* (JP), Norihito Inami, Shinya Fujita, Ryotaro Ozasa, Shuji Higashi, Shosaku Nomura



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-402 PROCOAGULANT PHOSPHOLIPIDS (PPL) LEVELS IN PREGNANT PATIENTS PRESENTING WITH SYMPTOMS OF DEEP VEIN THROMBOSIS (DVT)**  
Marilyn A Johnston\* (CA), Nancy McEwen, JS Ginsberg, WS Chan
- P-TH-403 PROCOAGULANT MICROVESICLES ARE ELEVATED IN ACUTE TRAUMATIC INJURY.**  
Nicola S Curry\* (UK), Amber Raja, Karim Brohi, Tina Gaarder, Per I. Johansson, Simon J. Stanworth, Paul Harrison
- P-TH-404 PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION HAVE INCREASED CONCENTRATIONS OF MICROPARTICLES FROM DIFFERENT CELLS**  
Christina Christersson\* (SE), Gerhard Wikstrom, Agneta Siegbahn
- P-TH-405 A MULTICOLOR FLOW CYTOMETRIC ASSAY FOR MEASUREMENT OF MICROPARTICLES OF DIFFERENT CELLULAR ORIGINS AND THEIR DIFFERENTIATION FROM CELL MEMBRANE FRAGMENTS**  
Fariborz Mobarrez\* (SE), Jovan Antovic, Gun Jorneskog, Nils Egberg, Hakan Wallen
- P-TH-406 SEPARATION INDEX: A USEFUL TOOL TO FOLLOW-UP AND COMPARE INSTRUMENT PERFORMANCE FOR MICROPARTICLE ANALYSIS BY FLOW CYTOMETRY**  
Francois Mullier\* (BE), Philippe Poncelet, Nicolas Bailly, Stephane Robert, Romaric Lacroix, Francine Garnache-Ottou, Sabeha Biichle, Jean-Michel Dogne, Francoise Dignat-George, Bernard Chatelain
- P-TH-407 THE INFLUENCE OF ELECTIVE PERCUTANEOUS INTERVENTION ON THE PLASMA MICROPARTICLES CONCENTRATION IN PATIENTS WITH CORONARY ARTERY DISEASE**  
Krystyna Maria Zawilska\* (PL), Justyna Maria Wachowiak
- P-TH-408 PLASMA MICROPARTICLE TISSUE FACTOR IS ELEVATED IN ANTIPHOSPHOLIPID SYNDROME**  
Nigel S Key\* (US), Rose Willemze, Robert Bradford, Robert AS Roubey
- P-TH-409 OPTIMIZATION OF MICROPARTICLE ANALYSIS PROTOCOLS FOR FLOW CYTOMETERS: FORWARD OR SIDE SCATTER ?**  
Philippe Poncelet\* (FR), Stephane Robert, Anne-Marie Faussat, Cecile Gameiro, Nicolas Bailly, Francois Mullier, Bernard Chatelain
- P-TH-410 QUANTIFICATION OF MICROPARTICLES BY FLOW CYTOMETRY IN WHOLE BLOOD: APPLICATION TO THE DIAGNOSIS OF HEREDITARY SPHEROCYTOSIS AND HEPARIN-INDUCED THROMBOCYTOPENIA**  
Francois Mullier\* (BE), Nicolas Bailly, Christian Chatelain, Jean-Michel Dogne, Bernard Chatelain

### Arterial vascular diseases

- P-TH-411 CHARACTERIZATION OF NAFTIDROFURYL AS A THROMBOXANE RECEPTOR ANTAGONIST.**  
Severine Robert\* (BE), Stephanie Rolin, Jonathan Douxfils, Julie Hardij, Emilie Varin, Bernard Chatelain, Julien Hanson, Kristel Vandenbosch, Nathalie Caron, Francois Mullier, Jean-Michel Dogne
- P-TH-412 FXIII LEVELS AND GENOTYPE IN MYOCARDIAL INFARCTION: POTENTIAL NOVEL PROGNOSTIC BIOMARKERS?**  
Donato Gemmati\* (IT), Giulia Zeri, Rosella Mari, Elisa Orioli, Monica Bovara, Vicente Sarquella, Stefano Moratelli, Mirko Pinotti, Francesco Bernardi, Rosaria M Stomeo, Roberto Ferrari, Lucia Ansani, Luisa M Serino



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-413 INTERACTION BETWEEN LRP D2080N POLYMORPHISM AND COAGULATION FACTOR VIII LEVELS MODULATES THE RISK OF MYOCARDIAL INFARCTION IN THE CHINESE HANS**  
Honggang Ren\* (CN), Tao Guo, Huafang Wang, Chunyan Sun, Xiaoping Zhang, Heng Mei, Liang Tang, Xiaohong Liu, Yu Hu
- P-TH-414 ACUTE CORONARY SYNDROME PATIENTS WITH DIFFERENT CLINICAL FEATURES ARE CHARACTERIZED BY DIFFERENT WHOLE PERIPHERAL BLOOD GENE EXPRESSION PROFILES**  
Betti Giusti\* (IT), Luciana Rossi, Ilaria Lapini, Alberto Magi, Anna Maria Palombella, Rossella Marcucci, Antonella Cordisco, David Antonucci, Gian Franco Gensini, Rosanna Abbate
- P-TH-415 LIPID PENTAD INDEX (LPI), LIPID TETRAD INDEX (LTI) AND ATHEROGENIC INDEX OF PLASMA (AIP) IN CENTRAL AND PERIPHERAL ARTERIAL DISEASES**  
Luciana Moreira Lima\* (BR), Maria Elisabeth Renno Santos, Maria das Gracias Carvalho, Adriano de Paula Sabino, Ana Paula Lucas Mota, Marinez Oliveira Sousa
- P-TH-416 DEFICIENCY OF COAGULATION INHIBITORS IN YOUNG ADULTS WITH ISCHEMIC STROKE**  
Neila Ben Romdhane\* (TN), hela Baccouche, Malak Lahmar, Sonia Mahjoub, Zeineb Manai
- P-TH-417 CONVENTIONAL AND NOVEL RISK FACTORS IN YOUNGER AND OLDER PATIENTS WITH MYOCARDIAL INFARCTION**  
Nebojsa M Antonijevic\* (RS), Antonijevic M Nebojsa, Bojan D Stojanovic, Aco Radanovic, Branko Jakovljevic, Slobodan Obradovic, Ivana Zivkovic, Mirjana Kovac, Valentina Djordjevic, Nebojsa Radovanovic, Jovan Perunicic
- P-TH-418 SOLUBLE RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS (SRAGE): A NEW BIOMARKER OF ARTERIAL THROMBOSIS DURING SYSTEMIC LUPUS ERYTHEMATOSUS**  
Helene Maillard-Lefebvre\* (FR), Nathalie Costedoat-Chalumeau, Nicolas Grossin, Julia Salleron, Sylvain Dubucquoi, Lucile Musset, Jean-Charles Piette, Eric Hachulla, Pierre-Yves Hatron, Eric Boulanger, Zahir Amoura, Marc Lambert
- P-TH-419 AN INCREASED TISSUE FACTOR PATHWAY INHIBITOR (TFPI) ACTIVITY IS ASSOCIATED WITH MYOCARDIAL INFARCTION IN YOUNG WOMEN; RESULTS FROM THE RATIO STUDY**  
Kristien Winckers\* (NL), Bob Siegerink, Connie Duckers, Lisbeth M Maurissen, Guido Tans, Elisabetta Castoldi, Henri M.H. Spronk, Ten Cate Hugo, Ale Algra, Tilman Hackeng, Frits Rosendaal
- P-TH-420 HYPERCOAGULATION, VASCULAR ENDOTHELIUM SUFFERING AND DAMAGE, PULMONARY ARTERIAL HYPERTENSION IN SICKLE CELL DISEASE**  
Margaret Musso\* (IT), Innocenzo Bianca, Roberto Musso, Luca Maugeri
- P-TH-421 CORRELATION BETWEEN PLASMA HOMOCYSTEINE LEVELS AND DEGREE OF LOWER LIMB ISCHEMIA IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE**  
Temirlan Gamzatov\* (RU), Anna Alexandrovna Gurzhiy, Veronika Mikhailovna Shmeleva, Ludmila Petrovna Papayan, Alexander Emelianovich Barsukov, Alexey Vladimirovich Svetlikov

### Health service and outcomes

- P-TH-422 FONDAPARINUX: APPLICATION AND SAFETY ASPECTS - A PROSPECTIVE GERMAN SINGLE-CENTER EXPERIENCE**  
Marc Schindewolf\* (DE), Julia Scheuermann, Hartmut Kroll, Ingo Marzi, Roland Kaufmann, Wolf-Henning Boehncke, Ralf J. Ludwig, Edelgard Lindhoff-Last

Thursday Posters



63

## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-423 THROMBOPHILIA TESTING IS OVER-UTILISED - AN AUDIT OF 500 CONSECUTIVE SCREENS**  
Joyce Low\* (AU), Susan Jarvis, Joanne Joseph
- P-TH-424 RISK FACTORS FOR VENOUS THROMBOEMBOLISM IN HOSPITALIZED MEDICAL PATIENTS**  
Ponlapat Rojnuckarin\* (TH), Noppacharn Uaprasert, Patinut Buranasupkajorn, Sarawut Siwamogsatham, Pranee Sutcharitchan
- P-TH-425 AN INNOVATIVE CLINIC APPROACH FOR WARFARINIZED ADULTS WITH CONGENITAL HEART DISEASE TO INCREASE PARTICIPATION IN THEIR HEALTH CARE**  
Aiko MD Bruce\* (CA), Mary Bauman, M Patricia Massicotte
- P-TH-426 AN INNOVATIVE CLINIC APPROACH FOR CHILDREN REQUIRING LONG TERM WARFARIN THERAPY TO INCREASE PARTICIPATION IN THEIR HEALTH CARE**  
Aiko MD Bruce\* (CA), Mary Bauman, M Patricia Massicotte
- P-TH-427 EMERGING CONCEPT: PREVENTABLE VENOUS THROMBOEMBOLISM IS AN ADVERSE EVENT**  
Charles Mahan\* (US), Mark T Holdsworth, Shawn M Welch, Matt E Borrego, Alex C Spyropoulos
- P-TH-428 COST-EFFECTIVENESS OF PHARMACOLOGICAL PROPHYLAXIS IN PREVENTING VENOUS THROMBOEMBOLISM AND ASSOCIATED LONG TERM COMPLICATIONS IN GYNAECOLOGICAL ONCOLOGY SURGERY**  
Kerry Hitos\* (AU), Charles Stratton, John P Fletcher
- P-TH-429 COST-EFFECTIVENESS OF PHARMACOLOGICAL PROPHYLAXIS IN PREVENTING VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING HIP FRACTURE SURGERY**  
Kerry Hitos\* (AU), Charles Stratton, John P Fletcher
- P-TH-430 HEMORRHAGIC COMPLICATIONS OF ANTICOAGULANT TREATMENT**  
Aleksandar R Maslac\* (RS), Mirjana K Kovac

### Experimental models

- P-TH-431 THE SAFETY/EFFICACY OF DABIGATRAN AND INFLUENCE OF VITAMIN K ON AV-SHUNT MODEL IN RAT.**  
Tsuyoshi Ohmura\* (JP), Kozaburo Ikegami, Joanne van Ryn, Katsuhiro Hori, Jeffrey Encinas, Ikuro Maruyama
- P-TH-432 EFFECTS OF ANTI-HUMAN VWF A3 DOMAIN MONOCLONAL ANTIBODY SZ-123 ON PLASMA VWF BINDING TO COLLAGEN AND PLATELET AGGREGATION OF RHESUS MONKEY AND BEAGLE DOG IN VITRO**  
Yiming Zhao\* (CN), Shundong Ji, Yang He, Miao Jiang, Fei Shen, Yunxiao Zhao, Changgeng Ruan
- P-TH-433 NDRG4-DEFICIENT MICE EXHIBIT SPATIAL LEARNING DEFICITS AND VULNERABILITIES TO CEREBRAL ISCHEMIA WITH THE DECREASED LEVEL OF BDNF IN THE CORTEX**  
Hitomi Yamamoto\* (JP), Koichi Kokame, Tomohiko Okuda, Yukako Nakajo, Hiroji Yanamoto, Toshiyuki Miyata
- P-TH-434 COMBINATION OF EDOXABAN, AN ORALLY ACTIVE FACTOR XA INHIBITOR WITH ASPIRIN AND CLOPIDOGREL IN A RAT MODEL OF ARTERIAL THROMBOSIS**  
Yoshiyuki Morishima\* (JP), Yuko Honda, Chikako Kamisato, Akemi Kita, Naoko Edo, Toshihiko Kumada, Toshiro Shibano



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-435 EDOXABAN, AN ORAL DIRECT FACTOR XA INHIBITOR, AMELIORATES COAGULATION, MICROTHROMBI FORMATION, AND ACUTE LIVER INJURY IN LIPOPOLYSACCHARIDE-INDUCED ENDOTOXEMIA RATS**  
Yoshiyuki Morishima\* (JP), Yuko Honda, Tomoko Shibutani, Kengo Noguchi, Yusuke Ito, Toshiro Shibano
- P-TH-436 IN VITRO COMPARISON OF EP217609, UNFRACTIONATED HEPARIN, ENOXAPARIN AND FONDAPARINUX IN THE PREVENTION OF CARDIAC CATHETER THROMBOSIS**  
ERIC NEUHART\* (FR), Anja Kaeberich, Uwe Raaz, Alexander Vogt, Lars Maedgefessel, Claire Bal dit Sollier, Natacha Berge, Ludovic Drouet, Baerbel Hauroeder, Chantal Krezel, Michael Buerke, Karl Werdan, Axel Schlitt
- P-TH-437 GENERIC ARGATROBAN PREPARATIONS DIFFER IN THEIR ANTICOAGULANT AND ANTI-PROTEASE RESPONSES IN PATIENTS WITH LIVER DISEASE. DOSING IMPLICATIONS.**  
Jawed Fareed\* (US), Debra Hoppensteadt, Sofia Masood, Jurgita Zeimys, David VanThiel, Magdalena George, Vinod Bansal
- P-TH-438 SIMULTANEOUS OCCURRENCE OF NATURAL IMMUNITY, ATHEROGENIC IN VIVO LDL OXIDATION AND THROMBOXANE-MEDIATED PLATELET ACTIVATION IN ATHEROSCLEROSIS-PRONE (LDLR-/- AND APOE-/-) MICE**  
Eiji Matsuura\* (JP), Lianhua Shen, Yukana Matsunami, Nanhu Quan, Kazuo Kobayashi, Yehuda Shoefeld, Keiji Oguma, Luis R Lopez
- P-TH-439 ANTI-ATHEROGENIC PLAQUE REDUCTION, INHIBITION OF OXLDL/B2GPI AUTOANTIGEN AND THROMBOXANE PLATELET ACTIVATION BY PERSIMMON (DIOSPYROS KAKI) PEEL IN LDLR-/- DEFICIENT MICE**  
Eiji Matsuura\* (JP), Nanhu Quan, Kazuo Kobayashi, Yukana Matsunami, Masahiro Ide, Marina Makarova, Lianhua Shen, Soichi Ohno, Yang Zheng, Haruo Kobayashi, Luis R Lopez
- P-TH-440 IN VIVO FLUORESCENCE IMAGING OF THROMBOGENESIS IN MICROSURGICAL VESSEL REPAIRS**  
Brian C. Cooley\* (US), Glenn Shi, Roger A. Daley
- P-TH-441 HIGH FAT DIET BUT NOT OBESITY AS DETERMINANT OF THROMBIN GENERATION IN PLASMA**  
Caroline Sanchez\* (FR), Pierre Morange, Matthias Canault, Ilse Scroyen, Stephane Tanguy, Michel Grino, Marie-christine Alessi
- P-TH-442 COAGULATION AND COMPLEMENT ACTIVATION AFTER INTRAPULMONARY CHALLENGE WITH HOUSE DUST MITE EXTRACT AND/OR LIPOPOLYSACCHARIDE IN ASTHMA PATIENTS**  
Johannes Daan De Boer\* (NL), M Berger, PJ Sterk, D Wouters, S Zeerleder, JS Van der Zee, T Van der Poll
- P-TH-443 A NITRIC OXIDE (NO)-DONATING STATIN DISPLAYS ENHANCED ANTI-INFLAMMATORY AND ANTI-ATHEROGENIC ACTIVITIES IN A MODEL OF ATHEROSCLEROSIS-RELATED INFLAMMATION IN MICE**  
Stefania Momi\* (IT), Emanuela Falcinelli, Paolo F Alberti, Angela Monopoli, Daniela Miglietta, Ennio Ongini, Paolo Gresele

### von Willebrand factor

- P-TH-444 IN VIVO CLEAVAGE OF RECOMBINANT VWF IN PRECLINICAL AND CLINICAL SETTINGS**  
Peter L Turecek\* (AT), Katalin Varadi, Hanspeter Rottensteiner, Jutta Schreiner, Friedrich Scheifflinger



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-445 ADAMTS13 IN VON WILLEBRAND FACTOR (VWF) CONCENTRATES: IS AN INTACT VWF TRIPLET STRUCTURE IMPORTANT FOR VWF FUNCTION?**  
Christoph Kannicht\* (DE), Barbara A. Solecka, Mario Kroening, Birte Fuchs
- P-TH-446 ESSENTIAL ROLE OF THE P3 RESIDUE (LEU1603) OF VON WILLEBRAND FACTOR IN SCISSILE BOND CLEAVAGE BY ADAMTS13**  
Yaozu Xiang\* (UK), Rens de Groot, James TB Crawley, David A Lane
- P-TH-447 VWF CONTRIBUTES TO LONGER CIRCULATING HALF-LIFE (T1/2) OF PEGYLATED FVIII IN VIVO**  
John E. Murphy\* (US), Lilley Leong, Derek S. Sim, Elena Ho, Peter Kretschmer, Jian-Ming Gu, Fred Aswad, Rick Feldman, Jesper Haaning, Liang Tang
- P-TH-448 INDUCTION OF ENDOTHELIAL VON WILLEBRAND'S FACTOR EXPRESSION BY PRECURSOR B LYMPHOBLASTS**  
Derek C. H. Chan\* (CA), Helen M. Atkinson, Leslie R. Berry, Uma H. Athale, Anthony K. C. Chan
- P-TH-449 AMELIORATION OF MURINE VWD BY PLATELET-SPECIFIC EXPRESSION OF VWF**  
Sachiko Kanaji\* (US), Scot A Fahs, Qizhen Shi, Sandra L Haberichter, Robert R Montgomery
- P-TH-450 SINGLE NUCLEOTIDE GENE POLYMORPHISMS DIFFERENTIALLY ASSOCIATE WITH PLASMA LEVELS OF VON WILLEBRAND FACTOR IN EUROPEAN AND AFRICAN AMERICANS: AN ARIC STUDY**  
Marco Campo (US), Ashley Buchanan, Fuli Yu, Maja Barbalic, Woody Chambless, Aaron folsom, Eric Boerwinkle, Jing-fei Dong\*
- P-TH-452 GENETIC VARIATIONS IN THE VON WILLEBRAND FACTOR GENE AMONG DIFFERENT ETHNICITIES: FINDINGS FROM THE 1000 GENOME PROJECT**  
Fuli Yu (US), Jin Yu, Marco Campos, Richard Gibbs, Jing-fei Dong\*
- P-TH-453 EVALUATION OF VON WILLEBRAND FACTOR (VWF) CONCENTRATES BY PLATELET ADHESION TO TYPE III COLLAGEN USING A HIGH SHEAR *IN VITRO* FLOW ASSAY**  
Anne Riddell\* (UK), Thomas McKinnon, Saravanan Vinayagam, Keith Gomez
- P-TH-454 ASSOCIATION OF VWF -1793 C/G POLYMORPHISM WITH DIABETES, VASCULAR COMPLICATION AND CONVENTIONAL RISK FACTORS FOR CORONARY ARTERY DISEASE IN THAIS**  
Nantarat Komanasin\* (TH), Saran Saensiriphan, Boonsong Benjangkaprasert, Paisal Mongkolwongroj, Montien Puntumetakul

### von Willebrand disease

- P-TH-455 LATEST INTERIM RESULTS FROM A GERMAN PROSPECTIVE POST-MARKETING SURVEILLANCE OF TREATMENT OF VON WILLEBRAND'S DISEASE WITH A NEW GENERATION VWF/FVIII CONCENTRATE**  
Mario von Depka\* (DE), S. Alesci, J. Feddern, J. Kadar, W. Miesbach, M. Rieke, I. Scharrer
- P-TH-456 EXPERIENCE WITH A HIGH-PURITY VON WILLEBRAND FACTOR CONCENTRATE IN LONG-TERM PROPHYLAXIS: FINAL ANALYSIS OF A FRENCH COHORT STUDY**  
Jenny Goudemand\* (FR), Annie Borel-Derlon, Chantal Rothschild, Jeanne-Yvonne Borg, Group Post-Marketing Study, Anne-Cecile Jaffry, Francoise Bridey, Celine Henriet, Catherine Chatelanaz



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-457 BIOLOGICAL AND CLINICAL RESPONSES TO DESMOPRESSIN IN CHILDREN: PROSPECTIVE STUDY OF A LARGE COHORT WITH TYPE 1 VWD AND TYPE 2 VWD IN ONE SINGLE ARGENTINIAN CENTER**  
Mariana Bonduel\* (AR), Gabriela Sciuccati, Mirta Hepner, Juan Pablo Frontrouth, Graciela Pieroni, Aurora Feliu-Torres, Eliana Annetta, Mercedes Castanon
- P-TH-458 EXPRESSION STUDIES OF EIGHT MISSENSE MUTATIONS SPREAD THROUGH OUT THE VON WILLEBRAND FACTOR (VWF) IN TYPE 3 VON WILLEBRAND DISEASE (VWD) PATIENTS.**  
Luciano Baronciani\* (IT), Maria Solimando, Silvia La Marca, Giovanna Cozzi, Francesca Stufano, Maria Teresa Canciani, Augusto B Federici, Flora Peyvandi
- P-TH-459 SEX-CHANGE SURGERY IN A TYPE 3 VWD PATIENT**  
Bulent Zulfikar\* (TR), Ozcan Gurhan, Fikret Bezgl, Ergul Berber
- P-TH-460 ANALYSIS OF VON WILLEBRAND PROPEPTIDE RATIO IN THE SOUTH MORAVIAN POPULATION (CZECH REPUBLIC): THE BRNO-VWD STUDY.**  
Alain Peter Gadisseur\* (BE), P Smejkal, I Vangenechten, O Zapletal, F Bouddount, J Zavrelova, J Blatny, M Penka, JJ Michiels
- P-TH-461 CLINICAL EVALUATION OF A NEW VON WILLEBRAND FACTOR ACTIVITY ASSAY\*.**  
Ulrich Budde\* (DE), Reinhard Schneppenheim, Adriana Mendez, Juergen Patzke, Heidrun Muth
- P-TH-462 TWO UNRELATED VON WILLEBRAND DISEASE (VWD) TYPE 2A (IIE) FAMILIES CAUSED BY SKIPPING OF EXON 26 ON THE VON WILLEBRAND FACTOR (VWF) MRNA.**  
Luciano Baronciani\* (IT), Inmaculada Garcia-Oya, Maria Solimando, Silvia La Marca, Giovanna Cozzi, Francesca Stufano, Maria Teresa Canciani, Flora Peyvandi
- P-TH-463 EVALUATION OF PLATELET FUNCTION AND BLEEDING HISTORY IN VON WILLEBRAND DISEASE DIAGNOSTICS**  
Timea Szanto\* (FI), Lotta Joutsu-Korhonen, Riitta Lassila
- P-TH-464 MISSING MUTATION IN TYPE 1 VON WILLEBRAND DISEASE IN THE MCMDM-1VWD STUDY**  
Nasher Hussain Alyami\* (UK), Daniel J Hampshire, Jenny Goudemand, Giancarlo Castaman, Augusto B Federici, Ian R Peake, Anne C Goodeve, on behalf of the EU-VWD and ZPMCB-VWD study groups
- P-TH-465 CHARACTERISATION OF VON WILLEBRAND DISEASE MUTATIONAL SPECTRUM IN A TURKISH PATIENT COHORT**  
Daniel J Hampshire\* (UK), Adel M Abuzenadah, Nawal S Al-Shammari, Michaela Eckert, Rachael E Coyle, Ahlam M Al-Buhairan, Sarah L Messenger, Turkiz Gursel, Jorgen Ingerslev, Ian R Peake, Anne C Goodeve
- P-TH-466 FREQUENCY OF VON WILLEBRAND DISEASE AND OTHER BLEEDING DISORDERS AMONG WOMEN WITH IDIOPATHIC MENORRHAGIA IN CENTRAL PART OF IRAN**  
Manijeh Lak\* (IR), Ra Sharifian, Gh Toogeh, M Valadan, S Roostaei, K Karimi, M Managhchi, H Mansouritorghabeh
- P-TH-467 GENETIC ANALYSIS IN PATIENTS WITH A PHENOTYPE-BASED PUTATIVE DIAGNOSIS OF VON WILLEBRAND DISEASE TYPE I**  
Michael Steiner\* (DE), Manuela Hesse, Goran Matic, Beate Krammer-Steiner
- P-TH-468 THE USE OF DESMOPRESSIN (DDAVP) IN FOR TREATMENT AND PROPHYLAXIS OF BLEEDING DISORDERS IN PREGNANCY ..A SYSTEMATIC REVIEW**  
Rezan A Kadir\* (UK), Deri Trigg, Iosifina Stergiotou, Rezan Abdul-kadir





## POSTER PRESENTATIONS

Thursday, July 28, 2011

### TTP and related disorders

- P-TH-469 THE DEVELOPMENT OF ACUTE IDIOPATHIC TTP IS NOT ASSOCIATED WITH CHANGES IN T CELL OR T-REGULATORY CELL NUMBERS.**  
Vickie McDonald\* (UK), Arnold Pizzey, Samuel J Machin, Marie A Scully
- P-TH-471 THE STRUCTURAL COMPONENTS OF ADAMTS13 REQUIRED FOR SYSTEMIC ANTI-ARTERIAL THROMBOSIS IN VIVO**  
Juan (Jenny) Xiao\* (US), Sheng-Yu Jin, X. Long Zheng
- P-TH-472 THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) AND PREGNANCY IN THE UK: IDENTIFICATION OF SUBTYPE, MANAGEMENT AND OUTCOME OF SUBSEQUENT PREGNANCIES.**  
Mari R Thomas\* (UK), Raymond S Camilleri, Samuel J Machin, Amanda Clark, Desmond Creagh, Gillian Evans, Marie A Scully
- P-TH-473 PLATELET REACTIVE CONFORMATION AND MULTIMERIC PATTERN OF VON WILLEBRAND FACTOR IN ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA DURING ACUTE DISEASE AND REMISSION**  
Luca A Lotta\* (IT), Rossana Lombardi, Mariagabriella Mariani, Stefano Lancellotti, Raimondo De Cristofaro, Martine J Hollestelle, Pier Mannuccio Mannucci, Flora Peyvandi
- P-TH-474 ADAMTS13 ACTIVITY AND ANTIBODIES IN THE ANTIPHOSPHOLIPID SYNDROME**  
Manuel Cesar Campos\* (PT), Duarte Rego, Sara Morais, Monica Pereira, Margarida Lima
- P-TH-475 THROMBOTIC POTENTIAL IN HIV AND HIV ASSOCIATED TTP**  
Muriel Meiring\* (ZA), Mike Webb, Dominique Goedhals, Marius Coetzee, Vernon Louw
- P-TH-476 ACTIVATION OF COAGULATION AND FIBRINOLYSIS IN THROMBOTIC THROMBOCYTOPENIC PURPURA AND HEMOLYTIC UREMIC SYNDROME**  
Matthias Mottini (CH), Irmela Sulzer, Manuela Albisetti, Bernhard Laemmle, Johanna A Kremer Hovinga\*

### Laboratory tests

- P-TH-477 CORRELATION BETWEEN VON WILLEBRAND FACTOR (VWF) COLAGEN BINDING AND HEMOSIL VWF ACTIVITY ASSAYS**  
Manuela Carvalho (PT), Susana Fernandes, Manuela Reis, Bas van Haren, Waander van Heerde, Luis Manuel Cunha-Ribeiro\*
- P-TH-478 COLLAGEN BINDING ASSAY IN THE LABORATORY DIAGNOSIS OF VON WILLEBRAND DISEASE**  
Ksenia Bykowska (PL), Maria Podolak-Dawidziak, Ewa Stefanska-Windyga, Edyta Odnoczek, Jerzy Windyga\*
- P-TH-479 COMPARATIVE EVALUATION OF A NEW VON WILLEBRAND FACTOR ACTIVITY ASSAY\*.**  
Andreas R. Huber\* (CH), Ulrich Budde, Johann Patzke, Heidrun Muth
- P-TH-480 ESTABLISHMENT OF AN AUTOMATED VWF:RCO ASSAY FOR MEASURING PLASMA SAMPLES WITH LOW ACTIVITY**  
Katalin Varadi\* (AT), Hanspeter Rottensteiner, Eveline Gruber, Juergen Siekmann, Tobias Suiter, Friedrich Scheiflinger, Peter L. Turecek



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-481 REFERENCE INTERVAL FOR FACTOR VIII TO VON WILLEBRAND FACTOR ANTIGEN IS LOWER FOR INFANTS UNDER 6 MONTHS OF AGE COMPARED TO OLDER CHILDREN AND ADULTS**  
Rowena Punzalan\* (US), Joan Cox Gill, Robert R Montgomery, Sandra L Haberichter, Kenneth D Friedman
- P-TH-482 LOW DOSE RISTOCETIN INDUCED PLATELET AGGREGATION. WHICH DOSE IS LOW ENOUGH?**  
Juan Pablo Frontroth\* (AR), Mirta Hepner, Graciela Pieroni, Eliana Annetta, Mercedes Castanon, Gabriela Sciuccati, Aurora Feliu-Torres, Mariana Bonduel
- P-TH-483 EVALUATION OF AN AUTOMATED METHOD FOR THE MEASUREMENT OF RISTOCETIN COFACTOR ACTIVITY OF VON WILLEBRAND FACTOR (VWF:RCO)**  
Hannah Fortune (IE), Marie Rafferty, Niamh O'Connell, James O'Donnell, Mary Byrne\*
- P-TH-484 A MODIFIED AUTOMATED VWF:RCO ASSAY WITH ENHANCED DETECTION RANGE AND REDUCED VARIABILITY IN COMPARISON TO STANDARD AUTOMATED METHODS**  
Gerhard Gruber\* (AT), Monika Stadler, Bruce Schwartz, Sandra Janisch, Cornelia Zapfl, Christian Haderer, Andreas Hillarp
- P-TH-485 UTILITY OF PLATELET FUNCTION ANALYZER AS A SCREENING TOOL FOR THE DIAGNOSIS OF VON WILLEBRAND DISEASE IN ADOLESCENTS WITH MENORRHAGIA**  
Swati Naik\* (US), Jun Teruya, Jennifer Dietrich, Purvi Jariwala, Lakshmi Venkateswaran

### Hemophilia

- P-TH-486 LONG TERM OUTCOME OF TOTAL ELBOW ENDOPROTHESIS IN HEMOPHILIA ARTHROPATHY MAY BE SUPERIOR TO RADIAL HEAD PROSTHESIS: SOME CASE REPORTS**  
Peter Staritz\* (DE), Rainer Zimmermann, Peter Lages, Angela Huth-Kuehne
- P-TH-487 AN INVERSE SHIFTING-POLYMERASE CHAIN REACTION FOR GENOTYPING HEMOPHILIA-CAUSATIVE REARRANGEMENTS INVOLVING INT22H AND INT1H HOTSPOTS IN THE F8 GENE**  
Leila Kokabee\* (IR), Mostafa kokabee, Sirous Zeinali, Morteza karimipoor
- P-TH-488 THROMBIN GENERATION IN MILD AND MODERATE HAEMOPHILIA A**  
Simon Mcrae\* (AU), Susan Rodgers, Reanuga Gopal, Lay Tay, Andrew Atkins
- P-TH-489 IMPROVED PROGNOSIS OF ACQUIRED HEMOPHILIA A (AHA): RESULTS OF THE DUESSELDORF MONOCENTER STUDY.**  
Rudiger E. Scharf\* (DE), Roya Gheisari, Barbara Bomke, Till Hoffmann
- P-TH-490 AGE DISTRIBUTION OF THE HEMOPHILIC POPULATION IN EUROPE - AN EMERGING OLDER COHORT**  
Gerard Dolan\* (UK), Cedric Hermans, Jerzy Windyga
- P-TH-491 HEMARTHROSIS INCREASES THE ARTICULAR FIBRINOLYTIC SYSTEM IN A MURINE HEMOPHILIA MODEL**  
Roger EG Schutgens\* (NL), Laurens Nieuwenhuizen, Goris Roosendaal, Douwe Biesma, Floris Lafeber
- P-TH-492 DIFFERENCE IN TISSUE FACTOR PATHWAY INHIBITOR (TFPI) LEVELS BETWEEN HEMOPHILIA A AND B PATIENTS**  
Brigitte Tardy-Poncet\* (FR), Michele Plot, Celine Chapelle, Claire Berger, Lydia Campos, Patrick Mismetti, Herve Decousus, Bernard Tardy

Thursday Posters



69

## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-493 DELETION OF F8 GENE INVOLVING THE SEGMENTAL REPEAT INT22H AND ONE OF THE TWO EXTRAGENIC COPIES IN A CARRIER WOMAN.**  
Pilar Casana\* (ES), Ana Rosa Cid, Silvestre Jose Oltra, Francisco Martinez, Carmen Orellana, Monica Pilar Rosello, Sandra Monfort, Saturnino Haya, Jose Antonio Aznar
- P-TH-494 VARIOUS COMPLICATIONS IN HAEMOPHILIACS MANAGED BY HOSPITAL UNIVERSITY OF BATNA, ALGERIA**  
Nadjoua SAIDANE\* (DZ), Mahdia SAIDI, Chaouki DERDOUS, Samir ROUABHIA, Fatima SOLTANI, Yamina OUARHLENT
- P-TH-495 MECHANISM OF COMBINED *INT1H*-RELATED INVERSION, DELETION AND DUPLICATION INVOLVING *F8* EXPLAINS RECURRENT ABNORMAL DIAGNOSTIC PATTERN IN SEVERE HEMOPHILIA A**  
Suely M. Rezende\* (BR), Simone F. Pio, Sheila Soares, G. Correa, Christiane Muehle
- P-TH-496 BONE MINERAL DENSITY AND BONE TURNOVER IN PATIENTS WITH HAEMOPHILIA**  
Angelika Batorova\* (SK), Denisa Jankovicova, Eموke Stenova, Boris Steno, Tatiana Prigancova, Anna Morongova
- P-TH-497 CENTRAL VENOUS ACCESS DEVICE-ASSOCIATED MORBIDITY IN PAEDIATRIC PATIENTS WITH SEVERE HAEMOPHILIA**  
Jeremy David Robertson\* (AU), Katie Leanne Reeves
- P-TH-498 SEQUENTIAL INFUSION OF RFXIIA AND PLASMA-DERIVED ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE IN HAEMOPHILIA A PAEDIATRIC PATIENT WITH INHIBITORS**  
Paola Giordano\* (IT), Lassandro Giuseppe, Scaraggi Rosanna, Capriati Teresa, De Mattia Domenico, Scaraggi Francesco Antonio
- P-TH-499 BENEFITS OF A SPECIFIC AQUA-TRAINING FOR ADULT HAEMOPHILIA PATIENTS - RESULTS OF THE LONGITUDINAL WATERCISE STUDY (WAT-QOL)**  
Sylvia von Mackensen\* (DE), Barbara Eifrig, Dorothea Zaech, Astrid Wieloch, Janis Kalnins, Wolfgang Zeller
- P-TH-500 HAEMOPHILIA A FAMILIES WITH THE SAME MUTATION ARE OFTEN RELATED - A SURVEY OF THE SWEDISH POPULATION**  
Christer Hallden (SE), Rolf Ljung\*
- P-TH-501 SCREENING OF F8 GENE IN THE MAJORITY OF SLOVENIAN HEMOPHILIA A PATIENT POPULATION**  
Marusa Debeljak\* (SI), Lidija Kitanovski, Majda Benedik Dolnicar
- P-TH-502 EFFICACY AND SAFETY OF ANTITHROMBOTIC PROPHYLACTIC THERAPY WITH LOW-MOLECULAR-WEIGHT HEPARIN (LMWH) AFTER ORTHOPAEDIC SURGERY IN HAEMOPHILIA PATIENTS**  
Francesca Biondo\* (IT), Erminia Baldacci, Filippo La Cava, Annapaola Leporace, Luana Poggini, Cristina Santoro, Francesco Falez, Adriana Antonaci, Maria Gabriella Mazzucconi
- P-TH-503 EFFECTIVENESS OF TOOLS FOR MONITORING OF HAEMOPHILIC ARTROPATHY**  
Yesim Oymak\* (TR), Aysen Turedi Yildirim, Muge Gurcinar, Yontem Yaman, Carti Ozgur, Ozek Gulcihan, Altinay Firat, Canan Raziye Vergin
- P-TH-504 THROMBIN GENERATION IN PLATELET-RICH PLASMA COMPARED TO PLATELET-POOR PLASMA - BETTER CLINICAL CORRELATION IN INHIBITOR PATIENTS?**  
Bettina Geissler\* (DE), Hans-Georg Topf, Grischa Lischetzki, Manfred Rauh



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-505 LIFE QUALITY ASSESMENT IN HAEMOPHILIA PATIENTS AND EFFECT OF ARTHROPATHY**  
Yesim Oymak\* (TR), Aysen Turedi Yildirim, Erhan Eser, Arife Kaygusuz, Yontem Yaman, Carti Ozgur, Gulcihan Ozek, Burcak Tatli Gunes, Kaan Kavakli, Muge Gurcinar, Altinay Firat, Murat Hizarcioglu, Canan Raziye Vergin
- P-TH-506 THE NOVEL EXONIC SPLICE SITE AS A CAUSE OF MILD TYPE HEMOPHILIA A**  
Ingrid V Hrachovinova\* (CZ), Dana Provaznikova, Frantisek Marecek, Alena Janouskova, Alena Radovska, Petr Smejkal, Peter Salaj
- P-TH-507 SPONTANEOUS ILIOPSOAS HEMATOMA IN PATIENTS WITH VON WILLEBRAND DISEASE AND HEMOPHILIA A**  
Bijan Keikhaei\* (IR)

### Hemophilia therapy

- P-TH-508 STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF A RECOMBINANT HUMAN FACTOR IX DRUG CANDIDATE**  
Hanspeter Rottensteiner\* (AT), Peter L Turecek, Susanne Vejda, Katalin Varadi, Ernst Boehm, Manfred Reiter, Martin Kaliwoda, Wolfgang Mundt, Hartmut J Ehrlich, Friedrich Scheifflinger
- P-TH-509 BLEEDING PROPHYLAXIS WITH AN ANTI-INHIBITOR COAGULANT COMPLEX (AICC) IN PATIENTS WITH HEMOPHILIA A AND INHIBITORS CAN IMPROVE QUALITY OF LIFE: RESULTS OF THE PRO-FEIBA STUDY**  
Alessandro Gringeri\* (IT), Cindy Leissing, Paolo Cortesi, Lorenzo Giovanni Matovani
- P-TH-510 DIRECT COSTS OF CHILDREN WITH HAEMOPHILIA A UNDERGOING PROPHYLAXIS OR EPISODIC TREATMENT: RESULTS FROM THE ESPRIT STUDY.**  
Alessandro Gringeri\* (IT), Francesco Fusco, Silvia Riva, Sylvia von Mackensen, Lorenzo Giovanni Mantovani
- P-TH-511 THE EFFECTS OF REPEATED RADIOACTIVE SYNOVECTOMY ON THE TREATMENT OF HEMOPHILIC ARTHROPATHY**  
Bulent Zulfikar\* (TR), Onder Kilicoglu, Cunevt Turkmen, Fikret Bezgal, Neslihan Diler, Omer Taser
- P-TH-512 EUHASS: THE FIRST TWO YEARS OF ADVERSE EVENT MONITORING IN PERSONS WITH INHERITED BLEEDING DISORDERS IN EUROPE**  
Michael Makris\* (UK), Kathelijin Fischer, Gabriele Calizzani, Charles Hay, Christopher Ludlam, Thierry Lambert, Riitta Lassila, Pier Mannucci
- P-TH-513 MANAGEMENT OF CORONARY ARTERY DIEESEASE IN PATIENTS WITH HAEMOPHILIA**  
Barbara Bomke\* (DE), Ruediger E Scharf
- P-TH-514 PROPHYLAXIS TREATMENT IN YOUNG SEVERE HEMOPHILIA A PATIENTS: EFFICACY, FVIII CONSUMPTION, TROUGH FVIII LEVELS AND THERAPY COMPLIANCE**  
Francesca Biondo\* (IT), Cristina Santoro, Erminia Baldacci, Annapaola Leporace, Maria Gabriella Mazzucconi
- P-TH-515 ORTHOPAEDIC STATUS OF SEVERE HAEMOPHILIA A.B PATIENTS IN ONE HAEMATOLOGY DEPARTMENT IN ALGIERS**  
Meriem Bensadok\* (DZ), Salim Fourmas, Karima Wafia Chennoukh, Milad Aribi, Meriem Fadila Belhani

Thursday Posters



71

## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-516 THE DRAMATICALLY COMPLICATED SIXTH DECADE IN LIFE OF THE PATIENT WITH SEVERE HEMOPHILIA A (FRACTURES, INHIBITOR, LOWER EXTREMITY AMPUTATION, SUCCESSFUL ITI, THROMBOSIS)**  
Petr Smejkal\* (CZ), Alena Bulikova, Miloslava Matyskova, Gabriela Chlupova, Jarmila Kissova, Marie Slechtova, Miroslav Penka
- P-TH-517 DYNAMICS OF PLASMA FACTOR VIII DURING THE CONTINUOUS INFUSION OF FACTOR VIII CONCENTRATES IN TWENTY PATIENTS WITH HEMOPHILIA A**  
Katsumi Nishiya\* (JP), Keiji Nogami, Ichiro Tanaka, Masaru Shibata, Kenichi Ogiwara, Tomoko Matsumoto, Midori Shima
- P-TH-518 SPORTS ACTIVITIES WITH PROPHYLACTIC THERAPY CAN ENHANCE QOL OF HEMOPHILIC CHILDREN**  
Hisaya Nakadate\* (JP), Akira Ishiguro, Hirokazu Sakai

### Inhibitors: pathogenesis, prevention and treatment

- P-TH-519 IN VITRO CORRECTION OF THROMBIN GENERATION AND IMPROVEMENT OF CLOT STRUCTURE BY RECOMBINANT PORCINE FACTOR VIII IN PLASMA CONTAINING ANTI-FACTOR VIII INHIBITORY ANTIBODIES**  
Claude Negrier\* (FR), Johannes Oldenburg, Uri Martinowitz, Bernd Poetzsch, Jean-Claude Bordet, Raed Al Dieri, Yesim Dargaud, Coen Hemker, Martin Lee
- P-TH-520 USE OF ARTIFICIAL NEURAL NETWORKS FOR LARGE SCALE PREDICTION OF FACTOR VIII DERIVED CD4 T CELL EPITOPES.**  
Daniel P Hart\* (UK), Stuart Skelton, David S Moss, Clare E Sansom, Keith Gomez, Adrian J Shepherd
- P-TH-521 DIFFERENTIAL EXPRESSION OF CYTOKINE GENES BETWEEN INHIBITOR AND NON-INHIBITOR HA GROUPS**  
Sung ho Hwang\* (KR), Jeong A Lim, Hugh C Kim, Hyun Woo Lee, Ki Young Yoo, Hye Sun Kim
- P-TH-522 SEVERE HEMORRHAGE FROM ACQUIRED FACTOR V INHIBITOR WITH 2ND EXPOSURE TO TOPICAL BOVINE THROMBIN, RAPID RESPONSE TO STEROIDS AND PLASMAPHERESIS.**  
Futoshi Iioka\* (JP), daiki simomura, Yoshitomo Maesako, Fumihiko Nakamura, Takamasa Hayashi, Ohno Youichirou
- P-TH-523 ASSESSMENT OF QUALITY OF LIFE IN HEMOPHILIA PATIENTS WITH INHIBITORS. DEVELOPMENT OF AN INHIBITOR-SPECIFIC QUESTIONNAIRE**  
Sylvia von Mackensen\* (DE), Silvia Riva, Kate Khair, Thynn Thynn Yee, Angiola Rocino, Carmen Escuriola, Johannes Oldenburg, Alessandro Gringeri
- P-TH-524 HEMOJUVELIN IS RELATED TO IRON METABOLISM AND KIDNEY FUNCTION IN RENAL AND HEART ALLOGRAFT RECIPIENTS**  
Jolanta Malyszko\* (PL), Jacek Malyszko, Piotr Przybylowski, Ewa Koc-Zorawska, Michal Mysliwiec, Sylwia Kozlowska, Jerzy Sadowski
- P-TH-525 INHIBITORS IN MILD AND MODERATE HEMOPHILIA A: A HETEROGENEOUS PROBLEM**  
Christine L Kempton\* (US), Geoff Allen, Cynthia Gauger, Jeffery Hord, Rebecca Kruse-Jarres, Rajiv Pruthi, Christopher Walsh, Guy Young, J. Michael Soucie
- P-TH-526 IMMUNE RESPONSE GENE POLYMORPHISMS AND INHIBITOR DEVELOPMENT IN SEVERE HAEMOPHILIA A PATIENTS IN INDIA.**  
Patricia Pinto\* (IN), Kanjaksha Ghosh, Bipin Kulkarni, Shrimati Shetty



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-527 INHIBITOR DEVELOPMENT IN A MILD HAEMOPHILIA A MIMICKING ACQUIRED HAEMOPHILIA**  
Simon Mcrae\* (AU), Vaughan Williams, Ram Suppiah, C Pham
- P-TH-528 DEEP VENOUS THROMBOSIS IN A PATIENT WITH ACQUIRED HEMOPHILIA A: A CASE REPORT AND LITERATURE REVIEW**  
Zhou Rong-Fu\* (CN), Jian Ouyang, Hong Tao
- P-TH-529 "LOW-DOSE" IMMUNE TOLERANCE INDUCTION REGIMENS AND RITUXIMAB IN PEDIATRIC PATIENTS WITH CONGENITAL HEMOPHILIA A & B**  
Geoffrey A Allen\* (US)
- P-TH-530 SUCCESSFUL IMMUNE TOLERANCE INDUCTION IN A SEVERE 66-YEAR OLD HEMOPHILIA A PATIENT WITH A HIGH-TITRE INHIBITOR**  
Riitta Lassila\* (FI), Heidi Asmundela, Elina Armstrong

### Inherited coagulation disorders (except for von Willebrand disease)

- P-TH-531 INHERITED FXI DEFICIENCY IN POLAND**  
Jerzy Windyga\* (PL), Edyta Odnoczko, Beata Baran, Anna Pavlova, Anna Buczma, Johannes Oldenburg, Jerzy Windyga
- P-TH-532 THROMBIN GENERATION AND BLEEDING SCORE IN A LARGE GROUP OF PATIENTS WITH FVII DEFICIENCY**  
Marzia Menegatti\* (IT), Simona Maria Siboni, Marigrazia Clerici, Lidia Padovan, Veena Chantarangkul, Flora Peyvandi
- P-TH-533 INTRA-ABDOMINAL HEMATOMA AND AFIBRINOGENEMIA DIFFICULTIES TO DETECT THE ORIGIN OF BLEEDING**  
ZOHRA KACI\* (DZ), HADJIRA AHMIDATOU, KARIMA WAFIA CHENNOUKH, MERIEM FADILA BELHANI
- P-TH-534 IF THE PATIENT TOLD THE TRUTH: ASPIRIN-LIKE DEFECT**  
Zsuzsanna Wolf\* (DE), Marc Schindewolf, Edelgard Lindhoff-Last
- P-TH-535 THROMBOSIS IN PATIENTS WITH FACTOR VII DEFICIENCY AFTER TREATMENT WITH CONCENTRATE**  
Michael Makris\* (UK), Michael Makris, Ewa Stefanska-Windyga, Silvia Horneff, Flora Peyvandi, Toshko Lissitchkov, Annarita Tagliaferri, Johannes Oldenburg, Jerzy Wyndiga
- P-TH-536 RECURRENCE OF THE P.GLY262ASP MUTATION AND A NOVEL P.THR176\_GLN186 DELETION IN TWELVE PATIENTS WITH CONGENITAL FACTOR X DEFICIENCY**  
Ahmet F Oner\* (TR), Serdar Epcacan, Andrea Cairo, Marzia Menegatti, Sinan Akbayram, Flora Peyvandi, Ahmet F Oner
- P-TH-537 RARE BLEEDING DISORDERS: TWELVE YEARS OF DIAGNOSIS IN THE HAEMOSTASIS LABORATORY OF THE UNIVERSITY HOSPITAL OF BENI MESSOUS (ALGIERS, ALGERIA)**  
Karima W Chennoukh\* (DZ), Meriem Bensadok, Yasmina Berkouk, Nadia Zidani, Zohra Kaci, Mohamed Ramaoun, Meriem Belhani
- P-TH-538 FVII DEFICIENCY PLASMA LEVEL & BLEEDING HISTORY**  
Karima W Chennoukh\* (DZ), Meriem Bensadok, Yasmina Berkouk, Nadia Zidani, Zohra Kaci, Meriem Belhani
- P-TH-539 ISSUES IN THE AGING INDIVIDUAL WITH HEMOPHILIA AND OTHER INHERITED BLEEDING DISORDERS: UNDERSTANDING THE PATIENT'S PERSPECTIVE**  
Shannon Claire Jackson\* (CA), Claude Bartholomew, Neale Smith



## POSTER PRESENTATIONS

Thursday, July 28, 2011

### Acquired coagulation disorders

- P-TH-540 ACQUIRED SEVERE FACTOR VII DEFICIENCY IN TWO PATIENTS WITH SEPSIS ROLE OF POLYMORPHISMS OF THE F7 GENE**  
Elisabeth Mazoyer\* (FR), Anthony Leon, Jean Devignes, Muriel Giansily-Blaizot, Marie Toussaint, Thomas Lecompte
- P-TH-541 OWREN-BASED INR ANALYSIS IS SUPERIOR TO QUICK-BASED METHODS IN PATIENTS WITH CHRONIC LIVER DISEASE**  
Maria Magnusson (SE), Margareta Sten-Linder\*, Annika Bergquist, Bjorn Fischler, Antal Nemeth
- P-TH-542 ACQUIRED HEMOPHILIA A IN A PATIENT WITH AUTOIMMUNE HEPATITIS, AUTOIMMUNE THYREOIDITIS AND SERONEGATIVE RHEUMATOID ARTHRITIS**  
Christian Pfrepper\* (DE), Mathias Bruegel, Susette Unger, Dietger Niederwieser, Leanthe Braunert
- P-TH-543 FIBRINOGEN REPLACEMENT IN TRAUMATIC BLEEDING**  
Nicola S Curry\* (UK), Claire Rourke, Sirat Khan, James Beavis, Sarah Kingsland, Karim Brohi, Simon J. Stanworth
- P-TH-544 HIGHLY PURIFIED VWF/FVIII COMPLEX CONCENTRATE AS FIRST LINE THERAPY IN THREE PATIENTS AFFECTED BY ACQUIRED HAEMOPHILIA A AND CARDIOVASCULAR DISEASE**  
Sofia Barbar\* (IT), Marta Milan, Barbara Brandolin, Luca Spiezia, Graziella Saggiorato, Ezio Zanon
- P-TH-545 PROSPECTIVE CLINICAL AND BIOLOGICAL EVALUATION OF ANTIHEMORRHAGIC TREATMENT WITH FEIBA (FACTOR EIGHT INHIBITOR BYPASSING ACTIVITY) IN ACQUIRED HEMOPHILIA A, FEIBHAC STUDY**  
Jeanne-Yvonne Borg\* (FR), Claude Negrier, Isabelle Durieu, Herve Levesque, Sophie Voisin, Anne Lienhart, Sandra Regina, Anne Borel-Derlon, Study Group French FEIBHAC
- P-TH-546 ACQUIRED INHIBITORS AGAINST COAGULATION FACTOR IX IN AN OTHERWISE HEALTHY 3-YEAR-OLD GIRL WITH MILD BLEEDING SYMPTOMS - A CASE REPORT**  
Michael Damgaard\* (SE), Fariba Baghaei
- P-TH-547 CHANGES IN GLOBAL HAEMOSTASIS IN PEDIATRIC LIVER TRANSPLANTATION : A SINGLE CENTER EXPERIENCE**  
Johannes Schelling\* (DE), David Schmidt, Michael Melter, Selim Corbacioglu
- P-TH-548 HAEMORRHAGIC DISTURBANCES OF UNUSUAL CAUSES. DIAGNOSTIC CHALLENGES.**  
Gyorgy Pfliegler\* (HU), Erzsebet Kovacs, Krisztian Urban, Zsuzsa Bereczki
- P-TH-549 IN VITRO EFFECTS OF RESUSCITATION FLUIDS ON COAGULATION AND MARKERS OF INFLAMMATION IN HUMAN BLOOD**  
Michael A Dubick\* (US), Michael S Scherer, Martin G Schwacha
- P-TH-550 SUCCESFUL CLINICAL REMISSION OF ACQUIRED GLANZMANN'S THROMBASTHENIA WITH HIGH-DOSE PREDNISOLONE AND MULTIPLE PLASMAPHERESIS**  
Zsuzsanna Wolf\* (DE), Marc Schindewolf, Jan Schwonberg, Nguyen Duc Xuan, Edelgard Lindhoff-Last
- P-TH-551 UNEXPLAINED POST-OPERATIONAL BLEEDING IN A PATIENT WITH ANTI-FACTOR XIII B SUBUNIT ANTIBODY**  
Kohei Murata\* (JP), Masataka Ikeda, Masayoshi Souri, Akitada Ichinose



## POSTER PRESENTATIONS

Thursday, July 28, 2011

### Hemorrhagic disorders in women

- P-TH-552 SEVERE POST-PARTUM HAEMORRHAGE TREATED WITH RECOMBINANT ACTIVATED FACTOR VII IN EIGHTY WOMEN - DATA FROM THE UNISEVEN REGISTRY**  
Jan Blatny\* (CZ), Dagmar Seidlova, Miroslav Penka, Petra Ovesna, Petr Brabec, Pavel Sevcik, Pavel Ventruba, Vladimir Cerny
- P-TH-553 MULTIDISCIPLINARY CLINICS LEAD TO AN IMPROVED CLINICAL OUTCOME AND MARKED COST SAVINGS IN WOMEN WITH VON WILLEBRAND'S DISEASE (VWD)**  
Bella Madan\* (UK), Stacey Ferris, Debra Holloway
- P-TH-554 THIRD TRIMESTER AMNIOCENTESIS IN WOMEN WITH INHERITED BLEEDING DISORDERS (IBD) TO GUIDE MANAGEMENT OF LABOUR AND DELIVERY**  
Bella Madan\* (UK), Jacqueline Cutler, Lucy Chappell, Pippa Kyle
- P-TH-555 RISK FACTORS FOR POSTPARTUM HEMORRHAGE IN A COHORT OF 6011 ITALIAN WOMEN**  
Eugenia Biguzzi\* (IT), Franca Franchi, Federico Ambrogi, Buthaina Ibrahim, Paolo Bucciarelli, Barbara Acaia, Tatiana Radaelli, Elia Biganzoli, Pier Mannuccio Mannucci
- P-TH-556 THE PREVALENCE OF BLEEDING DISORDERS IN UNEXPLAINED AND EXPLAINED MENORRHAGIA**  
H. Marieke Knol\* (NL), Andre B Mulder, Dick H. Bogchelmann, Hanneke C. Kluin-Nelemans, Ate G.J. van der Zee, Karina Meijer
- P-TH-557 LOW VON WILLEBRAND FACTOR (VWF) LEVEL IS THE MORE FREQUENT FINDING IN A PROSPECTIVE COHORT OF CHILDBEARING WOMEN WITH BLEEDING HISTORY**  
Analia Sanchez-Luceros\* (AR), Adriana I Woods, Susana S Meschengieser, Silvia H Grosso, Alicia Blanco, Maria F Alberto, Emilse Bermejo, Maria A Lazzari
- P-TH-558 PREVALENCE AND CHARACTERISTICS OF COAGULATION ABNORMALITIES IN WOMEN WITH MULTIFETAL PREGNANCY AND INTRAUTERINE DEATH OF ONE TWIN**  
Predrag S Miljic\* (RS), Aleksandar Jovanovic, Aleksandar Ljubic
- P-TH-559 MENORRHAGIA IN HEMORRHAGIC DISORDERS: A NEW, SIMPLE QUANTITATIVE METHOD FOR ITS EVALUATION**  
Guglielmo Mariani\* (IT), Mariasanta Napolitano, Elvira Grandone, Assunta Orecchioni, Sergio Siragusa, Gaspare Carta, Giovanni Di Minno, Colaizzo Donatella, Mariagrazia Perilli, Alberto Dolce
- P-TH-560 POINT-OF-CARE PROTHROMBIN TIME TESTING AS AN EARLY PREDICTOR OF SEVERE POST PARTUM HEMORRHAGE**  
Sophie Susen\* (FR), Anne Bauters, Clotilde Pilla, Catherine Barre, Antoine Tournays, Alain Duhamel, Sandrine Depret-Mosser, Brigitte Jude, Anne-Sophie Ducloy
- P-TH-561 VARIOUS PRIMARY HAEMOSTATIC DISORDERS AND PRIMARY COAGULOPATHIC MASSIVE OBSTETRICAL HAEMORRHAGE**  
Alexander D. Makatsaria\* (RU), Viktoria O. Bizadze, Valentina V. Smyrigina, Svetlana V. Akinshina, Djamilya H. Khizroeva
- P-TH-562 INHERITED FACTOR VII DEFICIENCY IN POLISH WOMEN**  
Beata Baran\* (PL), Ewa Stefanska-Windyga, Beata Baran, Anna Pavlova, Johannes Oldenburg, Ksenia Bykowska, Jerzy Windyga
- P-TH-563 INCREASED BLEEDING IN CARRIERS OF HAEMOPHILIA AND SUBJECTS WITH VON WILLEBRAND'S DISEASE RESULT IN MENORRHAGIA AND REDUCED QUALITY OF LIFE**  
Cornelia Wermes\* (DE), Roswith Eisert, Arnold Ganser

Thursday Posters



75



## POSTER PRESENTATIONS

Thursday, July 28, 2011

**P-TH-564 ELECTRONIC BLEEDING QUESTIONNAIRE, ELECTRONIC PBAC AND THROMBOELASTOGRAPHY: NOVEL APPROACHES IN THE DIAGNOSIS OF MILD BLEEDING DISORDERS IN WOMEN**

Kimberly MacEachern\* (CA), Alexander Hamilton, Stephen Scovil, Hisham S Elbatarny, Maha Othman

### Laboratory tests

**P-TH-565 COMPARISON OF PERIOPERATIVE THROMBOELASTOGRAPHY (TEG) WITH CONVENTIONAL COAGULATION TESTS (PLATELET COUNT, APTT, INR AND FIBRINOGEN) IN SURGICAL PATIENTS**

Anna Agren\* (SE), Agneta Taune Wikman, Anders Ostlund, Gustaf Edgren

**P-TH-566 ENHANCED UNDERSTANDING OF PATHOPHYSIOLOGY AND PHENOTYPE IN CONGENITAL AFIBRINOGENEMIA USING MULTIPLE GLOBAL ASSAYS OF COAGULATION.**

Cristina Santoro (IT), Mindy L Simpson, Neil A Goldenberg, Linda Jacobson, Lisa Villalobos-Menuey, Marilyn J Manco-Johnson\*

**P-TH-567 THROMBOELASTOGRAPHY AS A GLOBAL ASSAY TO MONITOR BYPASSING AGENTS IN HEMOPHILIA PATIENTS WITH INHIBITORS**

Cristina Santoro (IT), Linda Jacobson, Michael Wang, Marilyn J Manco-Johnson\*

**P-TH-568 EVALUATION OF APTT CLOT WAVEFORM ANALYSIS BY IL ACL TOP IN PATIENTS WITH HAEMOPHILIA AND COMPARISON TO CLOT WAVE FORM ANALYSIS WITH MDA 180**

Anne Riddell\* (UK), Saman Aghighi, Tejas Gandhi, Elcid Vijayakumar, Sarah Brooks, Pratima Chowdary

**P-TH-569 A COMMERCIAL ELISA METHOD FOR IDENTIFYING TYPE 2N VON WILLEBRAND DISEASE PATIENTS AND CARRIERS**

Alessandra Casonato\* (IT), Elena Pontara, Francesca Sartorello, Maria Grazia Cattini, Viviana Daidone, Alessandra Casonato

**P-TH-570 AN APPROACH TO AN EXTERNAL QUALITY ASSURANCE PROGRAM (EQA) FOR THE PLATELET FUNCTION ANALYZER PFA-100: APPLICATION TO A SYSTEMATIC SCREENING OF PLATELET DISORDERS**

Gines Escolar\* (ES), Gines Escolar, Marcos Pino, Patricia Molina, Ana Maria Galan, Albert Barraso, Eduardo Arellano-Rodrigo, Juan Carlos Reverter, Gabriela Gutierrez, Maribel Diaz-Ricart

**P-TH-571 IS ENDOGENOUS THROMBIN POTENTIAL A USEFUL TOOL TO ADAPT THE PROPHYLACTIC TREATMENT SCHEME IN PEDIATRIC HEMOPHILIAC PATIENTS: A PRELIMINARY STUDY**

Caroline La\* (BE), Phu Quoc Le, Laurence Rozen, Alina Ferster, Thomas Reygaerts, Lambert Leenders, Anne Demulder

**P-TH-572 SCREENING OF BLEEDING DISORDERS USING A THROMBELASTOMETRIC THROMBIN GENERATION ASSAY**

Thomas Siegemund\* (US), Natalie Adam, Ute Scholz, Annelie Siegemund

**P-TH-573 DISCREPANCY IN THE MEASURED RESPONSE TO PLASMA-DERIVED FVII CONCENTRATE DEPENDING ON THROMBOPLASTIN SOURCE**

Anne Riddell\* (UK), William Pickering, Sarah Brooks, Keith Gomez



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-574 PREVALENCE OF HEMOSTATIC ALTERATIONS IN A LARGE CASE SERIES OF PATIENTS WITH RECURRENT SPONTANEOUS SUBCONJUNCTIVAL HEMORRHAGE (THE RED EYE)**  
Paolo Gresele\* (IT), Tiziana Fierro, Bartolini Anna, Mezzasoma AnnaMaria, Guglielmini Giuseppe, Cagini Carlo, Gresele Paolo

### Inflammatory cells and cytokines

- P-TH-575 NOVEL BIOMARKERS OF PROCOAGULANT ACTIVITY PRESENT IN THE PLASMA OF CIRRHOTICS WITH STERILE ASCITES WITH NOT PRESENT IN CIRRHOTICS WITHOUT ASCITES**  
David Hoffman Van Thiel\* (US), Christopher Mark Moore, Bashar M Attar, Magdalena M George, Niculae Ion Nedelcu, Evengelos Litinas, Giuliano Ramadori, Jawed Fareed, Raza Hamdani, Thethi Indermohan
- P-TH-576 PLASMA CLOTS INDUCE MONOCYTE INFLAMMATORY CYTOKINE PRODUCTION: NEW LINKS BETWEEN THROMBOSIS AND INFLAMMATION**  
Robert Adrian Campbell\* (US), Robert A Campbell, Tammy L Smith, Zechariah G Franks, Guy A Zimmerman, Andrew S Weyrich
- P-TH-577 5-HYDROXY-2-(4-HYDROXY-3-METHOXYPHENYL)-3,7-DIMETHOXY-4H-CHROMEN-4-ONE (MSF-2) SUPPRESSES FMLP-MEDIATED RESPIRATORY BURST IN HUMAN NEUTROPHILS**  
Chang-Hui Liao\* (TW), Jih-Jung Chen, Jieru-Egeria Lin, Chia-Hsin Liu, Ching-Ping Tseng, Tao-Yuan Day
- P-TH-578 RECENT THYMIC EMIGRANTS ESTIMATION AS AN APPROACH TO PREMATURE IMMUNOSENESCENCE SYNDROMES STUDY**  
Mark V Goloviznin\* (RU), Natalia S Lakhonina, Almira D Donetskova, Margarita F Nikonova, Alexander A Yarilin, Yulia R Buldakova, Anna S Tektova, Vitaly T Timofeev
- P-TH-579 PERIPHERIALISATION OF T-LYMPHOCYTES SELECTION PROCESSES AS A POSSIBLE CAUSE OF VASCULAR TRANSFORMATIONS IN SYSTEMIC AUTOIMMUNE INFLAMMATORY DISEASES**  
Mark V Goloviznin\* (RU), Yulia R Buldakova, Natalia S Lakhonina, Vitaly T Timofeev
- P-TH-580 LUTEIN, A NATURALLY OCCURRING CAROTENOID, MODULATES ACTIVITY OF MURINE MACROPHAGES**  
Wen-Bin Wu\* (TW), Huey-Ming Lo, Pi-Hui Wu
- P-TH-581 ANTI-INFLAMMATORY ACTIVITY OF RECOMBINANT THROMBOMODULIN PROTEINS**  
Hua-Lin Wu\* (TW), Yu-Ming Cheng, Bi-Ing Chang, Cheng-Hsiang Kuo, Guey-Yueh Shi
- P-TH-582 FACTOR XI STIMULATES NEUTROPHIL OXIDATIVE BURST AND INHIBITS CHEMOTAXIS**  
Asako Itakura\* (US), Norah G Verbout, David Gailani, Andras Gruber, Owen J McCarty
- P-TH-583 MONOCYTE SUBSETS DIFFERENTLY EXPRESS CD59 AND CORRELATE WITH CARDIOVASCULAR RISK FACTORS IN STABLE CAD PATIENTS**  
Konstantin A. Krychtiuk\* (AT), Stefan P. Kastl, Stefan Pfaffenberger, Katharina M. Katsaros, Sebastian L. Hofbauer, Anna Wonnerth, Walter S. Speidl, Gerald Maurer, Kurt Huber, Johann Wojta
- P-TH-584 BIOMARKERS OF INFECTION SEVERITY IN EMERGENCY DEPARTMENT PATIENTS**  
Eric Shappell\* (US), Mark Cichon, Jeanine Walenga, Debra Hoppensteadt, Jawed Fareed



## POSTER PRESENTATIONS

Thursday, July 28, 2011

**P-TH-585 THROMBOMODULIN PHENOTYPE OF A DISTINCT MONOCYTE SUBTYPE IS AN INDEPENDENT PROGNOSTIC MARKER FOR DISSEMINATED INTRAVASCULAR COAGULATION**

JI EUN KIM\* (KR), Hwang Sang Mee, Han Kyou-Sup, Kim Hyun Kyung

### Extracellular matrix

**P-TH-586 THROMBIN-CLEAVED FRAGMENTS OF OSTEOPONTIN ARE ELEVATED IN THE CEREBRAL SPINAL FLUID OF PRIMARY GLIOBLASTOMA AND AFFECT GLIOMA CELL BEHAVIOR**

John Morser\* (US), Yasuto Yamaguchi, Shadi Sharif, Xiaoyan Du, Timothy Myles, Larry Recht, Leung L. K. Lawrence

### Vascular development

**P-TH-587 PROGNOSTIC VALUE OF CIRCULATING ANNEXIN A5 IN PATIENTS WITH HEART FAILURE**

Leon J Schurgers\* (NL), Thor Ueland, Leonard Hofstra, Lars Gullestad, Pal Aukrust, Jagat Narula, Chris P Reutelingsperger

**P-TH-588 A NOVEL MUTATION (P.V228F) IN ACTIVIN RECEPTOR-LIKE KINASE 1 GENE CAUSING CHINESE FAMILY HEREDITARY HEMORRHAGIC TELANGIECTASIA**

Lin Lin Jiang\* (CN), Ye ling Lu, Xue Feng Wang, Qiu Lan Ding, Jing Dai

**P-TH-589 LINKS BETWEEN ANEMIA, IRON METABOLISM AND BONE DISEASES IN CHRONIC KIDNEY DISEASE-CKD**

Jolanta Malyszko\* (PL), Jacek Malyszko, Piotr Kozminski, Ewa Koc-Zorawska, Michal Mysliwiec

**P-TH-590 IDENTIFICATION OF NOVEL ENDOTHELIAL-SPECIFIC GENES REGULATED BY TRANSFORMING GROWTH FACTOR BETA SUPERFAMILY**

Osamu Nakagawa\* (JP), Satoshi Somekawa, Hisaki Hayashi, Sakabe Masahide, Tomoko Ioka, Ken Inada, Genki Satoh, Yoshihiko Saito

**P-TH-591 PAR-2, BUT NOT PAR-1, IS CRITICALLY INVOLVED IN COLLATERAL FORMATION IN A MOUSE HIND LIMB ISCHEMIA MODEL**

Lisa G van den Hengel\* (NL), Alwine A Hellingman, Hetty C de Boer, Annemarie M van Oeveren-Rietdijk, C Arnold Spek, Anton Jan van Zonneveld, Pieter H Reitsma, Jaap F Hamming, Paul HA Quax, Henri H Versteeg

### Tissue engineering

**P-TH-592 CONTROLLED ACTIVATION OF MORPHOGENESIS TO GENERATE A FUNCTIONAL HUMAN MICROVASCULATURE IN A SYNTHETIC MATRIX**

Sharon Gerecht (US), Donny Hanjaya-Putra\*, Vivek Bose, Yu-I Shen, Jane Yee, Sudhir Khetan, Jason A Burdick

**P-TH-593 VENOUS ENDOTHELIAL CELLS ARE LESS PROCOAGULANT COMPARED TO ARTERIAL ONES: IMPLICATIONS FOR VASCULAR TISSUE ENGINEERING**

Henri M H Spronk\* (NL), Irma Geenen, Daniel G.M. Molin, Mark J. Post, Rene van Oerle, Hugo ten Cate, Henri M.H. Spronk



## POSTER PRESENTATIONS

Thursday, July 28, 2011

### Experimental models

- P-TH-594 THE P2Y1 RECEPTOR CONTRIBUTES TO TNF $\alpha$ -INDUCED VASCULAR INFLAMMATION IN MICE**  
Beatrice Hechler\* (FR), Murielle Zerr, Stephanie Magnenat, Monique Freund, Jean-Pierre Cazenave, Catherine Leon, Christian Gachet
- P-TH-595 PROTEASE ACTIVATED RECEPTOR 1 CONTRIBUTES TO ANGIOTENSIN II-INDUCED CARDIOVASCULAR REMODELING AND INFLAMMATION**  
Rafal Pawlinski\* (US), Silvio Antoniak, Jessica C Cardenas, Nigel Mackman, Rafal Pawlinski
- P-TH-596 ALPHA-2-MACROGLOBULIN AS A BIOMARKER FOR GLUCOCORTICOID-INDUCED OSTEONECROSIS OF THE FEMORAL HEAD**  
Chantal Seguin\* (CA), Alberto Carli, Mireille Sayegh, Bouziane Azeddine, Ailian Li, Ayoub Nahal, Rene Michel, Janet E. Henderson, Edward J. Harvey
- P-TH-597 MICROPARTICLES (MPS) CONVEY CD14 FROM MONOCYTES TO LEUCOCYTES AND AMPLIFY LIPOPOLYSACCHARIDE (LPS)-INDUCED APOPTOSIS IN CELLULAR CROSSTALK MODELS**  
Xavier Delabranche\* (FR), Julie Boisrame-Helms, Asael Berger, Emmanuel Haas, Fatiha Zobairi, Michel Hasselmann, Ferhat Meziani, Florence Toti
- P-TH-598 VWF IS PROTECTIVE AGAINST STATUS EPILEPTICUS-INDUCED DEATH IN MICE**  
Georgette L Suidan\* (US), Alexander Brill, Simon F. De Meyer, Jaymie R Voorhees, Denisa D Wagner
- P-TH-599 INVESTIGATION OF IN VITRO MICROPARTICLE CLOTTING ACTIVITY**  
Nima Vaezzadeh\* (CA), Peter L Gross

### iPS cells and stem cells

- P-TH-600 ACCELERATION OF CORD BLOOD HEMATOPOIETIC STEM CELLS PROLIFERATION BY A NEW CYTOKINE COCKTAIL IN SERUM FREE MEDIUM**  
Kamonnaree Chotinantakul\* (TH), Seiji Okada, Wilairat Leeansaksiri

### Novel animal models

- P-TH-601 NOVEL MURINE HEMOPHILIA LINGUAL VEIN BLEEDING MODEL PROVIDES LOWER VARIATION AND HIGHER SENSITIVITY IN COMPARISON TO TAIL VEIN TRANSECTION MODEL (TVT)**  
Maria Koellnberger\* (US), Perry Liu, Derek Sim, Jim Newgren, Cornell Mallari, Yifan Xu, John E. Murphy, Jesper Haaning
- P-TH-602 A NOVEL MOUSE MODEL TO STUDY THROMBOGENESIS AND THROMBUS RESOLUTION WITH CONTINUOUS BLOOD FLOW IN THE INFERIOR VENA CAVA**  
Jose Antonio Diaz\* (US), Christine M. Alvarado, Shirley K. Wroblewski, Nichole Baker, Angela E. Hawley, Peter K. Henke, Benedict R. Lucchesi, Thomas W. Wakefield, Daniel D. Myers

### Nanotechnology

- P-TH-603 FIRST RESULTS OF THE BMBF (FEDERAL MINISTRY OF EDUCATION AND RESEARCH) FUNDED PROJECT "ON CHIP FLOW CHAMBER" TO MONITOR ANTICOAGULANT THERAPY AND COAGULATION DISEASES**  
Sascha Meyer dos Santos\* (DE), Ute Klinkhardt, Anita Zorn, Sebastian Harder



## POSTER PRESENTATIONS

Thursday, July 28, 2011

- P-TH-604 ASSESSMENT OF DIFFERENT METHODS STUDYING THE IMPACT OF CARBON NANOMATERIALS ON PLATELET FUNCTION**  
Julie Laloy\* (BE), Francois Mullier, Severine Robert, Lutfiye Alpan, Jorge Mejia, Jean-Pascal Piret, Nicolas Bailly, Stephane Lucas, Bernard Chatelain, Olivier Toussaint, Bernard Masereel, Stephanie Rolin, Jean-Michel Dogne
- P-TH-605 COLLAGEN NANOFIBERS ARRAYS AS A HOMOGENEOUS, REPEATABLE SUBSTRATE FOR PLATELET FLOW ASSAYS**  
Ryan Robert Hansen\* (US), Alena A Tipnis, Jorge A Di Paola, Keith B Neeves
- P-TH-606 CALIBRATED THROMBIN GENERATION TEST (CTGT) IS A POWERFUL PRECLINICAL TOXICOLOGICAL SCREENING TOOL TO ASSESS THE PROCOAGULANT ACTIVITY OF NANOMATERIALS**  
Severine Robert\* (BE), Julie Laloy, Catherine Marbehant, Francois Mullier, Jorge Mejia, Jean-Pascal Piret, Stephane Lucas, Bernard Chatelain, Jean-Michel Dogne, Olivier Toussaint, Bernard Masereel, Stephanie Rolin
- P-TH-607 NEW METHOD FOR COUNTING AND SIZING CLINICALLY RELEVANT MICROPARTICLES (MPS) IN THE 0.15 TO 1 MICRON SIZE RANGE**  
Don A Gabriel\* (US), Don A Gabriel, Richard T Stravitz, Regina Bowling, Samuel Glover, Nigel S Key
- P-TH-608 EVALUATION OF THE ELASTIC PROPERTIES BY ATOMIC FORCE MICROSCOPY OF ERYTHROCYTES AND LIPID PEROXIDATION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS**  
Lizaveta Drozd\* (BY), Elena Konstantinova, Inna Buko
- P-TH-609 TI(N,C,O) DIFFUSIVE LAYERS DEVELOPED ON TITANIUM ALLOY AS THE BLOOD CONTACT SURFACE**  
Malgorzata Gonsior\* (PL), Roman Kustos, Tadeusz Wierzchon, Tomasz Borowski, Maciej Ossowski, Elzbieta Czarnowska, Marek Sanak, Bogdan Walkowiak, Wieslawa Okroj, Magdalena Walkowiak-Przybyla, Bogdan Jakiella



Special Symposia 扉

Sunday, July 24, 2011

12:30-14:30

**Special Symposium**

**Room A**

**Made possible by enerous support from Baxter Healthcare Corporation**

**Future Directions in the Prediction and Prevention of FVIII Inhibitors**

*Chairpersons: Jan Astermark (SE) and Bruce Ewenstein (US)*

**Welcome and introduction**

*Jan Astermark (SE)*

12:30 – 12:45

**What can we learn from and how should we interpret pup studies?**

*Bruce Ewenstein (US)*

12:45 – 13:00

**Refining how we think about the inhibitor risk based on fviii mutation type**

*Tom Howard (US)*

13:00 – 13:15

**Antibody response versus immune tolerance against fviii: How can we design future therapeutics?**

*Birgit Reipert (AT)*

13:15 – 13:35

**Evidence for the role of novel immune response genes in inhibitor development**

*Jan Astermark (SE)*

13:35 – 13:50

**EPIC: A study on the prevention of inhibitors**

*Günter Auerswald (DE)*

13:50 – 14:05

**Questions and answers**

*Panel Discussion*

14:05 – 14:30

**Special Symposium**

**Annex Hall 1**

**The programme pported by an unrestricted educational grant from AstraZeneca**

**EBAC Accredited Educational Programme organised by the Sahlgrenska Academy – Gothenburg University**

*Course director: K. Swedberg (Gothenburg, Sweden)*

**This educational programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for one hour of External CME credits. Each participant should claim only those hours of credit that**



Sunday, July 24, 2011

12:30-14:30

have actually been spent in the educational activity. EBAC works in cooperation with the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS)

### Antiplatelet therapy: Improving the care of ACS patients through evidence-based approaches

Chairperson: *Philippe Gabriel Steg (FR)*

#### Welcome and introduction

*Philippe Gabriel Steg (FR)*

13:00 – 13:10

#### Improving care with oral antiplatelet therapy: Lessons from recent large outcomes trials

*Philippe Gabriel Steg (FR)*

13:10 – 13:25

#### New mechanisms, new agents in antiplatelet therapy

*Marco Cattaneo (IT)*

13:25 – 13:40

#### Biomarkers in ACS: Prognostic indicators or meaningful endpoints?

*Robert Storey (UK)*

13:40 – 13:55

#### Genetic influences on platelet function: Recent insights

*Paul Gurbel (US)*

13:55 – 14:10

#### Panel discussion

*Chairperson and Faculty*

14:10 – 14:30



### Special Symposium

Annex Hall 2

Made possible  generous support from *Biogen Idec Hemophilia & Swedish Orphan Biovitrum*

### Clinical Evaluation of Coagulation Factors with Prolonged Pharmacokinetic Activity

Chairpersons: *Glenn Pierce (US) and Alok Srivastava (IN)*

#### Welcome and introduction

*Glenn Pierce (US) and Alok Srivastava (IN)*

12:35 – 12:40

#### Bleeding risk and pharmacokinetics: Shifting paradigms?

*Alok Srivastava (IN)*

12:40 – 12:55

Special Symposia



3



Sunday, July 24, 2011

12:30-14:30

**Coagulation factor pharmacokinetics and implications for treatment**

*Sven Bjorkman (SE)* 12:55 – 13:10

**Mechanism of action of fc fusion proteins**

*Robert Peters (US)* 13:10 – 13:30

**Preclinical models for clinical pharmacokinetics and efficacy in hemophilia**

*Haiyan Jiang (US)* 13:30 – 13:45

**Clinical trial considerations for long-lasting rFVIII-Fc fusion protein**

*Neil Josephson (US)* 13:45 – 13:55

**Prolonged clinical activity of rFIX-Fc fusion protein in hemophilia b**

*Midori Shima (JP)* 13:55 – 14:05

**Summary conclusions**

*Alok Srivastava (IN)* 14:05 – 14:10

**Questions and answers**

*Glenn Pierce* 14:10 – 14:30



Sunday, July 24, 2011

15:00-17:00

**Special Symposium**

**Room A**

**Made possible  generous support from The IME Group and InforMEDical Communications, Inc. (Supported by an educational grant from Baxter)**

**Bypass Therapy Prophylaxis for Inhibitor Management in Hemophilia A**

*Chairperson: Cindy A. Leissing (US)*

**Doors open / Lunch served**

15:00 – 15:30

**Welcome and introduction**

*Cindy A. Leissing (US)* 15:30 – 15:35

**Bypass therapy: Prophylaxis versus on-demand therapy**

*Alessandro Gringeri (IT)* 15:35 – 16:00



Sunday, July 24, 2011

15:00-17:00

**Clinical trials of prophylactic therapy in hemophilia patients with inhibitors**

*Cindy A. Leissinger (US)*

16:00 – 16:25

**Achieving consensus and developing guidelines for prophylaxis in inhibitor management**

*Jerome M. Teitel (CA)*

16:25 – 16:50

**Panel discussion and Q&A**

*Chair and Panel*

16:50 – 17:00

**Symposium close**

17:00

**Special Symposium**

**Annex Hall 1**

**Made possible**  **generous support from Bayer Healthcare  
Pharmaceuticals**

**Prophylaxis: Current and Future Trends, Insights and Controversies**

*Chairpersons: David Lillicrap (CA) and Midori Shima (JP)*

**Welcome and introduction**

*David Lillicrap (CA)*

15:00 – 15:05

**Controversies in the use of prophylaxis: An interactive session**

*David Lillicrap (CA)*

15:05 – 15:15

**Prophylaxis with rFVIII in adults: New data from a prospectively  
designed study**

*Jerry Powell (US)*

15:15 – 15:40

**Long-term comparison of prophylaxis versus episodic treatment in a  
nested control study: Impact on joint health**

*Jørgen Ingerslev(DK)*

15:40 – 16:05

**New insights from preclinical research on modifying immune response  
and inhibitor binding**

*John Murphy (US)*

16:05 – 16:30

**Debate on the use of lifelong prophylaxis**

*Mike Makris (UK) and Kathelijn Fischer (NL)*

16:30 – 16:55

Special Symposia



5

Sunday, July 24, 2011

15:00-17:00

**Concluding remarks**

Midori Shima (JP) 

16:55 – 17:00

**Special Symposium**



**Annex Hall 2**

**Made possible  generous support from Sanofi**

**Toward Better Anticoagulation Management: Experience and Evidence with Enoxaparin**

Chairpersons: Shinya Goto (JP) and Ajay Kakkar (UK)

**Welcome and introduction**

Shinya Goto (JP)

15:00 – 15:05

**A call to action for VTE awareness**

Ajay Kakkar (UK)

15:05 – 15:20

**Update on VTE in Asia-Pacific**

Ben Chong (AU)

15:20 – 15:35

**Beyond Medenox: Reaching new horizons in non-surgical settings**

Roger Yusen (US)

15:35 – 15:50

**Medical oncology and thrombosis: What next?**

Alok Khorana (USA)

15:50 – 16:05

**Pleiotropic properties: Implications for anticoagulant differentiation**

Ludovic Drouet (FR)

16:05 – 16:20

**Panel discussion**

All Facilitator, Sarah Jarvis (UK)

16:20 – 16:50

**Concluding remarks**

Ajay Kakkar (UK)

16:50 – 17:00



Monday, July 25, 2011

18:15-20:15

**Special Symposium**

**Sakura**

**Made possible**  **generous support from Bayer**

**Long-Term Oral Anticoagulation: Debating the Future**

*Chairpersons: the Lord Kakkar (UK) and Kenneth Bauer (US)*

**Welcome and introductory presentation**

*Ajay Kakkar (UK)*

18:15 – 18:30

**Atrial fibrillation: Updates on recent therapeutic advances**

*Gregory Lip (UK)*

18:30 – 18:50

**Debate-style discussion**

*Gregory Lip (UK), Masatsugu Hori (JP)*

18:50 – 19:20

**VTE Treatment: Updates on recent therapeutic advances**

*Harry Büller (NL)*

19:20 – 19:40

**Debate-style discussion**

*Harry Büller (NL), Alexander GG Turpie (CA), Walter Ageno (IT)*

19:40 – 20:10

**Closing remarks**

*Kenneth Bauer (US)*

20:10 – 20:15

**Special Symposium**

**Room A**

**Supported by an educational grant provided by Novo Nordisk Health Care AG.**

**Challenges and Progress in the Management of Joint Health in Haemophilia Patients**

*Chairperson: Victor Blanchette (CA)*

*Co-Chair: Marilyn Manco-Johnson (US)*

**Welcome and introduction**

*Victor Blanchette (CA)*

18:15 – 18:25

**Pathogenesis of haemophilic arthropathy: Of mice and men**

*Leonard Valentino (US)*

18:25 – 18:45

Special Symposia



7

Monday, July 25, 2011

18:15-20:15

**Tools to characterise joint condition: Imaging & functionality - The role of imaging in the detection of early haemophilic arthropathy**

*Michael Manco-Johnson (US)*

18:45 – 19:05

**Tools to characterise joint condition: The role of functional assessments in the detection of early haemophilic arthropathy**

*Marilyn Manco-Johnson (US)*

19:05 – 19:25

**Joint health in the inhibitor-positive patient: An evolving challenge**

*Elena Santagostino (IT)*

19:25 – 19:55

**Questions & concluding remarks**

*Victor Blanchette (CA)*

19:55 – 20:15

**Special Symposium**

**Annex Hall 2**

*Made possible*  *generous support from CSL Behring*

**Factors for Life – Advances in Treatment of Congenital and Coagulopathic Bleeding Disorders**

*Chairpersons: Barbara Zieger (DE) and Steven Pipe (US)*

**Welcome and introduction**

*Steven Pipe (US)*

18:15 – 18:20

**CONGENITAL BLEEDING**

**Physiology of Von Willebrand Factor and its clinical implications for people with VWD**

*Reinhard Schneppenheim (DE)*

18:20 – 18:45

**Pioneering designs for recombinant coagulation factors**

*Stefan Schulte (DE)*

18:45 – 19:05

**Questions & answers**

*Barbara Zieger (DE)*

19:05 – 19:15

**ACQUIRED BLEEDING DISORDERS**

**The role of fibrinogen: A new paradigm in the treatment of coagulopathic bleeding**

*Benny Soerensen (UK)*

19:15 – 19:35



Monday, July 25, 2011

18:15-20:15

**Fibrinogen concentrate in the treatment of severe bleeding after aortic aneurysm graft surgery. Clinical results of a prospective clinical trial**

*Niels Rahe-Meyer (DE)* 19:35 – 20:00

**Questions & answers**

*Steven Pipe (US)* 20:00 – 20:10

**Concluding remarks**

*Barbara Zieger (DE)* 20:10 – 20:15

**Special Symposium**

**Room D**

**Made possible**  **generous support from Daiichi Sankyo, Co., Ltd.**

**Chronic Anticoagulation in AF: Optimization of Treatment**

*Chairpersons: Jeffrey Weitz (CA) and Yukihiro Koretsune (JP)*

**Registration and boxed dinner to be provided on first come first served basis**

18:15 – 18:30

**Welcome and introduction**

*Jeffrey Weitz (CA)* 18:30 – 18:35

**Focus on the guidelines**

*Takeshi Yamashita (JP)* 18:35 – 18:55

**Current perceptions of the barriers to anticoagulation**

*Raffaele De Caterina (IT)* 18:55 – 19:15

**Defining the clinical risks for bleeding in AF: Optimization of patient and treatment outcomes**

*Bradley C. Martin (US)* 19:15 – 19:35

**Next generation of anticoagulants**

*Jeffrey Weitz (CA)* 19:35 – 19:55

**Closing remarks**

*Yukihiro Koretsune (JP)* 19:55 – 20:15

Special Symposia



9

Monday, July 25, 2011

18:15-20:15

Special Symposium

Room B-1

Made possible  generous support from Otsuka Pharmaceutical Co., Ltd.

**Burdens on Anti-Thrombotic Therapy ~How Do You Select Anti-Platelet Agents?~**

*Chairperson: Takenori Yamaguchi (JP) and Philippe Gabriel Steg (FR)*

**Welcome and introduction**

**Risk & benefit of anti-thrombotic therapy: Still ignore the bleeding risk?**

*Shinya Goto (JP)*

**The latest evidence on stroke treatment in asian population : Impact of CSPSII**

*Shinichiro Uchiyama (JP)*

**New trends in anti-platelet agents: Updates with the current topics**

*William R. Hiatt (USA)*



Satellite Symposia 扉



## Satellite Symposia

Satellite Symposia take place on:

### Tuesday July 26 18:15 - 19:45

<b>Daiichi Sankyo, Co., Ltd.</b>	Room D
<b>Stago</b>	Room E
<b>Boehringer Ingelheim</b>	Annex Hall 1
<b>Novo Nordisk A/S</b>	Room A
<b>Alexion Pharmaceuticals</b>	Room B-2

### Wednesday July 27 14:15 - 15:45

<b>GlaxoSmithKline</b>	Room D
<b>Pfizer</b>	Sakura
<b>Loyola University Medical Center</b>	Room B-1



Tuesday July 26, 2011

18:15 - 19:45

**Novo Nordisk A/S**

**Room A**

**Progress in Haemophilia Care: New Molecules on the Horizon**

*Chairperson: Tadashi Matsushita (JP)*

**Welcome and introduction**

*Tadashi Matsushita (JP)*

18:15 – 18:18

**Changing possibilities in haemophilia: Bringing trials to life together**

*Stephanie Seremetis (DK)*

18:18 – 18:28

**Recombinant activated FVII analogue (vatreptacog alfa activated) for treatment of bleeds in haemophilia patients with inhibitors: Results from a global randomised phase 2 trial**

*Erich de Paula (BR)*

18:28 – 18:53

**The historical evolution of haemophilia clinical trial programmes for product approval: A clinician's perspective**

*Roshni Kulkarni (US)*

18:53 – 19:18

**Creating a paradigm shift in haemophilia B care: Results from the phase 1 trial of glycoPEGylated rFIX (N9-GP)**

*Paul Giangrande (UK)*

19:18 – 19:43

**Questions & concluding remarks**

*Tadashi Matsushita (JP)*

19:43 – 19:45

**Daiichi Sankyo, Co., Ltd.**

**Room D**

**Chronic Anticoagulation in Prevention and Treatment of VTE**

*Chairpersons: Harry Buller (NL) and Mitsuru Murata (JP)*

**Registration and Boxed Dinner to be provided on first come first served basis**

18:15 – 18:30

**Welcome and introduction**

*Harry Buller (NL)*

18:30 – 18:35

**Focus on the guidelines**

*Giancarlo Agnelli (IT)*

18:35 – 18:55

Satellite Symposia



3

**Tuesday July 26, 2011**

**18:15 - 19:45**

**Next generation anticoagulants-prevention focus**

*Takeshi Fuji (JP)*

18:55 – 19:15

**Next generation anticoagulants-treatment focus**

*Harry Buller (NL)*

19:15 – 19:35

**Closing remarks**

*Mitsuru Murata (JP)*

19:35 – 19:45

**Boehringer Ingelheim**

**Annex Hall 1**

**Join the revolution: Advances in Oral Anticoagulation**

*Chairperson: Ken Okumura (JP)*

**Chair's welcome and introduction**

*Ken Okumura (JP)*

18:15 – 18:20

**Breakthroughs in the prevention and treatment of VTE**

*Sam Schulman (CA)*

18:20 – 18:35

**Current challenges in stroke prevention in patients with atrial fibrillation**

*Jeffrey Weitz (CA)*

18:35 – 18:50

**New insights from the landmark phase III RE-LY® trial – Oral anticoagulation is evolving**

*Gregory Lip (UK)*

18:50 – 19:10

**Introducing a novel oral anticoagulant – Clinical practice implications**

*Michael Ezekowitz (US)*

19:10 – 19:30

**Panel discussion: Questions and answers from the floor**

*All faculty*

19:30 – 19:40

**Conclusions and closing remarks**

*Ken Okumura (JA)*

19:40 – 19:45



Tuesday July 26, 2011

18:15 - 19:45

**Stago**

**Room E**

**Can We Predict Interventions in Haemostasis and Thrombosis?**

*Chairperson: Kenneth Mann (US)*

**Introductory lecture: "Thrombin generation assays"; Why should we care?**

*Kenneth Mann (US)*

18:15 – 18:30

**Evaluation of clotting function of acquired hemophilia**

*Midori Shima (JP)*

18:30 – 18:50

**Predicting and following haemostasis in patients with hemophilia and inhibitors**

*Claude Negrier (FR)*

18:50 – 19:10

**Laboratory testing of the new oral factor xa inhibitors**

*Elisabeth Perzborn (DE)*

19:10 – 19:30

**Concluding remarks**

*Kenneth Mann (US)*

19:30 – 19:45

**Alexion Pharmaceuticals**

**Room B-2**

**Atypical Hemolytic Uremic Syndrome (aHUS): New Insights and Emerging Treatment Options**

*Chairperson: Yoshihiro Fujimura (JP)*

**Welcome and opening remarks**

*Yoshihiro Fujimura (JP)*

18:15 – 18:20

**Update on aHUS and the role of complement in disease pathogenesis**

*Craig B. Langman (US)*

18:20 – 18:45

**Eculizumab and terminal complement inhibition as a therapeutic strategy in aHUS**

*Christoph Licht (CA)*

18:45 – 19:25

**New insights on thrombotic microangiopathy (TMA) in Japan**

*Masanori Matsumoto (JP)*

19:25 – 19:40

Satellite Symposia



5

Tuesday July 26, 2011

18:15 - 19:45

**Discussion and concluding remarks**

*Yoshihiro Fujimura (JA)*

19:40 – 19:45

Wednesday July 27, 2011

14:15 - 15:45

**Loyola University Medical Center**

**Room B-1**

**Development of New Anticoagulant Drugs! Are Unmet Needs Met?**

*Chairpersons: Yasuo Ikeda (JP) and Samuel Goldhaber (US)*

*Moderator: M.M. Samama (FR)*

**Welcome and introduction**

*Paul Whelton (US)*

14:30 – 14:40

**Milestones in the development of newer anticoagulant drugs. What is achieved?**

*Jawed Fareed (US)*

14:40 – 14:50

**New oral anticoagulant drugs. The pros and cons.**

*Samuel Goldhaber (US)*

14:50 – 15:00

**Management of cancer associated thrombosis. The role of heparins.**

*M.M. Samama (FR)*

15:00 – 15:10

**Alternative anticoagulant management of heparin compromised patients. Role of anti-FXa and anti-FIIa agents.**

*Jeanine Walenga (US)*

15:10 – 15:20

**Newer parenteral anticoagulant advantages and disadvantages**

*John Fletcher (AU)*

15:20 – 15:30

**Safety issues related to newer anticoagulants**

*Russell Hull*

15:30 – 15:40

**Open discussion forum**

15:40 – 16:00



Tuesday July 26, 2011

18:15 - 19:45

GlaxoSmithKline

Room D

**Challenges in VTE Management in East and West**

Chairpersons: Kazuyuki Shimada (JP) and Masato Sakon (JP)

**Introduction**

Masato Sakon (JP)

14:15 – 14:20

**Risk and incidence of VTE in asian and western countries**

Walter Ageno (IT)

14:20 – 14:40

**Challenges in VTE prevention in north america and europe**

John W. Eikelboom (CA)

14:40 – 15:00

**Pharmacological prophylaxis of VTE in Japan**

Masataka Ikeda (JP)

15:00 – 15:20

**Update in the VTE treatment**

Mashio Nakamura (JP)

15:20 – 15:40

**Concluding remarks**

Kazuyuki Shimada (JP)

15:40 – 15:45

Pfizer

Sakura

**Managing Haemophilia for Life: Treatment Trends in Haemophilia B**

Chairperson: Man-Chiu Poon (CA)

**Chairperson's introduction**

Man-Chiu Poon (CA)

14:15 – 14:20

**The global haemophilia B landscape**

Man-Chiu Poon (CA)

14:20 – 14:35

**Current trends in Asia**

Renchi Yang (CN)

14:35 – 14:55

**Global perspectives on haemophilia B treatment**

Paul Monahan (US)

14:55 – 15:30

**Panel discussion**

Moderated by Chairperson

15:30 – 15:40

Satellite Symposia



7

Tuesday July 26, 2011

18:15 - 19:45

**Chairperson's summary**

*Man-Chiu Poon (CA)*

15:40 – 15:45

**Close**

15:45



Technical Symposia 扉



## Technical Symposia Sessions

Technical Symposia Sessions take place on:

**Wednesday July 27, 2011** **16:00 - 17:00**

**Inspiration Biopharmaceuticals, Inc.**

Room D

**Pfizer Japan, Inc.**

Room B-2



Wednesday July 27, 2011

16:00 - 17:00

**Inspiration Biopharmaceuticals, Inc.**

**Room D**

**Inhibitors to Factor VIII: Use of a Recombinant Porcine FVIII as a Future Treatment Option**

*Chairperson: Amy D. Shapiro (US)*

**Welcome and introduction**

*Amy Shapiro (US)*

16:00 – 16:05

**Overview of Inspiration Development Programs**

*Ed Gomperts (US)*

16:05 – 16:10

**Recombinant porcine FVIII: Ex-vivo results**

*Johannes Oldenburg (DE)*

16:10 – 16:25

**Recombinant porcine FVIII: Phase 1 and 2 studies–Safety and efficacy**

*Johnny Mahlangu (ZA)*

16:25 – 16:40

**Recombinant porcine FVIII: Safety and efficacy among the first acquired inhibitor patients**

*Anne Greist (US)*

16:40 – 16:55

**Questions and answers**

*All*

16:55 – 17:00

**Concluding remarks**

*Amy Shapiro (US)*

17:00

**Pfizer Japan Inc.**

**Room B-2**

**Prevention of Stroke-What Can We Learn from the Recent Clinical Trials?-**

*Chairperson: Shinichiro Uchiyama (JP)*

*Pierre Amarengo (FR)*

16:00-17:00

Technical Symposia



3

Exhibition and Sponsors 扉

## Sponsors

ISTH 2011 would like to thank the following

### PLATINUM SPONSORS

**Baxter**



**Bayer**



Daiichi-Sankyo



novo nordisk®

### GOLD SPONSORS



**Boehringer  
Ingelheim**

biogen idec

HEMOPHILIA



**sobi**

SWEDISH ORPHAN BIOFARM



**SANOFI**



# Sponsors

ISTH 2011 would like to thank the following

Exhibitor and Sponsorship

## SILVER SPONSORS



## BRONZE SPONSORS



## ISTH 2011 Partners



Accumetrics  
Alexion Pharmaceuticals, Inc.  
American Biochemical &  
Pharmaceuticals Limited  
Arteriosclerosis, Thrombosis,  
and Vascular Biology (ATVB)  
Astrazeneca  
Baxter  
Bayer Healthcare  
Biogen Idec Hemophilia  
Boehringer Ingelheim  
Cellix Limited  
Central Japan Railway Company  
Chrono-log Corporation  
CSL Behring GmbH  
Daiichi Sankyo Company,  
Limited  
Diagnostica Stago S.A.S.  
Elsevier B.V.  
Enzyme Research Laboratories /  
R2 Diagnostics, Inc.  
Finggal Link Co. Ltd.  
Fujimori Kogyo  
Gen-Probe  
GlaxoSmithKline  
Grifols International  
Haematologic Technologies, Inc.  
HYPHEN BioMed  
Inspiration Biopharmaceuticals,  
Inc  
Instrumentation Laboratory (II)  
Intelligent Imaging Innovations,  
Inc. (3i)  
ISTH

ISTH 2013  
ISTH SSC 2012  
Japan Pharma Consortium  
Kantar Health  
Kedrion Spa  
Leo Pharma  
LFB France  
Loyola University Chicago -  
Stritch School of Medicine  
Medirox  
Multiplate Services GmbH  
Novo Nordisk Haemophilia  
Foundation (Nnhf)  
Otsuka Pharmaceutical Co., Ltd.  
Pentapharm / Dsm  
Pfizer Inc  
Pfizer Japan Inc.  
Precision Biologic  
Provision Kinetics  
Roche Diagnostics Ltd.  
Rotem  
Sanofi-aventis  
Schattauer Publishers  
Siemens  
Springer Science+business  
Media  
Sysmex Corporation  
Talecris Biotherapeutics  
Technoclone GmbH  
Wiley-Blackwell  
World Federation of Hemophilia



## ISTH 2011 Partners

Accumetrics  
Alexion Pharmaceuticals, Inc.  
American Biochemical &  
Pharmaceuticals Limited  
Arteriosclerosis, Thrombosis,  
and Vascular Biology (ATVB)  
AstraZeneca  
Baxter  
Bayer HealthCare  
Biogen Idec Hemophilia &  
Swedish Orphan Biovitrum  
Boehringer Ingelheim  
Cellix Limited  
Central Japan Railway Company  
Chrono-log Corporation  
CSL Behring GmbH  
Daiichi Sankyo Company,  
Limited  
Elsevier B.V.  
Enzyme Research Laboratories /  
R2 Diagnostics, Inc.  
Finggal Link Co. Ltd.  
FUJIMORI KOGYO CO., LTD.  
(ZACROS)  
Gen-Probe  
GlaxoSmithKline  
Grifols International  
Haematologic Technologies, Inc.  
HYPHEN BioMed  
Inspiration Biopharmaceuticals,  
Inc.  
Instrumentation Laboratory  
Intelligent Imaging Innovations,  
Inc.

ISTH  
ISTH 2013  
ISTH SSC 2012  
Japan Pharma Consortium  
Kantar Health  
Kedrion Spa  
Leo Pharma  
LFB France  
Loyola University Chicago -  
Stritch School of Medicine  
Medirox  
Multiplate Services GmbH  
Novo Nordisk Health Care AG  
Otsuka Pharmaceutical Co., Ltd.  
Pentapharm / Dsm  
Pfizer Inc.  
Pfizer Japan Inc.  
Precision BioLogic  
Provision Kinetics  
Roche Diagnostics Ltd.  
Rotem  
Sanofi  
Schattauer Publishers  
Siemens  
Springer Science+Business  
Media  
Stago  
Sysmex Corporation  
Technoclone GmbH  
Wiley-Blackwell  
World Federation of Hemophilia



# Exhibition Area


The Exhibition is held concurrently with the ISTH 2011 Congress. The coffee break and lunch areas are located adjacent to the booths. Thanks to exhibitors from all over the world, attendees will have a complete overview of new findings in the domain of thrombosis and haemostasis





# Exhibition List

## Exhibitors

COMPANY		Booth Number
Accumetrics	Exhibition Hall 2	39
American Biochemical & Pharmaceuticals Limited	Exhibition Hall 1	34
AstraZeneca	Exhibition Hall 2	35
Baxter	Main Event Hall	3
Bayer HealthCare	Main Event Hall	10, 12
Biogen Idec Hemophilia & Swedish Orphan Biovitrum	Exhibition Hall 2	42
Boehringer Ingelheim	Exhibition Hall 1	24
Cellix Limited	Exhibition Hall 1	23
Chrono-log Corporation	Exhibition Hall 2	41
CSL Behring GmbH	Main Event Hall	11
Daiichi Sankyo Company, Limited	Main Event Hall	13
Enzyme Research Laboratories / R2 Diagnostics, Inc.	Exhibition Hall 2	37
Finggal Link Co. Ltd.	Exhibition Hall 2	70
Fujimori Kogyo	Exhibition Hall 2	40
Gen-Probe	Main Event Hall	19
GlaxoSmithKline	Exhibition Hall 2	45
Grifols International	Exhibition Hall 1	20 
Haematologic Technologies, Inc.	Main Event Hall	16
HemaCore LLC	Exhibition Hall 2	73
HYPHEN BioMed	Exhibition Hall 2	38
Instrumentation Laboratory	Exhibition Hall 2	50
Intelligent Imaging Innovations, Inc.	Exhibition Hall 1	52
ISTH	Main Event Hall	5
ISTH Academy	Hallway to Event Hall	73



# Exhibition List

COMPANY		Booth Number
ISTH 2013 Amsterdam	Main Event Hall	7
ISTH SSC 2012 Liverpool	Main Event Hall	6
Kantar Health	Exhibition Hall 2	71
Kedrion Spa	Exhibition Hall 1	21
Leo Pharma	Exhibition Hall 1	25
LFB France	Exhibition Hall 1	27
Medirox	Exhibition Hall 1	51
Multiplate Services Gmbh	Main Event Hall	17
Novo Nordisk Health Care AG	Main Event Hall	9, 18
Otsuka Pharmaceutical Co., Ltd.	Exhibition Hall 1	26
Pentapharm / Dsm	Exhibition Hall 2	44
Pfizer Inc	Exhibition Hall 2	36
Precision BioLogic	Main Event Hall	15
Provision Kinetics	Exhibition Hall 2	72
Roche Diagnostics Ltd.	Exhibition Hall 2	46
Rotem	Exhibition Hall 1	31
Stago	Main Event Hall	2
Sanofi	Main Event Hall	4
Schattauer Publishers	Exhibition Hall 2	47
Systemex / Siemens	Exhibition Hall 1	30
Technoclone Gmbh	Main Event Hall	14
Wiley-Blackwell	Exhibition Hall 1	33
World Federation of Hemophilia	Exhibition Hall 1	22

## Exhibitors



**Exhibition and Sponsor  
Profiles 扉**

## EXHIBITOR AND SPONSOR PROFILES

### 58TH ANNUAL MEETING OF THE SCIENTIFIC AND STANDARDIZATION COMMITTEE **BOOTH No. 6**

*Committee of the ISTH - SSC 2012, Liverpool*

*Address: ISTH Headquarters  
610 Jones Ferry Road Suite 205  
Carrboro, NC 27510  
tel: +1 919 929-3807  
fax: +1 919 929-3935  
www.ssc2012.com*

SSC 2012 (June 27-30, Liverpool UK) will bring together experts on practical matters related to blood coagulation, hemorrhagic disorders, and related standards and methods of research. It combines the SSC working sessions with educational programming, plenary presentations and hot topics.

### ACCUMETRICS **BOOTH No. 39**

*3985 Sorrento Valley Blvd.  
San Diego, CA 92121  
USA  
www.accumetrics.com*

**Accu:**metrics®

Accumetrics' family of VerifyNow® tests, which measures patient response to all major types of antiplatelet therapies (i.e. aspirin, Plavix®, Effient®, Ticlid®, ReoPro® and Integrilin®), provides physicians with rapid, easy and valuable tools to help make more informed treatment decisions.

### ALEXION PHARMACEUTICALS, INC. **SPONSOR**

*352 Knotter Drive,  
Cheshire, CT 06410,  
USA  
www.alxn.com*

**ALEXION**

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapeutic products aimed at treating patients with severe and life-threatening disease states.

### AMERICAN BIOCHEMICAL & PHARMACEUTICALS LIMITED **BOOTH No. 34**

*Global House,  
1 Ashley Avenue,  
Epsom, Surrey KT18 5AD,  
United Kingdom.  
www.abpcorp.com*

**abp**

American Biochemical & Pharmaceuticals Limited (abp) is well known as the source of RISTO.abp.CETIN (Ristocetin Sulphate). abp now introduces its new range of Platelet Function Reagents, highlighted by COLLAGEN (Equine Tendon Type 1) and Lyophilized Platelets, matched to abp's RISTO.abp.CETIN.



## EXHIBITOR AND SPONSOR PROFILES

### ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY (ATVB)

SPONSOR

10 Circle Drive, Suite 12,  
North Liberty, IA 52317  
USA  
[atvb.ahajournals.org](http://atvb.ahajournals.org)

ATVB publishes research on the biology, prevention, and impact of vascular diseases related to arteriosclerosis and thrombosis from a variety of disciplines including biochemistry, biophysics, cell and molecular biology, clinical investigation, epidemiology, genetics, lipoproteins, nutrition, metabolism, and pathology.

### ASTRAZENECA

BOOTH No. 35

SE-431 83 Mölndal,  
Sweden  
[www.astrazeneca.com](http://www.astrazeneca.com)



AstraZeneca is a global, innovation-driven, biopharmaceutical company with a primary focus on the discovery, development and commercialisation of prescription medicines that fulfil unmet medical needs in important areas of healthcare.

For more information please visit: [www.astrazeneca.com](http://www.astrazeneca.com)

### BAXTER

BOOTH No. 3

One Baxter Way,  
Westlake Village,  
CA 91362  
USA

[www.baxter.com](http://www.baxter.com)



Baxter's BioScience business is a leader in recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders. Baxter continues to innovate, advancing medical science and technology to improve patient care worldwide.

### BAYER HEALTHCARE

BOOTH No. 10 & 12

Bayer HealthCare AG  
Leverkusen  
Germany  
[www.bayerhealthcare.com](http://www.bayerhealthcare.com)



Bayer HealthCare, one of the world's leading, innovative companies in the healthcare and medical products industry, discovers and manufactures products that improve human health and enhance well-being and quality of life worldwide by diagnosing, preventing and treating diseases.

### BIAGEN IDEC HEMOPHILIA

BOOTH No. 42

133 Boston Post Road  
Weston, MA 02493  
USA  
[www.BiogenIdecHemophilia.com](http://www.BiogenIdecHemophilia.com)



We are Biogen Idec Hemophilia, and we're exploring ways to make clotting factors last longer. Backed by more than 30 years of biotechnology leadership and break-through therapies with global impact, we are blazing a new trail of scientific discovery toward long-lasting clotting factors.



## EXHIBITOR AND SPONSOR PROFILES

### BOEHRINGER INGELHEIM

BOOTH No. 24

Bingerstrasse 173,  
55216 Ingelheim,  
Germany  
[www.boehringer-ingelheim.com](http://www.boehringer-ingelheim.com)



The Boehringer Ingelheim group is one of the world's 15 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and approximately 42,000 employees.

### CELLIX LIMITED

BOOTH No. 23

Unit 3.81, Institute of Molecular Medicine,  
Trinity Health Centre,  
James's St., Dublin 8,  
Ireland  
[www.cellixltd.com](http://www.cellixltd.com)



Cellix produces microfluidic pumping solutions and disposable biochips capable of mimicking human capillaries for basic research in the areas of drug discovery, diagnostics and medical research. These are used to investigate cell adhesion, migration and transmigration studies in real-time under physiological conditions of flow – mimicking the same flow rates in human blood vessels.

### CHRONO-LOG CORPORATION

BOOTH No. 41

2 West Park Road,  
Havertown, PA 19083  
USA  
[www.chronolog.com](http://www.chronolog.com)



Manufacturer of the Multi-channel WBA and the Model 700 Whole Blood-Optical Lumi-Aggregation Systems. The Impedance Aggregation mode detects platelet defects and monitors anti-platelet drugs. Lumi-Aggregometry for performing simultaneous Secretion Studies can now be tested in up to four (4) samples at a time.

### CSL BEHRING GMBH

BOOTH No. 11

Emil-von-Behring-Strasse 76  
35041 Marburg  
Germany  
[www.cslobehring.com](http://www.cslobehring.com)

**CSL Behring**  
Biotherapies for Life™

CSL Behring is a global leader in the protein biotherapeutics industry. Passionate about improving the quality of patients' lives, CSL Behring manufactures and markets a range of plasma-derived and recombinant products for the treatment of Hemophilia, von Willebrand's disease and other bleeding disorders. For more information, visit [www.cslobehring.com](http://www.cslobehring.com)

### DAIICHI SANKYO COMPANY, LIMITED

BOOTH No. 13

3-5-1 Nihonbashi-honcho,  
Chuo-ku, Tokyo 103-8426,  
Japan  
[www.daiichisankyo.com](http://www.daiichisankyo.com)



The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients worldwide. The Group is actively engaged in the development of novel treatments for thrombotic disorders.



## EXHIBITOR AND SPONSOR PROFILES

### ELSEVIER B.V.

### SPONSOR

Radarweg 29,  
1043 NX Amsterdam,  
The Netherlands  
[www.elsevier.com](http://www.elsevier.com)



Elsevier is a leading publisher of more than 20,000 products and services, including journals, books, electronic products, services, databases and portals serving the global scientific, technical and medical (STM) communities.

### ENZYM RESEARCH LABORATORIES / R2 DIAGNOSTICS, INC.

### BOOTH No. 37

1801 Commerce Drive,  
South Bend, IN 46628  
USA  
[www.enzymeresearch.com](http://www.enzymeresearch.com)



Enzyme Research Laboratories provides purified proteins, monoclonal and polyclonal antibodies, immunodepleted plasmas, and ELISA reagents for hemostasis research. r2 Diagnostics produces innovative reagents and diagnostic kits for the clinical hemostasis laboratory. Custom projects are also available with both companies.

### FINGGAL LINK CO. LTD.

### BOOTH No. 70

Higashi-Komagata 2-13-13,  
Sumida-Ku, Tokyo 130-0005,  
Japan  
[www.finggal-link.com](http://www.finggal-link.com)

*Finggal Link*

Finggal Link presents ROTEM® as a haemostatic monitoring system for perioperative bleeding management; Calibrated Automated Thrombogram as a physiologic function test measuring thrombin concentration in clotting plasma; and Verigene system as a fully-automated multiplex technology for SNP analysis/infectious disease testing.

### FUJIMORI KOGYO CO., LTD. (ZACROS)

### BOOTH No. 40

1-23-7 Nishi-Shinjuku, Shinjuku-ku, Tokyo  
160-0023 Japan  
[www.zacros.co.jp/english/index.html](http://www.zacros.co.jp/english/index.html)



Fujimori Kogyo is a Japanese manufacturer which was established in 1914. "ZACROS" is our house name. We create new value of packaging, film and equipment. We are now developing T-TAS which is expected to observe thrombogenesis with a Whole Blood.

### GEN-PROBE

### BOOTH No. 19

20925 Crossroads Circle,  
Waukesha, WI 53186  
USA  
[www.gen-probe.com](http://www.gen-probe.com)



Gen-Probe is a leader in molecular diagnostics used for diagnosing infectious diseases, screening donated blood, assessing immune response for transfusion, measuring components of the coagulation pathway, helping ensure transplant compatibility, and aiding biomedical research/drug development.



## EXHIBITOR AND SPONSOR PROFILES

### GLAXOSMITHKLINE

BOOTH No. 45

980 Great West Road,  
Brentford, Middlesex, TW8 9GS  
United Kingdom  
[www.gsk.com](http://www.gsk.com)



GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

### GRIFOLS, S.A.

BOOTH No. 20 & 29

Parque Empresarial Can Sant Joan  
Av. de la Generalitat 152-158  
08174 Sant Cugat del Vallès, Barcelona,  
Spain  
[www.grifols.com](http://www.grifols.com)

# GRIFOLS

Grifols improves people's lives with high quality innovative hospital products and services. Our plasma-derived therapies have outstanding records of efficacy and safety and we are also a world-leading manufacturer of medical devices, analyzers and reagents used by blood banks, transfusion centers and clinical laboratories

## GTI DIAGNOSTICS PLEASE SEE GEN-PROBE LISTING

### HAEMATOLOGIC TECHNOLOGIES, INC.

BOOTH No. 16

57 River Road, Unit 1021,  
Essex Junction, Vermont 05452  
USA  
[www.haemtech.com](http://www.haemtech.com)



Haematologic Technologies, Inc. manufactures highly purified plasma proteins and associated research reagents involved in the regulation of blood coagulation and fibrinolysis. Our product line includes clotting factors, inhibitors and antibodies. Services include: custom protein purification, assay development, and stability testing.

### HAEMONETICS CORPORATION

SPONSOR

400 Wood Road  
Braintree, MA 02184-9114,  
USA  
[www.haemonetics.com](http://www.haemonetics.com)



Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions. Our devices, consumables, IT products, and consulting services deliver a suite of business for blood and plasma component collection and hospital transfusion services. <http://www.haemonetics.com/>.





## EXHIBITOR AND SPONSOR PROFILES

### HEMACORE LLC

BOOTH No. 73

34th street of 8 March, Moscow,  
Russia, 125319  
[www.hemacore.com](http://www.hemacore.com), [www.tromboimager.com](http://www.tromboimager.com)



HemaCore LLC is focused on blood coagulation disorders diagnostics, developing analytical systems and diagnostics kits for the new medical test with tremendous predictive ability of thrombosis. The test is now going into clinical trials and will be on market within 2 years.

### HYPHEN BioMed

BOOTH No. 38

155, Rue d'Eragny,  
95000- Neuville sur Oise,  
FRANCE  
[www.hyphen-biomed.com](http://www.hyphen-biomed.com)



Highly specialized company in the field of Thrombosis, Hemostasis, Fibrinolysis and related Auto-Immune disorders diagnostic reagents, HYPHEN BioMed is highly innovative, a major partner of pharmaceutical laboratories and offers IVDs, research reagents and customized solutions. Products are available worldwide through specialized distributors.

### INSPIRATION BIOPHARMACEUTICALS, INC

SPONSOR

28202 Cabot Road, te 300,  
SuiLaguna Niguel, CA 92677  
[www.inspirationbio.com](http://www.inspirationbio.com)



Inspiration Biopharmaceuticals is the only pharmaceutical company dedicated solely to developing therapies for hemophilia. Products in late-stage clinical trials are a recombinant FIX and a recombinant porcine FVIII. Inspiration's mission: Broaden access to care and improve treatment of hemophilia patients with inhibitors.

### INSTRUMENTATION LABORATORY (IL)

BOOTH No. 50

180 Hartwell Road  
Bedford, MA 01730  
[www.ilww.com](http://www.ilww.com)



IL's exhibit features: the ACL TOP Family of Hemostasis Testing Systems, including the new ACL TOP® 300 CTS in addition to the ACL AcuStar™ system. Combined with the HemosIL® line of reagents, IL offers complete disease state management for the hemostasis lab.

### INTELLIGENT IMAGING INNOVATIONS, INC. (3i)

BOOTH No. 52

5124 Washington St.  
Denver, Colorado  
USA

[www.intelligent-imaging.com](http://www.intelligent-imaging.com)



3i develops multi-modal systems controlled by its SlideBook-5.0™ software for avant-garde fluorescence microscopy imaging and analysis. System options: inverted and fixed stage microscopes, spinning disk confocals, high-power solid state lasers, FLIM, FRET, FRAP, Ratio Imaging, Rapid 4D image acquisition and 2-Photon microscopy.



## EXHIBITOR AND SPONSOR PROFILES



### XXIV ISTH CONGRESS & 59TH ANNUAL SSC MEETING BOOTH No. 7

*Congress secretariat  
MCI - Eurocongress  
Jan van Goyenkade 11  
1075 HP Amsterdam  
The Netherlands  
www.isth2013.org*



Up-to-date information regarding the congress programme is available on the website [www.isth.org](http://www.isth.org). Starting 2nd November 2012 the site will allow participants to register and to submit abstracts.



### KANTAR HEALTH

### BOOTH No. 71

*Kirkgate, 19-31 Church Street,  
Epsom, Surrey, KT17 4PF,  
UK  
www.kantarhealth.com*

**KANTAR HEALTH**

Kantar Health, a global consultancy and marketing insights organisation, is a leading strategic decision support partner to the life sciences industry.

### KARGER PUBLISHERS

### SPONSOR

*S. Karger AG  
Medical and Scientific Publishers  
Allschwilerstrasse 10  
P.O. Box CH – 4009 Basel  
Switzerland  
www.karger.com*

**KARGER**

S. Karger AG is a leading international publisher of books and journals in the basic and medical sciences. Our Journal Acta Haematologica is a well established and internationally recognized publication featuring balanced, wide-ranging coverage of current hematology research.

### KEDRION SPA

### BOOTH No. 21

*Loc. ai Conti - 55051  
Castelvecchio Pascoli - Barga (LU)  
Italy  
www.kedrion.com*



Kedrion is specialized in the development, production, commercialization and distribution of plasmaderivates. Kedrion works in four business areas: Plasmaderivates production and commercialization, Flu vaccines and synthetic pharmaceutical products distribution, Plasma collection and commercialization. Other activities such as technological know-how transfer.

### LFB

### BOOTH No. 27

*3 avenue des Tropiques - BP 305 Les Ulis  
91940 Courtaboeuf cedex  
France  
www.lfb.fr*



LFB is a biopharmaceutical group that develops, manufactures and markets plasma-derived medicinal products, for the treatment of serious and often rare diseases in several major therapeutic fields, namely immunology, hemostasis and intensive care.

In 2010, LFB's turnover reached € 411.6 million; €86.5 million were dedicated to the group's R&D activities.



## EXHIBITOR AND SPONSOR PROFILES

### LOYOLA UNIVERSITY CHICAGO - STRITCH SCHOOL OF MEDICINE

SPONSOR

2160 South First Avenue  
[www.meddean.luc.edu](http://www.meddean.luc.edu)



Loyola University Chicago Stritch School of Medicine serves a Jesuit tradition of academic excellence in education, research and clinical care that embraces social responsibility, service to those in need and respect for diversity of thought, opinion and belief.

### MEDIROX

BOOTH No. 51

SE-611 82 Nyköping, Sweden  
Phone: +46 (0)155 45 44 10  
Fax: +46 (0)155 26 30 11  
[www.mediros.se](http://www.mediros.se)



MediRox has produced instruments, diagnostic reagents and quality control material used in the areas of visco-elasticity and coagulation diagnostics since 1998. Our customers are located within laboratory diagnostics in healthcare. MediRox is ISO9000 certified, and all products are CE marked.

### MULTIPLATE SERVICES GMBH

BOOTH No. 17

Reichenbachstrasse 27,  
80469 Munich,  
Germany  
[www.multiplate.net](http://www.multiplate.net)



Multiplate® is the most widely applied platelet aggregometer in Europe for the monitoring of antiplatelet therapy. The application of Multiplate® delivers superior predictivity for stent thrombosis and allows for superior stratification of major bleeding risk and transfusion requirements.

### NOVO NORDISK HEALTH CARE AG

BOOTH No.9 & 18

Andreasstrasse 15  
CH-8050 Zurich  
Switzerland  
[www.novonordisk.com](http://www.novonordisk.com)



Headquartered in Denmark, Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. For more information, please visit our exhibit or [www.novonordisk.com](http://www.novonordisk.com).

### OTSUKA PHARMACEUTICAL CO., LTD.

BOOTH No. 26

Shinagawa Grand Central Tower 2-16-4 Konan,  
Minato-ku, Tokyo 108-8242,  
Japan  
[www.otsuka.co.jp/en](http://www.otsuka.co.jp/en)



Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a healthcare company with the corporate philosophy; "Otsuka-people creating new products for better health worldwide." Otsuka researches, develops, manufactures and markets innovative, original products with its focus on pharmaceutical products for the treatment of diseases and consumer products for the maintenance of everyday health.



## EXHIBITOR AND SPONSOR PROFILES

### PENTAPHARM / DSM

BOOTH No. 44

Engelgasse 109,  
P.O.Box, CH-4002 Basel,  
Switzerland  
[www.pentapharm.com](http://www.pentapharm.com)



Pentapharm develops and manufactures reagents for coagulation diagnostics. Products include test kits (APC-R FV Leiden, PiCT@UC, Reptilase@Time, TAFI, in-TDT® or OEM tests) and reagent raw materials for further manufacturing of diagnostic kits, including chromogenic and fluorogenic substrates, enzyme inhibitors and activators isolated from snake venom (e.g. Protac®, ecarin, batroxobin).

### PFIZER INC.

BOOTH No. 36

235 E. 42nd Street  
New York, NY 10017  
~~+1-212-733-2323~~  
USA  
[www.pfizer.com](http://www.pfizer.com)



At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

### PFIZER JAPAN INC.

SPONSOR

3-22-7, Bunka Quint Bldg.,  
Yoyogi, Shibuya-ku, Tokyo 151-8589  
Japan  
[www.pfizer.co.jp/pfizer/english/company](http://www.pfizer.co.jp/pfizer/english/company)



As the world's leading research-based pharmaceutical company, Pfizer discovers, develops, manufactures, and markets leading prescription medicines for humans and animals and many of the world's best-known consumer healthcare brands.

### PRECISION BIOLOGIC

BOOTH No. 15

140 Eileen Stubbs Avenue,  
Dartmouth, NS B3B 0A9  
Canada  
[www.precisionbiologic.com](http://www.precisionbiologic.com)

PrecisionBioLogic

Precision BioLogic develops, manufactures and sells CRYOcheck™ frozen controls, calibrators and reagents used for testing in coagulation labs around the globe. Our unique approach to serving customers is built on superior products, commitment to customer support and attention to detail.

### PROVISION KINETICS

SPONSOR

107 Skyline Drive,  
Arlington, Wisconsin 53911  
USA  
[www.provisionkinetics.com](http://www.provisionkinetics.com)



Provision Kinetics manufactures and distributes the Kinetichrome line of Anti-IIa and Anti-Xa heparin/LMW-heparin test kits. Our kits are designed and optimized for quality control and specification testing by pharmaceutical and medical device manufacturers.



## EXHIBITOR AND SPONSOR PROFILES

### ROCHE DIAGNOSTICS LTD.

BOOTH No. 46

Forrenstrasse,  
6343 Rotkreuz,  
Switzerland  
[www.roche.com](http://www.roche.com)



Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.

### TEM INTERNATIONAL GMBH

BOOTH No. 31

Martin-Kollar-Strasse 13,  
81829 Munich,  
Germany  
[www.rottem.de](http://www.rottem.de)



Tem International provides patient diagnostic devices for acute bleeding. The ROTEM® system provides rapid and clear results in whole blood. It gives a rapid overview about the coagulation status after 10 minutes allowing controlled targeted therapies and avoiding unnecessary transfusion.

### SANOFI

BOOTH No. 4

174 avenue de France  
75013 Paris  
France  
[en.sanofi.com/at-a-glance/edito.asp](http://en.sanofi.com/at-a-glance/edito.asp)



Sanofi is a diversified global healthcare company, focused on patients' needs. A worldwide presence, market leadership in vaccines with the Group's vaccine division Sanofi Pasteur, major biological products and a strong and long-established presence in emerging markets: these are the core strengths of sanofi. Company business activities also include consumer healthcare (OTC) products, generics and animal health products.

### SCHATTAUER PUBLISHERS

BOOTH No. 47

Hölderlinstr. 3  
70174 Stuttgart  
Germany  
[www.thrombosis-online.com](http://www.thrombosis-online.com)



THROMBOSIS AND HAEMOSTASIS, published since 1957, promotes standards in haematology, and is a leader at the cutting edge of basic and applied research in vascular biology. It is an invaluable resource for haematologists, clinical pharmacologists, cardiologists, surgeons, gynaecologists, internal specialists and laboratory physicians.



## EXHIBITOR AND SPONSOR PROFILES

### SIEMENS

BOOTH No. 30

**SIEMENS**

Siemens Healthcare Diagnostics Products GmbH  
Michael Nöh,  
Head of Hemostasis Business Unit Global Marketing  
Emil-von-Behring-Straße 76  
35041 Marburg  
Germany  
[www.siemens.com/healthcare](http://www.siemens.com/healthcare)

Siemens Healthcare Diagnostics, a global leader in clinical diagnostics, provides healthcare professionals in hospital, reference, and physician office laboratories and point-of-care settings with the vital information required to accurately diagnose, treat, and monitor patients. Our innovative portfolio of performance driven solutions and personalized customer care combine to streamline workflow, enhance operational efficiency, and support improved patient outcomes.

### SPRINGER SCIENCE+BUSINESS MEDIA

SPONSOR

Dordrecht,  
the Netherlands  
[www.springer.com](http://www.springer.com)

 **Springer**

Knowledge, Information and Quality are the three things that shape Springer's business activities. We develop, manage and disseminate knowledge – through books, journals and the Internet. We work with the world's best academics and authors in long-standing loyal partnerships based on mutual trust and we are always open to new input.

### STAGO

BOOTH No. 2

9 rue des Frères Chausson - 92600  
Asnières sur Seine  
France  
[www.stago.com](http://www.stago.com)

 **Stago**

Stago dedicates its research and innovative skills to develop and improve the accuracy of the medical diagnostic. The firm formulates, manufactures and markets worldwide, a broad range of reagents and fully automated systems for Haemostasis & Thrombosis.

Thanks to its Haemostasis expertise, Stago is recognized and is in a position to cooperate with the scientific community worldwide.

### SYSMEX CORPORATION

SPONSOR

1-5-1, Wakinohama-kaigandori, Chuo-ku,  
Kobe, Hyogo 651-0073,  
Japan  
[www.sysmex.co.jp](http://www.sysmex.co.jp)

 **sysmex**

Sysmex has given birth to a wide spectrum of products and services that feature advanced technology in the diagnostics field. At present, Sysmex's products and services are being used at medical institutions in over 160 countries around the world.



## EXHIBITOR AND SPONSOR PROFILES

### TECHNOCLONE GMBH

BOOTH No. 14

*Brunner Str. 67,  
1230 Vienna,  
Austria  
www.technoclone.com*



TECHNOCLONE is a world leading producer of global and special coagulation tests. The new optimized Ceveron® alpha TGA offers the unique feature of fully automated thrombin generation measurement in the routine: CV <5% and assay times <20min Peak Thrombin.

### WILEY-BLACKWELL

BOOTH No. 33

*350 Main Street  
Commerce Place  
Malden, MA 02148  
USA  
www.wiley.com*



Visit our booth for your copy of Journal of Thrombosis and Haemostasis, official journal of ISTH. Don't miss the 2011 State of the Art issue alongside Wiley-Blackwell's leading books, journals and databses bringing you the latest in hemostasis and thrombosis.

### WORLD FEDERATION OF HEMOPHILIA

BOOTH No. 22


*1425 Rene Levesque Boulevard West,  
Suite 1010, Montreal,  
Quebec, ~~Canada~~ H3G 1T7  
Canada  
www.wfh.org*



Through training programs, educational activities, and international congress, the World Federation of Hemophilia improves and sustains treatment for all people with inherited bleeding disorders. Visit our booth to enter to win free registration to the 2012 WFH Congress in Paris.



# Layout of the Congress Venue



## ISTH2011 Kyoto, Japan Floorplan






# Registration

## Registration

Registration fee	On-site
ISTH Member	JPY 80,000
ISTH Non Member in the process of acquiring membership	JPY 80,000
ISTH Non Member	JPY 100,000
Trainees and Students <sup>*1</sup> up to the age of 38	JPY 25,000
Nursing Forum Attendees	JPY 25,000
Exhibitors	JPY 50,000
Accompanying Persons <sup>*2</sup>	JPY 10,000
SSC Meeting attendance only Saturday July 23, Sunday July 24, 2011 <sup>*3</sup>	free
Welcome Reception	free
All Congress Party <sup>*4,5</sup>	JPY 7,500




### Fees payable in Japanese Yen (JPY) only.

- \*1 For trainees and students, a letter of confirmation from the Head of Department on departmental letterhead must be submitted. Students older than 38 can request a waiver from this age restriction, by providing a brief explanation and a letter from the Department Chair confirming their student status.
- \*2 Accompanying person must be a partner or a spouse of the registered participant.
- \*3 SSC-ONLY meeting registration is Free of Charge and good for two days.
- \*4 All Congress Party will be held on Wednesday 27, July 2011. On-Site Ticket Sale for All Congress Party is available only if there are still spaces.
- \*5 All Congress Party  open only for registered participants and their registered accompanying persons.



# Registration

## Entitlements


	ISTH Sessions	SSC Sessions	Opening Ceremony	Welcome Reception	Mini Program	Congress Bag	Final Program	SOA Book and CD-ROM	Abstract CD-ROM	Access to Exhibition Area	Scheduled Coffee Breaks	Congress Shuttle Service	Free Lunch Box
ISTH Member													
ISTH Non Member													
Trainees / Students													
Nursing Attendee 													
Exhibitors													
(Special Pass for Exhibitors) 													
Day Pass  for Symposium													
Accompanying Persons													
SSC Only (no badge)													
Press / Media													

## On-site Registration

The Registration Desk will be open as follows:

Saturday July 23, 2011 07:00 - 18:00  
 Sunday July 24, 2011 07:30 - 19:30  
 Monday July 25, 2011 07:30 - 18:30  
 Tuesday July 26, 2011 07:30 - 18:30  
 Wednesday July 27, 2011 07:30 - 18:30  
 Thursday July 28, 2011 07:30 - 17:45

## Cancellation of Registration

Cancellation must be made by informing the Registration Desk in writing either by fax or e-mail. For cancellations received after May 31, 2011, no refund are available. 



# Hotel and Transportation Information

## Hotels

JTB Global Marketing & Travel Inc. (JTB GMT) has been appointed as the official travel agent for the ISTH 2011 and handles hotel accommodations and tours. JTB GMT has reserved a large number of rooms in different hotel categories and offers discounted room rates for Congress participants. Only reservations made through JTB GMT will benefit from these rates. All of these hotels are located in the Kyoto City Center, or near the Convention Center. Please also note that availability of hotel accommodations at the time of on-site registration may be limited.

## Methods of Payment

No reservation will be confirmed in the absence of payment. Personal checks are not accepted. All payment must be in Japanese yen. If the remittance covers more than one person, please inform us the name of each participant.

Payment should be in the form of:

- One of the following credit cards:
  1. VISA 2. MasterCard 3. Diners Club 4. AMEX 5. JCB
- A bank transfer to JTB Global Marketing & Travel Inc.

## Cancellation

In the event of cancellation, the following cancellation fees will be deducted before any refund is made.

Up to 10 days before the first night of stay	-----	None
9 to 2 days before	-----	20% of daily room charge
1 day before	-----	80% of daily room charge
On the day of arrival or no notice given	-----	100% of daily room charge

If you have any inquiries please contact:

### **JTB Global Marketing & Travel Inc.**

JTB Bldg. 14F 2-3-11 Higashishinagawa,  
Shinagawa-ku, Tokyo 140-8604, Japan

Tel: +81-3-5796-5445

Fax: +81-3-5495-0685

E-mail: [isth2011@gmt.jtb.jp](mailto:isth2011@gmt.jtb.jp)



# Hotel and Transportation Information

## Map of Kyoto



- ① Grand Prince Hotel Kyoto
- ④ Kyoto Brighton Hotel
- ⑦ ANA Hotel Kyoto
- ⑪ Kyoto Kokusai Hotel
- ⑭ Kyoto New Hankyu Hotel
- ⑰ Hotel Avanshell Kyoto
- ⑲ Hotel Keihan Kyoto
- ⑳ Hotel Sunroute Kyoto
- ㉑ Kyoto Dai-ni Tower Hotel
- ㉒ Rhino Hotel Kyoto
- ㉓ Hotel Sunroute Kyoto
- ㉔ Court Hotel Kyoto Shijo
- ㉕ Hotel Hokke Club Kyoto
- ㉖ Hyatt Regency Kyoto Hotel

- ② Westin Miyako Hotel Kyoto
- ⑤ Hotel Granvia Kyoto
- ⑧ Hotel Monterey Kyoto
- ⑫ Kyoto Royal Hotel & Spa
- ⑮ Kyoto Century Hotel
- ⑱ Karasuma Kyoto Hotel
- ㉑ Kyoto Tower Hotel
- ㉒ Mitsui Garden Hotel Kyoto Shijo
- ㉓ Kyoto Garden Hotel
- ㉔ Hotel Oaks Kyoto Shijo
- ㉕ Hotel Rich Kyoto
- ㉖ APA Hotel Kyoto Ekimae
- ㉗ Kyoto Daiichi Hotel

- ③ Kyoto Hotel Okura
- ⑥ Hotel Nikko Princess Kyoto
- ⑩ Rihga Royal Hotel Kyoto
- ⑬ Kyoto Tokyu Hotel
- ⑯ New Miyako Hotel
- ⑲ Mitsui Garden Hotel Kyoto Sanjo
- ㉑ Hearton Hotel Kyoto
- ㉒ Aranvert Hotel Kyoto
- ㉓ Hotel Unizo Kyoto
- ㉔ Kyoto Central Inn
- ㉕ Hotel Alpha Kyoto
- ㉖ APA Hotel Kyoto Eki-Horikawa-Dori
- ㉗ Via Inn Kyoto Shijo Muromachi



# Hotel and Transportation Information

## The Official Congress Hotels

Class	Map No.	Hotel Name (Check-in & out time)	Room Rates (Japanese Yen / night / room)					Access to/from ICCK by subway	
			Double or Twin (2beds) Room		Single (1bed) Room	Double or Twin (2beds) Room			Single (1bed) Room
			Room rate Double Use Tax included	Room Rate Single Use Tax Included	Room Rate Single Use Tax Included	Room Rate Double Use With Breakfast Tax Included	Room Rate Single Use With Breakfast Tax Included		Room Rate Single Use With Breakfast Tax Included
A	1	Grand Prince Hotel Kyoto	19,000	17,000	---	24,000	19,500	---	ICCK 5 min walk
	2	Westin Miyako Hotel Kyoto /Deluxe room	32,000	28,500	---	37,800	31,400	---	Tozai Keage st 3 min
		Westin Miyako Hotel Kyoto /Superior room	23,000	19,500	---	28,800	22,400	---	
	3	Kyoto Hotel Okura	26,000	25,000	18,000	31,000	27,500	20,500	Tozai Shiyakushomae sta 1 min
	4	Kyoto Brighton Hotel	25,000	23,000	---	30,600	25,800	---	Imadegawa st. 15 min
	5	Hotel Granvia Kyoto	25,000	23,000	---	30,000	25,500	---	Kyoto st 3 min
41	Hyatt Regency Kyoto /Except July.23	24,150	24,150	---	30,150	27,150	---	Kyoto st 20 min.	
	Hyatt Regency Kyoto / July 23	42,000	42,000	---	48,000	45,000	---		
B	7	ANA Hotel Kyoto	17,000	14,000	11,000	21,000	16,000	13,000	Tozai Nijojo-mae sta. 5 min
	9	Hotel Monterey Kyoto	17,500	15,000	11,000	22,500	17,500	13,500	KarasumaOike st. 3 min
	10	RIHGA Royal Hotel Kyoto	18,000	14,000	11,500	22,000	16,000	13,500	Kyoto st. 10 min
	11	Kyoto Kokusai Hotel	15,000	13,000	8,500	18,000	14,500	10,000	Tozai Nijojo-mae sta. 5 min
	12	Kyoto Royal Hotel & Spa	17,000	14,500	11,500	20,000	16,000	13,000	Tozai Shiyakushomae sta. 5 min
	13	Kyoto Tokyu Hotel	15,700	12,300	10,300	19,700	14,300	12,300	Gojo st. 10 min
	14	Kyoto New Hankyu Hotel	20,000	17,500	11,000	24,200	19,600	13,100	Kyoto st. 5 min
	15	Kyoto Century Hotel	16,000	13,000	11,500	20,000	15,000	13,500	Kyoto st. 5 min
	16	New Miyako Hotel	18,000	15,000	---	22,200	17,100	---	Kyoto st. 7 min
	C	17	Hotel Avanshell Kyoto	14,000	10,000	10,000	14,500	10,500	10,500
18		Karasuma Kyoto Hotel	17,000	14,500	9,500	20,000	16,000	11,000	Shijo st. 1 min
19		Mitsui Garden Hotel Kyoto Sanjo	14,000	11,500	8,500	15,000	12,500	9,500	KarasumaOike st. 5 min
20		Hotel Keihan Kyoto	12,000	8,900	7,900	14,000	9,900	8,900	Kyoto st 5 min
21		Kyoto Tower Hotel	18,000	16,000	10,000	19,000	17,000	10,500	Kyoto st. 5 min
22		Hearton Hotel Kyoto	13,000	10,500	8,000	14,000	11,500	9,000	KarasumaOike st. 5 min
23		Hotel Gimmond Kyoto	14,000	10,000	8,000	16,000	11,000	9,000	KarasumaOike st. 5 min
24		Mitsui Garden Hotel Kyoto Shijo	16,000	12,500	9,500	18,000	13,500	10,500	Shijo st. 10 min
25		Aranvert Hotel Kyoto	14,000	11,000	8,000	16,000	12,000	9,000	Gojo st. 3 min
26		Kyoto Dai-ni Tower Hotel	16,000	14,000	9,000	18,400	15,200	10,200	Kyoto st. 5 min
D	27	Kyoto Garden Hotel	12,000	10,000	7,500	14,000	11,000	8,500	KarasumaOike st. 5 min
	28	Hotel Unizo Kyoto	13,000	11,550	7,000	15,750	12,600	8,400	KarasumaOike st. 7 min
	29	Rhino Hotel Kyoto	13,000	12,000	9,500	15,000	13,000	10,500	Hankyu Saiin st. 3 min
	30	Hotel Oaks Kyoto Shijo	11,000	8,500	6,500	13,000	9,500	7,500	Shijo st. 6 min
	31	Kyoto Central Inn	9,450	7,000	5,500	10,600	7,600	6,100	Shijo st. 6 min
	32	Hotel Sunroute Kyoto	12,500	10,700	8,200	14,900	11,900	9,400	Gojo st. 7 min
	33	Hotel Rich Kyoto	13,500	13,500	7,500	15,390	14,445	8,445	Shijo st. 6 min
	34	Hotel Alpha Kyoto	12,600	10,000	7,000	14,600	11,000	8,000	KarasumaOike st. 5 min
	35	Court Hotel Kyoto Shijo	12,500	9,500	6,500	13,550	10,550	7,550	Shijo st. 6 min
	40	Via Inn Kyoto Shijo Muromachi	---	---	6,500	---	---	6,500	Shijo st. 5 min
	36	APA Hotel Kyoto-ekimae	NA	NA	8,400	NA	NA	9,500	Kyoto st. 6 min
	37	APA Hotel Kyotoeki-Horikawadori	NA	NA	8,500	NA	NA	9,500	Kyoto st. 7 min
	38	Hotel Hokke Club Kyoto	12,000	11,000	7,000	14,000	12,000	8,000	Kyoto st. 5 min
39	Kyoto Daiichi Hotel	12,000	---	6,500	12,800	---	6,900	Kujo st. 5 min	

Room rates include service charge and 5% consumption tax.



# Hotel and Transportation Information

## Transportation

A complimentary shuttle service is available between the official Congress hotels and the congress center (ICC Kyoto) from July 23 to July 28.

Kyoto is a very convenient city with a highly developed train network. If your hotel is located near a train station, we recommend you to take a train. (Please see Kyoto Hotel Map on page < ページ番号が決まったら入れてください > to check the closest station to your hotel.)

## ISTH2011 Shuttle Bus Route

Red/Bus Stop (TBC)  
Black/Neighboring Hotels

	A	B	C	D	E
	Hotel	Hotel	Hotel	Hotel	Hotel
1	<b>New Miyako Hotel</b>	<b>Hotel Granvia Kyoto</b>	<b>Karasuma Kyoto Hotel</b>	<b>Aranvert Hotel Kyoto</b>	<b>Hyatt Regency Kyoto</b>
	<i>Hotel Keihan Kyoto</i>	<i>Kyoto Century Hotel</i>	<i>Hotel Nikko Princess Kyoto</i>		
	<i>Kyoto Dai-Ichi Hotel</i>	<i>Kyoto Tower Hotel</i>	<i>Mitsui Garden Hotel Kyoto Shijo</i>		
		<i>Kyoto Dai-ni Tower Hotel</i>	<i>Rhino Hotel Kyoto</i>		
		<i>Hotel Hokke Club Kyoto</i>	<i>Via Inn Kyoto Shijo Muromachi</i>		
	<i>Kyoto New Hankyu Hotel</i>				
2	<b>Rihga Royal Hotel Kyoto</b>	<b>Kyoto Brighton Hotel</b>	<b>Hotel Monterey Kyoto</b>	<b>Kyoto Hotel Okura</b>	<b>Westin Miyako Hotel Kyoto</b>
	<i>APA Hotel Kyoto Ekimae</i>		<i>Mitsui Garden Hotel Kyoto Sanjo</i>	<i>Kyoto Royal Hotel &amp; Spa</i>	
			<i>Hearton Hotel Kyoto</i>	<i>Hotel Alpha Kyoto</i>	
			<i>Hotel Gimmond Kyoto</i>	<i>Hotel Unizo Kyoto</i>	
			<i>Kyoto Garden Hotel</i>	<i>Kyoto Central Inn</i>	
3	<b>Kyoto Tokyu Hotel</b>		<b>Hotel Avanshell Kyoto</b>		
4	<b>ANA Hotel Kyoto</b>				
	<i>Kyoto Kokusai Hotel</i>				
	<i>Other reservation</i>				
	<b>ICC Kyoto</b>	<b>ICC Kyoto</b>	<b>ICC Kyoto</b>	<b>ICC Kyoto</b>	<b>ICC Kyoto</b>



# Hotel and Transportation Information

“How To get there”




From Kansai International Airport, you can easily get to the Conference Center by public transportation. It is 75 minutes by Airport Express, 95 minutes by Limousine Bus to Kyoto station. From there it is only a few stops by local subway line to the nearest station (Kokusai kaikan station) to the Conference Center. If you arrive at Narita Airport close to Tokyo, you could take Narita Express Train to Tokyo station, then Bullet Train to Kyoto station. Another option is Nagoya Centrair Airport which is approximately an hour away from Kyoto Station. All the signs in the stations are available in English.



# ISTH 2011 Congress Information

## Abstract CD-Rom

The Abstract CD-Rom includes all submitted abstracts as well as the abstracts of the Plenary, Presidential Symposium, State-of-the-Art and Symposia. It may be received at booth #4 in exchange for the Abstract CD-Rom ticket. 



## ATM (Automatic Teller Machine)


There are ATM's located at the "Kokusai Kaikan" subway station, the closest station of ICC Kyoto. Please ask the General Information Desk for further information.

## Badges

Congress Name Badges are issued upon check in at the Congress site and must be visible and used at all times throughout the ICC Kyoto for access to the meetings and official social functions.

## CME

### AMA PRA Credits

The Congress has been reviewed by the American Medical Association and approved for a maximum of 34 AMA PRA Category 1 Credits™. Credit claim forms will be available in your congress bag. In order to receive credit you must complete the claim form, pay the \$35 USD processing fee (waived for AMA members), and return the form to the AMA monitor's desk during the Congress or fax the form to AMA headquarters after the conference. A credit certificate will be emailed to physicians within 4 weeks of receipt of the claim form. Physicians should claim only the credit commensurate with the extent of their participation in the activity. One credit may be claimed for each hour of participation in approved sessions. If you should have any questions about this process, you may contact the AMA directly (Rita LePard, [rita.lepard@ama-assn.org](mailto:rita.lepard@ama-assn.org)/ phone:  312-464-5196/fax: 312-464-5830). Further information can be obtained at [www.ama-assn.org/go/internationalcme](http://www.ama-assn.org/go/internationalcme).

## Congress Bag

The Congress Bag will be distributed to registered participants at the Congress bag counter beside the Registration Desk.

## Congress Documents

The Congress documents should be collected on-site at the Registration Desk at the ICC Kyoto.





# ISTH 2011 Congress Information

## Congress News Daily

The ISTH 2011 Congress will feature a newspaper that will include scientific highlights. A new issue will be distributed each day from Monday, July 25 to Thursday, July 28.

## Congress Organizer

Japan Convention Services, Inc  
Daido Seimei Kasumigaseki Bldg.  
1-4-2 Kasumigaseki, Chiyoda-ku,  
Tokyo 100-0013, Japan

Tel: +81-3-3508-1202

Fax: +81-3-3508-0820

E-mail: [isth2011@convention.jp](mailto:isth2011@convention.jp)

Website: <http://www.isth2011.com/>



## Duplicating / Recording

Any form of duplication (recording, audio taping, digital taping, photography and video) of sessions including Poster Presentations is prohibited without the expressed written consent of the Congress Organizers.

## Exhibition

### Exhibition Area Information

The Congress Exhibition, featuring commercial displays of international organizations, sponsor pharmaceutical companies, media publishers and scientific societies, catering and lounge areas will be located in Event Hall and Exhibition Hall 1 & 2 (tent) of the Kyoto Convention Center in Kyoto.

### Exhibition Area Schedule

Monday	July 25, 2011	10:30 - 18:00
Tuesday	July 26, 2011	10:30 - 18:00
Wednesday	July 27, 2011	09:30 - 14:00
Thursday	July 28, 2011	09:30 - 16:00



# ISTH 2011 Congress Information

## Food & Beverage

### Coffee Breaks

Coffee breaks are included in the registration fee. Coffee will be served to delegates in the Exhibition Area, from Monday to Thursday during the session breaks. (For times, please see the Program at a Glance on page <p000>). Coffee breaks will be provided outside the meeting rooms during the SSC Annual Meeting and Education Program on Saturday and Sunday. It will also be possible to purchase coffee at the main lounge of ICC Kyoto.

### Lunch

Lunch bags are included in the registration fee, and may be collected at the Exhibition area upon presentation of your voucher.

## Future Meetings

Information about Future Meetings is available at booth #6 (ISTH SSC 2012 Liverpool) and booth #7 (ISTH 2013 Amsterdam) in the Exhibition Area.

## Internet

Wifi is provided at the main lounge of ICC Kyoto.

Member Café is situated inside the Exhibition.

**Baxter**

## ISTH General Membership Assembly

The ISTH Membership Meeting will take place on Wednesday July 27, from 11:00-11:15 in the Main Hall.

## ISTH Secretariat

The International Society on Thrombosis and Haemostasis Secretariat is located in Room 157 on the first Floor of the ICC Kyoto.

## Language

English is the official Congress language, and no translation services are offered by ISTH 2011.

## Messages

Participants can use the message options available at the Business Center located in the main lounge.





# ISTH 2011 Congress Information

## Media / Press Room

The Media Room is located in Room 522 on the fifth floor of the ICC Kyoto.

## Mini Program

A Mini Program will be handed out to participants  Inspiration 

## Poster Sessions

Poster sessions will take place in Exhibition Hall 1 & 2 (tent) of ICC Kyoto. Posters should be displayed on the assigned board during the following time on the day of their presentation. (Poster number and pins will be available at the poster board). The presenting authors for posters should attend their poster and be available for discussion on the day of  poster session. Posters should be dismantled during the designated time on the day of their presentation. Any posters remaining after the designated time will be discarded by ISTH2011

## Poster chedule

	<i>Monday 25.Jul</i>	<i>Tuesday 26.Jul</i>	<i>Wednesday 27.Jul</i>	<i>Thursday July 28</i>
<i>Set-up</i>	<i>9:00-10:30</i>	<i>9:00-10:30</i>	<i>9:00-10:00</i>	<i>9:00-10:30</i>
<i>Discussion</i>	<i>12:15-13:15</i>	<i>12:15-13:15</i>	<i>13:00-14:00</i>	<i>12:15-13:15</i>
<i>Dismantle</i>	<i>17:00-18:30</i>	<i>17:00-18:30</i>	<i>14:00-15:00</i>	<i>14:00-16:00</i>

## Registration k

The Registration Desk will be open as follows:

Saturday July 23, 2011 07:00 - 18:00

Sunday July 24, 2011 07:30 - 19:30

Monday July 25, 2011 07:30 - 18:30

Tuesday July 26, 2011 07:30 - 18:30

Wednesday July 27, 2011 07:30 - 18:30

Thursday July 28, 2011 07:30 - 17:45

Please arrive early if you wish to register on-site.

Please also note that availability of  congress party at that time may be limited.



# ISTH 2011 Congress Information

## Rules

### Smoking Policy

The ISTH 2011 Congress is a non-smoking event. Participants are kindly requested to refrain from smoking in the ICC Kyoto, including the Exhibition Area.

### Mobile Phones

Delegates are kindly requested to keep their mobile phones silenced in the rooms where scientific and educational sessions are being held, as well as during poster sessions.

## Speaker's Preview Room

Speakers are asked to bring their formatted PowerPoint presentations to the Speaker's Preview Room (Room 104) at least two hours before their session. Files from key drives or CD-ROMs can be transferred to the Congress servers at that time. All conference rooms contain state-of-the-art technical equipment.

### The Speakers' Preview Room will be open as follows:

Friday	July 22, 2011	15:00 - 18:00
Saturday	July 23, 2011	07:30 - 19:00
Sunday	July 24, 2011	07:30 - 19:00
Monday	July 25, 2011	07:30 - 19:00
Tuesday	July 26, 2011	07:30 - 19:00
Wednesday	July 27, 2011	07:30 - 16:00
Thursday	July 28, 2011	08:00 - 17:45

## State-of-the-Art Book and CD-Rom

The State-of-the-Art Book and is inside the Congress Bag. The CD-Rom may be received at booth #9 in exchange for the SOA CD-Rom ticket.



## Transportation from / to Hotels

### Shuttle Service

A complimentary shuttle service between ICC Kyoto and official Congress Hotels are available to participants from Saturday, July 23 to Thursday, July 28. For shuttle bus route please see page <p000>. The shuttle bus time table is handed out at ICC Kyoto and official Congress Hotels.

### Train

Kyoto is a very convenient city with highly developed train network. If your hotel is located near a train station, we recommend you to take a train.



# ISTH 2011 Congress Information

## Website of ISTH 2011

Updated information is available on the website: [www.isth2011.com](http://www.isth2011.com).

## ISTH 2011 Smart Planner

ISTH 2011 Smart Planner is an application available for iPod Touch / iPhone / iPad and android OS devices. The password for the application has been sent to all ISTH members and pre-registered participants. You may read all ISTH 2011 abstracts, check the Congress program, and make your own schedule via ISTH 2011 Smart Planner!



# Kyoto Information



## About Kyoto

Kyoto is special because it reigned as national capital for more than a 1000 years, which is not only the longest that any city has ruled Japan but also it was the center of activity throughout the formative years when what we now think of as Japanese culture was born, developed and refined. Kyoto is the city where today during your visit you can delve into Japanese history as well as experience the way of living that keeps Kyoto at the forefront of developing emerging technologies.

Japanese history and heritage lives on in the 1.5 million population modern Kyoto: Seventeen UNESCO World Cultural Heritage Sites are situated in a cityscape dominated by 2000 temples and shrines. The city offers you endless opportunities to gain meaningful hands-on experience of rich Kyoto culture through tea ceremony, sake brewing, kimono wearing, swordsmanship, and more.

At the same time Kyoto universities, research institutions, and pioneering companies (Nintendo, Shimadzu, Omron, Kyocera) are at the center of developing emerging technologies that will drive the world economy in the 21st century.



Kyoto is renowned for its safety and the compactness of Kyoto makes for wonderful strolling during free time. From the moment of arrival at Kansai International Airport - just



# Kyoto Information

75 minutes from the city center - you will be pampered with everything you need from refined Kyoto service.


\*For more information, please visit the following links:

- VISIT JAPAN 2011-JAPAN Tourism Agency  
<http://www.visitjapan.jp/eng/index.html>
- Kyoto Tourism Federation  
<http://www.kyoto-kankou.or.jp/english/>
- Kyoto City Web  
<http://www.city.kyoto.jp/koho/eng/index.html>
- City of Kyoto and Kyoto Tourism Council  
<http://www.kyoto.travel/>

## Getting to Kyoto

Kyoto is very accessible from overseas. It only takes a little over an hour by Airport Express Train from the nearest international airports (Kansai International Airport). Many direct flights around 11 hours are available from US and Europe, even closer from Asia and Australia.

From Kansai International Airport, you can easily get to the Conference Center by public transportation. It is 75 minutes by Airport Express, 95 minutes by Limousine Bus to Kyoto station. From there it is only a few stops by local subway line to the nearest station (Kokusaikaikan station) to the Conference Center. If you arrive at Narita Airport close to Tokyo, you could take Narita Express Train to Tokyo station, then Bullet Train to Kyoto station. Another option is Nagoya Centrair Airport which is approximately an hour away



# Kyoto Information

from Kyoto Station. All the signs in the stations are available in English.

## Getting Around

Kyoto is a convenient city with highly developed Train network. You usually do not need a car to move around.

### Subways

Two subway lines intersect Kyoto: the Karasuma line running north to south and the Tozai line running east to west. The Karasuma line is the fastest way to travel from north to south. Tickets can be purchased from the vending machines in the subway stations. Instructions for the machines are available in English. The electronic signs which show the names of the next stop in subway cars in subway cars are available in English as well.

### Trains

Kyoto is connected to Osaka via the Hankyu (downtown), Keihan (along east side of river) and JR (from Kyoto Stn.) lines; and to Nara by the JR and Kintetsu lines (both from Kyoto Stn.). The way to purchase tickets is essentially the same as on the subway.

**\*For more information, please visit the following links:**

Public transport in Kyoto:

<http://www.city.kyoto.jp/koho/eng/access/transport.html>

Kyoto train/subway route map

[http://www.kansaiscene.com/documents/Kyoto\\_Train\\_Subway\\_Map.pdf](http://www.kansaiscene.com/documents/Kyoto_Train_Subway_Map.pdf)

Kyoto city bus travel map

[http://www.city.kyoto.lg.jp/kotsu/cmsfiles/contents/0000019/19770/bus\\_navi\\_en200801.pdf](http://www.city.kyoto.lg.jp/kotsu/cmsfiles/contents/0000019/19770/bus_navi_en200801.pdf)

### Taxi

The normal fare is ¥630 for the first two kilometers, and more for additional distance. After midnight there is a 20% surcharge.

## Food

Japan is renowned for its regional specialties and Kyoto is no exception. Of particular note is *Kaiseki ryori*, an extremely refined cuisine consisting of multiple courses. It makes use of fresh seasonal ingredients, prepared in a simple manner to enhance the inherent flavor of the food, and elegantly arranged to appeal to the visual senses. There are also a lot of inexpensive food courts around Kyoto station to entertain you.





# Kyoto Information

## Climate

It becomes seriously hot and humid in summer, and it is hot even during nights. The average temperature of July in Kyoto is 26.8°C. (The average high temperature in July is 31.5 while the low is 23.2.)

## Currency

The unit of Japanese currency is yen (JPY, ¥). Coins are available in denominations of 1, 5, 10, 50, 100 and 500 yen and bank notes in denominations of 1,000, 2,000, 5,000 and 10,000 yen.

## Money Exchange

Cash or travelers checks can be exchanged at any "Authorized Foreign Exchange Bank" (signs are displayed in English) or at some of Kyoto's larger hotels and department stores. Main post offices will also cash traveler's checks.

## Credit Cards

All major hotels and most restaurants and shops accept credit cards. It is advisable to carry an identity card, passport or other form of photo identification. However, cash is recommended to go sightseeing since temples, shrines and many local stores do not accept credit cards.



## Taxes

There is a 5% consumption tax on retail purchases in Japan. If you dine at higher-end restaurants and stay at first-class accommodation, you will encounter a service charge, which varies from 10% to 15%.

## Tipping

Tipping is not necessary in Japan.



# Kyoto Information

## Business Hours

	Weekdays	Saturday	Sunday & National Holidays
Banks	09:00-15:00	closed	closed
Post Offices	09:00-17:00	closed	closed
Department Stores	10:00-20:00	10:00-20:00	10:00-19:30
Shops	10:00-20:00	10:00-20:00	10:00-20:00
Museums	10:00-17:00	10:00-17:00	10:00-17:00
Offices	09:00-17:00	closed	closed

\*Some main post offices are open seven days a week.

\*Most department stores are closed for two to three weekdays a month.

\*Most museums are closed on Mondays.

## Time

Japan has only one standard time zone: UTC/ GMT+9 hours. There is no Summer Time.

## Travel Insurance

Although Japan is a clean and relatively safe country, it is always advisable to take out travel insurance for the duration of your stay. The meeting organizers will not be held liable for illness, accidents or thefts suffered by participants.

## Electricity

The voltage in Japan is 100 Volt, which is different from North America (110V), Central Europe (220V) and most other regions of the world. Two kinds of frequencies are in use; 60Hz in the west (Kyoto), 50Hz in the east and Tokyo. Flat 2-pin plugs. (There are no columnar-shaped plugs or 3-pin plugs.)

## Telephone

### Mobile Phone

The Japanese mobile phones protocol is different from that in other parts of the world, so please check with your provider before you depart. Mobile phones are available for rental at the airport. It is very hard to find rental cell phones in Kyoto, so it is best to rent one at the airport.

### Public Phone

A direct overseas call can be made from a public telephone displaying an International and Domestic Telephone sign. These phones are not widespread, but can be found at airports, hotels, and other key facilities.




## Social Events

### Opening Ceremony and Welcome Reception

Sunday July 24, 2011, 17:30

#### **Included in the registration fee**

 Opening Ceremony will take place at the Main Hall in ICC Kyoto, followed by the welcome Reception, which will take place at the beautiful Japanese-style garden.

From 21:00 until 21:30 shuttle bus departures are scheduled to the official ISTH 2011 Congress Hotels.



## Social Events




### Presidential Dinner

Monday July 25, 2011, 19:00

#### Invitation only

This event will take place at *Kōdai-ji* temple (Cocktail Reception) and THE GARDEN ORIENTAL KYOTO (Dinner). The shuttle bus will leave ICC Kyoto at 18:45 for *Kōdai-ji* temple.

### All Congress Party

Wednesday July 27, 2011, 18:00 

#### Reservation fee of JPY 7,500 must be paid in advance

This event will take place at the Grand Prince Hotel  a short walk from ICC Kyoto.

If you would still like to register for the All Congress Party onsite, please inquire at the Registration Desk.

### Accompanying Persons' Program / Tours

All tours depart from and return to the ICC Kyoto.

Tours will take place only if a minimum of participants is met (please see page <No.80Tours > for details of each tour).

\*JTB Global Marketing & Travel Inc. (JTB GMT) is the official travel agent for the ISTH 2011 and will handle hotel accommodations and tours.



# Tours

## ISTH 2011 Tours Overview

### Saturday 23

World Cultural Heritage 1	13:00 - 16:30
Heian Shrine and Sanjusangendo	13:00 - 16:00

### Sunday 24

World Cultural Heritage 1	13:00 - 16:30
Flower (Lotus) and Arashiyama	9:00 - 13:00
Heian Shrine and Sanjusangendo	9:00 - 12:00

### Monday 25

World Cultural Heritage 1	9:00 - 12:30
World Cultural Heritage 3	13:00 - 16:00
Fushimi Inari and Japanese Sake Brewery	13:00 - 17:00

### Tuesday 26

World Cultural Heritage 2	9:00 - 13:00
Rapids Shooting and World Cultural Heritage	9:00 - 17:00

### Wednesday 27 (Excursion Day)

World Cultural Heritage 3	13:00 - 16:00
World Cultural Heritage 4	13:00 - 17:00
Flower (Lotus) and Arashiyama	9:00 - 13:00
Fushimi Inari and Japanese Sake Brewery	13:00 - 17:00
Mt. Hiei, Lake Biwa and Ohara	9:00 - 17:00

### Thursday 28

World Cultural Heritage 2	9:00 - 13:00
Nara 1 Day	8:30 - 18:00

## CANCELLATION

In the event of cancellation, the following cancellation fees will be deducted before any refund is made

7 - 2 days before the departure day of one day tours	· 30% of tour fare
1 day before	..... 40% of tour fare
Prior to starting time on the departure day	..... 50% of tour fare
After departure or failure to show without notice	..... 100% of tour fare

If you have any inquiries please contact:

JTB Global Marketing & Travel Inc. (JTBGMT)

JTB Bldg. 14F 2-3-11 Higashishinagawa, Shinagawa-ku, Tokyo 140-8604, Japan

Tel: +81-3-5796-5445 Fax: +81-3-5495-0685 E-mail: isth2011@gmt.jtb.jp



# Tours

## EX-1 World Cultural Heritage 1

**Date & Time** Saturday July 23, 2011, 13:00 - 16:30 / 3.5 hours  
Sunday July 24, 2011, 13:00 - 16:30 / 3.5 hours  
Monday July 25, 2011, 09:00 - 12:30 / 3.5 hours

**Fare** JPY6,500 per person

**Course** ICCK Nijo Castle Golden Pavilion (Kinkakuji-Temple) ICCK

**Nijo Castle** served as the residence of the Tokugawa Shoguns when they visited Kyoto. The typical style of art of the warrior class which can be observed here, is in clear contrast to that of the Court noble. The castle was built by Iyasu Tokugawa at the beginning of the 17th century. After the Meiji Restoration, it became the detached palace of the Imperial Household, but it was given to the city of Kyoto in 1939.



**Golden Pavilion** was originally the villa of a Court noble named Kintsune Saionji in the precincts of the present Kinkakuji Temple. The villa was greatly improved by its second owner, Yoshimitsu Ashikaga. He laid out an extensive garden and built a beautiful pavilion toward the end of the 14th century. The pavilion became known as the "Golden Pavilion" or Kinkaku because of its gorgeous gilding. After Yoshimitsu's death the villa was turned into a Buddhist Temple of the Zen sect under the name of Rokuonji. However, the temple is better known by its popular name Kinkakuji or the "Temple of the Golden Pavilion".

**Guide** English-speaking guide service is included

**Meals** No meal

**Minimum number of participants necessary for the tour**  
30 persons per coach

**Transportation** Motor coach



# Tours

## EX-2 World Cultural Heritage 2

**Date & Time** Tuesday July 26, 2011, 09:00 - 13:00 / 4 hours  
Thursday July 28, 2011, 09:00 - 13:00 / 4 hours

**Fare** JPY6,800 per person

**Course** ICCK Nishi Honganji Temple Kiyomizu Temple ICCK

**Nishi Honganji Temple** is one of the finest in Kyoto, and is often referred to by art critics as the finest existing example of Buddhist architecture. Originally it was founded in 1272 at Higashiyama, and moved to the present site three centuries later in 1591, after the donation of a plot of land by Hideyoshi Toyotomi. In 1602, Ieyasu Tokugawa fearing the growing power of the Shinshu sect, sought to weaken it by giving a former abbot permission to found a new branch of the sect, known as the Otani school.

**Kiyomizu Temple** is one of the oldest temples in Kyoto, its origin dating back to the 8th century. The temple is noted for the unique style of its architecture. Its

main hall stands on a cliff with a wooden platform in front, from which a panoramic view of Kyoto can be enjoyed. Most of the present buildings were reconstructed in 1633, but they reflect the style of the original ones, suggesting the style of residences of the 8th and 9th centuries.

**Guide** English-speaking guide service is included

**Meals** No meal

**Minimum number of participants necessary for the tour**

30 persons per coach

**Transportation** Motor coach



## EX-3 World Cultural Heritage 3

**Date & Time** Monday July 25, 2011, 13:00 - 16:00 / 4 hours  
Wednesday July 27, 2011, 13:00 - 16:00 / 4 hours

**Fare** JPY7,000 per person

**Course** ICCK Golden Pavilion (Kinkakuji-Temple) Daisen-in Temple ICCK

Golden Pavilion was originally the villa of a Court noble named Kintsune



## Tours

Saionji in the precincts of the present Kinkakuji Temple. The villa was greatly improved by its second owner, Yoshimitsu Ashikaga. He laid out an extensive garden and built a beautiful pavilion toward the end of the 14th century. The pavilion became known as the "Golden Pavilion" or Kinkaku because of its gorgeous gilding. After Yoshimitsu's death the villa was turned into a Buddhist Temple of the Zen sect under the name of Rokuonji. However, the temple is better known by its popular name Kinkakuji or the "Temple of the Golden Pavilion".

**Daisen-in Temple** founded in 1319 by Abbot Daito. Later, Abbot Ikkyu reconstructed it as one of the chief temple of the rinzai sect. Having been supported by tea masters, warriors and rich merchants, there are many subordinate temples in the precincts of this temple and almost all of them possess numerous priceless paintings and landscaped gardens dating from the 15th to the 17th centuries. The garden of Daisen-in is perhaps most remarkable. Karesansui (garden which uses white sand and rocks to symbolize water and lands) is known for its special scenic beauty.

Guide	English-speaking guide service is included
Meals	No meal
Minimum number of participants necessary for the tour	30 persons per coach
Transportation	Motor coach

### EX-4 World Cultural Heritage 4

**Date & Time** Wednesday July 27, 2011, 13:00 - 17:00 / 4 hours

**Fare** JPY7,000 per person

**Course** ICCK Shorei-in Temple Byodoin Temple ICCK

**Shoren-in** is well known for having been the residence of the head abbot of the Tendai sect, who, in pre-Restoration days, held the rank of Imperial prince. The present buildings date from 1895. The sliding screens of the Main Hall are decorated with paintings by Mitsunobu Kano, Motonobu Kano, Gukei Sumiyoshi, etc. The garden, of the best landscape gardens in Kyoto.

**Byodoin Temple** Designated a World Heritage site, Byodoin Temple was once the villa of Fujiwara Michinaga, the model for the hero in the Japanese classic "The Tale of Genji," was turned into a temple by Fujiwara's son in 1052 and now includes numerous national treasures. The main hall -- called Ho-oh-doh or "Phoenix Hall" -- was built in 1053 and is a national treasure. The hall enshrines a large statue of Amida Buddha sculpted by famous artist Jocho that is also a national treasure. The temple's elegant bell is considered one of the finest such bells in Japan and is another national treasure. The temple is located on the banks of the Uji River near Kyoto.

Guide	English-speaking guide service is included
Meals	No meal
Minimum number of participants necessary for the tour	30 persons per coach
Transportation	Motor coach





# Tours

## EX-5 Flower (Lotus) and Arashiyama

Date & Time Sunday July 24, 2011, 09:00 - 13:00 / 4 hours  
Wednesday July 27, 2011, 09:00 - 13:00 / 4 hours

Fare JPY6,500 per person

Course ICCK Ryoanji Temple Arashiyama Tenryuji Temple ICCK

**Ryoanji Temple** was founded by Priest Giten under the patronage of Katsumoto Hosokawa in 1448. Katsumoto Hosokawa was a famous general of the Ashikaga Shogunate and was a pious devotee of Zen Buddhism. The temple suffered a conflagration toward the end of the 18th century, and the present building was reconstructed after the fire. However, its gardens have remained intact, and the temple is especially noted for its five hundred year old rock garden, which contains no trees at all. The garden was constructed around 1450, soon after the founding of the temple. As it contains no plants, it is one of the very few old gardens which can be seen exactly as the designer made them. It is generally believed that the garden is the work of Soami, the most famous garden designer of his day. Some authorities maintain that another man named Zenami was the designer of this garden. It is the supreme example of a flat rock garden, and is the best specimen of the gardens classified as Karesansui or "Dry Landscape" type.



**Arashiyama** is a beautiful spot where one finds within its limited area all the beauties of nature. The beauty lies in the varied vegetation of the hillside facing the river. Large pines, interspersed with innumerable cherry and maple trees in their respective seasons, lend an exquisite beauty to the area.

**Tenryuji Temple** is the headquarters of the Tenryuji school of the Rinza sect. It was founded in 1339 by the first Ashikaga shogun, Takauji, in memory of Emperor Godaigo. The noted Priest Soseki, also known by the name of Muso-Kokushi, was the first superior. The temple was repeatedly ravaged by fire, the present buildings dating from 1900. The Main Hall, called Tahoden, located in the center of the grounds, contains the memorial tablet to Emperor Godaigo. In the Lecture Hall to the right of the Main Hall are statues of Sakyamuni, Monju and Fugen. A noted landscape garden designed by Muso-Kokushi is located at the rear of the abbot's quarters.

Guide English-speaking guide service is included

Meals No meal

Minimum number of participants necessary for the tour  
30 persons per coach

Transportation Motor coach



## Tours

### EX-6 Heian shrine and Sanjusangendo

**Date & Time** Saturday July 23, 2011, 13:00 - 16:00 / 3 hours  
Sunday July 24, 2011, 09:00 - 12:00 / 3 hours

**Fare** JPY6,500 per person

**Course** ICCK Sanjusangendo Heian shrine ICCK

#### Sanjusangendo

Sanjusangendo literally means the "hall of thirty-three spaces". It is so called because there are thirty-three spaces between the pillars in front of its extraordinarily long altar.

Thirty-three is an important symbolic number

in Buddhism, especially associated with the worship of Kannon. It is preached that Kannon manifests himself in thirty-three different forms to save mankind. Sanjusangendo is a temple with the longest frontage in Japan, measuring about 120m in length. The present building was reconstructed about the middle of the 13th century, and is regarded as one of the best specimens of architecture of its kind. The temple is also known as the "Temple of Thousand Images" because of its numerous Buddhist images. As well as the main image, there are one thousand carved wooden images of Kannon on the long altar.



**Heian Shrine** is the most representative Shinto shrine in Kyoto, and is dedicated to Emperor Kammu, the founder of the Kyoto Capital, and Emperor Komei, the last Emperor of the Kyoto Capital. Heian, which literally means "peace and tranquility", was the ancient name of Kyoto. Patterned after the Imperial Palace which was built toward the end of the 8th century, the shrine was erected in 1895 in commemoration of Kyoto's 1100th anniversary. The vermilion structures with their green roofs reflect the influence of Chinese palace architecture of the T'ang dynasty, which flourished in the 8th century. The garden at the rear of the shrine is well known for its weeping cherry trees, maple trees, azaleas, irises and waterlilies.

**Guide** English-speaking guide service is included

**Meals** No meal

**Minimum number of participants necessary for the tour**

30 persons per coach

**Transportation** Motor coach



## Tours

### EX-7 Fushimi Inari and Japanese Sake Brewery

**Date & Time** Monday July 25, 2011, 13:00 - 17:00 / 4 hours  
Wednesday July 27, 2011, 13:00 - 17:00 / 4 hours

**Fare** JPY7,500 per person

**Course** ICCK Fushimi Inari Gekeikan Sake Brewery ICCK

**Gekeikan Sake Brewery** Sake is a traditional Japanese rice wine, produced strictly from moldy rice, steamed rice and water; it has an alcoholic content of 15 to 17 per cent. It is inseparable from the daily life of the Japanese, to say nothing of all ceremonial occasions. Gekeikan has the honours of being appointed as purveyor to Imperial Household. Sake tasting will take place at the end of the tour.

**Fushimi Inari** Dedicated to the god of rice and sake, Fushimi Inari Shrine has a history stretching back to the early 700's, yet is still popular with modern merchants, who come here to pray for success in business. Behind the shrine is a four-kilometer pathway lined with ten thousand orange torii-style gates that have been donated by worshippers through the ages. The path leads to the top of Mt. Inari, which is also a place of veneration for believers. There are numerous smaller shrines along the way, as well as quaint food stands where one might stop and enjoy a brief snack. The hike to the mountaintop typically takes three hours.



**Guide** English-speaking guide service is included

**Meals** 1 lunch

**Minimum number of participants necessary for the tour**

30 persons per coach

**Transportation** Motor coach



## Tours

### EX-8 Rapids Shooting and World Cultural Heritage (Full day Tour)

Date & Time Tuesday July 26, 2011, 09:00 - 17:00 / 8 hours

Fare JPY18,000 per person

Course ICCK Kameoka (Rapids Shooting) Arashiyama lunch Tenryuji Temple  
Ryoanji Temple ICCK

**Rapids Shooting** is an exciting 16-kilometer, ninety-minute trip downstream, shooting the Hozu Rapids aboard a flat-bottomed boat from Kameoka to scenic Arashiyama. The changing beauty of the winding gorge will leave unforgettable memories.



**Arashiyama** is a beautiful spot where one finds within its limited area all the beauties of nature. The beauty lies in the varied vegetation of the hillside facing the river. Large pines, interspersed with innumerable cherry and maple trees in their respective seasons, lend an exquisite beauty to the area.

**Tenryuji Temple** is the headquarters of the Tenryuji school of the Rinzai sect. It was founded in 1339 by the first Ashikaga shogun, Takauji, in memory of Emperor Godaigo. The noted Priest Soseki, also known by the name of Muso-Kokushi, was the first superior. The temple was repeatedly ravaged by fire, the present buildings dating from 1900. The Main Hall, called Tahoden, located in the center of the grounds, contains the memorial tablet to Emperor Godaigo. In the Lecture Hall to the right of the Main Hall are statues of Sakyamuni, Monju and Fugen. A noted landscape garden designed by Muso-Kokushi is located at the rear of the abbot's quarters.

**Ryoanji Temple** was founded by Priest Giten under the patronage of Katsumoto Hosokawa in 1448. Katsumoto Hosokawa was a famous general of the Ashikaga Shogunate and was a pious devotee of Zen Buddhism. The temple suffered a conflagration toward the end of the 18th century, and the present building was reconstructed after the fire. However, its gardens have remained intact, and the temple is especially noted for its five hundred year old rock garden, which contains no trees at all. The garden was constructed around 1450, soon after the founding of the temple. As it contains no plants, it is one of the very few old gardens which can be seen exactly as the designer made them. It is generally believed that the garden is the work of Soami, the most famous garden designer of his day. Some authorities maintain that another man named Zenami was the designer of this garden. It is the supreme example of a flat rock garden, and is the best specimen of the gardens classified as Karesansui or "Dry Landscape" type.

Guide English-speaking guide service is included

Meals 1 lunch

Minimum number of participants necessary for the tour

30 persons per coach

Transportation Motor coach



## Tours

### EX-9 Nara 1 day (Full day Tour)

**Date & Time** Thursday July 28, 2011, 08:30 - 18:00 / 9.5 hours

**Fare** JPY13,000 per person

**Course** ICCK Kasuga Shrine Todaiji Temple lunch Horyuji Temple  
Kyoto St. ICCK

**Kasuga Shrine**  
consists of four small shrines. The contrasting colors of bright vermilion and the green of the woods in which it nestles, the shrine presents a striking picture. It is famous for the 3,000 antique lanterns made of stone and bronze which align both sides



of the street leading to the shrine. The lanterns are lighted twice a year, once in February and again in August.

**Todaiji Temple** boasts of two of the world's largest work of man. One is the Daibutsu or Great Buddha, the largest bronze statue on earth. So overwhelming is its size - it weighs 450 tons and a thumb alone is 1.6 meters long - that it took four long years and about 437 tons of bronze, a large amount of charcoal, and gold, mercury, vegetable wax and other materials to complete the original statue in 749. The other is the Daibutsuden or the Hall of the Great Buddha in which the Daibutsu is enclosed. It is the largest wooden structure made by man.

**Horyuji Temple** (Preserving the ideals of Prince Shotoku and the treasure house of ancient culture) Established in 607 A.D. by Prince Shotoku, a vigorous supporter of Buddhism, Horyuji Temple was Various national treasures representing Japanese Buddhist art are displayed, such as the statue of Kudara Kannon in the Kudara-Kannon-Do Hall of the Daihozoin treasure house. The precinct is divided into the West Precinct and the East Precinct. In the former are structures of the Asuka period or 8th century, such as the five-storied pagoda and the Kondo Hall. "Tamamushi-no-Zushi," a Buddhist altar of the Asuka period, Yumechigai Kannon statue, and other temple treasures are also found in this Precinct. The Tamamushi-no-Zushi, is decorated with the wings of jewel beetles laid under the metal openwork. In the East Precinct is the Yumedono, the eldest octagonal hall in Japan. "Guze Kannon" a life-sized wooden Buddhist statue of Prince Shotoku is kept here.

**Guide** English-speaking guide service is included

**Meals** 1 lunch

**Minimum number of participants necessary for the tour**  
30 persons per coach

**Transportation** Motor coach



## Tours

### EX-10 Mt. Hiei, Lake Biwa and Ohara (Full day Tour)

**Date & Time** Wednesday July 27, 2011, 09:00 - 17:00 / 8 hours

**Fare** JPY17,000 per person

**Course** ICCK Enryakuji Temple Otsu Lake Biwa Cruise Otsu  
Ohara Sanzenin/Jyakkoinn Temple CCK

**Enryakuji Temple** is located atop Mt. Hiei in a thick grove of Japanese cypress-trees. It was established in 788 by Priest Saicho, better known as Dengyo-Daishi (767-822), founder of the Tendai sect by order of Emperor Kammu. The object of its foundation was to protect the new capital from evil spirits which were supposed to come from the northeast direction.



**Lake Biwa:** is the largest fresh-water lake in Japan, with a circumference of 188 kilometers and an area of 674 square kilometers. The name is derived from the fact that the lake is shaped like the musical instrument called the biwa. Geologists hold the view that the lake was formed by the subsidence of the land. Tradition has it, however, that it was formed overnight in 286 B.C. by an earthquake, which produced Mt. Fuji at the same time. Enjoy a delightful cruise on Lake Biwa aboard a large sightseeing vessel called the "Michigan".

**Sanzen-in Temple** was built at Ohara as a residence for the brothers and sisters of deified emperors. The site was chosen since Ohara had been considered a holy place from ancient times by believers in Jodo, the Pure Land or Buddhist Heaven. The temple consists of a beautiful mansion and gardens set in secluded hills. Located west, Jakkoin temple is a convent built on a perfectly secluded site. It is famous as the place where the Empress Kenreimon-in, mother of the infant Emperor Antoku, became a nun in 1185. She spent the rest of her life here after her imperial son perished along with the rest of the Taira clan at Dan-no-ura (the present Shimonoseki, in western Japan). Her tomb lies on a hill behind the temple. The convent's garden is regarded as one of the finest places for maple-viewing in Kyoto.

**Guide** English-speaking guide service is included

**Meals** 1 lunch

**Minimum number of participants necessary for the tour**  
30 persons per coach

**Transportation** Motor coach



**Recommend a subscription  
for your library today!**

**Stop by  
booth #33  
for your free  
JTH USB  
while supplies last**

**jth**  
**Journal of  
Thrombosis and  
Haemostasis**



Journal of the International Society on  
Thrombosis and Haemostasis

**Edited by: Mike Greaves & David Lane**

**Do you have access to:**

- the official Journal of the ISTH?
- the number one international specialty journal in the field of thrombosis, bleeding disorders and vascular biology?
- original research reports, state-of-the art reviews, commentaries and debates on timely topics?
- highly cited articles written by internationally acclaimed experts in the field?

If not, recommend that your library subscribe to JTH! Use our convenient form online at:  
[wileyonlinelibrary.com/libraryreform](http://wileyonlinelibrary.com/libraryreform)




Don't miss the  
**2011 State of the Art issue**  
which contains the definitive  
collection of topical reviews  
in thrombosis and hemostasis  
written by internationally  
acclaimed experts in the  
field. These articles are  
freely available without a  
subscription. Visit the journal  
online to download these  
reviews today!

[wileyonlinelibrary.com/journal/jth](http://wileyonlinelibrary.com/journal/jth)

 **WILEY-  
BLACKWELL**

**No84**

11-31434



**BIOGEN IDEC HEMOPHILIA PRESENTS**

# FC FUSION

**The forward-thinking long-lasting technology**

- We're using unique Fc fusion technology to develop therapies that last longer.
- Fc fusion is an established technology that has been shown to extend the half-life of drugs by using a well-understood, naturally occurring pathway in the body.<sup>1</sup>
- By using recombinant DNA technology, Fc fusion links a therapeutic protein to the "Fc" portion of an immunoglobulin. Fc is a fragment of an endogenous antibody, which is designed to keep therapeutic proteins in circulation longer.<sup>1</sup>



**Want to learn more?**

See the Fc fusion video at **booth #42** or visit us online at [www.BiogenIdecHemophilia.com](http://www.BiogenIdecHemophilia.com).

**Reference:** 1. Lillcrap D. Extending half-life in coagulation factors: where do we stand? *Thromb Res.* 2008;122(suppl):S2-S8.



© 2011 Biogen Idec Inc and Swedish Orphan Biovitrum. All rights reserved. BIH 60-8010-01

**No85**



2013

**NETHERLANDS**

**ISTH**

XXIV CONGRESS  
OF THE INTERNATIONAL  
SOCIETY ON THROMBOSIS  
AND HAEMOSTASIS

**JUNE 29 - JULY 4**

Amsterdam, The Netherlands

**[www.isth2013.org](http://www.isth2013.org)**

**SEE YOU IN AMSTERDAM**

